PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Depre, C; Shipley, GL; Chen, WH; Han, QY; Doenst, T; Moore, ML; Stepkowski, S; Davies, PJA; Taegtmeyer, H				Depre, C; Shipley, GL; Chen, WH; Han, QY; Doenst, T; Moore, ML; Stepkowski, S; Davies, PJA; Taegtmeyer, H			Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy	NATURE MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; LEFT-VENTRICULAR HYPERTROPHY; RAT-HEART; MECHANICAL-STRESS; THYROID-HORMONE; ENHANCER FACTOR-2; SKELETAL-MUSCLE; GROWTH-FACTORS; MESSENGER-RNA; MYOCYTES	The cardiac response to increased work includes a reactivation of fetal genes. The response to a decrease in cardiac work is not known. Such information is of clinical interest, because mechanical unloading can improve the functional capacity of the failing heart. We compared here the patterns of gene expression in unloaded rat heart with those in hypertrophied rat heart. Both conditions induced a re-expression of growth factors and proto-oncogenes, and a downregulation of the 'adult' isoforms, but not of the 'fetal' isoforms, of proteins regulating myocardial energetics. Therefore, opposite changes in cardiac workload in vivo induce similar patterns of gene response. Reactivation of fetal genes may underlie the functional improvement of an unloaded failing heart.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Surg, Div Organ Transplantat, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin, Houston, TX 77030 USA.		Chen, Wenhao/J-6553-2019	Chen, Wenhao/0000-0002-0626-3739	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043133] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL43133] Funding Source: Medline; ORIP NIH HHS [NIH-RI-A139026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ORIP NIH HHS		BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BRAND T, 1995, J MOL CELL CARDIOL, V27, P5, DOI 10.1016/S0022-2828(08)80003-X; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; DEPRE C, IN PRESS CIRCULATION; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; Doevendans PA, 1996, INT J BIOCHEM CELL B, V28, P387, DOI 10.1016/1357-2725(95)00145-X; DORN GW, 1994, AM J PHYSIOL, V267, pH400, DOI 10.1152/ajpheart.1994.267.1.H400; GEENEN DL, 1992, CIRC RES, V70, P554, DOI 10.1161/01.RES.70.3.554; GEENEN DL, 1994, AM J PHYSIOL-HEART C, V267, pH2149, DOI 10.1152/ajpheart.1994.267.6.H2149; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GOULD GW, 1997, FACILITATIVE GLUCOSE, P67; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hasegawa K, 1997, CIRCULATION, V96, P3943; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KLEINMAN LH, 1978, AM J PHYSIOL, V234, pH515, DOI 10.1152/ajpheart.1978.234.5.H515; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1990, J BIOL CHEM, V265, P5391; KORECKY B, 1987, CIRC RES, V60, P824, DOI 10.1161/01.RES.60.6.824; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LIU ML, 1994, J BIOL CHEM, V269, P28514; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muller J, 1997, CIRCULATION, V96, P542; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Olivieri NF, 1997, LANCET, V350, P491, DOI 10.1016/S0140-6736(05)63080-2; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Robbins J, 1996, CARDIOVASC RES, V31, pE2; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHNEIDER MD, 1991, MOL BIOL MED, V8, P167; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	51	337	343	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1269	1275		10.1038/3253	http://dx.doi.org/10.1038/3253			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809550				2022-12-27	WOS:000076731000035
J	Miwa, K; Asano, M; Horai, R; Iwakura, Y; Nagata, S; Suda, T				Miwa, K; Asano, M; Horai, R; Iwakura, Y; Nagata, S; Suda, T			Caspase 1-independent IL-1 beta release and inflammation induced by the apoptosis inducer Fas ligand	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; TUMOR-NECROSIS-FACTOR; CD95 LIGAND; DIFFERENTIAL EXPRESSION; MEDIATED CYTOTOXICITY; MICE DEFICIENT; CELL-DEATH; INTERLEUKIN-1-BETA; NEUTROPHILS; CYTOKINES	Fas ligand is a well-characterized apoptosis inducer. Here we demonstrate that Fas ligand induces the processing and secretion of interleukin-1 beta (IL-1 beta) in peritoneal exudate cells. This IL-1 beta secretion is independent of IL-1 beta converting enzyme (caspase 1), yet it is inhibited by caspase inhibitors, indicating that a caspase(s) in addition to IL-1 beta converting enzyme can process IL-1 beta. Inoculation of tumor cells expressing Fas ligand into wild-type mice induces a massive neutrophil infiltration that is, in contrast, suppressed in IL-1 alpha/beta knockout mice. These results demonstrate a newly discovered role for Fas ligand in inflammation, and challenge the dogma that apoptosis does not induce inflammation.	Osaka Biosci Inst, Dept Biol Mol, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan	University of Tokyo; Osaka University; Kanazawa University	Suda, T (corresponding author), Osaka Biosci Inst, Dept Biol Mol, Osaka 5650874, Japan.		Iwakura, Yoichiro/E-5457-2011; Nagata, Shigekazu/AAG-3203-2019	Iwakura, Yoichiro/0000-0002-9934-5775; Nagata, Shigekazu/0000-0001-9758-8426				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; COLOTTA F, 1992, BLOOD, V80, P2012; DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873; Fantuzzi G, 1996, J IMMUNOL, V157, P291; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; IWAI K, 1994, BLOOD, V84, P1201; JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LINDEMANN A, 1988, J IMMUNOL, V140, P837; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakamoto Y, 1997, J IMMUNOL, V158, P5692; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Parsey MV, 1998, J IMMUNOL, V160, P1007; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Suda T, 1997, J ALLERGY CLIN IMMUN, V100, pS97, DOI 10.1016/S0091-6749(97)70013-7; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031	43	337	345	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1287	1292		10.1038/3276	http://dx.doi.org/10.1038/3276			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809553				2022-12-27	WOS:000076731000038
J	Bhatia, M; Bonnet, D; Murdoch, B; Gan, OI; Dick, JE				Bhatia, M; Bonnet, D; Murdoch, B; Gan, OI; Dick, JE			A newly discovered class of human hematopoietic cells with SCID-repopulating activity	NATURE MEDICINE			English	Article							HUMAN ENDOTHELIAL-CELLS; ACUTE MYELOID-LEUKEMIA; IMMUNE-DEFICIENT MICE; STEM-CELLS; BONE-MARROW; CORD-BLOOD; IN-VIVO; PROGENITOR CELLS; EXPRESSION; BIOLOGY	The detection of primitive hematopoietic cells based on repopulation of immune-deficient mice is a powerful tool to characterize the human stem-cell compartment. Here, we identify a newly discovered human repopulating cell, distinct from previously identified repopulating cells, that initiates multilineage hematopoiesis in NOD/SCID mice. We call such cells CD34(neg)-SCID repopulating cells, or CD34(neg)-SRC. CD34(neg)-SRC are restricted to a Lin(-)CD34(-)CD38(-) population without detectable surface markers for multiple lineages and CD38 or those previously associated with stem cells (HLA-DR, Thy-1 and CD34). In contrast to CD34(+) subfractions, Lin(-)CD34(-)CD38(-) cells have low clonogenicity in short-and long-term in vitro assays. The number of CD34(neg)-SRC increased in short-term suspension cultures in conditions that did not maintain SRC derived from CD34(+) populations, providing independent biological evidence of their distinctiveness. The identification of this newly discovered cell demonstrates complexity of the organization of the human stem-cell compartment and has important implications for clinical applications involving stem-cell transplantation.	Hosp Sick Children, Res Inst, Programs Caanc Blood & Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Dick, JE (corresponding author), Hosp Sick Children, Res Inst, Programs Caanc Blood & Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	dick@sickkids.on.ca		Dick, John/0000-0002-9527-8317				ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bensinger WI, 1996, BLOOD, V88, P4132; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bodine DM, 1996, BLOOD, V88, P89; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; CROISILLE L, 1994, BLOOD, V84, P4116, DOI 10.1182/blood.V84.12.4116.bloodjournal84124116; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GROSSET C, 1995, BLOOD, V86, P3763, DOI 10.1182/blood.V86.10.3763.bloodjournal86103763; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; Hogan DA, 1997, MICROB ECOL, V34, P90, DOI 10.1007/s002489900038; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KORPELAINEN EI, 1995, BLOOD, V86, P176, DOI 10.1182/blood.V86.1.176.bloodjournal861176; Krause DS, 1996, BLOOD, V87, P1; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LOUACHE F, 1994, BLOOD, V84, P3344; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pflumio F, 1996, BLOOD, V88, P3731, DOI 10.1182/blood.V88.10.3731.bloodjournal88103731; Phillips R A, 1991, Semin Immunol, V3, P337; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Zanjani ED, 1998, EXP HEMATOL, V26, P353	36	476	517	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1038	1045		10.1038/2023	http://dx.doi.org/10.1038/2023			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734397				2022-12-27	WOS:000075804100037
J	Mezey, E; Dehejia, A; Harta, G; Papp, MI; Polymeropoulos, MH; Brownstein, MJ				Mezey, E; Dehejia, A; Harta, G; Papp, MI; Polymeropoulos, MH; Brownstein, MJ			Alpha synuclein in neurodegenerative disorders: Murderer or accomplice?	NATURE MEDICINE			English	Editorial Material							MULTIPLE SYSTEM ATROPHY; OLIVOPONTOCEREBELLAR ATROPHY	Several neurodegenerative disorders are characterized by intracellular protein accumulations or inclusions, such as the Lewy bodies of Parkinson's disease. Although little is know about the origin of these accumulations and their specific affect on neurons, it seems likely that as they grow they prove fatal to the cell. Here Michael Brownstein and colleagues speculate on a broad role for alpha synuclein in the development of Lewy bodies and the other protein inclusions associated with neurodegeneration.	NINDS, NIH, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA; Semmelweis Univ Med, Sch Med, Dept Neurol, H-1083 Budapest, Hungary; NIMH, NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Mental Health (NIMH)	Mezey, E (corresponding author), NINDS, NIH, 9000 Rockville Pike,Bldg 36,Room 3D06, Bethesda, MD 20892 USA.		Brownstein, Michael/B-8609-2009; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691				Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; GRAHAM JG, 1969, J NEUROL NEUROSUR PS, V32, P28, DOI 10.1136/jnnp.32.1.28; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; KRUGER R, 1998, NAT GENET, V18, P1; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MEZEY E, IN PRESS MOL PSYCHIA; NAKAZATO Y, 1990, J NEUROPATH EXP NEUR, V49, P521, DOI 10.1097/00005072-199009000-00007; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Paulson HL, 1998, NEUROLOGY, V50, pA310; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; QUINN N, 1995, CURR OPIN NEUROL, V8, P323, DOI 10.1097/00019052-199508000-00013; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166	18	179	181	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					755	757		10.1038/nm0798-755	http://dx.doi.org/10.1038/nm0798-755			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662355	Green Published			2022-12-27	WOS:000074543900017
J	Pardoll, DM				Pardoll, DM			Cancer vaccines	NATURE MEDICINE			English	Review							MHC CLASS-I; LISTERIA-MONOCYTOGENES VACCINE; CYTOLYTIC T-LYMPHOCYTES; HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-ASSOCIATED ANTIGEN; ANTITUMOR IMMUNITY; DENDRITIC CELLS; SALMONELLA-TYPHIMURIUM; RECOMBINANT VACCINIA; ESTABLISHED TUMORS		Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Pardoll, DM (corresponding author), Johns Hopkins Oncol Ctr, 720 Rutland Ave,Ross 364, Baltimore, MD 21205 USA.							Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEASLEY RP, 1981, LANCET, V2, P1129; BEAUDENON S, 1986, NATURE, V321, P246, DOI 10.1038/321246a0; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BERNARDS R, 1987, P NATL ACAD SCI USA, V84, P6854, DOI 10.1073/pnas.84.19.6854; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Borysiewicz LK, 1996, LANCET, V347, P1523, DOI 10.1016/S0140-6736(96)90674-1; BRONTE V, 1995, J IMMUNOL, V154, P5282; Brossart P, 1998, CANCER RES, V58, P732; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen PW, 1996, J IMMUNOL, V156, P224; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; COX WI, 1992, RECOMBINANT POXVIRUS, P123; deGruijl TD, 1996, J GEN VIROL, V77, P2183, DOI 10.1099/0022-1317-77-9-2183; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FEARON ER, 1988, CANCER RES, V48, P2975; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Fu TM, 1997, MOL MED, V3, P362, DOI 10.1007/BF03401683; GISSMANN L, 1986, CIBA F SYMP, V120, P190; GOLUMBEK PT, 1993, CANCER RES, V53, P5841; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAYWOOD GR, 1971, J EXP MED, V133, P1171, DOI 10.1084/jem.133.6.1171; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IKONOMIDIS G, 1994, J EXP MED, V180, P2209, DOI 10.1084/jem.180.6.2209; Irvine KR, 1997, J NATL CANCER I, V89, P1595, DOI 10.1093/jnci/89.21.1595; ITAYA T, 1987, CANCER RES, V47, P3136; Juillard V, 1995, EUR J IMMUNOL, V25, P3467, DOI 10.1002/eji.1830251239; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; LATHE R, 1987, NATURE, V326, P878, DOI 10.1038/326878a0; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lin KY, 1996, CANCER RES, V56, P21; LINDENMANN J, 1967, J EXP MED, V126, P93, DOI 10.1084/jem.126.1.93; LIVINGSTON PO, 1985, CANCER, V55, P713, DOI 10.1002/1097-0142(19850215)55:4<713::AID-CNCR2820550407>3.0.CO;2-D; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MILLER JFAP, 1989, COLD SPRING HARB SYM, V54, P807; MINEV BR, 1994, CANCER RES, V54, P4155; MONTGOMERY DL, 1993, DNA CELL BIOL, V12, P777, DOI 10.1089/dna.1993.12.777; MOSS B, 1984, NATURE, V311, P67, DOI 10.1038/311067a0; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; NAUTS HC, 1989, CANCER SURV, V8, P713; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; NEWBORG MF, 1980, J IMMUNOL, V124, P571; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PAN ZK, 1995, CANCER RES, V55, P4776; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; POIRIER TP, 1988, J EXP MED, V168, P25, DOI 10.1084/jem.168.1.25; PORTNOY DA, 1992, CURR OPIN IMMUNOL, V4, P20, DOI 10.1016/0952-7915(92)90118-X; PREHN RT, 1957, J NATL CANCER I, V18, P769; Ressing ME, 1996, CANCER RES, V56, P582; RESTIFO NP, 1991, J IMMUNOL, V147, P1453; Robbins PF, 1996, CURR OPIN IMMUNOL, V8, P628, DOI 10.1016/S0952-7915(96)80078-1; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1996, ADV CANCER RES, V70, P145, DOI 10.1016/S0065-230X(08)60874-X; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHAFER R, 1992, J IMMUNOL, V149, P53; SCHULZ M, 1991, P NATL ACAD SCI USA, V88, P991, DOI 10.1073/pnas.88.3.991; Simons JW, 1997, CANCER RES, V57, P1537; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Srivastava P K, 1991, Semin Immunol, V3, P57; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Thomas L., 1959, CELLULAR HUMORAL ASP, P529; THOMAS MC, IN PRESS HUMAN GENE; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Toes REM, 1996, CANCER RES, V56, P3782; Toes REM, 1996, J IMMUNOL, V156, P3911; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; TROWSDALE J, 1980, J EXP MED, V152, pS11; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; URBAN JL, 1982, J EXP MED, V155, P557, DOI 10.1084/jem.155.2.557; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; Vierboom MPM, 1997, J EXP MED, V186, P695, DOI 10.1084/jem.186.5.695; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WANG M, 1995, J IMMUNOL, V154, P4685; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; Wick M, 1997, J EXP MED, V186, P229, DOI 10.1084/jem.186.2.229; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORTZEL RD, 1983, NATURE, V304, P165, DOI 10.1038/304165a0; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671; Xiang ZQ, 1996, VIROLOGY, V219, P220, DOI 10.1006/viro.1996.0239	127	433	499	2	45	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5		S			525	531		10.1038/nm0598supp-525	http://dx.doi.org/10.1038/nm0598supp-525			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585204	Bronze			2022-12-27	WOS:000073453500022
J	Heneine, W; Switzer, WM; Sandstrom, P; Brown, J; Vedapuri, S; Schable, CA; Khan, AS; Lerche, NW; Schweizer, M; Neumann-Haefelin, D; Chapman, LE; Folks, TM				Heneine, W; Switzer, WM; Sandstrom, P; Brown, J; Vedapuri, S; Schable, CA; Khan, AS; Lerche, NW; Schweizer, M; Neumann-Haefelin, D; Chapman, LE; Folks, TM			Identification of a human population infected with simian foamy viruses	NATURE MEDICINE			English	Article							T-LYMPHOTROPIC VIRUS; IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; PREVALENCE; RETROVIRUS; ANTIBODY; MONKEYS; COLONY	Studying the transmission of simian retroviruses to humans can help define the importance of these infections to public health. We identified a substantial prevalence (4/231, 1.8%) of infection with simian foamy viruses (SFV) among humans occupationally exposed to nonhuman primates. Evidence of SFV infection included seropositivity, proviral DNA detection and isolation of foamy virus. The infecting SFV originated from an African green monkey (one person) and baboons (three people), These infections have not as yet resulted in either disease or sexual transmission, and may represent benign endpoint infections.	Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Immunol & Diagnost Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; US FDA, Ctr Biol Evaluat & Res, Lab Retrovirus Res, Bethesda, MD 20892 USA; Univ Calif Lawrence Livermore Natl Lab, Calif Reg Primate Res Ctr, Simian Retrovirus Lab, Livermore, CA 95616 USA; Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Freiburg	Heneine, W (corresponding author), Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Atlanta, GA 30333 USA.							ACHONG BG, 1971, J NATL CANCER I, V46, P299; Ali M, 1996, AIDS RES HUM RETROV, V12, P1473, DOI 10.1089/aid.1996.12.1473; BIENIASZ PD, 1995, VIROLOGY, V207, P217, DOI 10.1006/viro.1995.1068; Digilio L, 1997, J VIROL, V71, P3684, DOI 10.1128/JVI.71.5.3684-3692.1997; FRANCHINI G, 1994, AIDS RES HUM RETROV, V10, P1047, DOI 10.1089/aid.1994.10.1047; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; HERCHENRODER O, 1994, VIROLOGY, V201, P187, DOI 10.1006/viro.1994.1285; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HOOKS JJ, 1975, BACTERIOL REV, V39, P169, DOI 10.1128/MMBR.39.3.169-185.1975; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LERCHE NW, 1994, LAB ANIM SCI, V44, P217; MCCLURE MO, 1994, J VIROL, V68, P7124, DOI 10.1128/JVI.68.11.7124-7130.1994; MURPHY FA, 1996, SCIENCE, V273, P726; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; NEUMANNHAEFELIN D, 1993, INTERVIROLOGY, V35, P196, DOI 10.1159/000150310; Otsyula M, 1996, ANN TROP MED PARASIT, V90, P65, DOI 10.1080/00034983.1996.11813027; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; RHODESFEUILLETTE A, 1979, J MED PRIMATOL, V8, P308; RUDOLPH DL, 1992, J CLIN MICROBIOL, V30, P858, DOI 10.1128/JCM.30.4.858-861.1992; SCHWEIZER M, 1995, AIDS RES HUM RETROV, V11, P161, DOI 10.1089/aid.1995.11.161; Schweizer M, 1997, J VIROL, V71, P4821, DOI 10.1128/JVI.71.6.4821-4824.1997; SCHWEIZER M, 1995, VIROLOGY, V207, P577, DOI 10.1006/viro.1995.1120; Sotir M, 1997, J MED PRIMATOL, V26, P233, DOI 10.1111/j.1600-0684.1997.tb00217.x; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995; VanBrussel M, 1996, J GEN VIROL, V77, P347, DOI 10.1099/0022-1317-77-2-347; Yamamoto S, 1996, J VIROL METHODS, V61, P135, DOI 10.1016/0166-0934(96)02078-2	32	184	188	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					403	407		10.1038/nm0498-403	http://dx.doi.org/10.1038/nm0498-403			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546784				2022-12-27	WOS:000072906800033
J	Lunardi-Iskandar, Y; Bryant, JL; Blattner, WA; Hung, CL; Flamand, L; Gill, P; Hermans, P; Birken, S; Gallo, RC				Lunardi-Iskandar, Y; Bryant, JL; Blattner, WA; Hung, CL; Flamand, L; Gill, P; Hermans, P; Birken, S; Gallo, RC			Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease	NATURE MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SIMIAN IMMUNODEFICIENCY VIRUS; KAPOSIS-SARCOMA; TRANSGENIC MICE; RHESUS-MONKEYS; BETA-SUBUNIT; CELL-LINE; AIDS; MANIFESTATIONS; EXPRESSION	The effects of clinical grade crude preparations of human chorionic gonadotropin (hCG) on Kaposi's sarcoma, HIV, SIV and hematopoiesis were examined in vitro and in vivo. In contrast to previous studies, we report that the antiviral activity of hCG associated factors is not due to the native hCG heterodimer, including its purified subunits or its major degradation product, the beta-core. Using gel permeation chromatography of the clinical grade hCC and urine concentrates from pregnant women, we demonstrate that an as yet unidentified hCC associated factor (HAF) with anti-HIV, anti-SIV, anti-KS and pro-hematopoietic activities elutes as two peaks corresponding to 15-30 kDa and 2-4 kDa.	Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Adv Biosci Labs Inc, Kensington, MD 20895 USA; Univ So Calif, Sch Med, Los Angeles, CA 90033 USA; Univ Libre Bruxelles, CHU St Pierre Hosp, Dept Malad Infect, B-1000 Brussels, Belgium; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	University System of Maryland; University of Maryland Baltimore; University of Southern California; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Columbia University	Gallo, RC (corresponding author), Univ Maryland, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.			Flamand, Louis/0000-0001-5010-4586	NICHD NIH HHS [HD 15454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD015454] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BIRKEN S, 1988, ENDOCRINOLOGY, V123, P572, DOI 10.1210/endo-123-1-572; BOURINBAIAR AS, 1995, IMMUNOL LETT, V44, P13, DOI 10.1016/0165-2478(94)00191-S; DICKIE P, 1991, VIROLOGY, V185, P109, DOI 10.1016/0042-6822(91)90759-5; FRANKS RR, 1995, PEDIATR RES, V37, P56, DOI 10.1203/00006450-199501000-00012; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gill PS, 1996, NEW ENGL J MED, V335, P1261, DOI 10.1056/NEJM199610243351702; Gill PS, 1997, J NATL CANCER I, V89, P1797, DOI 10.1093/jnci/89.23.1797; Griffiths SJ, 1997, NATURE, V390, P568, DOI 10.1038/37510; HARRIS PJ, 1995, LANCET, V346, P118, DOI 10.1016/S0140-6736(95)92140-0; Hermans P, 1998, J Hum Virol, V1, P82; HERMANS P, 1995, CELL MOL BIOL, V3, P357; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; KOPP JB, 1993, AIDS RES HUM RETROV, V9, P267, DOI 10.1089/aid.1993.9.267; LETVIN NL, 1990, J ACQ IMMUN DEF SYND, V3, P1023; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; MORSE JH, 1988, AM J REPROD IMMUNOL, V17, P134; MORSE JH, 1976, CELL IMMUNOL, V25, P178, DOI 10.1016/0008-8749(76)90108-8; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SHIJIRSLEV SV, 1993, PROBL ENDOKRINAL MOS, V39, P54; SWAPAN DE, 1997, J CLIN INVEST, V99, P1484	23	55	72	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					428	434		10.1038/nm0498-428	http://dx.doi.org/10.1038/nm0498-428			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546788				2022-12-27	WOS:000072906800037
J	Xu, HX; Gouras, GK; Greenfield, JP; Vincent, B; Naslund, J; Mazzarelli, L; Fried, G; Jovanovic, JN; Seeger, M; Relkin, NR; Liao, F; Checler, F; Buxbaum, JD; Chait, BT; Thinakaran, G; Sisodia, SS; Wang, R; Greengard, P; Gandy, S				Xu, HX; Gouras, GK; Greenfield, JP; Vincent, B; Naslund, J; Mazzarelli, L; Fried, G; Jovanovic, JN; Seeger, M; Relkin, NR; Liao, F; Checler, F; Buxbaum, JD; Chait, BT; Thinakaran, G; Sisodia, SS; Wang, R; Greengard, P; Gandy, S			Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides	NATURE MEDICINE			English	Article							PRECURSOR PROTEIN; IN-VIVO; HIPPOCAMPAL-NEURONS; SENILE PLAQUES; DISEASE; PRESENILIN-1; ESTRADIOL; SECRETION; VARIANTS; VITRO	Alzheimer's disease (AD) is characterized by the accumulation of cerebral plaques composed of 40- and 42-amino acid beta-amyloid (A beta) peptides, and autosomal dominant forms of AD appear to cause disease by promoting brain A beta accumulation. Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the onset of AD. Here we present evidence that physiological levels of 17 beta-estradiol reduce the generation of A beta by neuroblastoma cells and by primary cultures of rat, mouse and human embryonic cerebrocortical neurons. These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.	NYU, NS Kline Inst, Orangeburg, NY 10962 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Fisher Ctr Res Alzheimer Dis, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spect, New York, NY 10021 USA; Cornell Univ, Coll Med, New York, NY 10021 USA; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; Johns Hopkins Med Inst, Neuropathol Lab, Baltimore, MD 21205 USA	Nathan Kline Institute for Psychiatric Research; New York University; Rockefeller University; Rockefeller University; Rockefeller University; Cornell University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Johns Hopkins University; Johns Hopkins Medicine	Gandy, S (corresponding author), NYU, NS Kline Inst, Orangeburg, NY 10962 USA.	gandy@nki.rfmh.org	Buxbaum, Joseph D/G-6001-2010; Wang, Rong/A-8721-2009; Gouras, Gunnar/B-3021-2010; Xu, Huaxi/AAV-7177-2021; Checler, Frederic/C-1241-2009	Gouras, Gunnar/0000-0002-5500-6325; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118; Greenfield, Jeffrey/0000-0003-1904-1040; Buxbaum, Joseph/0000-0001-8898-8313	NIA NIH HHS [AG09464, AG11508, AG13780] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464, R01AG011508, R55AG011508, R01AG013780] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINGOLD KR, 1990, CECILS ESSENTIALS ME, P478; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1993, J BIOL CHEM, V268, P3021; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LARSON GH, 1994, BIOL REPROD, V50, P357, DOI 10.1095/biolreprod50.2.357; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; PerezTur J, 1995, NEUROREPORT, V7, P297; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Simons M, 1996, J NEUROSCI, V16, P899; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; ToranAllerand CD, 1996, DEV NEUROSCI-BASEL, V18, P36, DOI 10.1159/000111393; Vincent B, 1996, J NEUROSCI, V16, P5049; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081	35	456	481	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					447	451		10.1038/nm0498-447	http://dx.doi.org/10.1038/nm0498-447			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546791				2022-12-27	WOS:000072906800040
J	Mehta, D; George, SJ; Jeremy, JY; Izzat, MB; Southgate, KM; Bryan, AJ; Newby, AC; Angelini, GD				Mehta, D; George, SJ; Jeremy, JY; Izzat, MB; Southgate, KM; Bryan, AJ; Newby, AC; Angelini, GD			External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting	NATURE MEDICINE			English	Article							VENOUS ARTERIAL GRAFTS; HUMAN SAPHENOUS-VEIN; INTIMAL HYPERPLASIA; GENE-EXPRESSION; PROLIFERATION; ACCUMULATION; ANGIOPLASTY; OCCLUSION; SURGERY; BIOLOGY	Bypass of stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic heart disease. However, its long-term clinical success is limited(1,2). Late vein graft failure is the result of medial and intimal thickening consequent upon medial vascular smooth muscle cell migration, proliferation and extracellular matrix deposition, followed later by superimposed atherosclerosis(3). These changes directly compromise graft blood flow and provoke thrombosis. Vein graft wall thickening may represent an adaptation imposed by arterial hemodynamic factors(4-6), and these factors have been shown to promote vascular smooth muscle cell migration and proliferation through activation of key mediators including platelet-derived growth factor (PDGF)(7). Many pharmacological interventions aimed at preventing these long-term changes have proven unsuccessful in clinical evaluation(8). We recently demonstrated in a pig saphenous vein graft model that application of an external polyester stent to the outside of carotid interposition vein grafts reduced intimal hyperplasia and total wall thickness 1 month after implantation(9). However, it is not known whether the benefits of the stent are maintained in the longer term or what mechanisms underlie its effect. The present study therefore compared morphological changes and PDGF expression in stented grafts and contralateral unstented grafts in the same pigs, 6 months after graft implantation. Reduced medial thickening, neointima formation, and cell proliferation were sustained in externally stented grafts, and these effects were associated with a significant reduction in PDGF expression.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England	University of Bristol	Angelini, GD (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.		Izzat, Mohammad Bashar/I-1987-2019	Izzat, Mohammad Bashar/0000-0001-6758-8716; angelini, gianni/0000-0002-1753-3730				ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476; ANGELINI GD, 1992, J THORAC CARDIOV SUR, V103, P1093; Angelini GD, 1996, J THORAC CARDIOV SUR, V112, P79, DOI 10.1016/S0022-5223(96)70180-0; BARKER SGE, 1993, ARTERIOSCLER THROMB, V13, P70, DOI 10.1161/01.ATV.13.1.70; BARKER SGE, 1994, ATHEROSCLEROSIS, V105, P131, DOI 10.1016/0021-9150(94)90043-4; BRYAN AJ, 1994, CURR OPIN CARDIOL, V9, P641, DOI 10.1097/00001573-199411000-00002; CAMPEAU L, 1983, CIRCULATION, V68, P1; DOBRIN PB, 1989, SURGERY, V105, P393; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FRANCIS SE, 1994, J THORAC CARDIOV SUR, V108, P540, DOI 10.1016/S0022-5223(12)70266-0; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; George SJ, 1996, ATHEROSCLEROSIS, V120, P227, DOI 10.1016/0021-9150(95)05717-X; GOLDMAN S, 1994, CIRCULATION, V89, P1138, DOI 10.1161/01.CIR.89.3.1138; HOCH JR, 1994, SURGERY, V116, P463; HOCH JR, 1995, J VASC SURG, V22, P51, DOI 10.1016/S0741-5214(95)70088-9; Izzat MB, 1996, CIRCULATION, V94, P1741, DOI 10.1161/01.CIR.94.7.1741; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KARAYANNACOS PE, 1978, ANN SURG, V187, P183, DOI 10.1097/00000658-197802000-00016; KOHLER TR, 1989, J VASC SURG, V9, P277, DOI 10.1067/mva.1989.vs0090277; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; MORINAGA K, 1985, J VASC SURG, V2, P430, DOI 10.1067/mva.1985.avs0020430; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NEWBY AC, 1993, CARDIOVASC RES, V27, P1173, DOI 10.1093/cvr/27.7.1173; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL F, 1988, LAB ANIM, V22, P135, DOI 10.1258/002367788780864457; SOYOMBO AA, 1990, AM J PATHOL, V137, P1401; VIOLARIS AG, 1993, ANN THORAC SURG, V55, P667, DOI 10.1016/0003-4975(93)90273-K; ZILLA P, 1993, J CARDIAC SURG, V8, P32, DOI 10.1111/j.1540-8191.1993.tb00574.x; ZWOLAK RM, 1987, J VASC SURG, V5, P126, DOI 10.1067/mva.1987.avs0050126	29	125	148	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					235	239		10.1038/nm0298-235	http://dx.doi.org/10.1038/nm0298-235			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461200				2022-12-27	WOS:000072249800042
J	Hartmann, T; Bieger, SC; Bruhl, B; Tienari, PJ; Ida, N; Allsop, D; Roberts, GW; Masters, CL; Dotti, CG; Unsicker, K; Beyreuther, K				Hartmann, T; Bieger, SC; Bruhl, B; Tienari, PJ; Ida, N; Allsop, D; Roberts, GW; Masters, CL; Dotti, CG; Unsicker, K; Beyreuther, K			Distinct sites of intracellular production for Alzheimer's disease A beta 40/42 amyloid peptides	NATURE MEDICINE			English	Article							RAT HIPPOCAMPAL-NEURONS; PRECURSOR PROTEIN; BETA-PROTEIN; SECRETION; CELLS; METABOLISM; INHIBITION; FRAGMENTS; GOLD	The Alzheimer amyloid precursor protein (APP) is cleaved by several proteases, the most studied, but still unidentified ones, are those involved in the release of a fragment of APP, the amyloidogenic beta-protein A beta. Proteolysis by gamma-secretase is the last processing step resulting in release of A beta. Cleavage occurs after residue 40 of A beta [A beta(1-40)], occasionally after residue 42 [A beta(1-42)]. Even slightly increased amounts of this A beta(1-42) might be sufficient to cause Alzheimer's disease (AD) (reviewed in ref. 1, 2). It is thus generally believed that inhibition of this enzyme could aid in prevention of AD. Unexpectedly we have identified in neurons the endoplasmic reticulum (ER) as the site for generation of A beta(1-42) and the trans-Golgi network (TGN) as the site for A beta(1-40) generation. It is interesting that intracellular generation of A beta seemed to be unique to neurons, because we found that nonneuronal cells produced significant amounts of A beta(1-40) and A beta(1-42) only at the cell surface. The specific production of the critical A beta isoform in the ER of neurons links this compartment with the generation of A beta and explains why primarily ER localized (mutant) proteins such as the presenilins(3) could induce AD. We suggest that the earliest event taking place in AD might be the generation of A beta(1-42) in the ER.	DALHOUSIE UNIV, DEPT ANAT & NEUROBIOL, HALIFAX, NS B3H 4H2, CANADA; UNIV HEIDELBERG, DEPT ANAT & CELL BIOL, INF307, D-69120 HEIDELBERG, GERMANY; UNIV HELSINKI, DEPT NEUROL, FIN-00290 HELSINKI, FINLAND; SMITHKLINE BEECHAM, HARLOW CM19 5AW, ESSEX, ENGLAND; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	Dalhousie University; Ruprecht Karls University Heidelberg; University of Helsinki; GlaxoSmithKline; University of Melbourne; European Molecular Biology Laboratory (EMBL)	Hartmann, T (corresponding author), UNIV HEIDELBERG ZMBH, ZENTRUM MOL BIOL, INF282, D-69120 HEIDELBERG, GERMANY.		Hartmann, Tobias/AAB-8297-2022; Allsop, David/B-9725-2008; Tienari, Pentti J/A-4893-2012; Dotti, Carlos G/I-5533-2015	Allsop, David/0000-0002-0513-5575; Dotti, Carlos G/0000-0003-4052-1719; Hartmann, Tobias/0000-0001-7481-6430				Allsop D, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P717; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1996, J BIOL CHEM, V271, P13208, DOI 10.1074/jbc.271.22.13208; HAYAT MA, 1981, FIXATION ELECTRON MI; Heym C, 1981, TECHNIQUES NEUROANAT; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ida N, 1996, FEBS LETT, V394, P174, DOI 10.1016/0014-5793(96)00948-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; STRUM JM, 1971, J CELL BIOL, V51, P162, DOI 10.1083/jcb.51.1.162; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VANDEPLAS P, 1993, METHOD CELL BIOL, V37, P241, DOI 10.1016/S0091-679X(08)60253-8; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	35	634	652	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					1016	1020		10.1038/nm0997-1016	http://dx.doi.org/10.1038/nm0997-1016			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288729				2022-12-27	WOS:A1997XT84200035
J	Isacson, O; Breakefield, XO				Isacson, O; Breakefield, XO			Benefits and risks of hosting animal cells in the human brain	NATURE MEDICINE			English	Review							THYMIDINE KINASE GENE; PARKINSONS-DISEASE; LEUKEMIA-VIRUS; RAT-BRAIN; FUNCTIONAL RECOVERY; XENOGRAFT REJECTION; GLIOMA-CELLS; TUMORS; MECHANISM; SURVIVAL		HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET LAB, CHARLESTOWN, MA 02139 USA; MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Isacson, O (corresponding author), HARVARD UNIV, MCLEAN HOSP, NEUROREGENERAT LAB, BELMONT, MA 02178 USA.			Isacson, Ole/0000-0001-8091-8302				AHMED R, 1996, FIELDS VIROLOGY, P221; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; BARKER DD, 1991, MOL CELL BIOL, V11, P5154, DOI 10.1128/MCB.11.10.5154; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; BENABID AL, 1995, THERAPY PARKINSONS D, P381; BIRKMAYER W, 1961, Wien Klin Wochenschr, V73, P787; Bjorklund A, 1992, Curr Opin Neurobiol, V2, P683, DOI 10.1016/0959-4388(92)90039-N; BLAESE RM, 1994, 13 EUR ASS CANC RES; BRAVI D, 1994, ANN NEUROL, V36, P27, DOI 10.1002/ana.410360108; CANN AJ, 1996, FIELDS VIROLOGY, V3, P1849; Coffin JM, 1996, FIELDS VIROLOGY, P1767; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; ELION GB, 1983, J ANTIMICROB CHEMOTH, V12, P9, DOI 10.1093/jac/12.suppl_B.9; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; Guttman M, 1997, NEUROLOGY, V48, P1578, DOI 10.1212/WNL.48.6.1578; HAMMER C, 1992, TRANSPLANT P, V24, P2397; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; HONEY CR, 1991, EXP BRAIN RES, V85, P149; Hurtig HI, 1997, EXP NEUROL, V144, P10, DOI 10.1006/exnr.1996.6380; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; KAWAKAMI TG, 1978, J NATL CANCER I, V61, P1113; KLASSEN H, 1988, EXP NEUROL, V102, P102, DOI 10.1016/0014-4886(88)90082-9; KLASSEN H, 1990, BRAIN RES, V533, P181, DOI 10.1016/0006-8993(90)91338-H; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; KRAMM CM, 1995, BRAIN PATHOL, V5, P345, DOI 10.1111/j.1750-3639.1995.tb00615.x; KRIEG AM, 1997, SCI MED, V4, P34; KRISTAL BS, 1993, J VIROL, V67, P4142, DOI 10.1128/JVI.67.7.4142-4153.1993; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; LIEBER MM, 1975, P NATL ACAD SCI USA, V72, P2315, DOI 10.1073/pnas.72.6.2315; LOEFFLER JS, 1992, J CLIN ONCOL, V10, P1379, DOI 10.1200/JCO.1992.10.9.1379; LYNCH WP, 1991, NEURON, V7, P365, DOI 10.1016/0896-6273(91)90289-C; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MARSDEN CD, 1994, CLIN NEUROPHARMACOL, V17, pS32; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLINS JI, 1986, NATURE, V319, P333, DOI 10.1038/319333a0; Nagatsu T, 1996, NEUROCHEM RES, V21, P245, DOI 10.1007/BF02529141; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; PAKZABAN P, 1994, NEUROSCIENCE, V62, P989, DOI 10.1016/0306-4522(94)90338-7; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; PEDERSEN EB, 1995, EXP BRAIN RES, V106, P181; Philpott LM, 1997, CELL TRANSPLANT, V6, P203, DOI 10.1016/S0963-6897(97)00028-6; QUINN NP, 1990, PROG BRAIN RES, V82, P619; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; SACHS DH, 1990, HUM IMMUNOL, V28, P245, DOI 10.1016/0198-8859(90)90025-K; SAITOH Y, 1991, NEUROSCI LETT, V123, P77, DOI 10.1016/0304-3940(91)90162-M; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; STEELE DJR, 1995, ANNU REV MED, V46, P345; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; STOYE JP, 1991, J VIROL, V65, P1273, DOI 10.1128/JVI.65.3.1273-1285.1991; STRECKER RE, 1987, NEUROSCIENCE, V22, P169, DOI 10.1016/0306-4522(87)90207-7; TADA M, 1993, J NEURO-ONCOL, V17, P261, DOI 10.1007/BF01049981; TAKAMIYA Y, 1993, J NEUROSURG, V79, P104, DOI 10.3171/jns.1993.79.1.0104; Tam SY, 1997, BIOCHEM PHARMACOL, V53, P441; TAPSCOTT SJ, 1994, P NATL ACAD SCI USA, V91, P8185, DOI 10.1073/pnas.91.17.8185; TEMIN H, 1985, MOL BIOL EVOL, V6, P455; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; WELLER SK, 1981, J VIROL, V39, P713, DOI 10.1128/JVI.39.3.713-721.1981; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WILEY CA, 1993, BRAIN PATHOL, V3, P123, DOI 10.1111/j.1750-3639.1993.tb00736.x; WOLFF L, 1988, J VIROL, V62, P2158, DOI 10.1128/JVI.62.6.2158-2163.1988; Wood MJA, 1996, NEUROSCIENCE, V70, P775, DOI 10.1016/S0306-4522(96)83014-4; 1996, FED REGISTER, V61, P49920	77	55	56	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					964	969		10.1038/nm0997-964	http://dx.doi.org/10.1038/nm0997-964			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288721				2022-12-27	WOS:A1997XT84200027
J	Malins, DC; Polissar, NL; Sy, YZ; Gardner, HS; Gunselman, SJ				Malins, DC; Polissar, NL; Sy, YZ; Gardner, HS; Gunselman, SJ			A new structural analysis of DNA using statistical models of infrared spectra	NATURE MEDICINE			English	Article							AGENTS		MT WHISPER LIGHT STAT CONSULTING,SEATTLE,WA 98112; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; USA,CTR ENVIRONM HLTH RES,FT COLLINS,CO 80523; COLORADO STATE UNIV,CTR ENVIRONM TOXICOL & TECHNOL,GEOCENTERS INC,FT COLLINS,CO 80523	University of Washington; University of Washington Seattle; Colorado State University	Malins, DC (corresponding author), PACIFIC NW RES FDN,MOL EPIDEMIOL PROGRAM,720 BROADWAY,SEATTLE,WA 98122, USA.							Algan O, 1996, RADIAT RES, V146, P267, DOI 10.2307/3579456; Camplejohn RS, 1996, CANCER SURV, V26, P193; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; Dees C, 1996, RADIAT RES, V146, P444, DOI 10.2307/3579306; Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1; Jenner P, 1996, PATHOL BIOL, V44, P57; KIRBY RS, 1996, PROSTATE CANC; Malins DC, 1996, P NATL ACAD SCI USA, V93, P14047, DOI 10.1073/pnas.93.24.14047; Malins DC, 1997, P NATL ACAD SCI USA, V94, P259, DOI 10.1073/pnas.94.1.259; MALINS DC, 1995, CANCER, V75, P503, DOI 10.1002/1097-0142(19950115)75:2<503::AID-CNCR2820750213>3.0.CO;2-0; Malins DC, 1996, P NATL ACAD SCI USA, V93, P2557, DOI 10.1073/pnas.93.6.2557; Mandavilli BS, 1996, J NEUROCHEM, V67, P1559; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Monforte JA, 1997, NAT MED, V3, P360, DOI 10.1038/nm0397-360; OKAMOTO A, 1993, JPN J CANCER RES, V84, P93, DOI 10.1111/j.1349-7006.1993.tb02789.x; Sikka SC, 1995, J ANDROL, V16, P464; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; WENDER PA, 1991, P NATL ACAD SCI USA, V88, P8835, DOI 10.1073/pnas.88.19.8835	18	19	19	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					927	930		10.1038/nm0897-927	http://dx.doi.org/10.1038/nm0897-927			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256288				2022-12-27	WOS:A1997XP01400039
J	Sykes, M; Szot, GL; Swenson, KA; Pearson, DA				Sykes, M; Szot, GL; Swenson, KA; Pearson, DA			Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; T-CELLS; MARROW TRANSPLANTATION; CLONAL DELETION; HOST DISEASE; ENGRAFTMENT; MICE; ANTIGENS; EXPRESSION; LEUKEMIA	Donor-specific tolerance induced by bone marrow transplantation (BMT) would allow organ allografting without chronic immunosuppressive therapy. However, the toxicity(1) of conditioning regimens used to achieve marrow engraftment has precluded the clinical use of BMT for tolerance induction. We have developed a BMT strategy that achieves alloengraftment without toxic or myelosuppressive host conditioning. B6 mice received depleting anti-CD4 and anti-CD8 monoclonal antibodies, local thymic irradiation, and a high-dose (174 x 10(6)) of major histocompatibility (MHC)-mismatched B10.A bone marrow cells (BMCs) divided over days 0 through 4. High levels of donor cells were observed among white blood cells (WBCs) of all lineages. Permanent, multilineage mixed chimerism; donor-specific skin-graft tolerance; and in vitro tolerance were observed in most animals. Large numbers of donor class IIhigh cells were detected in thymuses of long-term chimeras, and their presence was associated with intrathymic deletion of donor-reactive host thymocytes. The treatment was not associated with significant myelosuppression, toxicity, or graft-versus-host disease (GVHD). Thus, high levels of allogeneic stem-cell engraftment can be achieved without myelosuppressive host conditioning. As stem-cell mobilization(2) and in vitro culture techniques' have increased the feasibility of administering high doses of hematopoietic cells to humans, this approach brings hematopoietic cell transplantation closer to clinical use for the induction of central deletional T-cell tolerance.			Sykes, M (corresponding author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,TRANSPLANTAT BIOL RES CTR,SURG SERV,MGH E,BOSTON,MA 02129, USA.			Szot, Gregory/0000-0002-3921-049X	NHLBI NIH HHS [R01-HL-49915, R01-HL-18646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; Hayashi H, 1996, BONE MARROW TRANSPL, V18, P285; KAUFMAN CL, 1994, BLOOD, V84, P2436; Lee LA, 1996, TRANSPLANTATION, V61, P125, DOI 10.1097/00007890-199601150-00024; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; OREILLY RJ, 1985, TRANSPLANT P, V17, P455; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCOLLAY R, 1980, J IMMUNOL, V124, P2845; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHERMAN LA, 1981, IMMUNOGENETICS, V12, P183, DOI 10.1007/BF01561661; Shizuru J A, 1996, Biol Blood Marrow Transplant, V2, P3; STEWART FM, 1993, BLOOD, V81, P2566; SYKES M, 1988, J IMMUNOL, V140, P2903; SYKES M, 1990, J EXP MED, V171, P645, DOI 10.1084/jem.171.3.645; Tomita Y, 1996, TRANSPLANTATION, V61, P477, DOI 10.1097/00007890-199602150-00028; TOMITA Y, 1994, J IMMUNOL, V153, P1087; Tomita Y, 1996, TRANSPLANTATION, V61, P469, DOI 10.1097/00007890-199602150-00027; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WATANABE M, 1983, TRANSPLANTATION, V36, P712, DOI 10.1097/00007890-198336060-00025	30	261	269	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					783	787		10.1038/nm0797-783	http://dx.doi.org/10.1038/nm0797-783			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212108				2022-12-27	WOS:A1997XG76700041
J	Breslow, JL				Breslow, JL			Cardiovascular disease burden increases, NIH funding decreases	NATURE MEDICINE			English	Editorial Material											Breslow, JL (corresponding author), ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Breslow, Jan L/B-7544-2008						0	91	102	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					600	601		10.1038/nm0697-600	http://dx.doi.org/10.1038/nm0697-600			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176478				2022-12-27	WOS:A1997XB97400021
J	DeSanctis, GT; Itoh, A; Green, FHY; Qin, SX; Kimura, T; Grobholz, JK; Martin, TR; Maki, T; Drazen, JM				DeSanctis, GT; Itoh, A; Green, FHY; Qin, SX; Kimura, T; Grobholz, JK; Martin, TR; Maki, T; Drazen, JM			T-lymphocytes regulate genetically determined airway hyperresponsiveness in mice	NATURE MEDICINE			English	Article							MAST-CELLS; ASTHMA; EOSINOPHILS; HYPERSENSITIVITY; RESPONSES; ALLERGEN; MEDIATE	Airway hyperresponsiveness (AHR) is a hallmark of asthma(1) and a heritable polygenic trait in the mouse(2). In the mouse, candidate gene products of hematopoietic origin implicated in asthma mapped to the regions of the previously defined quantitative trait loci(2). Since hematopoietic cells(3-5) have been implicated in the pathogenesis of asthma, we evaluated the role of hematopoietic cells in general and T cells specifically in the genetic modulation of native airway responsiveness in mice. Here, with the use of bone marrow transplantation, anti-T-cell monoclonal antibody treatment and T-cell transfer, we demonstrate that intrinsic non-atopic AHR is mediated by T lymphocytes. Our data support the novel concept that, in the absence of identified environmental influences, T cells enhance genetically determined airway responsiveness.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,COMBINED PROGRAM PULMONARY & CRIT CARE MED,BOSTON,MA 02115; UNIV CALGARY,RESP RES GRP,CALGARY,AB T2N 4N1,CANADA; LEUKOSITE INC,CAMBRIDGE,MA 02142; CHILDRENS HOSP,DEPT PEDIAT,BOSTON,MA 02115; BETH ISRAEL DEACONESS MED CTR,DEPT SURG,DIV ORGAN TRANSPLANTAT,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Calgary; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center			Drazen, Jeffrey M/E-5841-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36110] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BUSSE WW, 1992, ANN ALLERGY, V68, P286; CALVO M, 1994, J INVEST ALLERG CLIN, V4, P126; CHANG TL, 1990, J IMMUNOL, V145, P2803; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; MOORE MW, 1995, SCIENCE, V269, P1590; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; RENZ H, 1993, J IMMUNOL, V151, P1907; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; WALKER C, 1991, INT ARCH ALLER A IMM, V94, P241, DOI 10.1159/000235370	18	97	97	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					460	462		10.1038/nm0497-460	http://dx.doi.org/10.1038/nm0497-460			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095183				2022-12-27	WOS:A1997WQ82500039
J	Rehermann, B; Ferrari, C; Pasquinelli, C; Chisari, FV				Rehermann, B; Ferrari, C; Pasquinelli, C; Chisari, FV			The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CELL MEMORY; NUCLEOCAPSID ANTIGEN; EXPRESSION; INFECTION; DNA; REACTIVATION; TRANSMISSION; RECOGNIZE; EPITOPES	It is widely believed that the hepatitis B virus (HBV) is completely cleared by antiviral antibodies and specific cytotoxic T lymphocytes (CTLs) during acute viral hepatitis. We now demonstrate that traces of HBV are often detectable in the blood for many years after clinical recovery from acute hepatitis, despite the presence of serum antibodies and HBV-specific CTLs, which can be present at acute-stage levels. The strength of the CTL response to HBV following clinical recovery correlates with persistence of HBV DNA. It is of particular interest that HBV-specific CTLs from patients studied up to 23 years after clinical and serological recovery expressed activation markers (HLA-DR, CD69) indicating recent contact with antigen, These results suggest that sterilizing immunity to HBV frequently fails to occur after recovery from acute hepatitis and that traces of virus can maintain the CTL response for decades following clinical recovery, apparently creating a negative feedback loop that keeps the virus under control, perhaps for life.	UNIV PARMA, CATTEDRA MALATTIE INFETT, I-43100 PARMA, ITALY; AZIENDA OSPED PARMA, DIV MALATTIE INFETT, I-43100 PARMA, ITALY	University of Parma; University of Parma; University Hospital of Parma	Rehermann, B (corresponding author), SCRIPPS RES INST, DEPT MOL & EXPT MED, SBR 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ferrari, Carlo/D-5663-2017; Chisari, Francis V/A-3086-2008	Ferrari, Carlo/0000-0002-5461-6842; Chisari, Francis/0000-0002-4832-1044; Ferrari, Carlo/0000-0002-7843-4963; Rehermann, Barbara/0000-0001-6832-9951	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020001] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI 20001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445; BONINO F, 1981, HEPATOLOGY, V1, P386, DOI 10.1002/hep.1840010503; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; FAZEKAS D, 1982, J IMMUNOL METHODS, V49, pR11; GILLES PN, 1992, J VIROL, V66, P3955, DOI 10.1128/JVI.66.6.3955-3960.1992; GUILHOT S, 1992, J VIROL, V66, P2670, DOI 10.1128/JVI.66.5.2670-2678.1992; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MADSEN M, 1979, J IMMUNOL METHODS, V27, P61, DOI 10.1016/0022-1759(79)90239-4; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MARTIN BA, 1995, BONE MARROW TRANSPL, V15, P145; MCIVOR C, 1994, ANN INTERN MED, V121, P274, DOI 10.7326/0003-4819-121-4-199408150-00007; MICHALAK TI, 1994, J CLIN INVEST, V93, P230, DOI 10.1172/JCI116950; MISSALE G, 1993, J EXP MED, V177, P751, DOI 10.1084/jem.177.3.751; Muellbacher A., 1994, Journal of Experimental Medicine, V179, P317; NAYERSINA R, 1993, J IMMUNOL, V150, P4659; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; PREISLERADAMS S, 1993, ARCH VIROL, V133, P385, DOI 10.1007/BF01313777; Rehermann B, 1996, J CLIN INVEST, V97, P1655, DOI 10.1172/JCI118592; REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCOTTO J, 1983, HEPATOLOGY, V3, P279; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; THIERS V, 1988, LANCET, V2, P1273; WACHS ME, 1995, TRANSPLANTATION, V59, P230	30	646	667	1	26	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1104	1108		10.1038/nm1096-1104	http://dx.doi.org/10.1038/nm1096-1104			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837608				2022-12-27	WOS:A1996VK99500030
J	VanCott, JL; Chatfield, SN; Roberts, M; Hone, DM; Hohmann, EL; Pascual, DW; Yamamoto, M; Kiyono, H; McGhee, JR				VanCott, JL; Chatfield, SN; Roberts, M; Hone, DM; Hohmann, EL; Pascual, DW; Yamamoto, M; Kiyono, H; McGhee, JR			Regulation of host immune responses by modification of Salmonella virulence genes	NATURE MEDICINE			English	Article							NITRIC-OXIDE PRODUCTION; ALPHA-BETA; PHOP-PHOQ; ATTENUATED SALMONELLA; TYPHIMURIUM INFECTION; T-CELLS; MICE; MACROPHAGES; RESISTANCE; RECEPTOR	Modifying bacterial virulence genes to probe the nature of host immunity is mostly unexplored. Here we investigate whether host immune responses can be regulated by modification of bacterial virulence genes. In mice, attenuated Salmonella mutant strains with clinical relevance elicited differential host immune responses. Oral administration of a mutant strain with a PhoP-null phenotype promoted potent innate immune responses of macrophages that were sufficient for host defense. In contrast, administration of an Aro(-) mutant strain elicited stronger specific antibody and T-helper (Th)-cell responses, wherein Th1-type cells were required for clearance. Thus, genetic manipulation of bacteria may be used to broadly alter immune mechanisms that regulate attenuation within the host and to tailor host immunity to specific bacterial pathogens.	Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, MEDEVA, Vaccine Res Unit, London SW7 2AY, England; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Montana State Univ, Bozeman, MT 59717 USA; Osaka Univ, Microbial Dis Res Inst, Dept Mucosal Immun, Suita, Osaka 565, Japan; Univ Alabama Birmingham, Immunobiol Vaccine Ctr, Dept Microbiol, Birmingham, AL 35294 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Imperial College London; University of Glasgow; University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; Montana State University System; Montana State University Bozeman; Osaka University; University of Alabama System; University of Alabama Birmingham	VanCott, JL (corresponding author), Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.		Pascual, David/AAC-2248-2022; Kiyono, Hiroshi/AAC-6735-2022		NCRR NIH HHS [RR 13149] Funding Source: Medline; NIAID NIH HHS [AI 18958] Funding Source: Medline; NIDDK NIH HHS [DK 44240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALRAMADI BK, 1991, J IMMUNOL, V146, P2737; ALRAMADI BK, 1992, EUR J IMMUNOL, V22, P2249, DOI 10.1002/eji.1830220911; CHATFIELD SN, 1992, MICROB PATHOGENESIS, V12, P145, DOI 10.1016/0882-4010(92)90117-7; CHATFIELD SN, 1992, BIO-TECHNOL, V10, P888, DOI 10.1038/nbt0892-888; Cowley SC, 1996, MOL MICROBIOL, V20, P867, DOI 10.1111/j.1365-2958.1996.tb02524.x; CURTISS R, 1987, INFECT IMMUN, V55, P3035, DOI 10.1128/IAI.55.12.3035-3043.1987; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; EDWARDS CK, 1992, INFECT IMMUN, V60, P2514, DOI 10.1128/IAI.60.6.2514-2521.1992; Eisenstein TK, 1998, VACCINE, V16, P24, DOI 10.1016/S0264-410X(97)00160-6; Fujihashi K, 1998, METHOD MICROBIOL, V25, P257; GALAN JE, 1989, MICROB PATHOGENESIS, V6, P433, DOI 10.1016/0882-4010(89)90085-5; GANGADHARAM PRJ, 1984, AM REV RESPIR DIS, V130, P834; Gotschlich Emil C., 1993, P1287; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hess J, 1996, J IMMUNOL, V156, P3321; Hohmann EL, 1996, VACCINE, V14, P19, DOI 10.1016/0264-410X(95)00173-X; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Levine MM, 1996, J BIOTECHNOL, V44, P193, DOI 10.1016/0168-1656(95)00094-1; LISSNER CR, 1983, J IMMUNOL, V131, P3006; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1991, MOL MICROBIOL, V5, P2073, DOI 10.1111/j.1365-2958.1991.tb02135.x; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Pawelek JM, 1997, CANCER RES, V57, P4537; Snapper Clifford M., 1993, P837; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SZALAI AJ, 1995, J IMMUNOL, V155, P2557; TACKET CO, 1992, INFECT IMMUN, V60, P536, DOI 10.1128/IAI.60.2.536-541.1992; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; Umezawa K, 1997, INFECT IMMUN, V65, P2932, DOI 10.1128/IAI.65.7.2932-2940.1997; VanCott JL, 1996, J IMMUNOL, V156, P1504; VANCOTT JL, 1995, MUCOSAL IMMUNOL UPDA, V34, P12; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; Weintraub BC, 1997, INFECT IMMUN, V65, P2306, DOI 10.1128/IAI.65.6.2306-2312.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANG JF, 1995, J IMMUNOL, V155, P5728	43	111	119	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1247	1252		10.1038/3227	http://dx.doi.org/10.1038/3227			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809547	Bronze			2022-12-27	WOS:000076731000032
J	During, MJ; Xu, RL; Young, D; Kaplitt, MG; Sherwin, RS; Leone, P				During, MJ; Xu, RL; Young, D; Kaplitt, MG; Sherwin, RS; Leone, P			Peroral gene therapy of lactose intolerance using an adeno-associated virus vector	NATURE MEDICINE			English	Article							LACTASE-PHLORIZIN HYDROLASE; ADULT-TYPE HYPOLACTASIA; IN-VIVO; EXPRESSION; BRAIN; MILK	Gene therapy is usually reserved for severe and medically refractory disorders because of the toxicity, potential long-term risks and invasiveness of most gene transfer protocols. Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a beta-galactosidase transgene in both gut epithelial and lamina propria cells, and that this approach results in long-term phenotypic recovery in an animal model of lactose intolerance. A gene 'pill' associated with highly efficient and stable gene expression might be a practical and cost-effective strategy for even relatively mild disorders, such as lactase deficiency.	Univ Auckland, Sch Med, Dept Mol Med, Auckland, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, CNS Gene Therapy Ctr, Philadelphia, PA 19107 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; Rockefeller Univ, Dept Neurobiol, New York, NY 10021 USA	University of Auckland; Jefferson University; Yale University; Yale University; Rockefeller University	During, MJ (corresponding author), Univ Auckland, Sch Med, Dept Mol Med, 85 Park Rd, Auckland, New Zealand.	Matthew.During@mail.tju.edu	During, Matthew/AAC-1388-2020	Young, Deborah/0000-0003-1085-2824				Berns K I, 1979, Adv Virus Res, V25, P407, DOI 10.1016/S0065-3527(08)60574-6; BIRGE SJ, 1967, NEW ENGL J MED, V276, P445, DOI 10.1056/NEJM196702232760805; BULLER HA, 1989, AM J PHYSIOL, V257, pG616, DOI 10.1152/ajpgi.1989.257.4.G616; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DURING MJ, 1995, J CLIN INVEST, V95, P2403, DOI 10.1172/JCI117935; FLATZ G, 1987, ADV HUM GENET, V16, P1; Honkanen R, 1997, BONE, V21, P473, DOI 10.1016/S8756-3282(97)00172-5; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; LISKER R, 1975, AM J HUM GENET, V27, P662; MAIURI L, 1994, GASTROENTEROLOGY, V107, P54, DOI 10.1016/0016-5085(94)90060-4; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; SAHI T, 1973, LANCET, V2, P823; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SCRIMSHAW N S, 1988, American Journal of Clinical Nutrition, V48, P1083; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SERVICE RF, 1994, SCIENCE, V265, P1522, DOI 10.1126/science.8079164; STALLINGS VA, 1994, J PEDIATR GASTR NUTR, V18, P440, DOI 10.1097/00005176-199405000-00006; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	23	110	130	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1131	1135		10.1038/2625	http://dx.doi.org/10.1038/2625			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771745				2022-12-27	WOS:000076230100031
J	Hall, AR; Dix, BR; O'Carroll, SJ; Braithwaite, AW				Hall, AR; Dix, BR; O'Carroll, SJ; Braithwaite, AW			p53-dependent cell death apoptosis is required for a productive adenovirus infection	NATURE MEDICINE			English	Article							WILD-TYPE P53; GENE; EXPRESSION; P16(INK4); PROTEIN; MUTANT; TRANSACTIVATION; IMMORTALIZATION; INHIBITION; MUTATIONS	The p53 tumor suppressor protein binds to both cellular and viral proteins, which influence its biological activity. One such protein is the large E1b tumor antigen(1) (E1b58kDa) from adenoviruses (Ads), which abrogates the ability of p53 to transactivate various promoters(2). This inactivation of p53 function is believed to be the mechanism by which E1b58kDa contributes to the cell transformation process(2). Although the p53-E1b58kDa complex occurs during infection(3) and is conserved among different serotypes(4), there are limited data demonstrating that it has a role in virus replication. However, loss of p53 expression occurs after adenovirus infection of human cells(4,5) and an E1b58kDa deletion mutant (Onyx-015, also called dl 1520) selectively replicates in p53-defective cells(6,7). These (and other) data indicate a plausible hypothesis is that loss of p53 function may be conducive to efficient adenovirus replication. However, wild-type (wt) Ad5 grows more efficiently in cells expressing a wt p53 protein(5). These studies indicate that the hypothesis may be an oversimplification. Here, we show that cells expressing wt p53, as well as p53-defective cells, allow adenovirus replication, but only cells expressing wt p53 show evidence of virus-induced cytopathic effect. This correlates with the ability of adenovirus to induce cell death. Our data indicate that p53 plays a necessary part in mediating cellular destruction to allow a productive adenovirus infection. In contrast, p53-deficient cells are less sensitive to the cytolytic effects of adenovirus and as such raise questions about the use of E1b58kDa-deficient adenoviruses in tumor therapy(6,7).	Univ Otago, Dunedin Sch Med, Cell Transformat Grp, Dept Pathol, Dunedin, New Zealand	University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Cell Transformat Grp, Dept Pathol, POB 913, Dunedin, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz						ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; EVDOKIOU A, 1997, THESIS U ADELAIDE; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; LEHMAN TA, 1991, CANCER RES, V51, P4090; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PHILIPSON L, 1973, COMPREHENSIVE VIROLO, V3, P143; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Precious B., 1985, VIROLOGY PRACTICAL A, P193; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROMANO JW, 1989, ONCOGENE, V4, P1483; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHARMA S, 1993, MOL CELL BIOL, V12, P5581; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WHITAKER NJ, 1995, ONCOGENE, V11, P971; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	29	212	221	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1068	1072		10.1038/2057	http://dx.doi.org/10.1038/2057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734403				2022-12-27	WOS:000075804100043
J	Kasten, E; Wust, S; Behrens-Baumann, W; Sabel, BA				Kasten, E; Wust, S; Behrens-Baumann, W; Sabel, BA			Computer-based training for the treatment of partial blindness	NATURE MEDICINE			English	Article							RESIDUAL VISION; DEFICITS; RECOVERY	Partial blindness after brain injury has been considered non-treatable. To evaluate whether patients with visual-field defects can profit from computer-based visual restitution training (VRT), two independent clinical trials were conducted using patients with optic nerve (n = 19) or post-chiasmatic brain injury (n = 19). In post-chiasma patients, VRT led to a significant improvement (29.4%) over baseline in the ability to detect visual stimuli; in optic nerve patients, the effects were even more pronounced (73.6% improvement). Visual-field enlargements were confirmed by the observation of a visual-field expansion of 4.9 degrees-5.8 degrees of visual angle and improved acuity in optic nerve patients. Ninety five percent of the VRT-treated patients showed improvements, 72.2% confirmed visual improvements subjectively. Patients receiving a placebo training did not show comparable improvements. In conclusion, VRT with a computer program improves vision in patients with visual-field defects and offers a new, cost-effective therapy for partial blindness.	Univ Magdeburg, Fac Med, Inst Med Psychol, D-39120 Magdeburg, Germany; Univ Magdeburg, Fac Med, Eye Clin, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Sabel, BA (corresponding author), Univ Magdeburg, Fac Med, Inst Med Psychol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Bernhard.Sabel@Medizin.Uni-Magdeburg.DE	Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543; Wust, Stefan/0000-0002-2315-8949				AULHORN E, 1985, SOZIALE INTEGRATION, P368; CHOW KL, 1972, EXP NEUROL, V34, P409, DOI 10.1016/0014-4886(72)90038-6; COWEY A, 1967, Q J EXP PSYCHOL, V19, P232, DOI 10.1080/14640746708400098; EYSEL UT, 1978, BRAIN RES, V158, P107, DOI 10.1016/0006-8993(78)90009-4; FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Kasten E, 1997, SPATIAL VISION, V10, P499, DOI 10.1163/156856897X00456; KASTEN E, 1995, RESTOR NEUROL NEUROS, V8, P113, DOI 10.3233/RNN-1995-8302; KASTEN E, IN PRESS J CLIN EXP; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; Sabel BA, 1997, ADV NEUROL, V73, P251; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Teuber HL., 1960, VISUAL FIELD DEFECTS, DOI [10.4159/harvard.9780674593121, DOI 10.4159/HARVARD.9780674593121]; Wessinger CM, 1997, J COGNITIVE NEUROSCI, V9, P203, DOI 10.1162/jocn.1997.9.2.203; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1060, DOI 10.1152/jn.1965.28.6.1060; Zihl J, 1990, Z NEUROPSYCHOL, V2, P95	19	235	243	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1083	1087		10.1038/2079	http://dx.doi.org/10.1038/2079			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734406				2022-12-27	WOS:000075804100047
J	Sharipo, A; Imreh, M; Leonchiks, A; Imreh, S; Masucci, MG				Sharipo, A; Imreh, M; Leonchiks, A; Imreh, S; Masucci, MG			A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappa B alpha with the proteasome: A new mechanism for selective inhibition of proteolysis	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; SIGNAL-INDUCED PHOSPHORYLATION; DEGRADATION; ACTIVATION; DISSOCIATION; PATHWAY; IDENTIFICATION; SUFFICIENT; ANTIBODIES; PROTEINS	The Epstein-Barr virus nuclear antigen 1 contains a glycine-alanine repeat that inhibits in cis MHC class I-restricted presentation. We report here that insertion of a minimal glycine-alanine repeat motif in different positions of I kappa B alpha protects this NF-kappa B inhibitor from signal-induced degradation dependent on ubiquitin-proteasome, and decreases its basal turnover in vivo resulting in constitutive dominant-negative mutants. The chimeras are phosphorylated and ubiquitinated in response to tumor necrosis factor alpha, but are then released from NF-kappa B and fail to associate with the proteasome. This explains how functionally competent I kappa B alpha is protected from proteasomal disruption and identifies the glycine-alanine repeat as a new regulator of proteolysis.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Kirchenstein Inst Microbiol & Virol, Riga, Latvia	Karolinska Institutet; Riga Stradins University	Masucci, MG (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	maria.masucci@mtc.ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Berg A., 1993, GENE DEV, V7, P2064; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Goldberg AL, 1997, BIOL CHEM, V378, P131; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lin L, 1996, MOL CELL BIOL, V16, P2248; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Oldstone MBA, 1997, VIROLOGY, V234, P179, DOI 10.1006/viro.1997.8674; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; RISE NR, 1993, EMBO J, V12, P4685; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; Thiel BL, 1997, BIOPOLYMERS, V41, P703, DOI 10.1002/(SICI)1097-0282(199706)41:7<703::AID-BIP1>3.0.CO;2-T; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; Yates JL, 1996, VIROLOGY, V222, P1, DOI 10.1006/viro.1996.0392	41	107	111	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					939	944		10.1038/nm0898-939	http://dx.doi.org/10.1038/nm0898-939			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701247				2022-12-27	WOS:000075107400038
J	Blower, SM; Porco, TC; Darby, G				Blower, SM; Porco, TC; Darby, G			Predicting and preventing the emergence of antiviral drug resistance in HSV-2	NATURE MEDICINE			English	Article							HERPES-SIMPLEX VIRUS; GENITAL HERPES; TUBERCULOSIS EPIDEMICS; CONTROLLED TRIAL; ORAL ACYCLOVIR; TRANSMISSION; INFECTION; SUPPRESSION; FREQUENCY; TYPE-2	Genital herpes, caused by herpes simplex virus, is the most prevalent sexually transmitted disease worldwide. in many developing countries genital herpes is untreated, and in the United States only 10% of cases are treated. We present a mathematical model that we use as a health policy tool to predict the levels of antiviral drug resistance that would emerge, if treatment rates were increased, and to identify the key factors in determining the emergence of drug resistance. We use our results to suggest control measures for herpes epidemics that would prevent the emergence of substantial levels of antiviral drug resistance.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Univ Calif San Francisco, Dept Med, HSE, San Francisco, CA 94143 USA	GlaxoSmithKline; University of California System; University of California San Francisco	Blower, SM (corresponding author), Dept Publ Hlth, AIDS Off, 25 van Ness,Suite 500, San Francisco, CA 94102 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER; NIDA NIH HHS [R29DA08153] Funding Source: Medline; PHS HHS [R01-09531] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRY DW, 1985, SCAND J INFECT DIS, P155; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; BLOWER SM, IN PRESS J MOL MED; Collins P., 1991, REV MED VIROL, V1, P19; DARBY G, 1981, NATURE, V289, P81, DOI 10.1038/289081a0; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; IMAN RL, 1988, RISK ANAL, V8, P71, DOI 10.1111/j.1539-6924.1988.tb01155.x; KAPLAN E, IN PRESS HDB HIV PRE; KOST RG, 1993, NEW ENGL J MED, V329, P1777, DOI 10.1056/NEJM199312093292405; LARDER BA, 1985, VIROLOGY, V146, P262, DOI 10.1016/0042-6822(85)90009-1; Marchant J, 1997, HERPES J, V4, P36; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; PORCO TC, IN PREESS IMA J MATH; PORCO TC, IN PRESS THEOR POPUL; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Safrin S, 1997, REV MED VIROL, V7, P145, DOI 10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; WADE JC, 1983, J INFECT DIS, V148, P1077, DOI 10.1093/infdis/148.6.1077; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; WILDY P, 1982, SOC GENERAL MICROBIO, V33, P133	36	101	103	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1998	4	6					673	678		10.1038/nm0698-673	http://dx.doi.org/10.1038/nm0698-673			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623975				2022-12-27	WOS:000074008300032
J	Cheynier, R; Gratton, S; Halloran, M; Stahmer, I; Letvin, NL; Wain-Hobson, S				Cheynier, R; Gratton, S; Halloran, M; Stahmer, I; Letvin, NL; Wain-Hobson, S			Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTED RHESUS-MONKEYS; IMMUNE ACTIVATION; T-LYMPHOCYTES; CELLS; HIV; PATHOGENESIS; INDIVIDUALS; INFLUENZA; DNA	The impact of antigenic stimulation on the dynamics of simian immunodeficiency virus (SIV) replication was studied following repeated intravenous BCC inoculation of a SIV infected macaque. At the site of a delayed type hypersensitivity reaction to purified protein derivative of M. tuberculosis, a distinctive SIV variant was noted, probably as a result of the infiltration of activated antigen-specific T cell clones as opposed to infection by blood borne virus in situ. The dynamics of SIV quasispecies in peripheral blood suggests sequential waves of viral replication, illustrating the role of antigenic stimulation as a driving force in viral dissemination and pathogenesis.	Inst Pasteur, Unite Retrovirol Mol, F-75724 Paris 15, France; Harvard Univ, Sch Med, Div Viral Pathogenesis, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Cheynier, R (corresponding author), Inst Pasteur, Unite Retrovirol Mol, 28 Rue Dr Roux, F-75724 Paris 15, France.		Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X	NIAID NIH HHS [AI-20729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020729, R01AI020729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bandelt HJ, 1992, MOL PHYLOGENET EVOL, V1, P242, DOI 10.1016/1055-7903(92)90021-8; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; BLEAVINS MR, 1995, TOXICOLOGY, V95, P103, DOI 10.1016/0300-483X(95)90402-6; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHEN ZW, 1993, J IMMUNOL, V151, P2177; CHEN ZW, 1992, J VIROL, V66, P3913, DOI 10.1128/JVI.66.6.3913-3917.1992; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Cheynier R, 1996, IMMUNOGENETICS, V43, P83; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; Dittmer U, 1997, J GEN VIROL, V78, P2523, DOI 10.1099/0022-1317-78-10-2523; DOPAZO J, 1993, P NATL ACAD SCI USA, V90, P10320, DOI 10.1073/pnas.90.21.10320; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; Galai N, 1997, LANCET, V349, P180, DOI 10.1016/S0140-6736(05)60982-8; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Gerna G, 1998, AIDS, V12, P118; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KURAMOTO Y, 1993, CLIN EXP DERMATOL, V18, P111, DOI 10.1111/j.1365-2230.1993.tb00989.x; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MCILROY D, 1995, J VIROL, V69, P4737, DOI 10.1128/JVI.69.8.4737-4745.1995; OBRIEN WA, 1995, BLOOD, V86, P1082; PELLETIER E, 1995, VIROLOGY, V208, P644, DOI 10.1006/viro.1995.1195; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PILKINGTON C, 1993, ARCH DIS CHILD, V69, P644, DOI 10.1136/adc.69.6.644; Ravn P, 1997, J IMMUNOL, V158, P1949; ROTA S, 1994, EUR J EPIDEMIOL, V10, P713, DOI 10.1007/BF01719287; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; STANLEY SK, 1996, NEW ENGL J MED, V334, P122; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	38	41	42	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					421	427		10.1038/nm0498-421	http://dx.doi.org/10.1038/nm0498-421			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546787				2022-12-27	WOS:000072906800036
J	Martins, VR; Graner, E; Garcia-Abreu, J; de Souza, SJ; Mercadante, AF; Veiga, SS; Zanata, SM; Neto, VM; Brentani, RR				Martins, VR; Graner, E; Garcia-Abreu, J; de Souza, SJ; Mercadante, AF; Veiga, SS; Zanata, SM; Neto, VM; Brentani, RR			Complementary hydropathy identifies a cellular prion protein receptor	NATURE MEDICINE			English	Article							GLUTATHIONE-S-TRANSFERASE; CLATHRIN-COATED PITS; MOLECULAR-BIOLOGY; SCRAPIE; FIBRONECTIN; DISEASES; CELLS; POLYPEPTIDES; ENDOCYTOSIS; PEPTIDES	Prions, the etiological agents for infectious degenerative encephalopathies, act by entering the cell and inducing conformational changes in PrPc (a normal cell membrane sialoglycoprotein), which result in cell death. A specific cell-surface receptor to mediate PrPc and prion endocytosis has been predicted. Complementary hydropathy let us generate a hypothetical peptide mimicking the receptor binding site. Antibodies raised against this peptide stain the surface of mouse neurons and recognize a 66-kDa membrane protein that binds PrPc both in vitro and in vivo. Furthermore, both the complementary prion peptide and antiserum against it inhibit the toxicity of a prion-derived peptide toward neuronal cells in culture. Such reagents might therefore have therapeutic applications.	Ludwig Inst Canc Res, BR-01509010 Sao Paulo, Brazil; Fundacao Antonio Prudente, BR-01509010 Sao Paulo, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, BR-21949900 Rio de Janeiro, Brazil	Ludwig Institute for Cancer Research; A.C.Camargo Cancer Center; Universidade Federal do Rio de Janeiro	Brentani, RR (corresponding author), Ludwig Inst Canc Res, Rua Prof Antonio Prudente,109-4A, BR-01509010 Sao Paulo, Brazil.		Graner, Edgard/K-4411-2012; Moura-Neto, VIVALDO/V-9913-2019; Abreu, Jose G/ABB-1199-2021; Martins, Vilma/N-5446-2019; Mercadante, Adriana Frohlich/AAG-7099-2020; Veiga, Silvio Sanches/C-2194-2013; Zanata, Silvio/AAC-9670-2021; de Souza, Sandro Jose/AAG-6270-2020; Martins, Vilma R/E-2547-2012; Abreu, Jose G/G-6159-2010; Graner, Edgard/P-4651-2019	Graner, Edgard/0000-0002-4737-7935; Moura-Neto, VIVALDO/0000-0002-6266-043X; Abreu, Jose G/0000-0002-1363-1755; Veiga, Silvio Sanches/0000-0002-9691-1225; Zanata, Silvio/0000-0003-2818-6954; Martins, Vilma R/0000-0002-2909-8502; Abreu, Jose G/0000-0002-9875-7786; 				ARVAN P, 1983, METHOD ENZYMOL, V98, P75; ASKANAS V, 1993, NEUROSCI LETT, V159, P111, DOI 10.1016/0304-3940(93)90811-X; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BASTER K, 1986, CELL, V46, P417; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRENTANI RR, 1990, J MOL EVOL, V31, P239, DOI 10.1007/BF02109501; BRENTANI RR, 1988, J THEOR BIOL, V135, P495, DOI 10.1016/S0022-5193(88)80272-8; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GARCIAABREU J, 1995, J NEUROSCI RES, V40, P471, DOI 10.1002/jnr.490400406; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDGABER D, 1991, NATURE, V351, P106, DOI 10.1038/351106a0; HALFTER W, 1989, EUR J NEUROSCI, V1, P297, DOI 10.1111/j.1460-9568.1989.tb00797.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; NETO VM, 1983, EMBO J, V2, P1243, DOI 10.1002/j.1460-2075.1983.tb01576.x; OESCH B, 1994, PHILOS T R SOC B, V343, P443, DOI 10.1098/rstb.1994.0042; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUZA S J D, 1992, Journal of Biological Chemistry, V267, P13763; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	32	156	158	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1376	1382		10.1038/nm1297-1376	http://dx.doi.org/10.1038/nm1297-1376			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396608				2022-12-27	WOS:000072249500034
J	Ram, Z; Culver, KW; Oshiro, EM; Viola, JJ; DeVroom, HL; Otto, E; Long, ZF; Chiang, Y; McGarrity, GEJ; Muul, LM; Katz, D; Blaese, RM; Oldfield, EH				Ram, Z; Culver, KW; Oshiro, EM; Viola, JJ; DeVroom, HL; Otto, E; Long, ZF; Chiang, Y; McGarrity, GEJ; Muul, LM; Katz, D; Blaese, RM; Oldfield, EH			Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells	NATURE MEDICINE			English	Article							THYMIDINE KINASE GENE; EXPERIMENTAL GLIOMAS; RAT-BRAIN; IN-VIVO; TRANSDUCTION; REGRESSION; GANCICLOVIR; INVIVO	Intratumoral implantation of murine cells modified to produce retroviral vectors containing the herpes simplex virus-thymidine kinase (HSV-TK) gene induces regression of experimental brain tumors in rodents after ganciclovir (GCV) administration. We evaluated this approach in 15 patients with progressive growth of recurrent malignant brain tumors. Antitumor activity was detected in five of the smaller tumors (1.4 +/- 0.5 ml). In situ hybridization for HSV-TK demonstrated survival of vector-producing cells (VPCs) at 7 days but indicated limited gene transfer to tumors, suggesting that indirect, "bystander," mechanisms provide local antitumor activity in human tumors. However, the response of only very small tumors in which a high density of vector-producing cells had been placed suggests that techniques to improve delivery and distribution of the therapeutic gene will need to be developed if clinical utility is to be achieved with this approach.	NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA; NCI, Metab Branch, Bethesda, MD 20892 USA; Genet Therapy Inc, Gaithersburg, MD USA; Natl Ctr Human Genome Res, Clin Gene Therapy Branch, Bethesda, MD 20892 USA; NINDS, Off Clin Director, Bethesda, MD 20892 USA; NINDS, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Oldfield, EH (corresponding author), NINDS, Surg Neurol Branch, Bldg 36,Rm 4D04,10-5D37,10 Ctr Dr, Bethesda, MD 20892 USA.							BARBA D, 1993, J NEUROSURG, V79, P729, DOI 10.3171/jns.1993.79.5.0729; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; BOVIATSIS E, 1994, CANCER RES, V15, P5745; BURGER P, 1994, ATLAS TUMOR PATHOL, P59; Burger PC, 1991, SURG PATHOLOGY NERVO; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FREEMAN SM, 1993, CANCER RES, V53, P5274; HAAPALA DK, 1985, J VIROL, V58, P327; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; IshiiMorita H, 1997, GENE THER, V4, P244, DOI 10.1038/sj.gt.3300379; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; LYONS RM, 1995, CANCER GENE THER, V2, P273; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEREZCRUET MJ, 1994, J NEUROSCI RES, V39, P506, DOI 10.1002/jnr.490390417; RAM Z, 1993, CANCER RES, V53, P83; RAM Z, 1994, J NEUROSURG, V81, P256, DOI 10.3171/jns.1994.81.2.0256; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; WU JK, 1994, NEUROSURGERY, V35, P1094, DOI 10.1227/00006123-199412000-00012	29	569	581	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1354	1361		10.1038/nm1297-1354	http://dx.doi.org/10.1038/nm1297-1354			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396605				2022-12-27	WOS:000072249500031
J	Mazzoli, S; Trabattoni, D; Caputo, SL; Piconi, S; Ble, C; Meacci, F; Ruzzante, S; Salvi, A; Semplici, F; Longhi, R; Fusi, ML; Tofani, N; Biasin, M; Villa, ML; Mazzotta, F; Clerici, M				Mazzoli, S; Trabattoni, D; Caputo, SL; Piconi, S; Ble, C; Meacci, F; Ruzzante, S; Salvi, A; Semplici, F; Longhi, R; Fusi, ML; Tofani, N; Biasin, M; Villa, ML; Mazzotta, F; Clerici, M			HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY SERUM NEGATIVITY; CD8(+) T-CELLS; SEXUAL TRANSMISSION; RHESUS MACAQUES; HOMOSEXUAL MEN; INFECTION; VACCINE; TYPE-1; RESPONSES	HIV-specific mucosal and cellular immunity was analyzed in heterosexual couples discordant for HIV status in serum and in HIV-unexposed controls. HIV-specific IgA but not IgG was present in urine and vaginal wash samples from HIV-exposed seronegative individuals (ESN), whereas both IgA and IgG were observed in their HIV-seropositive partners; antibodies were not detected in low-risk controls. Envelope protein (Env) peptide-stimulated interleukin-2 (IL-2) production by peripheral blood mononuclear cells (PBMCs) was detected in 9 out of 16 ESNs, 5 out of 16 HIV-infected patients and 1 out of 50 controls. Env peptide-stimulated PBMCs of ESNs produced more IL-2 and less IL-10 compared with those of HIV-infected individuals; no differences were observed in chemokine production or in CCR5 expression. These data demonstrate that a compartmentalized immune response to pathogens is possible in humans and raise the possibility of protective roles for cell-mediated immunity and mucosal IgA in HIV-seronegative individuals exposed to HIV.	UNIV MILAN, PADIGL LITA, CATTEDRA IMMUNOL, I-20157 MILAN, ITALY; OSPED SM ANNUNZIATA, ASL 10, CTR MST UO MALATTIE INFETT, I-50100 FLORENCE, ITALY; OSPED L SACCO, DIV MALATTIE INFETT 1, I-21057 MILAN, ITALY; CNR, IST CHIM ORMONI, I-20131 MILAN, ITALY	University of Milan; University of Milan; Luigi Sacco Hospital; Consiglio Nazionale delle Ricerche (CNR)			Trabattoni, Daria/G-7424-2012; biasin, mara/G-7426-2012	Trabattoni, Daria/0000-0001-9535-3359; biasin, mara/0000-0003-3671-4235; Lo Caputo, Sergio/0000-0002-4729-7548; Mazzoli, Sandra/0000-0002-6266-5492; Clerici, Mario/0000-0001-5920-6191				ALEXANDER NJ, 1990, FERTIL STERIL, V54, P1; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BELEC L, 1994, LANCET, V343, P1046, DOI 10.1016/S0140-6736(94)90168-6; BUKAWA H, 1995, NAT MED, V1, P681, DOI 10.1038/nm0795-681; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLARICI M, 1994, JAMA-J AM MED ASSOC, V271, P42; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; Clerici M, 1996, AIDS, V10, P1432, DOI 10.1097/00002030-199610000-00019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296; EMILIE D, 1992, J BIOL CHEM, V267, P20565; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; GIORGI JV, 1987, J IMMUNOL, V138, P3725; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HILLEMAN MR, 1995, NAT MED, V1, P1126, DOI 10.1038/nm1195-1126; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1297; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Lehner T, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P437, DOI 10.1016/B978-012394330-9/50033-8; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; Mazzoli S, 1996, Infect Dis Obstet Gynecol, V4, P136; MCKENZIE SW, 1996, AIDS, V10, P29; Miller C. J., 1992, Laboratory Investigation, V68, P129; Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PECKHAM CS, 1991, LANCET, V337, P253; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; SALVATO MS, 1994, J MED PRIMATOL, V23, P125, DOI 10.1111/j.1600-0684.1994.tb00112.x; SHAFFERMAN A, 1989, AIDS RES HUM RETROV, V5, P33, DOI 10.1089/aid.1989.5.33; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; STAATS HF, 1996, IMMUNOLOGY HIV INFEC, P387; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; TURNER V, 1993, BIOTECHNOLOGY, V11, P696; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; URNOVITZ HB, 1993, LANCET, V342, P1458, DOI 10.1016/0140-6736(93)92934-L; Urnovitz HB, 1996, TRENDS BIOTECHNOL, V14, P361, DOI 10.1016/0167-7799(96)10048-2; *WHO, 1995, WEEKLY EPIDEMIOL REC, V70, P5; Zeitz M, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P421, DOI 10.1016/B978-012394330-9/50032-6	54	363	374	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1250	1257		10.1038/nm1197-1250	http://dx.doi.org/10.1038/nm1197-1250			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359700				2022-12-27	WOS:A1997YD89600034
J	Sommer, A				Sommer, A			Clinical research and the human condition: Moving from observation to practice	NATURE MEDICINE			English	Editorial Material							VITAMIN-A SUPPLEMENTATION; TRIAL; MORTALITY; CHILDREN; MEASLES				Sommer, A (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, 615 N WOLFE ST SUITE 1041, BALTIMORE, MD 21205 USA.							BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; Beaton G. H., 1992, EFFECTIVENESS VITAMI; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; Ellison JB, 1932, BRIT MED J, V1932, P708, DOI 10.1136/bmj.2.3745.708; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KEUSCH GT, 1990, NEW ENGL J MED, V323, P985, DOI 10.1056/NEJM199010043231408; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; Sommer A., 1995, VITAMIN A DEFICIENCY, V3rd; Sommer A., 1996, VITAMIN A DEFICIENCY, P19; TARWOTJO I, 1987, AM J CLIN NUTR, V45, P1466, DOI 10.1093/ajcn/45.6.1466; *WHO, 1982, TECH REP SER, V672; 1987, WEEKLY EPIDEMIOLOGIC, V62, P133	13	12	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1997	3	10					1061	1063		10.1038/nm1097-1061	http://dx.doi.org/10.1038/nm1097-1061			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334706				2022-12-27	WOS:A1997XZ28700020
J	Tsurumi, Y; Murohara, T; Krasinski, K; Chen, DF; Witzenbichler, B; Kearney, M; Couffinhal, T; Isner, JM				Tsurumi, Y; Murohara, T; Krasinski, K; Chen, DF; Witzenbichler, B; Kearney, M; Couffinhal, T; Isner, JM			Reciprocal relation between VEGF and NO in the regulation of endothelial integrity	NATURE MEDICINE			English	Article							VASCULAR-PERMEABILITY FACTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR VEGF; HYPOXIC INDUCTION; PROTEIN-KINASE; ANGIOGENESIS; EXPRESSION; BINDING; ARTERIES; RECEPTOR	Balloon angioplasty disrupts the protective endothelial lining of the arterial wall, rendering arteries susceptible to thrombosis and intimal thickening. We show here that Vascular endothelial growth factor (VEGF), an endothelial cell mitogen, is upregulated in medial smooth muscle cells of the arterial wall in response to balloon injury. Both protein kinase C (PKC) and tyrosine kinase pp60(src) mediate augmented VEGF expression. In contrast, nitric oxide (NO) donors inhibit PKC-induced VEGF upregulation by interfering with binding of the transcription factor activator protein-1 (AP-1) to the VEGF promoter. Inhibition of VEGF promoter activation suggests that NO secreted by a restored endothelium functions as the negative feedback mechanism that downregulates VEGF expression to basal levels. Administration of a neutralizing VEGF antibody impaired reendothelialization following balloon injury performed in vivo. These findings establish a reciprocal relation between VEGF and NO in the endogenous regulation of endothelial integrity following arterial injury.	TUFTS UNIV,ST ELIZABETHS MED CTR BOSTON,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS MED CTR BOSTON,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University			Witzenbichler, Bernhard/ABC-2525-2021; Couffinhal, Thierry/M-6857-2014; Murohara, Toyoaki/M-4958-2014	Couffinhal, Thierry/0000-0002-9217-2533; 	NHLBI NIH HHS [HL 02824, HL 40518, HL 57516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL040518, K07HL002824] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Asahara T, 1996, CIRCULATION, V94, P3291, DOI 10.1161/01.CIR.94.12.3291; ASAHARA T, 1997, SCIENCE, V275, P965; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BROCK TA, 1991, AM J PATHOL, V138, P213; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Couffinhal T, 1997, AM J PATHOL, V150, P1673; COUFFINHAL T, 1996, CIRCULATION, V94; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLUGELMAN MY, 1993, CIRCULATION, V88, P2493, DOI 10.1161/01.CIR.88.6.2493; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOCH AE, 1994, J IMMUNOL, V152, P4149; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; Lee SL, 1996, AM J PHYSIOL-LUNG C, V270, pL362, DOI 10.1152/ajplung.1996.270.3.L362; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LIU MY, 1995, AM J PHYSIOL-LUNG C, V268, pL729, DOI 10.1152/ajplung.1995.268.5.L729; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LUSCHER TF, 1993, ANNU REV MED, V44, P395, DOI 10.1146/annurev.med.44.1.395; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; PARK JE, 1994, J BIOL CHEM, V269, P25646; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SAFFITZ JE, 1996, CIRCULATION, V94, P1; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Takeshita S, 1996, LAB INVEST, V75, P487; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VanBelle E, 1997, CIRCULATION, V95, P438; VANBELLE E, IN PRESS J AM COLL C; vanderZee R, 1997, CIRCULATION, V95, P1030; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741	62	307	319	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					879	886		10.1038/nm0897-879	http://dx.doi.org/10.1038/nm0897-879			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256279				2022-12-27	WOS:A1997XP01400030
J	Ma, SW; Zhao, DL; Yin, ZQ; Mukherjee, R; Singh, B; Qin, HY; Stiller, CR; Jevnikar, AM				Ma, SW; Zhao, DL; Yin, ZQ; Mukherjee, R; Singh, B; Qin, HY; Stiller, CR; Jevnikar, AM			Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; NONOBESE DIABETIC MICE; INSULIN; IMMUNIZATION; SUPPRESSION; ISOFORM; CLONING; MOUSE	Oral administration of protein can induce antigen-specific immune hyporesponsiveness(1). However, the utility of oral tolerance to autoantigens in the treatment of autoimmune diseases may be limited when candidate autoantigens cannot be produced by conventional systems in quantities sufficient for clinical studies. Plants may be ideally suited for this purpose, as they can synthesize, glycosylate and assemble mammalian proteins to provide huge quantities of relatively low cost soluble proteins(2). Furthermore, edible transgenic plants could provide a simple and direct method of autoantigen delivery for oral tolerance. Therefore, the aim of this study was to determine whether a transgenic plant expression system was capable of synthesizing the diabetes-associated autoantigen, glutamic acid decarboxylase (GAD)(3,4) in an immunogenic form and whether the oral administration of an autoantigen expressed by a plant could directly induce protective immune responses in a mouse model of diabetes. We show that a GAD-expressing transgenic plant, given as a dietary supplement, inhibits the development of diabetes in the non-obese diabetic (NOD) mouse.	UNIV WESTERN ONTARIO,SIEBENS DRAKE RES INST,LONDON,ON N6G 2V4,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,JOHN P ROBARTS RES INST,TRANSPLANTAT IMMUNOBIOL GRP,LONDON,ON N6G 2V4,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Jevnikar, Anthony M./G-3309-2011; Singh, Bhagirath/C-4010-2013	Singh, Bhagirath/0000-0002-9792-8694				Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; DEAIZPURUA HJ, 1992, P NATL ACAD SCI USA, V89, P9841, DOI 10.1073/pnas.89.20.9841; DEBLOCK M, 1988, THEOR APPL GENET, V76, P767, DOI 10.1007/BF00303524; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KARLSEN AE, 1991, P NATL ACAD SCI USA, V88, P8337, DOI 10.1073/pnas.88.19.8337; KATAROVA Z, 1990, EUR J NEUROSCI, V2, P190, DOI 10.1111/j.1460-9568.1990.tb00412.x; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; QIN HY, 1995, AUTOIMMUNITY, V21, P50; SIJMONS PC, 1990, BIO-TECHNOL, V8, P217, DOI 10.1038/nbt0390-217; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	24	154	173	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					793	796		10.1038/nm0797-793	http://dx.doi.org/10.1038/nm0797-793			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212110				2022-12-27	WOS:A1997XG76700043
J	Woldbye, DPD; Larsen, PJ; Mikkelsen, JD; Klemp, K; Madsen, TM; Bolwig, TG				Woldbye, DPD; Larsen, PJ; Mikkelsen, JD; Klemp, K; Madsen, TM; Bolwig, TG			Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CLONING; BRAIN; RAT; NEURONS	Neuropeptide Y (NPY) is widely distributed in interneurons of the central nervous system (CNS), including the hippocampus and cerebral cortex, in concentrations exceeding those of any other known neuropeptides(1,2). Sequence data comparing different species show that NPY is highly conserved(3). This suggests a critical role in regulation of regional neuronal excitability. Kainic acid, a glutamate agonist at kainic acid receptors, causes severe limbic motor seizures culminating in status epilepticus(4). We here report that NPY administered into the lateral ventricle is a powerful inhibitor of motor as well as electroencephalographic (EEC) seizures induced by kainic acid. This effect was mediated via receptors with a pharmacological profile similar to the recently cloned rat Y5 receptor(5). The present study is the first to demonstrate that NPY possesses anticonvulsant activity. This is consistent with the concept that NPY is an endogenous anticonvulsant and suggests that agonists acting at Y5-like receptors may constitute a novel group of drugs in antiepileptic therapy.	UNIV COPENHAGEN,INST MED ANAT,DK-2200 COPENHAGEN N,DENMARK; COPENHAGEN UNIV HOSP,RIGSHOSP O6234,LAB EXPT NEUROPSYCHIAT,DK-2100 COPENHAGEN,DENMARK; H LUNDBECK & CO AS,DEPT NEUROBIOL,DK-2500 COPENHAGEN,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen; Lundbeck Corporation	Woldbye, DPD (corresponding author), UNIV COPENHAGEN,DEPT PHARMACOL,NEUROPHARMACOL LAB,3 BLEGDAMSVEJ,DK-2200 COPENHAGEN N,DENMARK.			Woldbye, David/0000-0002-6321-3850				BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; CHRONWALL BM, 1985, NEUROSCIENCE, V15, P1159, DOI 10.1016/0306-4522(85)90260-X; COLMERS WF, 1994, TRENDS NEUROSCI, V17, P373, DOI 10.1016/0166-2236(94)90046-9; DREIFUSS FE, 1985, EPILEPSIA, V26, P268; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; GEHLERT DR, 1994, LIFE SCI, V55, P551, DOI 10.1016/0024-3205(94)00481-1; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GREBER S, 1994, BRIT J PHARMACOL, V113, P737, DOI 10.1111/j.1476-5381.1994.tb17055.x; Hendry S. H. C., 1993, BIOL NEUROPEPTIDE Y, P65; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LIU Z, 1993, BRAIN RES, V631, P51, DOI 10.1016/0006-8993(93)91185-U; McQuiston AR, 1996, J NEUROSCI, V16, P1422; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SZREDER Z, 1994, GEN PHARMACOL-VASC S, V25, P85, DOI 10.1016/0306-3623(94)90014-0; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435; Woldbye DPD, 1996, BRAIN RES, V737, P162, DOI 10.1016/0006-8993(96)00730-5; Woldbye DPD, 1996, BRAIN RES, V720, P111, DOI 10.1016/0006-8993(96)00158-8	21	223	229	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					761	764		10.1038/nm0797-761	http://dx.doi.org/10.1038/nm0797-761			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212103				2022-12-27	WOS:A1997XG76700036
J	Pantaleo, G				Pantaleo, G			How immune-based interventions can change HIV therapy	NATURE MEDICINE			English	Editorial Material							INFECTION; DISEASE				Pantaleo, G (corresponding author), CHU VAUDOIS,DIV INFECT DIS,DEPT MED,LAB AIDS IMMUNOPATHOGENESIS,CH-1011 LAUSANNE,SWITZERLAND.		Pantaleo, Giuseppe/K-6163-2016					CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COREY L, 1995, J INFECT DIS, V171, P521, DOI 10.1093/infdis/171.3.521; EBERL G, EUR J IMMUNOL, V26, P2709; Emery S, 1996, AIDS, V10 Suppl A, pS159, DOI 10.1097/00002030-199601001-00022; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251	13	82	82	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					483	486		10.1038/nm0597-483	http://dx.doi.org/10.1038/nm0597-483			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142107				2022-12-27	WOS:A1997WX54300018
J	Tanaka, T; Manome, Y; Wen, P; Kufe, DW; Fine, HA				Tanaka, T; Manome, Y; Wen, P; Kufe, DW; Fine, HA			Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth	NATURE MEDICINE			English	Article							HUMAN ADENOVIRUS TYPE-5; FACTOR-IV; IN-VIVO; GENE-THERAPY; GLIOBLASTOMA; CARCINOMA; GLIOMAS; PROGRESSION; SUPPRESSION; AGM-1470	Chronic systemic delivery of therapeutic proteins, such as inhibitors of angiogenesis, present a number of difficult pharmacological challenges. To overcome these problems for one such protein, we constructed retroviral and adenoviral vectors that express a novel, secretable form of the antiangiogenic protein, platelet factor 4 (sPF4). Vector-mediated sPF4 transduction selectively inhibits endothelial cell proliferation in vitro, and results in hypovascular tumors that grow slowly in vivo. Additionally, tumor-associated angiogenesis is inhibited and animal survival is prolonged, following transduction of established intracerebral gliomas by an sPF4-expressing adenoviral vector. These data support the concept that targeted antiangiogenesis, using virally mediated gene transfer, represents a promising strategy for delivering antiangiogenic therapy.	DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV NEUROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Wen, Patrick/AAE-3776-2022	Manome, Yoshinobu/0000-0002-8755-8976				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BREM S, 1972, J NATL CANCER I, V48, P347; Brem S, 1976, Clin Neurosurg, V23, P440; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dong YH, 1996, HUM GENE THER, V7, P713, DOI 10.1089/hum.1996.7.6-713; FINE HA, 1994, PERSPECT NEUROL SURG, V5, P115; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MAXWELL M, 1991, CANCER RES, V51, P1345; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RICE CD, 1992, J NEURO-ONCOL, V13, P43; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STADDON A, 1994, P AN M AM SOC CLIN, V13, P3; TAKAMIYA Y, 1994, NEUROSURGERY, V34, P869, DOI 10.1227/00006123-199405000-00013; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504	30	167	187	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					437	442		10.1038/nm0497-437	http://dx.doi.org/10.1038/nm0497-437			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095178				2022-12-27	WOS:A1997WQ82500034
J	Borrow, P; Lewicki, H; Wei, XP; Horwitz, MS; Peffer, N; Meyers, H; Nelson, JA; Gairin, JE; Hahn, BH; Oldstone, MBA; Shaw, GM				Borrow, P; Lewicki, H; Wei, XP; Horwitz, MS; Peffer, N; Meyers, H; Nelson, JA; Gairin, JE; Hahn, BH; Oldstone, MBA; Shaw, GM			Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus	NATURE MEDICINE			English	Article							HIV-1 INFECTION; CHORIOMENINGITIS VIRUS; RESPONSES; TYPE-1; RECOGNITION; VARIANTS; MEMORY; PLASMA; SEQUENCES; VIREMIA	The HIV-1-specific cytotoxic T lymphocyte (CTL) response is temporally associated with the decline in viremia during primary HIV-1 infection, but definitive evidence that it is of importance in virus containment has been lacking. Here we show that in a patient whose early CTL response was focused on a highly immunodominant epitope in gp160, there was rapid elimination of the transmitted virus strain and selection for a virus population bearing amino acid changes at a single residue within this epitope, which conferred escape from recognition by epitope-specific CTL. The magnitude (>100-fold), kinetics (30-72 days from onset of symptoms) and genetic pathways of virus escape from CTL pressure were comparable to virus escape from antiretroviral therapy, indicating the biological significance of the CTL response in vivo. One aim of HIV-1 vaccines should thus be to elicit strong CTL responses against multiple codominant viral epitopes.	OREGON HLTH SCI UNIV, DEPT MOL MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; CNRS, UPR 9021, INST PHARMACOL & BIOL STRUCT, F-31077 TOULOUSE, FRANCE; UNIV ALABAMA, DEPT MED, DIV HEMATOL ONCOL, BIRMINGHAM, AL 35294 USA	Oregon Health & Science University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Alabama System; University of Alabama Birmingham	Borrow, P (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, 10550 N TORREY PINES RD IMM-6, LA JOLLA, CA 92037 USA.			Borrow, Persephone/0000-0002-3877-9780; Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037430, R01AI009484, R37AI009484, R01AI035467, R29AI037430, R37AI035467] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37430, AI 35467, AI 09484] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, P11; Flynn JN, 1996, J IMMUNOL, V157, P3658; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KORBER B, 1995, HIV MOL IMMUNOLOGY D; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MYERS G, 1995, HUMAN RETROVIRUSES A; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0	39	919	944	0	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					205	211		10.1038/nm0297-205	http://dx.doi.org/10.1038/nm0297-205			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018240				2022-12-27	WOS:A1997WF08800040
J	Porter, PL; Malone, KE; Heagerty, PJ; Alexander, GM; Gatti, LA; Firpo, EJ; Daling, JR; Roberts, JM				Porter, PL; Malone, KE; Heagerty, PJ; Alexander, GM; Gatti, LA; Firpo, EJ; Daling, JR; Roberts, JM			Expression of cell-cycle regulators p27(Kip1) and cyclin E, alone and in combination, correlate with survival in young breast cancer patients	NATURE MEDICINE			English	Article							KINASE; GENE	Mutations in certain genes that regulate the cell cycle, such as p16 and p53, are frequently found in human cancers(1). However, tumor-specific mutations are uncommon in genes encoding cyclin E and the CDK inhibitor p27(Kip1), two cell-cycle regulators that are also thought to contribute to tumor progression(2-8). It is now known that levels of both cyclin E and p27 can be controlled by posttranscriptional mechanisms, indicating that expression of these proteins can be altered by means other than simply mutation of their respective genes(9,10). Thus, changes in p27 and cyclin E protein levels in tumors might be more common than previously anticipated and may be indicators of tumor behavior.	UNIV WASHINGTON,DIV PUBL HLTH SCI,PROGRAM EPIDEMIOL,SEATTLE,WA 98109; UNIV WASHINGTON,DIV PUBL HLTH SCI,PROGRAM BIOSTAT,SEATTLE,WA 98109; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT BIOSTAT,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOL,SEATTLE,WA 98109; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98109	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Porter, PL (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM CANC BIOL,C1-105,1100 FAIRVIEW AVE N,SEATTLE,WA 98109, USA.				NCI NIH HHS [N01-CN-05230, R01-CA 59736, R21-CA 66186] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059736, R21CA066186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLUMAN B, 1996, GENE DEV, V10, P1979; CLURMAN BE, 1995, J NATL CANCER I, V87, P1499, DOI 10.1093/jnci/87.20.1499; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GERDES J, 1992, J PATHOL, V168, P85, DOI 10.1002/path.1711680114; KEYOMARSI K, 1994, CANCER RES, V54, P380; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KONSTANTIN S, 1996, CANCER RES, V56, P2400; LEACH FS, 1993, CANCER RES, V53, P1986; LIN DY, 1993, J AM STAT ASSOC, V88, P1341, DOI 10.2307/2291275; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823	20	805	825	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					222	225		10.1038/nm0297-222	http://dx.doi.org/10.1038/nm0297-222			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018243				2022-12-27	WOS:A1997WF08800043
J	Riley, DJ; Nikitin, AY; Lee, WH				Riley, DJ; Nikitin, AY; Lee, WH			Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb-+/- mice	NATURE MEDICINE			English	Article							CARCINOMA-CELLS; PROTEIN; EXPRESSION; MOUSE; P53; PRODUCT; CANCER; APOPTOSIS; PHASE; LUNG	The retinoblastoma gene (RB) is the prototypic tumor suppressor. Studies to date have demonstrated cancer suppression with tumor cells reconstituted with RB ex vivo and implanted into immunodeficient mice, as well as with germline transmission of a human RB transgene into tumor-prone Rb-+/- mice. To mimic the therapy of cancer more closely, spontaneous pituitary melanotroph tumors arising in immunocompetent Rb-+/- mice were treated with a recombinant adenovirus carrying RB cDNA. Intratumoral RB gene transfer decreased tumor cell proliferation, reestablished innervation by growth-regulatory dopaminergic neurons, inhibited the growth of tumors, and prolonged the life spans of treated animals.	UNIV TEXAS,HLTH SCI CTR,CTR MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA 58318] Funding Source: Medline; NEI NIH HHS [EY 05758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Berry DE, 1996, ONCOGENE, V12, P1809; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FALCONI G, 1964, ENDOCRINOLOGY, V74, P301, DOI 10.1210/endo-74-2-301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HASSKOGAN DA, 1995, EMBO J, V14, P461; HENSEL CH, 1990, CANCER RES, V50, P3067; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HU NP, 1994, ONCOGENE, V9, P1021; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; MADREPERLA SA, 1990, CANCER RES, V61, P6381; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OOKAWA K, 1993, ONCOGENE, V8, P2175; PACK RJ, 1984, EUR J RESPIR DIS, V65, P559; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; RUSSELL ELIZABETH S., 1966, P511; SHIZMU E, 1994, ONCOGENE, V9, P2441; SLARK RS, 1995, J CELL BIOL, V129, P779; SOUSA R, 1990, NEUROSCIENCE, V34, P403, DOI 10.1016/0306-4522(90)90149-X; SOUSA R, 1992, J NEUROSCI, V12, P2130; WANG NP, 1993, ONCOGENE, V8, P279; Weidenman B., 1985, CELL, V41, P1017; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573	49	66	69	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1316	1321		10.1038/nm1296-1316	http://dx.doi.org/10.1038/nm1296-1316			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946829				2022-12-27	WOS:A1996VW51500036
J	Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD				Gear, RW; Miaskowski, C; Gordon, NC; Paul, SM; Heller, PH; Levine, JD			Kappa-opioids produce significantly greater analgesia in women than in men	NATURE MEDICINE			English	Article							SEX-DIFFERENCES; SWIM ANALGESIA; PAIN; GENDER; PHARMACOKINETICS; PREGNANCY; MORPHINE; RECEPTOR; RATS; GONADECTOMY	Sex differences in human responses to nociceptive stimuli and painful pathological conditions have generally indicated that women report higher pain levels or exhibit less tolerance than men for given stimulus intensities (reviewed in ref. 1 and 2). However, studies have not evaluated sex differences in analgesic responses. We recently reported the opioid agonist-antagonist that pentazocine, which acts predominantly at kappa-receptors, produced significantly better postoperative analgesia in females than in males(3,4) in patients who underwent surgery for the removal of their third molars (wisdom teeth). In the current study, we evaluated the hypothesis that this sex difference is a characteristic of kappa-opioid agonism. In order to determine whether there are sex differences associated with kappa-opioid agonism, the analgesic efficacy of two other predominantly kappa-opioid analgesics, nalbuphine and butorphanol, was compared in males and females who underwent surgery for the removal of third molar teeth. We found that both nalbuphine and butorphanol produced significantly greater analgesia in females as compared with males. Considering our earlier findings, we conclude that kappa-opioid analgesia is greater in females than in males, probably reflecting a difference in kappa-opioid-activated endogenous pain modulating circuits.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV RHEUMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RESTORAT DENT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ORAL & MAXILLOFACIAL SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; KAISER FDN HOSP,HAYWARD,CA 94545	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente			Paul, Steve/ABE-5400-2020		NINR NIH HHS [NR 03923 T32-DE07204] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003923] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ALOISI AM, 1994, NEUROSCI LETT, V179, P79, DOI 10.1016/0304-3940(94)90939-3; BAAMONDE AI, 1989, NEUROPHARMACOLOGY, V28, P967, DOI 10.1016/0028-3908(89)90197-4; BEATTY WW, 1970, J COMP PHYSIOL PSYCH, V73, P446, DOI 10.1037/h0030216; CANDIDO J, 1992, PHARMACOL BIOCHEM BE, V42, P685, DOI 10.1016/0091-3057(92)90015-8; COGAN R, 1986, PAIN, V27, P63, DOI 10.1016/0304-3959(86)90223-X; COYLE DE, 1995, NEUROSCI LETT, V186, P135, DOI 10.1016/0304-3940(95)11304-F; DAWSONBASOA MB, 1993, BRAIN RES, V601, P241, DOI 10.1016/0006-8993(93)91716-6; DYRENFURTH I, 1974, BIORHYTHMS HUMAN REP, P171; FAUCETT J, 1994, J PAIN SYMPTOM MANAG, V9, P383, DOI 10.1016/0885-3924(94)90175-9; Fillingim RB, 1995, PAIN FORUM, V4, P209, DOI 10.1016/S1082-3174(11)80022-X; Gear RW, 1996, NEUROSCI LETT, V205, P207, DOI 10.1016/0304-3940(96)12402-2; GINTZLER AR, 1980, SCIENCE, V210, P193, DOI 10.1126/science.7414330; GORDON NC, 1995, NEUROSCIENCE, V69, P345, DOI 10.1016/0306-4522(95)00335-G; HALPERN SH, 1996, ANESTH ANALG, V82, pS159; JAILLON P, 1989, CLIN PHARMACOL THER, V46, P226, DOI 10.1038/clpt.1989.130; KEPLER KL, 1989, PHARMACOL BIOCHEM BE, V34, P119, DOI 10.1016/0091-3057(89)90363-8; KEPLER KL, 1991, PAIN, V45, P87, DOI 10.1016/0304-3959(91)90168-W; KEPLER KL, 1988, PHARMACOL BIOCHEM BE, V29, P83, DOI 10.1016/0091-3057(88)90278-X; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; MARKS HE, 1972, PHYSIOL BEHAV, V8, P1113, DOI 10.1016/0031-9384(72)90206-5; MUSACCHIO JM, 1990, NEUROPSYCHOPHARMACOL, V3, P191; Pande AC, 1996, CLIN NEUROPHARMACOL, V19, P92, DOI 10.1097/00002826-199619010-00009; PARE WP, 1969, J COMP PHYSIOL PSYCH, V69, P214, DOI 10.1037/h0028196; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; ROMERO MT, 1986, PHYSIOL BEHAV, V37, P893, DOI 10.1016/S0031-9384(86)80009-9; ROMERO MT, 1988, PHYSIOL BEHAV, V44, P257, DOI 10.1016/0031-9384(88)90147-3; SANDER HW, 1988, BRAIN RES, V474, P343, DOI 10.1016/0006-8993(88)90448-9; SHYU WC, 1994, EUR J CLIN PHARMACOL, V47, P57; UNRUH AM, 1993, PAIN, V65, P123; WILSON SJ, 1986, AM J OBSTET GYNECOL, V155, P340, DOI 10.1016/0002-9378(86)90822-7	31	341	351	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1248	1250		10.1038/nm1196-1248	http://dx.doi.org/10.1038/nm1196-1248			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898754				2022-12-27	WOS:A1996VQ10100042
J	Premack, BA; Schall, TJ				Premack, BA; Schall, TJ			Chemokine receptors: Gateways to inflammation and infection	NATURE MEDICINE			English	Editorial Material							SIGNAL-TRANSDUCTION; LEUKOCYTE; RANTES; CELLS; ACTIVATION		DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Premack, BA (corresponding author), STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305, USA.				NIAID NIH HHS [AI/AR 36535] Funding Source: Medline; NIDDK NIH HHS [DK 41324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COCCHI F, 1996, NATURE MED, V2; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DENG H, 1996, NATURE, V381, P667; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fouchier RAM, 1996, VIROLOGY, V219, P87, DOI 10.1006/viro.1996.0225; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; HARROWE G, 1995, VIROLOGY, V210, P490, DOI 10.1006/viro.1995.1367; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KUANG Y, 1996, J BIOL CHEM, V271, P3875; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RAPORT CJ, 1996, J LEUKOCYTE BIOL, V59, P19; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHUITEMAKER H, 1994, J LEUKOCYTE BIOL, V56, P218; Strieter RM, 1996, J IMMUNOL, V156, P3583; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TURNER L, 1995, J IMMUNOL, V155, P2437; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WU D, 1993, SCIENC E, V262, P101	39	553	599	1	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1174	1178		10.1038/nm1196-1174	http://dx.doi.org/10.1038/nm1196-1174			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898734				2022-12-27	WOS:A1996VQ10100022
J	Scrocchi, LA; Brown, TJ; MacLusky, N; Brubaker, PL; Auerbach, AB; Joyner, AL; Drucker, DJ				Scrocchi, LA; Brown, TJ; MacLusky, N; Brubaker, PL; Auerbach, AB; Joyner, AL; Drucker, DJ			Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; 7-36 AMIDE; DIABETES-MELLITUS; INSULIN RELEASE; RAT-BRAIN; INCRETIN; CELL; POLYPEPTIDE; CLONING; HORMONE	Glucagon-like peptide 1 (GLP1) is postulated to regulate blood glucose and satiety, but the biological importance of GLP1 as an incretin and neuropeptide remains controversial. The regulation of nutrient-induced insulin secretion is dependent on the secretion of incretins, gut-derived peptides that potentiate insulin secretion from the pancreatic islets'. To ascertain the relative physiological importance of GLP1 as a regulator of feeding behavior and insulin secretion, we have generated mice with a targeted disruption of the GLP1 receptor gene (GLP1R). These GLP1R(-/-) mice are viable, develop normally but exhibit circulating insulin. It is surprising that they also exhibit abnormal levels of blood glucose following intraperitoneal glucose challenge. Intracerebroventricular administration of GLP1 inhibited-feeding in wild-type mice but not in GLP1R(-/-) mice; however, no evidence for abnormal body weight or feeding behavior was observed in GLP1R(-/-) mice. These observations demonstrate that GLP1 plays a central role in the regulation of glycemia; however, disruption of GLP1/GLP1R signaling in the central nervous system is not associated with perturbation of feeding behavior or obesity in vivo.	UNIV TORONTO,DEPT MED,TORONTO,ON M5G 2C4,CANADA; TORONTO HOSP,BANTING & BEST DIABET CTR,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA; NYU,MED CTR,SKIRBALL INST BIOMOL MED,DEPT CELL BIOL PHYSIOL & NEUROSCI,NEW YORK,NY 10016	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University			Brown, Theodore J./E-2192-2013; Drucker, Daniel J/A-4092-2010	Brown, Theodore J./0000-0002-3074-4516; MacLusky, Neil/0000-0002-9202-0564				AKESSON TR, 1987, NEUROENDOCRINOLOGY, V45, P257, DOI 10.1159/000124737; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; DALESSIO DA, 1994, J CLIN INVEST, V93, P2263, DOI 10.1172/JCI117225; DAlessio DA, 1996, J CLIN INVEST, V97, P133, DOI 10.1172/JCI118380; DALESSIO DA, 1995, DIABETES, V44, P1433, DOI 10.2337/diabetes.44.12.1433; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUPRE J, 1995, DIABETES, V44, P626, DOI 10.2337/diabetes.44.6.626; EGAN JM, 1994, ENDOCRINOLOGY, V135, P2070, DOI 10.1210/en.135.5.2070; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HEINRICHS SC, 1992, PEPTIDES, V13, P879, DOI 10.1016/0196-9781(92)90044-4; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOOSEIN NM, 1984, FEBS LETT, V178, P83, DOI 10.1016/0014-5793(84)81245-4; HVIDBERG A, 1994, METABOLISM, V43, P104, DOI 10.1016/0026-0495(94)90164-3; KANSE SM, 1988, FEBS LETT, V241, P209, DOI 10.1016/0014-5793(88)81063-9; KREYMANN B, 1987, LANCET, V2, P1300; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; RITZEL R, 1995, DIABETOLOGIA, V38, P720, DOI 10.1007/s001250050344; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; ToftNielsen MB, 1996, DIABETES, V45, P552, DOI 10.2337/diabetes.45.5.552; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VILLANUEVAPENACARRILLO ML, 1994, DIABETOLOGIA, V37, P1163, DOI 10.1007/BF00418382; WEI Y, 1995, FEBS LETT, V358, P219, DOI 10.1016/0014-5793(94)01430-9; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Willms B, 1996, J CLIN ENDOCR METAB, V81, P327, DOI 10.1210/jc.81.1.327; Wurst W., 1993, Gene targeting: a practical approach., P33	36	615	675	0	35	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1254	1258		10.1038/nm1196-1254	http://dx.doi.org/10.1038/nm1196-1254			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898756				2022-12-27	WOS:A1996VQ10100044
J	Kraehenbuhl, JP; WainHobson, S				Kraehenbuhl, JP; WainHobson, S			Breaching barriers	NATURE MEDICINE			English	Editorial Material							TRANSMISSION; IMMUNITY; VIRUS; MODEL		INST PASTEUR,UNITE RETROVIROL MOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kraehenbuhl, JP (corresponding author), SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND.							BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56; Cohen J, 1996, SCIENCE, V272, P805, DOI 10.1126/science.272.5263.805; HOPKINS S, 1995, INFECT IMMUN, V63, P3279, DOI 10.1128/IAI.63.9.3279-3286.1995; Madara James L., 1994, Trends in Cell Biology, V4, P4, DOI 10.1016/0962-8924(94)90026-4; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; PARR MB, 1994, LAB INVEST, V70, P369; Phillips David M., 1994, Trends in Microbiology, V2, P454, DOI 10.1016/0966-842X(94)90804-4; YOUNG WG, 1985, AM J ANAT, V174, P173, DOI 10.1002/aja.1001740207	10	10	10	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1080	1082		10.1038/nm1096-1080	http://dx.doi.org/10.1038/nm1096-1080			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837603				2022-12-27	WOS:A1996VK99500025
J	Even-Ram, S; Uziely, B; Cohen, P; Grisaru-Granovsky, S; Maoz, M; Ginzburg, Y; Reich, R; Vlodavsky, I; Bar-Shavit, R				Even-Ram, S; Uziely, B; Cohen, P; Grisaru-Granovsky, S; Maoz, M; Ginzburg, Y; Reich, R; Vlodavsky, I; Bar-Shavit, R			Thrombin receptor overexpression in malignant and physiological invasion processes	NATURE MEDICINE			English	Article							TUMOR-CELLS; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; BASEMENT-MEMBRANE; IV COLLAGENASES; STROMAL CELLS; CANCER-CELLS; BREAST; METASTASIS; EXPRESSION	Although the involvement of soluble and matrix-immobilized proteases in tumor cell invasion and metastasis is well recognized, the role of proteolytically activated cell surface receptors has not been elucidated. We report here that thrombin receptor, a member of the protease-activated receptor family, is preferentially expressed in highly metastatic human breast carcinoma cell lines and breast carcinoma biopsy specimens. Introduction of thrombin receptor antisense cDNA considerably inhibited the invasion of metastatic breast carcinoma cells in culture through a reconstituted basement membrane. During placental implantation of the human embryo, thrombin receptor is transiently expressed in the invading cytotrophoblasts. These results emphasize the involvement of thrombin receptor in cell invasion associated with tumor progression and normal embryonic development.	Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Bar-Shavit, R (corresponding author), Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel.			Even-Ram, Sharona/0000-0002-5540-3822				ALBINI A, 1987, CANCER RES, V47, P3239; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; ESUMI N, 1991, CANCER RES, V51, P4549; FERNANDEZ PL, 1992, LAB INVEST, V66, P572; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.3.CO;2-6; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; KIM SY, 1997, BREAST CANC RES TREA, V43, P175; Lee KS, 1996, CLIN EXP METASTAS, V14, P512; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nehls V, 1996, MICROVASC RES, V51, P347, DOI 10.1006/mvre.1996.0032; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PAGE B, 1995, EURO C COMP, V6, P39; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1991, AM J PATHOL, V138, P1059; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Redman CWG, 1997, NAT MED, V3, P610, DOI 10.1038/nm0697-610; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SAIKI RK, 1988, SCIENCE, V239, P489; SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002-9378(94)90107-4; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOULE HD, 1990, CANCER RES, V50, P6075; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1994, INVAS METAST, V14, P303; WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514; WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; [No title captured]	44	383	403	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					909	914		10.1038/nm0898-909	http://dx.doi.org/10.1038/nm0898-909			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701242				2022-12-27	WOS:000075107400033
J	Unsworth, BR; Lelkes, PI				Unsworth, BR; Lelkes, PI			Growing tissues in microgravity	NATURE MEDICINE			English	Review							ROTATING-WALL VESSEL; SIMULATED MICROGRAVITY; DRUG-RESISTANCE; ZERO GRAVITY; CELL-LINE; IN-VITRO; CULTURE; DIFFERENTIATION; AGGREGATION; BIOREACTORS		Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA; Univ Wisconsin, Sch Med, Dept Med, Cell Biol Lab, Milwaukee, WI 53201 USA	Marquette University; University of Wisconsin System; University of Wisconsin Milwaukee	Unsworth, BR (corresponding author), Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA.		Lelkes, Peter/HGA-2907-2022; Lelkes, Peter I/S-1751-2019					Akins RE, 1997, IN VITRO CELL DEV-AN, V33, P337; Atala A, 1998, UROL CLIN N AM, V25, P39, DOI 10.1016/S0094-0143(05)70431-6; BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; Becker JL, 1997, IN VITRO CELL DEV-AN, V33, P325; BECKER JL, 1993, J CELL BIOCHEM, V51, P283, DOI 10.1002/jcb.240510307; BONTING SL, 1992, ADV SPACE BIOL MED, V2; CHOPRA V, 1998, IN VITRO CELL DEV, V33, P42; CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228; CLAASSEN DE, 1994, INT REV CYTOL, V156, P301, DOI 10.1016/S0074-7696(08)62257-3; Cogoli A, 1991, Adv Space Biol Med, V1, P183; COGOLI A, 1998, ADV SPACE BIOL MED, P33; CogoliGreuter M, 1996, J BIOTECHNOL, V47, P279, DOI 10.1016/0168-1656(96)01380-6; Cooper D, 1998, J LEUKOCYTE BIOL, V63, P550, DOI 10.1002/jlb.63.5.550; DAI WG, 1994, BIO-TECHNOL, V12, P797, DOI 10.1038/nbt0894-797; DINTENFASS L, 1986, BIORHEOLOGY, V23, P331; Fauza DO, 1998, J PEDIATR SURG, V33, P357, DOI 10.1016/S0022-3468(98)90462-6; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Francis KM, 1997, IN VITRO CELL DEV-AN, V33, P332; Freed LE, 1997, IN VITRO CELL DEV-AN, V33, P381; FREED LE, 1993, J CELL BIOCHEM, V51, P257, DOI 10.1002/jcb.240510304; Freed LE, 1998, EXP CELL RES, V240, P58, DOI 10.1006/excr.1998.4010; Freed LE, 1997, P NATL ACAD SCI USA, V94, P13885, DOI 10.1073/pnas.94.25.13885; FREED LE, 1997, PRINCIPLES TISSUE EN, P151; GALVAN DL, 1995, MOL BIOL CELL, V6, P975; GALVAN DL, 1995, IN VITRO CELL DEV, V31, pA10; GOODWIN TJ, 1993, P SOC EXP BIOL MED, V202, P181; Goodwin TJ, 1997, IN VITRO CELL DEV-AN, V33, P366; Guignandon A, 1997, BONE, V20, P109, DOI 10.1016/S8756-3282(96)00337-7; HAMMOND TG, 1995, IN VITRO CELLD EV BI, V31, pA9; HOFFMAN RM, 1993, STEM CELLS, V11, P105, DOI 10.1002/stem.5530110205; HOFFMAN RM, 1994, CANCER METAST REV, V13, P169, DOI 10.1007/BF00689634; Horneck G, 1997, RADIAT RES, V147, P376, DOI 10.2307/3579347; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Hymer WC, 1996, J BIOTECHNOL, V47, P289, DOI 10.1016/0168-1656(96)01373-9; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459; Jessup JM, 1997, IN VITRO CELL DEV-AN, V33, P352; JESSUP JM, 1993, J CELL BIOCHEM, V51, P290, DOI 10.1002/jcb.240510308; JESSUP JM, 1996, IN VITRO CELL DEV, V32, pA13; KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108; Khaoustov V. I., 1995, Hepatology, V22, p231A, DOI 10.1016/0270-9139(95)94647-0; Krewson C E, 1996, Tissue Eng, V2, P183, DOI 10.1089/ten.1996.2.183; KULESH DA, 1994, J CELL BIOCHEM, V55, P530, DOI 10.1002/jcb.240550412; Kunisada T, 1997, ACTA MED OKAYAMA, V51, P135; LANGER R, 1995, SCI AM, V273, P130; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lelkes PI, 1998, IN VITRO CELL DEV-AN, V34, P316; LONG JP, IN PRESS AVIAT SPACE; LORENZI G, 1995, BIORACK SPACELAB IML, P105; Margolis LB, 1997, AIDS RES HUM RETROV, V13, P1411, DOI 10.1089/aid.1997.13.1411; Mayer JE, 1997, CURR OPIN CARDIOL, V12, P528, DOI 10.1097/00001573-199711000-00005; Molnar G, 1997, IN VITRO CELL DEV-AN, V33, P386; MONTGOMERY POB, 1978, IN VITRO CELL DEV B, V14, P165; MOREIRA JL, 1995, BIOTECHNOL PROGR, V11, P575, DOI 10.1021/bp00035a012; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; OConnor KC, 1997, TISSUE ENG, V3, P161, DOI 10.1089/ten.1997.3.161; Pellis NR, 1997, IN VITRO CELL DEV-AN, V33, P398, DOI 10.1007/s11626-997-0012-7; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Rhee HW, 1998, J UROLOGY, V159, P5; Saltzman WM, 1997, P NATL ACAD SCI USA, V94, P13380, DOI 10.1073/pnas.94.25.13380; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SCHUSTER U, 1994, J UROLOGY, V151, P1707, DOI 10.1016/S0022-5347(17)35349-1; SCHWACHOFER JHM, 1990, ANTICANCER RES, V10, P963; Schwarz R P, 1992, J Tissue Cult Methods, V14, P51, DOI 10.1007/BF01404744; SEITZER U, 1995, CELL TISSUE RES, V282, P513, DOI 10.1007/s004410050502; Shinoka T, 1998, J THORAC CARDIOV SUR, V115, P536, DOI 10.1016/S0022-5223(98)70315-0; Shinoka T, 1997, CIRCULATION, V96, P102; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; SUTHERLAND RM, 1986, CANCER RES, V46, P5320; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; TORGAN CE, 1998, IN PRESS IN VITRO CE; Vens C, 1996, J BIOTECHNOL, V47, P203, DOI 10.1016/0168-1656(96)01355-7; WALTHER I, 1994, J BIOTECHNOL, V38, P21, DOI 10.1016/0168-1656(94)90144-9; Wolf D. A., 1991, NASA TECH PAPER, V3143, P1; Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	77	278	302	0	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					901	907		10.1038/nm0898-901	http://dx.doi.org/10.1038/nm0898-901			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701241				2022-12-27	WOS:000075107400032
J	Fleury, S; de Boer, RJ; Rizzardi, GP; Wolthers, KC; Otto, SA; Welbon, CC; Graziosi, C; Knabenhans, C; Soudeyns, H; Bart, PA; Gallant, S; Corpataux, JM; Gillet, M; Meylan, P; Schnyder, P; Meuwly, JY; Spreen, W; Glauser, MP; Miedema, F; Pantaleo, G				Fleury, S; de Boer, RJ; Rizzardi, GP; Wolthers, KC; Otto, SA; Welbon, CC; Graziosi, C; Knabenhans, C; Soudeyns, H; Bart, PA; Gallant, S; Corpataux, JM; Gillet, M; Meylan, P; Schnyder, P; Meuwly, JY; Spreen, W; Glauser, MP; Miedema, F; Pantaleo, G			Limited CD4(+) T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTES-T; PROGRESSION; PHENOTYPE; ANTIBODY; PLASMA; SYSTEM; KI-67; AIDS	We show that the fraction of proliferating CD4(+) lymphocytes is similar in HIV-infected subjects in the early stage of disease and in HIV-negative subjects, whereas the fraction of proliferating CD8(+) lymphocytes is increased 6.8-fold in HIV-infected subjects. After initiation of antiviral therapy, there is a late increase in proliferating CD4(+) T cells associated with the restoration of CD4(+) T-cell counts. These results provide strong support for the idea of limited CD4(+) T-cell renewal in the early stage of HIV infection and indicate that after effective suppression of virus replication, the mechanisms of CD4(+) T-cell production are still functional in early HIV infection.	Univ Lausanne, Ctr Hosp Vaudois, Dept Med, Lab AIDS Immunopathogenesis,Div Infect Dis, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Div Immunol, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Gen Surg, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Radiol, CH-1015 Lausanne, Switzerland; Univ Utrecht, Utrecht, Netherlands; Univ Amsterdam, Netherlands Red Cross, Blood Transfus Serv, Cent Lab,Dept Clin Viroimmunol, Amsterdam, Netherlands; Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Univ Lausanne, Inst Microbiol, CH-1015 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Utrecht University; University of Amsterdam; University of Amsterdam; GlaxoSmithKline; University of Lausanne	Pantaleo, G (corresponding author), Univ Lausanne, Ctr Hosp Vaudois, Dept Med, Lab AIDS Immunopathogenesis,Div Infect Dis, CH-1015 Lausanne, Switzerland.		de Boer, Rob/B-6050-2011; Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019; Wolthers, Katja C./E-5140-2018	de Boer, Rob/0000-0002-2130-691X; Wolthers, Katja C./0000-0003-1617-7049				BRUNO S, 1992, CELL PROLIFERAT, V25, P31, DOI 10.1111/j.1365-2184.1992.tb01435.x; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Clark DR, 1997, J INFECT DIS, V176, P649, DOI 10.1086/514086; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; GERDES J, 1984, J IMMUNOL, V133, P1710; GLICK RM, 1997, N ENGL J MD, V337, P734; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Paganin C, 1997, J CLIN INVEST, V99, P663, DOI 10.1172/JCI119209; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PRESS WH, 1988, CAMBRIDGE UP; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHWARTING R, 1986, J IMMUNOL METHODS, V90, P65, DOI 10.1016/0022-1759(86)90384-4; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	26	133	134	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					794	801		10.1038/nm0798-794	http://dx.doi.org/10.1038/nm0798-794			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662370	Green Published			2022-12-27	WOS:000074543900033
J	Roperch, JP; Alvaro, V; Prieur, S; Tuynder, M; Nemani, M; Lethrosne, F; Piouffre, L; Gendron, MC; Israeli, D; Dausset, J; Oren, M; Amson, R; Telerman, A				Roperch, JP; Alvaro, V; Prieur, S; Tuynder, M; Nemani, M; Lethrosne, F; Piouffre, L; Gendron, MC; Israeli, D; Dausset, J; Oren, M; Amson, R; Telerman, A			Inhibition of presenilin 1 expression is promoted by p53 and p21(WAF-1) and results in apoptosis and tumor suppression	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GENE; ACTIVATION; HOMOLOG	Previously, we cloned a cDNA fragment, TSIP 2 (tumor suppressor inhibited pathway clone 2), that detects by northern blot analysis of M1-LTR6 cells a 3-kb mRNA downregulated during p53-induced apoptosis(1). Cloning the full-length TSIP 2 cDNA showed that it corresponds to the presenilin 1 (PS1) gene, in which mutations have been reported in early-onset familial Alzheimer's disease(2-4). Here we demonstrate that PS1 is downregulated in a series of model systems for p53-dependent and p53-independent apoptosis and tumor suppression. To investigate the biological relevance of this downregulation, we stably transfected U937 cells with antisense PS1 cDNA. The downregulation of PS1 in these U937 transfectants results in reduced growth with an increased fraction of the cells in apoptosis. When injected into mice homozygous for severe combined immunodeficiency disease (scid/scid mice), these cells show a suppression of their malignant phenotype. Our results indicate that PS1, initially identified in a neurodegenerative disease, may also be involved in the regulation of cancer-related pathways.	CEPH, Human Polymorphism Study Ctr, Fondat Jean Dausset, F-75010 Paris, France; Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium; Inst Jacques Monod, Flow Cytometry Unit, F-75251 Paris, France; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	UDICE-French Research Universities; Universite Paris Cite; Weizmann Institute of Science	Telerman, A (corresponding author), CEPH, Human Polymorphism Study Ctr, Fondat Jean Dausset, 27 Rue Juliette Dodu, F-75010 Paris, France.			Israeli, David/0000-0003-2762-2195				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JINHE L, 1997, CELL, V90, P917; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; MICHIELI P, 1994, CANCER RES, V54, P3391; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; PARKER SB, 1995, SCIENCE, V267, P1724; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	20	154	159	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					835	838		10.1038/nm0798-835	http://dx.doi.org/10.1038/nm0798-835			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662377				2022-12-27	WOS:000074543900040
J	Marsh, DJ; Hollopeter, G; Kafer, KE; Palmiter, RD				Marsh, DJ; Hollopeter, G; Kafer, KE; Palmiter, RD			Role of the Y5 neuropeptide Y receptor in feeding and obesity	NATURE MEDICINE			English	Article							PARAVENTRICULAR NUCLEUS; FOOD-DEPRIVATION; OB/OB MICE; GENE; EXPRESSION; INGESTION; BEHAVIOR; LEPTIN; RATS	Neuropeptide Y (NPY), a 36-amino-acid neuromodulator abundantly expressed in the brain(1), has been implicated in the regulation of food intake and body weight(2-4). Pharmacological data suggest that NPY's stimulatory effect on appetite is transduced by the G-protein-coupled NPY Y5 receptor(5) (Y5R). We have inactivated the Y5R gene in mice and report that younger Y5R-null mice feed and grow normally; however, they develop mild late-onset obesity characterized by increased body weight, food intake and adiposity. Fasting-induced refeeding is unchanged in younger Y5R-null mice and they exhibit normal sensitivity to leptin. Their response to intracerebroventricular (icv) administration of NPY and related peptides is either reduced or absent. NPY deficiency attenuates the obesity syndrome of mice deficient for leptin(6) (ob/ob), but these effects are not mediated by NPY signaling through the Y5R because Y5R-null ob/ob mice are equally obese. These results demonstrate that the Y5R contributes to feeding induced by centrally administered NPY and its analogs, but is not a critical physiological feeding receptor in mice.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	palmiter@u.washington.edu						ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BECK B, 1990, BRAIN RES, V528, P245, DOI 10.1016/0006-8993(90)91664-3; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; DANIELS AJ, 1995, P NATL ACAD SCI USA, V92, P9067, DOI 10.1073/pnas.92.20.9067; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Kalra SP, 1997, NEURON, V19, P227, DOI 10.1016/S0896-6273(00)80934-4; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1985, PEPTIDES, V6, P1205, DOI 10.1016/0196-9781(85)90452-8; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	342	359	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					718	721		10.1038/nm0698-718	http://dx.doi.org/10.1038/nm0698-718			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623983				2022-12-27	WOS:000074008300040
J	Posavad, CM; Koelle, DM; Corey, L				Posavad, CM; Koelle, DM; Corey, L			Tipping the scales of herpes simplex virus reactivation: The important responses are local	NATURE MEDICINE			English	Editorial Material							GENITAL HERPES; T-LYMPHOCYTES; LESIONS; CLONES; GAMMA; RECOGNITION; FIBROBLASTS; INTERFERON; INFECTION; IMMUNITY		Univ Washington, Dept Lab Med, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Corey, L (corresponding author), Univ Washington, Dept Lab Med, 1124 Columbia St,Room M115, Seattle, WA 98104 USA.		Koelle, David/Q-6529-2016; Corey, Lawrence/AAE-1796-2020	Koelle, David/0000-0003-1255-9023; Corey, Lawrence/0000-0002-2179-2436	NCI NIH HHS [CA-70017] Funding Source: Medline; NIAID NIH HHS [AI-30731, AI-34616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731, P01AI034616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Carmack MA, 1996, J INFECT DIS, V174, P899, DOI 10.1093/infdis/174.5.899; CUNNINGHAM AL, 1985, J CLIN INVEST, V75, P226, DOI 10.1172/JCI111678; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; KOELLE DM, 1994, J INFECT DIS, V169, P956, DOI 10.1093/infdis/169.5.956; KOELLE DM, 1993, J CLIN INVEST, V91, P961, DOI 10.1172/JCI116317; KOELLE DM, 1994, J VIROL, V68, P2803, DOI 10.1128/JVI.68.5.2803-2810.1994; KOELLE DM, IN PRESS J CLIN INVE; Mikloska Z, 1996, J INFECT DIS, V173, P7, DOI 10.1093/infdis/173.1.7; Posavad CM, 1997, P NATL ACAD SCI USA, V94, P10289, DOI 10.1073/pnas.94.19.10289; Posavad CM, 1996, J VIROL, V70, P8165, DOI 10.1128/JVI.70.11.8165-8168.1996; Rinaldo C R Jr, 1993, Immunodeficiency, V5, P33; SCHMID DS, 1988, J IMMUNOL, V140, P3610; SCHMID DS, 1992, CURR TOP MICROBIOL, V179, P57; Tigges MA, 1996, J IMMUNOL, V156, P3901; TIGGES MA, 1992, J VIROL, V66, P1622, DOI 10.1128/JVI.66.3.1622-1634.1992; TORPEY DJ, 1989, J IMMUNOL, V142, P1325; TORSETH JW, 1986, J INFECT DIS, V153, P979, DOI 10.1093/infdis/153.5.979; VanVoorhis WC, 1996, J INFECT DIS, V173, P491, DOI 10.1093/infdis/173.2.491; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	22	69	72	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					381	382		10.1038/nm0498-381	http://dx.doi.org/10.1038/nm0498-381			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546773				2022-12-27	WOS:000072906800021
J	Sata, M; Walsh, K				Sata, M; Walsh, K			TNF alpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation	NATURE MEDICINE			English	Article							HUMAN ATHEROSCLEROTIC PLAQUE; SMOOTH-MUSCLE CELLS; LYMPHOCYTES-T; IN-VIVO; APOPTOSIS; IDENTIFICATION; ATHEROGENESIS; MACROPHAGES; REJECTION; MECHANISM	It is generally believed that the vascular endothelium serves as an inflammatory barrier by providing a nonadherent surface to leukocytes. Here, we report that Fas ligand (FasL) is expressed on vascular endothelial cells (ECs) and that it may function to actively inhibit leukocyte extravasation. TNF alpha downregulates FasL expression with an accompanying decrease in EC cytotoxicity toward co-cultured Fas-bearing cells. Local administration of TNF alpha to arteries down regulates endothelial Fast expression and induces mononuclear cell infiltration. Constitutive Fast expression markedly attenuates TNF alpha-induced cell infiltration and adherent mononuclear cells undergo apoptosis under these conditions. These findings suggest that endothelial Fast expression can negatively regulate leukocyte extravasation.	Tufts Univ, St Elizabeths Hosp, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA	Tufts University; University of Massachusetts System; University of Massachusetts Worcester; Tufts University	Walsh, K (corresponding author), Tufts Univ, St Elizabeths Hosp, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA.	kwalsh@opal.tufts.edu		Walsh, Kenneth/0000-0001-7580-2276	NHLBI NIH HHS [HL50692, R01 HL050692-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197-11, R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [R01 AG015052-02, AG15052, R37 AG015052, R01 AG015052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams MR, 1997, CIRCULATION, V95, P662, DOI 10.1161/01.CIR.95.3.662; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; EMESON EE, 1988, AM J PATHOL, V130, P369; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANSSON GK, 1989, AM J PATHOL, V135, P169; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; LIBBY P, 1991, LAB INVEST, V64, P5; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; Luscinskas FW, 1996, ANNU REV MED, V47, P413, DOI 10.1146/annurev.med.47.1.413; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MUNRO JM, 1987, HUM PATHOL, V18, P375; Muruve DA, 1997, HUM GENE THER, V8, P955, DOI 10.1089/hum.1997.8.8-955; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Niehans GA, 1997, CANCER RES, V57, P1007; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; PFIEFFER K, 1993, CELL, V73, P457; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TANAKA H, 1995, AM J PATHOL, V147, P617; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; VANDERWAL AC, 1989, LAB INVEST, V61, P166; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7	37	194	199	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					415	420		10.1038/nm0498-415	http://dx.doi.org/10.1038/nm0498-415			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546786	Green Accepted			2022-12-27	WOS:000072906800035
J	Choksi, S; Jameson, BA; Korngold, R				Choksi, S; Jameson, BA; Korngold, R			A structure-based approach to designing synthetic CD8 alpha peptides that can inhibit cytotoxic T-lymphocyte responses	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; DIFFERENTIATION ANTIGEN; VARIABLE REGIONS; CELL ACTIVATION; ALPHA-3 DOMAIN; CD8; IMMUNOGLOBULIN; COMPLEX; BINDING; POLYPEPTIDES	CD8 molecules function as co-receptors on cytotoxic T lymphocytes (CTLs), interacting with a nonpolymorphic region of the major histocompatibility complex (MHC) class I a3 domain on antigen-presenting cells. Analogues were designed from a structural model of the mouse CD8a molecule to identify surfaces involved in CD8 function. Peptides were screened for in vitro biological activity on alloreactive CTLs, and analogue SC4 (p54-59) was found to be inhibitory during both the generation and effector stages. SC4 was also able to significantly prolong skin allograft survival across a MHC class I barrier, Thus, such CD8 analogues may have therapeutic potential as immunoregulators of CTL immune responses.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Korngold, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, 233 S 10th St, Philadelphia, PA 19107 USA.							BAILEY DW, 1960, TRANSPLAN B, V25, P424; CAI ZL, 1994, J EXP MED, V179, P2005, DOI 10.1084/jem.179.6.2005; CLAYBERGER C, 1994, J IMMUNOL, V153, P946; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DOHERTY PC, 1985, BRIT MED BULL, V41, P7, DOI 10.1093/oxfordjournals.bmb.a072028; EICHMANN K, 1991, J IMMUNOL, V147, P2075; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FRANCO MD, 1994, CELL IMMUNOL, V157, P341, DOI 10.1006/cimm.1994.1232; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MASON DW, 1986, ANNU REV IMMUNOL, V4, P119, DOI 10.1146/annurev.immunol.4.1.119; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MESCHER MF, 1995, IMMUNOL REV, V146, P177, DOI 10.1111/j.1600-065X.1995.tb00689.x; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1994, J IMMUNOL, V152, P4358; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	35	19	19	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					309	314		10.1038/nm0398-309	http://dx.doi.org/10.1038/nm0398-309			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500604				2022-12-27	WOS:000073616200036
J	Goh, WC; Rogel, ME; Kinsey, CM; Michael, SF; Fultz, PN; Nowak, MA; Hahn, BH; Emerman, M				Goh, WC; Rogel, ME; Kinsey, CM; Michael, SF; Fultz, PN; Nowak, MA; Hahn, BH; Emerman, M			HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; RHESUS-MONKEYS; TYPE-1; GENE; INFECTION; PROTEIN; ARRESTS; G(2); DNA	The human immunodeficiency virus type 1 (HIV-1) encodes a protein, called Vpr, that prevents proliferation of infected cells by arresting them G(2) of the cell cycle. This Vpr-mediated cell-cycle arrest is also conserved among highly divergent simian immunodeficiency viruses, suggesting an important role in the virus life cycle. However, it has been unclear how this could be a selective advantage for the virus. Here we provide evidence that expression of the viral genome is optimal in the G(2) phase of the cell cycle, and that Vpr increases virus production by delaying cells at the point of the cell cycle where the long terminal repeat (LTR) is most active. Although Vpr is selected against when virus is adapted to tissue culture, we show that selection for Vpr function in vivo occurs in both humans and chimpanzees infected with HIV-1. These results suggest a novel mechanism for maximizing virus production in the face of rapid killing of infected target cells.	Fred Hutchinson Canc Res Ctr, Div Mol Med, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford	Emerman, M (corresponding author), Fred Hutchinson Canc Res Ctr, Div Mol Med, Suite C2-023,1100 Fairview Ave N, Seattle, WA 98109 USA.		Nowak, Martin A/A-6977-2008	Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034748, R37AI030927, R01AI030927] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34748, AI 30927] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Aldrovandi GM, 1996, J VIROL, V70, P1505, DOI 10.1128/JVI.70.3.1505-1511.1996; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOCH J, 1995, J VIROL, V69, P4807, DOI 10.1128/JVI.69.8.4807-4813.1995; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYERS G, 1994, HUMAN RETROVIRUSES A; NAKAYA T, 1994, FEBS LETT, V354, P17, DOI 10.1016/0014-5793(94)01074-9; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, BIOTECHNIQUES, V14, P70; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; REITZ MS, 1994, AIDS RES HUM RETROV, V10, P1143, DOI 10.1089/aid.1994.10.1143; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sharp PM, 1996, NATURE, V383, P586, DOI 10.1038/383586a0; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISS SH, 1988, SCIENCE, V239, P68, DOI 10.1126/science.3336776; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	39	432	436	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					65	71		10.1038/nm0198-065	http://dx.doi.org/10.1038/nm0198-065			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427608				2022-12-27	WOS:000072249700036
J	Weck, KE; Dal Canto, AJ; Gould, JD; O'Guin, AK; Roth, KA; Saffitz, JE; Speck, SH; Virgin, HW				Weck, KE; Dal Canto, AJ; Gould, JD; O'Guin, AK; Roth, KA; Saffitz, JE; Speck, SH; Virgin, HW			Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: A new model for virus-induced vascular disease	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; INFECTED ENDOTHELIAL-CELLS; CYTOMEGALOVIRUS-INFECTION; T-CELLS; TARGETED DISRUPTION; CORONARY-ARTERIES; APOLIPOPROTEIN-E; DEFICIENT MICE; SIMPLEX VIRUS; ATHEROSCLEROSIS	Fundamental issues remain unresolved regarding the possible contribution of viruses to vascular pathology, as well as the role of the immune system in regulating these processes. Here we demonstrate that infection of mice with gamma-herpesvirus 68 (gamma HV68) provides a novel model for addressing these issues. Interferon-gamma receptor-deficient (IFN gamma R-/-) mice died weeks to months after gamma HV68 infection from a severe large-vessel panarteritis. gamma HV68-infected B cell-deficient and normal weanling mice exhibited milder large-vessel arteritis. Immunohistochemical analyses demonstrated gamma HV68 antigen in arteritic lesions and revealed a striking tropism of gamma HV68 for smooth muscle cells. These studies demonstrate that IFN-gamma is essential for control of chronic vascular pathology induced by gamma HV68 and suggest gamma-herpesviruses as candidate etiologic agents for human vasculitis.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Virgin, HW (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Speck, Samuel/L-5893-2019	Roth, Kevin/0000-0002-0643-995X; Virgin, Herbert/0000-0001-8580-7628	NCI NIH HHS [CA 74730] Funding Source: Medline; NIAID NIH HHS [AI 39616, 1 K08 AI01279-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA074730, R01CA074730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039616, K08AI001279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DANGLER CA, 1995, VET PATHOL, V32, P127, DOI 10.1177/030098589503200205; DUMMER S, 1994, J MED VIROL, V44, P305, DOI 10.1002/jmv.1890440316; Dutia BM, 1997, J VIROL, V71, P4278, DOI 10.1128/JVI.71.6.4278-4283.1997; EHTISHAM S, 1993, J VIROL, V67, P5247, DOI 10.1128/JVI.67.9.5247-5252.1993; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FABRICANT CG, 1981, AM J PATHOL, V105, P176; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GREENE NB, 1986, CHEST, V89, P605, DOI 10.1378/chest.89.4.605; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; HENDRIX MGR, 1989, AM J PATHOL, V134, P1151; HENDRIX MGR, 1990, AM J PATHOL, V136, P23; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; HSU HY, 1995, J BIOL CHEM, V270, P19630, DOI 10.1074/jbc.270.33.19630; KERR GS, 1995, RHEUM DIS CLIN N AM, V21, P1041; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LIBBY P, 1991, LAB INVEST, V64, P5; LIE JT, 1987, PATHOL ANNU, V22, P125; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; MELNICK JL, 1995, BIOESSAYS, V17, P899, DOI 10.1002/bies.950171012; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MISTRIKOVA J, 1985, ACTA VIROL, V29, P312; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PERSOONS MCJ, 1994, CIRC RES, V75, P214, DOI 10.1161/01.RES.75.2.214; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RazaAhmad A, 1995, CAN J CARDIOL, V11, P1025; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sarawar SR, 1996, J VIROL, V70, P3264, DOI 10.1128/JVI.70.5.3264-3268.1996; Sarawar SR, 1997, J VIROL, V71, P3916, DOI 10.1128/JVI.71.5.3916-3921.1997; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; SHIH JCH, 1989, J NUTR, V119, P294, DOI 10.1093/jn/119.2.294; SHIH JCH, 1995, ADV EXP MED BIOL, V369, P89; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; SIEGEL RJ, 1993, CARDIOVASCULAR DISOR, P517; SORLIE PD, 1994, J MED VIROL, V42, P33, DOI 10.1002/jmv.1890420107; STEMME S, 1994, ANN MED, V26, P141, DOI 10.3109/07853899409147881; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; SUNILCHANDRA NP, 1994, AM J PATHOL, V145, P818; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P3275, DOI 10.1099/0022-1317-73-12-3275; TANAKA S, 1992, J VASC SURG, V16, P274, DOI 10.1016/0741-5214(92)90118-R; TSUKADA T, 1987, AM J PATHOL, V126, P51; Usherwood EJ, 1996, J GEN VIROL, V77, P2819, DOI 10.1099/0022-1317-77-11-2819; VANDAMMIERAS MCE, 1992, THROMB HAEMOSTASIS, V68, P364; VIRGIN HW, 1991, J VIROL, V65, P6772, DOI 10.1128/JVI.65.12.6772-6781.1991; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; VISSER MR, 1993, EUR HEART J, V14, P39; Weck KE, 1996, J VIROL, V70, P6775, DOI 10.1128/JVI.70.10.6775-6780.1996; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	60	180	186	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1346	1353		10.1038/nm1297-1346	http://dx.doi.org/10.1038/nm1297-1346			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396604				2022-12-27	WOS:000072249500030
J	Czubayko, F; LiaudetCoopman, EDE; Aigner, A; Tuveson, AT; Berchem, GJ; Wellstein, A				Czubayko, F; LiaudetCoopman, EDE; Aigner, A; Tuveson, AT; Berchem, GJ; Wellstein, A			A secreted FGF-binding protein can serve as the angiogenic switch in human cancer	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; FACTOR PLEIOTROPHIN; METASTASIS; EXPRESSION; TUMORIGENESIS; CLONING; LINE	The growth and metastatic spread of cancer is directly related to tumor angiogenesis(1), and the driving factors need to be understood to exploit this process therapeutically(2,3). However, tumor cells and their normal stroma express a multitude of candidate angiogenic factors(2), and very few specific inhibitors have been generated to assess which of these gene products are only innocent bystanders and which contribute significantly to tumor angiogenesis(4-6) and metastasis(6-8). Here we investigated whether the expression in tumors of a secreted fibroblast growth factor (FGF)-binding protein (FGF-BP)(9) that mobilizes and activates(10) locally stored FGFs (ref. 11) can serve as an angiogenic switch molecule(3). Developmental expression of the retinoid-regulated FGF-BP gene(12) is prominent in the skin and intestine during the perinatal phase and is down-modulated in the adult(13). The gene is, however, upregulated in carcinogen-induced skin tumors(13), in squamous cell carcinoma (SCC)(10) and in some colon cancer cell lines and tumor samples. To assess the significance of FGF-BP expression in tumors, we depleted human SCC (ME-180) and colon carcinoma (LS174T) cell lines of their endogenous FGF-BP by targeting with specific ribozymes. We found that the reduction of FGF-BP reduced the release of biologically active basic FCF (bFGF) from cells in culture. Furthermore, the growth and angiogenesis of xenograft tumors in mice was decreased in parallel with the reduction of FGF-BP. This suggests that human tumors can utilize FGF-BP as an angiogenic switch molecule.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University			Berchem, Guy/C-9364-2014; Aigner, Achim/R-4429-2017; Liaudet-Coopman, Emmanuelle/N-4744-2017	Berchem, Guy/0000-0003-0157-2257; Aigner, Achim/0000-0002-2778-6256; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASANO M, 1995, CANCER RES, V55, P5296; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN CJ, 1992, NUCLEIC ACIDS RES, V20, P4581, DOI 10.1093/nar/20.17.4581; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; KUAN SF, 1987, CANCER RES, V47, P5715; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1995, AM J PATHOL, V147, P9; WU DQ, 1991, J BIOL CHEM, V266, P16778	20	201	213	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1137	1140		10.1038/nm1097-1137	http://dx.doi.org/10.1038/nm1097-1137			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334727				2022-12-27	WOS:A1997XZ28700041
J	Masuzaki, H; Ogawa, Y; Sagawa, N; Hosoda, K; Matsumoto, T; Mise, H; Nishimura, H; Yoshimasa, Y; Tanaka, I; Mori, T; Nakao, K				Masuzaki, H; Ogawa, Y; Sagawa, N; Hosoda, K; Matsumoto, T; Mise, H; Nishimura, H; Yoshimasa, Y; Tanaka, I; Mori, T; Nakao, K			Nonadipose tissue production of leptin: Leptin as a novel placenta-derived hormone in humans	NATURE MEDICINE			English	Article							OBESE GENE; MESSENGER-RNA; EXPRESSION; WEIGHT; CLONING; PROTEIN; CELLS; MICE	Leptin is a circulating hormone that is expressed abundantly and specifically in the adipose tissue(1-5). It is involved in the regulation of energy homeostasis, as well as the neuroendocrine and reproductive systems(6-11). Here, we demonstrate production of leptin by nonadipose tissue, namely, placental trophoblasts and amnion cells from uteri of pregnant women. We show that pregnant women secrete a considerable amount of leptin from the placenta into the maternal circulation as compared with nonpregnant obese women. Leptin production was also detected in a cultured human choriocarcinoma cell line, BeWo cells, and was augmented during the course of forskolin-induced differentiation of cytotrophoblasts into syncytiotrophoblasts. Plasma leptin levels were markedly elevated in patients with hydatidiform mole or choriocarcinoma and were reduced after surgical treatment or chemotherapy. Leptin is also produced by primary cultured human amnion cells and is secreted into the amniotic fluid. The present study provides evidence for leptin as a novel placenta-derived hormone in humans and suggests the physiologic and pathophysiologic significance of leptin in normal pregnancy and gestational trophoblastic neoplasms.	KYOTO UNIV,GRAD SCH MED,DEPT MED & CLIN SCI,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,GRAD SCH MED,DEPT GYNECOL & OBSTET,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,GRAD SCH HUMAN & ENVIRONM STUDIES,OTSUKA DEPT INT PREVENT NUTR MED,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BURRES NS, 1987, CANCER RES, V47, P5059; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALLAS JL, 1995, SCIENCE, V269, P543; Hosoda K, 1996, BIOCHEM BIOPH RES CO, V221, P234, DOI 10.1006/bbrc.1996.0579; ITOH H, 1993, J CLIN ENDOCR METAB, V76, P907, DOI 10.1210/jc.76.4.907; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SANFILIPPO JS, 1987, HUMAN PLACENTA, P179; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	1003	1045	0	85	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1029	1033		10.1038/nm0997-1029	http://dx.doi.org/10.1038/nm0997-1029			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288733				2022-12-27	WOS:A1997XT84200039
J	Shirasawa, S; Yunker, AMR; Roth, KA; Brown, GA; Horning, S; Korsmeyer, SJ				Shirasawa, S; Yunker, AMR; Roth, KA; Brown, GA; Horning, S; Korsmeyer, SJ			Enx (Hox11L1)-deficient mice develop myenteric neuronal hyperplasia and megacolon	NATURE MEDICINE			English	Article							ENTERIC NERVOUS-SYSTEM; ENDOTHELIN-B RECEPTOR; NITRIC-OXIDE SYNTHASE; HIRSCHSPRUNGS-DISEASE; INTESTINAL DYSPLASIA; NADPH DIAPHORASE; TRANSGENIC MICE; HOX11 GENE; GUINEA-PIG; EXPRESSION	The isolated homeobox gene Enx (Hox11L1) is expressed in enteric neurons Innervating distal ileum, and proximal and distal colon. Enx-deficient mice develop megacolon with massive distension of the proximal colon. The number of myenteric ganglia, total neurons per ganglion, and NADPH diaphorase presumptive inhibitory neurons per ganglion are increased in the proximal and distal colon, but decreased in the distal ileum of all Enx(-/-) mice. Enx(-/-) mice provide a model for human neuronal intestinal dysplasia (NID), in which myenteric neuronal hyperplasia and megacolon are seen. These results suggest that Enx is required for the proper positional specification and differentiative cell fate of enteric neurons.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Roth, Kevin/0000-0002-0643-995X	NINDS NIH HHS [NS 35107] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035107] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barone V, 1996, AM J MED GENET, V62, P195, DOI 10.1002/(SICI)1096-8628(19960315)62:2<195::AID-AJMG15>3.0.CO;2-J; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; GABELLA G, 1984, J NEUROCYTOL, V13, P73, DOI 10.1007/BF01148319; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HEINICKE EA, 1987, J NEUROSCI METH, V21, P45, DOI 10.1016/0165-0270(87)90101-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Hug BA, 1996, MOL CELL BIOL, V16, P2906; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MUNAKATA K, 1985, J PEDIATR SURG, V20, P231, DOI 10.1016/S0022-3468(85)80109-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; REIFFERSCHEID P, 1982, HIRSCHSPRUNGS DISEAS, P133; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; ROTHMAN TP, 1982, J NEUROSCI, V2, P381; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHARLI AF, 1981, J PEDIATR SURG, V16, P164, DOI 10.1016/S0022-3468(81)80344-2; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TENNYSON VM, 1993, DEV DYNAM, V198, P28, DOI 10.1002/aja.1001980105; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; YOUNG HM, 1992, HISTOCHEMISTRY, V97, P375, DOI 10.1007/BF00270041; YUNKER AM, 1997, AM J PHYSL, V271	30	100	105	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					646	650		10.1038/nm0697-646	http://dx.doi.org/10.1038/nm0697-646			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176491				2022-12-27	WOS:A1997XB97400034
J	Haase, G; Kennel, P; Vigne, E; Akli, S; Revah, F; Schmalbruch, H; Kahn, A				Haase, G; Kennel, P; Vigne, E; Akli, S; Revah, F; Schmalbruch, H; Kahn, A			Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTONEURON SURVIVAL; MEDIATED TRANSFER; SKELETAL-MUSCLE; GROWTH-FACTOR; MOUSE MUTANT; CELL-DEATH; INVIVO; BDNF; DEGENERATION	Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy cause progressive paralysis, often leading to premature death. Neurotrophic factors have been suggested as therapeutic agents for motor neuron diseases, but their clinical use as injected recombinant protein was limited by toxicity and/or poor bioavailability. We demonstrate here that adenovirus-mediated gene transfer of neurotrophin-3 (NT-3) can produce substantial therapeutic effects in the mouse mutant pmn (progressive motor neuronopathy). After intramuscular injection of the NT-3 adenoviral vector, pmn mice showed a 50% increase in life span, reduced loss of motor axons and improved neuromuscular function as assessed by electromyography. These results were further improved by coinjecting an adenoviral vector coding for ciliary neurotrophic factor. Therefore, adenovirus-mediated gene transfer of neurotrophic factors offers new prospects for the treatment of motor neuron diseases.	INST COCHIN GENET MOL,INSERM,U129,F-75014 PARIS,FRANCE; INST DEV BIOL,INSERM,U382,F-13288 MARSEILLE,FRANCE; INST GUSTAVE ROUSSY,CNRS,PR2 URA 1301,F-94805 VILLEJUIF,FRANCE; UNIV COPENHAGEN,PANUM INST,INST MED PHYSIOL,DK-2200 COPENHAGEN N,DENMARK; RHONE POULENC RORER GENCELL,F-94403 VITRY SUR SEINE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Copenhagen; Sanofi-Aventis								AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BISCHOFF C, 1994, MUSCLE NERVE, V17, P842, DOI 10.1002/mus.880170803; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; Braun S, 1996, J NEUROL SCI, V136, P17, DOI 10.1016/0022-510X(95)00315-S; BRUNIALTI ALB, 1995, GENOMICS, V29, P131, DOI 10.1006/geno.1995.1223; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Finiels F, 1995, NEUROREPORT, V7, P373, DOI 10.1097/00001756-199512000-00088; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GHADGE GD, 1995, GENE THER, V2, P132; GRIESBECK O, 1995, J NEUROSCI RES, V42, P21, DOI 10.1002/jnr.490420104; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HANSEN S, 1978, J NEUROL NEUROSUR PS, V41, P773, DOI 10.1136/jnnp.41.9.773; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1995, ADV NEUROL, V68, P235; HITT M, 1994, CELL BIOL LAB HDB, V1, P479; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JOHNSON DR, 1967, J EMBRYOL EXP MORPH, V17, P543; Kennel PF, 1996, NEUROBIOL DIS, V3, P137, DOI 10.1006/nbdi.1996.0014; LANGFORD LA, 1983, ANAT REC, V205, P207, DOI 10.1002/ar.1092050211; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, DEV BRAIN RES, V25, P195; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; NAMBA T, 1967, AM J CLIN PATHOL, V47, P74; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OZCELIK T, 1991, GENOMICS, V10, P569, DOI 10.1016/0888-7543(91)90437-J; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; Sagot Y, 1996, J NEUROSCI, V16, P2335; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; VINCENT N, 1993, NAT GENET, V5, P130, DOI 10.1038/ng1093-130; WILLISON RG, 1964, J NEUROL NEUROSUR PS, V27, P386, DOI 10.1136/jnnp.27.5.386	46	206	217	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					429	436		10.1038/nm0497-429	http://dx.doi.org/10.1038/nm0497-429			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095177				2022-12-27	WOS:A1997WQ82500033
J	Hafezi, F; Steinbach, JP; Marti, A; Munz, K; Wang, ZQ; Wagner, EF; Aguzzi, A; Reme, CE				Hafezi, F; Steinbach, JP; Marti, A; Munz, K; Wang, ZQ; Wagner, EF; Aguzzi, A; Reme, CE			The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo	NATURE MEDICINE			English	Article							RAT RETINA; MESSENGER-RNA; EXPRESSION; MOUSE; MICE; JUN; DIFFERENTIATION; IDENTIFICATION; PROTOONCOGENES; TRANSCRIPTION	Apoptotic cell death in the retina was recently demonstrated in animal models of the hereditary human retinal dystrophy known as retinitis pigmentosa(1,2). Although recent evidence indicates that the proto-oncogene c-fos is a mediator of apoptosis(3-7), its precise role is unclear. In fact, under some conditions, c-fos may even protect against apoptotic cell death(8). In the retina, c-fos is physiologically expressed in a diurnal manner and is inducible by light(9,10). We previously observed a light-elicited, dose-dependent apoptotic response in rat photoreceptors(11). To determine whether c-fos is involved in the light-induced apoptotic pathway we have used control mice and mice lacking c-fos. We found that following dark adaptation and two hours of light exposure both groups of animals exhibited only a few apoptotic cells. However, at 12 and 24 additional hours after light exposure, apoptosis increased dramatically in controls but was virtually absent in those mice lacking c-fos. Therefore, c-fos is essential for light-induced apoptosis of photoreceptors. Notably, c-fos is continuously upregulated concomitant with apoptotic photoreceptor death in our system and in animal models of retinitis pigmentosa (Agarwal, N. et al., Invest. Ophthalmol. Vis. Sci. Suppl. 36, S638 and Rich, K.A, et al., Invest. Ophthalmol. Vis. Sci. Suppl. 35, 1833). Inhibition of c-fos expression might therefore represent a novel therapeutic strategy to retard the time course of retinal dystrophies and light-induced retinal degeneration.	UNIV CLIN ZURICH,DEPT OPHTHALMOL,CH-8091 ZURICH,SWITZERLAND; UNIV CLIN ZURICH,DEPT NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Hafezi, Farhad/A-1446-2010; Aguzzi, Adriano/A-3351-2008	Hafezi, Farhad/0000-0001-8935-4558; Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUDEHITHLU KP, 1993, BRAIN RES, V631, P77, DOI 10.1016/0006-8993(93)91189-Y; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MARINO S, 1995, LAB INVEST, V73, P103; MARTI A, 1994, ONCOGENE, V9, P1213; NIR I, 1993, MOL BRAIN RES, V19, P47, DOI 10.1016/0169-328X(93)90147-H; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Preston GA, 1996, MOL CELL BIOL, V16, P211; REINBOTH JJ, 1995, CURR EYE RES, V14, P1001, DOI 10.3109/02713689508998521; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; REME CE, 1994, INVEST OPHTH VIS SCI, V35, P78; REME CE, 1995, RETINAL DEGENERATION, P19; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; SZCZESNY PJ, 1995, CELL TISSUE PROTECTI, P163; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307	26	214	225	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					346	349		10.1038/nm0397-346	http://dx.doi.org/10.1038/nm0397-346			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055866				2022-12-27	WOS:A1997WL30500040
J	Catzavelos, C; Bhatacharya, N; Ung, YC; Wilson, JA; Roncari, L; Sandhu, C; Shaw, P; Yeger, H; MoravaProtzner, I; Kapusta, L; Franssen, E; Pritchard, KI; Slingerland, JM				Catzavelos, C; Bhatacharya, N; Ung, YC; Wilson, JA; Roncari, L; Sandhu, C; Shaw, P; Yeger, H; MoravaProtzner, I; Kapusta, L; Franssen, E; Pritchard, KI; Slingerland, JM			Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; DEPENDENT KINASE; P27; G1	Breast cancer is the second leading cause of cancer death in North American women. There is considerable need for reliable prognostic markers to assist clinicians in making management decisions. Although a variety of factors have been tested, only tumor stage, grade, size, hormone receptor status, and S-phase fraction are used on a routine basis(1). The cell cycle is governed by a family of cyclin-dependent kinases (cdks), which are regulated by associated cyclins and by phosphorylation(2). p27(Kip1), a cyclin-dependent kinase inhibitor, regulates progression from G(1) into S phase by binding and inhibiting cyclin/cdks(3,4). p27(Kip1) protein levels and/or activity are upregulated by growth inhibitory cytokines including transforming growth factor-beta (TGF-beta) and, thus, provide an important link between extracellular regulators and the cell cycle(5-7). Loss of p27(Kip1), a negative cell-cycle regulator, may contribute to oncogenesis and tumor progression. However, p27(Kip1) mutations in human tumors are extremely rare(8,9). We have demonstrated by immunohistochemistry that p27(Kip1) protein levels are reduced in primary breast cancers and that this is associated with tumor progression in both in situ and invasive lesions. This was confirmed by western analysis, reflected in increased G(1)/S-phase cyclin-dependent kinase activities and shown to be regulated posttranscriptionally by in situ hybridization. Furthermore, on multivariate analysis, low p27(KiP1) is a predictor of reduced disease-free survival. This simple and reliable immunohistochemical assay may become a routine part of breast cancer evaluation and may influence patient management.	SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL RES, TORONTO, ON M4N 3M5, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT PATHOL, TORONTO, ON M4N 3M5, CANADA; HOSP SICK CHILDREN, DEPT PAEDIAT LAB MED, TORONTO, ON M5G 1X8, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV RADIAT ONCOL, TORONTO, ON M4N 3M5, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV CLIN TRIALS & EPIDEMIOL, TORONTO, ON M4N 3M5, CANADA; TORONTO SUMMYBROOK REG CANC CLIN, DIV MED ONCOL, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University of Toronto; Sunnybrook Research Institute; University of Toronto; Sunnybrook Research Institute								Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Ferrando AA, 1996, HUM GENET, V97, P91; HARRIS JR, 1987, BREAST DIS, P327; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LODA M, 1996, NAT MED, V3, P230; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED SI, 1994, J CELL SCI, P69; *SAS I, 1990, SAS STAT US GUID, V2, P1027; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; StCroix B, 1996, NAT MED, V2, P1204; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang DS, 1996, AM J RESP CELL MOL, V14, P409, DOI 10.1165/ajrcmb.14.5.8624245; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	20	753	776	6	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					227	230		10.1038/nm0297-227	http://dx.doi.org/10.1038/nm0297-227			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018244				2022-12-27	WOS:A1997WF08800044
J	Ewing, AG; Gavin, PF; Hietpas, PB; Bullard, KM				Ewing, AG; Gavin, PF; Hietpas, PB; Bullard, KM			Continuous separations in microfabricated channels for monitoring ultrasmall biological environments	NATURE MEDICINE			English	Editorial Material							CAPILLARY ELECTROPHORESIS; CHROMAFFIN CELLS; VESICLES				Ewing, AG (corresponding author), PENN STATE UNIV,DEPT CHEM,DAVEY LAB 152,UNIVERSITY PK,PA 16802, USA.		Ewing, Andrew G/A-3650-2009					BERGQUIST J, 1994, P NATL ACAD SCI USA, V91, P12912, DOI 10.1073/pnas.91.26.12912; CHEN GY, 1995, J NEUROSCI, V15, P7747; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Gavin PF, 1996, J AM CHEM SOC, V118, P8932, DOI 10.1021/ja961368s; GUTTMAN A, 1990, ANAL CHEM, V62, P137, DOI 10.1021/ac00201a010; Huang X.C., 1995, ANAL CHEM, V64, P2149; JORGENSON JW, 1983, SCIENCE, V222, P266, DOI 10.1126/science.6623076; KOSTICHKA AJ, 1992, BIO-TECHNOL, V10, P78, DOI 10.1038/nbt0192-78; KRISTENSEN HK, 1994, J NEUROSCI METH, V51, P183, DOI 10.1016/0165-0270(94)90009-4; LESCZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LIU YM, 1995, J AM CHEM SOC, V117, P8871, DOI 10.1021/ja00139a029; Mesaros JM, 1996, ANAL CHEM, V68, P3441, DOI 10.1021/ac9601371; MESAROS JM, 1993, ANAL CHEM, V65, P3313, DOI 10.1021/ac00070a024; MESAROS JM, 1994, ANAL CHEM, V66, pA527; SULZER D, 1995, J NEUROSCI, V15, P4102; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WIGHTMAN RM, 1988, ELECTROANALYTICAL CH, P267; Woolley AT, 1996, ANAL CHEM, V68, P4081, DOI 10.1021/ac960718q	18	24	24	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					97	99		10.1038/nm0197-97	http://dx.doi.org/10.1038/nm0197-97			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986749				2022-12-27	WOS:A1997WA73300047
J	Marx, PA; Spira, AI; Gettie, A; Dailey, PJ; Veazey, RS; Lackner, AA; Mahoney, CJ; Miller, CJ; Claypool, LE; Ho, DD; Alexander, NJ				Marx, PA; Spira, AI; Gettie, A; Dailey, PJ; Veazey, RS; Lackner, AA; Mahoney, CJ; Miller, CJ; Claypool, LE; Ho, DD; Alexander, NJ			Progesterone implants enhance SIV vaginal transmission and early virus load	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; INTRAVAGINAL INOCULATION; RHESUS MACAQUES; INFECTION; TYPE-2; MODEL; CYCLE; HIV	Simian immunodeficiency virus (SIV) can cross the intact vaginal epithelium to establish a systemic infection in macaques (mac). Using this SIVmac model, we found that subcutaneous progesterone implants, which could mimic hormonally based contraceptives, thinned the vaginal epithelium and enhanced SIV vaginal transmission 7.7-fold over that observed in macaques treated with placebo implants and exposed to SIV in the follicular phase of the menstrual cycle. Progesterone treatment also increased the number of SIV DNA-positive cells in the vaginal lamina propria as detected by in situ polymerase chain reaction analysis. Moreover, plasma viral RNA was elevated for the first three months in macaques with progesterone implants, and three of the progesterone-treated macaques developed relatively rapid disease courses. This study shows that SIV genital infection and disease course are enhanced by subcutaneous implants containing progesterone when compared with the rate of vaginal transmission in the follicular phase.	NYU,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10016; CHIRON CORP,NUCLE ACID SYST,EMERYVILLE,CA 94608; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,SOUTHBOROUGH,MA 01772; NYU,MED CTR,LAB EXPT MED & SURG PRIMATES,TUXEDO PK,NY 10987; UNIV CALIF DAVIS,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616; EASTERN VIRGINIA MED SCH,CONRAD PROGRAM,ARLINGTON,VA 22209; NICHHD,CONTRACEPT DEV BRANCH,NIH,BETHESDA,MD 20892	New York University; Novartis; Harvard University; New York University; University of California System; University of California Davis; Eastern Virginia Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Marx, PA (corresponding author), ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,455 1ST AVE,7TH FLOOR,NEW YORK,NY 10016, USA.				NCRR NIH HHS [RR 00168] Funding Source: Medline; NIAID NIH HHS [AI 28147, AI 38573-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI028147, R01AI038573, U01AI028147] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DALY CC, 1994, GENITOURIN MED, V70, P110; ELLINWOOD WE, 1984, BIOL REPROD, V31, P714, DOI 10.1095/biolreprod31.4.714; FAWCETT DW, 1994, TXB HISTOLOGY, P857; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; KELL PD, 1992, J ROY SOC MED, V85, P706; KULLER L, 1994, J MED PRIMATOL, V23, P397, DOI 10.1111/j.1600-0684.1994.tb00127.x; MARX PA, 1993, SCIENCE, V260, P1363; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; OVERPECK JG, 1978, J TOXICOL ENV HEALTH, V4, P785, DOI 10.1080/15287397809529700; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PARAKKAL PF, 1972, BIOL REPROD, V6, P117, DOI 10.1093/biolreprod/6.1.117; PARR MB, 1994, LAB INVEST, V70, P369; PLOURDE PJ, 1994, HIV EPIDEMIOLOGY, P107; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RASHEED S, 1995, J REPROD MED, V40, P747; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STRATTON P, 1994, REPROD MED REV, V3, P113; TEEPE AG, 1990, ANTIVIR RES, V14, P227, DOI 10.1016/0166-3542(90)90004-Q	21	390	397	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1084	1089		10.1038/nm1096-1084	http://dx.doi.org/10.1038/nm1096-1084			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837605	Bronze			2022-12-27	WOS:A1996VK99500027
J	Cui, HM; Horon, IL; Ohlsson, R; Hamilton, SR; Feinberg, AP				Cui, HM; Horon, IL; Ohlsson, R; Hamilton, SR; Feinberg, AP			Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability	NATURE MEDICINE			English	Article							BECKWITH-WIEDEMANN SYNDROME; FACTOR-II GENE; WILMS-TUMOR; LUNG-CANCER; IGF2; METHYLATION; CARCINOMAS; EXPRESSION; RELAXATION; FREQUENCY	Loss of imprinting (LOI) is an epigenetic alteration of some cancers involving loss of parental origin-specific expression of imprinted genes. We observed LOI of the insulin-like growth factor-ii gene in twelve of twenty-seven informative colorectal cancer patients (44%), as well as in the matched normal colonic mucosa of the patients with LOI in their cancers, and in peripheral blood samples of four patients. Ten of eleven cancers (91%) with microsatellite instability showed LOI, compared with only two of sixteen tumors (12%) without microsatellite instability (P< 0.001). Control patients without cancer showed LOI in colonic mucosa of only two of sixteen cases (12%, P < 0.001) and two of fifteen blood samples (13%, P < 0.001). These data suggest that LOI in tumor and normal tissue identifies most colorectal cancer patients with microsatellite instability in their tumors, and that LOI may identify an important subset of the population with cancer or at risk of developing cancer.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Maryland Div Hlth Stat, Baltimore, MD 21201 USA; Uppsala Univ, Dept Anim Dev, S-75236 Uppsala, Sweden	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Uppsala University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1064 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.	afeinberg@jhu.edu	Cui, Hengmi/A-2598-2008; Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [R01CA065145, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA65145, CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BISGAARD ML, 1994, HUM MUTAT, V3, P121, DOI 10.1002/humu.1380030206; BOLAND CR, UNPUB NAT CANC I WOR; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Brassett C, 1996, J MED GENET, V33, P981, DOI 10.1136/jmg.33.12.981; Bubb VJ, 1996, ONCOGENE, V12, P2641; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Chetty R, 1998, J CLIN PATHOL-MOL PA, V51, P35, DOI 10.1136/mp.51.1.35; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Dietmaier W, 1997, CANCER RES, V57, P4749; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1994, COLD SPRING HARB SYM, V59, P357, DOI 10.1101/SQB.1994.059.01.040; FEINBERG AP, 1998, GENETIC BASIS HUMAN, P95; FORD D, 1995, AM J HUM GENET, V57, P1457; He LM, 1998, ONCOGENE, V16, P113, DOI 10.1038/sj.onc.1201501; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Kim H, 1998, PATHOL RES PRACT, V194, P3, DOI 10.1016/S0344-0338(98)80006-X; KIM HG, 1994, AM J PATHOL, V145, P148; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Ottini L, 1997, CANCER RES, V57, P4523; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147; Sekine I, 1997, JPN J CANCER RES, V88, P559, DOI 10.1111/j.1349-7006.1997.tb00419.x; Senba S, 1998, CANCER, V82, P279, DOI 10.1002/(SICI)1097-0142(19980115)82:2<279::AID-CNCR6>3.3.CO;2-D; Shinmura K, 1997, CANCER EPIDEM BIOMAR, V6, P693; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Thibodeau SN, 1998, CANCER RES, V58, P1713; VOGELSANG HE, 1997, LANGENBECKS ARCH C S, V114, P113; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	41	244	265	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1276	1280		10.1038/3260	http://dx.doi.org/10.1038/3260			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809551				2022-12-27	WOS:000076731000036
J	Allay, JA; Persons, DA; Galipeau, J; Riberdy, JM; Ashmun, RA; Blakley, RL; Sorrentino, BP				Allay, JA; Persons, DA; Galipeau, J; Riberdy, JM; Ashmun, RA; Blakley, RL; Sorrentino, BP			In vivo selection of retrovirally transduced hematopoietic stem cells	NATURE MEDICINE			English	Article							LONG-TERM HEMATOPOIESIS; RESISTANT BONE-MARROW; DIHYDROFOLATE-REDUCTASE; GENE-TRANSFER; IN-VIVO; NUCLEOSIDE TRANSPORT; PROGENITOR CELLS; MICE; METHOTREXATE; MOUSE	One of the main impediments to effective gene therapy of blood disorders is the resistance of human hematopoietic stem cells to stable genetic modification. We show here that a small minority of retrovirally transduced stem cells can be selectively enriched in vivo, which might be a way to circumvent this obstacle. We constructed two retroviral vectors containing an antifolate-resistant dihydrofolate reductase cDNA transcriptionally linked to a reporter gene. Mice were transplanted with transduced bone marrow cells and then treated with an antifolate-based regimen that kills unmodified stem cells. Drug treatment significantly increased the percentage of vector-expressing peripheral blood erythrocytes, platelets, granulocytes, and T and B lymphocytes. Secondary transplant experiments demonstrated that selection occurred at the level of hematopoietic stem cells. This system for in vivo stem-cell selection provides a means to increase the number of genetically modified cells after transplant, and may circumvent an substantial obstacle to successful gene therapy for human blood diseases.	St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol & Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA031922] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 31922, P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allay JA, 1997, EXP HEMATOL, V25, P1069; Allay JA, 1997, BLOOD, V90, P3546, DOI 10.1182/blood.V90.9.3546; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Blau CA, 1996, HUM GENE THER, V7, P2069, DOI 10.1089/hum.1996.7.17-2069; Blau CA, 1997, BLOOD, V89, P146, DOI 10.1182/blood.V89.1.146.146_146_154; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; COREY CA, 1990, BLOOD, V75, P337; Davis BM, 1997, CANCER RES, V57, P5093; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; HARRISON DE, 1980, BLOOD, V55, P77; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARLSSON S, 1991, BLOOD, V78, P2481; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LEWIS WS, 1995, J BIOL CHEM, V270, P5057, DOI 10.1074/jbc.270.10.5057; LI MX, 1994, BLOOD, V83, P3403; LYNCH TP, 1981, CANCER RES, V41, P560; Maze R, 1997, J IMMUNOL, V158, P1006; MOLINEUX G, 1994, BLOOD, V83, P3491; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; PODDA S, 1992, P NATL ACAD SCI USA, V89, P9676, DOI 10.1073/pnas.89.20.9676; RONGEN GA, 1995, J CLIN INVEST, V95, P658, DOI 10.1172/JCI117711; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Spencer HT, 1996, BLOOD, V87, P2579, DOI 10.1182/blood.V87.6.2579.bloodjournal8762579; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLSON JKV, 1989, CANCER RES, V49, P1866; ZHAO SC, 1994, CANCER GENE THER, V1, P27	34	178	182	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1136	1143		10.1038/2632	http://dx.doi.org/10.1038/2632			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771746				2022-12-27	WOS:000076230100032
J	Saez, E; Tontonoz, P; Nelson, MC; Alvarez, JGA; U, TM; Baird, SM; Thomazy, VA; Evans, RM				Saez, E; Tontonoz, P; Nelson, MC; Alvarez, JGA; U, TM; Baird, SM; Thomazy, VA; Evans, RM			Activators of the nuclear receptor PPAR gamma enhance colon polyp formation	NATURE MEDICINE			English	Article							APC(DELTA-716) KNOCKOUT MICE; OMEGA-6 FATTY-ACIDS; DIETARY-FAT; F344 RATS; COLORECTAL-CANCER; CARCINOGENESIS; EXPRESSION; CYCLOOXYGENASE-2; DIFFERENTIATION; EICOSANOIDS	A high-fat diet increases the risk of colon, breast and prostate cancer. The molecular mechanism by which dietary lipids promote tumorigenesis is unknown. Their effects may be mediated at least in part by the peroxisome proliferator-activated receptors (PPARs). These ligand-activated nuclear receptors modulate gene expression in response to fatty acids, lipid-derived metabolites and antidiabetic drugs. To explore the role of the PPARs in diet-induced carcinogenesis, we treated mice predisposed to intestinal neoplasia with a synthetic PPAR gamma ligand. Reflecting the pattern of expression of PPAR gamma in the gastrointestinal tract, treated mice developed a considerably greater number of polyps in the colon but not in the small intestine, indicating that PPAR gamma activation may provide a molecular link between a high-fat diet and increased risk of colorectal cancer.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92093 USA; VA Med Ctr, San Diego, CA 92161 USA; Univ Texas, Sch Med, Dept Pathol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; University of Texas System; University of Texas System	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; CANTELLO BCC, 1994, J MED CHEM, V37, P3977, DOI 10.1021/jm00049a017; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; Hioki K, 1997, CARCINOGENESIS, V18, P1863, DOI 10.1093/carcin/18.10.1863; HOGAN ML, 1984, J NATL CANCER I, V73, P1293; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Klurfeld DM, 1997, AM J CLIN NUTR, V66, P1530, DOI 10.1093/ajcn/66.6.1530S; LEFEBVRE AM, 1998, NAT MED, V4, pR30; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; OSHIMA M, 1995, CARCINOGENESIS, V16, P2605, DOI 10.1093/carcin/16.11.2605; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; REDDY BS, 1991, CANCER RES, V51, P487; REDDY BS, 1985, JNCI-J NATL CANCER I, V75, P791; REDDY BS, 1984, JNCI-J NATL CANCER I, V72, P745; REDDY BS, 1988, CANCER RES, V48, P6642; SANO H, 1995, CANCER RES, V55, P3785; Singh J, 1997, CANCER RES, V57, P3465; TEMPLE NJ, 1987, CANCER LETT, V37, P109, DOI 10.1016/0304-3835(87)90151-0; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Weisburger JH, 1997, J AM DIET ASSOC, V97, pS16, DOI 10.1016/S0002-8223(97)00725-6; *WHO, 1997, WORLD HLTH REP	35	517	537	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1058	1061		10.1038/2042	http://dx.doi.org/10.1038/2042			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734400				2022-12-27	WOS:000075804100040
J	Woiciechowsky, C; Asadullah, K; Nestler, D; Eberhardt, B; Platzer, C; Schoning, B; Glockner, F; Lanksch, WR; Volk, HD; Docke, WD				Woiciechowsky, C; Asadullah, K; Nestler, D; Eberhardt, B; Platzer, C; Schoning, B; Glockner, F; Lanksch, WR; Volk, HD; Docke, WD			Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury	NATURE MEDICINE			English	Article							PITUITARY-ADRENAL AXIS; NECROSIS-FACTOR-ALPHA; INDUCED SUPPRESSION; HLA-DR; SEPSIS; EXPRESSION; TRAUMA; CATECHOLAMINES; PREDICTION; SURGERY	The mechanism of immunodepression after brain injury is not yet clear. Here we demonstrate rapid systemic release of the immunoinhibitory cytokine interleukin-10, monocytic deactivation and a high incidence of infection in patients with 'sympathetic storm' due to acute accidental or iatrogenic brain trauma. In vitro studies showed that within minutes catecholamines trigger the secretion of interleukin-10 from unstimulated monocytes through a beta-adrenoreceptor-mediated, cAMP/protein kinase A-dependent pathway. We found that in a rat model of acute brain injury, the beta-receptor antagonist propranolol prevented the increase of interleukin-10 plasma levels. Rapid monocytic interleukin-10 release after sympathetic activation may represent a common pathway for immunodepression induced by stress and injury.	Humboldt Univ, Med Sch Charite, Dept Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Dept Dermatol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Dept Neurosurg, D-10098 Berlin, Germany; Univ Jena, Sch Med, Inst Anat 2, D-07740 Jena, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena	Docke, WD (corresponding author), Humboldt Univ, Med Sch Charite, Dept Med Immunol, D-10098 Berlin, Germany.	volkklim@rz.charite.hu-berlin.de	Asadullah, Khusru/AAG-9810-2021; volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668				ADCOCK IM, 1995, AM J PHYSIOL-CELL PH, V268, pC331, DOI 10.1152/ajpcell.1995.268.2.C331; Asadullah K, 1995, Eur J Emerg Med, V2, P184, DOI 10.1097/00063110-199512000-00003; ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Chiolero R, 1994, New Horiz, V2, P432; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOBBIN JP, 1991, BRAIN BEHAV IMMUN, V5, P339, DOI 10.1016/0889-1591(91)90029-A; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; DOCKE WD, 1997, CRIT CARE MED, V25, pA50; DOCKE WD, 1997, 4 INT C IMM CONS TRA, P293; DUNN AJ, 1993, CIBA F SYMP, V172, P226; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FABIAN TC, 1995, SURGERY, V118, P63, DOI 10.1016/S0039-6060(05)80011-X; GIBBONS RA, 1989, CLIN EXP IMMUNOL, V75, P371; GUILLOU PJ, 1993, LANCET, V342, P217, DOI 10.1016/0140-6736(93)92303-B; HAHN PY, 1995, SHOCK, V4, P269, DOI 10.1097/00024382-199510000-00007; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JAREK MJ, 1993, CRIT CARE MED, V21, P543, DOI 10.1097/00003246-199304000-00015; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; Justice Blair, 1994, Comprehensive Therapy, V20, P232; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; KARLSBERG RP, 1981, AM HEART J, V102, P24, DOI 10.1016/0002-8703(81)90408-7; KOFF WC, 1986, LYMPHOKINE RES, V5, P239; LIVINGSTON DH, 1988, ARCH SURG-CHICAGO, V123, P1309; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; NAITO Y, 1992, ANESTHESIOLOGY, V77, P426, DOI 10.1097/00000542-199209000-00004; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROTHWELL PM, 1995, CRIT CARE MED, V23, P78, DOI 10.1097/00003246-199501000-00015; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; STERNBERG EM, 1995, HORM RES, V43, P159, DOI 10.1159/000184268; Suberville S, 1996, EUR J IMMUNOL, V26, P2601, DOI 10.1002/eji.1830261110; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; Uotila P, 1996, CANCER IMMUNOL IMMUN, V43, P1; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; VOLK HD, 1989, CLIN TRANSPLANT, V3, P246; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; ZORRILLA EP, 1994, BRAIN BEHAV IMMUN, V8, P293, DOI 10.1006/brbi.1994.1028; ZWILLING BS, 1993, BRAIN BEHAV IMMUN, V7, P29, DOI 10.1006/brbi.1993.1003	42	342	376	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					808	813		10.1038/nm0798-808	http://dx.doi.org/10.1038/nm0798-808			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662372				2022-12-27	WOS:000074543900035
J	Jain, RK				Jain, RK			The next frontier of molecular medicine: Delivery of therapeutics	NATURE MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548	NCI NIH HHS [R35-CA-56591] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BAXTER LT, 1995, CANCER RES, V55, P4611; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Jain Rakesh K., 1997, Microcirculation (Philadelphia), V4, P1, DOI 10.3109/10739689709148314; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; KLAUSNER RD, 1997, NATIONS INVESTMENT C	9	324	349	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					655	657		10.1038/nm0698-655	http://dx.doi.org/10.1038/nm0698-655			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623964				2022-12-27	WOS:000074008300020
J	Batson, A				Batson, A			Win-win interactions between the public and private sectors	NATURE MEDICINE			English	Editorial Material									World Bank, Human Dev Network, Washington, DC 20433 USA	The World Bank	Batson, A (corresponding author), World Bank, Human Dev Network, 1818 H St NW, Washington, DC 20433 USA.								0	19	19	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			487	491		10.1038/nm0598supp-487	http://dx.doi.org/10.1038/nm0598supp-487			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585192	Bronze			2022-12-27	WOS:000073453500010
J	Schneider, J; Gilbert, SC; Blanchard, TJ; Hanke, T; Robson, KJ; Hannan, CM; Becker, M; Sinden, R; Smith, GL; Hill, AVS				Schneider, J; Gilbert, SC; Blanchard, TJ; Hanke, T; Robson, KJ; Hannan, CM; Becker, M; Sinden, R; Smith, GL; Hill, AVS			Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara	NATURE MEDICINE			English	Article							BROAD SPECIES-SPECIFICITY; CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-BERGHEI; INTERFERON-GAMMA; INFLUENZA-VIRUS; IMMUNITY; IMMUNIZATION; INFECTION; EPITOPES; ANTIGEN	Immunization with irradiated sporozoites can protect against malaria infection and intensive efforts are aimed at reproducing this effect with subunit vaccines. A particular sequence of subunit immunization with pre-erythrocytic antigens of Plasmodium berghei, consisting of single dose priming with plasmid DNA followed by a single boost with a recombinant modified vaccinia virus Ankara (MVA) expressing the same antigen, induced unprecedented complete protection against P. berghei sporozoite challenge in two strains of mice. Protection was associated with very high levels of splenic peptide-specific interferon-gamma-secreting CD8+ T cells and was abrogated when the order of immunization was reversed. DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DS, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England; Univ London Imperial Coll Sci Technol & Med, Dept Pure & Appl Biol, Mol & Cellular Parasitol Grp, London SW7 2BB, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; Imperial College London	Schneider, J (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DS, England.	joerg.schneider@ndm.ox.ac.uk	HILL, Adrian V>S>/C-1306-2008; Smith, Geoffrey L/G-2894-2012; Gilbert, Sarah C./H-2857-2019	Gilbert, Sarah C./0000-0002-6823-9750; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; ALCAMI A, 1995, J VIROL, V69, P4633; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; An LL, 1996, INFECT IMMUN, V64, P1685, DOI 10.1128/IAI.64.5.1685-1693.1996; Bender BS, 1996, J VIROL, V70, P6418, DOI 10.1128/JVI.70.9.6418-6424.1996; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; CARROLL MW, 1995, BIOTECHNIQUES, V19, P352; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Doolan DL, 1997, PARASITOL TODAY, V13, P171, DOI 10.1016/S0169-4758(97)01040-5; GAVIN MA, 1993, J IMMUNOL, V151, P3971; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; JAFFE RI, 1990, AM J TROP MED HYG, V42, P309, DOI 10.4269/ajtmh.1990.42.309; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; Lanar DE, 1996, INFECT IMMUN, V64, P1666, DOI 10.1128/IAI.64.5.1666-1671.1996; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; LOCKYER MJ, 1990, NUCLEIC ACIDS RES, V18, P376, DOI 10.1093/nar/18.2.376; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375; Moss B, 1996, Adv Exp Med Biol, V397, P7; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PLEBANSKI M, 1992, EUR J IMMUNOL, V22, P2353, DOI 10.1002/eji.1830220926; Plebanski M, 1997, J IMMUNOL, V158, P2849; Renggli J, 1997, PARASITE IMMUNOL, V19, P145, DOI 10.1046/j.1365-3024.1997.d01-190.x; Robson KJH, 1997, MOL BIOCHEM PARASIT, V84, P1, DOI 10.1016/S0166-6851(96)02774-0; RODRIGUES M, 1994, J IMMUNOL, V153, P4636; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SATCHIDANANDAM V, 1991, MOL BIOCHEM PARASIT, V48, P89, DOI 10.1016/0166-6851(91)90167-5; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SEDEGAH M, 1990, B WHO S, V68, P1009; SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353; Stickl H, 1971, Munch Med Wochenschr, V113, P1149; SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Thomson SA, 1996, J IMMUNOL, V157, P822; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; White KL, 1996, J IMMUNOL, V156, P3374	43	565	612	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1998	4	4					397	402		10.1038/nm0498-397	http://dx.doi.org/10.1038/nm0498-397			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546783				2022-12-27	WOS:000072906800032
J	Mann, JJ				Mann, JJ			The neurobiology of suicide	NATURE MEDICINE			English	Review							CEREBROSPINAL-FLUID MONOAMINE; CORTICOTROPIN-RELEASING-FACTOR; IMPULSIVE FIRE SETTERS; LOCUS-COERULEUS; 5-HYDROXYINDOLEACETIC ACID; BINDING-SITES; DEPRESSED INPATIENTS; AMINE METABOLITES; VIOLENT OFFENDERS; MAJOR DEPRESSION		New York State Psychiat Inst & Hosp, Dept Neurosci, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA	New York State Psychiatry Institute; Columbia University	Mann, JJ (corresponding author), New York State Psychiat Inst & Hosp, Dept Neurosci, 722 W 168th St,Box 28, New York, NY 10032 USA.	jjm@columbia.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048514, R01MH040210, P50MH046745, P30MH046745] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46745, MH48514, MH40210] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARANGO V, 1995, BRAIN RES, V688, P121, DOI 10.1016/0006-8993(95)00523-S; ARANGO V, 1993, BRAIN RES, V630, P271, DOI 10.1016/0006-8993(93)90666-B; Arango V, 1996, BIOL PSYCHIAT, V39, P112, DOI 10.1016/0006-3223(95)00107-7; Asberg M, 1986, Ann N Y Acad Sci, V487, P243, DOI 10.1111/j.1749-6632.1986.tb27903.x; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BECK AT, 1976, ARCH GEN PSYCHIAT, V33, P835; BOYD JH, 1983, NEW ENGL J MED, V308, P872, DOI 10.1056/NEJM198304143081504; BRENT DA, 1986, J AM ACAD CHILD PSY, V25, P242, DOI 10.1016/S0002-7138(09)60232-6; BRESLAU N, 1991, PSYCHIAT RES, V37, P11, DOI 10.1016/0165-1781(91)90102-U; BRODSKY BS, 1997, IN PRESS AM J PSYCHI; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; BROWN GL, 1982, ADV BIOCHEM PSYCHOPH, V34, P287; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BULIK CM, 1990, J AFFECT DISORDERS, V18, P29, DOI 10.1016/0165-0327(90)90114-N; BUNNEY WE, 1969, ARCH GEN PSYCHIAT, V21, P138; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; *CDCP, 1993, MMWR-MORBID MORTAL W, V41, P1; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; COOPER SJ, 1992, LANCET, V340, P940, DOI 10.1016/0140-6736(92)92819-2; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; DULIT RA, 1990, AM J PSYCHIAT, V147, P1002; FARRER LA, 1986, AM J MED GENET, V24, P305, DOI 10.1002/ajmg.1320240211; Frances A, 1986, Ann N Y Acad Sci, V487, P281, DOI 10.1111/j.1749-6632.1986.tb27907.x; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; HIGLEY JD, 1993, ARCH GEN PSYCHIAT, V50, P615; ISOMETSA E, 1995, BRIT MED J, V310, P1366, DOI 10.1136/bmj.310.6991.1366; ISOMETSA E, 1994, BRIT MED J, V308, P915, DOI 10.1136/bmj.308.6933.915; Jamison K R, 1986, Ann N Y Acad Sci, V487, P301, DOI 10.1111/j.1749-6632.1986.tb27909.x; Johns C A, 1986, Ann N Y Acad Sci, V487, P294; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; KAPUR S, 1992, BIOL PSYCHIAT, V32, P1, DOI 10.1016/0006-3223(92)90137-O; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MALONE KM, 1995, J AFFECT DISORDERS, V34, P173, DOI 10.1016/0165-0327(95)00015-F; Mann JJ, 1996, NEUROPSYCHOPHARMACOL, V15, P576, DOI 10.1016/S0893-133X(96)00102-9; Mann JJ, 1997, BIOL PSYCHIAT, V41, P162; MANN JJ, 1995, NEUROPSYCHOPHARMACOL, V13, P53, DOI 10.1016/0893-133X(95)00016-7; Mann JJ, 1996, BIOLOGY OF SCHIZOPHRENIA AND AFFECTIVE DISEASE, P197; Mann JJ, 1996, J NEURAL TRANSM, V103, P1337, DOI 10.1007/BF01271194; Mann JJ, 1997, AM J PSYCHIAT, V154, P1451; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; MANN JJ, 1994, PSYCHOPHARMACOLOGY 4; MARZUK PM, 1988, PSYCHIAT ANN, V18, P639; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MULDOON MF, 1993, METABOLISM, V42, P45, DOI 10.1016/0026-0495(93)90259-Q; MURPHY GE, 1990, ARCH GEN PSYCHIAT, V47, P383; MURPHY GE, 1992, ARCH GEN PSYCHIAT, V49, P459; MURPHY GE, 1988, ARCH GEN PSYCHIAT, V45, P593; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P577; NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34; NORDSTROM P, 1994, SUICIDE LIFE-THREAT, V24, P1; ORDWAY GA, 1994, J NEUROCHEM, V63, P617; ORDWAY GA, 1994, J NEUROCHEM, V62, P680; PANDEY GN, 1990, BIOL PSYCHIAT, V28, P215, DOI 10.1016/0006-3223(90)90576-N; RICH CL, 1988, ARCH GEN PSYCHIAT, V45, P589, DOI 10.1001/archpsyc.1988.01800300087012; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROOSE SP, 1983, AM J PSYCHIAT, V140, P1159; ROY A, 1995, AM J PSYCHIAT, V152, P1075; ROY A, 1991, ARCH GEN PSYCHIAT, V48, P29; ROY A, 1986, SUICIDE LIFE-THREAT, V16, P244; ROY A, 1990, AM J PSYCHIAT, V147, P761; ROY A, 1990, ACTA PSYCHIAT SCAND, V81, P58, DOI 10.1111/j.1600-0447.1990.tb06449.x; ROY A, 1986, AM J PSYCHIAT, V143, P1539; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; SCHOENFELD M, 1984, J NEUROL NEUROSUR PS, V47, P1283, DOI 10.1136/jnnp.47.12.1283; Schulsinger F., 1979, ORIGIN PREVENTION TR, P277; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Stengel E, 1973, SUICIDE ATTEMPTED SU; TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P600; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P604; WEIDEN PJ, 1991, SCHIZOPHR RES, V4, P379, DOI 10.1016/0920-9964(91)90314-H; WEISS GK, 1994, BRAIN RES BULL, V33, P219, DOI 10.1016/0361-9230(94)90255-0; WEISS JM, 1994, BRAIN RES BULL, V35, P561, DOI 10.1016/0361-9230(94)90170-8; WEISSMAN MM, 1989, NEW ENGL J MED, V321, P1209, DOI 10.1056/NEJM198911023211801	76	348	357	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1998	4	1					25	30		10.1038/nm0198-025	http://dx.doi.org/10.1038/nm0198-025			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427602				2022-12-27	WOS:000072249700030
J	Tanaka, M; Itai, T; Adachi, M; Nagata, S				Tanaka, M; Itai, T; Adachi, M; Nagata, S			Downregulation of Fas ligand by shedding	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; FACTOR RECEPTOR; SOLUBLE FORM; CD40 LIGAND; EXPRESSION; APOPTOSIS; DISINTEGRIN; INHIBITOR; REJECTION	Apoptosis-inducing Fas ligand (FasL) is a type II membrane protein, predominantly expressed in the activated T cells. FasL is cleaved by a putative metalloproteinase to produce a soluble form. Here, we blocked the shedding of human FasL by deleting its cleavage site. Although human Jurkat cells and mouse primary hepatocytes that express a low level of Fas were resistant to the soluble form of FasL, they were efficiently killed by membrane-bound FasL. Furthermore, soluble FasL inhibited cytotoxicity of the membrane-bound FasL. These results indicate that the membrane-bound form of FasL is the functional form and suggest that shedding of FasL is to prevent the killing of the healthy bystander cells by cytotoxic T cells.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CHRVONSKY AV, 1997, CELL, V89, P17; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; ITOH N, 1997, J EXP MED, V186, P6183; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KARP SE, 1992, J IMMUNOL, V149, P2076; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Pietravalle F, 1996, EUR J IMMUNOL, V26, P725, DOI 10.1002/eji.1830260333; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Solorzano CC, 1997, J IMMUNOL, V158, P414; SUDA T, 1995, J IMMUNOL, V154, P3806; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Tanaka M, 1997, J IMMUNOL, V158, P2303; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	45	600	622	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					31	36		10.1038/nm0198-031	http://dx.doi.org/10.1038/nm0198-031			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427603				2022-12-27	WOS:000072249700031
J	Geddes, BJ; Harding, TC; Lightman, SL; Uney, JB				Geddes, BJ; Harding, TC; Lightman, SL; Uney, JB			Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin	NATURE MEDICINE			English	Article							MESSENGER-RNA; NEUROHYPOPHYSEAL SYSTEM; NEUROPHYSIN; RESPONSES; VECTORS; NEURONS; STRESS	The ability of adenovirus (Ad) to transfect most cell types efficiently(1-3) has already resulted in human gene therapy trials involving the systemic administration of adenoviral constructs(4). However, because of the complexity of brain function and the difficulty in noninvasively monitoring alterations in neuronal gene expression, the potential of Ad gene therapy strategies for treating disorders of the CNS has been difficult to assess. In the present study, we have used an Ad encoding the arginine vasopressin cDNA (AdAVP)(5) in an AVP-deficient animal model of diabetes insipidus (the Brattleboro rat(6)), which allowed us to monitor chronically the success of the gene therapy treatment by noninvasive assays. Injection of AdAVP into the supraoptic nuclei (SON) of the hypothalamus resulted in expression of AVP in magnocellular neurons. This was accompanied by reduced daily water intake and urine volume, as well as increased urine osmolality lasting 4 months. These data show that a single gene defect leading to a neurological disorder can be corrected with an adenovirus-based strategy. This study highlights the potential of using Ad gene therapy for the long-term treatment of disorders of the CNS.	Univ Bristol, Dept Med Labs, Bristol BS2 8HW, Avon, England	University of Bristol	Uney, JB (corresponding author), Univ Bristol, Dept Med Labs, Marlborough St, Bristol BS2 8HW, Avon, England.			Lightman, Stafford/0000-0002-8546-9646	Biotechnology and Biological Sciences Research Council [GTH12528] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BENBARAK Y, 1985, J NEUROSCI, V5, P81; BURBACH JPH, 1984, NEUROENDOCRINOLOGY, V39, P582; Cheng DY, 1997, HUM GENE THER, V8, P755, DOI 10.1089/hum.1997.8.6-755; FOO NC, 1994, J BIOL CHEM, V269, P659; GAINER H, 1994, PHYSL REPROD, P4545; Geddes BJ, 1996, ENDOCRINOLOGY, V137, P5166, DOI 10.1210/en.137.11.5166; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; IVELL R, 1990, FRONT NEUROENDOCRIN, V11, P313; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; POW DV, 1992, NEUROSCIENCE, V50, P503, DOI 10.1016/0306-4522(92)90442-5; REPASKE DR, 1992, PROG BRAIN RES, V93, P295; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SOFRONIEW MV, 1985, HDB CHEM NEUROANAT 1, V4, P35; VALTIN H, 1967, AM J MED, V42, P814, DOI 10.1016/0002-9343(67)90098-8; VANLEEUWEN FW, 1994, BRAIN RES, V635, P328, DOI 10.1016/0006-8993(94)91456-7; Wagner JA, 1997, ANNU REV MED, V48, P203; WHITNALL MH, 1985, J NEUROSCI, V5, P98	20	75	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1402	1404		10.1038/nm1297-1402	http://dx.doi.org/10.1038/nm1297-1402			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396613				2022-12-27	WOS:000072249500039
J	Urnovitz, HB; Sturge, JC; Gottfried, TD				Urnovitz, HB; Sturge, JC; Gottfried, TD			Increased sensitivity of HIV-1 antibody detection	NATURE MEDICINE			English	Article							INFECTION; SERUM	Clinical trial results from 11,344 paired urine and serum samples revealed 1,181 HIV-1-positive individuals confirmed by western blot (WB). There were 25 discrepant samples: 10 were urine enzyme immunassay (EIA) and WB positive, serum non-reactive and serum WB negative or indeterminate, and 15 were serum EIA and WB positive, urine EIA non-reactive or urine WB negative or indeterminate. Serum samples, HIV-1 antibody WB confirmed, revealed a 99.15% sensitivity (1,171 out of 1,181); urine samples, HIV-1 antibody WB confirmed, showed a 98.73% sensitivity (1,166 out of 1,181). This study demonstrated that neither serum nor urine results alone are as sensitive for HIV-1 antibody detection as combined results of both samples.			Urnovitz, HB (corresponding author), CALYPTE BIOMED,1440 4TH ST,BERKELEY,CA 94710, USA.							*CAL BIOM, 1996, CAL HIV 1 UR EIA PAC; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; Gallo D, 1997, JAMA-J AM MED ASSOC, V277, P254, DOI 10.1001/jama.277.3.254; GOTTFRIED TD, 1990, TRENDS BIOTECHNOL, V8, P35, DOI 10.1016/0167-7799(90)90130-P; Hashida S, 1996, J VIROL METHODS, V62, P43, DOI 10.1016/0166-0934(96)02087-3; MAZZOLI S, 1997, IN PRESS NATURE MED, P1250; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; SORDILLO EM, 1997, W BLOT TESTING HIV E; URNOVITZ HB, 1993, LANCET, V342, P1458, DOI 10.1016/0140-6736(93)92934-L; Urnovitz HB, 1996, CLIN MICROBIOL REV, V9, P72, DOI 10.1128/CMR.9.1.72; Urnovitz HB, 1996, TRENDS BIOTECHNOL, V14, P361, DOI 10.1016/0167-7799(96)10048-2	11	23	24	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1258	1258		10.1038/nm1197-1258	http://dx.doi.org/10.1038/nm1197-1258			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359701	Bronze			2022-12-27	WOS:A1997YD89600035
J	Ayyavoo, V; Mahboubi, A; Mahalingam, S; Ramalingam, R; Kudchodkar, S; Williams, WV; Green, DR; Weiner, DB				Ayyavoo, V; Mahboubi, A; Mahalingam, S; Ramalingam, R; Kudchodkar, S; Williams, WV; Green, DR; Weiner, DB			HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GLUCOCORTICOID-INDUCED APOPTOSIS; CELL GROWTH-FACTOR; T-CELLS; PROTEIN; INHIBITION; INFECTION; GENE; EXPRESSION; CYCLE	The HIV-l accessory gene product Vpr can influence viral pathogenesis by affecting viral replication as well as host cell transcription and proliferation. We have investigated the effects of Vpr on host cell activation and confirm that it influences cellular proliferation. However, we have also found that Vpr modulates T-cell receptor (TCR)-triggered apoptosis in a manner similar to that of glucocorticoids. In the absence of TCR-mediated activation, Vpr induces apoptosis whereas in its presence, Vpr interrupts the expected induction of apoptosis. This regulation of apoptosis is linked to Vpr suppression of NF-kappa B activity via the induction of I kappa B, an inhibitor of NF-kappa B. Further, Vpr suppresses expression of IL-2, IL-10, IL-12, TNF alpha and IL-4, all of which are NF-kappa B-dependent. The effects of Vpr could be reversed by RU486. Our finding that Vpr can regulate NF-kappa B supports the hypothesis that some aspects of viral pathogenesis are the consequence of cell dysregulation by Vpr.	UNIV PENN,DEPT PATHOL & LAB MED,STELLAR CHANCE LABS 505,PHILADELPHIA,PA 19104; LA JOLLA INST ALLERGY & IMMUNOL,SAN DIEGO,CA 92121; ROCHE INST MOL BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; UNIV PENN,DEPT RHEUMATOL,STELLAR CHANCE LABS 912,PHILADELPHIA,PA 19104	University of Pennsylvania; La Jolla Institute for Immunology; Roche Holding; University of Pennsylvania			Weiner, David B/H-8579-2014; Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Ayyavoo, Velpandi/0000-0002-9043-0885; Mahalingam, Sundarasamy/0000-0003-4460-3949; Williams, William/0000-0003-3611-9284				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BYRON KA, 1992, IMMUNOLOGY, V77, P624; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CONNOR RI, 1995, VIROLOGY, V206, P936; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GILLIS S, 1979, J IMMUNOL, V123, P1624; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; Graziosi C, 1996, P NATL ACAD SCI USA, V93, P4386, DOI 10.1073/pnas.93.9.4386; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LU W, 1995, AIDS, V9, P35, DOI 10.1097/00002030-199501000-00005; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; Poli G, 1995, HUMAN CYTOKINES THEI, P421; Rafaeli Y, 1995, P NATL ACAD SCI USA, V92, P3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; TOBLER A, 1992, BLOOD, V79, P45; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang B, 1996, VIROLOGY, V223, P224, DOI 10.1006/viro.1996.0471; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHAO Y, 1995, J IMMUNOL, V154, P6346	44	219	229	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1117	1123		10.1038/nm1097-1117	http://dx.doi.org/10.1038/nm1097-1117			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334723				2022-12-27	WOS:A1997XZ28700037
J	Gussoni, E; Blau, HM; Kunkel, LM				Gussoni, E; Blau, HM; Kunkel, LM			The fate of individual myoblasts after transplantation into muscles of DMD patients	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; TRANSGENIC MDX MICE; ADENOVIRUS-MEDIATED TRANSFER; SKELETAL-MUSCLE; GENE-THERAPY; FULL-LENGTH; MULTINUCLEATED MYOTUBES; MINIDYSTROPHIN GENE; SYSTEMIC DELIVERY; MOUSE SKELETAL	Muscle biopsies from six patients with Duchenne muscular dystrophy (DMD) participating in a myoblast transplantation clinical trial were reexamined using a fluorescence in situ hybridization (FISH)-based method. Donor nuclei were detected in all biopsies analyzed, including nine where no donor myoblasts were previously thought to be present. In three patients, more than 10% of the original number of donor cells were calculated as present 6 months after implantation. Half of the detected donor nuclei were fused into host myofibers, and of these, nearly 50% produced dystrophin. These findings demonstrate that although donor myoblasts have persisted after injection, their microenvironment influences whether they fuse and express dystrophin. Our methodology could be used for developing new approaches to improve myoblast transfer efficacy and for the analysis of future gene-and/or cell-based therapies of numerous genetic disorders.	CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Stanford University	Gussoni, E (corresponding author), CHILDRENS HOSP,DIV GENET,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677	NINDS NIH HHS [NS23740] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DUNCKLEY MG, 1993, HUM MOL GENET, V2, P717, DOI 10.1093/hmg/2.6.717; EMERY A, 1988, DUCHENNE MUSCULAR DY, V1; ENGEL AG, 1994, MYOLOGY, P1130; FANIN M, 1995, MUSCLE NERVE, V18, P1115, DOI 10.1002/mus.880181007; FASSATI A, 1995, HUM GENE THER, V6, P1177, DOI 10.1089/hum.1995.6.9-1177; Griggs RC, 1990, MYOBLAST TRANSFER TH; GROUNDS MD, 1990, ADV EXP MED BIOL, V280, P101; GUERETTE B, 1995, MUSCLE NERVE, V18, P39; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HAUSCHKA SD, 1974, DEV BIOL, V37, P329, DOI 10.1016/0012-1606(74)90153-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KARPATI G, 1989, AM J PATHOL, V135, P27; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; KONIGSBERG IR, 1960, EXP CELL RES, V21, P414, DOI 10.1016/0014-4827(60)90273-1; KumarSingh R, 1996, HUM MOL GENET, V5, P913, DOI 10.1093/hmg/5.7.913; Landon D, 1982, SKELETAL MUSCLE PATH, P1; LAW PK, 1990, LANCET, V336, P114, DOI 10.1016/0140-6736(90)91628-N; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MORANDI L, 1995, NEUROMUSCULAR DISORD, V5, P291, DOI 10.1016/0960-8966(94)00070-P; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEGORARO E, 1995, NEUROLOGY, V45, P677, DOI 10.1212/WNL.45.4.677; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; ROY R, 1993, TRANSPLANT P, V25, P995; SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; VINCENT N, 1993, NAT GENET, V5, P130, DOI 10.1038/ng1093-130; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245; Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	57	235	246	1	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					970	977		10.1038/nm0997-970	http://dx.doi.org/10.1038/nm0997-970			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288722				2022-12-27	WOS:A1997XT84200028
J	Xu, DG; Crocker, SJ; Doucet, JP; StJean, M; Tamai, K; Hakim, AM; Ikeda, JE				Xu, DG; Crocker, SJ; Doucet, JP; StJean, M; Tamai, K; Hakim, AM; Ikeda, JE			Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus	NATURE MEDICINE			English	Article							CHOLINE-ACETYLTRANSFERASE ACTIVITY; FOREBRAIN ISCHEMIA; GERBIL HIPPOCAMPUS; TRANSIENT ISCHEMIA; CEREBRAL-ISCHEMIA; CNS NEURONS; APOPTOSIS; PROTEIN; K-252A; DEATH	We show here that transient forebrain ischemia selectively elevates levels of neuronal apoptosis inhibitory protein (NAIP) in rat neurons that are resistant to the injurious effects of this treatment. This observation suggests that increasing NAIP levels may confer protection against ischemic cell death. Consistent with this proposal, we demonstrate that two other treatments that increase neuronal NAIP levels, systemic administration of the bacterial alkaloid K252a and intracerebral injection of an adenovirus vector capable of overexpressing NAIP in vivo, reduce ischemic damage in the rat hippocampus. Taken together, these findings suggest that NAIP may play a key role in conferring resistance to ischemic damage and that treatments that elevate neuronal levels of this antiapoptotic protein may have utility in the treatment of stroke.	UNIV OTTAWA,NEUROSCI RES INST,OTTAWA,ON K1H 8M5,CANADA; MED & BIOL LABS CO LTD,NAKA KU,NAGOYA,AICHI 460,JAPAN; TOKAI UNIV,INST MED SCI,KANAGAWA 25911,JAPAN; APOPOTOGEN INC,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,MOL GENET RES LAB,OTTAWA,ON K1H 8L1,CANADA	University of Ottawa; Tokai University; University of Ottawa; Children's Hospital of Eastern Ontario	Xu, DG (corresponding author), UNIV OTTAWA,DEPT CELLULAR & MOL MED,OTTAWA,ON K1H 8M5,CANADA.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				CHENG B, 1994, J NEUROCHEM, V62, P1319; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GLICKSMAN MA, 1993, J NEUROCHEM, V61, P210, DOI 10.1111/j.1471-4159.1993.tb03557.x; GLICKSMAN MA, 1995, J NEUROCHEM, V64, P1502; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lawrence MS, 1996, J NEUROSCI, V16, P486; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MARUNO M, 1990, NEUROSCI LETT, V115, P155, DOI 10.1016/0304-3940(90)90447-H; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NITATORI T, 1995, J NEUROSCI, V15, P1001; Olfert ED, 1993, GUIDE CARE USE EXPT; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SmithSwintosky VL, 1996, EXP NEUROL, V141, P287, DOI 10.1006/exnr.1996.0163; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIDMANN R, 1991, J NEUROCHEM, V56, P789, DOI 10.1111/j.1471-4159.1991.tb01993.x; Xu DG, 1997, J COMP NEUROL, V382, P247	28	212	227	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					997	1004		10.1038/nm0997-997	http://dx.doi.org/10.1038/nm0997-997			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288726				2022-12-27	WOS:A1997XT84200032
J	Selivanova, G; Iotsova, V; Okan, I; Fritsche, M; Strom, M; Groner, B; Grafstrom, RC; Wiman, KG				Selivanova, G; Iotsova, V; Okan, I; Fritsche, M; Strom, M; Groner, B; Grafstrom, RC; Wiman, KG			Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; GENE-EXPRESSION; CELL-GROWTH; IN-VIVO; ACTIVATION; MUTATIONS; APOPTOSIS; CANCER; SEQUENCE; FORMS	We demonstrate here that synthetic 22-mer peptide 46, corresponding to the carboxy-terminal amino acid residues 361-382 of p53, can activate specific DNA binding of wild-type p53 in vitro and can restore the transcriptional transactivating function of at least some mutant p53 proteins in living cells. Introduction of peptide 46 in Saos-2 cells carrying a Tet-regulatable His-273 mutant p53 construct caused growth inhibition and apoptosis in the presence of mutant p53 but not in its absence, confirming that the effect of the peptide is mediated by reactivation of mutant p53. Moreover, peptide 46 caused apoptosis in mutant as well as wild-type p53-carrying human tumor cell lines of different origin, whereas p53 null tumor cells were not affected. These findings raise possibilities for developing drugs that restore the tumor suppressor function of mutant p53 proteins, thus selectively eliminating tumor cells.	KAROLINSKA INST,DEPT ENVIRONM MED,S-17177 STOCKHOLM,SWEDEN; INST EXPT CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY	Karolinska Institutet	Selivanova, G (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Grafström, Roland C/N-7217-2016; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CHO Y, 1994, SCIENCE, V265, P356; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OKAN I, 1995, ONCOGENE, V11, P1027; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	23	297	311	0	20	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					632	638		10.1038/nm0697-632	http://dx.doi.org/10.1038/nm0697-632			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176489				2022-12-27	WOS:A1997XB97400032
J	Dachs, GU; Patterson, AV; Firth, JD; Ratcliffe, PJ; Townsend, KMS; Stratford, IJ; Harris, AL				Dachs, GU; Patterson, AV; Firth, JD; Ratcliffe, PJ; Townsend, KMS; Stratford, IJ; Harris, AL			Targeting gene expression to hypoxic tumor cells	NATURE MEDICINE			English	Article							ERYTHROPOIETIN 3' ENHANCER; CYTOSINE DEAMINASE; BIOREDUCTIVE DRUGS; CANCER-THERAPY; SENSITIVITY; INVOLVEMENT; RADIATION; RSU-1069; INVITRO	Solid tumors with areas of low oxygen tension (hypoxia) have a poor prognosis, as cells in this environment often survive radiation and chemotherapy. In this report we describe how this hypoxic environment can be used to activate heterologous gene expression driven by a hypoxia-responsive element (HRE), which interacts with the transcriptional complex hypoxia-inducible factor-1 (HIF-1). Our results demonstrate that the HIF-1/HRE system of gene regulation is active in hypoxic tumor cells and show the potential of exploiting tumor-specific conditions for the targeted expression of diagnostic or therapeutic genes in cancer therapy.	UNIV MANCHESTER,SCH PHARM & PHARMACEUT SCI,MANCHESTER M13 9PL,LANCS,ENGLAND; MRC,EXPT ONCOL DIV,HARWELL OX11 0RD,BERKS,ENGLAND; MT VERNON HOSP,GRAY LAB,NORTHWOOD HA6 2JR,MIDDX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,ONCOL MOL LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,ERYTHROPOIETIN GRP,OXFORD OX3 9DU,ENGLAND; ADDENBROOKES HOSP,CAMBRIDGE CB2 2QG,ENGLAND	University of Manchester; University of Oxford; University of Oxford; University of Oxford; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Ratcliffe, Peter/0000-0002-2853-806X; Patterson, Adam/0000-0001-5138-1227; stratford, ian/0000-0002-5222-4765	NATIONAL CANCER INSTITUTE [P01CA055165] Funding Source: NIH RePORTER; Medical Research Council [G0500366] Funding Source: Medline; NCI NIH HHS [P01-CA-55165] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome Trust)		ADAMS GE, 1984, BRIT J CANCER, V49, P571, DOI 10.1038/bjc.1984.91; ANDERSEN L, 1989, ARCH MICROBIOL, V152, P115, DOI 10.1007/BF00456087; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; Connors TA, 1995, GENE THER, V2, P702; Dachs GU, 1996, BRIT J CANCER, V74, pS126; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HOECKEL M, 1996, SEMIN RADIAT ONCOL, V6, P1; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MANOME Y, 1994, CANCER RES, V54, P5408; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MOULDER JE, 1988, INT J RADIAT ONCOL, V14, P913, DOI 10.1016/0360-3016(88)90014-4; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; OLIVE PL, 1995, BRIT J CANCER, V71, P537, DOI 10.1038/bjc.1995.106; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STRATFORD IJ, 1989, INT J RADIAT ONCOL, V16, P973, DOI 10.1016/0360-3016(89)90898-5; Vaupel Peter W., 1993, P53; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WORKMAN P, 1993, CANCER METAST REV, V12, P73, DOI 10.1007/BF00689802; [No title captured]	27	330	360	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					515	520		10.1038/nm0597-515	http://dx.doi.org/10.1038/nm0597-515			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142119				2022-12-27	WOS:A1997WX54300030
J	Donnelly, SC; Haslett, C; Reid, PT; Grant, IS; Wallace, WAH; Metz, CN; Bruce, LJ; Bucala, R				Donnelly, SC; Haslett, C; Reid, PT; Grant, IS; Wallace, WAH; Metz, CN; Bruce, LJ; Bucala, R			Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome	NATURE MEDICINE			English	Article							LUNG INJURY; FACTOR MIF; ARDS; INTERLEUKIN-8; MECHANISMS; CYTOKINE; ELASTASE; RABBITS; SHOCK	Migration inhibitory factor (MIF) is known to exert significant pro-inflammatory effects and has the potential to override the anti-inflammatory action of glucocorticoids. In this study we have identified significant quantities of MIF in the alveolar airspaces of patients with acute respiratory distress syndrome (ARDS). We show in alveolar cells from patients with ARDS that MIF augments pro-inflammatory cytokine secretion (TNF alpha and IL-8), anti-MIF significantly attenuates TNF alpha and IL-8 secretion and MIF overrides, in a concentration-related fashion, the anti-inflammatory effects of glucocorticoids. These findings suggest that MIF may act as a mediator sustaining the pulmonary inflammatory response in ARDS and that an anti-MIF strategy may represent a novel therapeutic approach in inflammatory diseases such as ARDS.	UNIV EDINBURGH,RAYNE LAB,RESP MED UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT INTENS CARE,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; PICOWER INST MED RES,MANHASSET,NY 11030	University of Edinburgh; University of Edinburgh; University of Edinburgh; Northwell Health				Christine, Metz/0000-0002-1013-1691; Donnelly, Seamas/0000-0001-7145-1843	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035931] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35931] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHBAUGH DG, 1985, ARCH SURG-CHICAGO, V120, P530; BALDWIN SR, 1986, LANCET, V1, P11; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERNARD GR, 1987, NEW ENGL J MED, V317, P1365; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; HOOPER RG, 1990, CHEST, V97, P138, DOI 10.1378/chest.97.1.138; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; ROCKER GM, 1989, LANCET, V1, P120; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797	23	356	387	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					320	323		10.1038/nm0397-320	http://dx.doi.org/10.1038/nm0397-320			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055860				2022-12-27	WOS:A1997WL30500034
J	Schon, MP; Detmar, M; Parker, CM				Schon, MP; Detmar, M; Parker, CM			Murine psoriasis-like disorder induced by naive CD4(+) T cells	NATURE MEDICINE			English	Article							VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL GROWTH-FACTOR; VERSUS-HOST DISEASE; MINOR HISTOCOMPATIBILITY BARRIERS; EXPRESS HIGH-LEVELS; TRANSGENIC MICE; SKIN-DISEASE; ANIMAL-MODEL; MAST-CELLS; EPIDERMIS	Psoriasis is a complex disorder involving alterations of many cell types. Although evidence suggests a T-cell pathogenesis for psoriasis, a primary role of T cells has not been directly demonstrated. Here, we show that reconstitution of scid/scid mice with minor histocompatibility mismatched naive CD4(+) T lymphocytes resulted in skin alterations that strikingly resembled human psoriasis clinically, histopathologically and in cytokine expression. This skin disorder was diminished when memory T cells were coinjected. Thus, a subset of dysregulated CD4(+) T cells can cause tissue alterations seen in psoriasis without the presence of CD8(+) cells or a primary epithelial abnormality.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT PATHOL, BETH ISRAEL DEACONESS MED CTR, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT DERMATOL, BETH ISRAEL DEACONESS MED CTR, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Schon, MP (corresponding author), BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, 250 LONGWOOD AVE, BOSTON, MA 02115 USA.							ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BARKER JNWN, 1994, BAILLIERE CLIN RHEUM, V8, P429, DOI 10.1016/S0950-3579(94)80027-8; BERNARD BA, 1986, BRIT J DERMATOL, V114, P279, DOI 10.1111/j.1365-2133.1986.tb02818.x; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; Bullard DC, 1996, P NATL ACAD SCI USA, V93, P2116, DOI 10.1073/pnas.93.5.2116; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Christophers E, 1993, DERMATOLOGY GEN MED, P489; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; FEDY DJ, 1990, BRIT MED J, V300, P908; FINNERTY H, 1993, ONCOGENE, V8, P2293; FORMAN J, 1984, J EXP MED, V159, P1724, DOI 10.1084/jem.159.6.1724; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gilliam A. C., 1996, GRAFT VS HOST DIS, P291; Gilliam AC, 1996, J INVEST DERMATOL, V107, P377, DOI 10.1111/1523-1747.ep12363361; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; GRAMMER SF, 1994, HDB MOUSE MUTATIONS, P143; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KORNGOLD R, 1987, J EXP MED, V165, P1552, DOI 10.1084/jem.165.6.1552; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCGUIRE J, 1984, BRIT J DERMATOL, V111, P27, DOI 10.1111/j.1365-2133.1984.tb15579.x; MENSSEN A, 1995, J IMMUNOL, V155, P4078; MORRISSEY PJ, 1993, J EXP MED, V178, P237, DOI 10.1084/jem.178.1.237; MUELLER W, 1979, NEW ENGL J MED, V301, P555; MURPHY GF, 1994, J INVEST DERMATOL, V102, P451, DOI 10.1111/1523-1747.ep12373016; Nanney LB, 1996, J INVEST DERMATOL, V106, P1169, DOI 10.1111/1523-1747.ep12347791; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; NICKOLOFF BJ, 1995, AM J PATHOL, V146, P580; NICOLAS JF, 1991, LANCET, V338, P321, DOI 10.1016/0140-6736(91)90465-2; ONUMA A, 1994, J DERMATOL, V21, P223; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; PRINZ J, 1991, LANCET, V338, P320, DOI 10.1016/0140-6736(91)90464-Z; SCHLEGEL PG, 1995, J IMMUNOL, V155, P3856; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; SUNDBERG JP, 1990, J INVEST DERMATOL, V95, pS62, DOI 10.1111/1523-1747.ep12505816; Sundberg JP, 1994, HDB MOUSE MUTATIONS, P253; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Townsend RM, 1996, BLOOD, V88, P3038, DOI 10.1182/blood.V88.8.3038.bloodjournal8883038; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	51	133	143	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					183	188		10.1038/nm0297-183	http://dx.doi.org/10.1038/nm0297-183			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018237				2022-12-27	WOS:A1997WF08800037
J	Gunsalus, JR; Brady, DA; Coulter, SM; Gray, M; Edge, ASB				Gunsalus, JR; Brady, DA; Coulter, SM; Gray, M; Edge, ASB			Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation	NATURE MEDICINE			English	Article							RECEPTOR-DEFICIENT RABBITS; GENE-THERAPY; HEPATOCYTE TRANSPLANTATION; FAMILIAL HYPERCHOLESTEROLEMIA; RECOMBINANT ADENOVIRUSES; PARTIAL-HEPATECTOMY; WHHL RABBIT; LIVER; PIG; DELIVERY	Transplantation of xenogeneic hepatocytes would provide a novel therapy for liver disease and would help to solve the problem of an insufficient supply of donor organs. We have tested whether xenogeneic cells infused into the liver could correct the metabolic defect in the Watanabe heritable hyperlipidemic (WHHL) rabbit, an animal model for homozygous familial hypercholesterolemia, rand we have investigated whether the infused cells traverse the lining of the portal vasculature. We find that porcine hepatocytes are localized in the hepatic sinusoids after surgery and subsequently migrate out of the vessels and integrate into the hepatic parenchyma. The integrated porcine hepatocytes provide functional LDL receptors that lower serum cholesterol in the WHHL rabbit by 30-60% for at least 100 days.	DIACRIN INC,DEPT MOL & CELLULAR BIOL,CHARLESTOWN,MA 02129				Edge, Albert/Q-5448-2019	Nicoloro, Sarah/0000-0002-8638-4556	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK048596] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48596] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBISCHER P, 1991, DIABETES, V40, P482, DOI 10.2337/diabetes.40.4.482; ARBER N, 1988, LIVER, V8, P80; AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; BACHORIK PS, 1982, BIOCHEMISTRY-US, V21, P5675, DOI 10.1021/bi00265a044; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BLIKKENDAALLIEFTINCK LF, 1977, EXP MOL PATHOL, V26, P184, DOI 10.1016/0014-4800(77)90048-X; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJA LM, 1990, EUR HEART J, V11, P41, DOI 10.1093/eurheartj/11.suppl_E.41; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; FLEIG WE, 1986, J HEPATOL, V3, P19, DOI 10.1016/S0168-8278(86)80141-6; GERLACH JC, 1994, TRANSPLANTATION, V57, P1318, DOI 10.1097/00007890-199405150-00005; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Gumucio Jorge J., 1994, P1143; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; HAVEL RJ, 1989, ARTERIOSCLER, V9, P33; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAY MA, 1993, CELL TRANSPLANT, V2, P405, DOI 10.1177/096368979300200506; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LAGROST L, 1989, J LIPID RES, V30, P701; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LI J, 1995, J CLIN INVEST, V95, P768, DOI 10.1172/JCI117725; MAGANTO P, 1992, TRANSPLANT P, V24, P2826; MOSCIONI AD, 1993, SURGERY, V113, P304; OETTINGER HF, 1995, CELL TRANSPLANT, V4, P253, DOI 10.1016/0963-6897(95)90037-3; PANGBURN SH, 1981, J BIOL CHEM, V256, P3340; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SIMEONOVIC CJ, 1990, TRANSPLANTATION, V49, P849, DOI 10.1097/00007890-199005000-00002; SPADY DK, 1987, J LIPID RES, V28, P32; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TEJERA ML, 1992, TRANSPLANT P, V24, P160; VEMURU RP, 1992, FASEB J, V6, P2836, DOI 10.1096/fasebj.6.10.1634046; WANG J, 1991, TRANSPLANT P, V23, P894; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1992, J BIOL CHEM, V267, P963; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	41	76	77	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					48	53		10.1038/nm0197-48	http://dx.doi.org/10.1038/nm0197-48			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986740				2022-12-27	WOS:A1997WA73300036
J	Gimmi, CD; Morrison, BW; Mainprice, BA; Gribben, JG; Boussiotis, VA; Freeman, GJ; Park, SYL; Watanabe, M; Gong, JL; Hayes, DF; Kufe, DW; Nadler, LM				Gimmi, CD; Morrison, BW; Mainprice, BA; Gribben, JG; Boussiotis, VA; Freeman, GJ; Park, SYL; Watanabe, M; Gong, JL; Hayes, DF; Kufe, DW; Nadler, LM			Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells	NATURE MEDICINE			English	Article							LYMPHOCYTES-T; MUCIN; IMMUNITY; PROTEIN; EPITOPE; DF3; CARCINOMAS; EPISIALIN; ADHESION; CORE	Given the plethora of well-documented breast carcinoma-associated antigens in humans including MAGE-1, -2 and -3, mutated p53, p21ras, HER-2/neu and DF3/MUC-1, coupled with evidence that humoral and cytotoxic T-cell responses against these antigens exist(1-6), the central dilemma facing tumor immunologists is why the host immune response is so inefficient. One possibility is that tumor cells themselves are either inefficient or ineffective antigen-presenting cells (APCs). The failure of tumor cells to function as APCs may be due to their inability to process and present the antigen, the absence or insufficient numbers of adhesion and costimulatory molecules or, potentially, the secretion of inhibitory cytokines. Therefore, we sought to determine whether human breast cancer cell lines could function as APCs and, if not, to identify mechanism(s) responsible for this defect. Here, we show that human breast cancer cell lines fail to present alloantigen. This defect does not reside in their inherent capacity to present antigen but rather is due to apoptosis of activated T cells induced by exposure to the breast carcinoma-associated mucin antigen, DF3/MUC1. These results support the hypothesis that DF3/MUC1 may contribute to the paucity of clinically significant anticarcinoma-specific immune responses.	DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Gimmi, CD (corresponding author), DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019; Hayes, Daniel/ABE-1129-2020	Freeman, Gordon/0000-0002-7210-5616; 	NCI NIH HHS [CA 38493, UO1-CA 64057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA038493, U01CA064057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; DISIS ML, 1994, CANCER RES, V54, P16; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HAYES DF, 1990, J IMMUNOL, V145, P962; Hull S R, 1989, Cancer Commun, V1, P261; JEROME KR, 1991, CANCER RES, V51, P2908; JUNG V, 1990, J BIOL CHEM, V265, P1827; KOTERA Y, 1994, CANCER RES, V54, P2856; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MCKOLANIS J, 1996, P AM ASSOC CANC RES, V87, P3144; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565	20	155	162	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1367	1370		10.1038/nm1296-1367	http://dx.doi.org/10.1038/nm1296-1367			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946837				2022-12-27	WOS:A1996VW51500044
J	Larochelle, A; Vormoor, J; Hanenberg, H; Wang, JCY; Bhatia, M; Lapidot, T; Moritz, T; Murdoch, B; Xiang, LX; Kato, I; Williams, DA; Dick, JE				Larochelle, A; Vormoor, J; Hanenberg, H; Wang, JCY; Bhatia, M; Lapidot, T; Moritz, T; Murdoch, B; Xiang, LX; Kato, I; Williams, DA; Dick, JE			Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy	NATURE MEDICINE			English	Article							CORD-BLOOD-CELLS; STEM-CELLS; PROGENITOR CELLS; SCID MICE; ADENOSINE-DEAMINASE; IMMUNODEFICIENT MICE; EXPRESSION; ENGRAFTMENT; LEUKEMIA; INVITRO	The development of stem-cell gene therapy is hindered by the absence of repopulation assays for primitive human hematopoietic cells. Current methods of gene transfer rely on in vitro colony-forming cell (CFC) and long-term culture-initiating cell (LTC-IC) assays, as well as inference from other mammalian species. We have identified a novel human hematopoietic cell, the SCID-repopulating cell (SRC), a cell more primitive than most LTC-ICs and CFCs. The SRC, exclusively present in the CD4(+)CD8(-) fraction, is capable of multilineage repopulation of the bone marrow of nonobese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice). SRCs were rarely transduced with retroviruses, distinguishing them from most CFCs and LTC-ICs. This observation is consistent with the low level of gene marking seen in human gene therapy trials. An SRC assay may aid in the characterization of hematopoiesis, as well as the improvement of transduction methods.	UNIV TORONTO, HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1X8, CANADA; INDIANA UNIV, SCH MED, JAMES WHITCOMB RILEY HOSP CHILDREN, HERMAN WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, HOWARD HUGHES MED INST, INDIANAPOLIS, IN 46202 USA; TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Howard Hughes Medical Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Takara Holdings Inc.			Lapidot, Tsvee/A-1812-2010; Vormoor, Josef/GPS-7248-2022; Larochelle, Andre/P-1342-2016	Vormoor, Josef/0000-0002-1825-1890; Larochelle, Andre/0000-0003-0685-2186; Dick, John/0000-0002-9527-8317; Wang, Jean/0000-0001-7543-3917	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 53586] Funding Source: Medline; NIDDK NIH HHS [P50 DK 49218] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1993, BLOOD, V82, P1975; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; CASHMAN J, 1994, BLOOD, V84, pA368; CIVIN CI, 1984, J IMMUNOL, V133, P157; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; EAVES CJ, 1992, BLOOD CELLS, V18, P301; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; HARRISON DE, 1987, BLOOD, V69, P1021; HOCK RA, 1986, NATURE, V320, P275, DOI 10.1038/320275a0; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; HUGHES PFD, 1989, BLOOD, V74, P1915; Jonsson JI, 1996, BLOOD, V87, P1771; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LAROCHELLE A, 1995, HUM MOL GENET, V4, P163, DOI 10.1093/hmg/4.2.163; LIM B, 1989, P NATL ACAD SCI USA, V86, P8892, DOI 10.1073/pnas.86.22.8892; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122; MORITZ T, 1993, J EXP MED, V178, P529, DOI 10.1084/jem.178.2.529; Moritz T, 1996, BLOOD, V88, P855, DOI 10.1182/blood.V88.3.855.bloodjournal883855; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; OCHMAN H, 1988, GENETICS, V120, P621; Roath S, 1994, Prog Clin Biol Res, V389, P155; RUSTEN LS, 1994, BLOOD, V84, P1473; SCHUENING FG, 1991, BLOOD, V78, P2568; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; VORMOOR J, 1994, BLOOD, V83, P2489; VORMOOR J, 1995, HUMAN HEMATOPOIESIS, P197; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0	43	618	655	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1996	2	12					1329	1337		10.1038/nm1296-1329	http://dx.doi.org/10.1038/nm1296-1329			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946831				2022-12-27	WOS:A1996VW51500038
J	Tonin, P; Weber, B; Offit, K; Couch, F; Rebbeck, TR; Neuhausen, S; Godwin, AK; Daly, M; WagnerCostalos, J; Berman, D; Grana, G; Fox, E; Kane, MF; Kolodner, RD; Krainer, M; Haber, DA; Struewing, JP; Warner, E; Rosen, B; Lerman, C; Peshkin, B; Norton, L; Serova, O; Foulkes, WD; Lynch, HT; Lenoir, GM; Narod, SA; Garber, JE				Tonin, P; Weber, B; Offit, K; Couch, F; Rebbeck, TR; Neuhausen, S; Godwin, AK; Daly, M; WagnerCostalos, J; Berman, D; Grana, G; Fox, E; Kane, MF; Kolodner, RD; Krainer, M; Haber, DA; Struewing, JP; Warner, E; Rosen, B; Lerman, C; Peshkin, B; Norton, L; Serova, O; Foulkes, WD; Lynch, HT; Lenoir, GM; Narod, SA; Garber, JE			Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families	NATURE MEDICINE			English	Editorial Material							GENE		MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,RES INST,MONTREAL,PQ H3G 1A4,CANADA; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,CLIN GENET SERV,NEW YORK,NY 10021; UNIV PENN,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; UNIV UTAH,DEPT MED INFORMAT,GENET EPIDEMIOL GRP,SALT LAKE CITY,UT 84108; FOX CHASE CANC CTR,DIV BASIC SCI,PHILADELPHIA,PA 19111; FOX CHASE CANC CTR,DIV POPULAT SCI,PHILADELPHIA,PA 19111; COOPER HOSP UNIV MED CTR,DEPT MED,DIV HEMATOL ONCOL,CAMDEN,NJ 08103; DANA FARBER CANC INST,DIV HUMAN CANC GENET,BOSTON,MA 02115; DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CTR CANC,CTR CANC RISK ANAL,CHARLESTOWN,MA 02129; NCI,GENET EPIDEMIOL BRANCH,BETHESDA,MD 20892; NIH,LAB GENE TRANSFER,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL,TORONTO,ON M4N 3M5,CANADA; TORONTO GEN HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 2C4,CANADA; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; MEM SLOAN KETTERING CANC CTR,DEPT MED,BREAST CANC MED SERV,NEW YORK,NY 10021; INT AGCY RES CANC,F-69372 LYON,FRANCE; SIR MORTIMER B DAVIS JEWISH HOSP,CANC PREVENT RES UNIT,MONTREAL,PQ H3T 1E2,CANADA; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED & PUBL HLTH,OMAHA,NE 68178; UNIV TORONTO,WOMENS COLL HOSP,DEPT MED,TORONTO,ON M5G 1N8,CANADA; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; University of Pennsylvania; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Utah System of Higher Education; University of Utah; Fox Chase Cancer Center; Fox Chase Cancer Center; Rutgers State University Camden; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Georgetown University; Memorial Sloan Kettering Cancer Center; World Health Organization; International Agency for Research on Cancer (IARC); McGill University; Creighton University; University of Toronto; University Toronto Affiliates; Womens College Hospital; McGill University	Tonin, P (corresponding author), UNIV TORONTO,WOMENS COLL HOSP,DEPT MED,790 BAY ST,ROOM 750,TORONTO,ON M5G 1N8,CANADA.		Struewing, Jeffery P/C-3221-2008; Struewing, Jeffery P/I-7502-2013; Foulkes, William D./AAR-9586-2021; Rebbeck, Timothy/GLU-8348-2022; Narod, Steven A/AAA-6112-2022	Struewing, Jeffery P/0000-0002-4848-3334; Foulkes, William D./0000-0001-7427-4651; Rebbeck, Timothy/0000-0002-4799-1900; Krainer, Michael/0000-0002-7011-4957	NCI NIH HHS [CA 06516, CA 55914] Funding Source: Medline; NIAID NIH HHS [AI 28691] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516, R01CA055914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berman DB, 1996, AM J HUM GENET, V58, P1166; Berman DB, 1996, CANCER RES, V56, P3409; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; COUCH FJ, IN PRESS HUM MUTAT; Eastson D, 1995, AM J HUM GENET, V56, P256; Egan KM, 1996, LANCET, V347, P1645, DOI 10.1016/S0140-6736(96)91485-3; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P189; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; TONIN P, 1995, AM J HUM GENET, V57, P189; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	25	227	231	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1179	1183		10.1038/nm1196-1179	http://dx.doi.org/10.1038/nm1196-1179			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898735				2022-12-27	WOS:A1996VQ10100023
J	WhittumHudson, JA; An, LL; Saltzman, WM; Prendergast, RA; MacDonald, AB				WhittumHudson, JA; An, LL; Saltzman, WM; Prendergast, RA; MacDonald, AB			Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection	NATURE MEDICINE			English	Article							OUTER-MEMBRANE PROTEIN; T-CELLS; ANTIIDIOTYPIC ANTIBODIES; GENITAL-TRACT; MURINE MODEL; VACCINE; NEUTRALIZATION; PATHOGENESIS; IGG; MICROSPHERES	Chlamydia trachomatis is the leading cause worldwide of preventable infectious blindness (trachoma) and sexually transmitted disease, including nongonoccocal urethritis and pelvic inflammatory disease. To date, no effective vaccine against C. trachomatis infection has been identified. A monoclonal anti-idiotypic antibody (anti-Id) to the chlamydial exoglycolipid antigen (GLXA) was tested in a murine model of ocular chlamydial infection for its ability to induce systemic immunity, which reduces microbiologic and clinical disease. The anti-Id to GLXA, delivered either systemically in soluble form or orally after encapsulation in poly(lactide) microspheres, induced significant protective immunity against ocular challenge of mice with a human biovar of C. trachomatis. Protection was associated with induction of anti-GLXA antibody and anti-chlamydial neutralizing antibody.	UNIV MASSACHUSETTS, DEPT MICROBIOL, AMHERST, MA 01003 USA; JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BALTIMORE, MD 21218 USA	University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	WhittumHudson, JA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, WILMER OPHTHALMOL INST, BALTIMORE, MD 21287 USA.		MacDonald, Alan Bruce/AAX-9220-2020		NEI NIH HHS [EY 03324] Funding Source: Medline; NIAID NIH HHS [AI 24760] Funding Source: Medline; NIGMS NIH HHS [GM 43873] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN LL, 1993, THESIS U MASSACHUSET; BATTEIGER BE, 1993, J GEN MICROBIOL, V139, P2965, DOI 10.1099/00221287-139-12-2965; BLANCHARD TG, 1990, CHLAMYDIAL INFECT, P205; BROSSAY L, 1994, INFECT IMMUN, V62, P341, DOI 10.1128/IAI.62.2.341-347.1994; BRUNHAM RC, 1987, J INFECT DIS, V155, P749, DOI 10.1093/infdis/155.4.749; BYRNE GI, 1993, J INFECT DIS, V168, P415, DOI 10.1093/infdis/168.2.415; CAIN TK, 1995, INFECT IMMUN, V63, P1784, DOI 10.1128/IAI.63.5.1784-1789.1995; CAMPOS M, 1995, INVEST OPHTH VIS SCI, V36, P1477; CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; HARLOW E, 1994, ANTIBODIES, P139; HAWKINS RE, 1993, J IMMUNOTHER, V14, P273, DOI 10.1097/00002371-199311000-00004; Igietseme Joseph U., 1993, Regional Immunology, V5, P317; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KENNEDY R C, 1985, Biotechniques, V3, P404; KIYONO H, 1994, HDB MUCOSAL IMMUNOLO, P263; MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576; MICHALEK SM, 1983, ANN NY ACAD SCI, V409, P48, DOI 10.1111/j.1749-6632.1983.tb26859.x; MURDIN AD, 1995, INFECT IMMUN, V63, P1116, DOI 10.1128/IAI.63.3.1116-1121.1995; NEWHALL WJ, 1982, INFECT IMMUN, V38, P1181, DOI 10.1128/IAI.38.3.1181-1189.1982; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; PAL S, 1990, Regional Immunology, V3, P171; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; RANK RG, 1992, AM J PATHOL, V140, P927; REACHER MH, 1991, OPHTHALMOLOGY, V98, P334; REES ADM, 1987, EUR J IMMUNOL, V17, P197, DOI 10.1002/eji.1830170208; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; SALEHIHAD S, 1994, ACS SYM SER, P278; SCHACHTER J, 1990, SCAND J INFECT DIS, P55; SCHACHTER J, 1985, REV INFECT DIS, V7, P713; SCIEUX C, 1992, SEX TRANSM DIS, V19, P161, DOI 10.1097/00007435-199205000-00010; STEIN KE, 1985, CURR TOP MICROBIOL, V119, P57; STEPHENS RS, 1988, J EXP MED, V167, P817, DOI 10.1084/jem.167.3.817; STUART ES, 1991, IMMUNOLOGY, V74, P740; STUART ES, 1994, CURR MICROBIOL, V28, P85, DOI 10.1007/BF01569052; STUART ES, 1984, CURR MICROBIOL, V11, P123, DOI 10.1007/BF01567715; STUART ES, 1989, IMMUNOLOGY, V68, P469; STUART ES, 1987, IMMUNOLOGY, V61, P527; SU H, 1995, VACCINE, V13, P1023, DOI 10.1016/0264-410X(95)00017-U; SU H, 1995, INFECT IMMUN, V63, P3302, DOI 10.1128/IAI.63.9.3302-3308.1995; SU S, 1992, J IMMUNOL, V148, P234; TAYLOR HR, 1982, INVEST OPHTH VIS SCI, V23, P507; TAYLOR HR, 1987, J IMMUNOL, V138, P3023; TAYLOR HR, 1984, J CLIN MICROBIOL, V20, P391, DOI 10.1128/JCM.20.3.391-395.1984; TING LM, 1995, INFECT IMMUN, V63, P3600, DOI 10.1128/IAI.63.9.3600-3608.1995; TROIDLE KM, 1992, THESIS U MASSACHUSET; WAGAR EA, 1990, J INFECT DIS, V162, P922, DOI 10.1093/infdis/162.4.922; WESTERINK MAJ, 1993, SPRINGER SEMIN IMMUN, V15, P227; WESTROM L, 1993, GENITOURIN MED, V69, P9; WHITTUMHUDSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1976; Wyrick Priscilla B., 1994, Immunology and Infectious Diseases (Oxford), V4, P131	54	61	66	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1116	1121		10.1038/nm1096-1116	http://dx.doi.org/10.1038/nm1096-1116			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837610				2022-12-27	WOS:A1996VK99500032
J	Albert, ML; Darnell, JC; Bender, A; Francisco, LM; Bhardwaj, N; Darnell, RB				Albert, ML; Darnell, JC; Bender, A; Francisco, LM; Bhardwaj, N; Darnell, RB			Tumor-specific killer cells in paraneoplastic cerebellar degeneration	NATURE MEDICINE			English	Article							DENDRITIC CELLS; T-CELLS; ANTIGENS; ANTIBODY; VIRUS; LYMPHOCYTES; RESPONSES; MECHANISM; CANCER	Models for immune-mediated tumor regression in mice have defined an essential role for cytotoxic T lymphocytes (CTLs); however, naturally occurring tumor immunity in humans is poorly understood(1). Patients with paraneoplastic cerebellar degeneration (PCD) provide an opportunity to explore the mechanisms underlying tumor immunity to breast and ovarian cancer. Although tumor immunity and autoimmune neuronal degeneration in PCD correlates with a specific antibody response to the tumor and brain antigen cdr2(2,3), this humoral response has not been shown to be pathogenic(3,4). Here we present evidence for a specific cellular immune response in PCD patients. We have detected expanded populations of MHC class I-restricted cdr2-specific CTLs in the blood of 3/3 HLA-A2.1(+) PCD patients, providing the first description, to our knowledge, of tumor-specific CTLs using primary human cells in a simple recall assay. Cross-presentation of apoptotic cells by dendritic cells also led to a potent CTL response. These results indicate a model whereby immature dendritic cells that engulf apoptotic tumor cells can mature and migrate to draining lymph organs where they could induce a CTL response to tissue-restricted antigens. In PCD, peripheral activation of cdr2-specific CTLs is likely to contribute to the subsequent development of the autoimmune neuronal degeneration.	Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Darnell, RB (corresponding author), Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA.	darnelr@rockvax.rockefeller.edu	Albert, Matthew L/C-9782-2009; Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039516] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00102] Funding Source: Medline; NIAID NIH HHS [AI-39516] Funding Source: Medline; NIGMS NIH HHS [GM-07739] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BAROUCH D, 1995, J EXP MED, V182, P1847, DOI 10.1084/jem.182.6.1847; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Corradi JP, 1997, J NEUROSCI, V17, P1406; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; DALMAU J, 1995, CANCER, V75, P99, DOI 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DARNELL RB, 1993, LANCET, V341, P21, DOI 10.1016/0140-6736(93)92485-C; DEVITA VT, 1989, CNAC PRINCIPLES PRAC, P1930; DROPCHO EJ, 1987, P NATL ACAD SCI USA, V84, P4552, DOI 10.1073/pnas.84.13.4552; FATHALLAHSHAYKH H, 1991, P NATL ACAD SCI USA, V88, P3451, DOI 10.1073/pnas.88.8.3451; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; McMichael A, 1994, Curr Top Microbiol Immunol, V189, P75; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; SAKAI K, 1990, ANN NEUROL, V28, P692, DOI 10.1002/ana.410280515; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	25	342	362	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1321	1324		10.1038/3315	http://dx.doi.org/10.1038/3315			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809559				2022-12-27	WOS:000076731000044
J	Persons, DA; Allay, JA; Riberdy, JM; Wersto, RP; Donahue, RE; Sorrentino, BP; Nienhuis, AW				Persons, DA; Allay, JA; Riberdy, JM; Wersto, RP; Donahue, RE; Sorrentino, BP; Nienhuis, AW			Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells	NATURE MEDICINE			English	Article							MEDIATED GENE-TRANSFER; BONE-MARROW CELLS; PERIPHERAL-BLOOD LYMPHOCYTES; TITER RETROVIRAL VECTORS; SELECTABLE MARKER; PROGENITOR CELLS; MAMMALIAN-CELLS; T-LYMPHOCYTES; IN-VIVO; EXPRESSION		St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Nienhuis, AW (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, 332 N Lauderdale Dr, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bierhuizen MFA, 1997, BLOOD, V90, P3304, DOI 10.1182/blood.V90.9.3304; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Brenner MK, 1996, NEW ENGL J MED, V335, P337, DOI 10.1056/NEJM199608013350508; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Comoli P, 1996, NAT MED, V2, P1280, DOI 10.1038/nm1296-1280b; Conneally E, 1996, BLOOD, V87, P456, DOI 10.1182/blood.V87.2.456.bloodjournal872456; Donahue RE, 1996, BLOOD, V88, P4166; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Limon A, 1997, BLOOD, V90, P3316, DOI 10.1182/blood.V90.9.3316; MAVILIO F, 1994, BLOOD, V83, P1988; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; Ren SC, 1996, BLOOD, V87, P2518, DOI 10.1182/blood.V87.6.2518.bloodjournal8762518; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Rudoll T, 1996, GENE THER, V3, P695; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SORRENTINO BP, IN PRESS DEV GENE TH; STRAIR RK, 1990, NUCLEIC ACIDS RES, V18, P4759, DOI 10.1093/nar/18.16.4759; vanBeusechem VW, 1996, HUM GENE THER, V7, P1649, DOI 10.1089/hum.1996.7.14-1649; WARD M, 1994, BLOOD, V84, P1408; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; YANG Z, 1987, MOL CELL BIOL, V7, P3923, DOI 10.1128/MCB.7.11.3923; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	35	91	96	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1201	1205		10.1038/2704	http://dx.doi.org/10.1038/2704			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771757				2022-12-27	WOS:000076230100044
J	Bajou, K; Noel, A; Gerard, RD; Masson, V; Brunner, N; Holst-Hansen, C; Skobe, M; Fusenig, NE; Carmeliet, P; Collen, D; Foidart, JM				Bajou, K; Noel, A; Gerard, RD; Masson, V; Brunner, N; Holst-Hansen, C; Skobe, M; Fusenig, NE; Carmeliet, P; Collen, D; Foidart, JM			Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization	NATURE MEDICINE			English	Article							GENE DEFICIENT MICE; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; BREAST-CANCER; PAI-1; EXPRESSION; TUMOR; PROGNOSIS; INVIVO; SYSTEM	Acquisition of invasive/metastatic potential through protease expression is an essential event in tumor progression. High levels of components of the plasminogen activation system, including urokinase, but paradoxically also its inhibitor, plasminogen activator inhibitor 1 (PAI1), have been correlated with a poor prognosis for some cancers. We report here that deficient PAI1 expression in host mice prevented local invasion and tumor vascularization of transplanted malignant keratinocytes. When this PAI1 deficiency was circumvented by intravenous injection of a replication-defective adenoviral vector expressing human PAI1, invasion and associated angiogenesis were restored. This experimental evidence demonstrates that host-produced PAI is essential for cancer cell invasion and angiogenesis.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark; German Canc Res Ctr, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany	University of Liege; Rigshospitalet; University of Copenhagen; Helmholtz Association; German Cancer Research Center (DKFZ)	Foidart, JM (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Pathol Tower B23, B-4000 Liege, Belgium.		Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BIANCHI E, 1995, INT J CANCER, V60, P597, DOI 10.1002/ijc.2910600505; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOUKAMP P, 1990, CANCER RES, V50, P2840; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DENG G, 1996, J CELL BIOL, V134, P1; DEVRIES TJ, 1995, CANCER RES, V55, P4681; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; FUSENIG NE, 1978, B CANCER, V65, P271; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HEISS MM, 1995, J CLIN ONCOL, V13, P2084, DOI 10.1200/JCO.1995.13.8.2084; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KRISTENSEN P, 1990, HISTOCHEMISTRY, V93, P559, DOI 10.1007/BF00272198; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; KRUITHOF EKO, 1988, THROMB HAEMOSTASIS, V59, P7; KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P1126; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NAKAMURA M, 1992, THROMB RES, V65, P709, DOI 10.1016/0049-3848(92)90110-V; NAKARDA H, 1994, CANCER RES, V54, P2900; OSSOWSKI L, 1991, CANCER RES, V51, P274; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; SIER CFM, 1994, GASTROENTEROLOGY, V107, P1449, DOI 10.1016/0016-5085(94)90549-5; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; YU H, 1990, CANCER RES, V50, P7623	42	578	606	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					923	928		10.1038/nm0898-923	http://dx.doi.org/10.1038/nm0898-923			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701244	Green Submitted			2022-12-27	WOS:000075107400035
J	Lodmell, DL; Ray, NB; Parnell, MJ; Ewalt, LC; Hanlon, CA; Shaddock, JH; Sanderlin, DS; Rupprecht, CE				Lodmell, DL; Ray, NB; Parnell, MJ; Ewalt, LC; Hanlon, CA; Shaddock, JH; Sanderlin, DS; Rupprecht, CE			DNA immunization protects nonhuman primates against rabies virus	NATURE MEDICINE			English	Article							VACCINE; DISEASE; CELLS	More than 40,000 people die annually from rabies worldwide(1). Most of these fatalities occur in developing countries, where rabies is endemic, public health resources are inadequate and there is limited access to preventive treatment(2). Because of the high cost of vaccines derived from cell culture, many countries still use vaccines produced in sheep, goat or suckling mouse brain(3). The stability and low cost for mass production of DNA vaccines would make them ideal for use in developing countries(4). To investigate the potential of DNA vaccines for rabies immunization in humans, we vaccinated Macaca fascicularis (Cynomolgus) monkeys with DNA encoding the glycoprotein of the challenge virus standard rabies virus, or with a human diploid cell vaccine (HDCV). The monkeys then were challenged with a non-passaged rabies virus. DNA or HDCV vaccination elicited comparable primary and anamnestic neutralizing antibody responses. All ten vaccinated monkeys (DNA or HDCV) survived a rabies virus challenge, whereas monkeys vaccinated with only the DNA vector developed rabies. Furthermore, serum samples from DNA- or HDCV-vaccinated monkeys neutralized a global spectrum of rabies virus variants in vitro. This study shows that DNA immunization elicits protective immunity in nonhuman primates against lethal challenge with a human viral pathogen of the central nervous system. Our findings indicate that DNA vaccines may have a promising future in human rabies immunization.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Hamilton, MT 59840 USA; Ctr Dis Control & Prevent, Rabies Sect, Viral & Rickettsial Zooneses Branch, Div Viral & Rickettsial Dis,Natl Ctr Infect Dis, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA	Lodmell, DL (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Hamilton, MT 59840 USA.		Rupprecht, Charles/AAI-1544-2020					Arai YT, 1997, ARCH VIROL, V142, P1787, DOI 10.1007/s007050050197; CHARLTON KM, 1982, COMP IMMUNOL MICROB, V5, P113; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; DRESSEN DW, 1997, VACCINE S, V15; GLUCK R, 1991, VACCINES IMMUNOTHERA, P246; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; Krebs JW, 1997, J AM VET MED ASSOC, V211, P1525; Liu MA, 1997, VACCINE, V15, P909, DOI 10.1016/S0264-410X(96)00280-0; Lodmell DL, 1998, VACCINE, V16, P115, DOI 10.1016/S0264-410X(97)88325-9; Lu S, 1996, J VIROL, V70, P3978, DOI 10.1128/JVI.70.6.3978-3991.1996; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; Ray NB, 1997, VACCINE, V15, P892, DOI 10.1016/S0264-410X(96)00281-2; Robinson H L, 1997, Semin Immunol, V9, P271, DOI 10.1006/smim.1997.0083; SMITH AL, 1977, INTERVIROLOGY, V8, P92, DOI 10.1159/000148883; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535; SMITH JS, 1993, PROG MED VIROL, V40, P82; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; SMITH JS, 1986, J CLIN MICROBIOL, V24, P573, DOI 10.1128/JCM.24.4.573-580.1986; Ugen KE, 1997, VACCINE, V15, P927, DOI 10.1016/S0264-410X(96)00254-X; VODOPIJA I, 1991, NATURAL HIST RABIES, V2, P571; *WHO, 1985, WHO TECHN REP SER, V725; World Health Organization (WHO), 1992, WHO TECHN REP SER, V824	23	106	115	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					949	952		10.1038/nm0898-949	http://dx.doi.org/10.1038/nm0898-949			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701249				2022-12-27	WOS:000075107400040
J	Miller, LH; Hoffman, SL				Miller, LH; Hoffman, SL			Research toward vaccines against malaria	NATURE MEDICINE			English	Review							PLASMODIUM-FALCIPARUM; PROTECTIVE IMMUNITY; VACCINATION; PROTEINS; PEPTIDE; DOMAINS; IDENTIFICATION; ERYTHROCYTES; INDUCTION; EFFICACY		NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; USN, Med Res Inst, Malaria Program, Bethesda, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy	Miller, LH (corresponding author), NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.	louis_miller@nih.gov						AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; BALLOU WR, 1987, LANCET, V1, P1277; Baruch DI, 1997, BLOOD, V90, P3766, DOI 10.1182/blood.V90.9.3766; BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; Hoffman SL, 1997, IMMUNOL CELL BIOL, V75, P376, DOI 10.1038/icb.1997.59; Hoffman SL, 1996, MALARIA VACCINE DEV; Hoffman Stephen L., 1996, P35; Holder Anthony A., 1996, P77; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MITCHELL GH, 1975, IMMUNOLOGY, V29, P397; OCKENHOUSE CF, IN PRESS J INFECT DI; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; RENIA L, 1991, P NATL ACAD SCI USA, V88, P7963, DOI 10.1073/pnas.88.18.7963; Rodrigues EG, 1997, J IMMUNOL, V158, P1268; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; SEDEGAH M, 1998, IN PRESS P NATL ACAD; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; Sinnis Photini, 1996, P15; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; STOUTE JA, 1998, IN PRESS J INFECT DI; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Wang RB, 1996, J IMMUNOL, V157, P4061; WEISS W, 1998, IN PRESS J IMMUNOL; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2	40	90	95	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5		S			520	524		10.1038/nm0598supp-520	http://dx.doi.org/10.1038/nm0598supp-520			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585203	Bronze			2022-12-27	WOS:000073453500021
J	Kren, BT; Bandyopadhyay, P; Steer, CJ				Kren, BT; Bandyopadhyay, P; Steer, CJ			In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides	NATURE MEDICINE			English	Article							BILIRUBIN-UDP-GLUCURONOSYLTRANSFERASE; TRIPLE-HELIX FORMATION; HOMOLOGOUS RECOMBINATION; DNA OLIGONUCLEOTIDE; MISMATCH REPAIR; CELL-CYCLE; IN-VIVO; EXPRESSION; THERAPY; DEFICIENCY	A chimeric RNA/DNA oligonucleotide was constructed to induce a sequence mutation in the rat factor IX gene, resulting in prolonged coagulation. Oligonucleotides were targeted to hepatocytes in cell culture or in vivo by intravenous injection. Nucleotide conversion was both site-specific and dose-dependent. The mutated gene was associated in vivo with significantly reduced factor IX coagulant activity and a marked prolongation of the activated partial thromboplastin time. The results demonstrate that single base-pair alterations can be introduced in hepatocytes in situ by RNA/DNA oligonucleotides, suggesting a potentially powerful strategy for hepatic gene repair without the use of viral vectors.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kren, BT (corresponding author), Univ Minnesota, Sch Med, Dept Med, 420 Delaware St,SE, Minneapolis, MN 55455 USA.							Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; ARBONES ML, 1994, NAT GENET, V6, P90, DOI 10.1038/ng0194-90; Askari FK, 1996, GENE THER, V3, P381; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bowles N, 1995, ADV DRUG DELIVER REV, V17, P293, DOI 10.1016/0169-409X(95)00063-D; BULLA GA, 1992, GENE DEV, V6, P316, DOI 10.1101/gad.6.2.316; CHANG AGY, 1994, GASTROENTEROLOGY, V106, P1076, DOI 10.1016/0016-5085(94)90771-4; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Fan GS, 1996, ONCOGENE, V12, P1909; FANG WH, 1993, J BIOL CHEM, V268, P11838; GRAY GR, 1974, ARCH BIOCHEM BIOPHYS, V163, P426, DOI 10.1016/0003-9861(74)90495-0; Ilan Y, 1997, J CLIN INVEST, V99, P1098, DOI 10.1172/JCI119238; KEN BT, 1997, HEPATOLOGY, V25, P1462; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kotani H, 1996, MOL GEN GENET, V250, P626; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MONIA BP, 1993, J BIOL CHEM, V268, P14514; PROUTY SM, 1993, ONCOGENE, V8, P899; REINER AP, 1995, METABOLIC MOL BASES, P3181; SAKAGAMI K, 1994, P NATL ACAD SCI USA, V91, P8527, DOI 10.1073/pnas.91.18.8527; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; STRAUSS M, 1994, GENE THER, V1, P156; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Ye XH, 1996, J BIOL CHEM, V271, P3639; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	41	238	325	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					285	290		10.1038/nm0398-285	http://dx.doi.org/10.1038/nm0398-285			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500600				2022-12-27	WOS:000073616200032
J	Rosenberg, SA; Yang, JC; Schwartzentruber, DJ; Hwu, P; Marincola, FM; Topalian, SL; Restifo, NP; Dudley, ME; Schwarz, SL; Spiess, PJ; Wunderlich, JR; Parkhurst, MR; Kawakami, Y; Seipp, CA; Einhorn, JH; White, DE				Rosenberg, SA; Yang, JC; Schwartzentruber, DJ; Hwu, P; Marincola, FM; Topalian, SL; Restifo, NP; Dudley, ME; Schwarz, SL; Spiess, PJ; Wunderlich, JR; Parkhurst, MR; Kawakami, Y; Seipp, CA; Einhorn, JH; White, DE			Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma	NATURE MEDICINE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; LIMITING DILUTION ANALYSIS; CYTOLYTIC T-LYMPHOCYTES; PERIPHERAL-BLOOD; IN-VIVO; AUTOLOGOUS TUMOR; FREQUENCY-ANALYSIS; CELL RESPONSES; ANTIGEN GP100; INTERLEUKIN-2	The cloning of the genes encoding cancer antigens has opened new possibilities far the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic-peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.	NCI, Surg Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, SA (corresponding author), NCI, Surg Branch, Div Clin Sci, NIH, Bldg 10,Room 2B42,10 Ctr Dr, Bethesda, MD 20892 USA.		Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/M-6549-2019; Kawakami, Yutaka/E-7429-2013; Restifo, Nicholas Phillip/Z-1614-2019	Kawakami, Yutaka/0000-0003-4836-2855; Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BOON T, 1993, INT J CANCER, V54, P177, DOI 10.1002/ijc.2910540202; BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; BRONTE V, 1995, J IMMUNOL, V154, P5282; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Cormier JN, 1997, CANCER J, V3, P37; COULIE PG, 1992, INT J CANCER, V50, P289, DOI 10.1002/ijc.2910500220; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; HERR W, 1994, CANCER IMMUNOL IMMUN, V39, P93, DOI 10.1007/BF01525314; Hu XY, 1996, CANCER RES, V56, P2479; Irvine KR, 1996, J IMMUNOL, V156, P238; Jaeger E, 1996, INT J CANCER, V66, P162; Jager E, 1996, INT J CANCER, V67, P54, DOI 10.1002/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; KAWAKAMI Y, 1995, J IMMUNOL, V154, P3961; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LASARTE JJ, 1992, CELL IMMUNOL, V141, P211, DOI 10.1016/0008-8749(92)90140-K; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; Marincola FM, 1996, J IMMUNOTHER, V19, P266, DOI 10.1097/00002371-199607000-00003; MAZZOCCHI A, 1994, INT J CANCER, V58, P330, DOI 10.1002/ijc.2910580304; MINEV BR, 1994, CANCER RES, V54, P4155; NOGUCHI Y, 1995, P NATL ACAD SCI USA, V92, P2219, DOI 10.1073/pnas.92.6.2219; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Rao JB, 1996, J IMMUNOL, V156, P3357; RIVOLTINI L, 1995, J IMMUNOL, V154, P2257; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1995, CANCER J SCI AM, V1, P89; SALGALLER ML, 1995, CANCER RES, V55, P4972; Salgaller ML, 1996, CANCER RES, V56, P4749; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; SHIRAI M, 1994, J IMMUNOL, V152, P549; VASILAKOS JP, 1993, J IMMUNOL, V150, P2346	38	1540	1643	0	159	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					321	327		10.1038/nm0398-321	http://dx.doi.org/10.1038/nm0398-321			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500606	Green Accepted			2022-12-27	WOS:000073616200038
J	Matsumoto, M; Takeda, J; Inoue, N; Hara, T; Hatanaka, M; Takahashi, K; Nagasawa, S; Akedo, H; Seya, T				Matsumoto, M; Takeda, J; Inoue, N; Hara, T; Hatanaka, M; Takahashi, K; Nagasawa, S; Akedo, H; Seya, T			A novel protein that participates in nonself discrimination of malignant cells by homologous complement	NATURE MEDICINE			English	Article							IMMUNITY; SYSTEM; INNATE; SELENOCYSTEINE; DEPOSITION; PATHWAY; LINES; SELF; GENE; MCP	The human complement (C) system protects an individual against substances of nonself origin, including xenografts and microbial pathogens'. Human cells express C-regulatory proteins, CD46 and CD55, thereby circumventing attack by C3, a major effector of C (ref. 2). Nevertheless, certain malignant cells, particularly those undergoing apoptotic stress, can activate homologous C, overcoming the regulatory actions of CD46 and/or CD55 (ref. 3-5). The molecular mechanisms whereby malignant cells are tagged by homologous C3 remain largely unknown. We identified a novel gene product that converts human cells into targets for homologous complement. Only malignant cells and cell lines exposed to Fas or X-irradiation stimuli produced this protein, designated M161Ag, which was an unglycosylated 43-kDa protein. Analysis of cloned cDNAs indicated that this molecule was a secretory protein containing five amino acids encoded by TGA codons. Its functions were unique in that once secreted from the tumor cells, it bound back to the surface of these cells and activated homologous complement (C3) via the alternative pathway, allowing for C3 deposition on the membrane. This molecule may offer new insight into innate immunity; surveillance of tumor cells by complement is a common feature in the human immune system.	OSAKA MED CTR CANC & CARDIOVASC DIS,DEPT IMMUNOL,HIGASHINARI KU,OSAKA 537,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; HOKKAIDO UNIV,DEPT PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; JAPAN SCI & TECHNOL CORP,PRESTO,KYOTO 61902,JAPAN	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Hokkaido University; Japan Science & Technology Agency (JST)			美佐子, 松本/A-4497-2012; Seya, Tsukasa/A-4336-2012					ATKINSON JP, 1987, IMMUNOL TODAY, V8, P212, DOI 10.1016/0167-5699(87)90167-8; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HILL KE, 1991, J BIOL CHEM, V266, P10050; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; IWAI K, 1988, ANAL BIOCHEM, V171, P277, DOI 10.1016/0003-2697(88)90486-1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KIKKAWA S, 1996, JPN BIOCH SOC, V68, P703; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MATSUI H, 1994, FEBS LETT, V351, P419, DOI 10.1016/0014-5793(94)00897-3; MATSUMOTO M, 1992, BIOCHEM J, V281, P493, DOI 10.1042/bj2810493; MATSUMOTO M, 1993, EUR J IMMUNOL, V23, P2270, DOI 10.1002/eji.1830230933; MATSUMOTO M, 1995, J EXP MED, V181, P115, DOI 10.1084/jem.181.1.115; RAMOS OF, 1985, P NATL ACAD SCI USA, V82, P5470, DOI 10.1073/pnas.82.16.5470; SEYA T, 1990, J IMMUNOL, V145, P238; UMEMURA K, 1996, J BIOL CHEM, V271, P4581	19	26	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1266	1270		10.1038/nm1197-1266	http://dx.doi.org/10.1038/nm1197-1266			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359703				2022-12-27	WOS:A1997YD89600037
J	Wijnholds, J; Evers, R; vanLeusden, MR; Mol, CAAM; Zaman, GJR; Mayer, U; Beijnen, JH; vanderValk, M; Krimpenfort, P; Borst, P				Wijnholds, J; Evers, R; vanLeusden, MR; Mol, CAAM; Zaman, GJR; Mayer, U; Beijnen, JH; vanderValk, M; Krimpenfort, P; Borst, P			Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein	NATURE MEDICINE			English	Article							CONJUGATE EXPORT PUMP; ARACHIDONIC-ACID; BONE-MARROW; MAST-CELLS; GENE LEADS; MRP; GLUTATHIONE; TRANSPORTER; LEUKOTRIENES; OVEREXPRESSION	The multidrug resistance-associated protein (MRP) mediates the cellular excretion of many drugs, glutathione S-conjugates (CS-X) of lipophilic xenobiotics and endogenous cysteinyl leukotrienes(1-5). Increased MRP levels in tumor cells can cause multidrug resistance (MDR) by decreasing the intracellular drug concentration. The physiological role or roles of MRP remain ill-defined, however. We have generated MRP-deficient mice by using embryonic stem cell technology. Mice homozygous for the mrp mutant allele, mrp(-/-), are viable and fertile, but their response to an inflam matory stimulus is impaired. We attribute this defect to a decreased secretion of leukotriene C-4 (LTC4) from leukotriene-synthesizing cells. Moreover, the mrp(-/-) mice are hypersensitive to the anticancer drug etoposide. The phenotype of mrp(-/-) mice is consistent with a role for MRP as the main LTC4-exporter in leukotriene-synthesizing cells, and as an important drug exporter in drug-sensitive cells. Our results suggest that this ubiquitous(6) GS-X pump's is dispensable in mice, making treatment of MDR with MRP-specific reversal agents potentially feasible.	NETHERLANDS CANC INST, DIV MOL BIOL, NL-1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; SLOTERVAART HOSP, DEPT PHARM, NL-1066 EC AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital			Wijnholds, Jan/V-3896-2018	Wijnholds, Jan/0000-0003-0099-460X				CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DOMEN J, 1993, BLOOD, V82, P1445; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HAY DWP, 1995, TRENDS PHARMACOL SCI, V16, P304, DOI 10.1016/S0165-6147(00)89059-8; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Jedlitschky G, 1996, CANCER RES, V56, P988; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEIER I, 1994, J BIOL CHEM, V269, P27807; Lorico A, 1996, CANCER RES, V56, P5351; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Pulaski L, 1996, EUR J BIOCHEM, V241, P644, DOI 10.1111/j.1432-1033.1996.00644.x; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; Saxena M, 1996, BIOCHEM J, V320, P273, DOI 10.1042/bj3200273; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Stride BD, 1996, MOL PHARMACOL, V49, P962; VERHAGEN J, 1986, J CHROMATOGR, V378, P208, DOI 10.1016/S0378-4347(00)80714-8; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	29	381	386	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1275	1279		10.1038/nm1197-1275	http://dx.doi.org/10.1038/nm1197-1275			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359705				2022-12-27	WOS:A1997YD89600039
J	Lee, MK; Borchelt, DR; Kim, G; Thinakaran, G; Slunt, HH; Ratovitski, T; Martin, LJ; Kittur, A; Gandy, S; Levey, AI; Jenkins, N; Copeland, N; Price, DL; Sisodia, SS				Lee, MK; Borchelt, DR; Kim, G; Thinakaran, G; Slunt, HH; Ratovitski, T; Martin, LJ; Kittur, A; Gandy, S; Levey, AI; Jenkins, N; Copeland, N; Price, DL; Sisodia, SS			Hyperaccumulation of FAD-linked presenilin 1 variants in vivo	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; CHROMOSOME-1; LOCUS	Mutations in the presenilin 1 (PS1) and presenilin 2 (PS2) genes can cause Alzheimer's disease in affected members of the majority of early-onset familiar Alzheimer's disease (FAD) pedigrees(1-7). PS1 encodes an ubiquitously expressed, eight transmembrane protein(1,8-11). PS1 is endoproteolytically processed to an aminoterminal derivative (similar to 27-28 kDa) and a carboxy-terminal derivative (similar to 17-18 kDa). These polypeptides accumulate to saturable levels in the brains of transgenic mice, independent of the expression of PS1 holoprotein(12). We now document that, in the brains of transgenic mice, the absolute amounts of accumulated N- and C-terminal derivatives generated from the FAD-linked PS1 variants in which Glu replaces Ala at codon 246 (A246E) or Leu replaces Met at codon 146 (M146L) accumulate to a significantly higher degree (similar to 40-50%) than the fragments derived from wild-type PS1. Moreover, the FAD-linked Delta E9 PS1 variant, a polypeptide that is not subject to endoproteolytic cleavage in vivo, also accumulates in greater amounts than the fragments generated from wild-type human PS1. Thus, the metabolism of PS1 variants linked to FAD is fundamentally different from that of wild-type PS1 in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; CORNELL UNIV,COLL MED,NEW YORK,NY 10021; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	Johns Hopkins University; Johns Hopkins University; Cornell University; Emory University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lee, MK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,558 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Lee, Michael K/D-9491-2013; Levey, Allan/F-2104-2011	Lee, Michael K/0000-0001-5865-9682; Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05146, 1 P01-AG 14248] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3	20	130	133	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					756	760		10.1038/nm0797-756	http://dx.doi.org/10.1038/nm0797-756			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212102				2022-12-27	WOS:A1997XG76700035
J	Uhr, JW; Scheuermann, RH; Street, NE; Vitetta, ES				Uhr, JW; Scheuermann, RH; Street, NE; Vitetta, ES			Cancer dormancy: Opportunities for new therapeutic approaches	NATURE MEDICINE			English	Review							POLYMERASE CHAIN-REACTION; B-CELL LYMPHOMA; EPIDERMAL GROWTH-FACTOR; CLASS-SWITCH VARIANTS; MONOCLONAL-ANTIBODIES; TUMOR DORMANCY; BONE-MARROW; MICE; MELANOMA; RECOGNITION		UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, LAB MOL PATHOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PATHOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Uhr, JW (corresponding author), UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Scheuermann, Richard H./0000-0003-1355-892X				ALBELDA SM, 1993, LAB INVEST, V68, P4; [Anonymous], 2018, CANCER, V124, P1197, DOI [10.1002/cncr.31178, DOI 10.1002/CNCR.31178]; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALLAWAY MP, 1989, BRIT J PLAST SURG, V42, P46, DOI 10.1016/0007-1226(89)90111-2; CROXTALL JD, 1992, INT J CANCER, V50, P822, DOI 10.1002/ijc.2910500527; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DENKERS EY, 1985, J IMMUNOL, V135, P2183; DREBIN JA, 1988, ONCOGENE, V2, P387; ECCLES SA, 1975, NATURE, V257, P52, DOI 10.1038/257052a0; ECCLES SA, 1992, CELLULAR IMMUNE MECH; FENDLY BM, 1990, CANCER RES, V50, P1550; Folkman J, 1995, MOL BASIS CANC, P206; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HERLYN D, 1982, P NATL ACAD SCI-BIOL, V79, P4761, DOI 10.1073/pnas.79.15.4761; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Israel L, 1996, J THEOR BIOL, V178, P375, DOI 10.1006/jtbi.1996.0033; ISRAELI RS, 1995, J UROLOGY, V153, P573; ITO Y, 1994, LEUKEMIA LYMPHOMA, V16, P57, DOI 10.3109/10428199409114140; Jothy S, 1995, CANCER METAST REV, V14, P363, DOI 10.1007/BF00690604; KAMINSKI MS, 1986, J IMMUNOL, V136, P1123; KAWAKAMI Y, 1993, J IMMUNOTHER, V14, P88, DOI 10.1097/00002371-199308000-00002; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; KLUIN PM, 1996, PREMALIGNANCY TUMOR, P1; LEVY R, 1990, Journal of the National Cancer Institute Monographs, P61; LIOTTA LA, 1993, CANC PRINCIPLES PRAC, P134; LORIC S, 1995, CLIN CHEM, V41, P1698; LUNDY J, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P155; MARCHES R, 1996, THER IMMUNOL, V2, P125; MATSUZAWA A, 1996, PREMALIGNANCY TUMOR, P89; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; METZGER H, 1992, J IMMUNOL, V149, P1477; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NOBLE RL, 1975, CANCER RES, V35, P2935; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; PENN I, 1993, TRANSPLANTATION, V55, P742, DOI 10.1097/00007890-199304000-00011; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RACILA E, 1995, J EXP MED, V181, P1539, DOI 10.1084/jem.181.4.1539; RAMANI P, 1987, INT J CANCER, V40, P830, DOI 10.1002/ijc.2910400621; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SCOTT DW, 1985, CELL IMMUNOL, V93, P124, DOI 10.1016/0008-8749(85)90393-4; SIU H, 1986, J IMMUNOL, V137, P1376; STEPLEWSKI Z, 1985, P NATL ACAD SCI USA, V82, P8653, DOI 10.1073/pnas.82.24.8653; STEVENSON FK, 1990, CHEM IMMUNOL, V48, P126; STINGL G, 1995, IMMUNOL TODAY, V16, P330, DOI 10.1016/0167-5699(95)80148-0; THEODORESCU D, 1991, CANCER RES, V51, P4486; UHR JW, 1991, CANCER RES, V51, pS5045; VAAGE J, 1991, BRIT J CANCER, V63, P758, DOI 10.1038/bjc.1991.169; VITERTA ES, IN PRESS BLOOD; VITETTA ES, 1994, CANCER RES, V54, P5301; VUIST WMJ, 1994, BLOOD, V83, P899; WEISS L, 1983, J IMMUNOL, V130, P2452; Wheelock E F, 1981, Adv Cancer Res, V34, P107; WOODRUFF M, 1982, BRIT J CANCER, V46, P313, DOI 10.1038/bjc.1982.206; YEFENOF E, 1993, P NATL ACAD SCI USA, V90, P1829, DOI 10.1073/pnas.90.5.1829	60	173	178	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1997	3	5					505	509		10.1038/nm0597-505	http://dx.doi.org/10.1038/nm0597-505			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142117				2022-12-27	WOS:A1997WX54300028
J	Klauber, N; Rohan, RM; Flynn, E; DAmato, RJ				Klauber, N; Rohan, RM; Flynn, E; DAmato, RJ			Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470	NATURE MEDICINE			English	Article								Angiogenesis, the growth of new blood vessels, occurs normally in female reproductive organs. We tested the hypothesis that angiogenesis inhibition may affect fertility by studying the reproductive system in either pregnant or nonpregnant cycling mice after treatment with the angiogenesis inhibitor AGM-1470. Administration of AGM-1470 to pregnant mice resulted in complete failure of embryonic growth due to interference with decidualization, placental and yolk sac formation, and embryonic vascular development. When nonpregnant cycling female mice were chronically treated with AGM-1470, inhibition of endometrial maturation and corpora lutea was observed. These data suggest that processes in reproduction can be controlled through angiogenesis inhibition.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115; BOSTON UNIV,MED CTR,DEPT SURG,BOSTON,MA 02118	Harvard University; Boston Children's Hospital; Harvard Medical School; Boston University					NIGMS NIH HHS [T32 GM008716] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPLIN AK, 1973, BIOL REPROD, V8, P491, DOI 10.1093/biolreprod/8.4.491; Christenson LK, 1996, ENDOCRINOLOGY, V137, P367, DOI 10.1210/en.137.1.367; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOODGER AM, 1993, J REPROD FERTIL, V99, P451, DOI 10.1530/jrf.0.0990451; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; TAMURA H, 1987, BIOL REPROD, V36, P1149, DOI 10.1095/biolreprod36.5.1149; WELCH AO, 1991, AM J ANAT, V192, P347; [No title captured]	13	160	169	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					443	446		10.1038/nm0497-443	http://dx.doi.org/10.1038/nm0497-443			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095179				2022-12-27	WOS:A1997WQ82500035
J	Bohl, D; Naffakh, N; Heard, JM				Bohl, D; Naffakh, N; Heard, JM			Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts	NATURE MEDICINE			English	Article							INDUCIBLE GENE-EXPRESSION; TRANSGENIC MICE; RETROVIRUS VECTORS; MAMMALIAN-CELLS; RECOMBINANT RETROVIRUSES; REGULATED EXPRESSION; CHROMOSOMAL POSITION; PROMOTERS; ENHANCER; HYPOXIA	We investigated tetracycline regulation of gene expression in an experimental model relevant to gene therapy. Mouse primary myogenic cells were engineered for doxycycline-inducible and skeletal muscle-specific expression of the mouse erythropoietin (Epo) cDNA by using two retrovirus vectors. Gene expression increased 200 fold in response to both myogenic cell differentiation and doxycycline stimulation. After transplantation of transduced cells into mouse skeletal muscles, Epo secretion could be iteratively switched on and off over a five-month period, depending on the presence or the absence of doxycycline in the drinking water. We conclude that tetracycline regulation provides a suitable control system for adjusting the delivery of therapeutic proteins from engineered tissues over long periods of time.			Bohl, D (corresponding author), INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,CNRS,URA 1157,28 RUE DR ROUX,F-75724 PARIS,FRANCE.		Bohl, Delphine/L-8709-2016	Bohl, Delphine/0000-0001-8262-5642; Naffakh, Nadia/0000-0002-0424-0277				BAUER TR, 1994, HUM GENE THER, V5, P709, DOI 10.1089/hum.1994.5.6-709; BECK I, 1993, BLOOD, V82, P704; CONE RD, 1987, MOL CELL BIOL, V7, P887, DOI 10.1128/MCB.7.2.887; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; Hwang JJ, 1996, J VIROL, V70, P8138, DOI 10.1128/JVI.70.11.8138-8141.1996; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; Jacque JM, 1996, J VIROL, V70, P2930; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JENSEN JD, 1994, EUR J CLIN PHARMACOL, V46, P333; KLEIN J, 1975, BIOL MOUSE HISTOCOMP, P329; LI ZL, 1991, J BIOL CHEM, V266, P6562; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MADAN A, 1995, BLOOD, V85, P2735; Metcalf D, 1988, MOL CONTROL BLOOD CE; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Naffakh N, 1996, HUM GENE THER, V7, P11, DOI 10.1089/hum.1996.7.1-11; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; SAKAGUCHI M, 1987, BIOCHEM BIOPH RES CO, V146, P7, DOI 10.1016/0006-291X(87)90682-6; SALMONSON T, 1990, BRIT J PHARMACOL, V29, P703; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; VILE R, 1994, GENE THER, V1, P307; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YEE JK, 1987, P NATL ACAD SCI USA, V84, P5199; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	42	148	157	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					299	305		10.1038/nm0397-299	http://dx.doi.org/10.1038/nm0397-299			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055857				2022-12-27	WOS:A1997WL30500031
J	Michael, NL; Chang, G; Louie, LG; Mascola, JR; Dondero, D; Birx, DL; Sheppard, HW				Michael, NL; Chang, G; Louie, LG; Mascola, JR; Dondero, D; Birx, DL; Sheppard, HW			The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Delta ellular entry of human immunodeficiency virus type 1 (HIV-1) requires binding to both CD4 (ref. 1, 2) and to one of the chemokine receptors recently discovered to act as coreceptors(3-11). Viruses that infect T-cell lines to form syncytia (syncytium-inducing, SI) are frequently found in late-stage HIV disease and utilize the chemokine receptor CXCR-4; macrophage-tropic viruses are non-syncytium-inducing (NSI), found throughout disease and utilize CCR-5 (ref. 3-11). We postulated that CCR-5 gene defects might reduce infection risk in seronegative subjects and prolong AIDS-free survival in seropositive subjects with NSI but not SI virus. Homozygous (Delta ccr5/Delta ccr5) and heterozygous (CCR5/Delta ccr5) CCR-5 deletions (Delta ccr5)(12,13) were found in 7 (2.7%) and 51 (19.5%), respectively, of 261 seronegative subjects from the San Francisco Men's Health Study. CCR-5/Delta ccr5 genotype was identified in 33 of 172 (19.2%) nonprogressors and 25 of 234 (10.7%) progressors from the seropositive arm of this cohort. The Delta ccr5 allele conferred a significant protective effect against HIV-1 infection (P = 0.001) and a survival advantage against disease progression (P = 0.02). Although both progressing and nonprogressing CCR5/Delta ccr5 subjects were identified, a distinct survival advantage was shown for those with NSI virus (P < 0.0001). Thus, the protective effect of Delta ccr5 against disease progression is lost when the infecting virus uses CXCR-4 as a coreceptor.	HENRY M JAKCSON FDN,ROCKVILLE,MD 20850; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD 20889; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California Berkeley; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; California Department of Health Care Services	Michael, NL (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850, USA.		Mascola, John/AAI-7193-2021		NIAID NIH HHS [R01-AI-36661, R01-AI-34783, N01-AI-82515] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036661, R01AI034783, N01AI082515] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	22	416	434	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					338	340		10.1038/nm0397-338	http://dx.doi.org/10.1038/nm0397-338			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055864				2022-12-27	WOS:A1997WL30500038
J	Zhao, Y; Swenson, K; Sergio, JJ; Arn, JS; Sachs, DH; Sykes, M				Zhao, Y; Swenson, K; Sergio, JJ; Arn, JS; Sachs, DH; Sykes, M			Skin graft tolerance across a discordant xenogeneic barrier	NATURE MEDICINE			English	Article							T-CELL TOLERANCE; TRANSPLANTATION TOLERANCE; THYMIC EPITHELIUM; CLONAL DELETION; MONOCLONAL-ANTIBODIES; NEGATIVE SELECTION; CLASS-I; ANTIGENS; ANERGY; MICE	Specific T-cell tolerance may be essential for successful xenotransplantation in humans. Grafting of thymectomized, T cell-depleted normal mice with xenogeneic fetal pig thymus and liver (FP THY/LIV) tissue results in the recovery of functional CD4 antigen-positive cells. We have tested T-cell tolerance by skin grafting. Donor-matched pig skin survived permanently (>200 days), whereas allogeneic mouse skin was rapidly rejected. Nontolerant control mice rejected pig skin within 26 days. Both porcine and murine histocompatibility class IIhigh cells were detected in long-term thymus grafts, and T-cell repertoire analyses suggested that tolerance to both donors and recipients developed, at least in part, by intragraft clonal deletion. This study demonstrates the principle that tolerance, measured by the stringent criterion of skin grafting, can be induced across a widely disparate species barrier.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SURG SERV,TRANSPLANTAT BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039755] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 39755] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, 1995, XENO, V3, P19; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; Davies JD, 1996, J IMMUNOL, V156, P3602; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; GRUSBY MJ, 1995, ANNU REV IMMUNOL, V13, P417, DOI 10.1146/annurev.iy.13.040195.002221; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; GUERY JC, 1995, J IMMUNOL, V154, P536; HOUSSAINT E, 1990, IMMUNOL TODAY, V11, P357, DOI 10.1016/0167-5699(90)90141-U; ILDSTAD ST, 1985, J EXP MED, V162, P231, DOI 10.1084/jem.162.1.231; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KYEWSKI BA, 1984, NATURE, V308, P196, DOI 10.1038/308196a0; LAFFERTY KJ, 1994, CLIN TRANSPLANT, V8, P181; LEE LA, 1994, P NATL ACAD SCI USA, V91, P10864, DOI 10.1073/pnas.91.23.10864; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LORENZ RG, 1989, NATURE, V340, P557, DOI 10.1038/340557a0; LUNNEY JK, 1993, IMMUNOL TODAY, V14, P147, DOI 10.1016/0167-5699(93)90227-C; Martin C, 1991, Dev Immunol, V1, P265, DOI 10.1155/1991/57259; MILLER JFAP, 1960, BRIT J CANCER, V14, P93, DOI 10.1038/bjc.1960.11; MODIGLIANI Y, 1995, P NATL ACAD SCI USA, V92, P7555, DOI 10.1073/pnas.92.16.7555; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V124, P533; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SACHS DH, 1995, NAT MED, V1, P969, DOI 10.1038/nm0995-969; SACHS DH, 1981, MONOCLONAL ANTIBODIE, P95; SALAUN J, 1992, P NATL ACAD SCI USA, V89, P10420, DOI 10.1073/pnas.89.21.10420; SALAUN J, 1990, SCIENCE, V247, P1471, DOI 10.1126/science.2321009; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; SPEISER DE, 1992, J EXP MED, V175, P1277, DOI 10.1084/jem.175.5.1277; SYKES M, 1993, J EXP MED, V178, P223, DOI 10.1084/jem.178.1.223; SYKES M, 1994, IMMUNOL REV, V141, P245, DOI 10.1111/j.1600-065X.1994.tb00880.x; SYKES M, 1994, XENO, V2, P65; SYKES M, IN PRESS CURR OPIN I; TOMITA Y, 1994, J IMMUNOL, V153, P1087; Tomita Yukihiro, 1994, Xenotransplantation, V1, P109, DOI 10.1111/j.1399-3089.1994.tb00056.x; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; TOMONARI K, 1993, IMMUNOL REV, V131, P131, DOI 10.1111/j.1600-065X.1993.tb01534.x; WATANABE M, 1983, TRANSPLANTATION, V36, P712, DOI 10.1097/00007890-198336060-00025; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEIENS PW, 1994, TRANSPLANTATION, V57, P1795; YAMADA K, 1995, J IMMUNOL, V155, P5249; YANG YG, 1995, J IMMUNOL, V155, P1981; YIN DP, 1995, J IMMUNOL, V154, P6339	46	155	157	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1211	1216		10.1038/nm1196-1211	http://dx.doi.org/10.1038/nm1196-1211			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898747				2022-12-27	WOS:A1996VQ10100035
J	Dilloo, D; Bacon, K; Holden, W; Zhong, WY; Burdach, S; Zlotnik, A; Brenner, M				Dilloo, D; Bacon, K; Holden, W; Zhong, WY; Burdach, S; Zlotnik, A; Brenner, M			Combined chemokine and cytokine gene transfer enhances antitumor immunity	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-2 PRODUCTION; T-CELLS; CANCER; LINES; IL-2; TUMORIGENICITY; COSTIMULATION; HEMATOPOIESIS	The probability of producing a specific antitumor response should be increased by multiplying the number of T lymphocytes that encounter the malignant cells. We tested this prediction in a murine model, using a recently discovered T-cell chemokine, lymphotactin (Lptn). This chemokine increased tumor cell infiltration with CD4(+) lymphocytes but generated little antitumor activity. Coexpression of the T-cell growth factor interleukin-2 however, greatly expanded the T lymphocytes attracted by Lptn, affording protection from the growth of established tumor in a CD4(+) and CD8(+) T cell-dependent manner. Lesser synergy was seen with GM-CSF. Hence coexpression of a T-cell chemokine and T-cell growth factor potentiates antitumor responses in vivo, suggesting a general strategy to improve cancer immunotherapy.	ST JUDE CHILDRENS RES HOSP, CELL & GENE THERAPY PROGRAM, MEMPHIS, TN 38105 USA; DNAX RES INST MOL & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA; UNIV DUSSELDORF, LAB EXPT HEMATOL, D-40225 DUSSELDORF, GERMANY	St Jude Children's Research Hospital; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Heinrich Heine University Dusseldorf	Dilloo, D (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Zlotnik, Albert/C-3791-2011		NCI NIH HHS [CA 21765, CA 58211] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA058211, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong CA, 1996, CANCER RES, V56, P2191; ASHER AL, 1991, J IMMUNOL, V146, P3227; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BASKAR S, 1995, J EXP MED, V181, P619, DOI 10.1084/jem.181.2.619; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; CHEN L, 1995, J EXP MED, V181, P619; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FAKHRAI H, 1995, HUM GENE THER, V6, P591, DOI 10.1089/hum.1995.6.5-591; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FOREMAN NK, 1993, BRIT J CANCER, V67, P933, DOI 10.1038/bjc.1993.173; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GLIMCHER LH, 1982, J EXP MED, V155, P445, DOI 10.1084/jem.155.2.445; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GUINAN EC, 1994, BLOOD, V84, P3261; HOGGE DE, 1991, BLOOD, V77, P493; KARP SE, 1993, J IMMUNOL, V150, P896; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; KIM KJ, 1979, J IMMUNOL, V122, P549; LI CY, 1984, AM J CLIN PATHOL, V81, P204, DOI 10.1093/ajcp/81.2.204; MAASS G, 1995, P NATL ACAD SCI USA, V92, P5540, DOI 10.1073/pnas.92.12.5540; MARANINCHI D, 1991, BLOOD, V78, P2182; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; MELONI G, 1994, BLOOD, V84, P2158; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RUSSELL SJ, 1991, INT J CANCER, V47, P244, DOI 10.1002/ijc.2910470213; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHELL T, 1994, CYTOKINE HDB, P419; SCHMIDT W, 1995, P NATL ACAD SCI USA, V92, P4711, DOI 10.1073/pnas.92.10.4711; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SPENCER HT, IN PRESS BLOOD; TAHARA H, 1994, CANCER RES, V54, P182; Wakimoto H, 1996, CANCER RES, V56, P1828	39	195	206	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1090	1095		10.1038/nm1096-1090	http://dx.doi.org/10.1038/nm1096-1090			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837606				2022-12-27	WOS:A1996VK99500028
J	Robertson, MM				Robertson, MM			D2 be or not to be?	NATURE MEDICINE			English	Editorial Material							TOURETTES-SYNDROME; BASAL GANGLIA; BINDING		NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Robertson, MM (corresponding author), UCL, DEPT PSYCHIAT & BEHAV SCI, MIDDLESEX HOSP SITE, LONDON W1N 8AA, ENGLAND.							BEUTINK P, 1993, HDB TOURETTES SYNDRO, P517; GEORGE MS, 1994, PSYCHIAT RES-NEUROIM, V55, P193, DOI 10.1016/0165-1781(95)91245-9; GERLERNTER J, 1994, ARCH NEUROL-CHICAGO, V51, P397; HYDE TM, 1995, NEUROLOGY, V45, P1176, DOI 10.1212/WNL.45.6.1176; LECKMAN JF, 1987, ARCH GEN PSYCHIAT, V44, P100; MALISON RT, 1995, AM J PSYCHIAT, V152, P1359; MOARIARTY J, 1995, BRIT J PSYCHIAT, V167, P249; NOTHEN MM, 1994, AM J MED GENET, V54, P249, DOI 10.1002/ajmg.1320540311; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; PILOWSKY LS, 1994, BRIT J PSYCHIAT, V164, P16, DOI 10.1192/bjp.164.1.16; ROBERTSON MM, 1994, J CHILD PSYCHOL PSYC, V35, P597, DOI 10.1111/j.1469-7610.1994.tb01209.x; SINGER HS, 1992, ADV NEUROL, V58, P135; TURJANSKI N, 1994, J NEUROL NEUROSUR PS, V57, P688, DOI 10.1136/jnnp.57.6.688; WOLF SS, 1996, SCIENCE, V273, P1255; WONG DF, 1994, J NUCL MED P, V130	15	4	4	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1076	1077		10.1038/nm1096-1076	http://dx.doi.org/10.1038/nm1096-1076			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837600				2022-12-27	WOS:A1996VK99500022
J	Eriksson, PS; Perfilieva, E; Bjork-Eriksson, T; Alborn, AM; Nordborg, C; Peterson, DA; Gage, FH				Eriksson, PS; Perfilieva, E; Bjork-Eriksson, T; Alborn, AM; Nordborg, C; Peterson, DA; Gage, FH			Neurogenesis in the adult human hippocampus	NATURE MEDICINE			English	Article							DENTATE GYRUS; NEURONS; CELLS; DIFFERENTIATION; RAT; PROTEIN; BRAIN; MICE; NEUN	The genesis of new cells, including neurons, in the adult human brain has not yet been demonstrated. This study was undertaken to investigate whether neurogenesis occurs in the adult human brain, in regions previously identified as neurogenic in adult rodents and monkeys. Human brain tissue was obtained postmortem from patients who had been treated with the thymidine analog, bromodeoxyuridine (BrdU), that labels DNA during the S phase. Using immunofluorescent labeling for BrdU and for one of the neuronal markers, NeuN, calbindin or neuron specific enolase (NSE), we demonstrate that new neurons, as defined by these markers, are generated from dividing progenitor cells in the dentate gyrus of adult humans. Our results further indicate that the human hippocampus retains its ability to generate neurons throughout life.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Sahlgrens Univ Hosp, Inst Neurol, Dept Clin Neurosci, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden	Salk Institute; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Bjork-Eriksson, Thomas/0000-0003-3680-5196				ALTMAN J, 1967, NATURE, V214, P1098, DOI 10.1038/2141098a0; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DELRIO JA, 1989, DEV BRAIN RES, V49, P311, DOI 10.1016/0165-3806(89)90033-3; DOLBEARE F, 1995, HISTOCHEM J, V27, P339; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUENEAU G, 1982, DEV NEUROSCI-BASEL, V5, P345, DOI 10.1159/000112694; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kuhn HG, 1996, J NEUROSCI, V16, P2027; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	27	4556	4811	10	461	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1313	1317		10.1038/3305	http://dx.doi.org/10.1038/3305			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809557	Bronze			2022-12-27	WOS:000076731000042
J	Nowell, P; Rowley, J; Knudson, A				Nowell, P; Rowley, J; Knudson, A			Cancer genetics, cytogenetics - defining the enemy within	NATURE MEDICINE			English	Editorial Material							BURKITT-LYMPHOMA; RETINOBLASTOMA; DELETION; LEUKEMIA; CELLS		Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Chicago, Ctr Med, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Pennsylvania; University of Chicago; Fox Chase Cancer Center	Nowell, P (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.							Boveri T, 1929, ORIGIN MALIGNANT TUM; COLE LJ, 1965, SCIENCE, V150, P1782, DOI 10.1126/science.150.3705.1782; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCKE U, 1976, MED PEDIATR ONCOL, V2, P379, DOI 10.1002/mpo.2950020404; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HUNGERFORD DA, 1978, CYTOGENET CELL GENET, V20, P1, DOI 10.1159/000130834; Knudson A G, 1992, Semin Cancer Biol, V3, P99; Knudson A. G., 1973, ADV CANCER RES, V17, P317; KNUDSON AG, 1973, PROG MED GENET, V9, P113; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; NOWELL PC, 1960, CANCER RES, V20, P462; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1984, CANCER RES, V44, P3159; ROWLEY JD, IN PRESS J LAB CLIN; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837	21	20	22	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1107	1111		10.1038/2598	http://dx.doi.org/10.1038/2598			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771733				2022-12-27	WOS:000076230100019
J	Simon, F; Mauclere, P; Roques, P; Loussert-Ajaka, I; Muller-Trutwin, MC; Saragosti, S; Georges-Courbot, MC; Barre-Sinoussi, F; Brun-Vezinet, F				Simon, F; Mauclere, P; Roques, P; Loussert-Ajaka, I; Muller-Trutwin, MC; Saragosti, S; Georges-Courbot, MC; Barre-Sinoussi, F; Brun-Vezinet, F			Identification of a new human immunodeficiency virus type 1 distinct from group M and group O	NATURE MEDICINE			English	Article							WILD-CAPTURED CHIMPANZEE; HIV-1 GROUP; CAMEROON; SENSITIVITY; INFECTION; SUBTYPE; ISOLATE; AFRICA; SEQUENCE; GABON	A highly divergent HIV-1 isolate, designated YBF 30, was obtained in 1995 from a 40-year-old Cameroonian woman with AIDS. Depending on the genes studied, phylogenetic analysis showed that YBF30 branched either with SIVcpz-gab or between SIVcpz-gab and HIV-1 group M. The structural genes and tat vpr, and nef of YBF30 are approximately equidistant from those of HIV-1 group M and SIVcpz-gab. In contrast, vif and rev are closer to HIV-1 group M, and vpu is highly divergent. Using a YBF30 V3 loop peptide enzyme immunoassay, we screened 700 HIV-l-positive sera collected in Cameroon; three reacted strongly with the YBF30 peptides and one was confirmed as being related to YBF30 by genetic analysis of a pol fragment. YBF30 is as distinct from SIVcpz-gab as it is from HIV-1 group M and can thus be considered as the prototype strain of a new human immunodeficiency virus group.	Hop Bichat, Virol Lab, F-75877 Paris, France; Ctr Pasteur Cameroun, Yaounde, Cameroon; CEA, DRM, Serv Neurovirol, Fontenay Aux Roses, France; Inst Pasteur, Unite Biol Retrovirus, Paris, France; Hop Bichat, INSERM, IMEA, F-75877 Paris, France; Ctr Int Rech Med Franceville, Franceville, Gabon	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Centre Pasteur du Cameroun; CEA; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Simon, F (corresponding author), Hop Bichat, Virol Lab, F-75877 Paris, France.		Roques, Pierre/M-2212-2013; Barre-Sinoussi, Françoise/G-8355-2011	Roques, Pierre/0000-0003-1825-1054; Muller-Trutwin, Michaela/0000-0002-3854-2396				BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; Delaporte E, 1996, AIDS, V10, P903, DOI 10.1097/00002030-199607000-00014; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DENG N, 1996, NATURE, V381, P661; DONEHOWER LA, 1990, J VIROL METHODS, V28, P33, DOI 10.1016/0166-0934(90)90085-T; FELSENSTEIN J, 1993, PHYLIP INFERENCE PAC; Franklin A. S., 1994, CONTEMP ORG SYNTH, V1, P317; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; GESSAIN A, 1995, P NATL ACAD SCI USA, V92, P4041, DOI 10.1073/pnas.92.9.4041; GURTLER LG, 1994, J VIROL, V68, P1581; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; JANSSENS W, 1994, AIDS RES HUM RETROV, V10, P1191, DOI 10.1089/aid.1994.10.1191; KIMURA M, 1983, NEURTAL THEORY MOL E; LAURE F, 1988, LANCET, V1, P538; LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640, DOI 10.1128/JVI.69.9.5640-5649.1995; Mauclere P, 1997, AIDS RES HUM RETROV, V13, P987, DOI 10.1089/aid.1997.13.987; Mauclere P, 1997, AIDS, V11, P445, DOI 10.1097/00002030-199704000-00007; MAUCLERE P, 1995, AIDS RES HUM RETROV, V11, P989, DOI 10.1089/aid.1995.11.989; McCutchan FE, 1996, AIDS, V10, pS13; MYERS G, 1994, AIDS RES HUM RETROV, V10, P1317, DOI 10.1089/aid.1994.10.1317; MYERS G, 1996, HUMAN RETROVIRUSES A; NKENGASONG JN, 1994, AIDS, V8, P1405, DOI 10.1097/00002030-199410000-00006; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PEETERS M, 1992, AIDS, V6, P447, DOI 10.1097/00002030-199205000-00002; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; Sharp P.M., 1994, AIDS S1, V8, pS27; SIMON F, 1994, AIDS, V8, P1628, DOI 10.1097/00002030-199411000-00021; SIMON F, 1990, AIDS, V4, P1169, DOI 10.1097/00002030-199011000-00026; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994; VandenHaesevelde MM, 1996, VIROLOGY, V221, P346, DOI 10.1006/viro.1996.0384	36	396	427	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1032	1037		10.1038/2017	http://dx.doi.org/10.1038/2017			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734396				2022-12-27	WOS:000075804100036
J	Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO				Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO			A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet	NATURE MEDICINE			English	Article							E-DEFICIENT MICE; APOLIPOPROTEIN-E; KNOCKOUT MICE; RECEPTOR; LESIONS; LACKING; EXPRESSION; CLEARANCE; APOBEC-1; CELLS	Mutations in the low density lipoprotein (LDL) receptor gene cause familial hypercholesterolemia, a human disease characterized by premature atherosclerosis and markedly elevated plasma levels of LDL cholesterol and apolipoprotein (apo) B100. In contrast, mice deficient for the LDL receptor (Ldlr(-/-)) have only mildly elevated LDL cholesterol levels and little atherosclerosis. This difference results from extensive editing of the hepatic apoB mRNA in the mouse, which limits apoB100 synthesis in favor of apoB48 synthesis. We have generated Ldlr(-/-) mice that cannot edit the apoB mRNA and therefore synthesize exclusively apoB100. These mice had markedly elevated LDL cholesterol and apoB100 levels and developed extensive atherosclerosis on a chow diet. This authentic model of human familiar hypercholesterolemia will provide a new tool for studying atherosclerosis.	Genentech Inc, Cardiovasc Res, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Roche Holding; Genentech; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Chicago	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL 18577, HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180, P01HL018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DAVIDSON NO, 1995, RNA, V1, P3; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Kim E, 1998, J CLIN INVEST, V101, P1468; Kim E, 1998, J LIPID RES, V39, P703; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1996, CIRCULATION, V94; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sanan DA, 1998, P NATL ACAD SCI USA, V95, P4544, DOI 10.1073/pnas.95.8.4544; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	33	162	170	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					934	938		10.1038/nm0898-934	http://dx.doi.org/10.1038/nm0898-934			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701246				2022-12-27	WOS:000075107400037
J	Fueyo, J; Gomez-Manzano, C; Yung, WKA; Liu, TJ; Alemany, R; McDonnell, TJ; Shi, X; Rao, JS; Levin, VA; Kyritsis, AP				Fueyo, J; Gomez-Manzano, C; Yung, WKA; Liu, TJ; Alemany, R; McDonnell, TJ; Shi, X; Rao, JS; Levin, VA; Kyritsis, AP			Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; BINDING PROTEIN; CANCER-CELLS; P53 GENE; EXPRESSION; ADENOVIRUS; BRAIN; MICE; IDENTIFICATION	The transfer of apoptosis genes to tumors is one of the most promising strategies for cancer gene therapy. We have shown that massive apoptosis occurs when wild-type p53 expression is induced in glioma cells carrying a p53 gene mutation. However, adenovirus-mediated p53 gene transfer is ineffective in causing apoptosis in glioma cells that retain a wild-type p53 genotype. We evaluated the effect of E2F-1 overexpression on the growth of gliomas in vitro and in vivo. In the in vitro study, the adenovirus-mediated transfer of exogenous E2F-1 protein precipitated generalized apoptosis in gliomas. The treatment with Ad5CMV-E2F-1 of nude mice carrying subcutaneous gliomas arrested tumor growth. Our results indicate that E2F-1 has anti-glioma activity in vitro and in vivo.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurosurg, Houston, TX 77030 USA; Baxter Healthcare Corp, Unit Gene Therapy, Round Lake, IL 60073 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baxter International Inc	Fueyo, J (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335				Alemany R, 1997, J VIROL METHODS, V68, P147, DOI 10.1016/S0166-0934(97)00129-8; Alemany R, 1996, CANCER GENE THER, V3, P296; ARAP W, 1995, CANCER RES, V55, P1351; Attia M, 1996, CANCER RES, V126, P1787; EASTHAM JA, 1995, CANCER RES, V55, P5151; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1996, ONCOGENE, V12, P103; FUEYO J, IN PRESS NEUROLOGY; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; GomezManzano C, 1996, CANCER RES, V56, P694; GOMEZMANZANO C, 1998, GENE TRANSFER THERAP, P201; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hunt KK, 1997, CANCER RES, V57, P4722; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNG JM, 1995, ONCOGENE, V11, P2021; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; KYRITSIS AP, 1997, PRACTICE GUIDELINES, P473; LI Y, 1994, CANCER RES, V54, P6078; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STECK PA, 1986, J CELL BIOCHEM, V32, P1, DOI 10.1002/jcb.240320102; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	39	155	160	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					685	690		10.1038/nm0698-685	http://dx.doi.org/10.1038/nm0698-685			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623977				2022-12-27	WOS:000074008300034
J	Belaaouaj, A; McCarthy, R; Baumann, M; Gao, ZM; Ley, TJ; Abraham, SN; Shapiro, SD				Belaaouaj, A; McCarthy, R; Baumann, M; Gao, ZM; Ley, TJ; Abraham, SN; Shapiro, SD			Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis	NATURE MEDICINE			English	Article							LINEAGE	Neutrophil elastase (NE) is a potent serine proteinase(1,2) whose expression is limited to a narrow window during myeloid development. In neutrophils, NE is stored in azurophil granules along with other serine proteinases(3,4) (cathepsin G, proteinase 3 and azurocidin) at concentrations exceeding 5 mM (ref. 5). As a result of its capacity to efficiently degrade extracellular matrix, NE has been implicated in a variety of destructive diseases(6). Indeed, while much interest has focused on the pathologic effects of this enzyme, little is known regarding its normal physiologic function(s). Because previous in vitro data have shown that NE exhibits antibacterial activity(7-9), we investigated the role of NE in host defense against bacteria. Generating strains of mice deficient in NE (NE-/-) by targeted mutagenesis, we show that NE-/- mice are more susceptible than their normal littermates to sepsis and death following intraperitoneal infection with Gram negative (Klebsiella pneumoniae and Escherichia coli) but not Cram positive (Staphylococcus aureus) bacteria. Our data indicate that neutrophils migrate normally to sites of infection in the absence of NE, but that NE is required for maximal intracellular killing of Gram negative bacteria by neutrophils.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Genet, St Louis, MO 63110 USA; Duke Univ, Med Ctr, Dept Pathol & Microbiol, Durham, NC 27710 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Duke University	Shapiro, SD (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol, St Louis, MO 63110 USA.	sshapiro@imgate.wustl.edu	A, Bentaher/F-6531-2018; Bentaher, Abderrazzaq/M-4424-2017	A, Bentaher/0000-0001-6001-5456; 				BAKHA K, 1995, INFECT IMMUN, V63, P848; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; Belaaouaj K, 1997, MAMM GENOME, V8, P5, DOI 10.1007/s003359900337; Bieth JG, 1986, REGULATION MATRIX AC, P217; Blondin J., 1978, NEUTRAL PROTEASES HU, P39; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Liou TG, 1995, BIOCHEMISTRY-US, V34, P16171, DOI 10.1021/bi00049a032; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MIYASAKI KT, 1991, INFECT IMMUN, V59, P3760, DOI 10.1128/IAI.59.10.3760-3767.1991; ODEBERG H, 1976, INFECT IMMUN, V14, P1269, DOI 10.1128/IAI.14.6.1269-1275.1976; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1334, DOI 10.1164/ajrccm/146.5_Pt_1.1334; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; THORNE KJI, 1976, INFECT IMMUN, V14, P555, DOI 10.1128/IAI.14.2.555-563.1976; WEWERS MD, 1988, J CLIN INVEST, V82, P1260, DOI 10.1172/JCI113724; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	17	501	515	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					615	618		10.1038/nm0598-615	http://dx.doi.org/10.1038/nm0598-615			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585238				2022-12-27	WOS:000073399900036
J	Zitvogel, L; Regnault, A; Lozier, A; Wolfers, J; Flament, C; Tenza, D; Ricciardi-Castagnoli, P; Raposo, G; Amigorena, S				Zitvogel, L; Regnault, A; Lozier, A; Wolfers, J; Flament, C; Tenza, D; Ricciardi-Castagnoli, P; Raposo, G; Amigorena, S			Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes	NATURE MEDICINE			English	Article							ANTITUMOR IMMUNITY; T-LYMPHOCYTES; ANTIGEN; GENERATION; COOPERATE; INDUCTION; THERAPY; LIGAND; ALPHA; MICE	Dendritic cells (DCs) are professional antigen presenting cells with the unique capacity to Induce primary and secondary immune responses in vivo. Here, we show that DCs secrete antigen presenting vesicles, called exosomes, which express functional Major Histocompatibility Complex class I and class II, and T-cell costimulatory molecules. Tumor peptide-pulsed DC-derived exosomes prime specific cytotoxic T lymphocytes in vivo and eradicate or suppress growth of established murine tumors in a T cell-dependent manner. Exosome-based cell-free vaccines represent an alternative to DC adoptive therapy for suppressing tumor growth.	Inst Curie, INSERM, CJF 95 01, F-75006 Paris, France; Inst Curie, UMR144 CNRS, F-75006 Paris, France; Inst Gustave Roussy, Dept Biol Clin, Lab Immunol Cellulaire, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS URA 1301, F-94805 Villejuif, France; Univ Milan, CNR, Ctr Cellular & Mol Pharmacol, I-20129 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Amigorena, S (corresponding author), Inst Curie, INSERM, CJF 95 01, 12 Rue Lhomond, F-75006 Paris, France.	s.amigorena@curie.fr		ZITVOGEL, laurence/0000-0003-1596-0998; Amigorena, Sebastian/0000-0001-8583-8416				AMBE K, 1989, CANCER, V63, P496, DOI 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO;2-K; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cayeux S, 1997, J IMMUNOL, V158, P2834; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Dufour E, 1997, J IMMUNOL, V158, P3787; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Girolomoni G, 1997, IMMUNOL TODAY, V18, P102, DOI 10.1016/S0167-5699(97)01030-X; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; Iwasaki A, 1997, J IMMUNOL, V159, P11; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Lotze MT, 1996, ANN NY ACAD SCI, V795, P440, DOI 10.1111/j.1749-6632.1996.tb52715.x; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mayordomo JI, 1997, STEM CELLS, V15, P94, DOI 10.1002/stem.150094; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RAPOSO G, 1997, HDB EXPT IMMUNOLOGY, P1; Restifo NP, 1996, CURR OPIN IMMUNOL, V8, P658, DOI 10.1016/S0952-7915(96)80082-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schmidt W, 1997, P NATL ACAD SCI USA, V94, P3262, DOI 10.1073/pnas.94.7.3262; STAM NJ, 1986, J IMMUNOL, V137, P2299; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Tuting T, 1997, EUR J IMMUNOL, V27, P2702, DOI 10.1002/eji.1830271033; VONBOCKXMEER F, 1979, BIOCHIM BIOPHYS ACTA, V584, P76; Warnier G, 1996, INT J CANCER, V67, P303, DOI 10.1002/(SICI)1097-0215(19960717)67:2<303::AID-IJC24>3.0.CO;2-A; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Zitvogel L, 1996, EUR J IMMUNOL, V26, P1335, DOI 10.1002/eji.1830260624; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	35	1549	1677	6	288	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					594	600		10.1038/nm0598-594	http://dx.doi.org/10.1038/nm0598-594			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585234				2022-12-27	WOS:000073399900032
J	Bull, PC; Lowe, BS; Kortok, M; Molyneux, CS; Newbold, CI; Marsh, K				Bull, PC; Lowe, BS; Kortok, M; Molyneux, CS; Newbold, CI; Marsh, K			Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; ERYTHROCYTES; DIVERSITY; CYTOADHERENCE; EXPRESSION; ADHERENCE; RECEPTOR; PROTECTION; PHENOTYPES; PROTEINS	The feasibility of a malaria vaccine is supported by the fact that children in endemic areas develop naturally acquired immunity to disease. Development of disease immunity is characterized by a decrease in the frequency and severity of disease episodes over several years despite almost continuous infection(1), suggesting that immunity may develop through the acquisition of a repertoire of specific, protective antibodies directed against polymorphic target antigens(1-3). Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a potentially important family of target antigens, because these proteins are inserted into the red cell surface and are prominently exposed(4-6) and because they are highly polymorphic and undergo clonal antigenic variation(7,8,18), a mechanism of immune evasion maintained by a large family of vor genes(9-11). In a large prospective study of Kenyan children, we have used the fact that anti-PfEMP1 antibodies agglutinate infected erythrocytes in a variant-specific manner(10,12-16), to show that the PfEMP1 variants expressed during episodes of clinical malaria were less likely to be recognized by the corresponding child's own preexisting antibody response than by that of children of the same age from the same community. In contrast, a heterologous parasite isolate was just as likely to be recognized. The apparent selective pressure exerted by established anti-PfEMP1 antibodies on infecting parasites supports the idea that such responses provide variant-specific protection against disease.	Kenya Med Res Inst, CRC, Kilifi UNit, Kilifi, Kenya; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Kenya Medical Research Institute; University of Oxford	Bull, PC (corresponding author), Kenya Med Res Inst, CRC, Kilifi UNit, POB 230, Kilifi, Kenya.	pbull@africaonline.co.ke	Molyneux, Catherine/HGB-8464-2022	Molyneux, Catherine/0000-0001-9522-416X; Newbold, Chris/0000-0002-9274-3789; Bull, Peter/0000-0002-7674-6752	Wellcome Trust [061524] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANITA R, 1996, P NATL ACAD SCI USA, V93, P985; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BIGGS BA, 1992, J IMMUNOL, V149, P2047; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; INSELBURG J, 1984, EXP PARASITOL, V57, P48, DOI 10.1016/0014-4894(84)90061-4; IQBAL J, 1993, T ROY SOC TROP MED H, V87, P583, DOI 10.1016/0035-9203(93)90097-A; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245, DOI 10.4269/ajtmh.1993.49.245; Molineaux L, 1996, ANN TROP MED PARASIT, V90, P379, DOI 10.1080/00034983.1996.11813067; NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T; REEDER JC, 1994, AM J TROP MED HYG, V51, P45, DOI 10.4269/ajtmh.1994.51.45; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROBERTS DJ, 1993, PARASITOL TODAY, V9, P281, DOI 10.1016/0169-4758(93)90121-U; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	23	497	501	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					358	360		10.1038/nm0398-358	http://dx.doi.org/10.1038/nm0398-358			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500614	Green Accepted			2022-12-27	WOS:000073616200046
J	Donzella, GA; Schols, D; Lin, SW; Este, JA; Nagashima, KA; Maddon, PJ; Allaway, GP; Sakmar, TP; Henson, G; De Clercq, E; Moore, JP				Donzella, GA; Schols, D; Lin, SW; Este, JA; Nagashima, KA; Maddon, PJ; Allaway, GP; Sakmar, TP; Henson, G; De Clercq, E; Moore, JP			AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SELECTIVE-INHIBITION; CHEMOKINE RECEPTORS; DISEASE PROGRESSION; CELL-LINES; IN-VIVO; INFECTION; POTENT; CORECEPTOR; BICYCLAMS	The bicyclam AMD3100 (formula weight 830) blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5. AMD3100 prevents monoclonal antibody 12G5 from binding to CXCR4 but has no effect on binding of monoclonal antibody 2D7 to CCR5. It also inhibits binding of the CXC-chemokine, SDF-1 alpha, to CXCR4 and subsequent signal transduction, bur does not itself cause signaling and has no effect on RANTES signaling via CCR5. Thus, AMD3100 prevents CXCR4 functioning as both a HIV-1 co-receptor and a CXC-chemokine receptor. Development of small molecule inhibitors of HIV-1 entry is feasible.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Progen Pharmaceut, Tarrytown, NY 10591 USA; AnorMED, Langley, BC V2Y 1N5, Canada	Rockefeller University; KU Leuven; Howard Hughes Medical Institute; Rockefeller University	Moore, JP (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	jmoore@adarc.org	Schols, Dominique/AAC-1309-2021; Schols, Dominique/S-9057-2017; Sakmar, Thomas P/D-1833-2015; Este, Jose/B-5509-2008	Schols, Dominique/0000-0003-3256-5850; Schols, Dominique/0000-0003-3256-5850; Sakmar, Thomas P/0000-0002-2836-8953; Este, Jose/0000-0002-1436-5823; De Clercq, Erik/0000-0002-2985-8890	NIAID NIH HHS [AI 41420] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Datema R, 1996, ANTIMICROB AGENTS CH, V40, P750, DOI 10.1128/AAC.40.3.750; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DeVreese K, 1996, ANTIVIR RES, V29, P209, DOI 10.1016/0166-3542(95)00837-3; DeVreese K, 1996, J VIROL, V70, P689, DOI 10.1128/JVI.70.2.689-696.1996; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; KOITO A, 1995, VIROLOGY, V206, P878, DOI 10.1006/viro.1995.1010; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAYNE SP, 1991, J VIROL, V65, P3293, DOI 10.1128/JVI.65.6.3293-3300.1991; Litwin V, 1996, J VIROL, V70, P6437, DOI 10.1128/JVI.70.9.6437-6441.1996; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PANTALEO G, 1993, EUR J IMMUNOL, V21, P1771; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Potempa S, 1997, J VIROL, V71, P4419, DOI 10.1128/JVI.71.6.4419-4424.1997; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SAAG MS, 1994, J ACQ IMMUN DEF SYND, V7, pS2; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; Sylwester A, 1997, J IMMUNOL, V158, P3996; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TRKOLA A, IN PRESS J VIROL; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WU L, IN PRESS J EXP MED; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	49	648	697	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					72	77		10.1038/nm0198-072	http://dx.doi.org/10.1038/nm0198-072			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427609				2022-12-27	WOS:000072249700037
J	McKusick, VA				McKusick, VA			Observations over 50 years concerning intestinal polyposis, Marfan syndrome and achondroplasia	NATURE MEDICINE			English	Editorial Material											McKusick, VA (corresponding author), JOHNS HOPKINS UNIV HOSP,BLALOCK 1007,600 N WOLFE ST,BALTIMORE,MD 21287, USA.								0	5	5	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1065	1068		10.1038/nm1097-1065	http://dx.doi.org/10.1038/nm1097-1065			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334707				2022-12-27	WOS:A1997XZ28700021
J	Ross, GM; Shamovsky, IL; Lawrance, G; Solc, M; Dostaler, SM; Jimmo, SL; Weaver, DF; Riopelle, RJ				Ross, GM; Shamovsky, IL; Lawrance, G; Solc, M; Dostaler, SM; Jimmo, SL; Weaver, DF; Riopelle, RJ			Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins	NATURE MEDICINE			English	Article							TRK PROTOONCOGENE PRODUCT; HUMAN CARBONIC-ANHYDRASE; METAL-BINDING SITES; CELL-DEATH; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; RECEPTOR-BINDING; ION CHANNELS; ENZYMES	A role for Zn2+ in a variety of neurological conditions such as stroke, epilepsy and Alzheimer's disease has been postulated. In many instances, susceptible neurons are located in regions rich In Zn2+ where nerve growth factor (NGF) levels rise as a result of insult. Although the interaction of Zn2+ with this neurotrophin has previously been suggested, the direct actions of the ion on NGF function have not been explored. Molecular modeling studies predict that Zn2+ binding to NGF will Induce structural changes within domains of this neurotrophin that participate in the recognition of TrkA and p75(NTR). We demonstrate here that Zn2+ alters the conformation of NGF, rendering it unable to bind to p75(NTR) or TrkA receptors or to activate signal transduction pathways and biological outcomes normally induced by this protein. Similar actions of Zn2+ are also observed with other members of the NGF family, suggesting a modulatory role for this metal ion in neurotrophin function.	QUEENS UNIV, DEPT MED, KGH, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PHARMACOL & TOXICOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT CHEM, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada				Weaver, Donald/0000-0003-2042-6220				ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BERTINI I, 1982, STRUCT BOND, V48, P45; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DENT AJ, 1989, PHYSICA B, V158, P95, DOI 10.1016/0921-4526(89)90211-1; Dostaler SM, 1996, EUR J NEUROSCI, V8, P870, DOI 10.1111/j.1460-9568.1996.tb01574.x; Frade JM, 1996, NATURE, V383, P166; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREGORY DS, 1993, PROTEIN ENG, V6, P29, DOI 10.1093/protein/6.1.29; HANCOCK RD, 1989, CHEM REV, V89, P1875, DOI 10.1021/cr00098a011; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P9396, DOI 10.1021/bi00103a002; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Matthews DJ, 1994, CHEM BIOL, V1, P25, DOI 10.1016/1074-5521(94)90037-X; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; ROBINSON RC, 1995, BIOCHEMISTRY-US, V34, P4139, DOI 10.1021/bi00013a001; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYLETT RJ, 1994, TRENDS NEUROSCI, V17, P486, DOI 10.1016/0166-2236(94)90138-4; SARKAR B, 1982, J INDIAN CHEM SOC, V59, P1403; Shamovsky IL, 1996, J AM CHEM SOC, V118, P9743, DOI 10.1021/ja9611194; SHERIDAN RP, 1981, J AM CHEM SOC, V103, P1544, DOI 10.1021/ja00396a042; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UEDA Y, 1994, NEUROSCI LETT, V165, P203, DOI 10.1016/0304-3940(94)90745-5; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VANDERZEE CEE, 1996, JSCIENCE, V274, P1729; VEDANI A, 1989, J AM CHEM SOC, V111, P4075, DOI 10.1021/ja00193a045; Woo SB, 1996, J BIOL CHEM, V271, P24433, DOI 10.1074/jbc.271.40.24433; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; ZHANG D, PROTEIN DATA BANK	54	68	70	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1997	3	8					872	878		10.1038/nm0897-872	http://dx.doi.org/10.1038/nm0897-872			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256278				2022-12-27	WOS:A1997XP01400029
J	Albini, A; Soldi, R; Giunciuglio, D; Giraudo, E; Benelli, R; Primo, L; Noonan, D; Salio, M; Camussi, G; Rockl, W; Bussolino, F				Albini, A; Soldi, R; Giunciuglio, D; Giraudo, E; Benelli, R; Primo, L; Noonan, D; Salio, M; Camussi, G; Rockl, W; Bussolino, F			The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; KAPOSIS-SARCOMA; TRANSGENIC MICE; VIRUS TYPE-1; IN-VIVO; GENE; EXPRESSION; LESIONS	The HIV-1 Tat protein transactivates HIV, viral and some host cell genes(1). Tat can be released by infected cells(2) and acts extracellularly in the microenvironment, regulating functions of immunocompetent and mesenchymal cells(3,4). One of the most striking effects of Tat is the induction of a functional program in vascular cells related to angiogenesis and inflammation (migration, proliferation and expression of plasminogen activator inhibitor-1 and E selectin(5-7)). Tat induces growth of Kaposi's sarcoma (KS) spindle cells(8) and is angiogenic in vivo(7,9) and in transgenic mice(10-12). We previously reported that Tat is a direct angiogenic factor(7) and noted the Tat arginine- and lysine-rich sequence is similar to that of other potent angiogenic growth factors, such as vascular endothelial growth factor-A (VEGF-A). It is possible that Tat mimics one of these factors by interacting with its growth factor tyrosine kinase receptor. Here we demonstrate that Tat specifically binds and activates the Flk-1/kinase insert domain receptor (Flk-1/KDR), a VEGF-A tyrosine kinase receptor (for review see ref. 13), and that Tat-induced angiogenesis is blocked by agents blocking the Flk-1/KDR receptor. Endothelial cell stimulation by Tat occurs in the absence of activation of FLT-1, another VEGF-A tyrosine kinase receptor.	UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10126 TURIN,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV PAVIA,FAC MED 2,CATTEDRA NEFROL,I-21100 VARESE,ITALY; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	University of Turin; University of Genoa; IRCCS AOU San Martino IST; University of Pavia; Gesellschaft fur Biotechnologische Forschung mbH			Bussolino, Federico/AES-3951-2022; Giraudo, Enrico/K-3192-2016; Camussi, Giovanni/J-7624-2016; Giraudo, Enrico/K-6441-2019; Benelli, Roberto/AAF-3143-2019; Noonan, Douglas M/A-8620-2010; Bussolino, Federico/K-2500-2016	Giraudo, Enrico/0000-0003-4128-4786; Camussi, Giovanni/0000-0003-2795-232X; Giraudo, Enrico/0000-0003-4128-4786; Benelli, Roberto/0000-0002-9769-0954; Noonan, Douglas M/0000-0001-8058-0719; Salio, Mariolina/0000-0002-4821-3801; Bussolino, Federico/0000-0002-5348-1341; Albini, Adriana/0000-0002-9624-5103; PRIMO, Luca/0000-0002-1294-0441				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0	23	325	332	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1371	1375		10.1038/nm1296-1371	http://dx.doi.org/10.1038/nm1296-1371			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946838				2022-12-27	WOS:A1996VW51500045
J	Zubieta, JK; Gorelick, DA; Stauffer, R; Ravert, HT; Dannals, RF; Frost, JJ				Zubieta, JK; Gorelick, DA; Stauffer, R; Ravert, HT; Dannals, RF; Frost, JJ			Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving	NATURE MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; MESSENGER-RNA; EXPOSURE INCREASES; OPIATE RECEPTORS; BRAIN; BUPRENORPHINE; EXPRESSION; METABOLISM; STRIATUM; HUMANS	The endogenous opioid system has been recently implicated in the reinforcing actions of cocaine and other addictive drugs. In this study we examined mu opioid receptor binding in ten cocaine-dependent men and seven nonaddicted controls using positron emission tomography and [C-11]carfentanil. Mu opioid binding was increased in several brain regions of the cocaine addicts studied 1-4 days after their last use of cocaine. Binding was positively correlated with the severity of cocaine craving experienced at the time. The upregulation of mu opioid receptor binding persisted after 4 weeks of monitored cocaine abstinence. These findings demonstrate for the first time the involvement of the endogenous opioid system in cocaine dependence and cocaine craving in living human subjects.	JOHNS HOPKINS MED INST,DEPT RADIOL,DIV NUCL MED,BALTIMORE,MD 21287; NIDA,INTRAMURAL RES PROGRAM,TREATMENT BRANCH,BALTIMORE,MD 21224; JOHNS HOPKINS MED INST,DEPT NEUROSCI,DIV NUCL MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins Medicine			Gorelick, David/ABF-4941-2021; Zubieta, Jon-Kar/AAB-5565-2022		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009479] Funding Source: NIH RePORTER; NIDA NIH HHS [IR01-DA 09479] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		APA, 1987, DIAGN STAT MAN MENT, V3rd; BAIN GT, 1987, LIFE SCI, V40, P1119, DOI 10.1016/0024-3205(87)90575-3; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; CARROLL ME, 1992, PSYCHOPHARMACOLOGY, V106, P439, DOI 10.1007/BF02244812; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; CLOW DW, 1991, DEV BRAIN RES, V59, P179, DOI 10.1016/0165-3806(91)90098-4; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; GOODWIN GA, 1993, NEUROTOXICOL TERATOL, V15, P425, DOI 10.1016/0892-0362(93)90060-2; HALIKAS JA, 1991, COMPR PSYCHIAT, V32, P22, DOI 10.1016/0010-440X(91)90066-L; HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108; HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V16, P97, DOI 10.1016/0169-328X(92)90198-K; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567; MANNELLI P, 1993, BRIT J PSYCHIAT, V163, P39, DOI 10.1192/S0007125000292489; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; MELTZER CC, 1990, J COMPUT ASSIST TOMO, V14, P418, DOI 10.1097/00004728-199005000-00019; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHOTTENFELD RS, 1993, BIOL PSYCHIAT, V34, P66, DOI 10.1016/0006-3223(93)90258-F; SCHULZ R, 1980, PSYCHOPHARMACOLOGY, V68, P221, DOI 10.1007/BF00428107; STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993; TECH SK, 1994, J CLIN PHARMACOL, V14, P15; UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S; VOLKOW ND, 1988, BRIT J PSYCHIAT, V152, P641, DOI 10.1192/bjp.152.5.641; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621	32	207	216	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1225	1229		10.1038/nm1196-1225	http://dx.doi.org/10.1038/nm1196-1225			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898749				2022-12-27	WOS:A1996VQ10100037
J	Condon, C; Watkins, SC; Celluzzi, CM; Thompson, K; Falo, LD				Condon, C; Watkins, SC; Celluzzi, CM; Thompson, K; Falo, LD			DNA-based immunization by in vivo transfection of dendritic cells	NATURE MEDICINE			English	Article							GENETIC IMMUNIZATION; SOLUBLE-PROTEIN; T-LYMPHOCYTES; ANTIGEN; VACCINES; PATHWAY; IMMUNITY; PEPTIDES; INVIVO; MICE	Delivery of antigen in a manner that induces effective, antigen-specific immunity is a critical challenge in vaccine design. Optimal antigen presentation is mediated by professional antigen-presenting cells (APCs) capable of taking up, processing and presenting antigen to T cells in the context of costimulatory signals required for T-cell activation. Developing immunization strategies to optimize antigen presentation by dendritic cells, the most potent APCs, is a rational approach to vaccine design. Here we show that cutaneous genetic immunization with naked DNA results in potent, antigen-specific, cytotoxic T lymphocyte-mediated protective tumor immunity. This method of immunization results in the transfection of skin-derived dendritic cells, which localize in the draining lymph nodes. These observations provide a basis for further development of DNA-based vaccines and demonstrate the feasibility of genetically engineering dendritic cells in vivo.	UNIV PITTSBURGH,SCH MED,DEPT CELL BIOL & PHYSIOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Condon, C (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT DERMATOL,190 LOTHROP ST,PITTSBURGH,PA 15213, USA.		Watkins, Simon/ABG-2590-2021; Falo, Louis/ABD-1499-2020	Watkins, Simon/0000-0003-4092-1552; Celluzzi, Christina/0000-0002-2886-5597	NIAMS NIH HHS [AR01 1884] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALIJAGIC S, 1995, EUR J IMMUNOL, V25, P3100, DOI 10.1002/eji.1830251117; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; CIERNIK F, 1996, J IMMUNOL, V156, P2369; Conry RM, 1996, GENE THER, V3, P67; CONRY RM, 1995, GENE THER, V2, P59; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; FIDLER IJ, 1976, CANCER RES, V36, P3160; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUANG YCA, 1996, IMMUNITY, V4, P349; Irvine KR, 1996, J IMMUNOL, V156, P238; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KRISHNAN S, 1995, NAT MED, V1, P521, DOI 10.1038/nm0695-521; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Porgador A, 1996, J IMMUNOL, V156, P2918; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VANWILSEM EJG, 1994, J INVEST DERMATOL, V103, P217, DOI 10.1111/1523-1747.ep12393088; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YANG NS, 1995, NAT MED, V1, P481, DOI 10.1038/nm0595-481; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZHOU F, 1992, CANCER RES, V52, P6287	34	714	788	1	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1122	1128		10.1038/nm1096-1122	http://dx.doi.org/10.1038/nm1096-1122			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837611				2022-12-27	WOS:A1996VK99500033
J	Nurse, P; Masui, Y; Hartwell, L				Nurse, P; Masui, Y; Hartwell, L			Understanding the cell cycle	NATURE MEDICINE			English	Editorial Material							DIVISION CYCLE; GENETIC-CONTROL; M-PHASE; OOCYTES; YEAST; MATURATION; EVENTS; EGGS; MPF		Imperial Canc Res Fund, London WC2A 3PX, England; Univ Toronto, Ramsay Wright Zool Labs, Toronto, ON M5S 1A1, Canada; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Cancer Research UK; University of Toronto; Fred Hutchinson Cancer Center	Nurse, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GURDON JB, 1968, BIOL REV, V43, P233, DOI 10.1111/j.1469-185X.1968.tb00960.x; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; KISHIMOTO T, 1976, NATURE, V221, P273; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MURRAY A, 1993, CELL CYCLE; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WASSERMAN WJ, 1976, SCIENCE, V199, P1266; WASSERMAN WJ, 1978, J CELL BIOL, V78, pR12; WEINTRAUB H, 1982, CR ACAD SCI III-VIE, V295, P787; WOOD WB, 1967, SCI AM, V217, P61	21	116	123	1	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1103	1106		10.1038/2594	http://dx.doi.org/10.1038/2594			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771732				2022-12-27	WOS:000076230100018
J	van Zijl, PCM; Eleff, SM; Ulatowski, JA; Oja, JME; Ulug, AM; Traystman, RJ; Kauppinen, RA				van Zijl, PCM; Eleff, SM; Ulatowski, JA; Oja, JME; Ulug, AM; Traystman, RJ; Kauppinen, RA			Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging	NATURE MEDICINE			English	Article							HUMAN BRAIN-FUNCTION; MEAN TRANSIT TIME; GRADIENT-ECHO; SIGNAL CHANGES; RAT-BRAIN; CAT BRAIN; SENSORY STIMULATION; RELAXATION RATES; WATER PROTONS; IN-VIVO	The ability to measure the effects of local alterations in blood flow, blood volume and oxygenation by nuclear magnetic resonance has stimulated a surge of activity in functional MRI of many organs, particularly in its application to cognitive neuroscience. However, the exact description of these effects in terms of the interrelations between the MRI signal changes and the basic physiological parameters has remained an elusive goal. We here present this fundamental theory for spin-echo signal changes in perfused tissue and validate it in vivo in the cat brain by using the physiological alteration of hypoxic hypoxia. These experiments show that high-resolution absolute blood volume images can be obtained by using hemoglobin as a natural intravascular contrast agent. The theory also correctly predicts the magnitude of spin-echo MRI signal intensity changes on brain activation and thereby provides a sound physiological basis for these types of studies.	Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA; Univ Kuopio, AI Virtanen Inst, NMR Res Grp, FIN-70211 Kuopio, Finland	Johns Hopkins University; Johns Hopkins University; University of Eastern Finland	van Zijl, PCM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, 217 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Kauppinen, Risto A/F-3274-2011; Van Zijl, Peter C/ABF-3732-2020; Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322	NATIONAL CANCER INSTITUTE [T32CA009630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031490] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09630] Funding Source: Medline; NINDS NIH HHS [NS 31490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLERHAND A, 1964, J CHEM PHYS, V41, P2115, DOI 10.1063/1.1726215; ATALAY MK, 1993, RADIOLOGY, V189, P759, DOI 10.1148/radiology.189.3.8234701; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BANDETTINI PA, 1994, NMR BIOMED, V7, P12, DOI 10.1002/nbm.1940070104; BANDETTINI PA, 1995, INT J IMAG SYST TECH, V6, P133, DOI 10.1002/ima.1850060203; Barinaga M, 1997, SCIENCE, V276, P196, DOI 10.1126/science.276.5310.196; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P4, DOI 10.1002/mrm.1910340103; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; BROOKS RA, 1980, J COMPUT ASSIST TOMO, V4, P489, DOI 10.1097/00004728-198008000-00016; BRYANT RG, 1990, MAGNET RESON MED, V13, P133, DOI 10.1002/mrm.1910130112; DECRESPIGNY AJ, 1992, MAGN RESON MED, V27, P391, DOI 10.1002/mrm.1910270220; EICHLING JO, 1974, CIRC RES, V35, P358, DOI 10.1161/01.RES.35.3.358; EKSTROMJODAL B, 1979, ACTA NEUROL SCAND, V60, P26; FABRY ME, 1983, BIOCHEMISTRY-US, V22, P4119, DOI 10.1021/bi00286a020; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; GILLIS P, 1995, MAGNET RESON MED, V33, P93, DOI 10.1002/mrm.1910330114; GOMORI JM, 1987, J COMPUT ASSIST TOMO, V11, P684, DOI 10.1097/00004728-198707000-00025; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; HERBST MD, 1989, AM J PHYSIOL, V256, pC1097, DOI 10.1152/ajpcell.1989.256.5.C1097; HOPPEL BE, 1993, MAGN RESON MED, V30, P715, DOI 10.1002/mrm.1910300609; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; JEZZARD P, 1994, NMR BIOMED, V7, P35, DOI 10.1002/nbm.1940070107; KARCZMAR GS, 1994, NMR BIOMED, V7, P3, DOI 10.1002/nbm.1940070103; KOEHLER RC, 1984, J CEREBR BLOOD F MET, V4, P115, DOI 10.1038/jcbfm.1984.16; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; MEYER ME, 1995, MAGNET RESON MED, V34, P234, DOI 10.1002/mrm.1910340215; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; OGAWA S, 1993, MAGNET RESON MED, V29, P205, DOI 10.1002/mrm.1910290208; PAULSON OB, 1977, MICROVASC RES, V13, P113, DOI 10.1016/0026-2862(77)90120-0; PAWLIK G, 1981, BRAIN RES, V208, P35, DOI 10.1016/0006-8993(81)90619-3; PRIELMEIER F, 1994, MAGN RESON MED, V31, P678, DOI 10.1002/mrm.1910310615; ROBINSON SP, 1995, INT J RADIAT ONCOL, V33, P961; ROSTRUP E, 1995, NMR BIOMED, V8, P41, DOI 10.1002/nbm.1940080109; ROUSSEL SA, 1995, J CEREBR BLOOD F MET, V15, P578, DOI 10.1038/jcbfm.1995.71; SHARAN M, 1989, ANN BIOMED ENG, V17, P13, DOI 10.1007/BF02364271; SHOCKLEY RP, 1988, BRAIN RES, V454, P170, DOI 10.1016/0006-8993(88)90816-5; SHULMAN RG, 1993, P NATL ACAD SCI USA, V90, P3127, DOI 10.1073/pnas.90.8.3127; SLESJO BK, 1978, BRAIN ENERGY METABOL; SMITH AL, 1971, J APPL PHYSIOL, V31, P701, DOI 10.1152/jappl.1971.31.5.701; Song AW, 1996, MAGNET RESON MED, V35, P155, DOI 10.1002/mrm.1910350204; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; TURNER R, 1991, MAGNET RESON MED, V22, P159, DOI 10.1002/mrm.1910220117; UEKI M, 1992, ACTA ANAESTH SCAND, V36, P318, DOI 10.1111/j.1399-6576.1992.tb03474.x; Ulatowski JA, 1996, AM J PHYSIOL-HEART C, V270, pH466, DOI 10.1152/ajpheart.1996.270.2.H466; WU XS, 1992, CIRCULATION, V85, P730, DOI 10.1161/01.CIR.85.2.730; YE FQ, 1995, MAGNET RESON MED, V34, P713, DOI 10.1002/mrm.1910340510	53	395	399	1	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					159	167		10.1038/nm0298-159	http://dx.doi.org/10.1038/nm0298-159			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461188				2022-12-27	WOS:000072249800030
J	Bunting, KD; Sangster, MY; Ihle, JN; Sorrentino, BP				Bunting, KD; Sangster, MY; Ihle, JN; Sorrentino, BP			Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; RECEPTOR-GAMMA CHAIN; IMMUNE RECONSTITUTION; PERIPHERAL-BLOOD; LACKING JAK3; INTERLEUKIN-2; MUTATION; DEFECTS	Janus kinase-3 (JAK3) deficiency has recently been identified as a cause of severe combined immunodeficiency (SCID) in humans. We used a mouse model of Jak3-deficient SCID to test a gene therapy approach for treatment of this disease. Transfer of a Jak3 retroviral vector to repopulating hematopoietic stem cells resulted in increased numbers of T and B lymphocytes, reversal of hypogammaglobulinemia, restoration of T-cell activation upon stimulation with mitogens, and development of an antigen-specific immune response after immunization. Analysis for vector copy number in lymphoid and myeloid populations showed a large in vivo selective advantage for Jak3-expressing lymphoid cells. These results show that gene replacement is a feasible treatment strategy for this disease and that naturally occurring in vivo selection of corrected cells is an important advantage of this approach.	St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.			Sangster, Mark/0000-0002-1599-5894	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAY JA, 1995, BLOOD, V85, P3342, DOI 10.1182/blood.V85.11.3342.bloodjournal85113342; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1993, SEMIN HEMATOL, V30, P92; Candotti F, 1996, BLOOD, V87, P3097, DOI 10.1182/blood.V87.8.3097.bloodjournal8783097; Candotti F, 1996, J EXP MED, V183, P2687, DOI 10.1084/jem.183.6.2687; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DROR Y, 1993, BLOOD, V81, P2021; HIRCHHORN R, 1993, PEDIATR RES, V33, pS35; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; ORKIN S, 1997, STUDY PANEL CHAIRS R; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Smith MR, 1997, FEBS LETT, V408, P327, DOI 10.1016/S0014-5793(97)00456-0; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Spencer HT, 1996, BLOOD, V87, P2579, DOI 10.1182/blood.V87.6.2579.bloodjournal8762579; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Taylor N, 1996, BLOOD, V87, P3103, DOI 10.1182/blood.V87.8.3103.bloodjournal8783103; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VANLEEUWEN JEM, 1994, BLOOD, V84, P3936, DOI 10.1182/blood.V84.11.3936.bloodjournal84113936; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	34	119	136	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					58	64		10.1038/nm0198-058	http://dx.doi.org/10.1038/nm0198-058			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427607				2022-12-27	WOS:000072249700035
J	Zaitseva, M; Blauvelt, A; Lee, S; Lapham, CK; Klaus-Kovtun, V; Mostowski, H; Manischewitz, J; Golding, H				Zaitseva, M; Blauvelt, A; Lee, S; Lapham, CK; Klaus-Kovtun, V; Mostowski, H; Manischewitz, J; Golding, H			Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DENDRITIC CELLS; RHESUS MACAQUES; LYMPHOCYTE SUBSETS; GENITAL-TRACT; TRANSMISSION; ANTIGEN; BLOOD; REPLICATION; VARIANTS	Transmission of HIV-1 is predominantly restricted to macrophage (M Phi)-tropic strains. Langerhans cells (LCs) in mucosal epithelium, as well as macrophages located in the submucosal tissues, may be initial targets for HIV-1. This study was designed to determine whether restricted transmission of HIV-1 correlates with expression and function of HIV-1 co-receptors on LCs and macrophages. Using polyclonal rabbit IgGs specific for the HIV co-receptors cytokines CXCR4 and CCR5, we found that freshly isolated epidermal LCs (resembling resident mucosal LCs) expressed CCR5, but not CXCR, on their surfaces. In concordance with surface expression, fresh LCs fused with M Phi-tropic but not with T-tropic HIV-1 envelopes. However, fresh LCs did contain intracellular CXCR4 protein that was transported to the surface during in vitro culture. Macrophages expressed high levels of both co-receptors on their surfaces, but only CCR5 was functional in a fusion assay. These data provide several possible explanations for the selective transmission of M Phi-tropic HIV variants and for the resistance to infection conferred by the CCR5 deletion.	US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; US FDA, Div Cell & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Dermatol Branch, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Golding, H (corresponding author), US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bldg 29B,Room 4NN04,HFM 454,8800 Rockville Pike, Bethesda, MD 20892 USA.							AIBA S, 1990, J IMMUNOL, V145, P2791; Berger EA, 1997, AIDS, V11, pS3; BLAUVELT A, 1995, J IMMUNOL, V154, P3506; Blauvelt A, 1997, J CLIN INVEST, V100, P2043, DOI 10.1172/JCI119737; Blauvelt Andrew, 1997, American Journal of Medicine, V102, P16, DOI 10.1016/S0002-9343(97)00055-7; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; Cameron PU, 1996, J EXP MED, V183, P1851, DOI 10.1084/jem.183.4.1851; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; EDWARDS JNT, 1985, BRIT J OBSTET GYNAEC, V92, P974, DOI 10.1111/j.1471-0528.1985.tb03080.x; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Howell AL, 1997, J VIROL, V71, P3498, DOI 10.1128/JVI.71.5.3498-3506.1997; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MACATONIA SE, 1989, IMMUNOLOGY, V67, P285; MILLER CJ, 1992, LAB INVEST, V67, P628; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1993, LAB INVEST, V68, P129; NUOVO GJ, 1993, AM J PATHOL, V143, P40; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; PARR MB, 1991, BIOL REPROD, V45, P261, DOI 10.1095/biolreprod45.2.261; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROMANI N, 1992, SPRINGER SEMIN IMMUN, V13, P265; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZAMBRUNO G, 1995, IMMUNOL TODAY, V16, P520, DOI 10.1016/0167-5699(95)80044-1; ZHANG L, 1993, J VIROL, V67, P3354; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	43	311	321	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1369	1375		10.1038/nm1297-1369	http://dx.doi.org/10.1038/nm1297-1369			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396607				2022-12-27	WOS:000072249500033
J	Xia, YF; Haws, CM; Wine, JJ				Xia, YF; Haws, CM; Wine, JJ			Disruption of monolayer integrity enables activation of a cystic fibrosis ''bypass'' channel in human airway epithelia	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RECTIFYING CHLORIDE CHANNELS; HUMAN TRACHEAL EPITHELIUM; APICAL-MEMBRANE; CL CHANNELS; CELLS; CFTR; CAMP; JUNCTIONS; SECRETION	Cystic fibrosis (CF) is a genetic disease characterized by marked reduction in Cl- conductance across many epithelia. Two kinds of Cl- channels have been associated with CF. One channel, termed the cystic fibrosis transmembrane conductance regulator (CFTR), is directly coded by the CF gene(1-3). The other channel is an outwardly rectifying depolarization induced Cl- channel (ORDIC) that is distinguished from other outwardly rectifying chloride channels (ORCCs) because its activity is induced most reliably by patch excision and depolarization(4-7). An issue in current CF research is whether ORDIC channels are indirectly activated by CFTR to contribute a significant portion of apical membrane Cl- conductance in airway cells(6). We now show that ORDIC channels are readily activated in patches excised and depolarized from isolated cells, but are rarer or refractory to activation in patches from the apical membranes of confluent human airway epithelia. These findings have important implications for proposed therapies that would bypass the CFTR conductance by activating ORDIC channels.	STANFORD UNIV, CYST FIBROSIS RES LAB, STANFORD, CA 94305 USA	Stanford University					NHLBI NIH HHS [HL 42368] Funding Source: Medline; NIDDK NIH HHS [DK/HL51817] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ARMITAGE WJ, 1994, CRYOBIOLOGY, V31, P453, DOI 10.1006/cryo.1994.1055; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BIJMAN J, 1987, PFLUG ARCH EUR J PHY, V408, P511, DOI 10.1007/BF00585077; BRAYDEN DJ, 1993, AM J PHYSIOL, V264, pG325, DOI 10.1152/ajpgi.1993.264.2.G325; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GRAHAM A, 1992, J PHYSIOL-LONDON, V453, P475, DOI 10.1113/jphysiol.1992.sp019240; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; PISAM M, 1976, J CELL BIOL, V71, P907, DOI 10.1083/jcb.71.3.907; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN BQ, 1995, AM J PHYSIOL-LUNG C, V269, pL561, DOI 10.1152/ajplung.1995.269.5.L561; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHOEMAKER RL, 1986, BIOCHIM BIOPHYS ACTA, V858, P235, DOI 10.1016/0005-2736(86)90328-7; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1991, AM J PHYSIOL, V261, pG992, DOI 10.1152/ajpgi.1991.261.6.G992; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085	33	12	12	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					802	805		10.1038/nm0797-802	http://dx.doi.org/10.1038/nm0797-802			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212112				2022-12-27	WOS:A1997XG76700045
J	Kondo, T; Suda, T; Fukuyama, H; Adachi, M; Nagata, S				Kondo, T; Suda, T; Fukuyama, H; Adachi, M; Nagata, S			Essential roles of the Fas ligand in the development of hepatitis	NATURE MEDICINE			English	Article							CELL-MEDIATED CYTOTOXICITY; FULMINANT-HEPATITIS; MICE; APOPTOSIS; PERFORIN; PATHWAYS; PATHOGENESIS; INVOLVEMENT; MACROPHAGES; EXPRESSION	The Fas ligand (FasL) is expressed in activated T cells and induces apoptosis in Fas-bearing cells. A cytotoxic T lymphocyte (CTL) clone specific for hepatitis B surface antigen (HBsAg) causes an acute liver disease in HBsAg transgenic mice. Here we observed that the CTL clone killed hepatocytes expressing HBsAg in a Fas-dependent manner. Administration of the soluble form of Fas into HBsAg transgenic mice prevented the CTL-induced liver disease. In the second model, mice were primed with Propionibacterium acnes. A subsequent challenge with lipopolysaccharide (LPS) killed the mice by inducing liver injury. Neutralization of FasL rescued the mice from LPS-induced mortality, and Fas-null mice were resistant to LPS-induced mortality. These results suggest that FasL has an essential role in the development of hepatitis.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Osaka University			Kondo, Toru/F-9420-2012; Fukuyama, Hidehiro/N-5276-2018; Fukuyama, Hidehiro/AAY-6256-2021; Nagata, Shigekazu/AAG-3203-2019	Fukuyama, Hidehiro/0000-0002-6457-0630; Fukuyama, Hidehiro/0000-0002-6457-0630; Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ADACHI M, 1996, P NATL ACAD SCI USA, V93, P2137; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; BERKE G, 1994, CELL, V81, P9; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; DING AH, 1988, J IMMUNOL, V141, P2407; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERLUGA J, 1978, LANCET, V2, P610; FUJIOKA N, 1995, J LEUKOCYTE BIOL, V58, P90, DOI 10.1002/jlb.58.1.90; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KATAOKA T, 1994, J IMMUNOL, V153, P3938; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SATO T, 1993, J LEUKOCYTE BIOL, V53, P144, DOI 10.1002/jlb.53.2.144; SELGEN PO, 1976, METHOD CELL BIOL, V13, P29; STUEHR DJ, 1987, J IMMUNOL, V139, P518; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TORRES RM, 1992, J IMMUNOL, V148, P620; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; Vilanova M, 1996, SCAND J IMMUNOL, V43, P155, DOI 10.1046/j.1365-3083.1996.d01-25.x; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274	38	437	452	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					409	413		10.1038/nm0497-409	http://dx.doi.org/10.1038/nm0497-409			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095174				2022-12-27	WOS:A1997WQ82500030
J	Nicholas, J; Ruvolo, VR; Burns, WH; Sandford, G; Wan, XY; Ciufo, D; Hendrickson, SB; Guo, HG; Hayward, GS; Reitz, MS				Nicholas, J; Ruvolo, VR; Burns, WH; Sandford, G; Wan, XY; Ciufo, D; Hendrickson, SB; Guo, HG; Hayward, GS; Reitz, MS			Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS DISEASE; IL-6 SIGNAL TRANSDUCER; STIMULATORY FACTOR-II; DNA-SEQUENCES; GROWTH-FACTOR; ONCOSTATIN-M; CELL-GROWTH; IN-VITRO; IDENTIFICATION; EXPRESSION	Human herpesvirus-8 (HHV-8) has been detected in Kaposi's sarcoma (KS) lesions of all types (AIDS-related, classical and endemic), in body-cavity-based B-cell lymphomas (BCBLs) and in lesions of multicentric Castleman's disease (MCD). We have identified a major gamma-herpesvirus-divergent locus (DL-B) in HHV-8 DNA encoding several HHV-8 unique open reading frames (ORFs), including a homologue of interleukin-6 (IL-6) and two homologues of macrophage inflammatory protein MIP-1. We show that the HHV-8-encoded IL-6 homologue (vIL-6) shares functional properties with endogenous IL-6 proteins and that both vIL-6 and vMIP-1 transcripts are present at high levels following butyrate induction of an HHV-8(+) BCBL cell line. Low amounts of constitutive vIL-6, but not vMIP-1, mRNA were also detected. The presence of a functional IL-6 homologue encoded by HHV-8 may provide a mechanistic model for the hypothesized role of HHV-8 in KS, MCD and BCBL that involves the mitogenic effects of vIL-6 on surrounding cells. MIP-1 proteins may enhance these effects through the chemotactic recruitment of endogenous cytokine-producing cells into affected tissues and could potentially influence HIV disease progression in coinfected individuals through interactions with the HIV co-receptor CCR-5.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; UNIV MARYLAND,INST HUMAN VIROL,BALTIMORE,MD 21201; MED COLL WISCONSIN,DEPT HEMATOL ONCOL,MILWAUKEE,WI 53226	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Medical College of Wisconsin	Nicholas, J (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOSHOFF C, 1995, LANCET, V345, P1043; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GERRARD C, 1994, ANNU REV IMMUNOL, V12, P775; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; ISHIYAMA T, 1994, BRIT J HAEMATOL, V86, P483, DOI 10.1111/j.1365-2141.1994.tb04777.x; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NICHOLAS J, IN PRESS J VIROL; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STURZL M, 1995, ONCOGENE, V10, P2007; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; YAMAMURA Y, 1989, J CLIN INVEST, V84, P1707, DOI 10.1172/JCI114353; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; ZHANG XG, 1989, BLOOD, V74, P11	45	318	330	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					287	292		10.1038/nm0397-287	http://dx.doi.org/10.1038/nm0397-287			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055855				2022-12-27	WOS:A1997WL30500029
J	Loda, M; Cukor, B; Tam, SW; Lavin, P; Fiorentino, M; Draetta, GF; Jessup, JM; Pagano, M				Loda, M; Cukor, B; Tam, SW; Lavin, P; Fiorentino, M; Draetta, GF; Jessup, JM; Pagano, M			Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas	NATURE MEDICINE			English	Article							P27(KIP1); PATHWAY; GENE	The cell-cycle inhibitor p27 is a potential tumor suppressor, but its gene has never been found inactivated in human tumors(1-4). Because cell-cycle regulation of p27 cellular abundance occurs at the post-transcriptional level(5-7), we analyzed p27 protein expression and degradation in human colorectal carcinomas. Proteasome-mediated degradation activity of p27 was compared with its protein levels in a subset of tumor samples. We found that carcinomas with low or absent p27 protein displayed enhanced proteolytic activity specific for p27, suggesting that low p27 expression can result from increased proteasome-mediated degradation rather than altered gene expression. Patients whose tumors expressed p27 had a median survival of 151 months, whereas patients who lacked p27 (10%) had a median survival of 69 months. By multivariate analysis, p27 was found to be an independent prognostic marker. Lack of p27 was associated with poor prognosis (2.9 risk ratio for death; P = 0.003). The absence of p27 protein expression is thus a powerful negative prognostic marker in colorectal carcinomas, particularly in stage II tumors, and thereby may help in the selection of patients who will benefit from adjuvant therapy. These data suggest that aggressive tumors may result from the selection of a clone or clones that lack p27 due to increased proteasome-mediated degradation.	HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT SURG,BOSTON,MA 02215; MITOTIX INC,CAMBRIDGE,MA 02139; BOSTON BIOSTAT RES FDN INC,FRAMINGHAM,MA 01702; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY; HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; IRCCS European Institute of Oncology (IEO); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANCE; BROWN JP, IN PRESS BIOCH BIOPH; COX DR, 1972, J R STAT SOC B, V34, P187; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWAMATA N, 1995, CANCER RES, V55, P2266; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Loda M, 1996, AM J PATHOL, V149, P1553; Maki CG, 1996, CANCER RES, V56, P2649; MANTEL N, 1959, J NATL CANCER I, V22, P719; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P761; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; RISLO M, 1988, GASTROENTEROLOGY, V94, P899; SAHIN AA, 1994, MODERN PATHOL, V7, P17; Stegmaier K, 1996, CANCER RES, V56, P1413; YAN J, IN PRESS J BIOL CHEM	21	948	1001	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					231	234		10.1038/nm0297-231	http://dx.doi.org/10.1038/nm0297-231			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018245				2022-12-27	WOS:A1997WF08800045
J	Boppart, SA; Bouma, BE; Pitris, C; Southern, JF; Brezinski, ME; Fujimoto, JG				Boppart, SA; Bouma, BE; Pitris, C; Southern, JF; Brezinski, ME; Fujimoto, JG			In vivo cellular optical coherence tomography imaging	NATURE MEDICINE			English	Article							MICROSCOPY; BIOPSY; SKIN		MIT, Elect Res Lab, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Fujimoto, JG (corresponding author), MIT, Elect Res Lab, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave,Room 36-345, Cambridge, MA 02139 USA.		Boppart, Stephen A/C-7338-2009	Pitris, Costas/0000-0002-5559-1050; Boppart, Stephen/0000-0002-9386-5630	NCI NIH HHS [NIH-1-RO1-CA75289-01] Funding Source: Medline; NHLBI NIH HHS [NIH-1-R29-HL55686-01A1] Funding Source: Medline; NIAMS NIH HHS [NIH-RO1-AR44812-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075289] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boppart SA, 1997, P NATL ACAD SCI USA, V94, P4256, DOI 10.1073/pnas.94.9.4256; Boppart SA, 1996, DEV BIOL, V177, P54, DOI 10.1006/dbio.1996.0144; Bouma BE, 1996, OPT LETT, V21, P1839, DOI 10.1364/OL.21.001839; Brezinski ME, 1996, CIRCULATION, V93, P1206, DOI 10.1161/01.CIR.93.6.1206; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P326; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; Nieuwkoop P., NORMAL TABLE XENOPUS; PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; RAJYAGURU JM, 1997, MICROBIOLOGY, V43, P733; SCHMITT JM, 1994, PHYS MED BIOL, V39, P1705, DOI 10.1088/0031-9155/39/10/013; SCHMITT JM, 1995, DERMATOLOGY, V191, P93, DOI 10.1159/000246523; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; TRNBULL DH, 1995, P NATL ACAD SCI USA, V92, P2239	16	225	240	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					861	865		10.1038/nm0798-861	http://dx.doi.org/10.1038/nm0798-861			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662382				2022-12-27	WOS:000074543900045
J	McConnell, LM; Koenig, BA; Greely, HT; Raffin, TA				McConnell, LM; Koenig, BA; Greely, HT; Raffin, TA		Alzheimer Dis Working Grp Stanford Program Gen	Genetic testing and Alzheimer disease: Has the time come?	NATURE MEDICINE			English	Editorial Material								With the identification of several Alzheimer disease (AD)-associated genes, genetic testing for AD is possible. However, as for some other-late onset disorders, the ethical nad social implications of such tests are considerable. In response to the commercial availability and the likely increased use of AD genetic tests, The Stanford Program in Genomics, Ethics, and Society formed a broad-based working group to examine the pros and cons of testing. Here they present their recommendations.	Stanford Univ, Program Genom Eth & Soc, Palo Alto, CA 94304 USA	Stanford University	McConnell, LM (corresponding author), Stanford Univ, Program Genom Eth & Soc, 701 Welch Rd,Suite 1105, Palo Alto, CA 94304 USA.	lauramcc@leland.stanford.edu						[Anonymous], 1995, JAMA, V274, P1627; Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182; BROHOLM J, 1994, NEUROLOGY, V44, P1533; BUTLER RN, 1994, GERIATRICS, V49, P10; Farrer LA, 1997, NEUROLOGIST, V3, P13, DOI 10.1097/00127893-199701000-00003; Holtzman NA, 1997, PROMOTING SAFE EFFEC; Koenig BA, 1998, J WOMENS HEALTH, V7, P531, DOI 10.1089/jwh.1998.7.531; Lehrman S, 1997, NATURE, V389, P898, DOI 10.1038/39971; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; Post SG, 1997, JAMA-J AM MED ASSOC, V277, P832, DOI 10.1001/jama.277.10.832; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; Roses AD, 1996, ANN NY ACAD SCI, V802, P50, DOI 10.1111/j.1749-6632.1996.tb32598.x; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119	13	60	61	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					757	759		10.1038/nm0798-757	http://dx.doi.org/10.1038/nm0798-757			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662356				2022-12-27	WOS:000074543900018
J	Lee, JS; Feldman, AM				Lee, JS; Feldman, AM			Gene therapy for therapeutic myocardial angiogenesis: A promising synthesis of two emerging technologies	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; COLLATERAL DEVELOPMENT; BLOOD-FLOW; HEART; MODEL; LIMB		Univ Pittsburgh, Inst Heart, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, JS (corresponding author), Univ Pittsburgh, Inst Heart, G324,PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.							BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BAUTERS C, 1995, J VASC SURG, V21, P314, DOI 10.1016/S0741-5214(95)70272-5; Campbell AIM, 1998, J AM COLL CARDIOL, V31, p25A, DOI 10.1016/S0735-1097(97)83820-X; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Henry TD, 1998, J AM COLL CARDIOL, V31, p65A, DOI 10.1016/S0735-1097(97)83989-7; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; KIAGSBRUN M, 1989, PROG GROWTH FACTOR R, V1, P207; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LAZAROUS DF, 1995, CIRCULATION, V91, P145, DOI 10.1161/01.CIR.91.1.145; MAZUE G, 1993, TOXICOL PATHOL, V21, P490, DOI 10.1177/019262339302100508; Muhlhauser J, 1996, GENE THER, V3, P145; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKESHITA S, 1994, CIRCULATION, V90, P228; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588	18	37	39	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					739	742		10.1038/nm0698-739	http://dx.doi.org/10.1038/nm0698-739			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623987				2022-12-27	WOS:000074008300044
J	Bloom, BR; Widdus, R				Bloom, BR; Widdus, R			Vaccine visions and their global impact	NATURE MEDICINE			English	Editorial Material							INFECTION; DISEASE; IDENTIFICATION; RISK; DNA		Howard Hughes Med Inst, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; Childrens Vaccine Initiat, CH-1211 Geneva, Switzerland	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Bloom, BR (corresponding author), Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; FREDRICKS DN, IN PRESS CURR CLIN T; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SANDERSON JD, 1992, GUT, V33, P890, DOI 10.1136/gut.33.7.890; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; THOMAS L, 1995, LIVES CELL NOTES BIO, P153; TYTGAT GNJ, 1993, GASTROENTEROL CLIN N, V22, P127; Weck KE, 1997, NAT MED, V3, P1346, DOI 10.1038/nm1297-1346; *WHO, 1998, STRAT PLAN; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; 1997, NATURE, V388, P211	17	24	25	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			480	484		10.1038/nm0598supp-480	http://dx.doi.org/10.1038/nm0598supp-480			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585190	Bronze			2022-12-27	WOS:000073453500008
J	Crook, R; Verkkoniemi, A; Perez-Tur, J; Mehta, N; Baker, M; Houlden, H; Farrer, M; Hutton, M; Lincoln, S; Hardy, J; Gwinn, K; Somer, M; Paetau, A; Kalimo, H; Ylikoski, R; Poyhonen, M; Kucera, S; Haltia, M				Crook, R; Verkkoniemi, A; Perez-Tur, J; Mehta, N; Baker, M; Houlden, H; Farrer, M; Hutton, M; Lincoln, S; Hardy, J; Gwinn, K; Somer, M; Paetau, A; Kalimo, H; Ylikoski, R; Poyhonen, M; Kucera, S; Haltia, M			A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1	NATURE MEDICINE			English	Article							EARLY-ONSET; BETA-PROTEIN; GENE; MUTATIONS	We describe a novel variant of Alzheimer's disease (AD) in a Finnish pedigree with 17 affected individuals of both sexes in three generations. The disease is characterized by progressive dementia which is, in most cases, preceded by spastic paraparesis. Neuropathological investigations revealed numerous, distinct, large, round and eosinophilic plaques as well as neurofibrillary tangles and amyloid angiopathy throughout the cerebral cortex. The predominant plaques resembled cotton wool balls and were immunoreactive for AP but lacked a congophilic dense core or marked plaque-related neuritic pathology. Molecular genetic analysis revealed that the disease was caused by a deletion of exon 9 (Delta 9) of the presenilin 1 (PSI) gene from the mRNA: unlike previous examples of the Delta 9 variant, the deletion was not caused by a splice acceptor site mutation.	Mayo Clin Jacksonville, Jacksonville, FL 32084 USA; Univ Helsinki, Cent Hosp, Dept Clin Neurosci, FIN-00290 Helsinki, Finland; Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA; Family Fed Finland, FIN-00101 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Huddinge Hosp, Karolinska Inst, Div Geriatr Med, S-14186 Huddinge, Sweden; Oulu Univ Hosp, Dept Clin Genet, FIN-90220 Oulu, Finland; Univ Tampa, Dept Biol, Tampa, FL 33613 USA	Mayo Clinic; University of Helsinki; Helsinki University Central Hospital; Mayo Clinic; Mayo Clinic Phoenix; Family Federation of Finland; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Turku; Karolinska Institutet; University of Oulu; University of Tampa	Hardy, J (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32084 USA.		Gwinn, Katrina A/C-2508-2009; Houlden, Henry J/C-1532-2008; Poyhonen, Minna/K-4866-2018; Perez-Tur, Jordi/A-2143-2010; Hardy, John/C-2451-2009	Houlden, Henry J/0000-0002-2866-7777; Poyhonen, Minna/0000-0003-2037-2744; Perez-Tur, Jordi/0000-0002-9111-1712; Hardy, John/0000-0002-3122-0423; Farrer, Matthew/0000-0003-1159-5321; Gwinn, Katrina/0000-0002-8277-651X				CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; GBAUMEISTER R, 1997, GENES FUNC, V1, P149; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Hutton M, 1996, NEUROREPORT, V7, P801, DOI 10.1097/00001756-199602290-00029; Ishii K, 1997, NEUROSCI LETT, V228, P17, DOI 10.1016/S0304-3940(97)00347-9; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOWE J, 1997, GREENFIELDS NEUROPAT, P281; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MEHTA NM, IN PRESS ANN NEUROL; MULLAN M, 1995, AM J MED GENET, V60, P44, DOI 10.1002/ajmg.1320600109; PEREZTUR J, 1995, NEUROREPORT, V7, P204; PLOUGHMAN LM, 1989, AM J HUM GENET, V44, P543; Probst A, 1991, BRAIN PATHOL, V1, P229, DOI 10.1111/j.1750-3639.1991.tb00666.x; SATO S, IN RPESS HUMAN MUTAT; Schmidt ML, 1997, AM J PATHOL, V151, P69; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3	24	268	292	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					452	455		10.1038/nm0498-452	http://dx.doi.org/10.1038/nm0498-452			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546792				2022-12-27	WOS:000072906800041
J	Holcomb, L; Gordon, MN; McGowan, E; Yu, X; Benkovic, S; Jantzen, P; Wright, K; Saad, I; Mueller, R; Morgan, D; Sanders, S; Zehr, C; O'Campo, K; Hardy, J; Prada, CM; Eckman, C; Younkin, S; Hsiao, K; Duff, K				Holcomb, L; Gordon, MN; McGowan, E; Yu, X; Benkovic, S; Jantzen, P; Wright, K; Saad, I; Mueller, R; Morgan, D; Sanders, S; Zehr, C; O'Campo, K; Hardy, J; Prada, CM; Eckman, C; Younkin, S; Hsiao, K; Duff, K			Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes	NATURE MEDICINE			English	Article							IN-VIVO; A-BETA; DISEASE; DEFICITS; PLAQUES	Genetic causes of Alzheimer's disease (AD) include mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) genes(1). The mutant APP(K670N,M671L) transgenic line, Tg2576, shows markedly elevated amyloid beta-protein (A beta) levels at an early age and, by 9-12 months, develops extracellular AD-type A beta deposits in the cortex and hippocampus(2). Mutant PS1 transgenic mice do not show abnormal pathology, but do display subtly elevated levels of the highly amyloidogenic 42- or 43-amino acid peptide A beta 42(43) (ref. 3). Here we demonstrate that the doubly transgenic progeny from a cross between line Tg2576 and a mutant PS1(M146L) transgenic line develop large numbers of fibrillar A beta deposits in cerebral cortex and hippocampus far earlier than their singly transgenic Tg2576 littermates. In the period preceding overt A beta deposition, the doubly transgenic mice show a selective 41% increase in A beta 42(43) in their brains. Thus, the development of AD-like pathology is substantially enhanced when a PS1 mutation, which causes a modest increase in A beta 42(43), is introduced into Tg2576-derived mice. Remarkably, both doubly and singly transgenic mice showed reduced spontaneous alternation performance in a "Y" maze before substantial A beta deposition was apparent. This suggests that some aspects of the behavioral phenotype in these mice may be related to an event that precedes plaque formation.	Mayo Clin, Neurotransgen Lab, Jacksonville, FL 32224 USA; Mayo Clin, Neurogenet Lab, Jacksonville, FL 32224 USA; Mayo Clin, Mol Neuropathol Lab, Jacksonville, FL 32224 USA; Univ S Florida, Dept Pharmacol, Alzheimers Res Lab, Tampa, FL 33612 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; State University System of Florida; University of South Florida; University of Minnesota System; University of Minnesota Twin Cities	Duff, K (corresponding author), Mayo Clin, Neurotransgen Lab, Jacksonville, FL 32224 USA.	duff.karen@mayo.edu	Hardy, John/C-2451-2009; Duff, Karen EK/C-2510-2009; Morgan, David G/J-5989-2012; Gordon, Marcia N. N/K-2420-2012	Hardy, John/0000-0002-3122-0423; Gordon, Marcia N. N/0000-0002-4051-9283; Duff, Karen/0000-0002-6177-868X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033249] Funding Source: NIH RePORTER; NIA NIH HHS [AG146133] Funding Source: Medline; NINDS NIH HHS [NS 33249] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Good M, 1997, BEHAV NEUROSCI, V111, P487, DOI 10.1037/0735-7044.111.3.487; GORDON M, 1995, J COMP NEUROL, V388, P106; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO K, 1995, NEURON, V5, P1203; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; Laghmouch A, 1997, BEHAV GENET, V27, P67, DOI 10.1023/A:1025667426222; LALONDE R, 1994, BEHAV GENET, V24, P497, DOI 10.1007/BF01071563; Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104; Masliah E, 1996, J NEUROSCI, V16, P5795; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085	19	1090	1166	3	66	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					97	100		10.1038/nm0198-097	http://dx.doi.org/10.1038/nm0198-097			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427614				2022-12-27	WOS:000072249700042
J	Vigh, L; Literati, PN; Horvath, I; Torok, Z; Balogh, G; Glatz, A; Kovacs, E; Boros, I; Ferdinandy, P; Farkas, B; Jaszlits, L; Jednakovits, A; Koranyi, L; Maresca, B				Vigh, L; Literati, PN; Horvath, I; Torok, Z; Balogh, G; Glatz, A; Kovacs, E; Boros, I; Ferdinandy, P; Farkas, B; Jaszlits, L; Jednakovits, A; Koranyi, L; Maresca, B			Bimoclomol: A nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; MYOCARDIAL PROTECTION; MYOGENIC CELLS; RAT HEARTS; EXPRESSION; YEAST; TEMPERATURE; MODULATION; RESPONSES	Preservation of the chemical architecture of a cell or of an organism under changing and perhaps stressful conditions is termed homeostasis. An integral feature of homeostasis is the rapid expression of genes whose products are specifically dedicated to protect cellular functions against stress. One of the best known mechanisms protecting cells from various stresses is the heat-shock response which results in the induction of the synthesis of heat-shock proteins (HSPs or stress proteins)(1-3). A large body of information supports that stress proteins - many of them molecular chaperones(4-8) - are crucial for the maintenance of cell integrity during normal growth as well as during pathophysiological conditions(9-11), and thus can be considered ''homeostatic proteins.'' Recently emphasis is being placed on the potential use of these proteins in preventing and/or treating diseases(12-14). Therefore, it would be of great therapeutic benefit to discover compounds that are clinically safe yet able to induce the accumulation of HSPs in patients with chronic disorders such as diabetes mellitus, heart disease or kidney failure. Here we show that a novel cytoprotective hydroxylamine derivative, [2-hydroxy-3-(1-piperidinyl) propoxy]-3-pyridinecarboximidoil-chloride maleate, Bimoclomol(15), facilitates the formation of chaperone molecules in eukaryotic cells by inducing or amplifying expression of heat-shock genes. The cytoprotective effects observed under several experimental conditions, including a murine model of ischemia and wound healing in the diabetic rat, are likely mediated by the coordinate expression of all major HSPs. This nontoxic drug, which is under Phase II clinical trials, has enormous potential therapeutic applications.	BIOREX RES & DEV CO,H-8200 VESZPREM,HUNGARY; ALBERT SZENT GYORGYI MED UNIV,DEPT DERMATOL,H-6720 SZEGED,HUNGARY; ALBERT SZENT GYORGYI MED UNIV,DEPT BIOCHEM,H-6720 SZEGED,HUNGARY; CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Szeged University; Szeged University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Vigh, L (corresponding author), HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,TEMESVARI KRT 62,H-6721 SZEGED,HUNGARY.		Ferdinandy, Péter/H-9181-2019; Balogh, Gábor/AIC-8192-2022	Balogh, Gábor/0000-0002-4565-6850; Boros, Imre/0000-0001-8504-9687				BENSAUDE O, 1983, EMBO J, V2, P173, DOI 10.1002/j.1460-2075.1983.tb01401.x; BIRO K, 1994, DIABETOLOGIA S1, V37, P282; Carratu L, 1996, P NATL ACAD SCI USA, V93, P3870, DOI 10.1073/pnas.93.9.3870; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; DOXEY DL, 1995, LIFE SCI, V57, P1111, DOI 10.1016/0024-3205(95)02056-O; Ferdinandy P, 1995, CARDIOVASC RES, V30, P781, DOI 10.1016/S0008-6363(95)00136-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FRYDMAN J, 1994, NATURE, V370, P96; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; HEGEDUS E, 1995, DIABETOLOGIA S1, V37, P137; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JASZLITS L, 1993, J MOL CELL CARDIO S1, V25, P20; JEDNAKOVITS A, 1994, DIABETOLOGIA S1, V37, P19; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KNOWLTON AA, 1995, J MOL CELL CARDIOL, V27, P121, DOI 10.1016/S0022-2828(08)80012-0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOVIS C, 1994, RENAL FAILURE, V16, P179, DOI 10.3109/08860229409044859; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MAYTIN EV, 1995, J INVEST DERMATOL, V104, P448, DOI 10.1111/1523-1747.ep12605702; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; NISHIZAWA J, 1996, CIRCULATION, V92, P3137; NOVEL, 1988, Patent No. 207988; OBERRINGER M, 1995, BIOCHEM BIOPH RES CO, V214, P1009, DOI 10.1006/bbrc.1995.2386; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Plumier JCL, 1996, CELL STRESS CHAPERON, V1, P13, DOI 10.1379/1466-1268(1996)001<0013:HSIMPA>2.3.CO;2; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POLLA BS, 1990, DERMATOLOGICA, V180, P113, DOI 10.1159/000248008; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Sambrook J., 2002, MOL CLONING LAB MANU; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; VIGH L, 1993, P NATL ACAD SCI USA, V90, P9090, DOI 10.1073/pnas.90.19.9090; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P113, DOI 10.1016/0022-2828(92)93148-D	41	243	262	2	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1150	1154		10.1038/nm1097-1150	http://dx.doi.org/10.1038/nm1097-1150			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334730				2022-12-27	WOS:A1997XZ28700044
J	Lu, B; Figini, M; Emanueli, C; Geppetti, P; Grady, EF; Gerard, NP; Ansell, J; Payan, DG; Gerard, C; Bunnett, N				Lu, B; Figini, M; Emanueli, C; Geppetti, P; Grady, EF; Gerard, NP; Ansell, J; Payan, DG; Gerard, C; Bunnett, N			The control of microvascular permeability and blood pressure by neutral endopeptidase	NATURE MEDICINE			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; NEUROGENIC INFLAMMATION; SUBSTANCE-P; ANTAGONIST; INHIBITOR; ENZYME; RATS	Plasma extravasation from postcapillary venules is one of the earliest steps of inflammation(1). Substance P (SP) and bradykinin (BK) mediate extravasation and cause hypotension(2-6). The cell-surface enzyme neutral endopeptidase (NEP) inactivates both peptides(7,8). Thus, absence of NEP may predispose development of inflammation and hypotension. We examined these possibilities in mice in which the NEP gene was deleted by homologous recombination(9). There was widespread basal plasma extravasation in postcapillary venular endothelia in NEP-/- mice, which was reversed by recombinant NEP and antagonists of SP (NK1) and BK (B2) receptors. Mean arterial blood pressure was 20% lower in NEP-/- animals, but this was unaffected by reintroduction of recombinant NEP and the kinin receptor antagonists. The hypotension was also independent of nitric oxide (NO), because NEP-/- mice treated with a NO synthase inhibitor remained hypotensive relative to the wild type. Thus, NEP has important roles in regulating basal microvascular permeability by degrading SP and BK, and may regulate blood pressure set point through a mechanism that is independent of SP, BK and NO. The use of NEP antagonists as candidate drugs in cardiovascular disease is suggested by the blood pressure data reported herein.	HARVARD UNIV,SCH MED,DEPT PEDIAT,CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; UNIV FERRARA,INST PHARMACOL,I-44100 FERRARA,ITALY; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; EMORY UNIV,DEPT DERMATOL,ATLANTA,GA 30322	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Ferrara; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Emory University			Geppetti, Pierangelo/AHA-7897-2022	Emanueli, Costanza/0000-0002-2392-0702; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK 43207, DK 46285, DK 39957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R01DK039957, R37DK039957, R01DK046285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BORSON DB, 1989, J APPL PHYSIOL, V66, P2653, DOI 10.1152/jappl.1989.66.6.2653; BUNNETT NW, 1988, AM J PHYSIOL, V255, pG676, DOI 10.1152/ajpgi.1988.255.5.G676; BUNNETT NW, 1993, AM J PHYSIOL, V264, pC497; EDMONDSALT X, 1993, EUR J PHARMACOL, V250, P403; FIGINI M, 1994, AM J PHYSIOL, V272, pG785; GARDINER SM, 1992, BRIT J PHARMACOL, V106, P180, DOI 10.1111/j.1476-5381.1992.tb14312.x; GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119; GEPPETTI P, 1993, REGUL PEPTIDES, V47, P1, DOI 10.1016/0167-0115(93)90268-D; HWANG L, 1993, AM J PHYSIOL, V264, pG735, DOI 10.1152/ajpgi.1993.264.4.G735; JORIS I, 1982, STAIN TECHNOL, V57, P177, DOI 10.3109/10520298209066611; KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LEMBECK F, 1992, BRIT J PHARMACOL, V105, P527, DOI 10.1111/j.1476-5381.1992.tb09013.x; LIFTON RP, 1996, SCIENCE, V272, P666; LOTVALL JO, 1991, EUR J PHARMACOL, V200, P2117; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MATSAS R, 1986, NEUROSCIENCE, V18, P991, DOI 10.1016/0306-4522(86)90113-2; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PAYAN DG, 1992, INFLAMMATION BASIC P, P177; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; UMENO E, 1989, J APPL PHYSIOL, V66, P2647, DOI 10.1152/jappl.1989.66.6.2647; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763	26	134	138	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					904	907		10.1038/nm0897-904	http://dx.doi.org/10.1038/nm0897-904			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256283				2022-12-27	WOS:A1997XP01400034
J	Wang, YP; Becker, D				Wang, YP; Becker, D			Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth	NATURE MEDICINE			English	Article							HUMAN-MALIGNANT MELANOMAS; INTEGRIN ALPHA(V)BETA(3); HUMAN MELANOCYTES; EXPRESSION; CELLS; BFGF; DIFFERENTIATION; ORGANIZATION; PROGRESSION; APOPTOSIS	Unlike normal metanocytes, primary and metastatic human melanomas express high levels of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor-1 (FGFR-1) messenger RNA, and expression of these genes is essential in sustaining the proliferation of malignant melanomas in vitro. To determine whether bFGF and FGFR-1 are also required for tumor formation in these cells, liposome-mediated gene transfer was used to deliver episomal vectors containing antisense-oriented bFGF or FGFR-1 cDNAs into human melanomas, grown as subcutaneous tumors in nude mice. The growth of tumors injected with these constructs was completely arrested or the tumors regressed as a result of blocked intratumoral angiogenesis and subsequent necrosis. Thus, inhibition of bFGF/FGFR-1-mediated signaling may open a new avenue for the treatment of advanced-stage melanomas.			Wang, YP (corresponding author), UNIV PITTSBURGH,DEPT PATHOL,BIOMED SCI TOWER,E1057,211 LOTHROP ST,PITTSBURGH,PA 15213, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BECKER D, 1992, ONCOGENE, V7, P2302; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Folkman J, 1995, MOL BASIS CANC, P206; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GAYNOR R, 1980, NATURE, V286, P400, DOI 10.1038/286400a0; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, LAB INVEST, V56, P461; HOUGHTON AN, 1995, BIOL THERAPY CANC, P576; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIRKWOOD JM, 1995, BIOL THERAPY CANC PR, P388; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MARINCOLA FM, 1995, BIOL THERAPY CANC, P250; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NICKOLOFF RJ, 1993, J CLIN PATHOL, V43, P752; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VIGNOVICH J, 1993, INT J ONCOL, V2, P637; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; Wang YP, 1996, CELL GROWTH DIFFER, V7, P1733; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Yang JP, 1996, GENE THER, V3, P542	36	254	292	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					887	893		10.1038/nm0897-887	http://dx.doi.org/10.1038/nm0897-887			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256280				2022-12-27	WOS:A1997XP01400031
J	Connors, M; Kovacs, JA; Krevat, S; GeaBanacloche, JC; Sneller, MC; Flanigan, M; Metcalf, JA; Walker, RE; Falloon, J; Baseler, M; Stevens, R; Feuerstein, I; Masur, H; Lane, HC				Connors, M; Kovacs, JA; Krevat, S; GeaBanacloche, JC; Sneller, MC; Flanigan, M; Metcalf, JA; Walker, RE; Falloon, J; Baseler, M; Stevens, R; Feuerstein, I; Masur, H; Lane, HC			HIV infection induces changes in CD4(+) T-cell phenotype and depletions within the CD4(+) T-cell repertoire that are not immediately restored by antiviral or immune-based therapies	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD; MEMORY; LYMPHOCYTES; ANTIGEN; NAIVE; SUPERANTIGEN; REPLICATION; SEGMENTS; SUBSETS	Changes in CD4(+) T-cell surface marker phenotype and antigen receptor (TCR) repertoire were examined during the course of HIV infection and following therapy. A preferential decline in naive CD4(+) T cells was noted as disease progressed. Following protease inhibitor therapy, naive CD4(+) T cells increased only if they were present before initiation of therapy. Disruptions of the CD4(+) TCR repertoire were most prevalent in patients with the lowest CD4(+) T-cell counts. Antiviral or IL-12 therapy-induced increases in CD4(+) T-cell counts led to only minor changes in previously disrupted repertoires. Thus, CD4(+) T-cell death mediated by HIV-1 infection may result in a preferential decline in the number of naive CD4(+) T cells and disruptions of the CD4(+) T-cell repertoire that are not immediately corrected by antiviral or immune-based therapies.	NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20892; CLIN PUERTA DE HIERREO,SERV MED INTERNA 1,MADRID,SPAIN; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Arden Bernhard, 1995, Immunogenetics, V42, P455; Beverley P C, 1992, Semin Immunol, V4, P35; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOU CC, 1994, J ACQ IMMUN DEF SYND, V7, P665; CIBOTTI R, 1994, J EXP MED, V180, P861, DOI 10.1084/jem.180.3.861; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PUISIEUX I, 1994, J IMMUNOL, V153, P2807; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; REBAI N, 1994, P NATL ACAD SCI USA, V91, P1529, DOI 10.1073/pnas.91.4.1529; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; SALMON M, 1989, J IMMUNOL, V143, P907; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; Soudeyns H, 1993, Semin Immunol, V5, P175, DOI 10.1006/smim.1993.1021; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STEIS RG, 1991, J NATL CANCER I, V83, P1678, DOI 10.1093/jnci/83.22.1678; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Westby M, 1996, IMMUNOL TODAY, V17, P120, DOI 10.1016/0167-5699(96)80603-7; ZINKERNAGEL RM, 1994, DEV BIOL STAND, V82, P189	40	474	489	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					533	540		10.1038/nm0597-533	http://dx.doi.org/10.1038/nm0597-533			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142122				2022-12-27	WOS:A1997WX54300033
J	Monforte, JA; Becker, CH				Monforte, JA; Becker, CH			High-throughput DNA analysis by time-of-flight mass spectrometry	NATURE MEDICINE			English	Editorial Material							MATRIX				Monforte, JA (corresponding author), GENETRACE SYST INC,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA.				NHGRI NIH HHS [R01-HG00174] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000174] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Hall JM, 1996, GENOME RES, V6, P781, DOI 10.1101/gr.6.9.781; Hsu LYF, 1992, GENETIC DISORDERS FE, V3rd, P155; HUTHFEHRE T, 1992, RAPID COMMUN MASS SP, V6, P209, DOI 10.1002/rcm.1290060312; KARAS M, 1990, ANAL CHIM ACTA, V241, P175, DOI 10.1016/S0003-2670(00)83645-4; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; McLafferty FW., 1980, INTERPRETATION MASS, V3rd ed, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shaler TA, 1996, ANAL CHEM, V68, P576, DOI 10.1021/ac9502662; WU KJ, 1993, RAPID COMMUN MASS SP, V7, P142, DOI 10.1002/rcm.1290070206	10	58	76	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					360	362		10.1038/nm0397-360	http://dx.doi.org/10.1038/nm0397-360			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055869				2022-12-27	WOS:A1997WL30500043
J	Sandig, V; Brand, K; Herwig, S; Lukas, J; Bartek, J; Strauss, M				Sandig, V; Brand, K; Herwig, S; Lukas, J; Bartek, J; Strauss, M			Adenovirally transferred p6(INK4/CDKN2) and p53 genes cooperate to induce apoptotic tumor cell death	NATURE MEDICINE			English	Article							S-PHASE ENTRY; IN-VIVO; RECOMBINANT ADENOVIRUS; RETINOBLASTOMA-PROTEIN; CANCER CELLS; EXPRESSION; THERAPY; P16(INK4); P21; TRANSDUCTION	Repression of cell cycle progression by tumor suppressors might provide a means for tumor therapy. Here we demonstrate that ectopic overexpression of the p16(INK4/CDKN2) tumor suppressor from an adenovirus vector in various cell lines results in block of cell division and, subsequently, in a gradual reduction of the levels of the product of retinoblastoma susceptibility gene, pRb. Overexpression of p53 and p16(INK4/CDKN2), but not p53 on its own, induces apoptotic death only in tumor cells. Simultaneous adenoviral transfer of p16 and p53 genes leads to inhibition of tumor growth in nude mice. These results suggest that combined delivery of two cooperating genes like p16 and p53 could be the basis for the development of a new strategy for cancer gene therapy.	HUMBOLDT UNIV BERLIN,MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; HEPAVEC GMBH,D-13122 BERLIN,GERMANY; MAX PLANCK GESELL,D-13122 BERLIN,GERMANY; DANISH CANC SOC,DIV CANC BIOL,DEPT CELL CYCLE & CANC,DK-2100 COPENHAGEN,DENMARK	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Max Planck Society; Danish Cancer Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; An B, 1996, CANCER RES, V56, P438; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CARLSSON G, 1983, J CANCER RES CLIN, V105, P20, DOI 10.1007/BF00391826; CLAYMAN GL, 1995, CANCER RES, V55, P1; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELLEDGE SJ, 1993, CELL, V75, P805; FRIEDMANN T, 1992, CANCER, V70, P1810, DOI 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HE A, 1994, CANCER RES, V54, P5804; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUARD J, 1995, GENE THER, V2, P107; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KASSEISLER A, 1994, GENE THER, V1, P395; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LIEBER A, 1995, RECOMBINANT DNA METH, V2, P257; LIU TJ, 1994, CANCER RES, V54, P3662; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYASHITA T, 1995, CELL, V80, P293; MOTUKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABORI T, 1994, NATURE, V368, P753; NEVINS JR, 1992, SCIENCE, V258, P424; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTERSON GA, 1994, ONCOGENE, V9, P3375; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosenberg S.A., 1992, HUM GENE THER, V3, P75, DOI 10.1089/hum.1992.3.1-75; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG WW, 1994, CANCER GENE THER, V1, P1; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	51	207	220	1	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					313	319		10.1038/nm0397-313	http://dx.doi.org/10.1038/nm0397-313			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055859				2022-12-27	WOS:A1997WL30500033
J	Bach, FH; Ferran, C; Hechenleitner, P; Mark, W; Koyamada, N; Miyatake, T; Winkler, H; Badrichani, A; Candinas, D; Hancock, WW				Bach, FH; Ferran, C; Hechenleitner, P; Mark, W; Koyamada, N; Miyatake, T; Winkler, H; Badrichani, A; Candinas, D; Hancock, WW			Accommodation of vascularized xenografts: Expression of ''protective genes'' by donor endothelial cells in a host Th2 cytokine environment	NATURE MEDICINE			English	Article							NF-KAPPA-B; SMOOTH-MUSCLE CELLS; LONG-TERM SURVIVAL; HEART ALLOGRAFTS; T-CELLS; CARDIAC ALLOGRAFTS; ANTIBODY THERAPY; ACTIVATION; REJECTION; INHIBITION	Organ xenografts under certain circumstances survive in the presence of anti-graft antibodies and complement, a situation referred to as ''accommodation.'' We find that the endothelial cells (ECs) in hamster hearts that accommodate themselves in rats express genes, such as A20 and bcl-2, that in vitro protect ECs from apoptosis and prevent upregulation in those cells of proinflammatory genes such as cytokines, procoagulant and adhesion molecules. Hearts that are rejected do not express these genes. In addition, vessels of rejected hearts show florid transplant arteriosclerosis whereas those of accommodated hearts do not. Accommodated xenografts have an ongoing T helper cell type 2 (Th2) cytokine immune response, whereas the rejected grafts have a Th1 response. We propose a model for factors that contribute to the survival of xenografts and the avoidance of transplant arteriosclerosis.	NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	Bach, FH (corresponding author), NEW ENGLAND DEACONESS HOSP,DEPT SURG,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.			MIYATAKE, TSUKASA/0000-0002-6848-3972	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal A, 1996, TRANSPLANTATION, V61, P93, DOI 10.1097/00007890-199601150-00019; ALEXANDRE GPJ, 1991, CLIN TRANSPLANT, V5, P583; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BACH FH, 1991, TRANSPL P, V23, P205; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Dalmasso AP, 1996, XENOTRANSPLANTATION, V3, P54, DOI 10.1111/j.1399-3089.1996.tb00119.x; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FERRARESSO M, 1994, J IMMUNOL, V153, P3307; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANCOCK WW, 1992, TRANSPLANTATION, V53, P1276, DOI 10.1097/00007890-199206000-00022; HANCOCK WW, 1993, TRANSPLANTATION, V55, P1112, DOI 10.1097/00007890-199305000-00034; Hancock WW, 1996, AM J PATHOL, V148, P681; HASAN R, 1992, TRANSPLANTATION, V54, P408, DOI 10.1097/00007890-199209000-00004; HE XW, 1995, J CLIN INVEST, V95, P564, DOI 10.1172/JCI117699; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jaattela M, 1996, J IMMUNOL, V156, P1166; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KUPIECWEGLINSKI JW, 1993, J IMMUNOL, V151, P5053; LESNIKOSKI BA, 1995, TRANSPLANT P, V27, P290; MOTTRAM PL, 1995, TRANSPLANTATION, V59, P559; NAUME B, 1994, SCAND J IMMUNOL, V40, P128, DOI 10.1111/j.1365-3083.1994.tb03441.x; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PAPP I, 1992, J IMMUNOL, V148, P1308; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Robson SC, 1996, TRANSPLANT P, V28, P536; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; Shaddy Robert, 1996, Journal of Heart and Lung Transplantation, V15, pS97; SLAPAK M, 1990, TRANSPLANT P, V22, P1425; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TAKEUCHI T, 1992, TRANSPLANTATION, V53, P1281, DOI 10.1097/00007890-199206000-00023; TSUCHIDA A, 1992, J EXP MED, V175, P81, DOI 10.1084/jem.175.1.81; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vanhove Bernard, 1994, Xenotransplantation, V1, P17, DOI 10.1111/j.1399-3089.1994.tb00046.x; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Winkler Hans, 1995, Xenotransplantation, V2, P53, DOI 10.1111/j.1399-3089.1995.tb00067.x; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	49	328	346	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					196	204		10.1038/nm0297-196	http://dx.doi.org/10.1038/nm0297-196			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018239	Bronze			2022-12-27	WOS:A1997WF08800039
J	Sabel, BA; Engelmann, R; Humphrey, MF				Sabel, BA; Engelmann, R; Humphrey, MF			In vivo confocal neuroimaging (ICON) of CNS neurons	NATURE MEDICINE			English	Editorial Material							ADULT-RATS; IN-VIVO; CELLS; RECOVERY; HUMANS				Sabel, BA (corresponding author), UNIV MAGDEBURG,INST MED PSYCHOL,LEIPZIGER STR 44,D-39120 MAGDEBURG,GERMANY.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543				COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Engelmann R, 1996, EUR J NEUROSCI, V8, P220, DOI 10.1111/j.1460-9568.1996.tb01183.x; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; KISVARDAY ZF, 1994, EUR J NEUROSCI, V6, P1619, DOI 10.1111/j.1460-9568.1994.tb00553.x; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; PURVES D, 1987, J NEUROSCI, V7, P1492; SABEL BA, 1995, EXP BRAIN RES, V106, P93; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Schmitt U, 1996, RESTOR NEUROL NEUROS, V10, P61, DOI 10.3233/RNN-1996-10201; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618	13	49	53	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					244	247		10.1038/nm0297-244	http://dx.doi.org/10.1038/nm0297-244			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018248				2022-12-27	WOS:A1997WF08800050
J	Ishizaki, J; Nevins, JR; Sullenger, BA				Ishizaki, J; Nevins, JR; Sullenger, BA			Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function	NATURE MEDICINE			English	Article							S-PHASE; RETINOBLASTOMA PROTEIN; CYCLE CONTROL; TRANSCRIPTION; EXPRESSION; EVOLUTION; MOLECULE; RB	The control of cell proliferation is of central importance to the proper development of a multicellular organism, the homeostatic maintenance of tissues, and the ability of certain cell types to respond appropriately to environmental cues. Disruption of normal cell growth control underlies many pathological conditions, including endothelial proliferative disorders in cardiovascular disease as well as the development of malignant tumors. Particularly critical for the control of cell growth is the pathway involving the G(1) cyclin-dependent kinases that regulate the Rb family of proteins, which in turn control E2F transcription factor activity(1-7). Because E2F is critical for regulation of cell proliferation, we sought to identify and to develop specific inhibitors of E2F function that might also be useful in the control of cellular proliferation. Moreover, because the control of E2F activity appears to be the end result of G, regulatory cascades, the ability to inhibit E2F may be particularly effective in impeding a wide variety of proliferative events. We have used in vitro selection to isolate several unique RNA species from high complexity RNA libraries that avidly bind to the E2F family of proteins. These RNAs also inhibit the DNA binding capacity of the E2F proteins. We also show that an E2F RNA ligand can block the induction of S phase in quiescent cells stimulated by serum addition. As such, these data demonstrate the critical role for E2F activity in cell proliferation and suggest that such RNA molecules may be effective as therapeutic entities to control cellular proliferation.	DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University								Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; NEVINS JR, 1992, SCIENCE, V258, P424; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	27	59	64	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1386	1389		10.1038/nm1296-1386	http://dx.doi.org/10.1038/nm1296-1386			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946842				2022-12-27	WOS:A1996VW51500049
J	Buxbaum, JD; Choi, EK; Luo, YX; Lilliehook, C; Crowley, AC; Merriam, DE; Wasco, W				Buxbaum, JD; Choi, EK; Luo, YX; Lilliehook, C; Crowley, AC; Merriam, DE; Wasco, W			Calsenilin: A calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; APOPTOSIS; RECOVERIN; CLEAVAGE; CLONING; CELLS; ALG-3; PS2	Most early-onset familiar Alzheimer disease (AD) cases are caused by mutations ill the highly related genes presenilin 1 (PS1) and presenilin 2 (PS2)(1-3). Presenilin mutations produce increases in beta-amyloid (A beta) formation and apoptosis in many experimental systems. A cDNA (ALG-3) encoding the last 103 amino acids of PS2 has been identified as a potent inhibitor of apoptosis(4,5). Using this PS2 domain in the yeast two-hybrid system, we have identified a neuronal protein that binds calcium and presenilin, which we call calsenilin. Calsenilin interacts with both PS1 and PS2 in cultured cells, and can regulate the levels of a proteolytic product of PS2. Thus, calsenilin may mediate the effects of wild-type and mutant presenilins on apoptosis and on A beta formation. Further characterization of calsenilin may lead to an understanding of the normal role of the presenilins and of the role of the presenilins in Alzheimer disease.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; Harvard Univ, Massachusetts Gen Hosp E, Sch Med, Dept Neurol,Genet & Aging Unit, Boston, MA 02129 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313				BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Mattson MP, 1998, J NEUROCHEM, V70, P1; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shinozaki K, 1998, INT J MOL MED, V1, P797; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Zhang WJ, 1998, J NEUROSCI, V18, P914; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	22	294	310	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1177	1181		10.1038/2673	http://dx.doi.org/10.1038/2673			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771752				2022-12-27	WOS:000076230100038
J	Bartlett, JS; Samulski, RJ				Bartlett, JS; Samulski, RJ			Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy	NATURE MEDICINE			English	Article							DYE LABELING REAGENTS; SUCCINIMIDYL ESTERS; HELA-CELLS; PROTEOGLYCAN; EXPRESSION; SULFATE; ENTRY		Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bartlett, JS (corresponding author), Univ N Carolina, Gene Therapy Ctr, CB 7352,Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	jbart@med.unc.edu			NHLBI NIH HHS [HL048347] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT JS, 1995, INTERNET BOOK GENE T, P27; BARTLETT JS, IN PRESS HUM GENE TH; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Blomer U, 1997, J VIROL, V71, P6641; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; PERSSON R, 1983, J VIROL, V46, P956, DOI 10.1128/JVI.46.3.956-963.1983; SANNES PL, 1993, AM J RESP CELL MOL, V8, P245, DOI 10.1165/ajrcmb/8.3.245; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; SVENSSON U, 1984, J VIROL, V51, P687, DOI 10.1128/JVI.51.3.687-694.1984; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; VARGA MJ, 1991, J VIROL, V65, P6061, DOI 10.1128/JVI.65.11.6061-6070.1991; WESSENDORF MW, 1992, HISTOCHEMISTRY, V98, P81, DOI 10.1007/BF00716998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	19	27	30	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					635	637		10.1038/nm0598-635	http://dx.doi.org/10.1038/nm0598-635			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585242				2022-12-27	WOS:000073399900042
J	Ma, JKC; Hikmat, BY; Wycoff, K; Vine, ND; Chargelegue, D; Yu, L; Hein, MB; Lehner, T				Ma, JKC; Hikmat, BY; Wycoff, K; Vine, ND; Chargelegue, D; Yu, L; Hein, MB; Lehner, T			Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans	NATURE MEDICINE			English	Article							LOCAL PASSIVE-IMMUNIZATION; STREPTOCOCCUS-MUTANS; ANTIGEN-I/II; IGA; IMMUNOGLOBULIN; DEFENSE	A functional comparison was made between a monoclonal secretory antibody generated in transgenic plants and its parent murine IgG antibody. The affinity constants of both antibodies for a Streptococcus mutans adhesion protein were similar. However the secretory antibody had a higher functional affinity due to its dimeric structure. In the human oral cavity, the secretory antibody survived for up to three days, compared with one day for the IgG antibody. The plant secretory antibody afforded specific protection in humans against oral streptococcal colonization for at least four months. We demonstrate that transgenic plants can be used to produce high affinity, monoclonal secretory antibodies that can prevent specific microbial colonization in humans. These findings could be extended to the immunotherapeutic prevention of other mucosal infections in humans and animals.	Guys Hosp, United Med & Dent Sch, Dept Immunol, London SE1 9RT, England; Planet Biotechnol Inc, Mountain View, CA 94043 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Scripps Research Institute	Ma, JKC (corresponding author), Guys Hosp, United Med & Dent Sch, Dept Immunol, 28th Floor,Guys Tower,London Bridge, London SE1 9RT, England.			Ma, Julian/0000-0003-0767-0042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arntzen CJ, 1997, NAT BIOTECHNOL, V15, P221, DOI 10.1038/nbt0397-221; BEIGHTON D, 1991, CARIES RES, V25, P174, DOI 10.1159/000261363; CHILDERS NK, 1989, ANNU REV MICROBIOL, V43, P503, DOI 10.1146/annurev.mi.43.100189.002443; Corthesy B, 1997, BIOCHEM SOC T, V25, P471, DOI 10.1042/bst0250471; HAJISHENGALLIS G, 1992, INFECT IMMUN, V60, P5057, DOI 10.1128/IAI.60.12.5057-5064.1992; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; LOE H, 1963, ACTA ODONTOL SCAND, V21, P532; MA JK, 1989, CLIN EXP IMMUNOL, V77, P331; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MA JKC, 1987, INFECT IMMUN, V55, P1274, DOI 10.1128/IAI.55.5.1274-1278.1987; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; MAZANEC MB, 1992, VIRUS RES, V23, P1, DOI 10.1016/0168-1702(92)90063-F; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968; STEWARD MW, 1997, HDB EXPT IMMUNOLOGY; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; ZYLBER LJ, 1982, J CLIN MICROBIOL, V15, P253, DOI 10.1128/JCM.15.2.253-259.1982	20	349	408	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					601	606		10.1038/nm0598-601	http://dx.doi.org/10.1038/nm0598-601			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585235				2022-12-27	WOS:000073399900033
J	Jevtovic-Todorovic, V; Todorovic, SM; Mennerick, S; Powell, S; Dikranian, K; Benshoff, N; Zorumski, CF; Olney, JW				Jevtovic-Todorovic, V; Todorovic, SM; Mennerick, S; Powell, S; Dikranian, K; Benshoff, N; Zorumski, CF; Olney, JW			Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin	NATURE MEDICINE			English	Article							RAT; PHENCYCLIDINE; NEURONS; CORTEX; MK-801	Extensive research has failed to clarify the mechanism of action of nitrous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse. Other general anesthetics are thought to act by one of two mechanisms-blockade of NMDA glutamate receptors or enhancement of GABAergic inhibition(1). Here we show that N2O, at anesthetically-relevant concentrations, inhibits both ionic currents and excitotoxic neurodegeneration mediated through NMDA receptors and, like other NMDA antagonists, produces neurotoxic side effects which can be prevented by drugs that enhance GABAergic inhibition. The favorable safety record of N2O may be explained by the low concentrations typically used and by the fact that it is usually used in combination with GABAergic anesthetics that counteract its neurotoxic potential.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Jevtovic-Todorovic, V (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.		Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664	NATIONAL EYE INSTITUTE [R01EY008089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08089] Funding Source: Medline; NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DOHRN CS, 1993, DRUG ALCOHOL DEPEN, V31, P265, DOI 10.1016/0376-8716(93)90009-F; Farber NB, 1995, BIOL PSYCHIAT, V38, P788, DOI 10.1016/0006-3223(95)00046-1; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FRAGEN RJ, 1992, CLIN ANESTH, P385; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GONSOWSKI CT, 1994, ANESTH ANALG, V79, P710; HORNBEIN TF, 1982, ANESTH ANALG, V61, P553; ISHIMARU M, 1995, NEUROSCI LETT, V193, P1, DOI 10.1016/0304-3940(95)11650-L; JevtovicTodorovic V, 1997, J CEREBR BLOOD F MET, V17, P168, DOI 10.1097/00004647-199702000-00006; KOBLIN DD, 1981, ANESTH ANALG, V60, P138; LITTLE HJ, 1986, J PHYSIOL-LONDON, V374, P387, DOI 10.1113/jphysiol.1986.sp016086; LODGE D, 1982, EUR J PHARMACOL, V77, P203, DOI 10.1016/0014-2999(82)90022-X; Lodge D., 1987, EXCITATORY AMINO ACI, P83; MAHMOUDI NW, 1989, ANESTHESIOLOGY, V70, P345, DOI 10.1097/00000542-198902000-00027; MENNERICK S, 1995, J NEUROPHYSIOL, V73, P320, DOI 10.1152/jn.1995.73.1.320; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1989, NEUROENDOCRINE PEPTI, P891; ROTHMAN SM, 1991, J NEUROSCI, V4, P1483; STEVENS RK, 1992, CLIN ANESTH, P6; STEVENS WC, 1992, CLIN ANESTH, P39; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	25	445	466	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					460	463		10.1038/nm0498-460	http://dx.doi.org/10.1038/nm0498-460			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546794				2022-12-27	WOS:000072906800043
J	Glushakova, S; Grivel, JC; Fitzgerald, W; Sylwester, A; Zimmerberg, J; Margolis, LB				Glushakova, S; Grivel, JC; Fitzgerald, W; Sylwester, A; Zimmerberg, J; Margolis, LB			Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency	NATURE MEDICINE			English	Article							ANTIBODY-RESPONSE; VIRAL BURDEN; B-CELLS; INFECTION; DISEASE; PATHOGENESIS; PROGRESSION; INDIVIDUALS; ACTIVATION; TETANUS	Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear(1). Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia-inducing (NSI) viruses(2,3), which hyperactivate the immune system(4,5), and, in one view, cause immunodeficiency by "exhaustion"(4,6) of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M-and T-tropic HIV-1 isolates when cultured ex vivo(10,11). We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.	NIAID, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Margolis, LB (corresponding author), NIAID, Lab Cellular & Mol Biophys, NIH, Bldg 10,Room 10D14,10 Ctr Dr, Bethesda, MD 20892 USA.			Grivel, Jean-Charles/0000-0003-0365-3181				BARBI M, 1992, AIDS, V6, P1465, DOI 10.1097/00002030-199212000-00007; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CORNELISSEN M, 1995, J VIROL, V69, P1810, DOI 10.1128/JVI.69.3.1810-1818.1995; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; HOFFMANN MK, 1973, NATURE, V243, P408, DOI 10.1038/243408a0; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; LANE HC, 1981, J EXP MED, V154, P1043, DOI 10.1084/jem.154.4.1043; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MISHELL RI, 1966, SCIENCE, V153, P1004, DOI 10.1126/science.153.3739.1004; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SNAPPER CM, 1995, J IMMUNOL, V154, P1177; TERSMETTE M, 1989, LANCET, V1, P983; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	22	93	95	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					346	349		10.1038/nm0398-346	http://dx.doi.org/10.1038/nm0398-346			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500611				2022-12-27	WOS:000073616200043
J	Wang, YMF; Tsirka, SE; Strickland, S; Stieg, PE; Soriano, SG; Lipton, SA				Wang, YMF; Tsirka, SE; Strickland, S; Stieg, PE; Soriano, SG; Lipton, SA			Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice	NATURE MEDICINE			English	Article							CUZN-SUPEROXIDE-DISMUTASE; ARTERY OCCLUSION; TRANSGENIC MICE; INFARCT VOLUME; NEUROLOGICAL DEFICIT; REPERFUSION INJURY; CELL-DAMAGE; RATS; MODEL; BRAIN	Intravenous tissue plasminogen activator (tPA) is used to treat acute stroke because of its thrombolytic activity and its ability to restore circulation to the brain(1,2). However, this protease also promotes neurodegeneration after intracerebral injection of excitotoxins such as glutamate, and neuronal damage after a cerebral infarct is thought to be mediated by excitotoxins(3-8). To investigate the effects of tPA on cerebral viability during ischemia/reperfusion, we occluded the middle cerebral artery in wild-type and tPA-deficient mice with an intravascular filament. This procedure allowed us to examine the role of tPA in ischemia, independent of its effect as a thrombolytic agent. tPA-deficient mice exhibited similar to 50% smaller cerebral infarcts than wild-type mice. Intravenous injection of tPA into tPA(-/-) or wild-type mice produced larger infarcts, indicating that tPA can increase stroke-induced injury. Since tPA promotes desirable (thrombolytic) as well as undesirable (neurotoxic) outcomes during stroke, future therapies should be aimed at countering the excitotoxic damage of tPA to afford even better neuroprotection after an acute cerebral infarct.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Cerebrovasc & Neurosci Res Inst, Boston, MA 02115 USA; Childrens Hosp, Neurosurg Serv, Boston, MA 02115 USA; Childrens Hosp, Anesthesiol Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; SUNY Stony Brook, Med Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lipton, SA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cerebrovasc & Neurosci Res Inst, 221 Longwood Ave,LMRC 1st Floor, Boston, MA 02115 USA.	slipton@rics.bwh.harvard.edu	Soriano, Sulpicio/K-3501-2019; tao, li/G-7956-2011; Tsirka, Stella/AAD-4018-2019	Strickland, Sidney/0000-0002-3072-9244; Lipton, Stuart/0000-0002-3490-1259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035843, R01NS035704] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD 29587] Funding Source: Medline; NINDS NIH HHS [R01 NS35704, R29 NS 35843] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BUCHAN AM, 1992, STROKE, V23, P273, DOI 10.1161/01.STR.23.2.273; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P574, DOI 10.1038/jcbfm.1994.71; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	31	544	568	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					228	231		10.1038/nm0298-228	http://dx.doi.org/10.1038/nm0298-228			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461198				2022-12-27	WOS:000072249800040
J	Papandreou, CN; Usmani, B; Geng, YP; Bogenrieder, T; Freeman, R; Wilk, S; Finstad, CL; Reuter, VE; Powell, CT; Scheinberg, D; Magill, C; Scher, HI; Albino, AP; Nanus, DM				Papandreou, CN; Usmani, B; Geng, YP; Bogenrieder, T; Freeman, R; Wilk, S; Finstad, CL; Reuter, VE; Powell, CT; Scheinberg, D; Magill, C; Scher, HI; Albino, AP; Nanus, DM			Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression	NATURE MEDICINE			English	Article							CELL CARCINOMAS; GROWTH-FACTORS; RAT-BRAIN; EXPRESSION; BOMBESIN; RECEPTOR; PEPTIDE; ENKEPHALINASE; ANTIGEN; GENE	Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). We report that NEP expression and catalytic activity are lost in vitro in androgen-independent but not androgen-dependent PC cell lines. In vivo, NEP protein expression is commonly decreased in cancer cells of metastatic PC specimens from patients with androgen-independent but not androgen-dependent PC. Overexpression of NEP in androgen-independent PC cells or incubation with recombinant NEP inhibits PC cell growth. Furthermore, in androgen-dependent PC cells, expression of NEP is transcriptionally regulated by androgen and decreases with androgen withdrawal. These data suggest that decreased NEP expression, common in androgen-independent PCs, is facilitated by the elimination of androgens, and that NEP loss plays an important role in the development of androgen-independent PC by allowing Pt cells to use mitogenic neuropeptides as an alternate source to androgen in order to stimulate cell proliferation.	Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Coll Med,Genitourinary Oncol Serv, Mem Sloan Kettering Canc Ctr, Dept Med,Div Solid Tumor Oncol, New York, NY 10021 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Urol Oncol Res Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Hematopoiet Canc Immunochem Lab, New York, NY 10021 USA; Amer Hlth Fdn, San Francisco, CA 94080 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; American Health Foundation	Nanus, DM (corresponding author), New York Hosp, Cornell Med Ctr, Dept Med, Div Hematol & Med Oncol, 520 E 70th St,Suite ST-341, New York, NY 10021 USA.				NCI NIH HHS [CA 05826, CA 57475] Funding Source: Medline; NINDS NIH HHS [NS 17392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826, R29CA057475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAMSSON PA, 1993, J ANDROL, V14, P307; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Bogenrieder T, 1997, PROSTATE, V33, P225; BOLOGNA M, 1989, CANCER, V63, P1714; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BORSON DB, 1991, AM J PHYSIOL, V260, pL83, DOI 10.1152/ajplung.1991.260.2.L83; CASEY ML, 1991, J BIOL CHEM, V266, P23041; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; Cohen AJ, 1996, CANCER RES, V56, P831; COHEN R, 1991, BR J UROL, V68, P57; Cussenot O, 1996, J UROLOGY, V155, P1340, DOI 10.1016/S0022-5347(01)66261-X; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; Duncan MD, 1996, J SURG RES, V63, P359, DOI 10.1006/jsre.1996.0276; FOURNIEZALUSKI MC, 1979, BIOCHEM BIOPH RES CO, V91, P130, DOI 10.1016/0006-291X(79)90593-X; Frame KL, 1996, BRIT J CANCER, V74, P807, DOI 10.1038/bjc.1996.440; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; Gschwend JE, 1997, PROSTATE, V33, P166; Hoffman AD, 1996, CLIN CANCER RES, V2, P1077; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; ISRAELI RS, 1994, CANCER RES, V54, P1807; KENNY AJ, 1989, LANCET, V2, P785; KENNY J, 1993, BIOCHEM SOC T, V21, P663, DOI 10.1042/bst0210663; Klocker Helmut, 1996, P28; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NABEYA Y, 1995, INT J CANCER, V64, P1; NANUS DM, 1989, J CLIN ONCOL, V7, P1105, DOI 10.1200/JCO.1989.7.8.1105; NANUS DM, 1989, J EXP MED, V169, P953, DOI 10.1084/jem.169.3.953; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NANUS DM, 1997, CELL SURFACE PEPTIDA, P353; Nelson JB, 1996, CANCER RES, V56, P663; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; Papandreou CN, 1996, INT J ONCOL, V8, P1237; PINSKI J, 1993, CANCER LETT, V71, P189, DOI 10.1016/0304-3835(93)90115-P; REILE H, 1994, PROSTATE, V25, P29, DOI 10.1002/pros.2990250105; ROZENGURT E, 1995, CANCER SURV, V24, P81; Scher HI, 1996, JNCI-J NATL CANCER I, V88, P1623, DOI 10.1093/jnci/88.22.1623; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; STEINER MS, 1995, J UROLOGY, V153, P1085, DOI 10.1016/S0022-5347(01)67516-5; SUNDAY ME, 1992, J CLIN INVEST, V90, P2517, DOI 10.1172/JCI116145; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026	48	242	244	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					50	57		10.1038/nm0198-050	http://dx.doi.org/10.1038/nm0198-050			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427606				2022-12-27	WOS:000072249700034
J	Radda, GK				Radda, GK			Medical research: The national interest	NATURE MEDICINE			English	Editorial Material									MRC, London W1N 4AL, England		Radda, GK (corresponding author), MRC, 20 Pk Crescent, London W1N 4AL, England.							*NAT AC POL ADV GR, 1996, SURV RES EQ UK U CVC; THOMSON AL, 1987, HALF CENTURY MED RES, P1; 1993, CM2250; 1993, MRC NEWS, P59	4	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1311	1314		10.1038/nm1297-1311	http://dx.doi.org/10.1038/nm1297-1311			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396592				2022-12-27	WOS:000072249500018
J	Michael, NL; Louie, LG; Rohrbaugh, AL; Schultz, KA; Dayhoff, DE; Wang, CE; Sheppard, HW				Michael, NL; Louie, LG; Rohrbaugh, AL; Schultz, KA; Dayhoff, DE; Wang, CE; Sheppard, HW			The role of CCR5 and CCR2 polymorphisms in HTV-1 transmission and disease progression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; TYPE-1; ALLELE; GENE; AIDS	Entry of human immunodeficiency virus type 1 (HIV-1) into target cells requires both CD4(ref. 1, 2) and one of a growing number of G-protein-coupled seven-transmembrane receptors'. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 or CXCR4 although other receptors, including CCR2B and CCR3, function as minor co-receptors(4-6). CCR3 appears critical in central nervous system infection(7). A 32-base pair inactivating deletion in CCRS (Delta 32) common to Northern European populations(8) has been associated with reduced(9-15), but not absolute(16-19), HIV-1 transmission risk and delayed disease progression(11-15,20). A more commonly distributed transition causing a valine to isoleucine switch in transmembrane domain I of CCR2B (641) with unknown functional consequences was recently shown to delay disease progression but not reduce infection risk(21). Although we confirm the lack of association of CCR2B 641 with transmission, we cannot confirm the association with delayed progression. Although subjects with CCRS Delta 32 defects had significantly reduced median viral load at study entry, providing a plausible explanation for the association with delayed progression, this association was not seen with CCR2B 641. Further studies are needed to define the role of CCR2B 641 in HIV pathogenesis.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; HENRY M JACKSON FDN,ROCKVILLE,MD 20850; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California Berkeley; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; California Department of Health Care Services	Michael, NL (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,13 TAFT COURT,SUITE 200,ROCKVILLE,MD 20850, USA.		McNulty, Amy/K-7368-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036661, R01AI034783, N01AI082515] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-34783, R01-AI-36661, N01-AI-82515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balotta C, 1997, AIDS, V11, pF67, DOI 10.1097/00002030-199710000-00001; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rappaport J, 1997, LANCET, V349, P922, DOI 10.1016/S0140-6736(05)62697-9; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	28	216	228	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1160	1162		10.1038/nm1097-1160	http://dx.doi.org/10.1038/nm1097-1160			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334732				2022-12-27	WOS:A1997XZ28700046
J	Ng, ST; Zhou, JA; Adesanya, OO; Wang, J; LeRoith, D; Bondy, CA				Ng, ST; Zhou, JA; Adesanya, OO; Wang, J; LeRoith, D; Bondy, CA			Growth hormone treatment induces mammary gland hyperplasia in aging primates	NATURE MEDICINE			English	Article							FACTOR-I; BREAST-CANCER; GENE-EXPRESSION; PROLACTIN; SYSTEM; PROLIFERATION; THERAPY	The decline of growth hormone (CH) and insulin-like growth factor I (ICF-I) production during aging has been likened to the decrease in gonadal steroids in menopause. The repletion of GH/IGF-I levels in aging individuals is suggested to restore the lean tissue anabolism characteristic of youth(1). In addition to anabolic effects on musculoskeletal tissues, CH also stimulates mammary glandular growth in some species(2-4), although its effects on primate mammary growth remain unclear(5). Some clinical observations implicate GH in human mammary growth, for example, gynecomastia occurs in some children treated with CH (ref. 6), and tall stature and acromegaly are associated with an increased incidence of breast cancer(7,8). To investigate the effects of GH/ICF-I augmentation on mammary tissue in a model relevant to aging humans, we treated aged female rhesus monkeys with CH, IG F-l, GH + ICF-I or saline diluent for 7 weeks. ICF-I treatment was associated with a twofold increase, GH with a three-to fourfold increase, and GH + IGF-I with a four-to fivefold increase in mammary glandular size and epithelial proliferation index. These mitogenic effects were directly correlated with circulating GH and IGF-I levels, suggesting that either CH or its downstream effector ICF-I stimulates primate mammary epithelial proliferation.	NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA; NIDDKD, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Adesanya OO, 1996, J CLIN ENDOCR METAB, V81, P1967, DOI 10.1210/jc.81.5.1967; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BONDY CA, 1994, ANN INTERN MED, V120, P593, DOI 10.7326/0003-4819-120-7-199404010-00011; DJIANE J, 1981, P NATL ACAD SCI-BIOL, V78, P7445, DOI 10.1073/pnas.78.12.7445; FORSYTH IA, 1991, BAILLIERE CLIN ENDOC, V5, P809, DOI 10.1016/S0950-351X(10)80016-3; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; KLEINBERG DL, 1985, J CLIN INVEST, V75, P1943, DOI 10.1172/JCI111910; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; MALOZOWSKI S, 1995, J PEDIATR-US, V126, P659, DOI 10.1016/S0022-3476(95)70372-1; MARTINEZ AJ, 1992, MAYO CLIN PROC, V67, P1011, DOI 10.1016/S0025-6196(12)60937-9; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; NABARRO JDN, 1987, CLIN ENDOCRINOL, V26, P481, DOI 10.1111/j.1365-2265.1987.tb00805.x; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; Toogood AA, 1997, J CLIN ENDOCR METAB, V82, P1462, DOI 10.1210/jc.82.5.1462; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	23	152	155	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1997	3	10					1141	1144		10.1038/nm1097-1141	http://dx.doi.org/10.1038/nm1097-1141			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334728	Green Published			2022-12-27	WOS:A1997XZ28700042
J	WithersWard, ES; Amado, RG; Koka, PS; Jamieson, BD; Kaplan, AH; Chen, ISY; Zack, JA				WithersWard, ES; Amado, RG; Koka, PS; Jamieson, BD; Kaplan, AH; Chen, ISY; Zack, JA			Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SCID-HU MOUSE; PROTEASE INHIBITOR; MICE; VARIANTS; PATHOGENICITY; LYMPHOCYTES; REPLICATION; DEPLETION; MODEL	Stem cell gene therapy strategies for AIDS require that differentiation-inducing stromal elements of HIV-infected individuals remain functionally intact to support the maturation of exogenous progenitor cells into mature CD4(+) cells. To investigate the feasibility of stem cell reconstitution strategies in AIDS, we used the SCID-hu mouse to examine the ability of HIV-infected CD4(+) cell-depleted human thymic implants to support renewed thymopoiesis. Here we report that following treatment of these implants with antiretroviral drugs, new thymopoiesis is initiated. This suggests that antiviral therapies might allow de novo production of T lymphocytes and provides support for the concept of therapeutic strategies aimed at reconstitution of the peripheral CD4(+) T-cell compartment.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT IMMUNOL & MICROBIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL GENET & MICROBIOL,LOS ANGELES,CA 90095; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center					NIAID NIH HHS [AI 36554, AI 36555, AI 36059] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036554, R37AI036059, R01AI036059, R01AI036555] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKINA RK, 1994, BLOOD, V84, P1393; Aldrovandi GM, 1996, J VIROL, V70, P1505, DOI 10.1128/JVI.70.3.1505-1511.1996; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; An DS, 1997, J VIROL, V71, P1397, DOI 10.1128/JVI.71.2.1397-1404.1997; AUTRAN B, 1997, SCIENCE, V27, P112; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JAMIESON BD, 1995, J VIROL, V69, P6259, DOI 10.1128/JVI.69.10.6259-6264.1995; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; JAMIESON BD, IN PRESS J VIROL; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KANESHIMA H, 1991, P NATL ACAD SCI USA, V88, P4523, DOI 10.1073/pnas.88.10.4523; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; ROSENZWEIG M, 1993, AIDS, V7, P1601, DOI 10.1097/00002030-199312000-00009; SATO A, 1995, ANTIVIR RES, V27, P151, DOI 10.1016/0166-3542(95)00004-6; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	55	55	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1102	1109		10.1038/nm1097-1102	http://dx.doi.org/10.1038/nm1097-1102			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334721				2022-12-27	WOS:A1997XZ28700035
J	Melero, I; Shuford, WW; Newby, SA; Aruffo, A; Ledbetter, JA; Hellstrom, KE; Mittler, RS; Chen, LP				Melero, I; Shuford, WW; Newby, SA; Aruffo, A; Ledbetter, JA; Hellstrom, KE; Mittler, RS; Chen, LP			Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors	NATURE MEDICINE			English	Article							RECEPTOR SUPERFAMILY; NECROSIS-FACTOR; COSTIMULATION; GROWTH; EXPRESSION; CYTOKINES; PROTEINS; IMMUNITY; LIGAND; CTLA-4	The 4-1BB glycoprotein is a member of the tumor necrosis factor receptor superfamily(1-4) and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells(5,6). Expression of 4-1BB is restricted to primed CD4(+) and CD8(+) T cells(7), and 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers a dual mitogenic signal for T-cell activation and growth(8-12). These observations suggest an important role for 4-1BB in the amplification of T cell-mediated immune responses. We now show that administration of anti-4-1BB monoclonal antibodies can eradicate established large tumors in mice, including the poorly immunogenic Ag104A sarcoma and the highly tumorigenic P815 masto cytoma. The immune response induced by anti-4-1BB monoclonal antibodies is mediated by both CD8(+) and CD4(+) T cells and is accompanied by a marked augmentation of tumor-selective cytolytic T-cell activity. Our data suggest that a similar approach may be efficacious for immunotherapy of human cancer.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb			Melero, Ignacio/T-7600-2019	Melero, Ignacio/0000-0002-1360-348X				ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DEBENEDETTE MA, 1995, J EXP MED, V181, P985, DOI 10.1084/jem.181.3.985; ELLENHORN JDI, 1988, SCIENCE, V242, P569, DOI 10.1126/science.2902689; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HURTADO JC, 1995, J IMMUNOL, V155, P3360; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; KOWN BS, 1989, P NATL ACAD SCI USA, V86, P1963; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; Li YW, 1996, J EXP MED, V183, P639, DOI 10.1084/jem.183.2.639; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; POLLOK KE, 1995, EUR J IMMUNOL, V25, P488, DOI 10.1002/eji.1830250227; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Schreiber Hans, 1993, P1143; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; YANG GC, 1995, J IMMUNOL, V155, P3897	25	711	883	1	39	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					682	685		10.1038/nm0697-682	http://dx.doi.org/10.1038/nm0697-682			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176498				2022-12-27	WOS:A1997XB97400041
J	Ananthaswamy, HN; Loughlin, SM; Cox, P; Evans, RL; Ullrich, SE; Kripke, ML				Ananthaswamy, HN; Loughlin, SM; Cox, P; Evans, RL; Ullrich, SE; Kripke, ML			Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens	NATURE MEDICINE			English	Article							XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMAS; TUMOR SUPPRESSOR GENE; ULTRAVIOLET-RADIATION; AMINOBENZOIC ACID; MICE; DNA; PHOTOCARCINOGENESIS; PREVENTION; EXPOSURE	UV-induced mutations in the p53 tumor suppressor gene pray an essential role in skin cancer development. We report here that such mutations cars be detected in UV-irradiated mouse skin months before the gross appearance of skin tumors. Application of SPF-15 sunscreens to mouse skin before each UV irradiation nearly abolished the frequency of p53 mutations. These results indicate that p53 mutation is an early event in UV skin carcinogenesis and that inhibition of this event may serve as an early end point for assessing protective measures against skin cancer development.			Ananthaswamy, HN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,1515 HOLCOMBE BLVD,BOX 178,HOUSTON,TX 77030, USA.							Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BLUM HF, 1959, CARCINOGENESIS ULTRA; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; *COSM TOIL FRAGR A, 1995, INT COSM INGR DICT; DERIJCKE S, 1989, DERMATOLOGICA, V179, P196, DOI 10.1159/000248359; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; FOURTANIER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P549, DOI 10.1111/j.1751-1097.1992.tb04277.x; Fourtanier A, 1996, PHOTOCHEM PHOTOBIOL, V64, P688, DOI 10.1111/j.1751-1097.1996.tb03125.x; FREEMAN SE, 1988, PHOTODERMATOLOGY, V5, P243; GILCHREST BA, 1990, ANNU REV MED, V41, P199; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; KANJILAL S, 1995, CANCER RES, V55, P3604; KANJILAL S, 1993, CANCER RES, V53, P2961; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; KLIGMAN LH, 1982, J INVEST DERMATOL, V78, P181, DOI 10.1111/1523-1747.ep12506359; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; KRESS S, 1992, CANCER RES, V52, P6400; KRIPKE M L, 1991, Journal of Dermatology (Tokyo), V18, P429; KRIPKE ML, 1977, CANCER RES, V37, P1395; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE NJ, 1980, J INVEST DERMATOL, V74, P181, DOI 10.1111/1523-1747.ep12535093; MOLES JP, 1993, ONCOGENE, V8, P583; MORISON WL, 1984, J INVEST DERMATOL, V83, P405, DOI 10.1111/1523-1747.ep12273470; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Nataraj AJ, 1996, P NATL ACAD SCI USA, V93, P7961, DOI 10.1073/pnas.93.15.7961; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P165; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; Ren ZP, 1996, ONCOGENE, V12, P765; Roberts LK, 1996, PHOTOCHEM PHOTOBIOL, V63, P874, DOI 10.1111/j.1751-1097.1996.tb09645.x; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SATO M, 1993, CANCER RES, V53, P2944; Scotto J, 1978, Natl Cancer Inst Monogr, P169; Urbach F, 1969, LONG TERM FIELD MEAS; URBACH F, 1978, NATL CANCER I MONOGR, V50, P5; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WOLF P, 1993, J INVEST DERMATOL, V100, P254, DOI 10.1111/1523-1747.ep12469038; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	48	169	170	2	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					510	514		10.1038/nm0597-510	http://dx.doi.org/10.1038/nm0597-510			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142118				2022-12-27	WOS:A1997WX54300029
J	Benimetskaya, L; Loike, JD; Khaled, Z; Loike, G; Silverstein, SC; Cao, L; Khoury, JE; Cai, TQ; Stein, CA				Benimetskaya, L; Loike, JD; Khaled, Z; Loike, G; Silverstein, SC; Cao, L; Khoury, JE; Cai, TQ; Stein, CA			Mac-1 (CDllb/CD18) is an oligodeoxynucleotide-binding protein	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; ANTISENSE OLIGODEOXYNUCLEOTIDES; TYROSINE PHOSPHORYLATION; OLIGONUCLEOTIDE UPTAKE; SCAVENGER RECEPTORS; MOUSE MODEL; HL-60 CELLS; I-DOMAIN; CD11B/CD18	We have studied the interactions of phosphodiester and phosphorothioate oligodeoxynucleotides with Mac-1 (CD11b/CD18; alpha M beta 2), a heparin-binding integrin found predominately on the surface of polymorphonuclear leukocytes (PMNs), macrophages and natural killer cells. Binding of a homopolymer of thymidine occurred on both the alpha M and beta 2 subunits. Soluble fibrinogen, a natural ligand for Mac-1, was an excellent competitor of the binding of a phosphorothioate oligodeoxynucleotide to both TNF-alpha-activated and nonactivated PMNs. Upregulation of cell-surface Mac-1 expression increased cell-surface binding of oligodeoxynucleotides. Binding was inhibited by anti-Mac-1 monoclonal antibodies, and the increase in cell-surface binding was correlated with a three- to fourfold increase in internalization by PMNs. An oligodeoxynucleotide inhibited beta 2-dependent migration through Matrigel, but the production of reactive oxygen species in PMNs adherent to fibrinogen dramatically increased. Thus, our data demonstrate that Mac-1 is a cell-surface receptor for oligodeoxynucleotides that can mediate their internalization and that this binding may have important functional consequences.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University					NCI NIH HHS [CA 60639] Funding Source: Medline; NIAID NIH HHS [AI 20516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020516, R37AI020516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTERI D, 1988, J BIOL CHEM, V263, P7007; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; CAI T, 1995, J BIOL CHEM, V270, P14538; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COOMBE DR, 1994, BLOOD, V84, P739; COTTER FE, 1994, ONCOGENE, V9, P3049; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ElKhoury J, 1996, NATURE, V382, P716; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; Krieg A M, 1991, Antisense Res Dev, V1, P161; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOIKE J, 1986, AM J PHYSIOL, V251, pC28; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOIKE JD, 1995, J EXP MED, V181, P1763, DOI 10.1084/jem.181.5.1763; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MOHRI H, 1993, ARCH BIOCHEM BIOPHYS, V303, P27, DOI 10.1006/abbi.1993.1251; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Sambrook J., 2002, MOL CLONING LAB MANU; SHOJI Y, 1991, NUCLEIC ACIDS RES, V19, P5543, DOI 10.1093/nar/19.20.5543; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, CANCER RES, V53, P2239; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; TONKINSON JL, 1994, NUCLEIC ACIDS RES, V22, P4268, DOI 10.1093/nar/22.20.4268; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAKUBOV L, 1993, J BIOL CHEM, V268, P18818; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Zhao Q, 1993, Antisense Res Dev, V3, P53; ZHAO QY, 1994, BLOOD, V84, P3660, DOI 10.1182/blood.V84.11.3660.bloodjournal84113660; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	42	214	218	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					414	420		10.1038/nm0497-414	http://dx.doi.org/10.1038/nm0497-414			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095175				2022-12-27	WOS:A1997WQ82500031
J	Kosaka, H; Seiyama, A				Kosaka, H; Seiyama, A			Elevation of oxygen release by nitroglycerin without an increase in blood flow in the hepatic microcirculation	NATURE MEDICINE			English	Article							HEMOGLOBIN; RATS	The effect of nitroglycerin on oxygen (O-2) release in the micro-circulation was investigated by examining single, unbranched hepatic sinusoids of rats using dual-spot microspectroscopy. Nitroglycerin significantly increased O-2 release from erythrocytes flowing in the sinusoids. Differences in O-2 saturation of hemoglobin per unit length of the sinusoid were significantly enhanced, while there were no significant changes in erythrocyte velocity, hemoglobin concentration or oxyhemoglobin flow into the sinusoids, or in regional hepatic blood flow measured with a laser tissue blood flow meter. No change was noted for hepatic O-2 consumption measured in isolated liver perfused with hemoglobin-free oxygenated buffer. Isosorbide dinitrate showed a similar but slower effect. These findings suggest that nitroglycerin and isosorbide dinitrate enhance O-2 release from erythrocytes without significantly increasing tissue blood flow.	OSAKA UNIV, SCH MED, DEPT PHYSIOL 1, OSAKA 565, JAPAN	Osaka University								CHEN SS, 1993, AM J PHYSIOL, V264, pG375, DOI 10.1152/ajpgi.1993.264.2.G375; Douglas CG, 1912, J PHYSIOL-LONDON, V44, P275; FUJII M, 1993, J BIOL CHEM, V268, P15386; HILLE R, 1979, J BIOL CHEM, V254, P2110; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHANDELWAL SR, 1993, AM J PHYSIOL, V265, pH1450, DOI 10.1152/ajpheart.1993.265.4.H1450; Kosaka H, 1996, BIOCHEM BIOPH RES CO, V218, P749, DOI 10.1006/bbrc.1996.0133; KOSAKA H, 1994, BIOCHEM BIOPH RES CO, V204, P1055, DOI 10.1006/bbrc.1994.2569; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KOSAKA H, 1996, METHODS NITRIC OXIDE, P373; KURZ MA, 1993, BIOCHEM J, V292, P545, DOI 10.1042/bj2920545; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; OKADA Y, 1976, AM J PHYSIOL, V230, P471, DOI 10.1152/ajplegacy.1976.230.2.471; SCHMIDSCHOENBEIN GW, 1975, MICROVASC RES, V10, P153, DOI 10.1016/0026-2862(75)90003-5; Seiyama A, 1996, AM J PHYSIOL-HEART C, V271, pH1, DOI 10.1152/ajpheart.1996.271.1.H1; Seiyama A, 1996, AM J PHYSIOL-HEART C, V270, pH1704, DOI 10.1152/ajpheart.1996.270.5.H1704; SEIYAMA A, 1994, AM J PHYSIOL, V267, pH944, DOI 10.1152/ajpheart.1994.267.3.H944; WAYLAND H, 1967, J APPL PHYSIOL, V22, P333, DOI 10.1152/jappl.1967.22.2.333; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104	19	25	28	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1997	3	4					456	459		10.1038/nm0497-456	http://dx.doi.org/10.1038/nm0497-456			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095182				2022-12-27	WOS:A1997WQ82500038
J	Steiner, JP; Connolly, MA; Valentine, HI; Hamilton, GS; Dawson, TM; Hester, L; Snyder, SH				Steiner, JP; Connolly, MA; Valentine, HI; Hamilton, GS; Dawson, TM; Hester, L; Snyder, SH			Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A	NATURE MEDICINE			English	Article							NERVE GROWTH-FACTOR; PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC BINDING-PROTEIN; CHOLINERGIC NEURONS; MAMMALIAN PROTEIN; CYCLOPHILIN; IMMUNOPHILIN; TRANSPLANTATION; REGENERATION; CALCINEURIN	We show that the nonimmunosuppressive analogues of the immunosuppressive drugs FK506, rapamycin and cyclosporin A promote neurite outgrowth both in PC12 cells and sensory neuronal cultures of dorsal root ganglia with potencies resembling their immunosuppressive homologues. Neurotrophic potencies of the immunophilin ligands resemble their potencies in binding to and inhibiting the rotamase activity of FKBP-12 or cyclophilin. Since nonimmunosuppressive immunophilin ligands, which are devoid of calcineurin inhibitory activity, are equally neurotrophic, inhibition of calcineurin activity is not the mediator of the neurotrophic effects. The immunophilin ligands are neurotrophic in intact animals. FK506 and L-685,818 (the C18-hydroxy, C21-ethyl derivative of FK506) treatment of rats with crushed sciatic nerves enhances both functional and morphologic recovery. The striking potency of these agents, their bioavailability and the dissociation of neurotrophic from immunosuppressant actions argue for their therapeutic relevance in the treatment of neurodegenerative diseases.	GUILFORD PHARMACEUT INC,DEPT MED CHEM,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Steiner, JP (corresponding author), GUILFORD PHARMACEUT INC,DEPT NEUROBIOL RES,6611 TRIBUTARY ST,BALTIMORE,MD 21224, USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APFEL SC, 1992, ANN NEUROL, V31, P76, DOI 10.1002/ana.410310114; APFEL SC, 1994, BRAIN RES, V634, P7, DOI 10.1016/0006-8993(94)90252-6; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1989, NATURE, V340, P351; GOLD BG, 1994, RESTOR NEUROL NEUROS, V6, P287, DOI 10.3233/RNN-1994-6404; GOLD BG, 1995, J NEUROSCI, V15, P7509; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; KAHAN BD, 1994, TRANSPLANT P, V26, P3082; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1995, J NEUROSCI, V15, P2985; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; MCMAHON SB, 1995, CURR OPIN NEUROBIOL, V5, P616, DOI 10.1016/0959-4388(95)80067-0; MUELLER AR, 1994, TRANSPLANTATION, V58, P155, DOI 10.1097/00007890-199407270-00006; OCAIN TD, 1993, BIOCHEM BIOPH RES CO, V192, P1340, DOI 10.1006/bbrc.1993.1563; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SPIK G, 1991, J BIOL CHEM, V266, P10735; STARZL TE, 1990, JAMA-J AM MED ASSOC, V264, P63, DOI 10.1001/jama.264.1.63; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; *US MULT FK506 LIV, 1994, NEW ENGL J MED, V331, P1154	37	338	382	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					421	428		10.1038/nm0497-421	http://dx.doi.org/10.1038/nm0497-421			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095176				2022-12-27	WOS:A1997WQ82500032
J	Fink, DJ; Glorioso, JC				Fink, DJ; Glorioso, JC			Engineering herpes simplex virus vectors for gene transfer to neurons	NATURE MEDICINE			English	Editorial Material							LATENCY-ASSOCIATED TRANSCRIPT; TYPE-1 LATENCY; EXPRESSION; PROMOTER; GANGLIA; MOUSE; RNA		UNIV PITTSBURGH,SCH MED,DEPT MOL GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; VET ADM MED CTR,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BATCHELOR AH, 1992, J VIROL, V66, P3573, DOI 10.1128/JVI.66.6.3573-3582.1992; Bentz J, 1993, VIRAL FUSION MECH, P201; CHEN XW, 1995, J VIROL, V69, P7899, DOI 10.1128/JVI.69.12.7899-7908.1995; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DOBSON AT, 1989, J VIROL, V63, P3844, DOI 10.1128/JVI.63.9.3844-3851.1989; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOINS WF, 1994, J VIROL, V68, P2239, DOI 10.1128/JVI.68.4.2239-2252.1994; HO DY, 1989, P NATL ACAD SCI USA, V86, P7596, DOI 10.1073/pnas.86.19.7596; LEIDEN JM, 1980, J VIROL, V33, P272, DOI 10.1128/JVI.33.1.272-285.1980; Marconi P, 1996, P NATL ACAD SCI USA, V93, P11319, DOI 10.1073/pnas.93.21.11319; Oligino T, 1996, GENE THER, V3, P892; RAMAKRISHNAN R, 1994, J VIROL, V68, P7083, DOI 10.1128/JVI.68.11.7083-7091.1994; Ramakrishnan R, 1996, J VIROL, V70, P6519, DOI 10.1128/JVI.70.9.6519-6523.1996; ROIZMAN B, 1990, P1795; SOARES MK, 1996, J VIROL, V70, P5384; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; Wu NX, 1996, J VIROL, V70, P6358, DOI 10.1128/JVI.70.9.6358-6369.1996	20	60	66	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					357	359		10.1038/nm0397-357	http://dx.doi.org/10.1038/nm0397-357			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055868				2022-12-27	WOS:A1997WL30500042
J	Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K				Miyagawa, K; Rosch, J; Stanczyk, F; Hermsmeyer, K			Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm	NATURE MEDICINE			English	Article							ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; RHESUS-MONKEYS; PROGESTERONE; PROGESTAGEN; DISEASE; THERAPY; RISK	Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17 beta in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.	OREGON HLTH SCI UNIV,OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,CHARLES DOTTER INST INTERVENT RADIOL,PORTLAND,OR 97201; UNIV SO CALIF,SCH MED,WOMENS & CHILDRENS HOSP,LOS ANGELES,CA 90033	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Children's Hospital Los Angeles; University of Southern California					NHLBI NIH HHS [HL51723] Funding Source: Medline; NICHD NIH HHS [HD18185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams Michael R., 1994, P243; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; GILMORE JP, 1983, HDB PHYSL 2 2, V3, P885; Gorodeski George I., 1994, P199; HEALY B, 1995, JAMA-J AM MED ASSOC, V273, P240, DOI 10.1001/jama.273.3.240; HERMSMEYER K, IN PRESS J AM COLL C; HIROI M, 1975, STEROIDS, V26, P373, DOI 10.1016/0039-128X(75)90082-3; JIANG CW, 1992, EUR J PHARMACOL, V211, P163, DOI 10.1016/0014-2999(92)90524-8; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MEIRIK O, 1995, LANCET, V346, P1582; MILLER VM, 1991, AM J PHYSIOL, V261, pR1022, DOI 10.1152/ajpregu.1991.261.4.R1022; MISHRA SK, 1994, J CARDIOVASC PHARM, V24, P1, DOI 10.1097/00005344-199407000-00001; POULTER NR, 1995, LANCET, V346, P1575; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; RESKO JA, 1975, ENDOCRINOLOGY, V97, P425, DOI 10.1210/endo-97-2-425; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; Stanczyk Frank Z., 1994, P69; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILLIAMS CL, 1995, GOODMAN GILMANS PHAR, P1411; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	225	231	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					324	327		10.1038/nm0397-324	http://dx.doi.org/10.1038/nm0397-324			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055861				2022-12-27	WOS:A1997WL30500035
J	Patience, C; Takeuchi, Y; Weiss, RA				Patience, C; Takeuchi, Y; Weiss, RA			Infection of human cells by an endogenous retrovirus of pigs	NATURE MEDICINE			English	Article							HUMAN SERUM; XENOTRANSPLANTATION; COMPLEMENT; TRANSPLANTATION; INACTIVATION; ANTIBODY; PATIENT	The possible use of pig organs and tissues as xenografts in humans is actively being considered in biomedical research. We therefore examined whether pig endogenous retrovirus (PERV) genomes can be infectiously transmitted to human cells in culture. Two pig kidney cell lines spontaneously produce C-type retrovirus particles. Cell-free retrovirus produced by the PK-15 kidney cell line (PERV-PK) infected pig, mink and human kidney 293 cell lines and co-cultivation of X-irradiated PK-15 cells with human cells resulted in a broader range of human cell infection, including human diploid fibroblasts and B- and T-cell lines. Kidney, heart and spleen tissue obtained from domestic pigs contained multiple copies of integrated PERV genomes and expressed viral RNA. Upon passage in human cells PERV-PK could rescue a Moloney retroviral vector and acquired resistance to lysis by human complement.			Patience, C (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.							ACHONG BG, 1976, BRIT J CANCER, V34, P203, DOI 10.1038/bjc.1976.144; Allan JS, 1996, NAT MED, V2, P18, DOI 10.1038/nm0196-18; ARMSTRONG JA, 1971, J GEN VIROL, V10, P195, DOI 10.1099/0022-1317-10-2-195; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BENVENISTE RE, 1975, P NATL ACAD SCI USA, V72, P4090, DOI 10.1073/pnas.72.10.4090; BENVENISTE RE, 1974, NATURE, V248, P17, DOI 10.1038/248017a0; BOSTOCK DE, 1973, J NATL CANCER I, V50, P933, DOI 10.1093/jnci/50.4.933; COFFIN JM, 1985, RNA TUMOR VIRUSES; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FODER WL, 1994, P NATL ACAD SCI USA, V91, P11153; GOODCHILD NL, 1995, VIROLOGY, V206, P164, DOI 10.1016/S0042-6822(95)80031-X; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Gunsalus JR, 1997, NAT MED, V3, P48, DOI 10.1038/nm0197-48; Homer, 1946, ODYSSEY; Institute of Medicine, 1996, XEN SCI ETH PUBL POL; KAWAKAMI TG, 1978, J NATL CANCER I, V61, P1113; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; LEHRMAN S, 1995, NATURE, V378, P756, DOI 10.1038/378756b0; LEVY JA, 1973, SCIENCE, V182, P1151, DOI 10.1126/science.182.4117.1151; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; LIEBER MM, 1975, P NATL ACAD SCI USA, V72, P2315, DOI 10.1073/pnas.72.6.2315; MAKOWKA L, 1995, TRANSPLANTATION, V59, P1654, DOI 10.1097/00007890-199506270-00002; MCALLISTER RM, 1972, NATURE-NEW BIOL, V235, P3, DOI 10.1038/newbio235003a0; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MOENNIG V, 1974, VIROLOGY, V57, P179, DOI 10.1016/0042-6822(74)90119-6; *NUFF COUNC BIOETH, 1996, AN TO HUM TRANSPL ET; Patience C, 1996, J VIROL, V70, P2654, DOI 10.1128/JVI.70.4.2654-2657.1996; PATIENCE C, IN PRESS TRENDS GENE; Purcell DFJ, 1996, J VIROL, V70, P887, DOI 10.1128/JVI.70.2.887-897.1996; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; RYAN US, 1995, NAT MED, V1, P967, DOI 10.1038/nm0995-967; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SCADDEN DT, 1990, J VIROL, V64, P424, DOI 10.1128/JVI.64.1.424-427.1990; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simpson GR, 1996, VIROLOGY, V222, P451, DOI 10.1006/viro.1996.0443; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; STOYE JP, 1995, NAT MED, V1, P1100, DOI 10.1038/nm1195-1100a; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; TODARO GJ, 1974, VIROLOGY, V58, P65, DOI 10.1016/0042-6822(74)90141-X; Tristem M, 1996, J VIROL, V70, P8241, DOI 10.1128/JVI.70.11.8241-8246.1996; Tristem M, 1996, BIOTECHNIQUES, V20, P608; WEISS RA, 1978, NATL CANCER I MONOGR, V48, P183; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465	50	897	968	0	45	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					282	286		10.1038/nm0397-282	http://dx.doi.org/10.1038/nm0397-282			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055854				2022-12-27	WOS:A1997WL30500028
J	Wyand, MS; Manson, KH; Lackner, AA; Desrosiers, RC				Wyand, MS; Manson, KH; Lackner, AA; Desrosiers, RC			Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus	NATURE MEDICINE			English	Article							UPSTREAM U3 SEQUENCES; RHESUS-MONKEYS; SIV VACCINE; NEF GENE; CHALLENGE; MACAQUES; INFECTION; PROTECTION; RESPONSES; ABSENCE	A major safety concern of using live-attenuated vaccine strategies against AIDS is the potential exposure of neonates or fetuses to vaccine virus from the mother, Here we report that high viral loads and disease were observed in only 2 of 18 neonatal monkeys infected with gene-deleted vaccine strains of simian immunodeficiency virus. Pathogenicity was restricted to neonates born to unvaccinated mothers, that is, lacking maternal immunity, and that received extremely high doses of vaccine virus orally. No in utero transmission af vaccine virus was observed in four neonates born to mothers vaccinated during the second trimester. Our results suggest that the live attenuated vaccine approach should remain a viable option for preventing HIV infection and disease in high-risk human populations.	HARVARD UNIV, NEW ENGLAND REG PRIMATE RES CTR, SCH MED, SOUTHBOROUGH, MA 01772 USA; TSI MASON LABS, WORCESTER, MA 01608 USA	Harvard University					NCRR NIH HHS [RR 0 0168] Funding Source: Medline; NIAID NIH HHS [AI 35365, N01-AI O5O84SI] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; CRANAGE M, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P203; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1994, AIDS RES HUM RETROV, V10, P839, DOI 10.1089/aid.1994.10.839; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Deacon NJ, 1996, SCIENCE, V271, P1791, DOI 10.1126/science.271.5257.1791; DESROSIERS RC, 1995, 10 C CENT GARD RETR, P197; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; GIAVEDONI LD, 1993, J VIROL, V67, P577, DOI 10.1128/JVI.67.1.577-583.1993; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; HORVATH CJ, 1993, J LEUKOCYTE BIOL, V53, P532, DOI 10.1002/jlb.53.5.532; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; LEWIS MG, 1994, AIDS RES HUM RETROV, V10, P213, DOI 10.1089/aid.1994.10.213; MILLS KHG, 1993, J MED PRIMATOL, V22, P104; PUTKONEN P, 1993, J MED PRIMATOL, V22, P100; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; STAHLHENNIG C, 1993, AIDS, V7, P787, DOI 10.1097/00002030-199306000-00005; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	26	96	98	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					32	36		10.1038/nm0197-32	http://dx.doi.org/10.1038/nm0197-32			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986737				2022-12-27	WOS:A1997WA73300033
J	Ashcroft, FM				Ashcroft, FM			Sweet news for hypoglycemic babies	NATURE MEDICINE			English	Editorial Material							SULFONYLUREA RECEPTOR; BETA-CELL				Ashcroft, FM (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; DUNNE MJ, 1993, FRONTIERS INSULIN SE, P153; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inoue H, 1996, DIABETES, V45, P825, DOI 10.2337/diabetes.45.6.825; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Lindley KJ, 1996, ARCH DIS CHILD, V74, P373, DOI 10.1136/adc.74.5.373; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; THOMAS PM, 1995, SCIENCE, V268, P425	10	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1301	1302		10.1038/nm1296-1301	http://dx.doi.org/10.1038/nm1296-1301			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946820				2022-12-27	WOS:A1996VW51500027
J	Friedman, A; Kaufer, D; Shemer, J; Hendler, I; Soreq, H; TurKaspa, I				Friedman, A; Kaufer, D; Shemer, J; Hendler, I; Soreq, H; TurKaspa, I			Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response	NATURE MEDICINE			English	Article							HUMAN ACETYLCHOLINESTERASE; CHOLINESTERASES; PERMEABILITY; CONSEQUENCES; EXPRESSION; ISCHEMIA; DRUGS; GENE	Pyridostigmine, a carbamate acetylcholinesterase (AChE) inhibitor, is routinely employed in the treatment of the autoimmune disease myasthenia gravis(1). Pyridostigmine is also recommended by most Western armies for use as pretreatment under threat of chemical warfare, because of its protective effect against organophospsphate poisoning(2,3). Because of this drug's quaternary ammonium group, which prevents its penetration through the blood-rain barrier, the symptoms associated with its routine use primarily reflect perturbations in peripheral nervous system functions(1,4). Unexpectedly, under a similar regimen, pyridostigmine administration during the Persian Gulf War resulted in a greater than threefold increase in the frequency of reported central nervous system symptoms(5). This increase was not due to enhanced absorption (or decreased elimination) of the drug, because the inhibition efficacy of serum butyrylcholinesterase was not modified(5). Because previous animal studies have shown stress-induced disruption of the blood-brain barrier(4), an alternative possibility was that the stress situation associated with war allowed pyridostigmine penetration into the brain. Here we report that after mice were subjected to a forced swim protocol (shown previously to simulate stress(7)), an increase in blood-brain barrier permeability reduced the pyridostigmine dose required to inhibit mouse brain AChE activity by 50% to less than 1/100th of the usual dose. Under these conditions, peripherally administered pyridostigmine increased the brain levels of c-fos oncogene and AChE mRNAs. Moreover, in vitro exposure to pyridostigmine increased both electrical excitability and c-fos mRNA levels in brain slices, demonstrating that the observed changes could be directly induced by pyridostigmine. These findings suggest that peripherally acting drugs administered under stress may reach the brain and affect centrally controlled functions.	ISRAEL DEF FORCES MED CORPS,JERUSALEM,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,CHAIM SHEBA MED CTR,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Friedman, A (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.			Soreq, Hermona/0000-0002-0955-526X				AGNOLI A, 1983, CLIN NEUROPHARMACOL, V6, P311, DOI 10.1097/00002826-198312000-00005; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; BENNATHAN D, 1991, LIFE SCI, V48, P1493, DOI 10.1016/0024-3205(91)90187-G; BLICK DW, 1994, TOXICOL APPL PHARM, V126, P311, DOI 10.1006/taap.1994.1121; BORLAND RG, 1985, HUM TOXICOL, V4, P293, DOI 10.1177/096032718500400310; BROWN DA, 1983, TRENDS NEUROSCI, V6, P302, DOI 10.1016/0166-2236(83)90144-3; BRUST P, 1991, EXP PATHOL-JENA, V42, P213, DOI 10.1016/S0232-1513(11)80068-X; DEYI X, 1981, FUNDAMENT APPL TOXIC, V1, P217; DIRUHUMBER P, 1979, J PHARM, V31, P295; EHRHARTBORNSTEI.M, 1991, J ENDOCRINOL, V131, P5; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; FRIEDMAN A, 1989, EUR J NEUROSCI, V1, P374, DOI 10.1111/j.1460-9568.1989.tb00802.x; GAVAGHAN H, 1994, NATURE, V369, P8, DOI 10.1038/369008a0; GLICKSON M, 1991, FUNDAM APPL TOXICOL, V16, P288; HARIK SI, 1991, ANN NY ACAD SCI, V640, P47; IWASAKI Y, 1988, ACTA NEUROL SCAND, V78, P236, DOI 10.1111/j.1600-0404.1988.tb03653.x; LOEWENSTEINLICHTENSTEIN Y, 1995, NAT MED, V1, P1082, DOI 10.1038/nm1095-1082; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MELIA KR, 1994, J NEUROSCI, V14, P5929; NEVILLE LF, 1990, J BIOL CHEM, V265, P20735; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; SCHWARZ M, 1995, PHARMACOL THERAPEUT, V67, P283, DOI 10.1016/0163-7258(95)00019-D; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; SHARMA HS, 1991, NEUROSCI RES, V10, P211; TAYLOR P, 1990, PHARMACOL BASIS THER, P122; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WHITTAKER M, 1986, MONOGR HUM GENET, P65	28	300	305	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1382	1385		10.1038/nm1296-1382	http://dx.doi.org/10.1038/nm1296-1382			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946841				2022-12-27	WOS:A1996VW51500048
J	Antel, JP; Becher, B; Owens, T				Antel, JP; Becher, B; Owens, T			Immunotherapy for multiple sclerosis: From theory to practice	NATURE MEDICINE			English	Editorial Material											Antel, JP (corresponding author), MCGILL UNIV,DEPT NEUROL & NEUROSURG,NEUROIMMUNOL UNIT,MONTREAL,PQ H3A 2B4,CANADA.		Becher, Burkhard/ABE-4225-2020	Becher, Burkhard/0000-0002-1541-7867; Owens, Trevor/0000-0001-9315-6036; antel, jack/0000-0002-5148-0636				Bell JI, 1996, NAT GENET, V13, P377, DOI 10.1038/ng0896-377; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; JERNE NK, 1984, IMMUNOL REV, V79, P5, DOI 10.1111/j.1600-065X.1984.tb00484.x; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; RUDICK R, IN PRESS ANN NEUROL; Talbot PJ, 1996, ANN NEUROL, V39, P233, DOI 10.1002/ana.410390213; Vandenbark AA, 1996, NAT MED, V2, P1109, DOI 10.1038/nm1096-1109; WINHAGEN A, 1996, J IMMUNOL, V157, P1127	11	13	14	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1074	1075		10.1038/nm1096-1074	http://dx.doi.org/10.1038/nm1096-1074			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837599				2022-12-27	WOS:A1996VK99500021
J	Ambs, S; Merriam, WG; Ogunfusika, MO; Bennett, WP; Ishibe, N; Hussain, SP; Tzeng, EE; Geller, DA; Billiar, TR; Harris, CC				Ambs, S; Merriam, WG; Ogunfusika, MO; Bennett, WP; Ishibe, N; Hussain, SP; Tzeng, EE; Geller, DA; Billiar, TR; Harris, CC			P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; INDUCED APOPTOSIS; SUPPRESSOR GENE; MESSENGER-RNA; IN-VITRO; EXPRESSION; ANGIOGENESIS; HEPATOCYTES; INHIBITION	The finding of frequent nitric oxide synthase expression in human cancers indicates that nitric oxide has a pathophysiological role in carcinogenesis. To determine the role of nitric oxide in tumor progression, we generated human carcinoma cell lines that produced nitric oxide constitutively. Cancer cells expressing inducible nitric oxide synthase that had wild-type p53 had reduced tumor growth in athymic nude mice, whereas those with mutated p53 had accelerated tumor growth associated with increased vascular endothelial growth factor expression and neovascularization. Our data indicate that tumor-associated nitric oxide production may promote cancer progression by providing a selective growth advantage to tumor cells with mutant p53, and that inhibitors of inducible nitric oxide synthase may have therapeutic activity in these tumors.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Hussain, S. Perwez/0000-0002-2294-522X; Ambs, Stefan/0000-0001-7651-9309				Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONG ZY, 1994, CANCER RES, V54, P789; Edwards P, 1996, J SURG RES, V63, P49, DOI 10.1006/jsre.1996.0221; Ellie E, 1995, NEUROREPORT, V7, P294, DOI 10.1097/00001756-199512290-00070; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geng YJ, 1996, CANCER RES, V56, P866; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nicotera P, 1995, ADV NEUROIMMUNOL, V5, P411, DOI 10.1016/0960-5428(95)00025-9; PIAZZA GA, 1995, CANCER RES, V55, P3110; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAK J, 1995, CANCER RES, V55, P4575; Thomsen LL, 1997, CANCER RES, V57, P3300; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vermeulen PB, 1996, MICROVASC RES, V51, P164, DOI 10.1006/mvre.1996.0018; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	33	254	277	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1371	1376		10.1038/3957	http://dx.doi.org/10.1038/3957			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846573				2022-12-27	WOS:000077336900031
J	Friesen, HG				Friesen, HG			The Medical Research Council of Canada: Integrating research to Canada's health care system	NATURE MEDICINE			English	Editorial Material									Med Res Council Canada, Ottawa, ON K1A 0W9, Canada		Friesen, HG (corresponding author), Med Res Council Canada, Holland Cross,Tower B,5th Floor,1600 Scott St, Ottawa, ON K1A 0W9, Canada.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1353	1355		10.1038/3936	http://dx.doi.org/10.1038/3936			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846564				2022-12-27	WOS:000077336900021
J	Pratico, D; Tangirala, RK; Rader, DJ; Rokach, J; FitzGerald, GA				Pratico, D; Tangirala, RK; Rader, DJ; Rokach, J; FitzGerald, GA			Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice	NATURE MEDICINE			English	Article							APOLIPOPROTEIN-E; OXIDATIVE MODIFICATION; MEMORIAL-LECTURE; HYPERCHOLESTEROLEMIA; LESIONS; ATHEROGENESIS; LDL	Oxidative modification of low density lipoprotein (LDL) has been implicated in atherogenesis'. Evidence consistent with this hypothesis includes the presence of oxidized lipids in atherosclerotic lesions(2,3), the newly discovered biological properties conferred on LDL by oxidation(1,4) and the acceleration of atherogenesis by in vivo delivery of the gene for 15-lipoxygenase(5), an oxidizing enzyme present in atherosclerotic lesions(6). However, it is still unknown whether oxidative stress actually coincides with the evolution of the disease or whether it is of functional relevance to atherogenesis in vivo. Isoprostanes are products of arachidonic acid catalyzed by free radicals, which reflect oxidative stress and lipid peroxidation in vivo(7). Elevation of tissue and urinary isoprostanes is characteristic of human atherosclerosis(8,9). Here, deficiency in apolipoprotein E in the mouse (apoE(-/-)) resulted in atherogenesis and an increase in iPF2(alpha)-VI, an F-2-isoprostane(10), in urine, plasma and vascular tissue. Supplementation with vitamin E significantly reduced isoprostane generation, but had no effect on plasma cholesterol levels in apoE(-/-) mice. Aortic lesion areas and IPF2(alpha)-VI levels in the arterial wall were also reduced significantly by vitamin E. Our results indicate that oxidative stress is increased in the apoE(-/-) mouse, is of functional importance in the evolution of atherosclerosis and can be suppressed by oral administration of vitamin E.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NHLBI NIH HHS [HL5400, HL,AG55323] Funding Source: Medline; NIDDK NIH HHS [DK-44730] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bird DA, 1998, J LIPID RES, V39, P1079; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; FREUBIS J, 1995, ATHEROSCLEROSIS, V117, P617; Fruebis J, 1997, J LIPID RES, V38, P2455; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAYEK T, 1991, ARTERIOSCLER THROMB, V11, P1295, DOI 10.1161/01.ATV.11.5.1295; KUHN H, 1994, J EXP MED, V179, P1911; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1998, J INVEST MED, V46, P51; PRATICO D, 1997, AGENTS ACTIONS, V48, P26; PRATICO D, 1997, J CLIN INVEST, V100, P2027; REILLY MP, IN PRESS CIRCULATION; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; SANTARELLI E, 1994, SMALL BUS ECON, V6, P95, DOI 10.1007/BF01065182; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; Steinberg D, 1997, CIRCULATION, V95, P1062; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	27	443	453	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1189	1192		10.1038/2685	http://dx.doi.org/10.1038/2685			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771755				2022-12-27	WOS:000076230100041
J	Mummidi, S; Ahuja, SS; Gonzalez, E; Anderson, SA; Santiago, EN; Stephan, KT; Craig, FE; O'Connell, P; Tryon, V; Clark, RA; Dolan, MJ; Ahuja, SK				Mummidi, S; Ahuja, SS; Gonzalez, E; Anderson, SA; Santiago, EN; Stephan, KT; Craig, FE; O'Connell, P; Tryon, V; Clark, RA; Dolan, MJ; Ahuja, SK			Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression	NATURE MEDICINE			English	Article							INFECTION; RECEPTOR; ENTRY; LESTR/FUSIN; INDIVIDUALS; RESISTANCE; COFACTOR; LIGAND; ALLELE; SDF-1	Allelic variants for the HIV-1 co-receptors chemokine receptor 5 (CCR5) and CCR2, as well as the ligand for the co-receptor CXCR4 stromal-derived factor (SDF-1), have been associated with a delay in disease progression. We began this study to test whether polymorphisms in the CCR5 regulatory regions influence the course of HIV-1 disease, as well as to examine the role of the previously identified allelic variants in 1,090 HIV-1 infected individuals. Here we describe the evolutionary relationships between the phenotypically important CCR5 alleles, define precisely the CCR5 regulatory sequences that are linked to the CCR5-Delta 32 and CCR2-64i polymorphisms, and identify genotypes associated with altered rates of HIV-1 disease progression. The disease-retarding effects of the CCR2-641 allele were found in African Americans but not in Caucasians, and the SDF1-3'A/3'A genotype was associated with an accelerated progression to death. In contrast, the CCR5-Delta 32 allele and a CCR5 promoter mutation with which it is tightly linked were associated with limited disease-retarding effects. Collectively, these findings draw attention to a complex array of genetic determinants in the HIV-host interplay.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA; Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA; Wilford Hall USAF Med Ctr, Dept Med, Infect Dis Serv, Lackland AFB, TX 78236 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA.		Clark, Robert/Q-6764-2019; Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Clark, Robert/0000-0002-4892-3619; Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Garred P, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)22001-0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; Katzenstein TL, 1997, J ACQ IMMUN DEF SYND, V16, P10, DOI 10.1097/00042560-199709010-00002; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Meyer L, 1997, AIDS, V11, pF73, DOI 10.1097/00002030-199711000-00001; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morawetz RA, 1997, EUR J IMMUNOL, V27, P3223, DOI 10.1002/eji.1830271220; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Rizzardi GP, 1998, NAT MED, V4, P252, DOI 10.1038/nm0398-252; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; Weatherall D, 1997, GENOME RES, V7, P967, DOI 10.1101/gr.7.10.967; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	34	285	300	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					786	793		10.1038/nm0798-786	http://dx.doi.org/10.1038/nm0798-786			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662369				2022-12-27	WOS:000074543900032
J	Saldarini, RJ				Saldarini, RJ			For vaccines, the future is now	NATURE MEDICINE			English	Editorial Material									Wyeth Lederle Vaccines & Pediat, Radnor, PA 19087 USA	Pfizer	Saldarini, RJ (corresponding author), Wyeth Lederle Vaccines & Pediat, 280 King Prussia Rd, Radnor, PA 19087 USA.								0	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			485	487		10.1038/nm0598supp-485	http://dx.doi.org/10.1038/nm0598supp-485			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585191	Bronze			2022-12-27	WOS:000073453500009
J	George, JF; Sweeney, SD; Kirklin, JK; Simpson, EM; Goldstein, DR; Thomas, JM				George, JF; Sweeney, SD; Kirklin, JK; Simpson, EM; Goldstein, DR; Thomas, JM			An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow	NATURE MEDICINE			English	Article							ALLOGRAFT TOLERANCE; CHIMERISM; MICE; CELL; MECHANISM; CD8	Medawar and co-workers originally demonstrated that injection of donor bone marrow (DBM) into immune-incompetent neonatal rodents could induce tolerance to grafts from animals of the same strain as the bone marrow donor(1). Induction of tolerance in this manner can also be accomplished in mature mice, dogs and monkeys if the resident T-cell populations in the recipient are depleted by a polyclonal antithymocyte globulin or an anti-T cell immunotoxin(2-4.) The molecular mechanisms by which bone marrow cells mediate the induction of tolerance remain uncertain. Here we examined a well-established adult mouse model of antithymocyte globulin and DBM treatment and show that expression of functional pas ligand (Fast, also CD95L) an the injected bone marrow cells is required for tolerance induction. The results indicate that a state of microchimerism per se is insufficient for the induction of tolerance in T cell-depleted transplant recipients. Moreover, the results are consistent with the hypothesis that tolerance induced by DBM involves an apoptotic process leading to deletion of graft-reactive cells.	Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Jackson Laboratory	George, JF (corresponding author), Univ Alabama, Dept Surg, Room 739 ZRB, Birmingham, AL 35294 USA.		Simpson, Elizabeth/H-1183-2012	Simpson, Elizabeth/0000-0002-0654-4303; Goldstein, Daniel/0000-0001-6695-979X				Bergstrom DE, 1997, MAMM GENOME, V8, P510, DOI 10.1007/s003359900486; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; GOZZO J J, 1970, Surgical Forum (Chicago), V21, P281; HARTNER WC, 1987, TRANSPLANT P, V19, P476; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAUFMAN CL, 1994, BLOOD, V84, P2436; LUBAROFF DM, 1973, J IMMUNOL, V111, P65; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; MONACO AP, 1995, CHIMERISM TOLERANCE, P99; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; SAYEGH MH, 1995, J AM SOC NEPHROL, V6, P1143; SHARABI Y, 1992, BONE MARROW TRANSPL, V9, P191; SMITH JP, 1994, TRANSPLANTATION, V58, P324, DOI 10.1097/00007890-199408000-00013; Starzl TE, 1996, IMMUNOL TODAY, V17, P588; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; THOMAS JM, 1983, TRANSPLANTATION, V36, P104; THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018; VERBANAC KKM, 1994, TRANSPLANTATION, V57, P893, DOI 10.1097/00007890-199403270-00022; WOOD KJ, 1995, CHIMERISM TOLERANCE, P15; ZHANG L, 1995, J IMMUNOL, V155, P3464	21	85	87	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					333	335		10.1038/nm0398-333	http://dx.doi.org/10.1038/nm0398-333			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500608				2022-12-27	WOS:000073616200040
J	Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ				Ashcroft, GS; Dodsworth, J; vanBoxtel, E; Tarnuzzer, RW; Horan, MA; Schultz, GS; Ferguson, MWJ			Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RAT BONE; CELLS; EXPRESSION; SKIN; QUANTITATION; FIBROBLASTS; CYTOKINES; HORMONE	The cellular and molecular mechanisms underlying the effects of aging on human cutaneous wound healing are poorly understood, and the possible role of reproductive hormones in this process has never been investigated. We report that aging in healthy females was associated with a reduced rate of cutaneous wound healing, but an improved quality of scarring both microscopically and macroscopically, and with reduced levels of transforming growth factor-beta 1 (TCF-beta 1) immunostaining and steady-state mRNA in the wound. These age-related changes were reversed by the systemic administration of hormone replacement therapy (HRT). Moreover, ovariectomized young female rodents exhibited a marked delay in repair of acute incisional wounds, which was reversed by the topical application of estrogen. The cellular mechanism underlying these changes appears to Involve an estrogen-induced increase in latent TCF-beta 1 secretion by dermal fibroblasts. These results suggest that both the rate and quality of wound healing depend on reproductive hormone levels.	UNIV MANCHESTER, SCH BIOL SCI, CELLS IMMUNOL & DEV DIV, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV S MANCHESTER HOSP, DEPT GERIATR MED, MANCHESTER M20 2LR, LANCS, ENGLAND; UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32610 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; State University System of Florida; University of Florida				Tarnuzzer, Roy/0000-0002-3725-4173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashcroft GS, 1997, J INVEST DERMATOL, V108, P430, DOI 10.1111/1523-1747.ep12289705; ASHCROFT GS, 1995, J ANAT, V187, P1; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; FrazierJessen MR, 1996, J IMMUNOL, V156, P3036; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MALET C, 1991, J CLIN ENDOCR METAB, V73, P8, DOI 10.1210/jcem-73-1-8; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; OVERALL CM, 1995, J CELL PHYSIOL, V164, P17, DOI 10.1002/jcp.1041640104; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PIERARD GE, 1995, J AM GERIATR SOC, V43, P662, DOI 10.1111/j.1532-5415.1995.tb07202.x; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; SCHMIDT JB, 1994, MATURITAS, V20, P25, DOI 10.1016/0378-5122(94)90097-3; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tarnuzzer RW, 1996, BIOTECHNIQUES, V20, P670; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075	22	407	423	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1209	1215		10.1038/nm1197-1209	http://dx.doi.org/10.1038/nm1197-1209			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359694				2022-12-27	WOS:A1997YD89600028
J	Scarlatti, G; Tresoldi, E; Bjorndal, A; Fredriksson, R; Colognesi, C; Deng, HK; Malnati, MS; Plebani, A; Siccardi, AG; Littman, DR; Fenyo, EM; Lusso, P				Scarlatti, G; Tresoldi, E; Bjorndal, A; Fredriksson, R; Colognesi, C; Deng, HK; Malnati, MS; Plebani, A; Siccardi, AG; Littman, DR; Fenyo, EM; Lusso, P			In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; V3 DOMAIN; INFECTION; TYPE-1; CELLS; CHILDREN; ENTRY; REQUIREMENTS; MIP-1-ALPHA	Following the identification of the C-C chemokines RANTES, MIP-1 alpha and MIP-1 beta as major human immunodeficiency virus (HIV)-suppressive factors produced by CD8(+) T cells(1), several chemokine receptors were found to serve as membrane co-receptors for primate immunodeficiency lentiretroviruses(2-8). The two most widely used co-receptors thus far recognized, CCR5 and CXCR4 are expressed by both activated T lymphocytes and mononuclear phagocytes. CCR5, a specific RANTES, MIP-1 alpha and MIP-1 beta receptor, is used preferentially by non-MT2-tropic HIV-1 and HIV-2 strains(3-7,9,10) and by simian immunodeficiency virus (SIV)(11), whereas CXCR4, a receptor for the C-X-C chemokine SDF-1 (ref. 12, 13), is used by MT2-tropic HIV-1 and HIV-2, but not by SIV (ref. 2-7, 9-11, 14). Other receptors with a more restricted cellular distribution, such as CCR2b, CCR3 and STRL33, can also function as co-receptors for selected viral isolates(4,6,8). The third variable region (V3) of the gp120 envelope glycoprotein of HIV-1 has been fingered as a critical determinant of the co-receptor choice(4,15). Here, we document a consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection. Viral isolates obtained during the asymptomatic stages generally used only CCR5 as a co-receptor and were inhibited by RANTES, MIP-1 alpha and MIP-1 beta, but not by SDF-1. By contrast, the majority of the isolates derived after the progression of the disease were resistant to C-C chemokines, having acquired the ability to use CXCR4 and, in some cases, CCR3, while gradually losing CCR5 usage. Surprisingly, most of these isolates were also insensitive to SDF-1, even when used in combination with RANTES. An early acquisition of CXCR4 usage predicted a poor prognosis. In children who progressed to AIDS without a shift to CXCR4 usage, all the sequential isolates were CCR5-dependent but showed a reduced sensitivity to C-C chemokines. Discrete changes in the V3 domain of gp120 were associated with the loss of sensitivity to C-C chemokines and the shift in co-receptor usage. These results suggest an adaptive evolution of HIV-1 in vivo, leading to escape from the control of the antiviral C-C chemokines.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; SAN RAFFAELE SCI INST,DIBIT,UNIT HUMAN VIROL,I-20132 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,UNIT IMMUNOBIOL HIV,I-20132 MILAN,ITALY; NYU,SKIRBALL INST BIOMOL MED,HOWARD HUGHES MED INST,NEW YORK,NY; UNIV MILAN,CLIN PEDIAT 1,I-20128 MILAN,ITALY	Karolinska Institutet; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Howard Hughes Medical Institute; New York University; University of Milan			Malnati, Mauro/AAN-4207-2020; scarlatti, gabriella/H-1482-2018; Plebani, Alessandro/C-8593-2011	scarlatti, gabriella/0000-0003-2316-2689; Malnati, mauro/0000-0001-5355-1680				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; ASJO B, 1986, LANCET, V2, P660; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; Heredia A, 1997, AIDS, V11, P1198, DOI 10.1097/00002030-199709000-00025; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Martin N, 1996, AIDS RES HUM RETROV, V12, P1565, DOI 10.1089/aid.1996.12.1565; MORIUCHI M, 1996, P NATL ACAD SCI USA, V93, P15341; MYERS G, 1995, HUMAN RETROVIRUSES A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	34	530	549	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1259	1265		10.1038/nm1197-1259	http://dx.doi.org/10.1038/nm1197-1259			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359702				2022-12-27	WOS:A1997YD89600036
J	Duncan, G; Wormstone, IM; Liu, CSC; Marcantonio, JM; Davies, PD				Duncan, G; Wormstone, IM; Liu, CSC; Marcantonio, JM; Davies, PD			Thapsigargin-coated intraocular lenses inhibit human lens cell growth	NATURE MEDICINE			English	Article							POSTERIOR CAPSULE OPACIFICATION; SURVIVAL	Cataract is responsible for rendering several million people blind throughout the world(1) and is also by far the most common cause of row visual acuity. Although cataract surgery is common, routine and effective, posterior capsule opacification (PCO) occurs in 30-50% of patients following modern cataract surgery. This condition arises from stimulated cell growth within the capsular bag after surgery(2). The resulting decline in visual acuity requires expensive laser treatment(2), and PCO therefore prevents modern cataract surgery from being carried out routinely in underdeveloped countries. The present study, using a human lens capsular bag culture system(3), has confirmed that cells from a wide age range of donors proliferate in the absence of added serum protein(4) and explains why PCO is such a common problem even in aged patients. This study also provides one possible solution for PCO by using polymethylmethacrylate (PMMA) implanted intraocular lenses as a drug delivery system. PMMA lenses coated with thapsigargin, a hydrophobic inhibitor of endoplasmic reticulum (ER) (Ca2+)-ATPase(5), greatly reduced cell growth in the capsular bag at relatively low coating concentrations (200 nM) but, more significantly, induced total cell death of the residual anterior epithelial cells at higher concentrations (> 2 mu M).	W NORWICH HOSP,NORWICH NR2 3TU,NORFOLK,ENGLAND		Duncan, G (corresponding author), UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND.		Wormstone, Michael/D-1861-2009	Wormstone, Michael/0000-0002-6423-7766				APPLE DJ, 1992, SURV OPHTHALMOL, V37, P73, DOI 10.1016/0039-6257(92)90073-3; BEHARCOHEN FF, 1995, INVEST OPHTH VIS SCI, V36, P2434; COLE DF, 1974, EYE, P71; Duncan G, 1996, CELL CALCIUM, V19, P83, DOI 10.1016/S0143-4160(96)90015-9; Emery J., 1996, Investigative Ophthalmology and Visual Science, V37, pS758; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; IBARAKI N, 1995, AM J OPHTHALMOL, V119, P706, DOI 10.1016/S0002-9394(14)72774-6; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; Liu CSC, 1996, INVEST OPHTH VIS SCI, V37, P906; POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2544; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; Wormstone IM, 1997, INVEST OPHTH VIS SCI, V38, P396	14	101	107	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1026	1028		10.1038/nm0997-1026	http://dx.doi.org/10.1038/nm0997-1026			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288732				2022-12-27	WOS:A1997XT84200038
J	Morishita, R; Sugimoto, T; Aoki, M; Kida, I; Tomita, N; Moriguchi, A; Maeda, K; Sawa, Y; Kaneda, Y; Higaki, J; Ogihara, T				Morishita, R; Sugimoto, T; Aoki, M; Kida, I; Tomita, N; Moriguchi, A; Maeda, K; Sawa, Y; Kaneda, Y; Higaki, J; Ogihara, T			In vivo transfection of cis element ''decoy'' against nuclear factor-kappa B binding site prevents myocardial infarction	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; ISCHEMIA-REPERFUSION INJURY; TRANSCRIPTION FACTOR; SMOOTH-MUSCLE; IN-VIVO; GENE-EXPRESSION; POTENTIAL ROLE; MESSENGER-RNA; RAT-HEART; CELLS	The transcriptional factor nuclear factor-kappa B (NF kappa B) plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes that might be Involved in myocardial damage after ischemia and reperfusion. Therefore, we hypothesized that synthetic double-stranded DNA with high affinity for NF kappa B could be introduced in vivo as ''decoy'' cls elements to bind the transcriptional factor and to block the activation of genes mediating myocardial infarction, thus providing effective therapy for myocardial infarction. Treatment before and after infarction by transfection of NF kappa B decoy, but not scrambled decoy, oligodeoxynucleotides before coronary artery occlusion or immediately after reperfusion had a significant inhibitory effect on the area of infarction. Here, we report the first successful in vivo transfer of NF kappa B decoy oligodeoxynucleotides to reduce the extent of myocardial infarction following reperfusion, providing a new therapeutic strategy for myocardial infarction.	OSAKA UNIV,SCH MED,DEPT GERIATR MED,SUITA,OSAKA 565,JAPAN; FUJISAWA PHARMACEUT CO LTD,OSAKA 532,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Astellas Pharmaceuticals; Osaka University; Osaka University								BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BILLUPS KL, 1995, J LAB CLIN MED, V125, P626; BRENNAN DC, 1990, KIDNEY INT, V38, P1039, DOI 10.1038/ki.1990.310; COTRAN RS, 1989, PATHOLOGIC BASIS DIS, P611; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; MORISHITA R, 1994, J CLIN INVEST, V94, P824, DOI 10.1172/JCI117402; MORITA M, 1993, AM J PATHOL, V143, P419; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NEWTON RC, 1993, J IMMUNOL METHODS, V161, P257, DOI 10.1016/0022-1759(93)90301-M; OZ MC, 1995, CIRCULATION, V92, P428, DOI 10.1161/01.CIR.92.9.428; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; SAWA Y, 1995, CIRCULATION, V92, P479, DOI 10.1161/01.CIR.92.9.479; SAWA Y, 1994, ANN THORAC SURG, V58, P1386, DOI 10.1016/0003-4975(94)91919-4; SOBEL BE, 1972, CIRCULATION, V46, P640, DOI 10.1161/01.CIR.46.4.640; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; THOMAE KR, 1993, SURGERY, V114, P272; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; WILSON I, 1993, CIRCULATION, V88, P372; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; YAMAZAKI T, 1993, AM J PATHOL, V143, P410; YOUKER KA, 1994, CIRCULATION, V89, P2736, DOI 10.1161/01.CIR.89.6.2736	27	549	597	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					894	899		10.1038/nm0897-894	http://dx.doi.org/10.1038/nm0897-894			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256281				2022-12-27	WOS:A1997XP01400032
J	LowBeer, D; Stoneburner, RL; Mukulu, A				LowBeer, D; Stoneburner, RL; Mukulu, A			Empirical evidence for the severe but localized impact of AIDS on population structure	NATURE MEDICINE			English	Article							DEMOGRAPHIC-IMPACT; INFECTION; UGANDA; COHORT; HIV-1; MORTALITY; DYNAMICS; EPIDEMIC; DISTRICT; SPREAD	Despite considerable speculation on the demographic impact of AIDS, there has been, until now, little scientific evidence to establish its existence or scale. Because of the widespread implications of these predictions, methods to combine demography and epidemiology to study empirical situations have been an urgent priority. This study derives the extent and mechanisms of demographic impacts of AIDS from routine data (the 1991 census) in a severely affected country, Uganda. Three characteristics are of particular note: first, the emergence of demographic impacts much earlier than previously estimated; second, their localization with negative population growth at parish but not at district or national scales; third, a greater impact on the number of children than previously predicted(1,2), due as much to changes in population fertility as mortality. The emergence of demographic impacts at this stage highlights original aspects of the interdependence of HIV infection and demographic growth not previously recorded and the need to target preventive interventions to youth in developing countries.	WHO,GLOBAL PROGRAMME AIDS,SURVEILLANCE EVALUAT & FORECASTING UNIT,CH-1211 GENEVA 27,SWITZERLAND; INT CTR MIGRAT & HLTH,CH-1214 GENEVA,SWITZERLAND; MINIST FINANCE & ECON PLANNING,DEPT STAT,ENTEBBE,UGANDA	World Health Organization	LowBeer, D (corresponding author), UNIV CAMBRIDGE,DEPT GEOG,DOWNING PL,CAMBRIDGE CB2 3EN,ENGLAND.							ANDERSON RM, 1988, NATURE, V332, P228, DOI 10.1038/332228a0; ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BARNETT T, 1992, AIDS AFRICA; CHIN J, 1991, B WORLD HEALTH ORGAN, V69, P399; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; Demeny Coale AJ., 1966, REGIONAL MODEL LIFE; GIBB D, 1994, AIDS S1, V8, pS275; HUNTER SS, 1990, SOC SCI MED, V31, P681, DOI 10.1016/0277-9536(90)90250-V; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; MAY RM, 1985, MATH BIOSCI, V77, P141, DOI 10.1016/0025-5564(85)90093-8; Mertens TE, 1996, B WORLD HEALTH ORGAN, V74, P121; *MIN FIN EC PLANN, 1995, REP UG 1991 POP HOUS; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; OBBO C, 1993, SOC SCI MED, V36, P949, DOI 10.1016/0277-9536(93)90086-J; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; Stoneburner RL, 1996, AM J EPIDEMIOL, V144, P682, DOI 10.1093/oxfordjournals.aje.a008981; STONEBURNER RL, 1993, AM J EPIDEMIOL, V138, P1093, DOI 10.1093/oxfordjournals.aje.a116827; *SYST INC, 1982, SYST 5 01 WIND; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; *WHO, 1991, AIDS EP ITS DEM CONS	21	16	16	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					553	557		10.1038/nm0597-553	http://dx.doi.org/10.1038/nm0597-553			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142126				2022-12-27	WOS:A1997WX54300037
J	Telenti, A; Philipp, WJ; Sreevatsan, S; Bernasconi, C; Stockbauer, KE; Wieles, B; Musser, JM; Jacobs, WR				Telenti, A; Philipp, WJ; Sreevatsan, S; Bernasconi, C; Stockbauer, KE; Wieles, B; Musser, JM; Jacobs, WR			The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol	NATURE MEDICINE			English	Article							STREPTOMYCIN RESISTANCE; RIFAMPICIN-RESISTANCE; SMEGMATIS; MUTATIONS; ARABINOGALACTAN; POLYMERASE	Ethambutol (EMB), a frontline antituberculous drug, targets the mycobacterial cell wall, a unique structure among prokaryotes which consists of an outer layer of mycolic acids covalently bound to peptidoglycan via the arabinogalactan. EMB inhibits the polymerization of cell wall arabinan, and results in the accumulation of the lipid carrier decaprenol phosphoarabinose(1,2), which suggests that the drug interferes with the transfer of arabinose to the cell wall acceptor. Unfortunately, resistance to EMB has been described in up to 4% of clinical isolates of Mycobacterium tuberculosis and is prevalent among isolates from patients with multidrug-resistant tuberculosis(3). We used resistance to EMB as a tool to identify genes participating in the biosynthesis of the mycobacterial cell wall. This approach led to the identification of the embCAB gene cluster, recently proposed to encode for mycobacterial arabinosyl transferases(4). Resistance to EMB results from an accumulation of genetic events determining overexpression of the Emb protein(s), structural mutation in EmbB, or both. Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED RES INST,BRONX,NY 10461; BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine	Telenti, A (corresponding author), UNIV BERN,INST MED MICROBIOL,CH-3010 BERN,SWITZERLAND.		Sreevatsan, Srinand/V-6808-2019	Sreevatsan, Srinand/0000-0002-5162-2403; Wieles, Brigitte/0000-0001-9631-3404; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037015, R01AI037004] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-37015, AI-37004] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi_17050889.x; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; GANGADHARAM PR, 1970, AM REV RESPIR DIS, V102, P653; HEIFETS LB, 1986, ANTIMICROB AGENTS CH, V30, P927, DOI 10.1128/AAC.30.6.927; HONORE N, 1994, ANTIMICROB AGENTS CH, V38, P238, DOI 10.1128/AAC.38.2.238; Kocagoz T, 1996, ANTIMICROB AGENTS CH, V40, P1768, DOI 10.1128/AAC.40.8.1768; LAZLO A, IN PRESS INT J TUBER; LEVIN ME, 1993, MOL MICROBIOL, V8, P277, DOI 10.1111/j.1365-2958.1993.tb01572.x; Maddry JA, 1996, RES MICROBIOL, V147, P106, DOI 10.1016/0923-2508(96)80211-7; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Takiff HE, 1996, P NATL ACAD SCI USA, V93, P362, DOI 10.1073/pnas.93.1.362; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; Telenti A, 1996, RES MICROBIOL, V147, P73, DOI 10.1016/0923-2508(96)80207-5; TELENTI A, 1997, CLIN CHEST MED, V18; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; ZHANG Y, 1992, NATURE, V358, P501	30	351	391	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					567	570		10.1038/nm0597-567	http://dx.doi.org/10.1038/nm0597-567			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142129				2022-12-27	WOS:A1997WX54300040
J	Rice, WG; Turpin, JA; Huang, MJ; Clanton, D; Buckheit, RW; Covell, DG; Wallqvist, A; McDonnell, NB; DeGuzman, RN; Summers, MF; Zalkow, L; Bader, JP; Haugwitz, RD; Sausville, EA				Rice, WG; Turpin, JA; Huang, MJ; Clanton, D; Buckheit, RW; Covell, DG; Wallqvist, A; McDonnell, NB; DeGuzman, RN; Summers, MF; Zalkow, L; Bader, JP; Haugwitz, RD; Sausville, EA			Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACID-BINDING-PROTEINS; REVERSE TRANSCRIPTION; STRAND TRANSFER; ZINC FINGERS; INFECTIVITY; DNA; RNA	Nucleocapsid p7 (NCp7) proteins of human immunodeficiency virus type 1 (HIV-1) contain two zinc binding domains of the sequence Cys-(X)(2)-Cys-(X)(4)-His-(X)(4)-Cys (CCHC)(1,2). The spacing pattern and metal-chelating residues (3 Cys, 1 His) of these nucleocapsid CCHC zinc fingers are highly conserved among retroviruses(1,3,4). These CCHC domains are required during both the early(5,6) and late(7,8) phases of retroviral replication, making them attractive targets for antiviral agents. Toward that end, we have identified a number of antiviral chemotypes that electrophilically attack the sulfur atoms of the zinc-coordinating cysteine residues of the domains(9-14). Such nucleocapsid inhibitors were directly virucidal by preventing the initiation of reverse transcription(15) and blocked formation of infectious virus from cells through modification of CCHC domains within Gag precursors(16). Herein we report that azodicarbonamide (ADA) represents a new compound that inhibits HIV-1 and a broad range of retroviruses by targeting the the nucleocapsid CCHC domains. Vandevelde et al.(17) also recently disclosed that ADA inhibits HIV-1 infection via an unidentified mechanism and that ADA was introduced into Phase I/II clinical trials in Europe for advanced AIDS. These studies distinguish ADA as the first known nucleocapsid inhibitor to progress to human trials and provide a lead compound for drug optimization.	NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,ANTI AIDS VIRUS DRUG SCREENING LAB,FREDERICK,MD 21702; FREDERICK RES CTR,SO RES INST,VIROL RES GRP,FREDERICK,MD 21701; SAIC FREDERICK,NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,FREDERICK,MD 21702; UNIV MARYLAND BALTIMORE CTY,HOWARD HUGHES MED INST,BALTIMORE,MD 21228; UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228; GEORGIA INST TECHNOL,DEPT CHEM,ATLANTA,GA 30332; NCI,DEV THERAPEUT PROGRAM,DIV CANC TREATMENT,DIAG & CTR,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County; University System of Georgia; Georgia Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rice, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,LAB ANTIVIRAL DURG MECHANISMS,FREDERICK,MD 21702, USA.		wallqvist, anders/W-2584-2019	wallqvist, anders/0000-0002-9775-7469	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; Gorelick RJ, 1996, J VIROL, V70, P2593, DOI 10.1128/JVI.70.4.2593-2597.1996; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; Rice WG, 1996, J MED CHEM, V39, P3606, DOI 10.1021/jm960375o; Rice WG, 1997, ANTIMICROB AGENTS CH, V41, P419, DOI 10.1128/AAC.41.2.419; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; South T L, 1990, Adv Inorg Biochem, V8, P199; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; Turpin JA, 1996, J VIROL, V70, P6180, DOI 10.1128/JVI.70.9.6180-6189.1996; Turpin JA, 1997, ANTIVIR CHEM CHEMOTH, V8, P60, DOI 10.1177/095632029700800107; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567; Wallqvist A, 1996, PROTEINS, V25, P403, DOI 10.1002/(SICI)1097-0134(199608)25:4<403::AID-PROT1>3.0.CO;2-E; YOU JC, 1994, J BIOL CHEM, V269, P31491	20	100	110	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					341	345		10.1038/nm0397-341	http://dx.doi.org/10.1038/nm0397-341			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055865	Green Published			2022-12-27	WOS:A1997WL30500039
J	Tishon, A; Manchester, M; Scheiflinger, F; Oldstone, MBA				Tishon, A; Manchester, M; Scheiflinger, F; Oldstone, MBA			A model of measles virus-induced immunosuppression: Enhanced susceptibility of neonatal human PBLs	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD LEUKOCYTES; SCID MICE; ANTIBODY-PRODUCTION; DISRUPT FUNCTIONS; HUMAN-LYMPHOCYTES; CELL-CYCLE; INFECTION; MOUSE; SUPPRESSION	Measles virus (MV) still incites one of the most contagious infections of humankind. Despite the development and use of an excellent live attenuated virus vaccine, over one million infants and children continue to die each year from measles(1-3). The main cause of morbidity and mortality is virus-induced immunosuppression of lymphocyte function, which allows secondary infections. Here we report an in vivo model for the study of MV-induced immunosuppression. Human peripheral blood leukocytes (PBLs) grafted onto mice with severe combined immunodeficiency disease (SCID mice) to create hu-PBLS-SCID mice produce human IgG that is suppressed by MV infection. Immunosuppression is dependent on the involvement of live virus and is dramatically more severe for PBLs obtained from newborns than PBLs from adults. Suppression of IgG synthesis by PBLs from newborns occurs as early as ten days after administration of MV to hu-PBLS-SCID mice compared with 44 days required for PBLs from adults. Further, MV infection of SCID mice reconstituted with PBLs from newborns reduces IgG production 26+/-5-fold (mean+/-1 s.e.m.) as compared with only a 6+/-0.5-fold reduction in adults. MV RNA could be detected in live human PBLs recovered from SCID mice as long as 110 days after MV infection began. The profound immunosuppression we observe in PBLs from infants probably contributes to the morbidity and mortality observed in infants vaccinated with measles virus. Further, this model should be useful for accessing the potential immunosuppressive abilities of newly isolated field (wildtype) virus isolates and newly designed vaccines containing attenuated MV or subunit vaccines, as well as in dissecting the role played by maternal antibodies to MV on the ability of the virus to enhance or abort the virus-induced immunosuppression.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Manchester, Marianne/0000-0002-7143-5744	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019185] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BLACK FL, 1989, PROG MED VIROL, V36, P1; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CASALI P, 1984, J EXP MED, V159, P1322, DOI 10.1084/jem.159.5.1322; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; DUCHOSAL MA, 1992, CELL IMMUNOL, V139, P468, DOI 10.1016/0008-8749(92)90086-5; GELLIN BG, 1994, J INFECT DIS, V170, pS1, DOI 10.1093/infdis/170.Supplement_1.S1; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MARKOWITZ LE, 1987, PEDIATR INFECT DIS J, V6, P809, DOI 10.1097/00006454-198709000-00001; Markowitz LE, 1994, VACCINES, P229; MCCHESNEY MB, 1989, J INFECT DIS, V159, P757, DOI 10.1093/infdis/159.4.757; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MCCHESNEY MB, 1987, J VIROL, V61, P3441, DOI 10.1128/JVI.61.11.3441-3447.1987; MCCHESNEY MB, 1988, J IMMUNOL, V140, P1269; MCCHESNEY MB, 1986, J EXP MED, V163, P1331; MEIZLIK EH, 1948, AM J DIS CHILD, V76, P83, DOI 10.1001/archpedi.1948.02030030090010; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; MOSIER DE, 1993, P NATL ACAD SCI USA, V90, P2443, DOI 10.1073/pnas.90.6.2443; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; TYOR WR, 1993, P NATL ACAD SCI USA, V90, P8658, DOI 10.1073/pnas.90.18.8658; UEKI Y, 1990, J EXP MED, V171, P19, DOI 10.1084/jem.171.1.19; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297; YANAGI Y, 1992, VIROLOGY, V187, P280, DOI 10.1016/0042-6822(92)90316-H	33	24	24	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1250	1254		10.1038/nm1196-1250	http://dx.doi.org/10.1038/nm1196-1250			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898755				2022-12-27	WOS:A1996VQ10100043
J	Lemere, CA; Lopera, F; Kosik, KS; Lendon, CL; Ossa, J; Saido, TC; Yamaguchi, H; Ruiz, A; Martinez, A; Madrigal, L; Hincapie, L; Arango, JCL; Anthony, DC; Koo, EH; Goate, AM; Selkoe, DJ; Arango, JCV				Lemere, CA; Lopera, F; Kosik, KS; Lendon, CL; Ossa, J; Saido, TC; Yamaguchi, H; Ruiz, A; Martinez, A; Madrigal, L; Hincapie, L; Arango, JCL; Anthony, DC; Koo, EH; Goate, AM; Selkoe, DJ; Arango, JCV			The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology	NATURE MEDICINE			English	Article							AMYLOID-BETA-PROTEIN; SENILE PLAQUES; DISEASE; PRECURSOR; GENE	Missense mutations in the presenilin 1 (PS1) gene cause the most common form of dominant early-onset familial Alzheimer's disease (FAD)(1,2) and are associated with increased levels of amyloid beta-peptides (A beta) ending at residue 42 (A beta 42) in plasma and skin fibroblast media of gene carriers(3). A beta 42 aggregates readily and appears to provide a nidus for the subsequent aggregation of A beta 40 (ref. 4), resulting in the formation of innumerable neuritic plaques. To obtain in vivo information about how PS1 mutations cause AD pathology at such early ages, we characterized the neuropathological phenotype of four PS1-FAD patients from a large Colombian kindred(5) bearing the codon 280 Glu to Ala substitution (Glu280Ala) PS1 mutation(2). Using antibodies specific to the alternative carboxy-termini of A beta, we detected massive deposition of A beta 42, the earliest and predominant form of plaque A beta to occur in AD (ref. 6-8), in many brain regions. Computer-assisted quantification revealed a significant increase in A beta 42 but not A beta 40, burden in the brains from 4 PS1-FAD patients compared with those from 12 sporadic AD patients. Severe cerebellar pathology included numerous A beta 42-reactive plaques, many bearing dystrophic neurites and reactive glia. Our results in brain tissue are consistent with recent biochemical evidence of increased A beta 42 levels in PS1-FAD patients and strongly suggest that mutant PS1 proteins alter the proteolytic processing of the beta-amyloid precursor protein at the C-terminus of A beta to favor deposition of A beta 42.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV ANTIOQUIA,DEPT NEUROL,MEDELLIN,COLOMBIA; UNIV ANTIOQUIA,DEPT BIOCHEM,MEDELLIN,COLOMBIA; UNIV ANTIOQUIA,DEPT PATHOL,MEDELLIN,COLOMBIA; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; TOKYO METROPOLITAN INST MED SCI,DEPT MOL BIOL,TOKYO,JAPAN; GUNMA UNIV,COLL MED CARE & TECHNOL,GUNMA,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidad de Antioquia; Universidad de Antioquia; Universidad de Antioquia; Washington University (WUSTL); Washington University (WUSTL); Tokyo Metropolitan Institute of Medical Science; Gunma University			Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Anthony, Douglas/0000-0002-3815-2240; Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [AG 06173, AG 00634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006173, R01AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lopera F, 1994, ACTA NEUROL COLOMB, V10, P173; Mann DMA, 1996, AM J PATHOL, V148, P1257; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song X.-H., 1995, Society for Neuroscience Abstracts, V21, P1501; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882	25	419	436	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1146	1150		10.1038/nm1096-1146	http://dx.doi.org/10.1038/nm1096-1146			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837617				2022-12-27	WOS:A1996VK99500039
J	Wise, RA; Ranaldi, R				Wise, RA; Ranaldi, R			Cocaine vaccines revisited	NATURE MEDICINE			English	Editorial Material									CONCORDIA UNIV,DEPT PSYCHOL,MONTREAL,PQ H3G 1M8,CANADA	Concordia University - Canada	Wise, RA (corresponding author), CONCORDIA UNIV,DEPT BEHAV NEUROBIOL,MONTREAL,PQ H3G 1M8,CANADA.		Wise, Roy A/A-6465-2012					BAGASRA O, 1992, IMMUNOPHARMACOLOGY, V23, P173, DOI 10.1016/0162-3109(92)90023-6; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DEWIT H, 1977, CAN J PSYCHOL, V31, P195, DOI 10.1037/h0081662; FITCH TE, 1993, DRUG ALCOHOL DEPEN, V33, P11; Fox BS, 1996, NAT MED, V2, P1129, DOI 10.1038/nm1096-1129; JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414; KILLIAN A, 1978, PHARMACOL BIOCHEM BE, V9, P347, DOI 10.1016/0091-3057(78)90295-2; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315	10	8	8	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1073	1074		10.1038/nm1096-1073	http://dx.doi.org/10.1038/nm1096-1073			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837598				2022-12-27	WOS:A1996VK99500020
J	Brooks-Kayal, AR; Shumate, MD; Jin, H; Rikhter, TY; Coulter, DA				Brooks-Kayal, AR; Shumate, MD; Jin, H; Rikhter, TY; Coulter, DA			Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy	NATURE MEDICINE			English	Article							MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; GENE-EXPRESSION; RAT HIPPOCAMPUS; GRANULE CELLS; STATUS-EPILEPTICUS; DELTA-SUBUNIT; DENTATE GYRUS; A RECEPTORS; NEURONS	Temporal robe epilepsy is the most prevalent seizure disorder in adults. Compromised inhibitory neurotransmitter function in the hippocampus contributes to the hyperexcitability generating this condition, but the underlying molecular mechanisms are unknown. Combining patch-clamp recording and single-cell mRNA amplification (aRNA) techniques in single dentate granule cells, we demonstrate that expression of GABA(A) receptor subunit mRNAs is substantially altered in neurons from epileptic rats. These changes in gene expression precede epilepsy onset by weeks and correlate with profound alterations in receptor function, indicating that aberrant GABA(A) receptor expression and function has an essential role in the process of epileptogenesis.	Childrens Hosp Philadelphia, Pediat Reg Epilepsy Progam, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol & Anat, Richmond, VA 23298 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Virginia Commonwealth University; Virginia Commonwealth University	Brooks-Kayal, AR (corresponding author), Childrens Hosp Philadelphia, Pediat Reg Epilepsy Progam, 34th & Civ Btr Blvd, Philadelphia, PA 19104 USA.			Rikhter, Tatiana/0000-0003-4049-0238; Coulter, Douglas/0000-0002-1486-119X	NICHD NIH HHS [HD28815] Funding Source: Medline; NINDS NIH HHS [K08 NS01936, R01 NS32403] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001936, R01NS032403] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Brooks-Kayal AR, 1998, J NEUROCHEM, V70, P1017; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; BUREAU M, 1990, MOL PHARMACOL, V37, P497; Burgard EC, 1996, MOL PHARMACOL, V50, P119; Cao YX, 1996, P NATL ACAD SCI USA, V93, P9844, DOI 10.1073/pnas.93.18.9844; DEDEYN P, 1990, ACTA NEUROL BELG, P90; Donnelly JL, 1996, NEUROPHARMACOLOGY, V35, P1233, DOI 10.1016/S0028-3908(96)00053-6; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Fisher JL, 1998, J NEUROSCI, V18, P2944; FRASER DD, 1995, J NEUROSCI, V15, P2720; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jones A, 1997, J NEUROSCI, V17, P1350; KAMPHUIS W, 1995, MOL BRAIN RES, V31, P33, DOI 10.1016/0169-328X(95)00022-K; KILLISCH I, 1991, NEURON, V7, P927, DOI 10.1016/0896-6273(91)90338-Z; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mellor JR, 1998, J NEUROSCI, V18, P2822; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; PERLIN JB, 1993, P NATL ACAD SCI USA, V90, P1741, DOI 10.1073/pnas.90.5.1741; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rice A, 1996, P NATL ACAD SCI USA, V93, P9665, DOI 10.1073/pnas.93.18.9665; SAXENA NC, 1994, J NEUROSCI, V14, P7077; SAXENA NC, 1996, MOL PHARMACOL, V49, P458; SCHWARZER C, 1995, NEUROSCIENCE, V69, P705, DOI 10.1016/0306-4522(95)00348-M; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Sloviter RS, 1996, J COMP NEUROL, V373, P593; TASKER JG, 1991, NEUROCHEM RES, V16, P251, DOI 10.1007/BF00966088; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VICINI S, 1991, NEUROPSYCHOPHARMACOL, V4, P9; WALKER MC, 1995, J NEUROCHEM, V65, P725; White H S, 1998, Adv Neurol, V76, P29; WHITEHOUSE K, 1995, IEEE MULTIMEDIA, V2, P6; Whiting PJ, 1997, J NEUROSCI, V17, P5027; WISDEN W, 1992, J NEUROSCI, V12, P1040	45	585	592	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1166	1172		10.1038/2661	http://dx.doi.org/10.1038/2661			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771750				2022-12-27	WOS:000076230100036
J	Kohn, DB; Hershfield, MS; Carbonaro, D; Shigeoka, A; Brooks, J; Smogorzewska, EM; Barsky, LW; Chan, R; Burotto, F; Annett, G; Nolta, JA; Crooks, G; Kapoor, N; Elder, M; Wara, D; Bowen, T; Madsen, E; Snyder, FF; Bastian, J; Muul, L; Blaese, RM; Weinberg, K; Parkman, R				Kohn, DB; Hershfield, MS; Carbonaro, D; Shigeoka, A; Brooks, J; Smogorzewska, EM; Barsky, LW; Chan, R; Burotto, F; Annett, G; Nolta, JA; Crooks, G; Kapoor, N; Elder, M; Wara, D; Bowen, T; Madsen, E; Snyder, FF; Bastian, J; Muul, L; Blaese, RM; Weinberg, K; Parkman, R			T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34(+) cells in ADA-deficient SCID neonates	NATURE MEDICINE			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; PEG-ADA; THERAPY; ENGRAFTMENT; REVERSION; PATIENT; MOLONEY; VIRUS	Adenosine deaminase-deficient severe combined immunodeficiency was the first disease investigated for gene therapy because of a postulated production or survival advantage for gene-corrected T lymphocytes, which may overcome inefficient gene transfer. Four years after three newborns with this disease were given infusions of transduced autologous umbilical cord blood CD34(+) cells, the frequency of gene-containing T lymphocytes has risen to 1-10%, whereas the frequencies of other hematopoietic and lymphoid cells containing the gene remain at 0.01-0.1%. Cessation of polyethylene glycol-conjugated adenosine deaminase enzyme replacement in one subject led to a decline in immune function, despite the persistence of gene-containing T lymphocytes. Thus, despite the long-term engraftment of transduced stem cells and selective accumulation of gene-containing T lymphocytes, improved gene transfer and expression will be needed to attain a therapeutic effect.	Childrens Hosp Los Angeles, Div Immunol Res Bone Marrow Transplantat, Los Angeles, CA 90027 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84132 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5CT, Canada; Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Natl Ctr Human Genome Res, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA	Children's Hospital Los Angeles; Duke University; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; Alberta Childrens Hospital; University of Calgary; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kohn, DB (corresponding author), Childrens Hosp Los Angeles, Div Immunol Res Bone Marrow Transplantat, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087; Nolta, Jan/0000-0003-4576-8542	NCRR NIH HHS [M01 RR000043, 3 MO1 RR0043-35S1] Funding Source: Medline; NHLBI NIH HHS [P50 HL054850, 1P50 HL54850] Funding Source: Medline; NIDDK NIH HHS [R01 DK053041-06, R01 DK053041, DK20902, R01 DK020902] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020902, R01DK053041] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; DESGROSEILLERS L, 1984, J VIROL, V52, P448, DOI 10.1128/JVI.52.2.448-456.1984; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; GATTI RA, 1968, LANCET, V2, P1366; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1995, HUM MUTAT, V5, P107, DOI 10.1002/humu.1380050202; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOCK RA, 1989, BLOOD, V74, P876; Hoogerbrugge PM, 1996, GENE THER, V3, P179; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PARKMAN R, 1975, NEW ENGL J MED, V292, P714, DOI 10.1056/NEJM197504032921402; RUHL E, 1997, BLOOD S1 2, V90, pB417; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; TJONNFJORD GE, 1994, BLOOD, V84, P3584; TSICHLIS PN, 1987, ANTICANCER RES, V7, P171; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626	22	252	264	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					775	780		10.1038/nm0798-775	http://dx.doi.org/10.1038/nm0798-775			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662367	Green Accepted			2022-12-27	WOS:000074543900030
J	Rapalino, O; Lazarov-Spiegler, O; Agranov, E; Velan, GJ; Yoles, E; Fraidakis, M; Solomon, A; Gepstein, R; Katz, A; Belkin, M; Hadani, M; Schwartz, M				Rapalino, O; Lazarov-Spiegler, O; Agranov, E; Velan, GJ; Yoles, E; Fraidakis, M; Solomon, A; Gepstein, R; Katz, A; Belkin, M; Hadani, M; Schwartz, M			Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; MOTOR EVOKED-POTENTIALS; APOLIPOPROTEIN-A-I; WALLERIAN DEGENERATION; NEUROTROPHIC FACTORS; CORTICOSPINAL AXONS; NEURONS REGENERATE; IMMUNE-SYSTEM; OPTIC NERVES	Postinjury recovery in most tissues requires an effective dialog with macrophages; however, in the mammalian central nervous system, this dialog may be restricted (possibly due to its immune-privileged status), which probably contributes to its regeneration failure. We circumvented this by implanting macrophages, pre-exposed ex vivo to peripheral nerve segments, into transected rat spinal cord. This stimulated tissue repair and partial recovery of motor function, manifested behaviorally by movement of hind limbs, plantar placement of the paws and weight support, and electrophysiologically by cortically evoked hind-limb muscle response. We substantiated these findings immunohistochemically by demonstrating continuity of labeled nerve fibers across the transected site, and by tracing descending fibers distally to it by anterograde labeling. In recovered rats, re-transection of the cord above the primary transection site led to loss of recovery, indicating the involvement of long descending spinal tracts. Injection of macrophages into the site of injury is relatively non-invasive and, as the cells are autologous, it may be developed into a clinical therapy.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Beit Levinstein Hosp, Raanana, Israel; Meir Hosp, Dept Orthoped, Kefar Sava, Israel; Karolinska Inst, Dept Neurosci, Stockholm, Sweden; Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Karolinska Institutet; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.ac.il	Belkin, Michael/AAK-4728-2020; Lazarov, Orly/F-9406-2015; Solomon, Arieh/AAF-4361-2021	Rapalino, Otto/0000-0002-5038-4183; Lazarov, Orly/0000-0002-5887-948X				AGUAYO AJ, 1981, J EXP BIOL, V95, P231; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BENZEEVBRANN A, INPRESS GLIA; BISBY MA, 1990, BRAIN RES, V530, P117, DOI 10.1016/0006-8993(90)90666-Y; BLAUGRUND E, 1993, J COMP NEUROL, V330, P105, DOI 10.1002/cne.903300109; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brooks CM, 1940, J NEUROPHYSIOL, V3, P66, DOI 10.1152/jn.1940.3.1.66; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FaberElman A, 1995, FASEB J, V9, P1605, DOI 10.1096/fasebj.9.15.8529840; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; Grill R, 1997, J NEUROSCI, V17, P5560; GRUNER JA, 1993, J NEUROTRAUM, V10, P327, DOI 10.1089/neu.1993.10.327; HAREL A, 1989, J NEUROCHEM, V52, P1218, DOI 10.1111/j.1471-4159.1989.tb01869.x; HAREL A, 1990, J NEUROCHEM, V55, P1237, DOI 10.1111/j.1471-4159.1990.tb03130.x; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hikawa N, 1996, CELL MOL NEUROBIOL, V16, P517, DOI 10.1007/BF02150231; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; KONRAD PE, 1990, BRAIN RES, V522, P14, DOI 10.1016/0006-8993(90)91572-X; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LAZAROVSPIEGLER O, IN PRESS GLIA; LAZAROVSPIEGLER O, IN PRESS MOL MED TOD; LAZAROVSPIEGLER O, IN PRESS VISION RES; LEVY WJ, 1984, NEUROSURGERY, V15, P214, DOI 10.1227/00006123-198408000-00011; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MEDIRATTA NK, 1983, J PHYSIOL-LONDON, V336, P545, DOI 10.1113/jphysiol.1983.sp014597; NANCE DM, 1990, BRAIN RES BULL, V25, P139, DOI 10.1016/0361-9230(90)90264-Z; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWARTZ M, 1995, MOL MED TODAY, V1, P60, DOI 10.1016/S1357-4310(95)92274-1; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SIMPSON RK, 1987, NEUROSURGERY, V20, P131; STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086; Streilein J. Wayne, 1993, Regional Immunology, V5, P253; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451	54	636	663	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					814	821		10.1038/nm0798-814	http://dx.doi.org/10.1038/nm0798-814			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662373				2022-12-27	WOS:000074543900036
J	Robb, L; Li, RL; Hartley, L; Nandurkar, HH; Koentgen, F; Begley, CG				Robb, L; Li, RL; Hartley, L; Nandurkar, HH; Koentgen, F; Begley, CG			Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation	NATURE MEDICINE			English	Article							LEUKEMIA INHIBITORY FACTOR; BLASTOCYST IMPLANTATION; ALPHA-CHAIN; EXPRESSION; METALLOPROTEINASES; REQUIREMENT; PREGNANCY; CLONING; INVITRO; EMBRYO	During early pregnancy, ir! response to the implanting embryo, the surrounding uterine stroma undergoes a dramatic transformation into a specialized tissue known as the decidua. The decidua encapsulates the developing embryo, facilitating nutrient transfer and limiting trophoblast invasion. Here we show that female mice with a null mutation of the interleukin-11 receptor alpha chain are infertile because of defective decidualization. A temporal analysis revealed IL-11 expression is maximal in the normal pregnant uterus at the time of decidualization, and in situ hybridization studies showed expression of the IL-11 and the IL-ll receptor alpha chain in the developing decidual cells. These observations reveal a previously unrecognized critical role for IL-ll signaling in female reproduction.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital	Robb, L (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	robb@wehi.edu.au	Nandurkar, Harshal/AAO-7443-2020	Nandurkar, Harshal/0000-0002-8767-116X				Afonso S, 1997, DEVELOPMENT, V124, P3415; Alexander CM, 1996, DEVELOPMENT, V122, P1723; APLIN JD, 1994, REPROD BIOL, P327; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; Bilinski P, 1996, BIOCHEM J, V320, P359, DOI 10.1042/bj3200359; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; Chard T, 1995, HUM REPROD UPDATE, V1, P385, DOI 10.1093/humupd/1.4.385; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DEY SK, 1996, REPROD ENDOCRINOLOGY, P422; Du XX, 1996, J CELL PHYSIOL, V168, P362; DU XX, 1994, BLOOD, V83, P2023; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; KIRBY DRS, 1968, EPITHELIAL MESENCHYM, P64; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Nandurkar HH, 1996, ONCOGENE, V12, P585; Nandurkar HH, 1997, BLOOD, V90, P2148; Noble LS, 1996, J CLIN ENDOCR METAB, V81, P174, DOI 10.1210/jc.81.1.174; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; PSYCHOYOS A, 1973, HDB PHYSL, P187; Robb L, 1997, GENOMICS, V40, P387, DOI 10.1006/geno.1996.4579; Robb L, 1996, J BIOL CHEM, V271, P13754, DOI 10.1074/jbc.271.23.13754; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STEWART CL, 1994, MOL REPROD DEV, V39, P233, DOI 10.1002/mrd.1080390217; TOMIDA M, 1994, J BIOCHEM-TOKYO, V115, P557, DOI 10.1093/oxfordjournals.jbchem.a124375; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	30	360	373	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					303	308		10.1038/nm0398-303	http://dx.doi.org/10.1038/nm0398-303			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500603				2022-12-27	WOS:000073616200035
J	Liu, JL; Marino, MW; Wong, G; Grail, D; Dunn, A; Bettadapura, J; Slavin, AJ; Old, L; Bernard, CCA				Liu, JL; Marino, MW; Wong, G; Grail, D; Dunn, A; Bettadapura, J; Slavin, AJ; Old, L; Bernard, CCA			TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; FACTOR-ALPHA; DEFICIENT MICE; ENCEPHALOMYELITIS; LYMPHOTOXIN; DISEASE; IMMUNE; PREVENTION; ACTIVATION	Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by localized areas of demyelination(1). Although the etiology and pathogenesis of MS remain largely unknown, it is generally assumed that immune responses to myelin antigens contribute to the disease process(1,2). The exact sequence of events, as well as the molecular mediators that lead to myelin destruction, is yet to be defined(2,3) As a potent mediator of inflammation, the cytopathic cytokine, tumor necrosis factor (TNF) has been considered to be a strong candidate in the pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis (EAE)(3-5). However, its role in immune-mediated demyelination remains to be elucidated. To determine the contribution of TNF to the pathogenesis of the MS-like disease provoked by the myelin oligodendrocyte glycoprotein (MOG)(6), we have tested mice with an homologous disruption of the gene encoding TNF (ref. 7). Here we report that upon immunization with MOG, mice lacking TNF develop severe neurological impairment with high mortality and extensive inflammation and demyelination. We show further that inactivation of the TNF gene converts MOG-resistant mice to a state of high susceptibility. Furthermore, treatment with TNF dramatically reduces disease severity in both TNF-/- mice and in other TNF+/+ mice highly susceptible to the MOG-induced disease. These findings indicate that TNF is not essential for the induction and expression of inflammatory and demyelinating lesions, and that it may limit the extent and duration of severe CNS pathology.	La Trobe Univ, Neuroimmunol Lab, Melbourne, Vic 3083, Australia; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA; Genentech Inc, S San Francisco, CA 94090 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia	La Trobe University; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center; Roche Holding; Genentech; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Bernard, CCA (corresponding author), La Trobe Univ, Neuroimmunol Lab, Melbourne, Vic 3083, Australia.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Bernard CCA, 1997, J MOL MED-JMM, V75, P77, DOI 10.1007/s001090050092; BERNARD CCA, 1992, CURR OPIN IMMUNOL, V4, P760, DOI 10.1016/0952-7915(92)90058-M; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Ichikawa M, 1996, J IMMUNOL, V157, P919; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; Jayaram BM, 1996, J NEUROCHEM, V66, pS41; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Navikas V, 1996, J NEUROSCI RES, V45, P322, DOI 10.1002/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PAYA CV, 1990, INT IMMUNOL, V2, P909, DOI 10.1093/intimm/2.9.909; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Willenborg DO, 1996, J IMMUNOL, V157, P3223	26	469	485	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					78	83		10.1038/nm0198-078	http://dx.doi.org/10.1038/nm0198-078			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427610				2022-12-27	WOS:000072249700038
J	Olson, L				Olson, L			Regeneration in the adult central nervous system: Experimental repair strategies	NATURE MEDICINE			English	Review							RAT SPINAL-CORD; NEURAL RECOGNITION MOLECULES; NEURITE GROWTH-INHIBITORS; PERIPHERAL-NERVE; SCHWANN-CELLS; OPTIC-NERVE; IN-VITRO; CLINICAL-APPLICATION; CORTICOSPINAL TRACT; AXONAL REGENERATION		Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet	Olson, L (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.							Aebischer P, 1996, HUM GENE THER, V7, P851, DOI 10.1089/hum.1996.7.7-851; AGUAYO AJ, 1978, NEUROSCI LETT, V9, P97, DOI 10.1016/0304-3940(78)90055-1; AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; APTEL SC, 1996, CIBA F SYMP, V196, P98; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; Bahr M, 1996, J NEUROBIOL, V30, P281, DOI 10.1002/(SICI)1097-4695(199606)30:2<281::AID-NEU9>3.0.CO;2-1; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-CNE8>3.0.CO;2-#; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; Bregman B S, 1997, Adv Neurol, V72, P257; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brustle O, 1996, CURR OPIN NEUROBIOL, V6, P688, DOI 10.1016/S0959-4388(96)80104-8; Bunge R P, 1997, Adv Neurol, V72, P305; BUNGE RP, 1993, ADV NEUROL, V59, P75; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CARLSTEDT TP, 1995, MICROSURG, V16, P13, DOI 10.1002/micr.1920160106; CARTER DA, 1994, J NEUROSCI, V14, P590; Casella CTB, 1996, GLIA, V17, P327, DOI 10.1002/(SICI)1098-1136(199608)17:4<327::AID-GLIA7>3.0.CO;2-W; CHENG H, 1995, EXP NEUROL, V136, P149, DOI 10.1006/exnr.1995.1092; Cheng H, 1997, J COMP NEUROL, V380, P155, DOI 10.1002/(SICI)1096-9861(19970407)380:2<155::AID-CNE1>3.0.CO;2-2; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHENG H, 1997, IN PRESS EXP NEUROL; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; DATE I, 1995, NEUROSURGERY, V37, P515, DOI 10.1227/00006123-199509000-00022; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; DECHANT G, 1994, PROG NEUROBIOL, V42, P347, DOI 10.1016/0301-0082(94)90075-2; Decherchi P, 1996, BRAIN RES, V726, P181, DOI 10.1016/0006-8993(96)00331-9; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Dyck PJ, 1997, NEUROLOGY, V48, P501, DOI 10.1212/WNL.48.2.501; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; FERNANDEZVALLE C, 1995, J NEUROCYTOL, V24, P667, DOI 10.1007/BF01179817; GAGE FH, 1985, EXP BRAIN RES, V60, P584; Gallo G, 1997, J NEUROSCI, V17, P5445; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Grill R, 1997, J NEUROSCI, V17, P5560; HOWLAND DR, 1995, EXP NEUROL, V135, P123, DOI 10.1006/exnr.1995.1072; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; JOOSTEN EAJ, 1995, J NEUROSCI RES, V41, P481, DOI 10.1002/jnr.490410407; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; KEIRSTEAD HS, 1995, J NEUROSCI, V15, P6963; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LI Y, 1994, J NEUROSCI, V14, P4050; Lindsay RM, 1996, CIBA F SYMP, V196, P39; LINDVALL O, 1994, J NEUROL, V242, pS54, DOI 10.1007/BF00939243; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; Lotz B, 1996, NEUROLOGY, V46, P1244; MARTINI R, 1994, J NEUROSCI, V14, P7180; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Nakahara Y, 1996, CELL TRANSPLANT, V5, P191, DOI 10.1016/0963-6897(95)02028-4; NYGREN LG, 1974, BRAIN RES, V78, P377, DOI 10.1016/0006-8993(74)90922-6; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; OLSON L, 1969, HISTOCHEMISTRY, V17, P349, DOI 10.1007/BF00305459; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SCHACHNER M, 1994, PROG BRAIN RES, V100, P25; Schachner Melitta, 1994, Current Opinion in Neurobiology, V4, P726, DOI 10.1016/0959-4388(94)90016-7; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, NEUROCHEM RES, V21, P755, DOI 10.1007/BF02532297; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; Smale KA, 1996, EXP NEUROL, V137, P225, DOI 10.1006/exnr.1996.0021; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; STITTMATTER S, 1995, CELL, V80, P445; STROMBERG I, 1992, J COMP NEUROL, V315, P445, DOI 10.1002/cne.903150407; STROMBERG I, 1990, J NEUROSCI RES, V25, P405, DOI 10.1002/jnr.490250318; SYDOW O, 1995, EUR J NEUROL, V2, P445, DOI 10.1111/j.1468-1331.1995.tb00154.x; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; Tuszynski MH, 1996, CIBA F SYMP, V196, P85; Unsicker K, 1996, CELL TISSUE RES, V286, P175, DOI 10.1007/s004410050686; VARGA ZM, 1995, EUR J NEUROSCI, V7, P2119, DOI 10.1111/j.1460-9568.1995.tb00634.x; Wang Y, 1996, CELL TISSUE RES, V286, P225, DOI 10.1007/s004410050691; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0; XU X, 1995, GLIA, V13, P309; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; ZHOU FC, 1995, CELL TRANSPLANT, V4, P103, DOI 10.1016/0963-6897(94)00042-I	95	89	97	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1329	1335		10.1038/nm1297-1329	http://dx.doi.org/10.1038/nm1297-1329			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396602				2022-12-27	WOS:000072249500028
J	Roman, M; MartinOrozco, E; Goodman, S; Nguyen, MD; Sato, Y; Ronaghy, A; Kornbluth, RS; Richman, DD; Carson, DA; Raz, E				Roman, M; MartinOrozco, E; Goodman, S; Nguyen, MD; Sato, Y; Ronaghy, A; Kornbluth, RS; Richman, DD; Carson, DA; Raz, E			Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants	NATURE MEDICINE			English	Article							GAMMA PRODUCTION; OLIGONUCLEOTIDES; IMMUNIZATION; IMMUNITY; CYTOKINE; VACCINES; ANTIGEN; CELLS; IFN	An adjuvant role for certain short bacterial immunostimulatory DNA sequences (ISSs) has recently been proposed on the basis of their ability to stimulate T helper-1 (Th1) responses in gene-vaccinated animals. We report here that noncoding, ISS-enriched plasmid DNAs or ISS oligonucleotides (ISS-ODNs) potently stimulate immune responses to coadministered antigens. The ISS-DNAs suppress IgE synthesis, but promote IgG and interferon-gamma (IFN-gamma) production. They furthermore initiate the production of IFN-gamma, IFN-alpha, IFN-beta, and interleukins 12 and 18, all of which foster. Th1 responses and enhance cell-mediated immunity. Consideration should be given to adding noncoding DNA adjuvants to inactivated or subunit viral vaccines that, by themselves, provide only partial protection from infection.	DYNAVAX TECHNOL CORP,SAN DIEGO,CA 92121; FUKUSHIMA MED COLL,DEPT INTERNAL MED 2,FUKUSHIMA 96012,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO VET AFFAIRS MED CTR,LA JOLLA,CA 92093	Fukushima Medical University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Martin-Orozco, Elena/C-2553-2008	Martin-Orozco, Elena/0000-0002-6303-481X; Kornbluth, Richard/0000-0002-0218-2026	NIAID NIH HHS [AI 29614, AI 37305] Funding Source: Medline; NIAMS NIH HHS [AR 41897] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI029614, R01AI037305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Bradley LM, 1996, J IMMUNOL, V157, P1350; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Broide D., 1997, Journal of Allergy and Clinical Immunology, V99, pS129; Burke Rae Lynn, 1993, P367; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Cowdery J, 1996, J IMMUNOL, V156, P4570; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Freund J, 1937, P SOC EXP BIOL MED, V37, P509; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MANICKAN E, 1995, J IMMUNOL, V155, P259; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ J, 1964, ADV IMMUNOL, V4, P397, DOI 10.1016/S0065-2776(08)60712-9; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RAZ E, 1994, CATIONIC LIPID INHIB, P71; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAEGASHI Y, 1995, J EXP MED, V181, P953, DOI 10.1084/jem.181.3.953; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072	33	788	936	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					849	854		10.1038/nm0897-849	http://dx.doi.org/10.1038/nm0897-849			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256274	Bronze			2022-12-27	WOS:A1997XP01400025
J	Grob, PM; Cao, YZ; Munchmore, E; Ho, DD; Norris, S; Pav, JW; Shih, CK; Adams, J				Grob, PM; Cao, YZ; Munchmore, E; Ho, DD; Norris, S; Pav, JW; Shih, CK; Adams, J			Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; PROTECTION; PREVENTION; IMMUNIZATION; LYMPHOCYTES; REPLICATION; CHALLENGE; BURDEN; BLOOD	Chimpanzees were challenged with HIV-1(IIB) while receiving a short regimen of nevirapine (Viramune), a nonnucleoside inhibitor of HIV-1 reverse transcriptase. The untreated, control chimpanzee developed an infection characterized by seroconversion, viremia in peripheral blood mononuclear cells (PBMCs), and plasma positive for viral RNA. In contrast, the three nevirapine-treated chimpanzees remained negative for all viral markers with the exception of nested polymerase chain reaction (PCR) analysis of PBMCs for viral DNA. Although PBMCs from the three nevirapine-treated chimpanzees tested intermittently positive for viral DNA, this PCR signal disappeared and remained negative for the final five months of the study. These data indicate that orally administered nevirapine provided protection from HIV-1 infection in the chimpanzee model.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT DRUG METAB & PHARMACOKINET,RIDGEFIELD,CT 06877; ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; LAB EXPT MED & SURG PRIMATES,TUXEDO PK,NY 10987	Boehringer Ingelheim; Rockefeller University	Grob, PM (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,900 RIDGEBURN RD,RIDGEFIELD,CT 06877, USA.							ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; Berman PW, 1996, J INFECT DIS, V173, P52, DOI 10.1093/infdis/173.1.52; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141; CHESSMAN SH, 1993, ANTIMICROB AGENTS CH, V37, P178; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAA ES, 1991, NEW ENGL J MED, V324, P961; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; FULTZ PN, 1991, J INFECT DIS, V163, P441, DOI 10.1093/infdis/163.3.441; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Hattox Susan, 1992, Pharmaceutical Research (New York), V9, pS268; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; ISRAEL ZR, 1994, J VIROL, V68, P1843, DOI 10.1128/JVI.68.3.1843-1853.1994; Jayaraj Andrew, 1992, Pharmaceutical Research (New York), V9, pS334; JOHNSON BK, 1993, AIDS RES HUM RETROV, V9, P375, DOI 10.1089/aid.1993.9.375; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MURPHY RL, 1996, EXPERT OPIN INV DRUG, V5, P1183; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SCHEIF WA, 1994, AIDS RES HUM RETROV, V10, P107; TSAI CC, 1994, J INFECT DIS, V169, P260, DOI 10.1093/infdis/169.2.260; WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	34	32	32	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					665	670		10.1038/nm0697-665	http://dx.doi.org/10.1038/nm0697-665			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176494				2022-12-27	WOS:A1997XB97400037
J	Grossman, Z; Herberman, RB				Grossman, Z; Herberman, RB			T-cell homeostasis in HIV infection is neither failing nor blind: Modified cell counts reflect an adaptive response of the host	NATURE MEDICINE			English	Editorial Material							RECEPTOR LIGAND; AIDS; LYMPHOCYTES; ACTIVATION; TOLERANCE		UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grossman, Z (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,DEPT PHYSIOL & PHARMACOL,IL-69978 TEL AVIV,ISRAEL.		Grossman, Zvi/A-9643-2008					ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; ARNOLD B, 1993, IMMUNOL TODAY, V14, P12, DOI 10.1016/0167-5699(93)90317-E; Bachmann MF, 1996, EUR J IMMUNOL, V26, P2017, DOI 10.1002/eji.1830260908; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GROSSMAN Z, 1982, EUR J IMMUNOL, V12, P747, DOI 10.1002/eji.1830120909; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; GROSSMAN Z, 1992, P NATL ACAD SCI USA, V89, P10365, DOI 10.1073/pnas.89.21.10365; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; GROSSMAN Z, 1993, IMMUNOL REV, V133, P45, DOI 10.1111/j.1600-065X.1993.tb01509.x; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KAWAI K, 1995, NATURE, V374, P68, DOI 10.1038/374068a0; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; MADDOX J, 1995, NATURE, V373, P189, DOI 10.1038/373189a0; MALONE JL, 1992, J INFECT DIS, V165, P185, DOI 10.1093/infdis/165.1.185; MARGOLICK JB, 1993, J ACQ IMMUN DEF SYND, V6, P153; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Westby M, 1996, IMMUNOL TODAY, V17, P120, DOI 10.1016/0167-5699(96)80603-7; Westermann J, 1996, IMMUNOL TODAY, V17, P278, DOI 10.1016/0167-5699(96)80545-7; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; 1996, IMMUNOL REV, V149	30	60	61	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					486	490		10.1038/nm0597-486	http://dx.doi.org/10.1038/nm0597-486			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142108				2022-12-27	WOS:A1997WX54300019
J	Brownell, AL; Jenkins, BG; Elmaleh, DR; Deacon, TW; Spealman, RD; Isacson, O				Brownell, AL; Jenkins, BG; Elmaleh, DR; Deacon, TW; Spealman, RD; Isacson, O			Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; N-ACETYLASPARTATE; HUMAN GLIOMAS; D2 RECEPTORS; C-11 CFT; DOPAMINE; PET; STRIATUM; LACTATE	We used brain imaging to study long-term neurodegenerative and bioadaptive neurochemical changes in a primate model of Parkinson disease. We gradually induced a selective loss of nigrostriatal dopamine neurons, similar to that of Parkinson disease, by creating oxidative stress through infusion of the mitochondrial complex 1 inhibitor MPTP for 14 +/- 5 months. Repeated evaluations over 3 years by positron emission tomography (PET) demonstrated progressive and persistent loss of neuronal dopamine pre-synaptic re-uptake sites; repeated magnetic resonance spectroscopy (MRS) studies indicated a 23-fold increase in lactate and macromolecules in the striatum region of the brain for up to 10 months after the last administration of MPTP. By 2 years after the MPTP infusions, these MRS striatal lactate and macromolecule values had returned to normal levels. In contrast, there were persistent increases in striatal choline and decreases in N-acetylaspartate. Thus, these combined PET/MRS studies demonstrate patterns of neurochemical changes that are both dynamic and persistent long after selective dopaminergic degeneration.	Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA; McLean Hosp, Neuroregenerat Labs, Belmont, MA 02178 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital	Isacson, O (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.			Isacson, Ole/0000-0001-8091-8302	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCRR NIH HHS [P51RR00168-36] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALGER JR, 1990, RADIOLOGY, V177, P633, DOI 10.1148/radiology.177.3.2243962; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Brooks D. J., 1993, Neurology, V43, pS6; Brownell AL, 1996, J NUCL MED, V37, P1186; Brownell G. L., 1989, International Journal of Imaging Systems and Technology, V1, P207, DOI 10.1002/ima.1850010210; BROWNELL GL, 1985, METABOLISM HUMAN BRA, P13; BUGIANI O, 1980, EUR NEUROL, V19, P339, DOI 10.1159/000115172; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DDB, 1985, NATURE, V317, P244; CARVEY PM, 1993, PHARMACOL BIOCHEM BE, V46, P195, DOI 10.1016/0091-3057(93)90340-Y; CHESLER DA, 1973, TOMOGRAPHIC IMAGING, P176; Clarke CE, 1997, MOVEMENT DISORD, V12, P297, DOI 10.1002/mds.870120306; Cruz CJ, 1997, MAGN RESON IMAGING, V15, P619, DOI 10.1016/S0730-725X(97)00079-9; DAVIES CA, 1994, BRAIN, V11, P49; DELFORGE J, 1991, J CEREBR BLOOD F MET, V11, P914, DOI 10.1038/jcbfm.1991.156; DERENZO SE, 1988, IEEE T NUCL SCI, V35, P659, DOI 10.1109/23.12807; DUNNETT SB, 1986, NEUROSCI LETT, V68, P127, DOI 10.1016/0304-3940(86)90242-9; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; Federico F, 1997, MOVEMENT DISORD, V12, P903, DOI 10.1002/mds.870120611; FOSTER DM, 1994, BMES BULL, V18, P19; FROHNA PA, 1995, SYNAPSE, V19, P46, DOI 10.1002/syn.890190107; FROST JJ, 1993, ANN NEUROL, V34, P423, DOI 10.1002/ana.410340331; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; GJAEDDE A, 1990, QUANT IMAGING, P51; GUIMAREAEAS AR, 1995, NEUROSCIENCE, V69, P1093; HANTRAYE P, 1986, LIFE SCI, V39, P1375, DOI 10.1016/0024-3205(86)90336-X; HANTRAYE P, 1992, NEUROREPORT, V3, P265, DOI 10.1097/00001756-199203000-00013; HERHOLZ K, 1992, ANN NEUROL, V31, P319, DOI 10.1002/ana.410310315; Higuchi T, 1997, MAGNET RESON MED, V37, P851, DOI 10.1002/mrm.1910370608; HOLSHOUSER BA, 1995, MAGNET RESON MED, V33, P589, DOI 10.1002/mrm.1910330502; HUGG JW, 1992, J CEREBR BLOOD F MET, V12, P734, DOI 10.1038/jcbfm.1992.104; Hwang JH, 1996, MAGNET RESON MED, V35, P633, DOI 10.1002/mrm.1910350502; IMAI H, 1988, BRAIN RES, V474, P327, DOI 10.1016/0006-8993(88)90446-5; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; KAUFMAN MJ, 1991, SYNPASE, V9; LANGE CS, 1984, RADIAT RES, V100, P1, DOI 10.2307/3576516; Leenders KL, 1997, J NEURAL TRANSM-SUPP, P39; MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006-8993(88)90124-2; Petrukhin Konstantin E., 1992, Human Molecular Genetics, V1, P349, DOI 10.1093/hmg/1.5.349; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Schapira AHV, 1997, BAILLIERE CLIN NEUR, V6, P15; Strauss I, 1997, MAGNET RESON MED, V37, P24, DOI 10.1002/mrm.1910370106; Temlett JA, 1996, CURR OPIN NEUROL, V9, P303, DOI 10.1097/00019052-199608000-00011; UNGERSTEDT U, 1968, EUR J PHARMACOL, V5, P107, DOI 10.1016/0014-2999(68)90164-7; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; WULLNER U, 1994, EXP NEUROL, V126, P305, DOI 10.1006/exnr.1994.1069	47	75	82	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1308	1312		10.1038/3300	http://dx.doi.org/10.1038/3300			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809556				2022-12-27	WOS:000076731000041
J	Nurse, P				Nurse, P			The Imperial Cancer Research Fund - Cancer research for the future	NATURE MEDICINE			English	Editorial Material									Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Nurse, P (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1224	1227		10.1038/3202	http://dx.doi.org/10.1038/3202			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809534				2022-12-27	WOS:000076731000019
J	Corder, EH; Robertson, K; Lannfelt, L; Bogdanovic, N; Eggertsen, G; Wilkins, J; Hall, C				Corder, EH; Robertson, K; Lannfelt, L; Bogdanovic, N; Eggertsen, G; Wilkins, J; Hall, C			HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; AIDS DEMENTIA; BETA; MICROGLIA; PROTEIN; ACCUMULATION; CYTOKINES; EPSILON-4	HIV produces a chronic viral infection of the central nervous system that elicits chronic glial activation and overexpression of glial cytokines(1-5) that are also implicated in Alzheimer disease (AD) pathogenesis(6-11). A genetic risk factor for AD is the E4 isoform for apolipoprotein E (APOE)(12,13). Here we compare the frequency of neurologic symptoms for subjects with and without the E4 isoform (E4(+)and E4(-), respectively) in an HIV cohort(14-17). Compared with E4(-) subjects, twice as many E4(+) subjects were demented (30% compared with 15%) or had peripheral neuropathy (70% compared with 39%) at least once, and they had threefold more symptomatic examinations (13% compared with 3% and 42% compared with 14%, respectively)(P < 0.0001). Thus, neurologic symptoms for HIV-infection and AD are linked through an etiologic risk factor. Long-term survivors of HIV infection with E4 may be at high risk for AD; conversely, gene-viral interactions may speed AD pathogenesis.	Odense Univ, Odense, Denmark; Duke Univ, Durham, NC USA; Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Clin Chem, S-14186 Huddinge, Sweden	University of Southern Denmark; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Karolinska Institutet; Karolinska Institutet	Corder, EH (corresponding author), Odense Univ, Odense, Denmark.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036518, P01NS026680] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS36518, R01-NS34234, P01-NS26680] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; Buttini M, 1998, NAT MED, V4, P441, DOI 10.1038/nm0498-441; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Dunlop O, 1997, ACTA NEUROL SCAND, V95, P315, DOI 10.1111/j.1600-0404.1997.tb00217.x; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; HALL CD, 1992, ANN CLIN LAB SCI, V22, P139; HALL M, 1996, NEUROLOGY, V46, P697; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; MCGEER PL, 1994, NEUROPATH APPL NEURO, V20, P191; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mrak RE, 1997, J NEUROVIROL, V3, P241, DOI 10.3109/13550289709029465; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; ROBERTSON KR, 1992, SEMIN NEUROL, V12, P18, DOI 10.1055/s-2008-1041153; ROBERTSON KR, 1993, ARCH NEUROL-CHICAGO, V50, P807, DOI 10.1001/archneur.1993.00540080018007; SAS Institute, 1996, SAS STAT SOFTW CHANG; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408	25	197	205	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1182	1184		10.1038/2677	http://dx.doi.org/10.1038/2677			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771753				2022-12-27	WOS:000076230100039
J	Soto, C; Sigurdsson, EM; Morelli, L; Kumar, RA; Castano, EM; Frangione, B				Soto, C; Sigurdsson, EM; Morelli, L; Kumar, RA; Castano, EM; Frangione, B			beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy	NATURE MEDICINE			English	Article							A-BETA; TRANSGENIC MICE; DISEASE; PROTEIN; NEUROTOXICITY; CONFORMATION; FRAGMENT; PLAQUES	Inhibition of cerebral amyloid beta-protein deposition seems to be an important target for Alzheimer's disease therapy. Amyloidogenesis could be inhibited by short synthetic peptides designed as beta-sheet breakers. Here we demonstrate a 5-residue peptide that inhibits amyloid beta-protein fibrillogenesis, disassembles preformed fibrils in vitro and prevents neuronal death induced by fibrils in cell culture. In addition, the beta-sheet breaker peptide significantly reduces amyloid beta-protein deposition in vivo and completely blocks the formation of amyloid fibrils in a rat brain model of amyloidosis. These findings may provide the basis for a new therapeutic approach to prevent amyloidosis in Alzheimer's disease.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Univ Buenos Aires, IDEHU, RA-1053 Buenos Aires, DF, Argentina	New York University; New York University; University of Buenos Aires	Soto, C (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	Claudio.Soto@mcfpo.med.nyu.edu		Sigurdsson, Einar/0000-0003-1451-0952	NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG10953, AG05891] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R37AG005891, R35AG010953] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUKE CR, 1995, CRRENT PROTOCOLS IMM; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HILSICH C, 1992, J MOL BIOL, V228, P460; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JANOSSY G, 1973, CLIN EXP IMMUNOL, V14, P581; Jimenez-Huete A, 1998, ALZHEIMERS REP, V1, P41; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Sigurdsson EM, 1996, NEUROBIOL AGING, V17, P893, DOI 10.1016/S0197-4580(96)00169-8; Sigurdsson EM, 1997, NEUROBIOL AGING, V18, P591, DOI 10.1016/S0197-4580(97)00154-1; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOTO C, 1994, J NEUROCHEM, V63, P1191; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; SOTO C, UNPUB; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	30	763	833	3	109	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					822	826		10.1038/nm0798-822	http://dx.doi.org/10.1038/nm0798-822			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662374				2022-12-27	WOS:000074543900037
J	Liu, MA				Liu, MA			Vaccine developments	NATURE MEDICINE			English	Review							SIMIAN IMMUNODEFICIENCY VIRUS; ATTENUATED SIV; IN-VIVO; VECTOR; CELLS; LIVE; GLYCOPROTEIN; IMMUNIZATION; EXPRESSION; CHALLENGE		Chiron Vaccines Res, Meryville, CA 94608 USA		Liu, MA (corresponding author), Chiron Vaccines Res, 4560 Horton St,Q3-101, Meryville, CA 94608 USA.							ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; [Anonymous], 1927, VACCINATION PREVENTI; Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Caley IJ, 1997, J VIROL, V71, P3031, DOI 10.1128/JVI.71.4.3031-3038.1997; CLEMENTSMANN ML, IN PRESS J INFECT DI; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Davis NL, 1996, J VIROL, V70, P3781, DOI 10.1128/JVI.70.6.3781-3787.1996; Dietrich G, 1998, NAT BIOTECHNOL, V16, P181, DOI 10.1038/nbt0298-181; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Flarend RE, 1997, VACCINE, V15, P1314, DOI 10.1016/S0264-410X(97)00041-8; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fries LF, 1996, VACCINE, V14, P428, DOI 10.1016/0264-410X(95)00171-V; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; GOOSSENS PL, 1995, INT IMMUNOL, V7, P797, DOI 10.1093/intimm/7.5.797; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O; Gupta RK, 1996, VACCINE, V14, P1412, DOI 10.1016/S0264-410X(96)00073-4; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOTH DF, 1994, ANN INTERN MED, V8, P603; Jenner E., 1959, CLASSICS MED SURG, P213; Jezek Z, 1988, HUMAN MONKEYPOX; JONES L, 1986, NATURE, V319, P543, DOI 10.1038/319543a0; KUNDIG TM, 1993, VACCINE, V11, P1154, DOI 10.1016/0264-410X(93)90079-D; Levine M.M., 1997, NEW GENERATION VACCI; LOHMAN BL, 1994, J VIROL, V68, P7021, DOI 10.1128/JVI.68.11.7021-7029.1994; MAASSAB HF, 1985, VACCINE, V3, P355, DOI 10.1016/0264-410X(85)90124-0; MACATONIA SE, 1991, IMMUNOLOGY, V74, P399; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; ORME IM, 1995, TRENDS MICROBIOL, V3, P401, DOI 10.1016/S0966-842X(00)88987-8; Pasteur L., 1881, CR HEBD ACAD SCI, V92, P1378; PASTEUR L, 1882, CR HEBD ACAD SCI, V95, P1250; Rennels MB, 1996, PEDIATRICS, V97, P7; Robbins J B, 1996, Adv Exp Med Biol, V397, P169; ROONEY JF, 1988, J VIROL, V62, P1530, DOI 10.1128/JVI.62.5.1530-1534.1988; Ruprecht RM, 1996, AIDS RES HUM RETROV, V12, P459, DOI 10.1089/aid.1996.12.459; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; SMITH GL, 1983, GENE, V25, P21, DOI 10.1016/0378-1119(83)90163-4; TAMURA S, 1994, VACCINE, V12, P419, DOI 10.1016/0264-410X(94)90118-X; TREANOR JJ, 1995, PEDIATR INFECT DIS J, V14, P301, DOI 10.1097/00006454-199504000-00010; Ward G, 1997, J VIROL, V71, P7442, DOI 10.1128/JVI.71.10.7442-7447.1997; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	53	67	94	4	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			515	519		10.1038/nm0598supp-515	http://dx.doi.org/10.1038/nm0598supp-515			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585202	Bronze			2022-12-27	WOS:000073453500020
J	Sipkins, DA; Cheresh, DA; Kazemi, MR; Nevin, LM; Bednarski, MD; Li, KCP				Sipkins, DA; Cheresh, DA; Kazemi, MR; Nevin, LM; Bednarski, MD; Li, KCP			Detection of tumor angiogenesis in vivo by alpha(v)beta(3)-targeted magnetic resonance imaging	NATURE MEDICINE			English	Article							PARAMAGNETIC POLYMERIZED LIPOSOMES; INTEGRIN ALPHA(V)BETA(3); BLOOD-VESSELS; CARCINOMA; DISEASE; CANCER	Angiogenesis, the formation of new blood vessels, is a requirement for malignant tumor growth and metastasis(1-3). In the absence of angiogenesis, local tumor expansion is suppressed at a few millimeters and cells lack routes for distant hematogenous spread. Clinical studies have demonstrated that the degree of angiogenesis is correlated with the malignant potential of several cancers, including breast cancer and malignant melanoma(4-7). Moreover, the expression of a specific angiogenesis marker, the endothelial integrin alpha(nu)beta(3), has been shown to correlate with tumor grade(8-10). However, studies of tumor angiogenesis such as these have generally relied on invasive procedures, adequate tissue sampling and meticulous estimation of histologic microvessel density. In the present report, we describe a novel approach to detecting angiogenesis in vivo using magnetic resonance imaging (MRI) and a paramagnetic contrast agent targeted to endothelial alpha(nu)beta(3), via the LM609 monoclonal antibody(11). This approach provided enhanced and detailed imaging of rabbit carcinomas by directly targeting paramagnetic agents to the angiogenic vasculature. In addition, angiogenic 'hot spots' not seen by standard MRI were detected. Our strategy for MR imaging of alpha(nu)beta(3) thus represents a non-invasive means to assess the growth and malignant phenotype of tumors.	Stanford Univ, Sch Med, Dept Radiol, Lucas MRS Res Ctr, Stanford, CA 94305 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Stanford University; Scripps Research Institute	Sipkins, DA (corresponding author), Stanford Univ, Sch Med, Dept Radiol, Lucas MRS Res Ctr, Stanford, CA 94305 USA.		Nevin, Linda/AAL-6321-2021	Nevin, Linda/0000-0003-4095-8574; Li, King/0000-0002-6473-2687	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54444] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1989, BIOCHIM BIOPHYS ACTA, V981, P27, DOI 10.1016/0005-2736(89)90078-3; Brasch Robert C., 1993, P1; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carrau RL, 1995, INVAS METAST, V15, P197; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gladson CL, 1996, J NEUROPATH EXP NEUR, V55, P1143, DOI 10.1097/00005072-199611000-00005; Gupta H, 1996, Magn Reson Imaging Clin N Am, V4, P171; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; JOLESZ FA, 1994, MAGN RESON QUART, V10, P85; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Storrs RW, 1995, JMRI-J MAGN RESON IM, V5, P719, DOI 10.1002/jmri.1880050617; STORRS RW, 1995, J AM CHEM SOC, V117, P7301, DOI 10.1021/ja00133a001; STRAULI P, 1984, B CANCER, V71, P447; Takebayashi Y, 1996, CANCER, V78, P226, DOI 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINREB JC, 1994, MAGN RESON QUART, V10, P67; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	20	743	801	0	99	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					623	626		10.1038/nm0598-623	http://dx.doi.org/10.1038/nm0598-623			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585240				2022-12-27	WOS:000073399900038
J	Tanelian, DL; Barry, MA; Johnston, SA; Le, T; Smith, GM				Tanelian, DL; Barry, MA; Johnston, SA; Le, T; Smith, GM			Semaphorin III can repulse and inhibit adult sensory afferents in vivo	NATURE MEDICINE			English	Article							GROWTH CONE GUIDANCE; FREE NERVE-ENDINGS; CORNEAL EPITHELIUM; SPINAL-CORD; A-DELTA; RABBIT; FIBER	During development, semaphorins (collapsin, fasciclin) mediate repulsive and inhibitory guidance of neurons(1-4). Semaphorin III, a secretable member of this family, is expressed by the ventral spinal cord at the time corresponding to projection of sensory afferents from the dorsal root ganglion (DRG) into the spinal cord(6). The inhibitory effect of E14 ventral cord is active only on nerve growth factor (NGF)-responsive sensory afferents (small-diameter A-delta and C fibers subserving sensations of temperature and pain)(5). Similarly, COS cells secreting recombinant semaphorin III are able to selectively repel DRG afferents whose growth is stimulated by NGF and not NT-3 (ref. 7). However, it is not known whether these molecules can exert a functional role in the fully developed adult peripheral nervous system. In this study, we demonstrated that gene gun transfection and production of semaphorin III in corneal epithelial cells in adult rabbits in vivo can cause repulsion of established A-delta and C fiber trigeminal sensory afferents. In addition, it is shown that, following epithelial wounding and denervation, semaphorin III is able to inhibit collateral nerve sprouts from innervating the reepithelialized tissue. These findings are significant in that they provide direct evidence that small-diameter adult sensory neurons retain the ability to respond to semaphorin III. In addition, the corneal gene gun technique may be generally used to study the in vivo effects of neural growth modulators by quantifying the amount of sensory nerve growth.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Mol Cardiol Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smith, GM (corresponding author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BEUERMAN RW, 1984, NEUROSCI LETT, V44, P99, DOI 10.1016/0304-3940(84)90228-3; EBENDAL T, 1983, EXP CELL RES, V148, P311, DOI 10.1016/0014-4827(83)90155-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; HELM R, 1995, NATURE, V373, P663; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MACIVER MB, 1993, J NEUROSCI, V13, P4511; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Nguyen DH, 1997, CORNEA, V16, P192; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; Smith GM, 1996, EXP NEUROL, V139, P156, DOI 10.1006/exnr.1996.0090; Tanelian DL, 1997, BIOTECHNIQUES, V23, P484, DOI 10.2144/97233st06; TANELIAN DL, 1984, EXP NEUROL, V84, P165, DOI 10.1016/0014-4886(84)90013-X; TANELIAN DL, 1995, J NEUROPHYSIOL, V73, P1568, DOI 10.1152/jn.1995.73.4.1568; TANELIAN DL, 1990, J NEUROSCI METH, V32, P213, DOI 10.1016/0165-0270(90)90143-4; WILLIAMS RS, 1995, P NATL ACAD SCI USA, V88, P361; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209	20	105	116	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1398	1401		10.1038/nm1297-1398	http://dx.doi.org/10.1038/nm1297-1398			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396612				2022-12-27	WOS:000072249500038
J	Chinery, R; Brockman, JA; Peeler, MO; Shyr, Y; Beauchamp, RD; Coffey, RJ				Chinery, R; Brockman, JA; Peeler, MO; Shyr, Y; Beauchamp, RD; Coffey, RJ			Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBP beta	NATURE MEDICINE			English	Article							NF-KAPPA-B; CYCLIN-DEPENDENT KINASES; VITAMIN-E; INDUCED APOPTOSIS; CDK INHIBITORS; IN-VIVO; CELLS; P53; ALPHA; P21	Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Five-fluorouracil (5FU) remains the single most effective treatment for advanced disease, despite a response rate of only 20%. Herein, we show that the antioxidants pyrrolidinedithiocarbamate and vitamin E induce apoptosis in CRC cells. This effect is mediated by induction of p21(WAF1/CIP1), a powerful inhibitor of the cell cycle, through a mechanism involving C/EBP beta (a member of the CCAAT/enhancer binding protein family of transcription factors), independent of p53. Antioxidants significantly enhance CRC tumor growth inhibition by cytotoxic chemotherapy in vitro (5FU and doxorubicin) and in vivo (5FU). Thus, chemotherapeutic agents administered in the presence of antioxidants may provide a novel therapy for colorectal cancer.	VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT SURG,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,VANDERBILT CANC CTR,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System				Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053319] Funding Source: NIH RePORTER; NCI NIH HHS [CA 4613, CA 69457] Funding Source: Medline; NIGMS NIH HHS [GM 53319] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ADV COL CANC MET, 1992, J CLIN ONCOL, V10, P896; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3313; CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HARPER JW, 1993, CELL, V75, P805; HERRMANN R, 1990, CANCER TREAT REV, V17, P51, DOI 10.1016/0305-7372(90)90016-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMARIE E, 1986, METHOD FIND EXP CLIN, V8, P51; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETERS GJ, 1995, EUR J CANCER, V31A, P1299, DOI 10.1016/0959-8049(95)00172-F; POLL V, 1990, CELL, V63, P643; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRAHBU NS, 1996, CLIN CANCER RES, V2, P1221; RAUTALAHTI M, 1993, ANN MED, V25, P435; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stone WL, 1997, JNCI-J NATL CANCER I, V89, P1006, DOI 10.1093/jnci/89.14.1006; SUNDERMAN FW, 1991, ANN CLIN LAB SCI, V21, P70; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsai JC, 1996, J BIOL CHEM, V271, P3667; TURLEY JM, 1995, CELL GROWTH DIFFER, V6, P655; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu GS, 1996, CLIN CANCER RES, V2, P623; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	311	316	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1233	1241		10.1038/nm1197-1233	http://dx.doi.org/10.1038/nm1197-1233			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359698				2022-12-27	WOS:A1997YD89600032
J	Moses, AV; Williams, SE; Strussenberg, JG; Heneveld, ML; Ruhl, RA; Bakke, AC; Bagby, GC; Nelson, JA				Moses, AV; Williams, SE; Strussenberg, JG; Heneveld, ML; Ruhl, RA; Bakke, AC; Bagby, GC; Nelson, JA			HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; MARROW STROMAL CELLS; ADHESION MOLECULE-1 VCAM-1; BONE-MARROW; KAPOSIS-SARCOMA; FUNCTIONAL CD40; IL-6 PRODUCTION; LEUKEMIA CELLS; TUMOR-CELLS; IN-VITRO	Human immunodeficiency virus (HIV)-1 infection is associated with the development of aggressive extranodal B-cell non-Hodgkin's lymphomas. Using microvascular endothelial cell (MVEC)enriched bone marrow stromal cultures, HIV infection of stromal MVECs from lymphoma patients induced the outgrowth of malignant B cells. MVECs were the only HIV-infected cells in the stroma, and purified brain MVECs also induced a phenotype supportive of neoplastic B-cell attachment and proliferation. HIV infection of MVECs stimulated surface expression of CD40 and allowed preferential induction of the vascular cell adhesion molecule VCAM-1 after CD40 triggering. B-lymphoma cells expressed the CD40 ligand (CD40L), and blocking of CD40-CD40L interactions between HIV-infected MVECs and B-lymphoma cells inhibited B-cell attachment and proliferation. These observations suggest that HIV promotes B-lymphoma cell growth through facilitating attachment of lymphoma cells to HIV-infected MVECs and represent a novel mechanism through which viruses may induce malignancies.	OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201; VET AFFAIRS MED CTR,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University	Moses, AV (corresponding author), OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,L220,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Bagby, Grover/0000-0001-6830-2046	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051519] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49887] Funding Source: Medline; NIMH NIH HHS [MH 51519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Astrin S M, 1992, Curr Top Microbiol Immunol, V182, P399; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BROSHOFF C, 1995, NAT MED, V1, P1274; CAMPANA D, 1993, BLOOD, V81, P1025; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; CASTLE BE, 1993, J IMMUNOL, V151, P1777; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; DELECLUSE HJ, 1993, BLOOD, V82, P552; DITTEL BN, 1993, BLOOD, V81, P2272; FREEDMAN AS, 1993, SEMIN HEMATOL, V30, P318; FREEDMAN AS, 1992, BLOOD, V79, P206; Gaidano G, 1995, ADV CANCER RES, V67, P113, DOI 10.1016/S0065-230X(08)60712-5; GAIDANO G, 1993, LEUKEMIA, V7, P1621; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREEN DF, 1992, KIDNEY INT, V41, P956, DOI 10.1038/ki.1992.146; GROOPMAN JE, 1986, BLOOD, V67, P612; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; JACOBSEN K, 1990, EUR J IMMUNOL, V20, P2395, DOI 10.1002/eji.1830201106; JARVIS LJ, 1995, J IMMUNOL, V155, P2359; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MANABE A, 1994, BLOOD, V83, P758; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moses A V, 1996, J NeuroAIDS, V1, P85; Moses AV, 1996, BLOOD, V87, P919, DOI 10.1182/blood.V87.3.919.bloodjournal873919; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; Moses AV, 1996, J VIROL, V70, P3401, DOI 10.1128/JVI.70.6.3401-3406.1996; Pammer J, 1996, AM J PATHOL, V148, P1387; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; PELLICI PG, 1986, J EXP MED, V164, P2049; Pinchuk LM, 1996, J IMMUNOL, V157, P4363; PREVOT S, 1993, HISTOPATHOLOGY, V22, P151, DOI 10.1111/j.1365-2559.1993.tb00094.x; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SHIRAMIZU B, 1992, J CLIN ONCOL, V10, P383, DOI 10.1200/JCO.1992.10.3.383; SIMMONS PJ, 1992, BLOOD, V80, P388; STEFFAN AM, 1992, P NATL ACAD SCI USA, V89, P1582, DOI 10.1073/pnas.89.5.1582; SUBAR M, 1988, BLOOD, V72, P667; TANG JH, 1993, BLOOD, V82, P3415; TELENTI A, 1990, J CLIN MICROBIOL, V28, P2187, DOI 10.1128/JCM.28.10.2187-2190.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WOLF ML, 1991, J IMMUNOL, V147, P3324; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	55	39	41	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1242	1249		10.1038/nm1197-1242	http://dx.doi.org/10.1038/nm1197-1242			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359699				2022-12-27	WOS:A1997YD89600033
J	Chen, SG; Parchi, P; Brown, P; Capellari, S; Zou, WQ; Cochran, EJ; VnencakJones, CL; Julien, J; Vital, C; Mikol, J; Lugaresi, E; AutilioGambetti, L; Gambetti, P				Chen, SG; Parchi, P; Brown, P; Capellari, S; Zou, WQ; Cochran, EJ; VnencakJones, CL; Julien, J; Vital, C; Mikol, J; Lugaresi, E; AutilioGambetti, L; Gambetti, P			Allelic origin of the abnormal prion protein isoform in familial prion diseases	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; CODON-178ASN PRNP MUTATION; SCRAPIE PRION; DNA POLYMORPHISM; PRP 27-30; INSOMNIA; GENE; TRANSMISSION; SEPARATION; CONVERSION	The hallmark of prion diseases is the presence of an aberrant isoform of the prion protein (PrPres) that is insoluble in nondenaturing detergents and resistant to proteases. We investigated the allelic origin of PrPres in brains of subjects heterozygous for the D178N mutation linked to fatal familial insomnia (FFI) and a subtype of Creutzfeldt-Jakob disease (CJD(178)), as well as for insertional mutations associated with another CJD subtype. We found that in FFI and CJD(178) subjects, only mutant PrP was detergent-insoluble and protease-resistant. Therefore, PrPres derives exclusively from the mutant allele carrying the D178N mutation. In contrast, in the CJD subtype harboring insertional mutations, wild-type PrP was also detergent-insoluble and likely to be protease-resistant. Our findings indicate that the participation of the wild-type PrP in the formation of PrPres depends on the type of mutations, providing an insight into the molecular mechanisms underlying the phenotypic heterogeneity in familial prion diseases.	NINCDS,CNS STUDIES LAB,NIH,BETHESDA,MD 20892; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612; VANDERBILT UNIV,MED CTR,DEPT PATHOL,NASHVILLE,TN 37232; CHU BORDEAUX,DEPT NEUROL,F-33604 PESSAC,FRANCE; CHU BORDEAUX,DEPT PATHOL,F-33604 PESSAC,FRANCE; HOP LARIBOISIERE,F-75475 PARIS,FRANCE; UNIV BOLOGNA,INST NEUROL,I-40123 BOLOGNA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rush University; Vanderbilt University; CHU Bordeaux; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Bologna	Chen, SG (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106, USA.		Zou, Wenquan/ABF-2875-2020; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021; Zou, Wenquan/GWQ-3489-2022; capellari, sabina/F-5545-2012; Parchi, Piero/L-9833-2015; Chen, Shu/Z-2943-2019	Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; capellari, sabina/0000-0003-1631-1439; Parchi, Piero/0000-0002-9444-9524; 	NIA NIH HHS [AG08992, AG08155] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG008992, R37AG008155] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAYER EA, 1987, ANAL BIOCHEM, V161, P262, DOI 10.1016/0003-2697(87)90450-7; BERTONI JM, 1992, JAMA-J AM MED ASSOC, V268, P2413, DOI 10.1001/jama.268.17.2413; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; BROWN P, 1992, ANN NEUROL, V31, P282, DOI 10.1002/ana.410310309; Capellari S, 1997, NEUROLOGY, V49, P133, DOI 10.1212/WNL.49.1.133; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chapman J, 1996, NEUROLOGY, V46, P758, DOI 10.1212/WNL.46.3.758; CHAPMAN J, 1993, J NEUROL NEUROSUR PS, V56, P1109, DOI 10.1136/jnnp.56.10.1109; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Cochran EJ, 1996, NEUROLOGY, V47, P727, DOI 10.1212/WNL.47.3.727; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PALMER MS, 1993, HUM MOL GENET, V2, P541, DOI 10.1093/hmg/2.5.541; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2	45	80	90	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1009	1015		10.1038/nm0997-1009	http://dx.doi.org/10.1038/nm0997-1009			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288728				2022-12-27	WOS:A1997XT84200034
J	Choppin, PW				Choppin, PW			The Howard Hughes Medical Institute and science in central Europe, the Baltics and the former Soviet Union	NATURE MEDICINE			English	Editorial Material											Choppin, PW (corresponding author), HOWARD HUGHES MED INST,4000 JONES BRIDGE RD,CHEVY CHASE,MD 20815, USA.							1997, CHRONICLE HIGHE 0725, pA13	1	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					949	950		10.1038/nm0997-949	http://dx.doi.org/10.1038/nm0997-949			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288712				2022-12-27	WOS:A1997XT84200018
J	Jonas, WB				Jonas, WB			Researching alternative medicine	NATURE MEDICINE			English	Editorial Material							COMPLEMENTARY MEDICINE; RHEUMATOID-ARTHRITIS; METAANALYSIS; TRIAL				Jonas, WB (corresponding author), NIH,OFF ALTERNAT MED,9000 ROCKVILLE PIKE,BLDG 31,ROOM 5B35,MSC 2182,BETHESDA,MD 20892, USA.							Ader R, 1985, PLACEBO THEORY RES M, P306; Altman Roy D., 1994, Seminars in Arthritis and Rheumatism, V23, P25, DOI 10.1016/S0049-0172(10)80023-X; ANDERSON WH, 1993, AIDS, V74, P561; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BERMAN BM, 1995, OSTEOARTHR CARTILAGE, V3, P139, DOI 10.1016/S1063-4584(05)80046-9; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Boissel JP, 1996, CRITICAL LIT REV EFF; BRAUD WG, 1992, SUBTLE ENERGIES, V2, P1; CARLSTON M, 1997, IN PRESS FAM MED; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; Dowie J, 1996, BRIT MED J, V313, P170, DOI 10.1136/bmj.313.7050.170a; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; HALLIDAY J, 1993, COMPLEMENTARY THER S, V1, P32; Jonas WB, 1996, INFLAMM RES, V45, P330, DOI 10.1007/BF02252945; KJELDSENKRAGH J, 1995, SCAND J RHEUMATOL, V24, P85, DOI 10.3109/03009749509099290; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; Lavigne J V, 1992, Arthritis Care Res, V5, P101, DOI 10.1002/art.1790050209; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Neil Andrew, 1994, Current Opinion in Lipidology, V5, P6, DOI 10.1097/00041433-199402000-00002; RADIN DI, 1989, FOUND PHYS, V19, P1499, DOI 10.1007/BF00732509; TAO XL, 1987, CHIN J MED, V26, P399; TAO XL, 1987, CHUNG HUA NEI KO TSA, V26, P444; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; 1997, INT J TECH ASSESS HL, V13, P111; [No title captured]; 1997, ALTERNATIVE THERAPIE, V3, P49	35	28	28	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					824	827		10.1038/nm0897-824	http://dx.doi.org/10.1038/nm0897-824			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256264				2022-12-27	WOS:A1997XP01400015
J	Suzuki, JI; Isobe, M; Morishita, R; Aoki, M; Horie, S; Okubo, Y; Kaneda, Y; Sawa, Y; Matsuda, H; Ogihara, T; Sekiguchi, M				Suzuki, JI; Isobe, M; Morishita, R; Aoki, M; Horie, S; Okubo, Y; Kaneda, Y; Sawa, Y; Matsuda, H; Ogihara, T; Sekiguchi, M			Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide	NATURE MEDICINE			English	Article							ARTERY DISEASE; INHIBITION; HYPERPLASIA; EXPRESSION; HEART; GENE	Craft coronary arteriosclerosis, which limits the long-term survival of allograft recipients, is characterized by diffuse intimal thickening composed of proliferative smooth muscle cells(1,2). We observed that messenger RNA of the cell cycle regulatory enzyme cyclin-dependent kinase (cdk) 2 kinase, which mediates smooth muscle cell proliferation, was elevated in the thickened intima of coronary arteries of murine heterotopic cardiac allografts. We studied the effects of antisense phosphorothioate oligodeoxynucleotide (ODN) against this enzyme using gene transfer mediated by a hemagglutinating virus of Japan (HVJ)-liposome complex intraluminally delivered to inhibit the intimal hyperplasia. At 30 days after transplantation, antisense cdk2 kinase ODN treatment had dramatically inhibited neointimal formation in the allografts. Expression of vascular cell adhesion molecule-1 was also suppressed by antisense cdk2 kinase. However, these effects were not observed in the sense or scrambled ODN-treated allografts. Thus, an intraluminal administration of antisense ODN directed to a specific cell cycle regulatory gene can inhibit neointimal formation after cardiac transplantation.	SHINSHU UNIV,SCH MED,DEPT INTERNAL MED 1,MATSUMOTO,NAGANO 390,JAPAN; OSAKA UNIV,SCH MED,DEPT GERIATR MED,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 1,SUITA,OSAKA 565,JAPAN	Shinshu University; Osaka University; Osaka University; Osaka University								BOTAS J, 1995, CIRCULATION, V92, P1126, DOI 10.1161/01.CIR.92.5.1126; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dzau VJ, 1996, P NATL ACAD SCI USA, V93, P11421, DOI 10.1073/pnas.93.21.11421; EICH DM, 1993, CIRCULATION, V87, P261, DOI 10.1161/01.CIR.87.1.261; Furukawa Y, 1996, CIRCULATION, V93, P333, DOI 10.1161/01.CIR.93.2.333; Hosenpud J D, 1993, Transpl Immunol, V1, P237, DOI 10.1016/0966-3274(93)90031-3; HOSENPUD JD, 1995, J HEART LUNG TRANSPL, V14, P805; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; POLLAK R, 1993, NEW ENGL J MED, V328, P1851; SAWA Y, 1995, CIRCULATION, V92, P479, DOI 10.1161/01.CIR.92.9.479; SUZUKI J, IN PRESS J HEART LUN; Suzuki JI, 1996, CIRCULATION, V94, P1118, DOI 10.1161/01.CIR.94.5.1118; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0	20	106	112	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					900	903		10.1038/nm0897-900	http://dx.doi.org/10.1038/nm0897-900			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256282				2022-12-27	WOS:A1997XP01400033
J	Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM				Davis, KD; Taub, E; Houle, S; Lang, AE; Dostrovsky, JO; Tasker, RR; Lozano, AM			Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms	NATURE MEDICINE			English	Article							POSTEROVENTRAL PALLIDOTOMY; NEURONAL-ACTIVITY; DISEASE; SUPPLEMENTARY; APOMORPHINE; TREMOR; AREA	Studies of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in monkeys(1,2) suggest that excessive inhibitory outflow from the internal segment of the globus pallidus (GPi) suppresses the motor thalamus, which reduces activation of the cerebral cortex motor system, resulting in the slowness and poverty of movement of Parkinson's disease (PD)(3). This hypothesis is supported by reports of high rates of spontaneous neuronal discharges and hypermetabolism in GPi (ref. 4-7) and impaired activation of the supplementary motor area (SMA) and dorsolateral prefrontal regions(8,9) in PD patients. Furthermore, lesion or chronic high-frequency electrical (likely inactivating) stimulation of GPi (ref. 10-14) is associated with marked improvements in akinesia and rigidity, and the impaired activation of SMA is reversed when the akinesia is treated with dopamine agonists's. To test whether improvement in motor function with pallidal surgery can be attributed to increased activity in premotor cortical regions, we assessed the changes in regional cerebral blood flow (rCBF) and parkinsonian symptoms during disruption of GPi activity with high-frequency stimulation delivered through implanted brain electrodes. Positron emission tomography (PET) revealed an increase in rCBF in ipsilateral premotor cortical areas during GPi stimulation, which improved rigidity and bradykinesia. These results suggest that disrupting the excessive inhibitory output of the basal ganglia reverses parkinsonism, via a thalamic relay, by activation of brain areas involved in the initiation of movement.	UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROSURG,DEPT SURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,PET CTR,CLARKE INST PSYCHIAT,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,TORONTO WESTERN HOSP,DIV NEUROL,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Lozano, Andres M/A-5058-2012; Lang, Anthony/ABF-8114-2021	Lozano, Andres M./0000-0001-8257-3694; Houle, Sylvain/0000-0002-4231-6316; Lang, Anthony/0000-0003-1229-3667				Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beric A, 1996, ADV NEUROL, V69, P123; CEBALLOSBAUMANN AO, 1994, LANCET, V344, P814, DOI 10.1016/S0140-6736(94)92369-8; COLEBATCH JG, 1990, LANCET, V336, P1028, DOI 10.1016/0140-6736(90)92489-5; CRIDLAND RA, 1988, BRAIN RES BULL, V20, P429, DOI 10.1016/0361-9230(88)90132-3; DEIBER MP, 1993, BRAIN, V116, P267, DOI 10.1093/brain/116.1.267; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Eidelberg D, 1996, ANN NEUROL, V39, P450, DOI 10.1002/ana.410390407; EIDELBERG D, 1994, J CEREBR BLOOD F MET, V14, P783, DOI 10.1038/jcbfm.1994.99; EKBLOM A, 1988, J NEUROL NEUROSUR PS, V51, P481, DOI 10.1136/jnnp.51.4.481; FILION M, 1991, BRAIN RES, V547, P142; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GRAFTON ST, 1995, ANN NEUROL, V37, P776, DOI 10.1002/ana.410370611; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HUTCHISON WD, 1994, NEUROREPORT, V5, P1533, DOI 10.1097/00001756-199407000-00031; JENKINS IH, 1992, ANN NEUROL, V32, P749, DOI 10.1002/ana.410320608; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; Parent A., 1996, CARPENTERS HUMAN NEU, V9th. Edn; PLAYFORD ED, 1993, ADV NEUROL, V60, P506; RASCOL O, 1992, ARCH NEUROL-CHICAGO, V49, P144, DOI 10.1001/archneur.1992.00530260044017; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Talairach J., 1988, COPLANAR STEREOTAXIC	29	167	173	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					671	674		10.1038/nm0697-671	http://dx.doi.org/10.1038/nm0697-671			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176495				2022-12-27	WOS:A1997XB97400038
J	Weaver, JC; McGrath, P; Adams, S				Weaver, JC; McGrath, P; Adams, S			Gel microdrop technology for rapid isolation of rare and high producer cells	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; SECRETION CAPTURE; HYBRIDOMA CELLS; REPORT WEB; FLUORESCENCE; CLONING; IGG		ONE CELL SYST INC,CAMBRIDGE,MA 02139; MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)								CARLSSON R, 1989, BIO-TECHNOL, V7, P567, DOI 10.1038/nbt0689-567; GIFT EA, 1995, NAT BIOTECHNOL, V14, P884; GRAY F, 1995, J IMMUNOL METHODS, V182, P155, DOI 10.1016/0022-1759(94)00319-R; KENNEY JS, 1995, BIO-TECHNOL, V13, P787, DOI 10.1038/nbt0895-787; MEILHOC E, 1989, J IMMUNOL METHODS, V121, P167, DOI 10.1016/0022-1759(89)90157-9; NGUYEN BT, 1995, CYTOMETRY, V21, P111, DOI 10.1002/cyto.990210202; OZTURK SS, 1990, HYBRIDOMA, V9, P167, DOI 10.1089/hyb.1990.9.167; PARKS DR, 1979, P NATL ACAD SCI USA, V76, P1962, DOI 10.1073/pnas.76.4.1962; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; RYAN C, 1995, J CLIN MICROBIOL, V33, P1720, DOI 10.1128/JCM.33.7.1720-1726.1995; SEN S, 1990, ENZYME MICROB TECH, V12, P571, DOI 10.1016/0141-0229(90)90129-E; Sullivan Susan J., 1995, Molecular Biology of the Cell, V6, p445A; UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119; UZGIRIS AJ, 1994, GENOME SCI TECHNOLOG; WEAVER JC, 1988, BIO-TECHNOL, V6, P1084, DOI 10.1038/nbt0988-1084; WEAVER JC, 1990, METHOD ENZYMOL, V2, P234; WEAVER JC, 1995, FLOW CYTOMETRY APPL, P39; WILLIAMS GB, 1990, J CLIN MICROBIOL, V28, P1002, DOI 10.1128/JCM.28.5.1002-1008.1990	18	36	47	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					583	585		10.1038/nm0597-583	http://dx.doi.org/10.1038/nm0597-583			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142132				2022-12-27	WOS:A1997WX54300043
J	TerGrigorov, VS; Krifuks, O; Liubashevsky, E; Nyska, A; Trainin, Z; Toder, V				TerGrigorov, VS; Krifuks, O; Liubashevsky, E; Nyska, A; Trainin, Z; Toder, V			A new transmissible AIDS-like disease in mice induced by alloimmune stimuli	NATURE MEDICINE			English	Article							LYMPHOPROLIFERATIVE DISEASE; ACQUIRED IMMUNODEFICIENCY; PATHOGENESIS; MOUSE; HIV; AUTOANTIBODIES; INDUCTION; PREGNANCY; LYMPHOMAS; ANTIBODY	The search for a suitable and reliable animal model for human AIDS that is easy to use on a large scale continues. Here we describe a new condition in mice that closely resembles human AIDS, namely, chronic lymphoproliferation with dramatic depletion of CD4-positive cells, progressive impairment of the immune responses, and Kaposi's sarcoma-like tumors or terminal B-lymphomas. The AIDS-like disease was primarily induced by mating BALB/c female mice to C57BL/6 males during a 1-year period (7-10 allogeneic pregnancies) followed by immunization with paternal lymphocytes. The disease is sexually and vertically transmissible, transferrable by cell-free plasma and is associated with autoimmune reactions to major histocompatibility complex antigens and CD4 cells. We hope that this becomes a model for studying the mechanisms of AIDS immunopathogenesis and immune-based treatment approaches.	TEL AVIV UNIV,SACKLER FAC MED,DEPT EMBRYOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	TerGrigorov, VS (corresponding author), KIMRON VET INST,DEPT PATHOL & IMMUNOL,IL-50250 BET DAGAN,ISRAEL.							ALTAN H, 1994, RES IMMUNOL, V145, P165; BLANK M, 1987, AM J REPROD IMMUNOL, V14, P49; CHAN WL, 1992, J EXP MED, V176, P1203, DOI 10.1084/jem.176.4.1203; CUNNIGHAM RK, 1994, IMMUNOL RES, V13, P21, DOI 10.1007/BF02918221; DALGLEISH AG, 1992, J ROY COLL PHYS LOND, V26, P152; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; GLEICHER N, 1992, AM J REPROD IMMUNOL, V28, P269, DOI 10.1111/j.1600-0897.1992.tb00812.x; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HABESHAW J, 1992, IMMUNOL TODAY, V13, P207, DOI 10.1016/0167-5699(92)90155-Z; HARANGHERA N, 1994, ADV CANCER RES, V63, P245, DOI 10.1016/S0065-230X(08)60402-9; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HUNT JS, 1992, CURR OPIN IMMUNOL, V4, P591, DOI 10.1016/0952-7915(92)90032-A; IEVLEVA ES, 1976, INT J CANCER, V17, P798, DOI 10.1002/ijc.2910170617; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; MITSUYASU RT, 1988, BLOOD REV, V2, P222, DOI 10.1016/0268-960X(88)90011-2; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; PATTENGALE PK, 1983, J NATL CANCER I, V70, P164; REED E, 1991, AM J REPROD, V20, P116; REICHERT CM, 1983, AM J PATHOL, V112, P357; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; SHEARER GM, 1986, MT SINAI J MED, V53, P605; SHIPOVA LY, 1994, EXP TOXICOL PATHOL, V46, P409, DOI 10.1016/S0940-2993(11)80125-9; SLAVIN S, 1978, NATURE, V272, P624, DOI 10.1038/272624a0; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; SUSAL G, 1996, IMMUNOL TODAY, V17, P114; TERGRIGOROV V, 1992, LEUKEMIA S16, V3, P171; TERGRIGOROV V, 1993, J CELL BIOCH S1, V170, P129; TERGRIGOROV VS, 1988, EKSP ONKOL, V6, P44; THACORE HR, 1994, IMMUNOBIOLOGY, V190, P195, DOI 10.1016/S0171-2985(11)80269-X; VOGEL J, 1988, NATURE, V335, P605	32	13	14	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					37	41		10.1038/nm0197-37	http://dx.doi.org/10.1038/nm0197-37			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986738				2022-12-27	WOS:A1997WA73300034
J	Huang, YX; Paxton, WA; Wolinsky, SM; Neumann, AU; Zhang, LQ; He, T; Kang, S; Ceradini, D; Jin, ZQ; Yazdanbakhsh, K; Kunstman, K; Erickson, D; Dragon, E; Landau, NR; Phair, J; Ho, DD; Koup, RA				Huang, YX; Paxton, WA; Wolinsky, SM; Neumann, AU; Zhang, LQ; He, T; Kang, S; Ceradini, D; Jin, ZQ; Yazdanbakhsh, K; Kunstman, K; Erickson, D; Dragon, E; Landau, NR; Phair, J; Ho, DD; Koup, RA			The role of a mutant CCR5 allele in HIV-1 transmission and disease progression	NATURE MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; IMMUNODEFICIENCY; COHORT	A 32-nucleotide deletion (Delta 32) within the beta-chemokine receptor 5 (CCR5) gene has been described in subjects who remain uninfected despite extensive exposure to HIV-1. This allele was found to be common in the Caucasian population with a frequency of 0.0808, but was not found in people of African or Asian ancestry. To determine its role in HIV-1 transmission and disease progression, we analyzed the CCR5 genotype of 1252 homosexual men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS). No infected participant was found to be homozygous for the Delta 32 allele, whereas 3.6% of at-risk but uninfected Caucasian participants were homozygous, showing the highly protective role of this genotype against sexual acquisition of HIV-1. No evidence was found to suggest that heterozygotes were protected against HIV-1 infection, but a limited protective role against disease progression was noted. The Delta 32 allele of CCR5 is therefore an important host factor in HIV-1 transmission and pathogenesis.	AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; ROCKEFELLER UNIV,NEW YORK,NY 10016; NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,LAB IMMUNOCHEM,NEW YORK,NY 10021; ROCHE MOL SYST,BRANCHBURG,NJ 08876	Rockefeller University; Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory; New York Blood Center; Roche Holding			paxton, william/R-9747-2019; /ABE-5226-2021; Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Paxton, William/0000-0001-5200-0801; Paxton, William/0000-0002-2654-5186	NIAID NIH HHS [AI 32535, AI 35168, AI 45218] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONNOR RI, IN PRESS J VIROL; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	23	1084	1135	0	76	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1240	1243		10.1038/nm1196-1240	http://dx.doi.org/10.1038/nm1196-1240			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898752				2022-12-27	WOS:A1996VQ10100040
J	Kennard, ML; Feldman, H; Yamada, T; Jefferies, WA				Kennard, ML; Feldman, H; Yamada, T; Jefferies, WA			Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; BETA-PROTEIN; MISSENSE MUTATIONS; GENE; FERRITIN; ALUMINUM; TRANSFERRIN; PEPTIDE; LOCUS	Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age. A biochemical marker for monitoring the onset and progression of the disease would be a valuable tool for disease management. In addition, such a marker might be used as an end point in clinical intervention protocols. Here we provide evidence that the soluble form of the iron binding protein p97 is found in elevated amounts in the serum of Alzheimer's patients compared with healthy controls. This biochemical marker has the potential for identifying subjects afflicted with the disease and possibly for monitoring the onset and longitudinal progression of the disease.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER HOSP & HLTH SCI CTR, DEPT MED, DIV NEUROL, VANCOUVER, BC V6T 2B5, CANADA; CHIBA UNIV, SCH MED, DEPT NEUROL, CHUO KU, CHIBA 260, JAPAN	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Chiba University				Feldman, Howard/0000-0002-9258-4538				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BLASS JP, 1993, NEUROLOGY, V43, pS25; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; BROWN JP, 1981, J IMMUNOL, V127, P539; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; DEDMAN DJ, 1992, BIOCHEM J, V287, P509, DOI 10.1042/bj2870509; EHMANN WD, 1986, NEUROTOXICOLOGY, V7, P197; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GRUNDKEIQBAL I, 1990, ACTA NEUROPATHOL, V81, P105, DOI 10.1007/BF00334497; Jefferies WA, 1996, BRAIN RES, V712, P122, DOI 10.1016/0006-8993(95)01407-1; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KENNARD ML, 1993, BIOTECHNOL BIOENG, V42, P480, DOI 10.1002/bit.260420411; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KITAGUCHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1453, DOI 10.1016/0006-291X(90)91030-V; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; ROBINSON SR, 1996, ALZHEIMERS RES, V1, P191; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; WANG GP, 1991, ACTA NEUROPATHOL, V82, P6, DOI 10.1007/BF00310917; ZUBENKO GS, 1992, J NEUROPATH EXP NEUR, V51, P459, DOI 10.1097/00005072-199207000-00008	46	141	146	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1230	1235		10.1038/nm1196-1230	http://dx.doi.org/10.1038/nm1196-1230			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898750				2022-12-27	WOS:A1996VQ10100038
J	Hughes, DE; Dai, AH; Tiffee, JC; Li, HH; Mundy, GR; Boyce, BF				Hughes, DE; Dai, AH; Tiffee, JC; Li, HH; Mundy, GR; Boyce, BF			Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; BONE-RESORPTION; CELL-DEATH; IN-VIVO; OSTEOPOROSIS; TAMOXIFEN; CALVARIA; MASS; RATS	Postmenopausal osteoporosis, the most common bone disease in the developed world(1), is associated with estrogen deficiency. This deficiency induces increased generation and activity of osteoclasts, which perforate bone trabeculae, thus reducing their strength and increasing fracture risk. Estrogen replacement prevents these effects(2), indicating that estrogen negatively regulates osteoclast formation and function, but how it does this is unclear. Because functional osteoclast life span and thus the amount of bone that osteoclasts resorb could also be enhanced following estrogen deficiency, and since sex steroids regulate apoptosis in other target tissues(3), we investigated whether estrogen may affect osteoclast function by promoting apoptosis. 17 beta-Estradiol promoted apoptosis of murine osteoclasts in vitro and in vivo by two- to threefold. Tamoxifen, which has estrogenic effects on bone resorption(4), and transforming growth factor-beta 1 (TGF-beta), whose production by osteoblasts is increased by estrogen(5), had similar effects in vitro. Anti-TGF-beta antibody inhibited TGF-beta-, estrogen- and tamoxifen-induced osteoclast apoptosis, indicating that TGF-beta might mediate this effect. These findings suggest that estrogen may prevent excessive bone loss before and after the menopause by limiting osteoclast life span through promotion of apoptosis. The development of analogues to promote this mechanism specifically could be a useful and novel therapeutic approach to prevent postmenopausal osteoporosis.	UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT ORAL HEAD & NECK PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043510, P01AR039529] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 43510, AR 39529] Funding Source: Medline; NIDDK NIH HHS [DK 45299] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDREUIL J, 1995, J BONE MINER RES, V10, P971; BONEWALD LF, 1992, EXP HEMATOL, V20, P1249; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; GARRETT IR, 1989, J BONE MINER RES, V4, P789; GOULDING A, 1992, BONE MINER, V18, P143, DOI 10.1016/0169-6009(92)90854-7; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; HUGHES DE, 1994, J BONE MINER RES  S1, V9, pS138; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140-6736(93)90571-W; LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211; MELTON LJ, 1995, J BONE MINER RES, V10, P175; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; OURSLER MJ, 1994, P NATL ACAD SCI USA, V91, P5227, DOI 10.1073/pnas.91.12.5227; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1473; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; ZHENG MH, 1995, BONE S, V16, pS93	27	630	684	0	44	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1132	1136		10.1038/nm1096-1132	http://dx.doi.org/10.1038/nm1096-1132			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837613				2022-12-27	WOS:A1996VK99500035
J	Raisz, LG				Raisz, LG			Estrogen and bone: New pieces to the puzzle	NATURE MEDICINE			English	Editorial Material							RESORPTION				Raisz, LG (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.							CAPUTO CB, 1976, ENDOCRINOLOGY, V98, P1065, DOI 10.1210/endo-98-4-1065; Draper MW, 1996, J BONE MINER RES, V11, P835; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; JILKA RL, 1992, SCIENCE, V257, P8; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066; KE HZ, 1995, BONE, V17, P491, DOI 10.1016/8756-3282(95)00346-2; KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054; MIYAURA C, 1995, J BONE MINER RES, V10, P1365; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; Raisz Lawrence G., 1996, P661; VARGAS S, IN PRESS J BONE MINE; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	15	11	16	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1077	1078		10.1038/nm1096-1077	http://dx.doi.org/10.1038/nm1096-1077			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837601				2022-12-27	WOS:A1996VK99500023
J	Coffey, DS				Coffey, DS			Self-organization, complexity and chaos: The new biology for medicine	NATURE MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA	Johns Hopkins University	Coffey, DS (corresponding author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.							Adami C., 1998, INTRO ARTIFICIAL LIF; BIEBRICHER CK, 1995, 16546 EUR; BUDRENE EO, 1995, NATURE, V376, P49, DOI 10.1038/376049a0; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; DENTON TA, 1990, AM HEART J, V120, P1419, DOI 10.1016/0002-8703(90)90258-Y; EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; Glanz J, 1997, SCIENCE, V277, P1758, DOI 10.1126/science.277.5333.1758; Gleick J., 1987, CHAOS; GOLDBERGER A L, 1990, Scientific American, V262, P42; Gupta S, 1998, SCIENCE, V280, P912, DOI 10.1126/science.280.5365.912; KAUFFMAN SA, 1993, ORIGIN ORDER SELF OR; Langton C. G., 1992, SANTA FE I STUDIES S, V10; Lewin R, 1993, COMPLEXITY LIFE EDGE; Malins DC, 1998, P NATL ACAD SCI USA, V95, P7637, DOI 10.1073/pnas.95.13.7637; Poon CS, 1997, NATURE, V389, P492, DOI 10.1038/39043; Posadas EM, 1996, CANCER RES, V56, P3682; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; SCHWAB ED, 1997, ADV MOL CEL, V24, P207; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608	20	195	198	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					882	885		10.1038/nm0898-882	http://dx.doi.org/10.1038/nm0898-882			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701230				2022-12-27	WOS:000075107400020
J	Kimura, Y; Koga, H; Araki, N; Mugita, N; Fujita, N; Takeshima, H; Nishi, T; Yamashima, T; Saido, TC; Yamasaki, T; Moritake, K; Saya, H; Nakao, M				Kimura, Y; Koga, H; Araki, N; Mugita, N; Fujita, N; Takeshima, H; Nishi, T; Yamashima, T; Saido, TC; Yamasaki, T; Moritake, K; Saya, H; Nakao, M			The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas	NATURE MEDICINE			English	Article							NEUROFIBROMATOSIS TYPE-2 GENE; CALCIUM-CHANNEL ANTAGONISTS; SEQUENCE-ANALYSIS; MU-CALPAIN; PHOSPHORYLATION; INHIBITION; PROTEINS; CELLS; ACTIVATION; MUTATIONS	Neurofibromatosis type 2 (NF2) protein, also known as merlin or schwannomin, is a tumor suppressor, and NF2 is mutated in most schwannomas and meningiomas. Although these tumors are dependent on NF2, some lack detectable NF2 mutations, which indicates that alternative mechanisms exist for inactivating merlin. Here, we demonstrate cleavage of merlin by the ubiquitous protease calpain and considerable activation of the calpain system resulting in the loss of merlin expression in these tumors. Increased proteolysis of merlin by calpain in some schwannomas and meningiomas exemplifies tumorigenesis linked to the calpain-mediated proteolytic pathway.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Shimane Med Univ, Dept Neurosurg, Izumo, Shimane 6930021, Japan; Kanazawa Univ, Sch Med, Dept Neurosurg, Kanazawa, Ishikawa 9200934, Japan; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510106, Japan	Kumamoto University; Kumamoto University; Shimane University; Kanazawa University; RIKEN	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Sado, Takaomi/AAN-2759-2021; Saya, Hideyuki/J-4325-2013; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Burkhart WA, 1996, ANAL BIOCHEM, V236, P364, DOI 10.1006/abio.1996.0184; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Eldridge R, 1981, Adv Neurol, V29, P57; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Harada T, 1996, J NEUROSURG, V84, P847, DOI 10.3171/jns.1996.84.5.0847; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Jay D, 1997, BIOCHEM BIOPH RES CO, V232, P555, DOI 10.1006/bbrc.1997.6238; JENSEN RL, 1995, NEUROSURGERY, V36, P365, DOI 10.1227/00006123-199502000-00017; JENSEN RL, 1995, NEUROSURGERY, V37, P937, DOI 10.1227/00006123-199511000-00013; KOGA H, IN PRESS ONCOGENE; Lee JH, 1997, NEUROSURGERY, V40, P578, DOI 10.1097/00006123-199703000-00031; LEKANNE DRH, 1994, AM J HUM GENET, V54, P1022; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MILLER CG, 1995, TECH PROT CHEM, V6, P219, DOI 10.1016/S1080-8914(06)80029-3; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEKIDO Y, 1995, CANCER RES, V55, P1227; Selliah N, 1996, J IMMUNOL, V156, P3215; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; STEMMERRACHAMIM.OA, 1997, AM J PATHOL, V151, P1649; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x	50	95	96	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					915	922		10.1038/nm0898-915	http://dx.doi.org/10.1038/nm0898-915			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701243				2022-12-27	WOS:000075107400034
J	Molberg, O; Mcadam, SN; Korner, R; Quarsten, H; Kristiansen, C; Madsen, L; Fugger, L; Scott, H; Noren, O; Roepstorff, P; Lundin, KEA; Sjostrom, H; Sollid, LM				Molberg, O; Mcadam, SN; Korner, R; Quarsten, H; Kristiansen, C; Madsen, L; Fugger, L; Scott, H; Noren, O; Roepstorff, P; Lundin, KEA; Sjostrom, H; Sollid, LM			Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease	NATURE MEDICINE			English	Article							SMALL-INTESTINAL MUCOSA; MASS-SPECTROMETRY; CROSS-LINKING; BINDING; SPECIFICITY; ENDOCYTOSIS; PROTEINS; ANTIGEN	The action of tissue Transglutaminase(1) (TGase) on specific protein-bound glutamine residues plays a critical role in numerous biological processes(2-5). Here we provide evidence for a new role of this enzyme in the common, HLA-DQ2 (and DQ8) associated(6) enteropathy, celiac disease (CD). The intestinal inflammation in CD is precipitated by exposure to wheat gliadin in the diet(7) and is associated with increased mucosal activity of TGase(8). This enzyme has also been identified as the main target for CD-associated anti-endomysium autoantibodies(9), and is known to accept gliadin as one of its few substrates(10). We have examined the possibility that TGase could be involved in modulating the reactivity of gliadin specific T cells. This could establish a link between previous reports of the role of TGase in CD and the prevailing view of CD as a T-cell mediated disorder(7,11,12). We found a specific ef feet of TGase on T-cell recognition of gliadin. This effect was limited to gliadin-specific T cells isolated from intestinal CD lesions. We demonstrate that TGase mediates its effect through an ordered and specific deamidation of gliadins. This deamidation creates an epitope that binds efficiently to DQ2 and is recognized by gut-derived T cells. Generation of epitopes by enzymatic modification is a new mechanism that may be relevant for breaking of tolerance and initiation of autoimmune disease.	Univ Oslo, Rikshosp, Inst Transplantat Immunol, N-0027 Oslo, Norway; Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, N-0027 Oslo, Norway; Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark; Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8200 Aarhus N, Denmark; Univ Copenhagen, Rigshosp, Dept Clin Immunol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Biochem C, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Southern Denmark; Aarhus University; Rigshospitalet; University of Copenhagen; University of Copenhagen	Lundin, KEA (corresponding author), Ulleval Hosp, Dept Med, Oslo, Norway.		Lundin, Knut E. A./AAW-9519-2021; Sollid, Ludvig/N-9691-2015; Körner, Roman/G-8565-2011	Lundin, Knut E. A./0000-0003-1713-5545; Sollid, Ludvig/0000-0001-8860-704X; Körner, Roman/0000-0001-9285-9290				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; COOKS RG, 1991, CHEM ENG NEWS, V69, P26, DOI 10.1021/cen-v069n012.p026; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FRAZER AC, 1959, LANCET, V2, P252; GJERTSEN HA, 1994, SCAND J IMMUNOL, V39, P567, DOI 10.1111/j.1365-3083.1994.tb03414.x; HALSTENSEN TS, 1992, PROG HISTOCHEM CYTOC, V26, P201, DOI 10.1016/S0079-6336(11)80096-3; HAMADA JS, 1994, CRIT REV FOOD SCI, V34, P283, DOI 10.1080/10408399409527664; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Johansen BH, 1996, INT IMMUNOL, V8, P177, DOI 10.1093/intimm/8.2.177; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kwok WW, 1996, J EXP MED, V183, P1253, DOI 10.1084/jem.183.3.1253; LARRE C, 1994, J FOOD BIOCHEM, V17, P267; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LUNDIN KEA, 1994, HUM IMMUNOL, V41, P285, DOI 10.1016/0198-8859(94)90047-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MacDonald TT, 1992, COELIAC DISEASE, P283; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; Molberg O, 1998, GASTROENTEROLOGY, V114, P115, DOI 10.1016/S0016-5085(98)70639-0; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; Sollid LM, 1997, GUT, V41, P851, DOI 10.1136/gut.41.6.851; TESHIGAWARA K, 1985, MICROBIOL IMMUNOL, V29, P737, DOI 10.1111/j.1348-0421.1985.tb00877.x; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WIESER H, 1995, COELIAC DIS, P191	33	869	889	3	74	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1998	4	6					713	717		10.1038/nm0698-713	http://dx.doi.org/10.1038/nm0698-713			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623982				2022-12-27	WOS:000074008300039
J	Folkers, GK; Fauci, AS				Folkers, GK; Fauci, AS			The role of US Government agencies in vaccine research and development	NATURE MEDICINE			English	Editorial Material							STATES		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Folkers, GK (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P624; Belshe RB, 1998, LANCET, V351, P460, DOI 10.1016/S0140-6736(98)22007-1; BLOOM BR, 1994, SCIENCE, V265, P1378, DOI 10.1126/science.8073275; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P1245; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR MORB MORTAL WKL, V46, P765; *DEP HHS, FISC YEAR 1999 JUST, V2; DOUGLAS RG, 1996, B NY ACAD MED, P113; Fauci AS, 1996, LANCET, V348, P1002; GELLIN B, 1998, JORDAN REPORT ACCELE; JENKS S, 1995, J NATL CANCER I, V87, P642, DOI 10.1093/jnci/87.9.642-a; Levine M.M., 1997, NEW GENERATION VACCI; Marcuse EK, 1997, PEDIATRICS, V100, P1015, DOI 10.1542/peds.100.6.1015; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P489, DOI 10.1001/jama.279.7.489; *NAT I ALL INF DIS, 1995, HIV AIDS RES AG; *NAT I ALL INF DIS, 1998, NIH AIDS RES REF REA; TANOUYE E, 1998, WALL STREET J   0225; *WHO, WORLD HLTH REP 1997; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269; 1997, NATURE, V388, P211; 1997, CVI STRATEGIC PLAN M	22	14	14	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			491	494		10.1038/nm0598supp-491	http://dx.doi.org/10.1038/nm0598supp-491			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585193	Bronze			2022-12-27	WOS:000073453500011
J	Hedley, ML; Curley, J; Urban, R				Hedley, ML; Curley, J; Urban, R			Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses	NATURE MEDICINE			English	Article							DNA VACCINES; INDUCTION; IMMUNIZATION		Pangaea Pharmaceut Inc, Cambridge, MA 02138 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Hedley, ML (corresponding author), Pangaea Pharmaceut Inc, 763E Concord Ave, Cambridge, MA 02138 USA.	mlhedley@pangaea-pharm.com						Anton LC, 1997, J IMMUNOL, V158, P2535; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Fayolle C, 1996, IMMUNOLOGY, V89, P41, DOI 10.1046/j.1365-2567.1996.d01-704.x; IWASAKI A, 1997, IMMUNOLOGY, V159, P11; KANKE M, 1988, Journal of Parenteral Science and Technology, V42, P157; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; OKADA H, 1995, CRIT REV THER DRUG, V12, P1; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; TABATA Y, 1990, ADV POLYM SCI, V94, P107; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662	12	195	218	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					365	368		10.1038/nm0398-365	http://dx.doi.org/10.1038/nm0398-365			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500615				2022-12-27	WOS:000073616200047
J	Little, DP; Braun, A; O'Donnell, MJ; Koster, H				Little, DP; Braun, A; O'Donnell, MJ; Koster, H			Mass spectrometry from miniaturized arrays for full comparative DNA analysis	NATURE MEDICINE			English	Article									Sequenom Inc, San Diego, CA 92121 USA	Sequenom	Little, DP (corresponding author), Sequenom Inc, 11555 Sorrento Valley Rd, San Diego, CA 92121 USA.							Blanchard AP, 1996, NAT BIOTECHNOL, V14, P1649, DOI 10.1038/nbt1296-1649; Braun A, 1997, CLIN CHEM, V43, P1151; Braun A, 1997, GENOMICS, V46, P18, DOI 10.1006/geno.1997.5011; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; COTTER RJ, 1997, TIME FLIGHT MASS SPE, P113; Eng C, 1997, NAT BIOTECHNOL, V15, P422, DOI 10.1038/nbt0597-422; Fields GB, 1997, CLIN CHEM, V43, P1108; Guo Z, 1997, NAT BIOTECHNOL, V15, P331, DOI 10.1038/nbt0497-331; Haff LA, 1997, GENOME RES, V7, P378, DOI 10.1101/gr.7.4.378; Henry C, 1997, ANAL CHEM, V69, pA243, DOI 10.1021/ac971589w; Higgins GS, 1997, BIOTECHNIQUES, V23, P710, DOI 10.2144/97234st05; Koster H, 1996, NAT BIOTECHNOL, V14, P1123, DOI 10.1038/nbt0996-1123; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Linder MW, 1997, CLIN CHEM, V43, P254; Little DP, 1997, EUR J CLIN CHEM CLIN, V35, P545; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; Little DP, 1997, J MOL MED-JMM, V75, P745, DOI 10.1007/s001090050160; LITTLE DP, 1997, INT J MASS SPECTROM, V169; ODonnell MJ, 1997, ANAL CHEM, V69, P2438, DOI 10.1021/ac961007v; Ross PL, 1997, ANAL CHEM, V69, P4197, DOI 10.1021/ac9703966; TANG K, 1995, NUCLEIC ACIDS RES, V23, P3126, DOI 10.1093/nar/23.16.3126	21	70	93	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1413	1416		10.1038/nm1297-1413	http://dx.doi.org/10.1038/nm1297-1413			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396615				2022-12-27	WOS:000072249500041
J	Treutiger, CJ; Heddini, A; Fernandez, V; Muller, WA; Wahlgren, M				Treutiger, CJ; Heddini, A; Fernandez, V; Muller, WA; Wahlgren, M			PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CEREBRAL MALARIA; CELLS; CD31; IDENTIFICATION; SEQUESTRATION; MIGRATION; DOMAINS; CULTURE; GAMMA	Excessive binding of Plasmodium falciparum-infected red blood cells (pRBCs) to the vascular endothelium (cytoadherence) and to uninfected erythrocytes (resetting) may lead to occlusion of the microvasculature and thereby contribute directly to the acute pathology of severe human malaria(1,2). A number of endothelial receptors have been identified as targets for the pRBCs, including CD36, intercellular adhesion molecule-1 (ICAM-1) and chondroitin-4-sulfate (CSA)(3-5). In vitro, CD36 is the most frequent target of strains from patients with mild as well as severe P. falciparum malaria, but is expressed at low levels on the cerebral microvasculature(6) and therefore seems unlikely to be involved in the evolution of cerebral disease. Strains of P. falciparum that form rosettes are associated both with the occurrence of cerebral malaria and severe anemia(7-9). Here we report that malaria-infected RBCs adhere to platelet/endothelial cell adhesion molecule-1 (PECAM-1/CD31) on the vascular endothelium. pRBCs bind to endothelial cells, to PECAM-1/CD31 transfected cells, and directly to recombinant PECAM-1/CD31 absorbed onto plastic. Soluble PECAM-1/CD31 and monoclonal antibodies specific for the amino-terminal segment of PECAM-1/CD31 (domains 1-4) blocked the binding. Interferon-gamma (IFN-gamma)-essential for the development of cerebral malaria in the mouse-was found to augment adhesion of human pRBCs to PECAM-1/CD31 on endothelial cell monolayers. Our results suggest that PECAM-1/CD31 is a virulence-associated endothelial receptor of P. falciparum-infected RBCs.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Cornell Univ, Med Ctr, New York Hosp, Dept Pathol, New York, NY 10021 USA	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Cornell University; NewYork-Presbyterian Hospital	Wahlgren, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL146849, R01HL046849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46849] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1997, LEUKOCYTE TYPING, V6; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; ROMER LH, 1995, J IMMUNOL, V154, P6582; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403; Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tang QZ, 1996, J EXP MED, V184, P1435, DOI 10.1084/jem.184.4.1435; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503; TURNER GDH, 1994, AM J PATHOL, V145, P1057; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; WAHLGREN M, 1994, PARASITOL TODAY, V10, P73, DOI 10.1016/0169-4758(94)90400-6; WILSON GA, 1996, CELL ADHESION MOL, P42	26	166	167	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1405	1408		10.1038/nm1297-1405	http://dx.doi.org/10.1038/nm1297-1405			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396614				2022-12-27	WOS:000072249500040
J	Lee, WS; Harder, JA; Yoshizumi, M; Lee, ME; Haber, E				Lee, WS; Harder, JA; Yoshizumi, M; Lee, ME; Haber, E			Progesterone inhibits arterial smooth muscle cell proliferation	NATURE MEDICINE			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS; EXPRESSION; CONTRACTION; ESTRADIOL; HORMONE; PROTEIN; INJURY; PLASMA	Mortality from atherosclerotic cardiovascular disease is lower in premenopausal women than in age-matched men. It is also lower in postmenopausal women who take estrogens and progestins together rather than estrogens alone. Progesterone receptors were detected in human and rat aortic smooth muscle cells in vivo and in vitro (in subculture). We examined the effect of progesterone on proliferation of smooth muscle cells, important constituents of atherosclerotic plaques. Progesterone at physiologic levels inhibited DNA synthesis and proliferation in these cells in a dose-dependent manner, and pretreatment with the progesterone receptor antagonist RU486 blocked inhibition. Cyclin A and E messenger RNA levels decreased after progesterone treatment but those of cyclin B and D1 did not change. This cell cycle-dependent inhibition of arterial smooth muscle cell proliferation by progesterone may represent a mechanism for the hormone's protective effect against atherosclerosis.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health					NIGMS NIH HHS [R01 GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALLIS JRG, 1981, J ENDOCRINOL, V89, P337, DOI 10.1677/joe.0.0890337; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; INGEGNO MD, 1988, LAB INVEST, V59, P353; Knauthe R, 1996, ENDOCRINOLOGY, V137, P3220, DOI 10.1210/en.137.8.3220; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; LEE WS, 1994, J BIOL CHEM, V269, P12032; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MCGILL HC, 1979, ATHER REV, V4, P157; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; MORGAN KG, 1985, PFLUG ARCH EUR J PHY, V405, P77, DOI 10.1007/BF00591101; MURRAY TR, 1990, J CELL PHYSIOL, V143, P26, DOI 10.1002/jcp.1041430105; SHAABAN MM, 1973, J OBSTET GYN BR COMM, V80, P776; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STAMLER J, 1953, CIRC RES, V1, P94, DOI 10.1161/01.RES.1.1.94; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WEIGENSBERG BI, 1984, ATHEROSCLEROSIS, V52, P253, DOI 10.1016/0021-9150(84)90055-8; Williams JK, 1997, NAT MED, V3, P273, DOI 10.1038/nm0397-273; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	24	96	97	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1005	1008		10.1038/nm0997-1005	http://dx.doi.org/10.1038/nm0997-1005			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288727				2022-12-27	WOS:A1997XT84200033
J	Bonnet, D; Dick, JE				Bonnet, D; Dick, JE			Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell	NATURE MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; PROGENITOR CELLS; STEM-CELLS; SCID MOUSE; MICE; DIFFERENTIATION; ABNORMALITIES	On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clinical heterogeneity. Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice)-termed the SCID leukemia-initiating cell, or SL-IC-possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34(++) CD38(-), similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation. The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.	UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1X8, CANADA	University of Toronto	Bonnet, D (corresponding author), HOSP SICK CHILDREN, RES INST, DEPT GENET, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA.			Dick, John/0000-0002-9527-8317				BARTRAM CR, 1989, LEUKEMIA, V3, P247; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; CASHMAN J, IN PRESS BLOOD; CESANO A, 1992, ONCOGENE, V7, P827; CIVIN CI, 1984, J IMMUNOL, V133, P157; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FEURINGBUSKE M, 1995, LEUKEMIA, V9, P1318; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; GRIFFIN JD, 1986, BLOOD, V68, P1185; HAASE D, 1995, BLOOD, V86, P2906; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LAROCHELLE A, 1995, HUM MOL GENET, V4, P163, DOI 10.1093/hmg/4.2.163; MCCULLOCH EA, 1983, BLOOD, V62, P1; MEHROTRA B, 1995, BLOOD, V86, P1139; MOORE MAS, 1973, J NATL CANCER I, V50, P603, DOI 10.1093/jnci/50.3.603; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; SAWYERS CL, 1992, BLOOD, V79, P2089, DOI 10.1182/blood.V79.8.2089.bloodjournal7982089; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; TASWELL C, 1981, J IMMUNOL, V126, P1614; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; VANLOM K, 1993, BLOOD, V82, P884; VORMOOR J, 1994, BLOOD, V83, P2489; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156	38	4941	5463	16	537	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					730	737		10.1038/nm0797-730	http://dx.doi.org/10.1038/nm0797-730			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212098				2022-12-27	WOS:A1997XG76700031
J	Kroemer, G				Kroemer, G			The proto-oncogene Bcl-2 and its role in regulating apoptosis	NATURE MEDICINE			English	Review							PROGRAMMED CELL-DEATH; INHIBITION; SURVIVAL; OVEREXPRESSION; ONCOPROTEIN; GENERATION				Kroemer, G (corresponding author), CNRS,UNITE PROPRE RECH 420,19 RUE GUY MOQUET,BP 8,F-94801 VILLEJUIF,FRANCE.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BOYD JM, 1995, ONCOGENE, V11, P1921; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lawrence MS, 1996, J NEUROSCI, V16, P486; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1996, ONCOGENE, V13, P21; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHLBASAKI F, 1997, NATURE, V386, P728; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsao N, 1996, J IMMUNOL, V157, P1107; Uhlmann EJ, 1996, CANCER RES, V56, P2506; WANG, 1996, GENE DEV, V10, P2859; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	64	1627	1682	2	56	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					614	620		10.1038/nm0697-614	http://dx.doi.org/10.1038/nm0697-614			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176486				2022-12-27	WOS:A1997XB97400029
J	Massaro, GD; Massaro, D				Massaro, GD; Massaro, D			Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats	NATURE MEDICINE			English	Article							LUNG; DEXAMETHASONE; BINDING	Pulmonary emphysema is a common disease(1) in which destruction of the lung's gas-exchange structures (alveoli)(2) leads to inadequate oxygenation(3), disability(4) and frequently death(1); lung transplantation provides its only remediation. Because treatment of normal rats with all-trans-retinoic acid increases the number of alveoli(5), we tested whether a similar effect would occur in rats with emphysema. Elastase was instilled into rat lungs, producing changes characteristic of human(2) and experimental(6) emphysema: increased lung volume reflecting a loss of lung elastic recoil, larger but fewer alveoli and diminished volume-corrected alveolar surface area due to destruction of alveolar walls. Treatment with all-trans-retinoic acid reversed these changes providing nonsurgical remediation of emphysema and suggesting the possibility of a similar effect in humans.			Massaro, GD (corresponding author), GEORGETOWN UNIV,SCH MED,LUNG BIOL LAB,PRECLIN SCI BLDG,GM-12,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037666, R01HL020366, R37HL020366] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37666, HL 20366] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Christie RV, 1934, J CLIN INVEST, V13, P295, DOI 10.1172/JCI100588; GILCHREST BA, 1994, J CLIN INVEST, V94, P1711, DOI 10.1172/JCI117516; GRUMMER MA, 1995, PEDIATR PULM, V20, P234, DOI 10.1002/ppul.1950200406; Guyer B, 1996, PEDIATRICS, V98, P1007; KAPLAN PD, 1973, J LAB CLIN MED, V82, P349; KARLINSKY JB, 1978, AM REV RESPIR DIS, V117, P1109; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1985, J CLIN INVEST, V76, P1297, DOI 10.1172/JCI112103; Massaro GD, 1996, ANNU REV PHYSIOL, V58, P73; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; OKABE T, 1984, EXP CELL RES, V154, P125, DOI 10.1016/0014-4827(84)90673-6; ONG DE, 1976, P NATL ACAD SCI USA, V73, P3976, DOI 10.1073/pnas.73.11.3976; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SHOTT S, 1990, STATISTICS HLTH PROF, P229; TENNEY SM, 1963, NATURE, V197, P54, DOI 10.1038/197054a0; THURLBEC.WM, 1967, THORAX, V22, P483, DOI 10.1136/thx.22.6.483; WEST JR, 1951, AM J MED, V10, P481, DOI 10.1016/0002-9343(51)90294-X	19	395	420	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					675	677		10.1038/nm0697-675	http://dx.doi.org/10.1038/nm0697-675			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176496				2022-12-27	WOS:A1997XB97400039
J	Spada, S; Pluckthun, A				Spada, S; Pluckthun, A			Selectively infective phage (SIP) technology: A novel method for in vivo selection of interacting protein-ligand pairs	NATURE MEDICINE			English	Article							DISPLAY; SURFACE		UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				ADEY NB, 1995, GENE, V156, P27, DOI 10.1016/0378-1119(95)00058-E; Bai C, 1996, METHOD ENZYMOL, V273, P331; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; Duenas M, 1996, IMMUNOLOGY, V89, P1, DOI 10.1046/j.1365-2567.1996.d01-708.x; Duenas M, 1996, MOL IMMUNOL, V33, P279, DOI 10.1016/0161-5890(95)00137-9; DUENAS M, 1994, BIO-TECHNOL, V12, P999, DOI 10.1038/nbt1094-999; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; GRAMATIKOFF K, 1995, BIOL CHEM H-S, V376, P321; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; Krebber C, 1995, FEBS LETT, V377, P227, DOI 10.1016/0014-5793(95)01348-2; KREBBER C, 1993, Patent No. 102484; KREBBER C, 1997, J MOL BIOL, V268, P619; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9	14	30	31	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					694	696		10.1038/nm0697-694	http://dx.doi.org/10.1038/nm0697-694			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176500				2022-12-27	WOS:A1997XB97400043
J	Blankesteijn, WM; EssersJanssen, YPG; Verluyten, MJA; Daemen, MJAP; Smits, JFM				Blankesteijn, WM; EssersJanssen, YPG; Verluyten, MJA; Daemen, MJAP; Smits, JFM			A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart	NATURE MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CELLS; HETEROGENEITY	Myocardial infarction results in the formation of granulation tissue in the injured ventricular wall. This tissue contains myofibroblasts in highly organized arrays; their contractile properties may help to prevent the infarct area from dilatation. The mechanisms that control myofibroblast alignment are unknown. We found that myofibroblasts express a homologue of Drosophila tissue polarity gene frizzled (fz2) when migrating into the granulation tissue. The expression is decreased after the cells have aligned. This suggests that fz2 is involved in the spatial control of cardiac wound repair after infarction, possibly through intra- and intercellular transmission of polarity signals as in developing Drosophila. Mutations in the fz2 gene may impair myofibroblast alignment in the infarct area, thereby resulting in ventricular dilatation and aneurism following infarction.	MAASTRICHT UNIV,CARDIOVASC RES INST MAASTRICHT,DEPT PATHOL,NL-6200 MD MAASTRICHT,NETHERLANDS	Maastricht University	Blankesteijn, WM (corresponding author), MAASTRICHT UNIV,CARDIOVASC RES INST MAASTRICHT,DEPT PHARMACOL,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.							ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blankesteijn WM, 1996, J MOL CELL CARDIOL, V28, P1187; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; EYDEN BP, 1993, ULTRASTRUCT PATHOL, V17, P611, DOI 10.3109/01913129309027797; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; GUBB D, 1993, DEVELOPMENT, P269; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; MIEROP LHS, 1986, AM J CARDIOL, V58, P133; PASSIER RCJJ, 1995, AM J PHYSIOL-HEART C, V269, pH1268, DOI 10.1152/ajpheart.1995.269.4.H1268; Pizzuti A, 1996, AM J HUM GENET, V58, P722; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; SUN Y, 1994, CARDIOVASC RES, V28, P1423, DOI 10.1093/cvr/28.9.1423; VRACKO R, 1991, LAB INVEST, V65, P214; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILLEMS IEMG, 1994, AM J PATHOL, V145, P868; WILLEMS IEMG, 1994, LAB INVEST, V71, P127; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	22	90	97	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					541	544		10.1038/nm0597-541	http://dx.doi.org/10.1038/nm0597-541			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142123				2022-12-27	WOS:A1997WX54300034
J	Boyer, JD; Ugen, KE; Wang, B; Agadjanyan, M; Gilbert, L; Bagarazzi, ML; Chattergoon, M; Frost, P; Javadian, A; Williams, WV; Refaeli, Y; Ciccarelli, RB; McCallus, D; Coney, L; Weiner, DB				Boyer, JD; Ugen, KE; Wang, B; Agadjanyan, M; Gilbert, L; Bagarazzi, ML; Chattergoon, M; Frost, P; Javadian, A; Williams, WV; Refaeli, Y; Ciccarelli, RB; McCallus, D; Coney, L; Weiner, DB			Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVITY; IMMUNE-RESPONSES; INFECTION; IMMUNIZATION; MICE; TRANSMISSION; INJECTION; ANTIGEN; INFANT	Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyze the immunogenicity and efficacy of an HIV-1 DNA vaccine encoding env, rev and gag/pol in a chimpanzee model system. The immunized animals developed specific cellular and humoral immune responses. Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus and followed for 48 weeks after challenge. Polymerase chain reaction coupled with reverse transcription (RT-PCR) results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection. These studies serve as ait important benchmark for the use of DNA vaccine technology for the production of protective immune responses.	UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; COULSTON FDN,WHITE SANDS RES CTR,ALAMOGORDO,NM 88310; HOSP UNIV PENN,PHILADELPHIA,PA 19104; HARVARD UNIV,DEPT PATHOL,BOSTON,MA 02115; APOLLON INC,MALVERN,PA 19355	State University System of Florida; University of South Florida; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University	Boyer, JD (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,505 STELLAR CHANCE BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014; Ugen, Kenneth E/H-6544-2011; Bagarazzi, Mark L/AAU-1383-2021	Williams, William/0000-0003-3611-9284				BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BRINCHMANN JE, 1994, J INFECT DIS, V169, P730, DOI 10.1093/infdis/169.4.730; DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOEDERT JJ, 1989, LANCET, V2, P1351; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1038; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HAYNES JR, 1994, AIDS RES HUM RETROV, V10, pS43; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LOWRIE DB, 1994, VACCINE, V12, P1537, DOI 10.1016/0264-410X(94)90080-9; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; LU S, 1996, J VIROL, V70, P378; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MONTIFIORI DC, 1988, J CLIN MICROBIOL, V6, P231; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; OKUDA K, 1995, AIDS RES HUM RETROV, V11, P933, DOI 10.1089/aid.1995.11.933; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Ugen KE, 1997, J INFECT DIS, V175, P63, DOI 10.1093/infdis/175.1.63; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VANDAMME AM, 1995, J VIROL METHODS, V52, P121, DOI 10.1016/0166-0934(94)00151-6; VANDAMME AM, 1994, VERH K ACAD GENEESKD, V3, P231; VINGERHOETS JH, 1995, CLIN EXP IMMUNOL, V100, P425; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; Wang B, 1995, ANN NY ACAD SCI, V772, P186, DOI 10.1111/j.1749-6632.1995.tb44744.x; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	40	321	338	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					526	532		10.1038/nm0597-526	http://dx.doi.org/10.1038/nm0597-526			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142121	Bronze			2022-12-27	WOS:A1997WX54300032
J	Cao, YZ; Krogstad, P; Korber, BT; Koup, RA; Muldoon, M; Macken, C; Song, JL; Jin, ZQ; Zhao, JQ; Clapp, S; Chen, ISY; Ho, DD; Ammann, AJ; Mullins, J; Walker, B; Wolinsky, S; Bardeguez, A; Crane, M; Hanson, C; Hamill, H; Luzuriaga, K; Palumbo, P; VanDyke, R; Widmayer, S; Wiznia, A				Cao, YZ; Krogstad, P; Korber, BT; Koup, RA; Muldoon, M; Macken, C; Song, JL; Jin, ZQ; Zhao, JQ; Clapp, S; Chen, ISY; Ho, DD; Ammann, AJ; Mullins, J; Walker, B; Wolinsky, S; Bardeguez, A; Crane, M; Hanson, C; Hamill, H; Luzuriaga, K; Palumbo, P; VanDyke, R; Widmayer, S; Wiznia, A			Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the Prevention of HIV Transmission from Mother to Infant	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; TYPE-1; QUANTITATION	Most HIV-1 infections of children result from mother-to-infant transmission, which may occur perinatally or postnatally, as a consequence of breast feeding(1-8). In this study, the influence of maternal viral load on transmission of infection to infants from non-breast-feeding mothers was examined using samples of plasma and peripheral blood mononuclear cells (PBMCs) collected at several time points during pregnancy and the 6-month period after delivery. These samples were analyzed by several quantitative methods, including virus cultures of PBMCs and polymerase chain reaction (PCR) assays for HIV-1 RNA in plasma and DNA in PBMCs. The risk of transmission increased slightly with a higher viral load, but transmission and nontransmission occurred over the entire range of values for each assay. No threshold value of virus load was identified which discriminated between transmitters and nontransmitters. We also noted a significant rise in viral load and a decline in CD4(+) lymphocytes in the six months after delivery. These findings suggest that a high maternal viral load is insufficient to fully explain vertical transmission of HIV-1. Additional studies are needed to examine the post-partum increase in viremia.	ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; LOS ALAMOS NATL LAB, LOS ALAMOS, NM 87545 USA; SANTA FE INST, SANTA FE, NM 87501 USA; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT MATH, MANCHESTER M60 1QD, LANCS, ENGLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA; PEDIAT AIDS FDN, SANTA MONICA, CA USA	Rockefeller University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; University of Manchester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Wolinsky, Steven/B-2893-2012; Muldoon, Mark R/C-7505-2009; Muldoon, Mark/T-9192-2019; Krogstad, Paul/AAQ-8495-2020	Muldoon, Mark/0000-0002-5004-7195; Korber, Bette/0000-0002-2026-5757				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KHOURI YF, 1995, J CLIN INVEST, V95, P732, DOI 10.1172/JCI117720; Krogstad P, 1996, AIDS RES HUM RETROV, V12, P977, DOI 10.1089/aid.1996.12.977; KROGSTAD PA, 1995, HIV RES METHODS PRAC, P143; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCOTT GB, 1995, PEDIATRICS, V96, P977; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; SPRECHER S, 1986, LANCET, V2, P288; STIEHM ER, 1991, J PEDIATR-US, V118, P410, DOI 10.1016/S0022-3476(05)82157-2; VONSEIDLEIN L, 1994, SEMINARS PEDIAT INFE, V5, P78; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; ZIEGLER JB, 1985, LANCET, V1, P896	19	146	150	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1997	3	5					549	552		10.1038/nm0597-549	http://dx.doi.org/10.1038/nm0597-549			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142125				2022-12-27	WOS:A1997WX54300036
J	Gong, JL; Chen, DS; Kashiwaba, M; Kufe, D				Gong, JL; Chen, DS; Kashiwaba, M; Kufe, D			Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells	NATURE MEDICINE			English	Article							CYTOTOXIC T-LYMPHOCYTES; COLONY-STIMULATING FACTOR; IN-VITRO; ANTIGEN; GENERATION; PEPTIDE	Dendritic cells (DCs) are potent antigen-presenting cells that prime naive cytotoxic T-cells (CTLs)(1). In this study, we have fused DCs with MC38 carcinoma cells. The fusion cells were positive for major histocompatibility (MHC) class I and II, costimulating molecules and intercellular cell adhesion molecule-1 (ICAM-1). The results show that the fusion cells stimulate naive T cells in the primary mixed lymphocyte reaction (MLR) and induce MC38 tumor-specific CTLs in vivo. Antibody-mediated depletion experiments demonstrate that induction of CD4(+) and CD8(+) CTLs protects against challenge with tumor cells. We also show that immunization with the fusion cells induces rejection of established metastases. These findings represent the first demonstration that fusions of DCs and tumor cells can be used in the treatment of cancer.			Gong, JL (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.							AKAGI I, IN PRESS J IMMUNOTHE; BAKKER ABH, 1995, CANCER RES, V55, P5330; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; INABA K, 1987, J EXP MED, V166, P182, DOI 10.1084/jem.166.1.182; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; LIU LM, 1993, J EXP MED, V177, P1299, DOI 10.1084/jem.177.5.1299; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MEHTADAMANI A, 1994, J IMMUNOL, V153, P996; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315	22	527	579	0	21	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					558	561		10.1038/nm0597-558	http://dx.doi.org/10.1038/nm0597-558			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142127				2022-12-27	WOS:A1997WX54300038
J	Ware, JA; Simons, M				Ware, JA; Simons, M			Angiogenesis in ischemic heart disease	NATURE MEDICINE			English	Review							FIBROBLAST GROWTH-FACTOR; VECTOR INDUCES ANGIOGENESIS; COLLATERAL BLOOD-FLOW; ENDOTHELIAL-CELLS; MONONUCLEAR PHAGOCYTES; NITRIC-OXIDE; RABBIT MODEL; PROLIFERATION; MYOCARDIUM; HYPOXIA		HARVARD UNIV, SCH MED,BETH ISRAEL DEACONESS MED CTR, CARDIOVASC DIV,CARDIOVASC ANGIOGENESIS CTR, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ware, JA (corresponding author), HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, VASC BIOL UNIT, BOSTON, MA 02215 USA.		Ware, Joseph/AAC-2843-2022; Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734	NHLBI NIH HHS [HL 51043, HL 47032, HL 38820] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047032, R01HL051043, R01HL038820, R29HL038820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BATTLER A, 1993, J AM COLL CARDIOL, V22, P2001, DOI 10.1016/0735-1097(93)90790-8; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; GORDON S, 1992, CURR OPIN IMMUNOL, V4, P25, DOI 10.1016/0952-7915(92)90119-Y; Harada K, 1996, AM J PHYSIOL-HEART C, V270, pH1791, DOI 10.1152/ajpheart.1996.270.5.H1791; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; Hariawala MD, 1996, J SURG RES, V63, P77, DOI 10.1006/jsre.1996.0226; HASHIMOTO E, 1994, AM J PHYSIOL-HEART C, V267, pH1948; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Ito W, 1996, CIRCULATION, V94, P3560; Joukov V, 1996, EMBO J, V15, P290; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; KUZUYA M, 1995, J CELL PHYSIOL, V164, P658, DOI 10.1002/jcp.1041640324; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LAZAROUS DF, 1995, CIRCULATION, V91, P145, DOI 10.1161/01.CIR.91.1.145; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LI J, 1996, CIRCULATION, V94, P1; Lopez John J., 1996, Journal of the American College of Cardiology, V27, p30A; MAZUE G, 1991, ANN NY ACAD SCI, V638, P329, DOI 10.1111/j.1749-6632.1991.tb49043.x; MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161; MOORE JW, 1985, AM J PATHOL, V120, P87; MUHLHAUSER J, 1995, CIRC RES, V77, P1077, DOI 10.1161/01.RES.77.6.1077; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PADUA RR, 1995, MOL CELL BIOCHEM, V143, P129, DOI 10.1007/BF01816946; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; Polverini PJ, 1996, AM J PATHOL, V148, P1023; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SASAYAMA S, 1992, CIRCULATION, V85, P1197, DOI 10.1161/01.CIR.85.3.1197; Schaper W, 1996, CIRC RES, V79, P911, DOI 10.1161/01.RES.79.5.911; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SELLKE FW, 1994, AM J PHYSIOL-HEART C, V267, pH1303, DOI 10.1152/ajpheart.1994.267.4.H1303; Sharma H S, 1992, EXS, V61, P255; SHEN H, 1993, BLOOD, V81, P2767; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simons M, 1996, NAT MED, V2, P519, DOI 10.1038/nm0596-519; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; UNGER EF, 1993, AM J PHYSIOL, V264, pH1567, DOI 10.1152/ajpheart.1993.264.5.H1567; UNGER EF, 1993, CARDIOVASC RES, V27, P785, DOI 10.1093/cvr/27.5.785; WESTERNACHER D, 1995, J MOL CELL CARDIOL, V27, P1535, DOI 10.1016/S0022-2828(95)90326-7; XELLKE FW, 1996, AM J PHYSIOL, V271, pH713; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; YANG WD, 1994, BIOCHEM BIOPH RES CO, V203, P1160, DOI 10.1006/bbrc.1994.2304	64	258	283	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					158	164		10.1038/nm0297-158	http://dx.doi.org/10.1038/nm0297-158			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018233				2022-12-27	WOS:A1997WF08800033
J	Hoffman, SL; Crutcher, JM; Puri, SK; Ansari, AA; Villinger, F; Franke, ED; Singh, PP; Finkelman, F; Gately, ML; Dutta, GP; Sedegah, M				Hoffman, SL; Crutcher, JM; Puri, SK; Ansari, AA; Villinger, F; Franke, ED; Singh, PP; Finkelman, F; Gately, ML; Dutta, GP; Sedegah, M			Sterile protection of monkeys against malaria after administration of interleukin-12	NATURE MEDICINE			English	Article							RECOMBINANT HUMAN INTERLEUKIN-12; SCHISTOSOMA-MANSONI; GAMMA-INTERFERON; IFN-GAMMA; IL-12; CELLS; HEPATOCYTES; LYMPHOCYTES; EXPRESSION; INDUCTION	An estimated 300-500 million new infections and 1.5-2.7 million deaths attributed to malaria occur annually in the developing world(1), and every year tens of millions of travelers from countries where malaria is not transmitted visit countries with malaria. Because the parasites that cause malaria have developed resistance to many antimalarial drugs, new methods for prevention are required. Intraperitoneal injection into mice of one dose of 150 ng (approximately 7.5 mu g per kg body weight) recombinant mouse interleukin-12 (rmIL-12) 2 days before challenge with Plasmodium yoelii sporozoites protects 100% of mice against malaria(2). We report that one subcutaneous injection of 10 mu g/kg recombinant human IL-12 (rhIL-12) 2 days before challenge with P. cynomolgi sporozoites protected seven of seven rhesus monkeys. Protection was associated with marked increases in plasma levels of interferon-gamma (IFN-gamma), and relative increases of lymphoid cell messenger RNA coding for IFN-gamma and several other cytokines. We speculate that rIL-12 protects monkeys through IFN-gamma-dependent elimination of P. cynomolgi-infected hepatocytes. This first report of rIL-12-induced protection of primates against: an infectious agent supports assessment of rhIL-12 for immunoprophylaxis of human malaria.	CENT DRUG RES INST,DIV MICROBIOL,LUCKNOW 22601,UTTAR PRADESH,INDIA; EMORY UNIV,WINSHIP CANC CTR,ATLANTA,GA 30322; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Emory University; University System of Ohio; University of Cincinnati; Roche Holding	Hoffman, SL (corresponding author), USN,MED RES INST,MALARIA PROGRAM,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.		Villasante, Eileen D/G-3602-2011		PHS HHS [1R01-27057-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; Gately MK, 1996, DRUGS, V52, P18, DOI 10.2165/00003495-199600522-00005; LING P, 1995, J IMMUNOL, V154, P116; MAHESHWARI RK, 1990, B WORLD HEALTH ORGAN, V68, P138; MAHESHWARI RK, 1986, INFECT IMMUN, V53, P628, DOI 10.1128/IAI.53.3.628-630.1986; MALHOTRA K, 1988, INFECT IMMUN, V56, P3305, DOI 10.1128/IAI.56.12.3305-3309.1988; MELLOUK S, 1994, INFECT IMMUN, V62, P4043, DOI 10.1128/IAI.62.9.4043-4046.1994; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MORRIS SC, 1994, J IMMUNOL, V152, P1047; NADEAU RR, 1995, J PHARMACOL EXP THER, V274, P78; PURI SK, 1988, J INTERFERON RES, V8, P201, DOI 10.1089/jir.1988.8.201; SARMIENTO UM, 1994, LAB INVEST, V71, P862; SCHMIDT LH, 1982, AM J TROP MED HYG, V31, P646, DOI 10.4269/ajtmh.1982.31.646; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700; STEVENSON MM, 1995, J IMMUNOL, V155, P2545; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; VILLINGER F, 1993, CYTOKINE, V5, P469, DOI 10.1016/1043-4666(93)90038-7; VILLINGER F, 1995, J IMMUNOL, V155, P3946; WHO, 1995, WHO FACT SHEET, V94, P1; WU CY, 1994, J IMMUNOL, V152, P1141; WYNN TA, 1995, J IMMUNOL, V154, P4701; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551	22	118	119	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					80	83		10.1038/nm0197-80	http://dx.doi.org/10.1038/nm0197-80			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986746				2022-12-27	WOS:A1997WA73300042
J	StCroix, B; Florenes, VA; Rak, JW; Flanagan, M; Bhattacharya, N; Slingerland, JM; Kerbel, RS				StCroix, B; Florenes, VA; Rak, JW; Flanagan, M; Bhattacharya, N; Slingerland, JM; Kerbel, RS			Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents	NATURE MEDICINE			English	Article							METASTATIC BREAST-CANCER; GROWTH-FACTOR-BETA; HUMAN MALIGNANCIES; ALKYLATING-AGENTS; DRUG-RESISTANCE; CDK INHIBITORS; IN-VITRO; CHEMOTHERAPY; CHEMOSENSITIVITY; SPHEROIDS	A low proliferating fraction in solid tumors limits the effectiveness of cell cycle-dependent chemotherapeutic agents. To understand the molecular basis of such ''kinetic'' resistance we cultured tumor cells as multicellular spheroids and examined levels of p27(Kip1), a cyclin-dependent kinase inhibitor known to be upregulated by intercellular contact in normal cells. When transferred from monolayer to three-dimensional culture, a consistent upregulation (up to 15-fold) of p27 protein was observed in a panel of mouse and human carcinoma cell lines. Antisense-oligonucleotide-mediated downregulation of p27 in EMT-6 mammary tumor cell spheroids reduced intercellular adhesion, increased cell proliferation, sensitized tumor cells to 4-hydroperoxycyclophosphamide, and restored drug- or radiation-induced cell-cycle perturbations repressed in spheroid culture. Our results implicate p27 as a regulator of drug resistance in solid tumors and suggest that tumor-targeted p27 antagonists may be useful chemosensitizers in conjunction with conventional anticancer therapy.	SUNNYBROOK HLTH SCI CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; TORONTO SUNNYBROOK REG CANC CTR,TORONTO,ON,CANADA; GILEAD SCI INC,FOSTER CITY,CA 94404	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Gilead Sciences					NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BRIFFORD M, 1992, CYTOMETRY, V13, P250, DOI 10.1002/cyto.990130306; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CONTE PF, 1987, J CLIN ONCOL, V5, P339, DOI 10.1200/JCO.1987.5.3.339; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMANCHEBOITREL MT, 1993, CYTOTECHNOLOGY, V12, P347, DOI 10.1007/BF00744672; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ferrando AA, 1996, HUM GENET, V97, P91; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GORE SD, 1995, CLIN CANCER RES, V1, P295; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIETANEN P, 1995, BRIT J CANCER, V71, P1029, DOI 10.1038/bjc.1995.198; HINZ G, 1983, RADIAT ENVIRON BIOPH, V21, P255, DOI 10.1007/BF01341462; HOFFMAN RM, 1994, CANCER METAST REV, V13, P169, DOI 10.1007/BF00689634; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KAWAMATA N, 1995, CANCER RES, V55, P2266; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; KIYOKAWA H, 1971, CELL, P85; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LITTLE JB, 1973, RADIOLOGY, V106, P689, DOI 10.1148/106.3.689; MENDONCA MS, 1990, RADIAT RES, V122, P38, DOI 10.2307/3577580; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; OREILLY SM, 1992, EUR J CANCER, V28A, P681, DOI 10.1016/S0959-8049(05)80124-8; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; REMVIKOS Y, 1989, J NATL CANCER I, V81, P1383, DOI 10.1093/jnci/81.18.1383; REMVIKOS Y, 1993, EUR J CANCER, V29A, P1843, DOI 10.1016/0959-8049(93)90534-M; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SANO Y, 1983, EUR J CANCER CLIN ON, V19, P1451, DOI 10.1016/0277-5379(93)90015-W; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Spirin KS, 1996, CANCER RES, V56, P2400; SPYRATOS F, 1992, CANCER, V69, P470, DOI 10.1002/1097-0142(19920115)69:2<470::AID-CNCR2820690233>3.0.CO;2-L; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TANNOCK I, 1978, CANCER TREAT REP, V62, P1117; Tannock IF, 1994, CURRENT CANC THERAPE, P3; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tonkinson JL, 1996, CANCER INVEST, V14, P54, DOI 10.3109/07357909609018436; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang W, 1995, CLIN CANCER RES, V1, P1051	51	251	256	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1204	1210						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898746				2022-12-27	WOS:A1996VQ10100034
J	Yao, SL; Akhtar, AJ; McKenna, KA; Bedi, GC; Sidransky, D; Mabry, M; Ravi, R; Collector, MI; Jones, RJ; Sharkis, SJ; Fuchs, EJ; Bedi, A				Yao, SL; Akhtar, AJ; McKenna, KA; Bedi, GC; Sidransky, D; Mabry, M; Ravi, R; Collector, MI; Jones, RJ; Sharkis, SJ; Fuchs, EJ; Bedi, A			Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34(cdc2) kinase	NATURE MEDICINE			English	Article							WILD-TYPE P53; CANCER-THERAPY; ANTICANCER AGENTS; MICE DEFICIENT; IN-VIVO; M-PHASE; APOPTOSIS; CYCLE; INHIBITION; PHOSPHORYLATION	The induction of tumor cell death by anticancer therapy results from a genetic program of autonomous cell death termed apoptosis. Because the p53 tumor suppressor gene is a critical component for induction of apoptosis in response to DNA damage, its inactivation in cancers may be responsible for their resistance to genotoxic anticancer agents. The cellular response to DNA damage involves a cell-cycle arrest at both the G(1)/S and G(2)/M transitions; these checkpoints maintain viability by preventing the replication or segregation of damaged DNA. The arrest at the G(1) checkpoint is mediated by p53-dependent induction of p21(WAF1/CIP1), whereas the G(2) arrest involves inactivation of p34(cdc2) kinase. following DNA damage, p53-deficient cells fail to arrest at G(1) and accumulate at the G(2)/M transition. We demonstrate that abrogation of G(2) arrest by caffeine-mediated activation of p34(cdc2) kinase results in the selective sensitization of p53-deficient primary and tumor cells to irradiation-induced apoptosis. These data suggest that pharmacologic activation of p34(cdc2) kinase may be a useful therapeutic strategy for circumventing the resistance of p53-deficient cancers to genotoxic anticancer agents.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KHARBANDA S, 1994, CANCER RES, V54, P1412; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOCK RB, 1994, CANCER RES, V54, P4933; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	29	157	170	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1140	1143		10.1038/nm1096-1140	http://dx.doi.org/10.1038/nm1096-1140			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837615				2022-12-27	WOS:A1996VK99500037
J	Osada, M; Ohba, M; Kawahara, C; Ishioka, C; Kanamaru, R; Katoh, I; Ikawa, Y; Nimura, Y; Nakagawara, A; Obinata, M; Ikawa, S				Osada, M; Ohba, M; Kawahara, C; Ishioka, C; Kanamaru, R; Katoh, I; Ikawa, Y; Nimura, Y; Nakagawara, A; Obinata, M; Ikawa, S			Cloning and functional analysis of human p51, which structurally and functionally resembles p53	NATURE MEDICINE			English	Article							TRANSCRIPTIONAL ACTIVATION; SUPPRESSION; CELLS; GENE	The p53 tumor suppressor gene, which is induced by DNA damage and/or stress stimuli, causes cells to undergo G1-arrest or apoptotic death; thus it plays an essential role in human carcino-genesis(1,2). We have searched for p53-related genes by using degenerate PCR, and have identified two cDNA fragments similar to but distinct from p53: one previously reported, p73 (refs. 3,4), and the other new. We cloned two major splicing variants of the latter gene and named these p51A and p51B(a human homologue of rat Ket). The p51A gene encodes a 448-amino-acid protein with a molecular weight of 50.9 kDa; and p51B, a 641-amino-acid protein with a molecular weight of 71.9 kDa. In contrast with the ubiquitous expression of p53, expression of p51 mRNA was found in a limited number of tissues, including skeletal muscle, placenta, mammary gland, prostate, trachea, thymus, salivary gland, uterus, heart and lung. In p53-deficient cells, p51A induced growth-suppression and apoptosis, and upregulated p21(waf-1) through p53 regulatory elements. Mutations in p51 were found in some human epidermal tumors.	Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9800872, Japan; Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1130034, Japan; Chiba Canc Ctr Res Inst, Biochem Lab, Chiba 2600801, Japan	Tohoku University; Tohoku University; Tokyo Medical & Dental University (TMDU); Chiba Cancer Center	Ikawa, S (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan.	sikawa@idac.tohoku.ac.jp	井川, 俊太郎/L-5911-2015	Ishioka, Chikashi/0000-0002-3023-1227				ANSEN R, 1997, CURR OPIN GENE DEV, V7, P46; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DCKMAN S, 1997, SCIENCE, V277, P1605; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; TAHASHI H, IN PRESS CANC RES; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x	20	466	489	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					839	843		10.1038/nm0798-839	http://dx.doi.org/10.1038/nm0798-839			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662378				2022-12-27	WOS:000074543900041
J	Magliani, W; Polonelli, L; Conti, S; Salati, A; Rocca, PF; Cusumano, V; Mancuso, G; Teti, G				Magliani, W; Polonelli, L; Conti, S; Salati, A; Rocca, PF; Cusumano, V; Mancuso, G; Teti, G			Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CAPSULAR POLYSACCHARIDE; IMMUNOLOGICAL PROPERTIES; III POLYSACCHARIDE; CONJUGATE VACCINE; IMMUNIZATION; PROTECTION; ANTIBODIES; BACTERIA; PROTEIN	We investigated whether immunization with recombinant anti-idiotypic antibody fragments mimicking the conformation of the capsular antigen can protect against infection by group B streptococcus, an important neonatal pathogen. Single-chain fragment-variable anti-idiotypes competed with the type III carbohydrate for binding to type-specific antibodies and elicited, in mice, the production of protective immunoglobulins reacting against the type III polysaccharide. Moreover, maternal immunization with soluble or phage-displayed fragments protected neonatal mice against streptococcal infection. These data indicate that recombinant anti-idiotypic antibodies may be useful in developing protein images of relevant carbohydrate epitopes and, ultimately, in preventing infections by encapsulated bacteria.	Univ Messina, Fac Med & Chirurg, Ist Microbiol, I-98125 Messina, Italy; Univ Parma, Fac Med & Chirurg, Ist Microbiol, I-43100 Parma, Italy	University of Messina; University of Parma	Teti, G (corresponding author), Univ Messina, Fac Med & Chirurg, Ist Microbiol, Via Consolare Valeria 1, I-98125 Messina, Italy.		Conti, Stefania/N-3558-2015	Conti, Stefania/0000-0001-9973-8352; Mancuso, Giuseppe/0000-0001-5454-3228				Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; ALAALDEEN DAA, 1995, MOL CLIN ASPECTS BAC; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1995, NFECT DIS FETUS NEWB, P980; Cusumano V, 1996, INFECT IMMUN, V64, P2941, DOI 10.1128/IAI.64.8.2941-2944.1996; DISCHE Z, 1948, J BIOL CHEM, V175, P595; FINNE J, 1983, LANCET, V2, P355; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; GRIFFISS JM, 1987, REV INFECT DIS, V9, P176; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; KORTT AA, 1994, EUR J IMMUNOL, V23, P206; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; Larsson C, 1996, INFECT IMMUN, V64, P3518, DOI 10.1128/IAI.64.9.3518-3523.1996; MADOFF LC, 1992, INFECT IMMUN, V60, P4989, DOI 10.1128/IAI.60.12.4989-4994.1992; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MANCUSO G, 1994, INFECT IMMUN, V62, P2748, DOI 10.1128/IAI.62.7.2748-2753.1994; Mancuso G, 1997, INFECT IMMUN, V65, P3731, DOI 10.1128/IAI.65.9.3731-3735.1997; MANCUSO G, 1994, INFECT IMMUN, V62, P4997, DOI 10.1128/IAI.62.11.4997-5002.1994; MCNAMARA MK, 1984, SCIENCE, V226, P1325, DOI 10.1126/science.6505692; PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236, DOI 10.1128/IAI.62.8.3236-3243.1994; Paoletti LC, 1996, INFECT IMMUN, V64, P677, DOI 10.1128/IAI.64.2.677-679.1996; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; STEIN KE, 1984, J EXP MED, V160, P1001, DOI 10.1084/jem.160.4.1001; TETI G, 1992, HYBRIDOMA, V11, P13, DOI 10.1089/hyb.1992.11.13; TETI G, 1993, INFECT IMMUN, V61, P227, DOI 10.1128/IAI.61.1.227-235.1993; TETI G, 1992, J IMMUNOL RES, V4, P67; WESSELS MR, 1992, INFECT IMMUN, V60, P392, DOI 10.1128/IAI.60.2.392-400.1992; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; WESTERINK MAJ, 1988, INFECT IMMUN, V56, P1120, DOI 10.1128/IAI.56.5.1120-1127.1988; WESTERINK MAJ, 1990, IDIOTYPIC NETWORK DI, P107	34	50	54	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					705	709		10.1038/nm0698-705	http://dx.doi.org/10.1038/nm0698-705			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623980	Bronze			2022-12-27	WOS:000074008300037
J	Heilman, CA; Baltimore, D				Heilman, CA; Baltimore, D			HIV vaccines - where are we going?	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIBODY-RESPONSES; NEUTRALIZING ANTIBODIES; INFECTION; AIDS; ENV		NIAID, Div Aids, NIH, Bethesda, MD 20892 USA; CALTECH, Pasadena, CA 91125 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); California Institute of Technology	Heilman, CA (corresponding author), NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.							ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carmichael A, 1996, J VIROL, V70, P8468, DOI 10.1128/JVI.70.12.8468-8476.1996; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; DSouza MP, 1996, AIDS RES HUM RETROV, V12, P1, DOI 10.1089/aid.1996.12.1; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; GORDON MR, 1990, ANN NY ACAD SCI, V616, P270; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; KALAMS SA, 1998, UNPUB SCIENCE; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; MCKNIGHT A, 1992, AIDS, V6, P799, DOI 10.1097/00002030-199208000-00005; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; Moore J P, 1995, AIDS, V9 Suppl A, pS117; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; REITTER JN, 1997, 11 C CENT GARD RETR; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; SODROSKI JG, 1998, 5 C RETR OPP INF FEB; SPERTZEL RO, 1989, ANTIVIR RES, V12, P223, DOI 10.1016/0166-3542(89)90050-8; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; VANCOTT TC, 1997, 11 C CENT GARD RETR; WEBER J, 1997, 11 C CENT GARD RETR; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; ZOLLAPAZNER S, 1997, 11 C CENT GARD RETR; 1996, AIDS RES HUM RETROVI, V12, P1129	38	50	54	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5		S			532	534		10.1038/nm0598supp-532	http://dx.doi.org/10.1038/nm0598supp-532			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585205	Bronze			2022-12-27	WOS:000073453500023
J	Roberts, I				Roberts, I			A short history of walking	NATURE MEDICINE			English	Editorial Material							MORTALITY; INJURY		Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Roberts, I (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	Ian.Roberts@ich.ucl.ac.uk						CAIRD R, 1994, STORY HUMAN EVOLUTIO; CHATWI B, 1988, SONGLINES; *DEP ENV TRANSP RE, 1997, ROAD ACC GREAT BRIT; *DEP TRANSP, 1995, TRANSP STAT REP NAT; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hillman M., 1991, ONE FALSE MOVE STUDY; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Morris JN, 1997, SPORTS MED, V23, P306, DOI 10.2165/00007256-199723050-00004; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; Roberts I, 1997, Inj Prev, V3, P89; Roberts I, 1996, BRIT MED J, V313, P784; Vander Post L., 1962, LOST WORLD KALAHARI; Ward H., 1994, PEDESTRIAN ACTIVITY	14	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					263	264		10.1038/nm0398-263	http://dx.doi.org/10.1038/nm0398-263			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500590				2022-12-27	WOS:000073616200021
J	Olthoff, KM; Judge, TA; Gelman, AE; da Shen, X; Hancock, WW; Turka, LA; Shaked, A				Olthoff, KM; Judge, TA; Gelman, AE; da Shen, X; Hancock, WW; Turka, LA; Shaked, A			Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsiveness following transduction with CTLA4Ig	NATURE MEDICINE			English	Article							IN-VIVO; IMMUNE-RESPONSES; EXPRESSION; TRANSPLANT; GRAFTS; RAT; HEPATOCYTES; REJECTION; MICE	The immune response of liver transplant recipients was modulated via adenovirus-mediated transduction of the cold-preserved liver with sequences encoding CTLA4lg. Transplanted allografts demonstrated rapid transient local expression and recombinant protein production shortly after revascularization, resulting in intact liver function, indefinite survival of the recipient, and the development of donor-specific unresponsiveness. Lymphocytic infiltration of the graft was mainly of the T helper 2 (Th2) subset and was not associated with injury to primary cellular targets of the alloimmune response. These findings demonstrate a successful outcome of a feasible and potentially clinically relevant system of gene delivery of sequences encoding proteins capable of inhibiting the alloimmune response.	Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Harvard Univ, New England Deaconess Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; Harvard University; Harvard Medical School	Olthoff, KM (corresponding author), Univ Penn, Dept Surg, 4 Silverstein, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK46311-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUCHINCLOSS H, 1993, P NATL ACAD SCI USA, V90, P3373, DOI 10.1073/pnas.90.8.3373; BALIGA P, 1994, TRANSPLANTATION, V58, P1082, DOI 10.1097/00007890-199411270-00005; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; CSETE ME, 1994, TRANSPLANTATION, V57, P1502; DRAZAN KE, 1995, J SURG RES, V59, P299, DOI 10.1006/jsre.1995.1168; DRAZAN KE, 1995, TRANSPLANTATION, V59, P670, DOI 10.1097/00007890-199503150-00004; DRAZAN KE, 1994, SURGERY, V116, P197; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Judge TA, 1996, J IMMUNOL, V156, P2294; KAMADA N, 1979, TRANSPLANTATION, V28, P47, DOI 10.1097/00007890-197907000-00011; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1990, J HEART TRANSPLANT, V9, P720; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SHAKED A, 1994, TRANSPLANTATION, V57, P1508; SHAKED A, 1994, TRANSPLANTATION, V57, P32, DOI 10.1097/00007890-199401000-00007; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WANG J, 1992, TRANSPLANTATION, V53, P703; Yang Y, 1996, GENE THER, V3, P137; Yang YP, 1996, J VIROL, V70, P7209, DOI 10.1128/JVI.70.10.7209-7212.1996	25	122	128	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					194	200		10.1038/nm0298-194	http://dx.doi.org/10.1038/nm0298-194			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461193				2022-12-27	WOS:000072249800035
J	Agrawal, B; Krantz, MJ; Reddish, MA; Longenecker, BM				Agrawal, B; Krantz, MJ; Reddish, MA; Longenecker, BM			Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2	NATURE MEDICINE			English	Article							ACTIVE SPECIFIC IMMUNOTHERAPY; BREAST-CANCER; IN-VITRO; ACTIVATION MARKERS; SIALYL-TN; LYMPHOCYTES; EXPRESSION; CARCINOMA; CYCLOPHOSPHAMIDE; APOPTOSIS	A number of adenocarcinomas abundantly express and secrete underglycosylated MUC1 mucin. Underglycosylation exposes tandem repeat peptide sequences on cancer-associated MUC1 mucin that are normally cryptic. High levels of MUC1 mucin are correlated with a poor prognosis and immunosuppression in adenocarcinoma patients. In this report we show that cancer-associated MUC1 mucin, affinity-purified from ascites fluids of cancer patients, and synthetic tandem repeats of MUC1 mucin core peptide can suppress human T-cell proliferative responses. This MUC1 mucin-induced suppression of T-cell responses can be reversed by the addition of exogenous IL-2 or anti-CD28 monoclonal antibody. These results are consistent with other studies showing that lymphocytes present in the vicinity of tumor cells are anergic and can be reactivated with exogenous interleukin-2. Overcoming MUC1 mucin-induced immunosuppression with IL-2 combined with active specific immunotherapy might be an effective immunotherapeutic strategy against human adenocarcinomas.	Biomira Inc, Edmonton, AB T6N 1H1, Canada		Longenecker, BM (corresponding author), Biomira Inc, 2011-94 St,Edmonton Res Pk, Edmonton, AB T6N 1H1, Canada.							Agrawal B, 1996, J IMMUNOL, V157, P2089; Agrawal B, 1996, J IMMUNOL, V157, P3229; ALEXANDER RB, 1995, J IMMUNOTHER, V17, P39, DOI 10.1097/00002371-199501000-00005; APOSTOLOPOULOS V, 1995, J IMMUNOL, V155, P5089; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BERD D, 1988, CANCER RES, V48, P1671; BERD D, 1982, CANCER RES, V42, P4862; BERD D, 1994, CANCER IMMUNOL IMMUN, V39, P141, DOI 10.1007/BF01533378; BERRUTI A, 1994, EUR J CANCER, V30A, P2082, DOI 10.1016/0959-8049(94)00356-A; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOHMIG GA, 1994, J IMMUNOL, V152, P3720; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURCHELL J, 1987, CANCER RES, V47, P5476; Chan DW, 1997, J CLIN ONCOL, V15, P2322, DOI 10.1200/JCO.1997.15.6.2322; Coventry BJ, 1996, J IMMUNOL, V156, P3486; DING L, 1992, CANCER IMMUNOL IMMUN, V36, P9; FONTENOT JD, 1993, CANCER RES, V53, P5386; FUNG PYS, 1991, CANCER RES, V51, P1170; FUNG PYS, 1990, CANCER RES, V50, P4308; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; KOBAYASHI H, 1992, J CLIN ONCOL, V10, P95, DOI 10.1200/JCO.1992.10.1.95; KUROSAKA A, 1988, J BIOL CHEM, V263, P8724; Luzzati AL, 1996, CLIN EXP IMMUNOL, V105, P403, DOI 10.1046/j.1365-2249.1996.d01-778.x; MacLean GD, 1997, J IMMUNOTHER, V20, P70, DOI 10.1097/00002371-199701000-00008; Mayumi H, 1996, IMMUNOBIOLOGY, V195, P129, DOI 10.1016/S0171-2985(96)80033-7; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; PARRY G, 1990, EXP CELL RES, V188, P302, DOI 10.1016/0014-4827(90)90174-9; Reddish MA, 1996, CANCER IMMUNOL IMMUN, V42, P303, DOI 10.1007/s002620050287; Reddish MA, 1992, J TUMOR MARKER ONCOL, V7, P19; Regimbald LH, 1996, CANCER RES, V56, P4244; SAD S, 1995, J EXP MED, V182, P1505, DOI 10.1084/jem.182.5.1505; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	38	259	280	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					43	49		10.1038/nm0198-043	http://dx.doi.org/10.1038/nm0198-043			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427605				2022-12-27	WOS:000072249700033
J	Bedwell, DM; Kaenjak, A; Benos, DJ; Bebok, Z; Bubien, JK; Hong, J; Tousson, A; Clancy, JP; Sorscher, EJ				Bedwell, DM; Kaenjak, A; Benos, DJ; Bebok, Z; Bubien, JK; Hong, J; Tousson, A; Clancy, JP; Sorscher, EJ			Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line	NATURE MEDICINE			English	Article							RECTIFYING CHLORIDE CHANNELS; CYSTIC-FIBROSIS GENE; MOLECULAR-BASIS; MESSENGER-RNA; REGULATOR; TERMINATION; TRANSPORT; PROTEIN; W1282X; CAMP	Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein(1). While 70% of CF chromosomes carry a deletion of the phenylalanine residue 508 (Delta F508) of CFTR, roughly 5% of all CF chromosomes carry a premature stop mutation(2). We reported that the aminoglycoside antibiotics C-418 and gentamicin can suppress two premature stop mutations [a stop codon in place of glycine residue 542 (G542X) and arginine residue 553 (R553X)] when expressed from a CFTR cDNA in HeLa cells(3). Suppression resulted in the synthesis of full-length CFTR protein and the appearance of a cAMP-activated anion conductance characteristic of CFTR function. However, it was unclear whether this approach could restore CFTR function in cells expressing mutant forms of CFTR from the nuclear genome. We now report that G-418 and gentamicin are also capable of restoring CFTR expression in a CF bronchial epithelial cell line carrying the CFTR W1282X premature stop mutation (a stop codon in place of tryptophan residue 1282). This conclusion is based on the reappearance of cAMP-activated chloride currents, the restoration of CFTR protein at the apical plasma membrane, and an increase in the abundance of CFTR mRNA levels from the W1282X allele.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bedwell, DM (corresponding author), UNIV ALABAMA,DEPT MICROBIOL,BEVILL BIOMED RES BLDG,ROOM 432,845 19TH ST S,BIRMINGHAM,AL 35294, USA.			Sorscher, Eric J./0000-0001-9341-3354; Bedwell, David/0000-0002-6605-818X				BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; *CYST FIBR GEN AN, 1994, HUM MUTAT, V4, P167; DEMOLOMBE S, 1994, EUR J CELL BIOL, V65, P214; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HASTY P, 1995, SOMAT CELL MOLEC GEN, V21, P177, DOI 10.1007/BF02254769; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; Tousson A, 1996, J CELL SCI, V109, P1325; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	20	251	269	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1280	1284		10.1038/nm1197-1280	http://dx.doi.org/10.1038/nm1197-1280			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359706				2022-12-27	WOS:A1997YD89600040
J	DeLuca, A; Baldi, A; Esposito, V; Howard, CM; Bagella, L; Rizzo, P; Caputi, M; Pass, HI; Giordano, GG; Baldi, F; Carbone, M; Giordano, A				DeLuca, A; Baldi, A; Esposito, V; Howard, CM; Bagella, L; Rizzo, P; Caputi, M; Pass, HI; Giordano, GG; Baldi, F; Carbone, M; Giordano, A			The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas	NATURE MEDICINE			English	Article							SUSCEPTIBILITY GENE; DNA-SEQUENCES; CELL-CYCLE; PRODUCT; SV40; PROTEIN; BINDING	The oncoprotein of simian virus-40, SV40 large T-antigen (Tag), is reported to target and to inactivate growth suppressive proteins such as the retinoblastoma family(1-3) and p53 (ref. 4, 5), leading to transformation of human cell lines in vitro, tumor production in rodents(6), and detection of Tag in several human cancers including mesotheliomas(7,8). The retinoblastoma family contains three members, pRb, p107 and pRb2/p130 (ref. 9), that are phosphorylated in a cell cycle-dependent manner(10,11), have cell growth suppressive properties(12) and bind to specific members of the E2F family and various cyctins(13). Even though mesotheliomas are among the most aggressive human cancers, alterations of important cell-cycle ''controllers,'' such as the Rb family genes, have never been reported in these tumors. We found the presence of SV40-like sequences in 86% of 35 archival specimens of mesothelioma. We also demonstrated that SV40 Tag, isolated from frozen biopsies of human mesothelioma, binds each of the retinoblastoma family proteins, pRb, p107 and pRb2/p130, in four of four specimens. We propose that the tumorigenic potential of SV40 Tag in some human mesotheliomas may arise from its ability to interact with and thereby inactivate several tumor and/or growth suppressive proteins.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107; UNIV NAPLES 2,FAC MED,IST TISIOL & MALATTIE RESP S MARCATILI,I-80122 NAPLES,ITALY; LOYOLA UNIV,DEPT PATHOL,CANC IMMUNOL PROGRAM,CARDINAL BERNARDIN CANC CTR,MAYWOOD,IL 60153; WAYNE STATE UNIV,KARMANOS CANC INST,DETROIT,MI 48201; UNIV NAPLES 2,FAC MED,IST ANAT PATOL,I-80122 NAPLES,ITALY	Jefferson University; Jefferson University; Universita della Campania Vanvitelli; Loyola University Chicago; Barbara Ann Karmanos Cancer Institute; Wayne State University; Universita della Campania Vanvitelli			De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471; BAGELLA, Luigi/0000-0003-2815-037X; Howard, Candace/0000-0001-6537-3551; Esposito, Vincenzo/0000-0003-4696-2363; Baldi, Alfonso/0000-0002-8693-3842	NCI NIH HHS [R01 CA 60999-01A1, R29 CA74283] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, CLIN CANCER RES, V2, P1239; BALDI A, IN PRESS CLIN CANC R; BARTEK J, 1992, ONCOGENE, V7, P101; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; CARBONE M, 1994, ONCOGENE, V9, P1781; CARBONE M, IN PRESS ONCOGENE; CARBONE M, 1997, NAT MED, V3, pR30; CLAUDIO PP, 1994, CANCER RES, V54, P5556; CLAUDIO RPP, 1996, CANCER RES, V56, P2003; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; LEWIS AM, 1976, BIOHAZARDS BIOL RES, P96; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014	22	184	185	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					913	916		10.1038/nm0897-913	http://dx.doi.org/10.1038/nm0897-913			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256285				2022-12-27	WOS:A1997XP01400036
J	Gravel, C; Gotz, R; Lorrain, A; Sendtner, M				Gravel, C; Gotz, R; Lorrain, A; Sendtner, M			Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons	NATURE MEDICINE			English	Article							MOTONEURONS IN-VIVO; FACTOR PREVENTS; CELL-DEATH; REGIONAL DISTRIBUTION; PERIPHERAL-NERVE; SCIATIC-NERVE; MESSENGER-RNA; NEWBORN RATS; MOUSE; BDNF	The neurotrophic factors ciliary neurotrophic factor and brain-derived neurotrophic factor can prevent motor neuron cell death during development(1,2) and after nerve lesion in neonatal rodents(3,4). However, local and systemic application of these factors to newborn rats with damaged motor nerves rescues motor neurons only transiently during the first two weeks after axotomy(5,6). In order to test the effect of continuous delivery of these factors, the effect of localized injection of CNTF- or BDNF-transducing recombinant adenoviruses into the lesioned nerves was investigated. Under such conditions, survival of axotomized motor neurons is maintained for at least 5 weeks. This way of delivery corresponds to the physiological situation in adult rodents, under which endogenous CNTF is present in the cytosol of Schwann cells and BDNF expression is upregulated after nerve lesion, making these factors available to the damaged motor neurons(7,8). Recent results show that overexpression of muscle-derived neurotrophin-3 prevents degeneration of axons and motor endplates, but has only little effect on the number of motor neuron cell bodies in a murine animal model of motor neuron disease(9). Therefore, techniques suitable for tonic exposure to both nerve- and muscle-derived neurotrophic factors may have implications for the design of future therapeutic strategies against human motor neuron disease.	UNIV WURZBURG,KLIN FORSCHERGRP NEUROREGENERAT,DEPT NEUROL,D-97080 WURZBURG,GERMANY; UNIV LAVAL ROBERT GIFFARD,CTR RECH,LAB TRANSFERT GENES,BEAUPORT,PQ G1J 2G3,CANADA	University of Wurzburg; Laval University			Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; *ALS CNTF TREATM S, 1995, CLIN NEUROPHARMACOL, V18, P500; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Dittrich F, 1996, EXP NEUROL, V141, P225, DOI 10.1006/exnr.1996.0157; ERIKSSON NP, 1994, NEUROREPORT, V5, P1445; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; IKEDA K, 1995, ANN NEUROL, V37, P505, DOI 10.1002/ana.410370413; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MITSUMOTO H, 1994, ANN NEUROL, V36, P142, DOI 10.1002/ana.410360205; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1985, TRENDS NEUROSCI, V8, P487, DOI 10.1016/0166-2236(85)90175-4; SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; TRIPATHY KS, 1996, NAT MED, V2, P545; VEJSADA R, 1994, NEUROREPORT, V5, P1889, DOI 10.1097/00001756-199410000-00012; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281	40	155	171	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					765	770		10.1038/nm0797-765	http://dx.doi.org/10.1038/nm0797-765			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212104				2022-12-27	WOS:A1997XG76700037
J	Lubeck, MD; Natuk, R; Myagkikh, M; Kalyan, N; Aldrich, K; Sinangil, F; Alipanah, S; Murthy, SCS; Chanda, PK; Nigida, SM; Markham, PD; ZollaPazner, S; Steimer, K; Wade, M; Reitz, MS; Arthur, LO; Mizutani, S; Davis, A; Hung, PP; Gallo, RC; Eichberg, J; RobertGuroff, M				Lubeck, MD; Natuk, R; Myagkikh, M; Kalyan, N; Aldrich, K; Sinangil, F; Alipanah, S; Murthy, SCS; Chanda, PK; Nigida, SM; Markham, PD; ZollaPazner, S; Steimer, K; Wade, M; Reitz, MS; Arthur, LO; Mizutani, S; Davis, A; Hung, PP; Gallo, RC; Eichberg, J; RobertGuroff, M			Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT ADENOVIRUS; GLYCOPROTEIN GP120; IMMUNE-RESPONSE; LYMPHOCYTES-T; INFECTION; ANTIBODY; MACAQUES; GP160; CELLS	A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1(MN)gp160 recombinants followed by boosting with HIV-1(SF2)gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to row-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.	WYETH AYERST RES,RADNOR,PA 19087; NCI,TUMOR CELL BIOL LAB,NIH,BETHESDA,MD 20892; CHIRON CORP,EMERYVILLE,CA 94608; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702; ADV BIOSCI LABS,KENSINGTON,MD 20895; VET AFFAIRS MED CTR,NEW YORK,NY 10010	Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036085, R01AI032424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36085, AI 32424] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; ARTHUR LO, 1995, J VIROL, V69, P3117, DOI 10.1128/JVI.69.5.3117-3124.1995; ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Berman PW, 1996, J INFECT DIS, V173, P52, DOI 10.1093/infdis/173.1.52; BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERMAN PW, 1994, AIDS, V8, P591, DOI 10.1097/00002030-199405000-00004; BRUCK C, 1994, VACCINE, V12, P1141, DOI 10.1016/0264-410X(94)90185-6; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHANDA PK, 1979, VIROLOGY, V175, P535; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; CLERICI M, 1991, J IMMUNOL, V146, P2214; DOE B, 1994, EUR J IMMUNOL, V24, P2369, DOI 10.1002/eji.1830241017; ELAMAD Z, 1995, AIDS, V9, P1313, DOI 10.1097/00002030-199512000-00003; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Girard M, 1996, J VIROL, V70, P8229, DOI 10.1128/JVI.70.11.8229-8233.1996; HAIGWOOD NL, 1990, AIDS RES HUM RETROV, V6, P855, DOI 10.1089/aid.1990.6.855; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; LUBECK MD, 1989, P NATL ACAD SCI USA, V86, P6763, DOI 10.1073/pnas.86.17.6763; LUBECK MD, 1994, AIDS RES HUM RETROV, V10, P1443, DOI 10.1089/aid.1994.10.1443; LUBECK MD, 1995, AIDS RES HUM RETROV, V11, P189; Murthy KK, 1996, AIDS RES HUM RETROV, V12, P1341, DOI 10.1089/aid.1996.12.1341; NATUK RJ, 1993, AIDS RES HUM RETROV, V9, P395, DOI 10.1089/aid.1993.9.395; NIEDRIG M, 1993, VACCINE, V11, P67, DOI 10.1016/0264-410X(93)90341-T; ROBERTGUROFF M, 1990, TECHNIQUES HIV RES, P179; RUBIN BA, 1988, VACCINES, P492; SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233; SHENK T, 1996, FIELDS VIROLOGY, P2111; SORENSEN AB, 1993, J VIROL, V67, P7118; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; ZARLING JM, 1987, J IMMUNOL, V139, P988; ZollaPazner S, 1995, AIDS RES HUM RETROV, V11, P1449, DOI 10.1089/aid.1995.11.1449	42	139	141	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					651	658		10.1038/nm0697-651	http://dx.doi.org/10.1038/nm0697-651			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176492				2022-12-27	WOS:A1997XB97400035
J	Cocchi, F; DeVico, AL; GarzinoDemo, A; Cara, A; Gallo, RC; Lusso, P				Cocchi, F; DeVico, AL; GarzinoDemo, A; Cara, A; Gallo, RC; Lusso, P			The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4 NEUTRALIZATION; T-CELLS; HTLV-III; TYPE-1; REPLICATION; IDENTIFICATION; MACROPHAGE; TROPISM; LYMPHOCYTES	The ability of CD8(+) T cells derived from human immunodeficiency virus (HIV)-infected patients to produce soluble HIV-suppressive factor(s) (HIV-SF)(1-3) has been suggested as an important mechanism of control of HIV infection in vivo(4,5). The C-C chemokines RANTES, MIP-1 alpha and MIP-1 beta were recently identified as the major components of the HIV-SF produced by both immortalized and primary patient CD8(+) T cells. Whereas they potently inhibit infection by primary and macrophage-tropic HIV-1 isolates, T-cell line-adapted viral strains tend to be insensitive to their suppressive effects(6). Consistent with this discrepancy, two distinct chemokine receptors, namely, CXCR4 (ref. 7) and CCR5 (ref. 8), were recently identified as potential co-receptors for T-cell line-adapted and macrophage-tropic HIV-1 isolates, respectively(9-12). Here, we demonstrate that the third hypervariable domain of the gp120 envelope glycoprotein is a critical determinant of the susceptibility of HIV-1 to chemokines. Moreover, we show that RANTES, MIP-1 alpha. and MIP-1 beta block the entry of HIV-1 into cells and that their antiviral activity is independent of pertussis toxin-sensitive signal transduction pathways mediated by chemokine receptors. The ability of the chemokines to block the early steps of HIV infection could be exploited to develop novel therapeutic approaches for AIDS.	UNIV MARYLAND,BIOTECNOL INST & SCH MED,CTR MED BIOTECHNOL,INST HUMAN VIROL,BALTIMORE,MD 21201; SAN RAFFAELE SCI INST,DIPARTIMENTO RIC BIOL & TECNOL,I-20132 MILAN,ITALY; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Cara, Andrea/M-4865-2015; Cara, Andrea/AAA-4238-2021	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Garzino-Demo, Alfredo/0000-0002-4095-6950				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOMEZ AM, 1994, CLIN EXP IMMUNOL, V97, P68; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; Sambrook J., 2002, MOL CLONING LAB MANU; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STAMATATOS L, 1994, J VIROL, V68, P4973, DOI 10.1128/JVI.68.8.4973-4979.1994; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WILLEY RL, 1993, J VIROL, V67, P3639, DOI 10.1128/JVI.67.6.3639-3643.1993	34	450	480	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1244	1247		10.1038/nm1196-1244	http://dx.doi.org/10.1038/nm1196-1244			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898753				2022-12-27	WOS:A1996VQ10100041
J	Pasqualini, R; Bourdoulous, S; Koivunen, E; Woods, VL; Ruoslahti, E				Pasqualini, R; Bourdoulous, S; Koivunen, E; Woods, VL; Ruoslahti, E			A polymeric form of fibronectin has antimetastatic effects against multiple tumor types	NATURE MEDICINE			English	Article							CELL-ADHESION; MELANOMA-CELLS; EXPERIMENTAL METASTASIS; MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDE; GENE-EXPRESSION; NUDE-MICE; INTEGRIN; RECEPTOR; INHIBITION	Metastasis accounts for most deaths in cancer patients. Tumor cell adhesion to the extracellular matrix through integrins is thought to be a critical step in metastasis and a potential target for therapeutic intervention. We show here that treatment of human osteosarcoma, melanoma and carcinoma cells with a polymeric form of fibronectin (sFN), before inoculation into nude mice, prevented tumor formation. Intraperitoneally administered sFN significantly reduced lung colonization from intravenously injected tumor cells (experimental metastasis) and from subcutaneous tumors in nude mice (spontaneous metastasis). Treatment with sFN blocked cell spreading and migration in vitro suggesting a possible mechanism for the antimetastatic effect.	UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND	University of California System; University of California San Diego; University of Helsinki	Pasqualini, R (corresponding author), LA JOLLA CANC RES FDN, BURNHAM INST, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA 62042, CA 30199, CA 58527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA062042, R01CA058527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BERLIN O, 1993, CANCER RES, V53, P4890; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; deBoer HC, 1995, J BIOL CHEM, V270, P30733, DOI 10.1074/jbc.270.51.30733; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOTLOIB L, 1995, KIDNEY INT, V47, P1274, DOI 10.1038/ki.1995.182; HAMILTON TC, 1983, CANCER RES, V43, P5379; HARDAN I, 1993, INT J CANCER, V55, P1023, DOI 10.1002/ijc.2910550624; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, SEMIN CANCER BIOL, V4, P277; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; KOMAZAWA H, 1993, CARBOHYD POLYM, V21, P299, DOI 10.1016/0144-8617(93)90063-A; KUMAGAI H, 1991, BIOCHEM BIOPH RES CO, V177, P74, DOI 10.1016/0006-291X(91)91950-H; LIOTTA LA, 1986, CANCER RES, V46, P1; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MITJANS F, 1995, J CELL SCI, V108, P2825; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SAIKI I, 1989, BRIT J CANCER, V59, P194, DOI 10.1038/bjc.1989.40; SOSZKA T, 1991, EXP CELL RES, V196, P6, DOI 10.1016/0014-4827(91)90449-5; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMADA KM, 1990, CANCER RES, V50, P4485; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	51	112	115	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1197	1203		10.1038/nm1196-1197	http://dx.doi.org/10.1038/nm1196-1197			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898745				2022-12-27	WOS:A1996VQ10100033
J	Kilby, JM; Hopkins, S; Venetta, TM; DiMassimo, B; Cloud, GA; Lee, JY; Alldredge, L; Hunter, E; Lambert, D; Bolognesi, D; Mathews, T; Johnson, MR; Nowak, MA; Shaw, GM; Saag, MS				Kilby, JM; Hopkins, S; Venetta, TM; DiMassimo, B; Cloud, GA; Lee, JY; Alldredge, L; Hunter, E; Lambert, D; Bolognesi, D; Mathews, T; Johnson, MR; Nowak, MA; Shaw, GM; Saag, MS			Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; DYNAMICS IN-VIVO; DEXTRAN SULFATE; LEUCINE-ZIPPER; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; PROTEASE INHIBITORS; COMBINATION THERAPY; SYNTHETIC PEPTIDE	T-20, a synthetic peptide corresponding to a region of the transmembrane subunit of the HIV 1 envelope protein, blocks cell fusion and viral entry at concentrations of less than 2 ng/ml in vitro. We administered intravenous T-20 (monotherapy) for 14 days to sixteen HIV-infected adults in four dose groups (3, 10, 30 and 100 mg twice daily). There were significant, dose-related declines in plasma HIV RNA in all subjects who received higher dose levels. All four subjects receiving 100 mg twice daily had a decline in plasma HIV RNA to less than 500 copies/ml, by bDNA assay. A sensitive RT-PCR assay (detection threshold 40 copies/ml) demonstrated that, although undetectable levels were not achieved in the 14-day dosing period, there was a 1.96 log(10) median decline in plasma HIV RNA in these subjects. This study provides proof-of-concept that viral entry can be successfully blocked in vivo. Short-term administration of T-20 seems safe and provides potent inhibition of HIV replication comparable to anti-retroviral regimens approved at present.	Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Trimeris Inc, Durham, NC 27707 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Duke Univ, Med Ctr, Dept Surg Oncol, Durham, NC 27710 USA; Princeton Univ, Inst Adv Study, Princeton, NJ 08540 USA; Univ Alabama Birmingham, Howard Hughes Med Inst, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University; Institute for Advanced Study - USA; Princeton University; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Kilby, JM (corresponding author), Univ Alabama Birmingham, Dept Med, 908 20th St S, Birmingham, AL 35294 USA.		Nowak, Martin A/A-6977-2008	Kilby, J. Michael/0000-0003-3222-1003	NCRR NIH HHS [M01 RR00032] Funding Source: Medline; PHS HHS [P30 A127767] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; CHEN ZQ, 1995, IMMUNOGENETICS, V41, P69; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Herz AVM, 1996, P NATL ACAD SCI USA, V93, P7247, DOI 10.1073/pnas.93.14.7247; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATTHEWS TJ, 1994, IMMUNOL REV, V140, P93, DOI 10.1111/j.1600-065X.1994.tb00866.x; McDonald CK, 1997, ARCH INTERN MED, V157, P951, DOI 10.1001/archinte.157.9.951; MENG TC, 1995, J ACQ IMMUN DEF SYND, V8, P152; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Nowak MA, 1997, J THEOR BIOL, V184, P205, DOI 10.1006/jtbi.1996.0307; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; SAAG MS, 1992, HOSP PRACT, V27, P26; *SAS I, 1989, SAS STAT US GUID VER, V1; Schockmel GA, 1997, J ACQ IMMUN DEF SYND, V14, P179, DOI 10.1097/00042560-199702010-00013; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SHACKLETON NJ, 1995, QUAT PROC, P1; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zinman B, 1997, DIABETES, V46, P440, DOI 10.2337/diabetes.46.3.440	48	878	983	0	80	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1302	1307		10.1038/3293	http://dx.doi.org/10.1038/3293			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809555				2022-12-27	WOS:000076731000040
J	Shields, AF; Grierson, JR; Dohmen, BM; Machulla, HJ; Stayanoff, JC; Lawhorn-Crews, JM; Obradovich, JE; Muzik, O; Mangner, TJ				Shields, AF; Grierson, JR; Dohmen, BM; Machulla, HJ; Stayanoff, JC; Lawhorn-Crews, JM; Obradovich, JE; Muzik, O; Mangner, TJ			Imaging proliferation in vivo with [F-18]FLT and positron emission tomography	NATURE MEDICINE			English	Article							CELLULAR PROLIFERATION; PET; 3'-AZIDO-3'-DEOXYTHYMIDINE; METABOLISM; TRANSPORT; PLASMA	Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18]FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.	Wayne State Univ, Detroit Med Ctr, Dept Med, Karmanos Canc Inst, Detroit, MI 48301 USA; Wayne State Univ, Detroit Med Ctr, Dept Radiol, Karmanos Canc Inst, Detroit, MI 48301 USA; Univ Washington, Dept Radiol, Imaging Res Lab, Seattle, WA 98195 USA; Univ Tubingen, Dept Nucl Med, Tuebingen, Germany; Oakland Vet Referral Serv, Bloomfield Hills, MI USA	Barbara Ann Karmanos Cancer Institute; Detroit Medical Center; Wayne State University; Barbara Ann Karmanos Cancer Institute; Detroit Medical Center; Wayne State University; University of Washington; University of Washington Seattle; Eberhard Karls University of Tubingen	Shields, AF (corresponding author), Wayne State Univ, Detroit Med Ctr, Dept Med, Karmanos Canc Inst, 5 Hudson,3990 John R St, Detroit, MI 48301 USA.				NCI NIH HHS [CA 39566] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039566] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CONTI PS, 1995, NUCL MED BIOL, V22, P783, DOI 10.1016/0969-8051(95)00017-R; CRAWFORD EJ, 1982, ADV ENZYME REGUL, V20, P3, DOI 10.1016/0065-2571(82)90005-X; Findlay M, 1996, J CLIN ONCOL, V14, P700, DOI 10.1200/JCO.1996.14.3.700; FLEXNER C, 1994, J INFECT DIS, V170, P1394, DOI 10.1093/infdis/170.6.1394; Grierson J. R., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P290; Grierson John R., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P60; HERHOLZ K, 1992, J NEURO-ONCOL, V12, P159; KONG XB, 1992, ANTIMICROB AGENTS CH, V36, P808, DOI 10.1128/AAC.36.4.808; KUBOTA R, 1992, J NUCL MED, V33, P1972; NICOLAS F, 1995, DRUG METAB DISPOS, V23, P308; Romer W, 1998, BLOOD, V91, P4464; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIELDS A, IN PRESS J NUCL MED; Shields AF, 1996, NUCL MED BIOL, V23, P17, DOI 10.1016/0969-8051(95)02005-5; Shields Anthony F., 1995, V1995, P129; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TJUVAJEV JG, 1994, J NUCL MED, V35, P1407; VANDERBORGHT T, 1991, APPL RADIAT ISOTOPES, V42, P103; vanEijkeren ME, 1996, ACTA ONCOL, V35, P737, DOI 10.3109/02841869609084008; Yamada Y, 1998, J NUCL MED, V39, P1160	20	983	1021	2	57	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1334	1336		10.1038/3337	http://dx.doi.org/10.1038/3337			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809561				2022-12-27	WOS:000076731000046
J	Zwacka, RM; Zhou, WH; Zhang, YL; Darby, CJ; Dudus, L; Halldorson, J; Oberley, L; Engelhardt, JF				Zwacka, RM; Zhou, WH; Zhang, YL; Darby, CJ; Dudus, L; Halldorson, J; Oberley, L; Engelhardt, JF			Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappa B activation	NATURE MEDICINE			English	Article							ISCHEMIA REPERFUSION INJURY; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; C-FOS; RECOMBINANT ADENOVIRUSES; MOUSE-LIVER; RAT-LIVER; JUN; PHOSPHORYLATION; EXPRESSION	Liver transplantation is the only therapeutic strategy for many inherited and acquired diseases. The formation of reactive oxygen species following ischemia/reperfusion is a cause of hepatocellular injury during transplantation. This report describes the therapeutic application of mitochondrial superoxide dismutase gene transfer to the liver for acute ischemia/reperfusion injury. Recombinant adenoviral expression of mitochondrial superoxide dismutase in mouse liver prior to lobar ischemia/reperfusion significantly reduced acute liver damage and associated redox activation of both NF-kappa B and AP1. These immediate early transcription factors represent common pathways by which cells respond to environmental stress. This work provides the foundation for redox-mediated gene therapies directed at ameliorating ischemia/reperfusion injury and associated acute rejection in orthotopic liver transplantation.	Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Dept Anat & Cell Biol, 51 Newton Rd, Iowa City, IA 52242 USA.			Zwacka, Ralf/0000-0003-2821-0387; Engelhardt, John/0000-0003-2389-9277	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051315] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA-66081] Funding Source: Medline; NIDCR NIH HHS [P50 DE-10758] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARTHUR MJP, 1985, GASTROENTEROLOGY, V898, P114; ATALLA SL, 1985, TRANSPLANTATION, V40, P584, DOI 10.1097/00007890-198512000-00002; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bradham CA, 1997, HEPATOLOGY, V25, P1128, DOI 10.1002/hep.510250514; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1996, METHODS ADENOVIRAL M, P169; GOODE HF, 1994, HEPATOLOGY, V19, P354; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAESCHKE H, 1988, BIOCHEM BIOPH RES CO, V150, P568, DOI 10.1016/0006-291X(88)90431-7; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIUCHI T, 1995, TRANSPLANTATION, V60, P49, DOI 10.1097/00007890-199507150-00010; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MATHEWS WR, 1994, FREE RADICAL BIO MED, V16, P763, DOI 10.1016/0891-5849(94)90191-0; OBERLEY TD, 1990, AM J PATHOL, V137, P199; Okuaki Y, 1996, LIVER, V16, P188; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Schlossberg H, 1996, HEPATOLOGY, V23, P1546, DOI 10.1053/jhep.1996.v23.pm0008675176; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shaked A, 1997, CLIN CHEM, V43, P1539; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STRASBERG SM, 1994, HEPATOLOGY, V20, P829, DOI 10.1002/hep.1840200410; SUZUKI S, 1994, TRANSPLANT P, V26, P3695; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175; Zwacka RM, 1997, J CLIN INVEST, V100, P279, DOI 10.1172/JCI119533; ZWACKA RM, IN PRESS HUMAN GENE	41	226	244	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					698	704		10.1038/nm0698-698	http://dx.doi.org/10.1038/nm0698-698			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623979				2022-12-27	WOS:000074008300036
J	Burton, DR; Moore, JP				Burton, DR; Moore, JP			Why do we not have an HIV vaccine and how can we make one?	NATURE MEDICINE			English	Editorial Material							VIRUS		Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; NYU, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Scripps Research Institute; Scripps Research Institute; New York University	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; jmoore@adarc.org						Baldridge JR, 1997, J VIROL, V71, P755, DOI 10.1128/JVI.71.1.755-758.1997; Berman PW, 1997, J INFECT DIS, V176, P384, DOI 10.1086/514055; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Corey L, 1998, J INFECT DIS, V177, P301, DOI 10.1086/514202; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Desrosiers R C, 1995, AIDS, V9 Suppl A, pS137; Excler JL, 1997, AIDS, V11, pS127; EZZELL C, 1997, J NIH RES, V9, P21; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; Hasenkrug KJ, 1997, P NATL ACAD SCI USA, V94, P7811, DOI 10.1073/pnas.94.15.7811; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Jassoy C, 1997, SPRINGER SEMIN IMMUN, V18, P341, DOI 10.1007/BF00813502; LIU MA, 1998, NATURE MED; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Nossal GJV, 1997, LANCET, V350, P1316, DOI 10.1016/S0140-6736(97)03257-1; Oldstone MBA, 1997, NEW ENGL J MED, V337, P1306, DOI 10.1056/NEJM199710303371811; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROWLANDJONES S, 1997, ADV IMMUNOL, V65, P448; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Sharpe SA, 1997, J GEN VIROL, V78, P1923, DOI 10.1099/0022-1317-78-8-1923; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Stott EJ, 1996, J ANTIMICROB CHEMOTH, V37, P185, DOI 10.1093/jac/37.suppl_B.185; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; VanCott TC, 1997, J VIROL, V71, P4319, DOI 10.1128/JVI.71.6.4319-4330.1997	28	102	136	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5		S			495	498		10.1038/nm0598supp-495	http://dx.doi.org/10.1038/nm0598supp-495			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585194	Bronze			2022-12-27	WOS:000073453500012
J	Ophascharoensuk, V; Fero, ML; Hughes, J; Roberts, JM; Shankland, SJ				Ophascharoensuk, V; Fero, ML; Hughes, J; Roberts, JM; Shankland, SJ			The cyclin-dependent kinase inhibitor p27(Kip1) safeguards against inflammatory injury	NATURE MEDICINE			English	Article							MICE LACKING; CELL-CYCLE; GLOMERULONEPHRITIS; PROLIFERATION; HYPERPLASIA; APOPTOSIS; RATS	The cyclin-dependent kinase inhibitor p27(Kip1) controls cell proliferation in response to normal mitogenic stimuli. We show here that p27(Kip1) also safeguards against excessive cell proliferation in specific pathophysiologic settings. We used experimental glomerulonephritis as a paradigm for immune mediated inflammation and ureteral obstruction as a model for non-immune mediated inflammation. Renal function was substantially decreased in nephritic p27(-/-) mice compared with control mice, and this was associated with increased glomerular cell proliferation, apoptosis and matrix protein accumulation. Tubular epithelial cell proliferation and apoptosis was also increased in p27(-/-) mice following ureteral obstruction. p27(Kip1) may have a general role in protecting cells and tissues from inflammatory injury.	Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Shankland, SJ (corresponding author), Univ Washington, Sch Med, Dept Med, Div Nephrol, Box 356521,1959 NE Pacific Ave, Seattle, WA 98195 USA.			Fero, Matthew/0000-0002-9967-4659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051096, R01DK052121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51096, DK 52121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkins RC, 1996, J AM SOC NEPHROL, V7, P2271; BAKER PJ, 1989, AM J PATHOL, V135, P185; Bisgaard HC, 1996, CLIN LAB MED, V16, P325, DOI 10.1016/S0272-2712(18)30272-5; BRADLEY GM, 1974, EXAMINATION URINE; BUTLER AR, 1975, CLIN CHIM ACTA, V59, P227, DOI 10.1016/0009-8981(75)90033-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; COUSER WG, 1985, AM J PHYSIOL, V249, P241; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Huang XR, 1997, KIDNEY INT, V51, P94, DOI 10.1038/ki.1997.12; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KERR PG, 1997, DIS KIDNEY, P1619; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MACLEOD DC, 1994, J AM COLL CARDIOL, V23, P59, DOI 10.1016/0735-1097(94)90502-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; Shankland SJ, 1997, KIDNEY INT, V51, P1088, DOI 10.1038/ki.1997.151; Shankland SJ, 1997, KIDNEY INT, V52, P404, DOI 10.1038/ki.1997.347; Shankland SJ, 1996, KIDNEY INT, V50, P1230, DOI 10.1038/ki.1996.432; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Thomas SE, 1998, J AM SOC NEPHROL, V9, P231; Truong LD, 1996, KIDNEY INT, V50, P200, DOI 10.1038/ki.1996.303; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WOLF NS, 1993, EXP HEMATOL, V21, P614	30	167	180	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					575	580		10.1038/nm0598-575	http://dx.doi.org/10.1038/nm0598-575			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585231				2022-12-27	WOS:000073399900029
J	Bach, FH; Fishman, JA; Daniels, N; Proimos, J; Anderson, B; Carpenter, CB; Forrow, L; Robson, SC; Fineberg, HV				Bach, FH; Fishman, JA; Daniels, N; Proimos, J; Anderson, B; Carpenter, CB; Forrow, L; Robson, SC; Fineberg, HV			Uncertainty in xenotransplantation: Individual benefit versus collective risk	NATURE MEDICINE			English	Editorial Material							REJECTION		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA; Tufts Univ, Dept Philosophy, Medford, MA 02155 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital; Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Bach, FH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	fbach@bidmc.harvard.edu	Proimos, Jenny/M-4529-2019; Robson, Simon C./AAA-8537-2021					*ADV GROUP ETH XEN, 1996, AN TISS HUM; BACH FH, 1991, TRANSPL P, V23, P205; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BERG P, 1975, P NATL ACAD SCI USA, V72, P1981, DOI 10.1073/pnas.72.6.1981; BERG P, 1975, SCIENCE, V188, P991, DOI 10.1126/science.1056638; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; COOPER DKC, 1993, TRANSPLANTATION, V56, P769, DOI 10.1097/00007890-199310000-00001; Daar AS, 1997, WORLD J SURG, V21, P975, DOI 10.1007/s002689900336; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; DALMASSO AP, 1996, XENOTRANSPLANTATION, V4, P55; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; *ETH XEN, 1996, AN HUM TRANSPL; Fishman JA, 1997, KIDNEY INT, pS41; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; Institute of Medicine, 1996, XEN SCI ETH PUBL POL; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Platt JL, 1996, CURR OPIN IMMUNOL, V8, P721, DOI 10.1016/S0952-7915(96)80091-4; SACHS DH, 1995, NAT MED, V1, P969, DOI 10.1038/nm0995-969; Stern P. C., 1996, UNDERSTANDING RISK I; 1996, DRAFT PUBLIC HLTH SE	21	173	173	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1998	4	2					141	144		10.1038/nm0298-141	http://dx.doi.org/10.1038/nm0298-141			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461178				2022-12-27	WOS:000072249800020
J	Zion, D				Zion, D			Ethical considerations of clinical trials to prevent vertical transmission of HIV in developing countries	NATURE MEDICINE			English	Editorial Material									Univ Tokyo, Sch Int Hlth, Tokyo, Japan; Monash Univ, Ctr Human Bioeth, Clayton, Vic 3168, Australia	University of Tokyo; Monash University	Zion, D (corresponding author), Univ Tokyo, Sch Int Hlth, Tokyo, Japan.		Zion, Deborah/M-8806-2014					Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Raz J., 1986, MORALITY FREEDOM, P166; Wilkinson M, 1997, BIOETHICS, V11, P373, DOI 10.1111/1467-8519.00078; Williams B., 1973, UTILITARIANISM, P77; WOOD AW, 1995, SOC PHILOS POLICY, V12, P136, DOI 10.1017/S0265052500004702	5	4	4	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					11	12		10.1038/nm0198-011	http://dx.doi.org/10.1038/nm0198-011			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427593				2022-12-27	WOS:000072249700021
J	Schonermark, MP; Bock, O; Buchner, A; Steinmeier, R; Benbow, U; Lenarz, T				Schonermark, MP; Bock, O; Buchner, A; Steinmeier, R; Benbow, U; Lenarz, T			Quantification of tumor cell invasion using confocal laser scan microscopy	NATURE MEDICINE			English	Article							BREAST-CANCER CELLS; ASSAY; MEMBRANE; INHIBITION; METASTASIS; ACTIVATION; GROWTH		DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH 03755; UNIV HANNOVER,DEPT BIOPHYS,D-30175 HANNOVER,GERMANY	Dartmouth College; Leibniz University Hannover	Schonermark, MP (corresponding author), HANNOVER MED SCH,DEPT OTOLARYNGOL HEAD & NECK SURG,D-30623 HANNOVER,GERMANY.							ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FLUG M, 1995, ACTA ANAT, V152, P69; Gohla A, 1996, CLIN EXP METASTAS, V14, P451, DOI 10.1007/BF00128961; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; Kleinman H. K, 1995, EXTRACELLULAR MATRIX, P289; KOHN EC, 1995, CANCER RES, V55, P1856; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MACKINNON WB, 1992, INVAS METAST, V12, P241; RUBIN M, 1994, CANCER RES, V54, P6549; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; STETLERSTEVENSO.WG, 1997, REGULATION ANGIOGENE, P413; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TEMPLETON NS, 1990, CANCER RES, V50, P5431; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WATSON SA, 1995, CANCER RES, V55, P3629; WELCH DR, 1989, INT J CANCER, V43, P449, DOI 10.1002/ijc.2910430318; WILSON T, 1989, TRENDS NEUROSCI, V12, P486, DOI 10.1016/0166-2236(89)90104-5; YU M, 1995, CANCER RES, V55, P3272	24	14	14	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1167	1171		10.1038/nm1097-1167	http://dx.doi.org/10.1038/nm1097-1167			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334733				2022-12-27	WOS:A1997XZ28700047
J	Stilgenbauer, S; Schaffner, C; Litterst, A; Liebisch, P; Gilad, S; BarShira, A; James, MR; Lichter, P; Dohner, H				Stilgenbauer, S; Schaffner, C; Litterst, A; Liebisch, P; Gilad, S; BarShira, A; James, MR; Lichter, P; Dohner, H			Biallelic mutations in the ATM gene in T-prolymphocytic leukemia	NATURE MEDICINE			English	Article							ATAXIA-TELANGIECTASIA; LIPOPROTEIN RECEPTOR; DEFICIENT MICE; TCL1 ONCOGENE; PROTEIN; REGION; IDENTIFICATION; ORGANIZATION; EXPRESSION; NEOPLASMS	Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, genome instability and predisposition to malignancies, particularly T-cel[ neoplasms(1-3). The responsible gene, designated ataxia-telongiectasia mutated(ATM), was recently identified by positional cloning in the chromosomal region 11q22.3-23.1 (ref. 4, 5) ATM is 150 kb in length, consists of 66 exons and encodes a nuclear phosphoprotein of approximately 350 kDa (ref. 4-9). Although ATM is considered to be a tumorigenic factor in several human cancers, it has not yet been found mutated in tumors of non-AT patients. Given the marked predisposition of AT patients to develop neoplasms of the T-cell lineage(3), we analyzed a series of T-cell leukemias (T-prolymphocytic leukemia, or T-PLL) in non-AT patients in search of genomic changes associated with the development of this disease. Among the recurrent aberrations identified, deletion of the chromosome arm 11q was very frequent. Subsequent molecular cytogenetic analyses allowed us to define a small commonly deleted segment at 11q22.3-23.1 in 15 of 24 T-PLLs studied. Since this critical region contained ATM, we further analyzed the remaining copy of the gene in six cases showing deletions affecting one ATM allele. In all six cases, mutations of the second ATM allele were identified, leading to the absence, premature truncation or alteration of the ATM gene product. Thus, our study demonstrates disruption of both ATM alleles by deletion or point mutation in T-PLL, suggesting that ATM functions as a tumor-suppressor gene in tumors of non-AT individuals.	UNIV HEIDELBERG,MED KLIN & POLIKLIN 4,D-69115 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,ABT ORG KOMPLEXER GENOME,D-69120 HEIDELBERG,GERMANY; SACKLER SCH MED,DEPT HUMAN GENET,IL-9978 TEL AVIV,ISRAEL; UNIV OXFORD,NUFFIELD DEPT CLIN MED,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Tel Aviv University; Sackler Faculty of Medicine; University of Oxford; Wellcome Centre for Human Genetics			Stilgenbauer, Stephan/ABE-6609-2020; Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DOHNER H, 1993, J NATL CANCER I, V85, P658, DOI 10.1093/jnci/85.8.658; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FINAN J, 1978, VIRCHOWS ARCH B, V29, P121; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; HARRIS NL, 1994, BLOOD, V84, P1361; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Lakin ND, 1996, ONCOGENE, V13, P2707; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MALJAIE SH, 1995, LEUKEMIA, V9, P1694; MEYN MS, 1995, CANCER RES, V55, P5991; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; NOWAK R, 1995, SCIENCE, V268, P1700, DOI 10.1126/science.7792589; PITTMAN S, 1982, LEUKEMIA RES, V6, P33, DOI 10.1016/0145-2126(82)90041-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; STILGENBAUER S, 1993, BLOOD, V81, P2118; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Thick J, 1996, ONCOGENE, V12, P379; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VANLEUVEN F, 1994, GENOMICS, V24, P78, DOI 10.1006/geno.1994.1584; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Vorechovsky I, 1996, CANCER RES, V56, P2726; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZECH L, 1984, NATURE, V308, P858, DOI 10.1038/308858a0	39	188	189	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1155	1159		10.1038/nm1097-1155	http://dx.doi.org/10.1038/nm1097-1155			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334731				2022-12-27	WOS:A1997XZ28700045
J	Lang, SM; Iafrate, AJ; StahlHennig, C; Kuhn, EM; Nisslein, T; Kaup, FJ; Haupt, M; Hunsmann, G; Skowronski, J; Kirchhoff, F				Lang, SM; Iafrate, AJ; StahlHennig, C; Kuhn, EM; Nisslein, T; Kaup, FJ; Haupt, M; Hunsmann, G; Skowronski, J; Kirchhoff, F			Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques	NATURE MEDICINE			English	Article							CD4 DOWN-REGULATION; TYPE-1 NEF; T-CELLS; GENE; HIV-1; REPLICATION; LYMPHOCYTES; INFECTION; INDUCTION; PROTEIN	The nef gene of simian immunodeficiency virus (SIV) is essential for high viral load and induction of AIDS in rhesus monkeys. A mutant form of the SIVmac239 Nef, which contains changes in a putative SH3-binding domain (amino acids 104 and 107 have been changed from PxxP to AxxA), does not associate with cellular serine/threonine kinases, but is fully active in CD4 downregulation and associates with the cellular tyrosine kinase Src. Infection of two rhesus macaques with SIVmac239 containing the mutant AxxA-Nef caused AIDS and rapid death in both animals. No reversions were observed in the majority of nef sequences analyzed from different time points during infection and from lymphatic tissues at the time of death. Our findings indicate that the putative SH3-ligand domain in SIVmac Nef and the association with cellular serine/threonine kinases are not important for efficient replication and pathogenicity of SIVmac in rhesus macaques.	UNIV ERLANGEN NURNBERG,INST CLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GERMAN PRIMATE CTR,D-37077 GOTTINGEN,GERMANY	University of Erlangen Nuremberg; Cold Spring Harbor Laboratory; Deutsches Primatenzentrum (DPZ)			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	PHS HHS [IA-35394] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CHACKERIAN B, 1995, VIROLOGY, V213, P386, DOI 10.1006/viro.1995.0011; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MYERS G, 1993, HUMAN RETROVIRUSES A; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; POTTS BJ, 1990, TECHNIQUES HIV RES, P103; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SKOWRONSKI J, 1995, HIV 1 PRACTICAL APPR, P231; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	40	83	83	1	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					860	865		10.1038/nm0897-860	http://dx.doi.org/10.1038/nm0897-860			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256276				2022-12-27	WOS:A1997XP01400027
J	Berard, AM; Foger, B; Remaley, A; Shamburek, R; Vaisman, BL; Talley, G; Paigen, B; Hoyt, RF; Marcovina, S; Brewer, HB; SantamarinaFojo, S				Berard, AM; Foger, B; Remaley, A; Shamburek, R; Vaisman, BL; Talley, G; Paigen, B; Hoyt, RF; Marcovina, S; Brewer, HB; SantamarinaFojo, S			High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase	NATURE MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; ESTER TRANSFER PROTEIN; CORONARY ATHEROSCLEROSIS; OXIDATIVE MODIFICATION; HUMAN SERUM; ESTERIFICATION; EXPRESSION; DISEASE; LESIONS	A subset of patients with high plasma HDL concentrations have enhanced rather than reduced atherosclerosis. We have developed a new transgenic mouse model overexpressing human lecithin-cholesteryl acyltransferase (LCAT) that has elevated HDL and increased diet-induced atherosclerosis. LCAT transgenic mouse HDLs are abnormal in both composition and function. Liver uptake of [H-3]cholesteryl ether incorporated in transgenic mouse HDL was reduced by 41% compared with control HDL, indicating ineffective transport of HDL-cholesterol to the liver and impaired reverse cholesterol transport. Analysis of this LCAT-transgenic mouse model provides in vivo evidence for dysfunctional HDL as a potential mechanism leading to increased atherosclerosis in the presence of high plasma HDL levels.	NHLBI, MOL DIS BRANCH, NIH, BETHESDA, MD 20892 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; NHLBI, LAB ANIM MED & SURG, NIH, BETHESDA, MD 20892 USA; UNIV WASHINGTON, NW LIPID RES LABS, SEATTLE, WA 98103 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle			Vaisman, Boris L/B-3453-2008		NHLBI NIH HHS [HL 32087, HL 30086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032087, P01HL030086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVIC P, 1984, CLIN METABOLIC ASPEC, P1; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEN CH, 1982, J LIPID RES, V23, P680; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; DUGI KA, IN PRESS J LIPID RES; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLOMSET JA, 1995, METABOLIC MOL BASES; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HIRANO K, 1995, ARTERIOSCL THROM VAS, V15, P1849, DOI 10.1161/01.ATV.15.11.1849; HOEG JM, 1996, P NATL ACAD SCI USA, V271, P4396; HUANG YD, 1995, ARTERIOSCL THROM VAS, V15, P1412, DOI 10.1161/01.ATV.15.9.1412; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KLEIN HG, 1995, J BIOL CHEM, V270, P9443, DOI 10.1074/jbc.270.16.9443; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARZETTA CA, 1993, ARTERIOSCLER THROMB, V13, P834, DOI 10.1161/01.ATV.13.6.834; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MORTON RE, 1981, J BIOL CHEM, V256, P1992; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RADER DJ, 1993, LANCET, V342, P1455, DOI 10.1016/0140-6736(93)92933-K; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKAI N, 1995, CIRCULATION S, V92; SAKU K, 1985, THROMB RES, V39, P1, DOI 10.1016/0049-3848(85)90116-1; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; TALL AR, 1993, J LIPID RES, V34, P1255; TERPSTRA AHM, 1988, FRESEN Z ANAL CHEM, V330, P149, DOI 10.1007/BF00470729; Tollefson J H, 1986, Methods Enzymol, V129, P797; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	45	181	190	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					744	749		10.1038/nm0797-744	http://dx.doi.org/10.1038/nm0797-744			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212100				2022-12-27	WOS:A1997XG76700033
J	Indolfi, C; Avvedimento, EV; DiLorenzo, E; Esposito, G; Rapacciuolo, A; Giuliano, P; Grieco, D; Cavuto, L; Stingone, AM; Ciullo, I; Condorelli, G; Chiarello, M				Indolfi, C; Avvedimento, EV; DiLorenzo, E; Esposito, G; Rapacciuolo, A; Giuliano, P; Grieco, D; Cavuto, L; Stingone, AM; Ciullo, I; Condorelli, G; Chiarello, M			Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury	NATURE MEDICINE			English	Article							SUCCESSFUL CORONARY ANGIOPLASTY; CYCLIC-AMP; BALLOON ANGIOPLASTY; ARTERIAL INJURY; RAT MODEL; RESTENOSIS; GROWTH; DIFFERENTIATION; PERSPECTIVE; MECHANISMS	Injury of the arterial wall induces the formation of the neointima(1). This structure is generated by the growth of mitogenically activated smooth muscle cells of the arterial wall(2-5). The molecular mechanism underlying the formation of the neointima involves deregulated cell growth, primarily triggered by the injury of the arterial wall(6-9). The activated gene products transmitting the injury-induced mitogenic stimuli have been identified and inhibited by several means: transdominant negative expression vectors, antisense oligodeoxynucleotides, adenovirus-mediated gene transfer, antibodies and inactivating drugs(8,10-12). Results of our study show that local administration of 3',5'-cyclic AMP and phosphodiesterase-inhibitor drugs (aminophylline and amrinone) to rats markedly inhibits neointima formation after balloon injury in vivo and in smooth muscle cells in vitro. The growth inhibitory effect of aminophylline was completely reversed by the inhibition of cAMP-dependent protein kinase A (PKA). These findings indicate an alternative approach to the treatment of diseases associated with injury-induced cell growth of the arterial wall, as stimulation of cAMP signaling is pharmacologically feasible in the clinical setting.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL MOL & CELLULARE, I-80131 NAPLES, ITALY; FAC MED & CHIRURG, DIPARTIMENTO MED SPERIMENTALE CLIN, I-88100 CATANZARO, ITALY; JEFFERSON MED COLL, KIMMEL CANC INST, PHILADELPHIA, PA 19107 USA	University of Naples Federico II; Jefferson University	Indolfi, C (corresponding author), UNIV NAPLES FEDERICO II, CATTEDRA CARDIOL, VIA S PANSINI 5, I-80131 NAPLES, ITALY.		Rapacciuolo, Antonio/AAR-8012-2020; Esposito, Giovanni/F-2880-2010; Condorelli, Gianluigi/Q-6736-2017	Rapacciuolo, Antonio/0000-0002-4739-7004; Esposito, Giovanni/0000-0003-0565-7127; Condorelli, Gianluigi/0000-0003-0481-6843; GRIECO, Domenico/0000-0002-7131-5742; INDOLFI, Ciro/0000-0003-1241-6487				ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1983, LAB INVEST, V49, P208; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUITERAS VP, 1987, AM J CARDIOL S, V60, pB50; HERRMAN JPR, 1993, DRUGS, V46, P249, DOI 10.2165/00003495-199346020-00003; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; INDOLFI C, 1995, CIRCULATION, V92, P1230, DOI 10.1161/01.CIR.92.5.1230; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Indolfi C, 1996, NAT MED, V2, P634, DOI 10.1038/nm0696-634; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Koumi S, 1995, J CLIN INVEST, V96, P2870, DOI 10.1172/JCI118358; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Laird JR, 1996, CIRCULATION, V93, P529, DOI 10.1161/01.CIR.93.3.529; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MITSUZAWA H, 1994, MOL GEN GENET, V243, P158, DOI 10.1007/BF00280312; *MULT EUR RES TRIA, 1991, CIRCULATION, V86, P100; NUNES GL, 1995, CIRCULATION, V92, P1697, DOI 10.1161/01.CIR.92.7.1697; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; VIRMANI R, 1994, AM HEART J, V127, P163, DOI 10.1016/0002-8703(94)90522-3; WILKINSON L, 1988, SYSTAT SYSTEM STAT; YOKOZAKI H, 1992, CANCER RES, V52, P2504; 1995, GOODMANS GILMANS PHA	42	169	169	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					775	779		10.1038/nm0797-775	http://dx.doi.org/10.1038/nm0797-775			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212106				2022-12-27	WOS:A1997XG76700039
J	Muramoto, T; DeArmond, SJ; Scott, M; Telling, GC; Cohen, FE; Prusiner, SB				Muramoto, T; DeArmond, SJ; Scott, M; Telling, GC; Cohen, FE; Prusiner, SB			Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; CULTURED-CELLS; TRANSMISSION; CONVERSION; FEATURES; RODENTS; ISOFORM; PLAQUES; SYSTEM	Mice were constructed carrying prion protein (PrP) transgenes with individual regions of putative secondary structure deleted. Transgenic mice with amino-terminal regions deleted remained healthy at >400 days of age, whereas those with either of carboxy-terminal alpha-helices deleted spontaneously developed fatal CNS illnesses similar to neuronal storage diseases. Deletion of either C-terminal helix resulted in PrP accumulation within cytoplasmic inclusions in enlarged neurons. Deletion of the penultimate C-terminal helix resulted in proliferation of rough endoplasmic reticulum. Mice with the C-terminal helix deleted were affected with nerve cell loss in the hippocampus and proliferation of smooth endoplasmic reticulum. Whether children with the human counterpart of this malady will be found remains to be determined.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805	NIA NIH HHS [AG 08967, AG 02132] Funding Source: Medline; NINDS NIH HHS [NS 14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bamborough P, 1996, COLD SPRING HARB SYM, V61, P495; BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HOLMAN RC, 1995, NEUROEPIDEMIOLOGY, V14, P174, DOI 10.1159/000109793; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; Phillips MJ., 1987, LIVER ATLAS TEXT ULT; PRUSINER SB, 1996, FIELDS VIROLOGY, P2901; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	40	106	107	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					750	755		10.1038/nm0797-750	http://dx.doi.org/10.1038/nm0797-750			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212101				2022-12-27	WOS:A1997XG76700034
J	Rappuoli, R				Rappuoli, R			Rational design of vaccines	NATURE MEDICINE			English	Editorial Material							MUTANTS				Rappuoli, R (corresponding author), CHIRON VACCINES, VIA FIORENTINA 1, I-53100 SIENA, ITALY.							DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; EDWARDS KM, 1995, PEDIATRICS, V96, P548; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GRECO D, 1996, INT C INFECT DIS; Greco Donato, 1996, Pediatric Research, V39, p173A; Hewlett EL, 1996, PEDIATRICS, V98, P800; Ibsen PH, 1996, VACCINE, V14, P359, DOI 10.1016/0264-410X(95)00230-X; NOSSAL GJV, 1990, UCLA SYM BI, V113, P309; PIZZA M, 1994, J EXP MED, V180, P2147, DOI 10.1084/jem.180.6.2147; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; Ramon G, 1924, ANN I PASTEUR PARIS, V38, P1	11	37	41	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					374	376		10.1038/nm0497-374	http://dx.doi.org/10.1038/nm0497-374			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095163				2022-12-27	WOS:A1997WQ82500019
J	Flowers, CR; Melmon, KL				Flowers, CR; Melmon, KL			Clinical investigators as critical determinants in pharmaceutical innovation	NATURE MEDICINE			English	Editorial Material							DRUG DEVELOPMENT; UNITED-STATES; PURINE PATH; 9-(2-HYDROXYETHOXYMETHYL)GUANINE; CHEMOTHERAPY		STANFORD UNIV, MED CTR, SCH MED, DIV CLIN PHARMACOL, STANFORD, CA 94305 USA	Stanford University	Flowers, CR (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DIV MED INFORMAT SCI, STANFORD, CA 94305 USA.		Flowers, Christopher R/F-1953-2010	Flowers, Christopher R/0000-0002-9524-3990				Allen T., 1966, MANAGING FLOW SCI TE; Allen T., 1984, MANAGING FLOW TECHNO; ARMSTRONG JM, 1992, CLIN EXP PHARMACOL P, V19, P51, DOI 10.1111/j.1440-1681.1992.tb00397.x; BURCHENAL JH, 1949, CANCER, V2, P119, DOI 10.1002/1097-0142(194901)2:1<119::AID-CNCR2820020111>3.0.CO;2-U; BURCHENAL JH, 1951, CANCER-AM CANCER SOC, V4, P549, DOI 10.1002/1097-0142(195105)4:3<549::AID-CNCR2820040308>3.0.CO;2-J; BURCHENAL JH, 1949, CANCER, V2, P113, DOI 10.1002/1097-0142(194901)2:1<113::AID-CNCR2820020110>3.0.CO;2-E; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; Calne R Y, 1979, Proc Eur Dial Transplant Assoc, V16, P305; CALNE RY, 1962, ANN NY ACAD SCI, V99, P743, DOI 10.1111/j.1749-6632.1962.tb45358.x; CALNE RY, 1960, LANCET, V1, P417; CALNE RY, 1980, NEPHRON, V26, P57, DOI 10.1159/000181952; CHAKRABARTI AK, 1974, CALIF MANAGE REV, V17, P58, DOI 10.2307/41164561; CHAKRABARTI AK, 1989, R&D MANAGE, V19, P161, DOI 10.1111/j.1467-9310.1989.tb00636.x; CLARKE DA, 1953, CANCER RES, V13, P593; CRUMPACKER C, 1988, REV INFECT DIS, V10, pS538; CRUMPACKER CS, 1989, NEW ENGL J MED, V321, P163, DOI 10.1056/NEJM198907203210306; CRUMPACKER CS, 1988, AIDS, V2, pS191, DOI 10.1097/00002030-198800001-00028; DAMANPOUR F, 1984, ADMIN SCI QUART, V29, P392, DOI 10.2307/2393031; DIMASI JA, 1994, CLIN PHARMACOL THER, V55, P609, DOI 10.1038/clpt.1994.78; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; DIMASI JA, 1994, REGUL TOXICOL PHARM, V19, P228, DOI 10.1006/rtph.1994.1021; DIMASI JA, 1991, CLIN PHARMACOL THER, V50, P471, DOI 10.1038/clpt.1991.172; ELION GB, 1963, CANCER RES, V23, P1207; ELION GB, 1950, J BIOL CHEM, V187, P511; ELION GB, 1975, ANN NY ACAD SCI, V255, P468, DOI 10.1111/j.1749-6632.1975.tb29251.x; ELION GB, 1962, CANCER CHEMOTH REP, P197; ELION GB, 1993, J MED VIROL, P2; ELION GB, 1989, IN VITRO CELL DEV B, V25, P321; ELION GB, 1951, J BIOL CHEM, V192, P505; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ELION GB, 1963, BIOCHEM PHARMACOL, V12, P85, DOI 10.1016/0006-2952(63)90012-1; ELION GB, 1959, J AM CHEM SOC, V81, P3042, DOI 10.1021/ja01521a033; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; FISCHER WA, 1982, R&D MANAGE, V12, P61, DOI 10.1111/j.1467-9310.1982.tb00484.x; GALBRAITH J, 1982, ORG DYNAMICS     WIN, P5; GERWIN D, 1981, IEEE T ENG MANAGE, V28, P62, DOI 10.1109/TEM.1981.6448588; GLOBE S, 1973, RES MANAGEMENT   JUL, P8; HAMILTON L, 1954, Ann N Y Acad Sci, V60, P304; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; HENDERSON R, 1994, HARVARD BUS REV, V72, P100; HENDERSON RM, 1990, ADMIN SCI QUART, V35, P9, DOI 10.2307/2393549; HITCHINGS GH, 1989, IN VITRO CELL DEV B, V25, P303; HITCHINGS GH, 1950, ANN NY ACAD SCI, V52, P1318, DOI 10.1111/j.1749-6632.1950.tb54032.x; HITCHINGS GH, 1950, J BIOL CHEM, V183, P1; HITCHINGS GH, 1948, J BIOL CHEM, V174, P765; HITCHINGS GH, 1985, CANCER RES, V45, P2415; KAUFMAN HE, 1964, SCIENCE, V145, P585, DOI 10.1126/science.145.3632.585; KAUFMAN HE, 1962, ARCH OPHTHALMOL-CHIC, V67, P583; KELLEY WN, 1994, CAREERS CLIN RES OBS, P1; KOSTAKIS A J, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P243; KOSTAKIS A J, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P280; LEE S, 1988, R&D MANAGE, V18, P257, DOI 10.1111/j.1467-9310.1988.tb00592.x; LIS Y, 1989, BRIT J CLIN PHARMACO, V28, P333, DOI 10.1111/j.1365-2125.1989.tb05435.x; MOHR LB, 1969, AM POLIT SCI REV, V63, P111, DOI 10.2307/1954288; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; MYRVIK QN, 1984, FUNDAMENTALS IMMUNOL, P1; NATHAN HC, 1961, P SOC EXP BIOL MED, V107, P796; PEARSON AW, 1990, TECHNOVATION, V10, P185, DOI 10.1016/0166-4972(90)90023-D; Pierce JL, 1977, ACAD MANAGE REV, V2, P27, DOI DOI 10.5465/AMR.1977.4409154; Porter R., 1993, COMPANION ENCY HIST, V2, P1576; PRENTIS RA, 1988, BRIT J CLIN PHARMACO, V25, P387, DOI 10.1111/j.1365-2125.1988.tb03318.x; Rosenberg N., 1991, SCI PUBL POLICY, V18, P335; Rosenberg NJ, 1983, MICROCLIMATE BIOL EN, P1; RUNDLES RW, 1966, ANN INTERN MED, V64, P229, DOI 10.7326/0003-4819-64-2-229; RUNDLES RW, 1963, T ASSOC AM PHYSICIAN, V76, P126; SCHABEL FM, 1968, CHEMOTHERAPY, V13, P321, DOI 10.1159/000220567; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SCHWARTZ R, 1958, P SOC EXP BIOL MED, V99, P164; SELBY PJ, 1979, LANCET, V2, P1267; TALLEY RW, 1963, BLOOD, V21, P352, DOI 10.1182/blood.V21.3.352.352; THIER SO, 1994, J ROY COLL PHYS LOND, V28, P541; THOMPSON RL, 1949, SCIENCE, V110, P454, DOI 10.1126/science.110.2861.454; THOMPSON RL, 1950, J IMMUNOL, V65, P529; VERHEYDEN JPH, 1975, ANN NY ACAD SCI, V255, P151, DOI 10.1111/j.1749-6632.1975.tb29220.x; VERHEYDEN JPH, 1975, J AM CHEM SOC, V97, P4386, DOI 10.1021/ja00848a042; Verheyden Julien P. H., 1993, P299; YU TF, 1964, AM J MED, V37, P885, DOI 10.1016/0002-9343(64)90131-7	79	29	32	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					136	143		10.1038/nm0297-136	http://dx.doi.org/10.1038/nm0297-136			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018224				2022-12-27	WOS:A1997WF08800024
J	Ledda, MF; Adris, S; Bravo, AI; Kairiyama, C; Bover, L; Chernajovsky, Y; Mordoh, J; Podhajcer, OL				Ledda, MF; Adris, S; Bravo, AI; Kairiyama, C; Bover, L; Chernajovsky, Y; Mordoh, J; Podhajcer, OL			Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells	NATURE MEDICINE			English	Article							EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; ENDOTHELIAL-CELLS; IV COLLAGENASE; BM-40 SPARC; BINDING; FIBRONECTIN; INVASION; LAMININ; PROTEIN	Acquisition of invasive/metastatic potential is a key event in tumor progression. Cell surface glycoproteins and their respective matrix ligands have been implicated in this process. Recent evidence reveals that the secreted glycoprotein SPARC (secreted protein, acidic and rich in cysteine) is highly expressed in different malignant tissues. The present study reports that the suppression of SPARC expression by human melanoma cells using a SPARC antisense expression vector results in a significant decrease in the in vitro adhesive and invasive capacities of tumor cells, completely abolishing their in vivo tumorigenicity. This is the first evidence that SPARC plays a key role in human melanoma invasive-metastatic phenotype development.	CONSEJO NACL INVEST CIENT & TECN, INST INVEST BIOQUIM BUENOS AIRES, INST INVEST BIOQUIM, RA-1405 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS & NAT, RA-1428 BUENOS AIRES, DF, ARGENTINA; HOSP E PERON, RA-1650 BUENOS AIRES, DF, ARGENTINA; KENNEDY INST, LONDON W6 7DW, ENGLAND	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Oxford				podhajcer, osvaldo/0000-0002-6512-8553				AIBELDA SM, 1993, LAB INVEST, V68, P4; AOKI K, 1995, CANCER RES, V55, P3810; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilat D, 1996, IMMUNOL TODAY, V17, P16, DOI 10.1016/0167-5699(96)80563-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; KAMIHAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P423, DOI 10.1006/bbrc.1994.1466; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KOCHEVAR GJ, 1992, CANCER, V69, P2311, DOI 10.1002/1097-0142(19920501)69:9<2311::AID-CNCR2820690918>3.0.CO;2-Q; LAIRD AD, 1994, CANCER RES, V54, P4224; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LEDDA F, IN PRESS J INVEST DE; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; MERCOLA D, 1995, CANCER GENE THER, V2, P47; Mok SC, 1996, ONCOGENE, V12, P1895; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Podhajcer OL, 1996, BREAST, V5, P13, DOI 10.1016/S0960-9776(96)90044-2; PODHAJCER OL, 1995, J INVEST DERMATOL, V104, P340, DOI 10.1111/1523-1747.ep12665371; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; RAO JS, 1993, CANCER RES, V53, P2208; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P71, DOI 10.1111/j.1432-1033.1991.tb16257.x; WEWER UM, 1987, CANCER RES, V47, P5691; YABKOWITZ R, 1993, CANCER RES, V53, P378	40	205	218	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1997	3	2					171	176		10.1038/nm0297-171	http://dx.doi.org/10.1038/nm0297-171			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018235				2022-12-27	WOS:A1997WF08800035
J	Citron, M; Westaway, D; Xia, WM; Carlson, G; Diehl, T; Levesque, G; JohnsonWood, K; Lee, M; Seubert, P; Davis, A; Kholodenko, D; Motter, R; Sherrington, R; Perry, B; Yao, H; Strome, R; Lieberburg, I; Rommens, J; Kim, S; Schenk, D; Fraser, P; Hyslop, PS; Selkoe, DJ				Citron, M; Westaway, D; Xia, WM; Carlson, G; Diehl, T; Levesque, G; JohnsonWood, K; Lee, M; Seubert, P; Davis, A; Kholodenko, D; Motter, R; Sherrington, R; Perry, B; Yao, H; Strome, R; Lieberburg, I; Rommens, J; Kim, S; Schenk, D; Fraser, P; Hyslop, PS; Selkoe, DJ			Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice	NATURE MEDICINE			English	Article							MISSENSE MUTATIONS; CULTURED-CELLS; PRECURSOR; PEPTIDE; GENE; EXPRESSION; TERMINUS	The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta(42) peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta(42) secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta(42) in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta(42) increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta(42) production, thus promoting cerebral beta-amyloidosis.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV TORONTO,DEPT MED NEUROL,CTR RES NEURODEGENERAT DIS,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOL GENET & PATHOL,TORONTO,ON M5S 1A8,CANADA; MCLAUGHLIN RES INST,GREAT FALLS,MT 59409; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; University of Toronto; University of Toronto; University of Toronto; McLaughlin Research Institute for Biomedical Sciences, Inc.; Harvard University; Harvard T.H. Chan School of Public Health	Citron, M (corresponding author), BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,221 LONGWOOD AVE,BOSTON,MA 02115, USA.		xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NATIONAL INSTITUTE ON AGING [R01AG012749, R01AG006173, R37AG006173] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [64309] Funding Source: Medline; NIA NIH HHS [AG 106812, AG 12749, AG 06173] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; FONCIN JF, 1985, REV NEUROL, V141, P194; FROMMELT P, 1991, ALZ DIS ASSOC DIS, V5, P36, DOI 10.1097/00002093-199100510-00005; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROGAEV EI, IN PRESS GENOMICS; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; WALTER J, IN PRESS MOL MED; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	28	1111	1178	0	52	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					67	72		10.1038/nm0197-67	http://dx.doi.org/10.1038/nm0197-67			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986743				2022-12-27	WOS:A1997WA73300039
J	Phillips, K; Gentry, T; McCowage, G; Gilboa, E; Smith, C				Phillips, K; Gentry, T; McCowage, G; Gilboa, E; Smith, C			Cell-surface markers for assessing gene transfer into human hematopoietic cells	NATURE MEDICINE			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; UMBILICAL-CORD BLOOD; ADENOSINE-DEAMINASE; ENGRAFTMENT; THERAPY; VIVO		DUKE UNIV,MED CTR,DEPT SURG,MOL THERAPEUT PROGRAM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University; Duke University			McCowage, Geoffrey/ABB-5072-2020	McCowage, Geoffrey/0000-0003-3471-8443	NIAID NIH HHS [1-KO8-AI 01121-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001121] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGNIS C, 1994, HUM GENE THER, V5, P1325, DOI 10.1089/hum.1994.5.11-1325; Brenner MK, 1996, NEW ENGL J MED, V335, P337, DOI 10.1056/NEJM199608013350508; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; Conneally E, 1996, BLOOD, V87, P456, DOI 10.1182/blood.V87.2.456.bloodjournal872456; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; DWARKI VJ, 1995, P NATL ACAD SCI USA, V92, P1023, DOI 10.1073/pnas.92.4.1023; EIPERS PG, 1995, BLOOD, V86, P3754; FisherAdams G, 1996, BLOOD, V88, P492, DOI 10.1182/blood.V88.2.492.bloodjournal882492; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; LU L, 1993, J EXP MED, V178, P2089, DOI 10.1084/jem.178.6.2089; MAVILIO F, 1994, BLOOD, V83, P1988; Medin JA, 1996, BLOOD, V87, P1754, DOI 10.1182/blood.V87.5.1754.bloodjournal8751754; MUENCH MO, 1994, LEUKEMIA LYMPHOMA, V16, P1, DOI 10.3109/10428199409114134; Neering SJ, 1996, BLOOD, V88, P1147, DOI 10.1182/blood.V88.4.1147.bloodjournal8841147; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; PLANELLES V, 1995, GENE THER, V2, P369; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Rudoll T, 1996, GENE THER, V3, P695; Smith C, 1992, J Hematother, V1, P155, DOI 10.1089/scd.1.1992.1.155; Sokolic RA, 1996, BLOOD, V87, P42, DOI 10.1182/blood.V87.1.42.bloodjournal87142; TRAN AC, 1995, J IMMUNOL, V155, P1000; Tumas DB, 1996, BLOOD, V87, P509, DOI 10.1182/blood.V87.2.509.bloodjournal872509; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	25	43	44	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1154	1156		10.1038/nm1096-1154	http://dx.doi.org/10.1038/nm1096-1154			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837618				2022-12-27	WOS:A1996VK99500040
J	Lefebvre, AM; Chen, IH; Desreumaux, P; Najib, J; Fruchart, JC; Geboes, K; Briggs, M; Heyman, R; Auwerx, J				Lefebvre, AM; Chen, IH; Desreumaux, P; Najib, J; Fruchart, JC; Geboes, K; Briggs, M; Heyman, R; Auwerx, J			Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; INTESTINAL NEOPLASIA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; COLORECTAL-CANCER; SULINDAC SULFONE; MAJOR MODIFIER; APC GENE; INHIBITION; EXPRESSION	The development of colorectal cancer, one of the most frequent cancers, is influenced by prostaglandins and fatty acids' Decreased prostaglandin production, seen in mice with mutations in the cyclooxygenase 2 gene or in animals and humans treated with cyclooxygenase inhibitors, prevents or attenuates colon cancer development(2-4). There is also a strong correlation between the intake of fatty acids from animal origin and colon cancer(5,6). Therefore, the peroxisome proliferator-activated receptor gamma (PPAR gamma; ref. 7), a downstream transcriptional mediator for prostaglandins and fatty acids which is highly expressed in the colon(8,9), may be involved in this process. Activation of PPAR gamma by two different synthetic agonists increased the frequency and size of colon tumors in C57BL/6J-APC(Min)/+ mice, an animal model susceptible to intestinal neoplasia. Tumor frequency was only increased in the colon, and did not change in the small intestine, coinciding with the colon-restricted expression of PPAR gamma. Treatment with PPAR gamma agonists increased beta-catenin levels both in the colon of C57BL/6J-APC(Min)/+ mice and in HT-29 colon carcinoma cells. Genetic abnormalities in the Wnt/wingless/APC pathway, which enhance the transcriptional activity of the beta-catenin-T-cell factor/lymphoid enhancer factor 1 transcription complex, often underly the development of colon tumors. Our data indicate that PPAR gamma activation modifies the development of colon tumors in C57BL/6J-APC(Min)/+ mice.	Inst Pasteur, Dept Atherosclerose, U325 INSERM, LBRE, F-59019 Lille, France; Catholic Univ Louvain, Dept Pathol, B-3000 Louvain, Belgium; CHU Lille, Hop Claude Huriez, Clin Malad Appareil Digestif, F-59037 Lille, France; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Catholique Louvain; Universite de Lille - ISITE; CHU Lille; Ligand Pharmaceuticals	Auwerx, J (corresponding author), Inst Pasteur, Dept Atherosclerose, U325 INSERM, LBRE, F-59019 Lille, France.		Desreumaux, Pierre F/R-6877-2018	Desreumaux, Pierre F/0000-0002-6127-5281; Auwerx, Johan/0000-0002-5065-5393; Lefebvre, Anne-Marie/0000-0001-5644-0441				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chiu CH, 1997, CANCER RES, V57, P4267; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLM E, 1995, CANCER RES, V55, P1373; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jacoby RF, 1996, CANCER RES, V56, P710; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2909; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SAEZ E, 1998, NAT MED, V4, pR30; SCHEPPACH W, 1994, GUT, V35, pS35, DOI 10.1136/gut.35.1_Suppl.S35; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	38	542	570	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1053	1057		10.1038/2036	http://dx.doi.org/10.1038/2036			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734399				2022-12-27	WOS:000075804100039
J	Qin, ZH; Richter, G; Schuler, T; Ibe, S; Cao, XT; Blankenstein, T				Qin, ZH; Richter, G; Schuler, T; Ibe, S; Cao, XT; Blankenstein, T			B cells inhibit induction of T cell-dependent tumor immunity	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELL; PROTEIN ANTIGENS; DEFICIENT MICE; LYMPH-NODES; MEMORY; LYMPHOCYTES; ANTIBODIES; TOLERANCE; RESPONSES; INVIVO	Cytotoxic T lymphocyte (CTL) mediated tumor immunity against major histocompatibility antigen (MHC) class I-positive but class Ii-negative tumors often requires help from CD4(+) T cells. These CD4 cells are activated by MHC class Ii-positive cells that present tumor derived antigens(1,2). Considering that different antigen presenting cells, such as B cells, macrophages and dendritic cells compete for antigen and influence the outcome of an immune response(3-13), we analyzed tumor immunity in B cell-deficient mice(14). These mice appear normal with regard to T cell immunity and tolerance to some pure foreign antigens(15-19), We show here that the low immunogenicity of tumors is caused by B cells whose presence in the priming phase results in disabled CD4(+) T cell help for CTL mediated tumor immunity. Instead, in the presence of B cells, a non-protective humoral immune response is induced. Our results may explain the enigmatic observation that tumor-reactive antibodies occur frequently in cancer patients(20).	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Second Mil Med Univ, Shanghai 200433, Peoples R China	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Naval Medical University	Qin, ZH (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.			Qin, Zhihai/0000-0001-9793-7964				Asano MS, 1996, J EXP MED, V183, P2165, DOI 10.1084/jem.183.5.2165; ASHWELL JD, 1988, J IMMUNOL, V140, P3697; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; Blankenstein T, 1996, REV PHYSIOL BIOCH P, V129, P1; CAVALLO F, 1992, J IMMUNOL, V149, P3627; Cayeux S, 1997, J IMMUNOL, V158, P2834; CONSTANT S, 1995, J IMMUNOL, V154, P4915; DiRosa F, 1996, J EXP MED, V183, P2153, DOI 10.1084/jem.183.5.2153; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; ELLENHORN JDI, 1990, J IMMUNOL, V144, P2840; EPSTEIN MM, 1995, J EXP MED, V182, P915, DOI 10.1084/jem.182.4.915; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; Feldman J D, 1972, Adv Immunol, V15, P167, DOI 10.1016/S0065-2776(08)60685-9; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; HOUBIERS JGA, 1995, BRIT J CANCER, V72, P637, DOI 10.1038/bjc.1995.386; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JANEWAY CA, 1987, J IMMUNOL, V138, P1051; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; Macaulay AE, 1998, J IMMUNOL, V160, P1694; MONACH PA, 1993, TRANSPLANTATION, V55, P1356; Phillips JA, 1996, J EXP MED, V183, P1339, DOI 10.1084/jem.183.4.1339; PREHN RT, 1971, J RETICULOENDOTH SOC, V10, P1; RON Y, 1987, J IMMUNOL, V138, P2848; ROWLEY DA, 1993, J EXP MED, V178, P835, DOI 10.1084/jem.178.3.835; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; Schreiber Hans, 1993, P1143; SCHULTZ KR, 1990, SCIENCE, V249, P921, DOI 10.1126/science.2118273; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Stockinger B, 1996, J EXP MED, V183, P891, DOI 10.1084/jem.183.3.891; Vella AT, 1996, P NATL ACAD SCI USA, V93, P951, DOI 10.1073/pnas.93.2.951	35	320	327	1	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					627	630		10.1038/nm0598-627	http://dx.doi.org/10.1038/nm0598-627			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585241				2022-12-27	WOS:000073399900039
J	Nathanielsz, PW; Jenkins, SL; Tame, JD; Winter, JA; Guller, S; Giussani, DA				Nathanielsz, PW; Jenkins, SL; Tame, JD; Winter, JA; Guller, S; Giussani, DA			Local paracrine effects of estradiol are central to parturition in the rhesus monkey	NATURE MEDICINE			English	Article							TIME-TREND ANALYSIS; PROGESTERONE RATIO; MATERNAL SHEEP; PLASMA; OXYTOCIN; FETAL; ESTROGEN; LABOR; CONNEXIN-43; EXPRESSION	The central biochemical mechanisms involved in primate parturition are still unclear. Studies in both humans and nonhuman primates such as the baboon and rhesus monkey indicate that many factors play a part in the cascade of interactive positive feedforward loops that progressively promote parturition: changes in maternal endocrinology, a nocturnal switch in myometrial activity from low amplitude, infrequent contractures to high amplitude, high frequency contractions (see Fig. 1), dilation of the cervix and biochemical changes in the fetal membranes that lead to rupture(1). Here we demonstrate that infusion of the aromatase inhibitor 4-hydroxyandrostenedione (40HA) inhibits conversion of androgen to estrogen and prevents premature delivery caused by administration of androgen to pregnant rhesus monkeys at 0.8 of pregnancy term. 40HA also inhibited the androstenedione induced maternal endocrine and fetal membrane biochemical changes, and alteration of myometrial activity patterns. Secondly, peripheral estrogen infusions increased myometrial activity but did not produce preterm delivery or fetal membrane changes. We conclude that paracrine functions of estrogen at its site of production play critical and central roles in delivery in the non-human primate.	Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA; NYU, Med Ctr, Dept Obstet & Gynecol, New York, NY 10016 USA	Cornell University; New York University	Nathanielsz, PW (corresponding author), Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA.			Giussani, Dino/0000-0002-1308-1204; Nathanielsz, Peter/0000-0001-8410-6280	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 21350] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMICO JA, 1990, NEUROENDOCRINOLOGY, V51, P543, DOI 10.1159/000125389; AMICO JA, 1990, NEUROENDOCRINOLOGY, V51, P437, DOI 10.1159/000125371; BUSTER JE, 1979, J CLIN ENDOCR METAB, V48, P139, DOI 10.1210/jcem-48-1-139; BUSTER JE, 1979, J CLIN ENDOCR METAB, V48, P133, DOI 10.1210/jcem-48-1-133; CHALLIS JRG, 1971, NATURE, V229, P208, DOI 10.1038/229208a0; CIBBAR R, 1995, J CLIN ENDOCR METAB, V80, P567; DARNE J, 1987, BRIT MED J, V294, P270, DOI 10.1136/bmj.294.6567.270; ELSNER CW, 1980, ENDOCRINOLOGY, V107, P801, DOI 10.1210/endo-107-3-801; Farber DM, 1997, BIOL REPROD, V56, P557, DOI 10.1095/biolreprod56.2.557; GERMAIN AM, 1996, PRENAT NEONAT MED, V1, P57; Haluska GJ, 1997, AM J OBSTET GYNECOL, V176, P682, DOI 10.1016/S0002-9378(97)70570-2; LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2562, DOI 10.1210/en.134.6.2562; LYE SJ, 1993, ENDOCRINOLOGY, V132, P2380, DOI 10.1210/en.132.6.2380; MAGYAR DM, 1980, ENDOCRINOLOGY, V107, P155, DOI 10.1210/endo-107-1-155; Mecenas CA, 1996, NAT MED, V2, P443, DOI 10.1038/nm0496-443; NATHANIELSZ PW, 1982, ENDOCRINOLOGY, V110, P1402, DOI 10.1210/endo-110-4-1402; NOVY MJ, 1983, AM J OBSTET GYNECOL, V145, P920, DOI 10.1016/0002-9378(83)90841-4; NOVY MJ, 1981, FETAL ENDOCRINOLOGY, P66; OLSON DM, 1995, SEMIN PERINATOL, V19, P52, DOI 10.1016/S0146-0005(95)80047-6; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; SIITERI PK, 1981, FETAL ENDOCRINOLOGY, P1; STEELE PA, 1976, J ENDOCRINOL, V69, P239, DOI 10.1677/joe.0.0690239; WILSON L, 1991, AM J OBSTET GYNECOL, V165, P1487; Wu WX, 1996, BIOL REPROD, V55, P762, DOI 10.1095/biolreprod55.4.762; ZHANG J, 1991, BIOL REPROD, V45, P395, DOI 10.1095/biolreprod45.3.395	25	58	58	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					456	459		10.1038/nm0498-456	http://dx.doi.org/10.1038/nm0498-456			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546793				2022-12-27	WOS:000072906800042
J	Apostolopoulos, V; Osinski, C; McKenzie, IFC				Apostolopoulos, V; Osinski, C; McKenzie, IFC			MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral	NATURE MEDICINE			English	Article							LIMITING DILUTION ASSAYS; CELLS; ANTIGEN; TUMOR; MICE; RECOGNITION; MODULATION; PROTEIN; MANNAN	Successful tumor immunotherapy with peptides requires the induction of cytotoxic T lymphocytes (CTLs) rather than antibodies. Mice immunized with mannan conjugated to MUC1, a peptide found in large amounts in breast cancer, develop Cn responses. In contrast, immunized patients produce high antibodies with poor CTL responses to MUC1. Here, we provide evidence that this "switch" in the immune response is due to the fact that antibodies against the Gal alpha(1,3)Gal epitope, which are normally present in humans but not mice, cross-read with MUC1 peptides. in particular, mice that lack the gene for the epitope (and that produce anti-Gal antibodies) (Gal(-/-) mice) are like humans in their response to MUC1 immunization in that they develop antibody rather than CTL responses. After we exposed macrophages from Gal(-/-) mice in vitro to MUC1, in the absence of Gal antibody, and adoptively transferred them into the mice, Car-mice produced a predominantly CTL response. The findings are of relevance for immunotherapy studies in humans and emphasize the differences seen in preclinical testing in rodents before clinical trials.	Austin Res Inst, Heidelberg, Vic 3084, Australia	Austin Research Institute	McKenzie, IFC (corresponding author), Austin Res Inst, Studley Rd, Heidelberg, Vic 3084, Australia.		Apostolopoulos, Vasso/Q-4525-2019	Apostolopoulos, Vasso/0000-0001-6788-2771				AMIGORENA S, 1992, SCIENCE, V286, P1801; APOSTOLOPOULOS V, 1994, CANCER RES, V54, P5186; Apostolopoulos V, 1996, IMMUNOL CELL BIOL, V74, P457, DOI 10.1038/icb.1996.76; Apostolopoulos V, 1996, VACCINE, V14, P930, DOI 10.1016/0264-410X(95)00258-3; APOSTOLOPOULOS V, 1995, P NATL ACAD SCI USA, V92, P10128, DOI 10.1073/pnas.92.22.10128; Bouige P, 1996, FEMS IMMUNOL MED MIC, V13, P71, DOI 10.1111/j.1574-695X.1996.tb00218.x; CELIS E, 1987, HEPATOLOGY, V7, P563, DOI 10.1002/hep.1840070324; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; DISIS ML, 1994, CANCER RES, V54, P1071; Galili U, 1997, IMMUNOL TODAY, V18, P281, DOI 10.1016/S0167-5699(97)80024-2; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; KARANIKAS V, 1997, J CLIN INVEST, V100, P2738; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3; McKenzie I F, 1994, Transpl Immunol, V2, P81, DOI 10.1016/0966-3274(94)90032-9; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Sandrin MS, 1997, GLYCOCONJUGATE J, V14, P97, DOI 10.1023/A:1018521217276; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SCHENDEL DJ, 1993, CANCER RES, V53, P4020; SINGER A, 1994, J NATL CANCER I, V86, P330; TASWELL C, 1981, J IMMUNOL, V126, P1614; Theobald M, 1995, P NATL ACAD SCI USA, V92, P11993, DOI 10.1073/pnas.92.26.11993; Vaughan HA, 1996, XENOTRANSPLANTATION, V3, P18, DOI 10.1111/j.1399-3089.1996.tb00114.x; VAUGHAN HA, 1994, TRANSPLANTATION, V58, P879, DOI 10.1097/00007890-199410270-00003	24	97	112	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					315	320		10.1038/nm0398-315	http://dx.doi.org/10.1038/nm0398-315			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500605				2022-12-27	WOS:000073616200037
J	Ferrara, N; Chen, H; Davis-Smyth, T; Gerber, HP; Nguyen, TN; Peers, D; Chisholm, V; Hillan, KJ; Schwall, RH				Ferrara, N; Chen, H; Davis-Smyth, T; Gerber, HP; Nguyen, TN; Peers, D; Chisholm, V; Hillan, KJ; Schwall, RH			Vascular endothelial growth factor is essential for corpus luteum angiogenesis	NATURE MEDICINE			English	Article							OVARIAN HYPERSTIMULATION SYNDROME; TYROSINE KINASE; FACTOR VEGF; IN-VIVO; RECEPTOR; EXPRESSION; FLT-1; NEOVASCULARIZATION; PROTEINS; BINDING	The development and endocrine function of the ovarian corpus luteum (CL) are dependent on the growth of new capillary vessels. Although several molecules have been implicated as mediators of CL angiogenesis, at present there is no direct evidence for the involvement of any. Here we report the unexpected finding that treatment with truncated soluble Flt-1 receptors, which inhibit vascular endothelial growth factor (VEGF) bioactivity, resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation. This effect was associated with inhibition of CL development and progesterone release. Failure of maturation of the endometrium was also observed. Areas of ischemic necrosis were demonstrated in the corpora lutea (CLs) of treated animals. However, no effect on the preexisting ovarian vasculature was observed. These findings demonstrate that, in spite of the redundancy of potential mediators, VEGF is essential for CL angiogenesis. Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Proc Sci, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.							AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHISHOLM V, 1995, DNA CLONING, V4, P1; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ENGEL T, 1972, AM J OBSTET GYNECOL, V112, P1052, DOI 10.1016/0002-9378(72)90180-9; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNERTY H, 1993, ONCOGENE, V8, P2293; GATES AH, 1971, MAMMALIAN EMBRYOLOGY, P46; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GOSPODAROWICZ D, 1978, P NATL ACAD SCI USA, V75, P847, DOI 10.1073/pnas.75.2.847; GOSPODAROWICZ D, 1985, ENDOCRINOLOGY, V117, P2283; KAMAT BR, 1995, AM J PATHOL, V146, P157; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; MURTHY YS, 1970, OBSTET GYNECOL, V36, P758; PARK JE, 1994, J BIOL CHEM, V269, P25646; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; Rothchild I, 1981, Recent Prog Horm Res, V37, P183; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706	25	509	585	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					336	340		10.1038/nm0398-336	http://dx.doi.org/10.1038/nm0398-336			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500609				2022-12-27	WOS:000073616200041
J	Xu, L; Sanchez, A; Yang, ZY; Zaki, SR; Nabel, EG; Nichol, ST; Nabel, GJ				Xu, L; Sanchez, A; Yang, ZY; Zaki, SR; Nabel, EG; Nichol, ST; Nabel, GJ			Immunization for Ebola virus infection	NATURE MEDICINE			English	Article							PLASMID DNA; GENE; VACCINATION; PROTECTION; INJECTION; IMMUNITY; PROTEIN; EXPRESSION; INHIBITION; INDUCTION	Infection by Ebola virus causes rapidly progressive, often fatal, symptoms of fever, hemorrhage and hypotension. Previous attempts to elicit protective immunity for this disease have not met with success. We report here that protection against the lethal effects of Ebola virus can be achieved in an animal model by immunizing with plasmids encoding viral proteins. We analyzed immune responses to the viral nucleoprotein (NP) and the secreted or transmembrane forms of the glycoprotein (sGP or GP) and their ability to protect against infection in a guinea pig infection model analogous to the human disease. Protection was achieved and correlated with antibody titer and antigen-specific T-cell responses to sGP or GP. Immunity to Ebola virus can therefore be developed through genetic vaccination and may facilitate efforts to limit the spread of this disease.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, 1150 W Med Ctr Dr,4520 MSRB 1, Ann Arbor, MI 48109 USA.							Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BOTTOMLY K, 1992, CURRENT PROTOCOLS IM; BOWEN ETW, 1977, LANCET, V1, P571; BURKREYEV AA, 1993, FEBS LETT, V323, P183; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; CLEGG JCS, 1997, NEW GENERATION VACCI, P749; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; HARRIS DT, 1987, J IMMUNOL, V138, P889; Iwasaki A, 1997, J IMMUNOL, V159, P11; Jahrling PB, 1996, ARCH VIROL, P135; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; KSIAZEK TG, 1991, LAB ANIM, V20, P34; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; MCCORMICK JB, 1983, J INFECT DIS, V147, P264, DOI 10.1093/infdis/147.2.264; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; Ohno T, 1997, GENE THER, V4, P361, DOI 10.1038/sj.gt.3300403; Peters C.J., 1996, FIELDS VIROLOGY, P1161; PETERS CJ, 1994, SEMIN VIROL, V5, P147, DOI 10.1006/smvy.1994.1015; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Sambrook J, 1994, MOL CLONING LAB MANU; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SANCHEZ A, 1989, VIROLOGY, V170, P81, DOI 10.1016/0042-6822(89)90354-1; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TAN BTG, 1985, HYBRIDOMA, V4, P115, DOI 10.1089/hyb.1985.4.115; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4	37	181	212	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1998	4	1					37	42		10.1038/nm0198-037	http://dx.doi.org/10.1038/nm0198-037			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427604	Bronze			2022-12-27	WOS:000072249700032
J	Waldman, T; Zhang, YG; Dillehay, L; Yu, J; Kinzler, K; Vogelstein, B; Williams, J				Waldman, T; Zhang, YG; Dillehay, L; Yu, J; Kinzler, K; Vogelstein, B; Williams, J			Cell-cycle arrest versus cell death in cancer therapy	NATURE MEDICINE			English	Article							DNA-DAMAGE; ANTICANCER AGENTS; G(1) ARREST; P21; P53; FIBROBLASTS; CHECKPOINT; INHIBITOR; PROTEIN; KINASES	In response to anticancer therapeutics, human colon cancer cells growing in vitro either enter into a stable arrest or die, depending on the integrity of their cell-cycle checkpoints(1). To test whether altered checkpoints can modulate sensitivity to treatment in vivo, xenografts were established from isogenic lines differing only in their p21 checkpoint status. Although all tumors with intact checkpoint function underwent regrowth after treatment with gamma-radiation, a significant fraction of checkpoint-deficient tumors were completely cured. This difference in sensitivity was not detected by the clonogenic survival assay, because both arrest and death preclude outgrowth of colonies. These results demonstrate that checkpoint status affects sensitivity to anticancer treatments in vivo, and these findings have important implications for identifying and testing new therapeutic compounds.	PROGRAM HUMAN GENET,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,RADIOBIOL LAB,BALTIMORE,MD 21287	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Waldman, T (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231, USA.		Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; LI CY, 1995, INT J ONCOL, V6, P233; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; REVESZ L, 1958, J NATL CANCER I, V20, P1157, DOI 10.1093/jnci/20.6.1157; REVESZ L, 1956, NATURE, V178, P1391, DOI 10.1038/1781391a0; TISHLER RB, 1995, CANCER RES, V55, P6021; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	17	345	354	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1034	1036		10.1038/nm0997-1034	http://dx.doi.org/10.1038/nm0997-1034			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288734				2022-12-27	WOS:A1997XT84200040
J	Watson, GE; Davis, BA; Raubertas, RF; Pearson, SK; Bowen, WH				Watson, GE; Davis, BA; Raubertas, RF; Pearson, SK; Bowen, WH			Influence of maternal lead ingestion on caries in rat pups	NATURE MEDICINE			English	Article							SALIVARY COMPOSITION; ENAMEL; EXPOSURE; HEALTH	Lead is one of the most toxic and pervasive pollutants in society, and although there has been some lowering of blood lead levels in recent years, the levels continue to be of concern for African Americans, central city residents, residents in the Northeast region of the United States, persons with low income, and those with low educational attainment(1). Notably, these are the persons and the region where the highest prevalence of dental caries is observed. Information relating lead toxicity to oral health is sparse, but the preponderance of epidemiological data shows a relation between lead in the environment and the prevalence of dental caries(2,3). Using our well-defined rat caries model(4), we found that pre- and perinatal exposure to lead results in an almost 40% increase in the prevalence of caries and a decrease in stimulated parotid function of nearly 30%. Levels of lead in milk from lead-treated darns were approximately 10 times as high as the corresponding blood lead levels, suggesting that lead is being concentrated by mammary glands. These findings may help in part to explain the comparatively high levels of dental caries observed in the inner cities of the United States where exposure to lead is common. Environmental sources of lead include drinking water, lead-based paint and, to a lesser extent, automobile and industrial emissions. In humans lead is accumulated and stored in bones (half-life of approximately 62 years(5)), and even maternal exposure to lead decades before pregnancy can subsequently result in exposure of the developing fetus to elevated levels of lead. Moreover, lead concentration in maternal blood has been shown to increase during pregnancy and lactation because of mobilization of stored lead from bone(6), and typically, lead is found in milk at a higher concentration than the level found in maternal plasma at the same time point(7).	UNIV ROCHESTER, SCH MED & DENT,DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT CLIN DENT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT BIOSTAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT,DEPT ENVIRONM HLTH, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester				Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE011549] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11549, DE07165] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APPLETON J, 1991, ARCH ORAL BIOL, V36, P377, DOI 10.1016/0003-9969(91)90008-I; BATSCHELET E, 1979, J MATH BIOL, V8, P15, DOI 10.1007/BF00280582; BEACH JR, 1988, PEDIATR RES, V23, P58, DOI 10.1203/00006450-198801000-00013; BOWEN WH, 1980, J AM DENT ASSOC, V100, P677, DOI 10.14219/jada.archive.1980.0211; BOWEN WH, 1988, J DENT RES, V67, P21, DOI 10.1177/00220345880670010301; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BRUDEVOLD F, 1977, J DENT RES, V56, P1165, DOI 10.1177/00220345770560100701; CLEYMAET R, 1991, SCI TOTAL ENVIRON, V104, P175, DOI 10.1016/0048-9697(91)90071-L; CURZON MEJ, 1978, ARCH ORAL BIOL, V23, P647, DOI 10.1016/0003-9969(78)90189-9; de Champlain J, 1970, ACTA PHYSIOL SCAND, V80, P276, DOI 10.1111/j.1748-1716.1970.tb04791.x; Diggle PJ, 2002, ANAL LONGITUDINAL DA; Gil F, 1996, SCI TOTAL ENVIRON, V192, P183, DOI 10.1016/S0048-9697(96)05313-2; KEYES PAUL H., 1958, JOUR DENTAL RES, V37, P1077, DOI 10.1177/00220345580370060801; KEYES PAUL H., 1959, JOUR DENTAL RES, V38, P525, DOI 10.1177/00220345590380031401; Lawson B F, 1971, S C Dent J, V29, P5; NAVIA JM, 1977, ANIMAL MODELS DENT R, P169; PAN AYS, 1981, J TOXICOL ENV HEALTH, V7, P273, DOI 10.1080/15287398109529978; RYU JE, 1978, J PEDIATR-US, V93, P476, DOI 10.1016/S0022-3476(78)81169-X; SCHNEYER CA, 1970, AM J PHYSIOL, V219, P1268, DOI 10.1152/ajplegacy.1970.219.5.1268; Stack MV, 1983, TRACE ELEMENTS DENTA, P357; THOMPSON GN, 1985, MED J AUSTRALIA, V143, P131, DOI 10.5694/j.1326-5377.1985.tb122859.x; WATSON GE, 1989, J DENT RES, V68, P1739, DOI 10.1177/00220345890680120401; WATSON GE, 1990, ARCH ORAL BIOL, V35, P435, DOI 10.1016/0003-9969(90)90206-P; WOLFF MS, 1983, AM J IND MED, V4, P259, DOI 10.1002/ajim.4700040120; Young JA, 1978, MORPHOLOGY SALIVARY	25	46	47	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					1024	1025		10.1038/nm0997-1024	http://dx.doi.org/10.1038/nm0997-1024			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288731				2022-12-27	WOS:A1997XT84200037
J	Lofman, C; Rigo, R; Block, M; Hulten, K; Enroth, H; Engstrand, L				Lofman, C; Rigo, R; Block, M; Hulten, K; Enroth, H; Engstrand, L			Bacterium-host interactions monitored by time-lapse photography	NATURE MEDICINE			English	Article							HELICOBACTER-PYLORI INFECTION; HUMAN GASTRIC EPITHELIUM; CANCER		UNIV UPPSALA HOSP,DEPT CLIN MICROBIOL,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,SWEDISH TELEVIS,S-75185 UPPSALA,SWEDEN; UPPSALA UNIV,BIOL MICROSCOPY & IMAGING UNIT,UPPSALA,SWEDEN; KAROLINSKA INST,DEPT MED EPIDEMIOL,S-10521 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Karolinska Institutet; Swedish Institute for Infectious Disease Control				Enroth, Helena/0000-0001-7684-5702; Hulten, Kristina/0000-0001-7446-157X				BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Falk P, 1996, J INTERN MED, V240, P319, DOI 10.1046/j.1365-2796.1996.75881000.x; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GRAHAM DY, 1994, PREV MED, V23, P712, DOI 10.1006/pmed.1994.1121; HANSSON LE, 1995, GASTROENTEROLOGY, V109, P885, DOI 10.1016/0016-5085(95)90398-4; ISENBERG H D, 1988, Clinical Microbiology Reviews, V1, P40; NOACH LA, 1994, J CLIN PATHOL, V47, P699, DOI 10.1136/jcp.47.8.699	9	19	19	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					930	931		10.1038/nm0897-930	http://dx.doi.org/10.1038/nm0897-930			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256289				2022-12-27	WOS:A1997XP01400040
J	Guo, YJ; Che, XY; Shen, F; Xie, TP; Ma, J; Wang, XN; Wu, SG; Anthony, DD; Wu, MC				Guo, YJ; Che, XY; Shen, F; Xie, TP; Ma, J; Wang, XN; Wu, SG; Anthony, DD; Wu, MC			Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies	NATURE MEDICINE			English	Article							T-CELLS; HEPATOMA-CELLS; CTLA-4; COSTIMULATION; ACTIVATION; CD28; B7	Antitumor immune responses are mediated primarily by T cells(1). Downregulation of the major histocompatiblity complex (MHC) and the molecules that costimulate the immune response is associated with defective signaling by tumor cells for T-cell activation(2-14). In vitro treatment with a combination of cytokines significantly increased the expression of MHC class I and adhesion molecules on tumor cell surfaces. When tumor cells were first incubated with a bispecific monoclonal antibody that binds antigen on tumor cells to CD28 on T cells, the modified tumor cells become immunogenic and are able to stimulate naive T cells, generating tumor-specific cytotoxic T cells in vitro. Immunization with the modified tumor cells elicits an immune response mediated by CD8(+) T cells. This response protected against a challenge with parental tumor cells and cured established tumors. The approach was effective in both low immunogenic and nonimmunogenic tumor model systems. Modification of tumor cells with this two-step procedure may provide a strategy for development of tumor vaccines that is effective for cancer immunotherapy.	SHANGHAI SECOND MILIT MED UNIV,TUMOR IMMUNOL & GENE THERAPY CTR,INST HEPATOBILIARY SURG,SHANGHAI 200433,PEOPLES R CHINA; SHANGHAI SECOND MILIT MED UNIV,CHANGHAI HOSP,SHANGHAI 200433,PEOPLES R CHINA; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CANC RES CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106	Naval Medical University; Naval Medical University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland								ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DARLINGTON GJ, 1980, J NATL CANCER I, V64, P809; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; MACLEAN JA, 1993, J IMMUNOL, V150, P1619; RENNER C, 1994, SCIENCE, V264, P833, DOI 10.1126/science.8171337; RESTIFO NP, 1995, BIOL THERAPY CANC, P3; TAKAHASHI H, 1993, SCIENCE, V259, P1460, DOI 10.1126/science.8451642; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; YANG GC, 1995, J IMMUNOL, V154, P2794	20	44	51	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					451	455		10.1038/nm0497-451	http://dx.doi.org/10.1038/nm0497-451			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095181				2022-12-27	WOS:A1997WQ82500037
J	Choate, KA; Medalie, DA; Morgan, JR; Khavari, PA				Choate, KA; Medalie, DA; Morgan, JR; Khavari, PA			Corrective gene transfer in the human skin disorder lamellar ichthyosis	NATURE MEDICINE			English	Article							KERATINOCYTE TRANSGLUTAMINASE; EPIDERMAL-KERATINOCYTES; BARRIER FUNCTION; DIFFERENTIATION; THERAPY; EXPRESSION; ANTIBODIES; TISSUE; CELLS; MICE	Lamellar ichthyosis (LI) is a disfiguring skin disease characterized by abnormal epidermal differentiation and defective cutaneous barrier function(1,2). LI has been associated with loss of keratinocyte transglutaminase 1 (TGase1)(3,4) an enzyme believed necessary for normal formation of the cornified epidermal barrier. Using LI as a prototype for therapeutic cutaneous gene delivery, we have used the human skin/immunodeficient mouse xenograft model to correct the molecular, histologic and functional abnormalities of LI patient skin in vivo. We have used TGase1-deficient primary keratinocytes from LI patients combined with high-efficiency transfer of functional TGase1 to regenerate engineered human LI epidermis on immunodeficient mice. Engineered LI epidermis displayed normal TGase1 expression in vivo, unlike unengineered LI epidermis where TGase1 was absent. Epidermal architecture was also normalized by TGase1 restoration, as was expression of the epidermal differentiation marker filaggrin. Engineered LI skin demonstrated restoration of cutaneous barrier function measures to levels seen in epidermis regenerated by keratinocytes from patients with normal skin, indicating functional correction in vivo of the proposed primary pathophysiologic defect in LI. These results confirm a major role for TGase1 in epidermal differentiation and demonstrate a potential future approach to therapeutic gene delivery in human skin.	STANFORD UNIV,SCH MED,MSLS,DEPT DERMATOL,STANFORD,CA 94305; VET ADM MED CTR,VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,SURG SERV,CAMBRIDGE,MA 02139; SHRINERS BURN INST,RES CTR,CAMBRIDGE,MA 02139	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Harvard University; Massachusetts General Hospital			Cantero, Domingo/E-5688-2011; Garcia, Manuel Macias/AAV-3578-2021	Cantero, Domingo/0000-0002-1643-2831; Garcia, Manuel Macias/0000-0003-3207-2159; Morgan, Jeffrey/0000-0002-7546-3443				BALE SJ, 1994, J INVEST DERMATOL, V102, pS49, DOI 10.1111/1523-1747.ep12388591; Briggaman R A, 1980, Curr Probl Dermatol, V10, P115; DALE BA, 1987, J INVEST DERMATOL, V88, P307; FENJVES ES, 1994, J INVEST DERMATOL, V103, pS70, DOI 10.1111/1523-1747.ep12399089; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GARLICK JA, 1991, J INVEST DERMATOL, V97, P824, DOI 10.1111/1523-1747.ep12489019; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; GREENHALGH DA, 1994, J INVEST DERMATOL, V103, pS63, DOI 10.1038/jid.1994.12; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KHAVARI PA, IN PRESS DERMATOL CL; KIM YH, 1992, J INVEST DERMATOL, V98, P191, DOI 10.1111/1523-1747.ep12555849; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LAVRIJSEN APM, 1993, BRIT J DERMATOL, V129, P547, DOI 10.1111/j.1365-2133.1993.tb00482.x; MANCINI AJ, 1994, PEDIATR RES, V36, P306, DOI 10.1203/00006450-199409000-00007; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; OTTEY KA, 1995, J INVEST DERMATOL, V104, P401, DOI 10.1111/1523-1747.ep12665893; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROOP DR, 1984, J BIOL CHEM, V259, P8037; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; TA BM, 1990, J CELL SCI, V95, P631; TAICHMAN LB, 1994, KERATINOCYTE HDB, P543; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VOGEL JC, 1993, ARCH DERMATOL, V129, P1478, DOI 10.1001/archderm.129.11.1478; WILLIAMS ML, 1987, DERMATOL CLIN, V5, P155, DOI 10.1016/S0733-8635(18)30772-1	30	134	138	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1263	1267		10.1038/nm1196-1263	http://dx.doi.org/10.1038/nm1196-1263			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898758				2022-12-27	WOS:A1996VQ10100046
J	Edelman, RR; Hatabu, H; Tadamura, E; Li, W; Prasad, PV				Edelman, RR; Hatabu, H; Tadamura, E; Li, W; Prasad, PV			Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging	NATURE MEDICINE			English	Article							PARENCHYMA	The imaging of regional ventilation in the lungs is essential for the evaluation of a variety of pathological conditions, such as emphysema, pneumonia and pulmonary embolism. We propose a novel approach for ventilation scanning, using magnetic resonance imaging (MRI) and inhaled molecular oxygen as a contrast agent, that directly depicts transfer of oxygen across the alveolus into the pulmonary vasculature. Molecular oxygen is only weakly paramagnetic but produces substantial signal changes in the lungs because of their large surface area. Ventilation defects were shown in a patient with bullous emphysema, and ventilation-perfusion mismatches were shown in two patients with pulmonary embolism.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Edelman, RR (corresponding author), BETH ISRAEL HOSP,DEPT RADIOL,AN-234,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Prasad, Pottumarthi/0000-0002-4214-5465				ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; ALSOP DC, 1995, MAGNET RESON MED, V33, P678, DOI 10.1002/mrm.1910330513; BERGIN CJ, 1993, J THORAC IMAG, V8, P12, DOI 10.1097/00005382-199324000-00003; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; CHIAROTTI G, 1955, NUOVO CIMENTO, V1, P863, DOI 10.1007/BF02731333; GLOVER GH, 1992, MAGNET RESON MED, V28, P275, DOI 10.1002/mrm.1910280209; Goodman LR, 1996, RADIOLOGY, V199, P25, DOI 10.1148/radiology.199.1.8633154; Harris P, 1986, HUMAN PULMONARY CIRC; HATABU H, IN PRESS MAGN RESON; HAYES M, 1980, SEMIN NUCL MED, V10, P243, DOI 10.1016/S0001-2998(80)80004-3; HENNIG J, 1988, MAGN RESON IMAGING, V6, P391, DOI 10.1016/0730-725X(88)90475-4; JAO JC, IN PRESS PHYS MED; Listerud J, 1992, Magn Reson Q, V8, P199; MacFall JR, 1996, RADIOLOGY, V200, P553, DOI 10.1148/radiology.200.2.8685356; MAYO JR, 1992, AM J ROENTGENOL, V159, P951, DOI 10.2214/ajr.159.5.1414805; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; MILIC-EMILI J, 1971, Seminars in Nuclear Medicine, V1, P246	17	313	318	1	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1236	1239		10.1038/nm1196-1236	http://dx.doi.org/10.1038/nm1196-1236			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898751				2022-12-27	WOS:A1996VQ10100039
J	Perretti, M; Croxtall, JD; Wheller, SK; Goulding, NJ; Hannon, R; Flower, RJ				Perretti, M; Croxtall, JD; Wheller, SK; Goulding, NJ; Hannon, R; Flower, RJ			Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration	NATURE MEDICINE			English	Article							TRANSENDOTHELIAL MIGRATION; NEUTROPHIL MIGRATION; ANNEXIN-I; DEXAMETHASONE; CELLS; RATS	Polymorphonuclear leukocyte (PMN) migration into sites of inflammation is fundamental to the host defense response. Activation of endothelial cells and PMNs increases the expression or activation of adhesion molecules, culminating in rolling and subsequent adherence of these cells to the vascular wall(1,2). Further activation of adherent PMNs, possibly by endothelial cell ligands, leads, within a few minutes, to extravasation itself. This process is not clearly understood, but adhesion molecules' or related proteins(4), as well as endogenous chemokines(5), may play an important role. The anti-inflammatory glucocorticoids delay extravasation(6), which implies that an inhibitory regulatory system exists. Resting PMNs contain abundant cytoplasmic lipocortin 1 (LC1, also called annexin I)(7), and the activity profile of this protein(8-10) suggests that it could reduce PMN responsiveness. To investigate this we have assessed neutrophil transmigration both in vivo and in vitro and examined the content and subcellular distribution of LC1 in PMNs by fluorescence-activated cell-sorting (FAGS) analysis, western blotting and confocal microscopy. We report that LC1 is mobilized and externalized following PMN adhesion to endothelial monolayers in vitro or to venular endothelium in vivo and that the end point of this process is a negative regulation of PMN transendothelial passage.			Perretti, M (corresponding author), WILLIAM HARVEY RES INST, DEPT BIOCHEM PHARMACOL, CHARTERHOUSE SQ, LONDON EC1M 6BQ, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNING JL, 1990, PROG CLIN BIOL RES, V349, P27; CARLOS TM, 1994, BLOOD, V84, P2068; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1990, BIOCHEM SOC T, V18, P1237, DOI 10.1042/bst0181237; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; LEBOUTEILLER PP, 1983, J IMMUNOL METHODS, V61, P301, DOI 10.1016/0022-1759(83)90224-7; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MANCUSO F, 1995, J IMMUNOL, V155, P377; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1996, BRIT J PHARMACOL, V118, P605, DOI 10.1111/j.1476-5381.1996.tb15444.x; PERRETTI M, 1993, J IMMUNOL, V150, P992; PERRETTI M, 1992, AGENTS ACTIONS, V35, P71, DOI 10.1007/BF01990954; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEVENS TRJ, 1988, BRIT J PHARMACOL, V93, pP139; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; WANG W, 1994, BIOCHEMISTRY-US, V33, P275, DOI 10.1021/bi00167a036	26	199	206	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1259	1262		10.1038/nm1196-1259	http://dx.doi.org/10.1038/nm1196-1259			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898757				2022-12-27	WOS:A1996VQ10100045
J	Fox, BS; Kantak, KM; Edwards, MA; Black, KM; Bollinger, BK; Botka, AJ; French, TL; Thompson, TL; Schad, VC; Greenstein, JL; Gefter, ML; Exley, MA; Swain, PA; Briner, TJ				Fox, BS; Kantak, KM; Edwards, MA; Black, KM; Bollinger, BK; Botka, AJ; French, TL; Thompson, TL; Schad, VC; Greenstein, JL; Gefter, ML; Exley, MA; Swain, PA; Briner, TJ			Efficacy of a therapeutic cocaine vaccine in rodent models	NATURE MEDICINE			English	Article							DISPOSITION; PHARMACOLOGY; INJECTION; ANIMALS; HUMANS; ABUSE	Cocaine abuse is a major medical and public health concern in the United States, with approximately 2.1 million people dependent on cocaine(1). Pharmacological approaches to the treatment of cocaine addiction have thus far been disappointing(2,3), and new therapies are urgently needed. This paper describes an immunological approach to cocaine addiction. Antibody therapy for neutralization of abused drugs has been described previously(4), including a recent paper demonstrating the induction of anti-cocaine antibodies(5). However, both the rapidity of entry of cocaine into the brain(6) and the high doses of cocaine frequently encountered(7) have created challenges for an antibody-based therapy. Here we demonstrate that antibodies are efficacious in an animal model of addiction. Intravenous cocaine self-administration in rats was inhibited by passive transfer of an anti-cocaine monoclonal antibody. To actively induce anti-cocaine antibodies, a cocaine vaccine was developed that generated a high-titer, long-lasting antibody response in mice. Immunized mice displayed a significant change in cocaine pharmacokinetics, with decreased levels of cocaine measured in the brain of immunized mice only 30 seconds after intravenous (i.v.) administration of cocaine. These data establish the feasibility of a therapeutic cocaine vaccine for the treatment of cocaine addiction.	BOSTON UNIV,DEPT PSYCHOL,BOSTON,MA 02215	Boston University	Fox, BS (corresponding author), IMMULOG PHARMACEUT CORP,610 LINCOLN ST,WALTHAM,MA 02154, USA.			Exley, Mark/0000-0002-5088-1032				BENOWITZ NL, 1993, PHARMACOL TOXICOL, V72, P3, DOI 10.1111/j.1600-0773.1993.tb01331.x; Bergman J., 1990, Behav Pharmacol, V1, P355; BODANSZKY M, 1992, PEPTIDE RES, V5, P134; BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; CARROLL FI, 1994, PHARM NEWS, V1, P11; GOLDBERG SR, 1983, PHARMACOL BIOCHEM BE, V19, P1011, DOI 10.1016/0091-3057(83)90408-2; Institute of Medicine, 1995, DEV MED TREATM OP CO; JATLOW P, 1988, YALE J BIOL MED, V61, P105; JATLOW P, 1991, LIFE SCI, V48, P1787, DOI 10.1016/0024-3205(91)90217-Y; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; JINDAL SP, 1989, J PHARM SCI, V78, P1009, DOI 10.1002/jps.2600781208; JOHANSON CE, 1989, PHARMACOL REV, V41, P3; KANTAK KM, 1992, PHARMACOL BIOCHEM BE, V41, P415, DOI 10.1016/0091-3057(92)90120-5; KATZ J, 1987, METHODS ASSESSING RE, P105; KIRCHNER JG, 1978, TECH CHEM, V14, P736; Nutt DJ, 1996, LANCET, V347, P31, DOI 10.1016/S0140-6736(96)91561-5; OLDENDORF WH, 1992, RES MONOGRAPH, V120, P13; ROTHSTEIN TL, 1983, MOL IMMUNOL, V20, P161, DOI 10.1016/0161-5890(83)90127-X; STEWARD MW, 1986, HDB EXPT IMMUNOLOGY, V1; WITHERS NW, 1995, J CLIN PSYCHOPHARM, V15, P63, DOI 10.1097/00004714-199502000-00010; Woods J. H., 1987, COCAINE CLIN BIOBEHA, P21	22	184	193	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1129	1132		10.1038/nm1096-1129	http://dx.doi.org/10.1038/nm1096-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837612				2022-12-27	WOS:A1996VK99500034
J	Gabrilovich, DI; Chen, HL; Cunningham, HT; Meny, GM; Nadaf, S; Kavanaugh, D; Carbone, DP				Gabrilovich, DI; Chen, HL; Cunningham, HT; Meny, GM; Nadaf, S; Kavanaugh, D; Carbone, DP			Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HUMAN BONE-MARROW; PERMEABILITY FACTOR; LANGERHANS CELLS; DOWN-REGULATION; NECROSIS-FACTOR; BEARING MICE; ANGIOGENESIS; ANTIGEN; CANCER	Inadequate presentation of tumor antigens by host professional antigen-presenting cells (APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors from the host immune system. Here, we show that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs. One factor responsible for these effects was identified as vascular endothelial growth factor (VEGF). Thus, VEGF may play a broader role in the pathogenesis of cancer than was previously thought, and therapeutic blockade of VEGF action may improve prospects for immunotherapy as well as inhibit tumor neovasculature.	UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75325; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75325	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Gabrilovich, Dmitry/ABE-7122-2020		NCI NIH HHS [R01-CA 61242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY J, 1991, J IMMUNOL, V146, P1717; Austyn J M, 1993, In Vivo, V7, P193; AXELSSON K, 1995, J NATL CANCER I, V87, P997, DOI 10.1093/jnci/87.13.997; BELLDEGRUN A, 1989, J IMMUNOL, V42, P4520; BERGFELT L, 1994, BRIT J DERMATOL, V130, P273, DOI 10.1111/j.1365-2133.1994.tb02921.x; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; BOCHNER BH, 1995, J NATL CANCER I, V87, P1603, DOI 10.1093/jnci/87.21.1603; BOSSI P, 1995, CANCER RES, V55, P5049; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; COZZOLINO F, 1987, J EXP MED, V166, P303, DOI 10.1084/jem.166.2.303; ERROI A, 1989, INT J CANCER, V41, P65; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P111, DOI 10.1006/cimm.1996.0140; GAZDAR AF, 1986, CANCER RES, V46, P6011; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; Hoehn GT, 1996, ONCOGENE, V12, P903; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; IOANNIDES CG, 1993, CLIN IMMUNOL IMMUNOP, V66, P91, DOI 10.1006/clin.1993.1012; KATO, 1995, CANCER RES, V55, P5687; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; REID CDL, 1990, BLOOD, V76, P1139; REID CDL, 1992, J IMMUNOL, V149, P2681; REYNOLDS NJ, 1995, BRIT J DERMATOL, V133, P157, DOI 10.1111/j.1365-2133.1995.tb02611.x; ROCK KL, 1993, J IMMUNOL, V150, P438; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROZENZWAJG M, 1996, BLOOD, V87, P535; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHEN H, 1993, BLOOD, V81, P2767; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520; Takano S, 1996, CANCER RES, V56, P2185; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TAN KC, 1994, J IMMUNOL, V153, P760; TAS MPR, 1993, CANCER IMMUNOL IMMUN, V36, P108, DOI 10.1007/BF01754410; TORIYAMA K, 1993, J INVEST DERMATOL, V100, P2695; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATSON GA, 1995, J IMMUNOL, V155, P3124; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	45	1462	1582	2	58	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1096	1103		10.1038/nm1096-1096	http://dx.doi.org/10.1038/nm1096-1096			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837607				2022-12-27	WOS:A1996VK99500029
J	King, CA; Spellerberg, MB; Zhu, DL; Rice, J; Sahota, SS; Thompsett, AR; Hamblin, TJ; Radl, J; Stevenson, FK				King, CA; Spellerberg, MB; Zhu, DL; Rice, J; Sahota, SS; Thompsett, AR; Hamblin, TJ; Radl, J; Stevenson, FK			DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma	NATURE MEDICINE			English	Article							B-CELL LYMPHOMA; IDIOTYPIC VACCINATION; TUMOR; IMMUNIZATION	Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.	Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Stevenson, FK (corresponding author), Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England.			Stevenson, Freda/0000-0002-0933-5021				Anderson R, 1996, INFECT IMMUN, V64, P3168, DOI 10.1128/IAI.64.8.3168-3173.1996; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; Conry RM, 1996, SEMIN ONCOL, V23, P135; DAVIS HL, 1995, MOL CELL BIOL HUMAN, P368; DYKE RJ, 1991, CELL IMMUNOL, V132, P70, DOI 10.1016/0008-8749(91)90007-X; EISEN HN, 1975, TRANSPLANT P, V7, P209; George A J, 1989, Int Rev Immunol, V4, P271, DOI 10.3109/08830188909044783; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KUMAR A, 1992, J IMMUNOL, V148, P1499; MANNING LS, 1992, BRIT J CANCER, V66, P1088, DOI 10.1038/bjc.1992.415; Rammensee H G, 1993, Chem Immunol, V57, P113; SCHEUERMANN RH, 1995, J EXP MED, V182, P903, DOI 10.1084/jem.182.4.903; Spellerberg MB, 1997, J IMMUNOL, V159, P1885; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Vollmers H. Peter, 1996, Human Antibodies and Hybridomas, V7, P37; WILSON A, 1990, J IMMUNOL, V145, P3973; Zhu D, 1998, IMMUNOLOGY, V93, P162, DOI 10.1046/j.1365-2567.1998.00428.x	22	225	262	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1281	1286		10.1038/3266	http://dx.doi.org/10.1038/3266			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809552				2022-12-27	WOS:000076731000037
J	Pitschke, M; Prior, R; Haupt, M; Riesner, D				Pitschke, M; Prior, R; Haupt, M; Riesner, D			Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy	NATURE MEDICINE			English	Article							DISEASE; PEPTIDE; DEMENTIA	Alzheimer's disease is associated with the intraparenchymal growth of plaque-like amyloid deposits(1-3). Amyloid plaques are formed by the progressive deposition and transformation of soluble amyloid beta-protein monomers into insoluble and fibrillar aggregates that contain amyloid beta-protein in a beta-pleated sheet conformation. This process is described as 'seeded polymerization' of the monomers with slow-nucleation and fast-growth kinetics(4). Soluble amyloid beta-protein monomers are present in the cortical extracellular space and in the cerebrospinal fluid(5,6) whereas insoluble aggregates so far can be found only by the examination of brain tissue by biopsy or autopsy. Here we present a biophysical method that uses the principle of seeded polymerization in combination with fluorescence correlation spectroscopy, which allowed us to detect single amyloid beta-peptide aggregates in the cerebrospinal fluid samples from Alzheimer's patients. All of 15 Alzheimer's samples but none of the 19 age-matched control samples produced large peaks with fluorescence correlation spectroscopy indicating the rapid aggregation of the fluorescent labelled synthetic amyloid beta-protein probe onto the amyloid beta-protein 'seeds' present in the cerebrospinal fluid. Our method could enable easy in vivo detection of the cerebral amyloid beta-protein pathology of Alzheimer's disease and might be of potential value to facilitate its routine diagnosis.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Neurol Klin, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Psychiat Klin, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Biol Med Forsch Zentrum, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Pitschke, M (corresponding author), Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany.							BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; Brown AM, 1997, J NEUROCHEM, V69, P1204; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; DILLING H, 1994, WHO INT KLASSIFIKATI; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; PRSINER SB, 1997, SCIENCE, V278, P245; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x	19	279	297	2	53	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					832	834		10.1038/nm0798-832	http://dx.doi.org/10.1038/nm0798-832			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662376				2022-12-27	WOS:000074543900039
J	Pedrazzini, T; Seydoux, J; Kunstner, P; Aubert, JF; Grouzmann, E; Beermann, F; Brunner, HR				Pedrazzini, T; Seydoux, J; Kunstner, P; Aubert, JF; Grouzmann, E; Beermann, F; Brunner, HR			Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor	NATURE MEDICINE			English	Article							NEUROPEPTIDE-Y; METABOLIC-RATE; FOOD-INTAKE; GENE; TISSUE; BRAIN	Neuropeptide Y (NPY) is a 36-amino-acid neurotransmitter which is widely distributed throughout the central and peripheral nervous system(1). NPY involvement has been suggested in various physiological responses including cardiovascular homeostasis(2) and the hypothalamic control of food intake(3). At least six subtypes of NPY receptors have been described(4,5). Because of the lack of selective antagonists, the specific role of each receptor subtype has been difficult to establish. Here we describe mice deficient for the expression of the Y1 receptor subtype. Homozygous mutant mice demonstrate a complete absence of blood pressure response to NPY, whereas they retain normal response to other vasoconstrictors. Daily food intake, as well as NPY-stimulated feeding, are only slightly diminished, whereas fast-induced refeeding is markedly reduced. Adult mice lacking the NPY Y1 receptor are characterized by increased body fat with no change in protein content. The higher energetic efficiency of mutant mice might result, in part, from the lower metabolic rate measured during the active period, associated with reduced locomotor activity. These results demonstrate the importance of NPY Y1 receptors in NPY-mediated cardiovascular response and in the regulation of body weight through central control of energy expenditure. In addition, these data are also indicative of a role for the Y1 receptor in the control of food intake.	Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	University of Lausanne; University of Geneva; Swiss Institute Experimental Cancer Research	Pedrazzini, T (corresponding author), Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland.	Thierry.Pedrazzini@chuv.hospvd.ch						AMINIAN K, 1993, MED BIOL ENG COMPUT, V31, P399, DOI 10.1007/BF02446695; Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196-9781(96)00347-6; BARDE YA, 1975, J PHYSIOL-LONDON, V252, P523, DOI 10.1113/jphysiol.1975.sp011156; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; GROUZMANN E, 1992, PEPTIDES, V13, P1049, DOI 10.1016/0196-9781(92)90004-M; GRUNDEMAR L, 1993, GEN PHARMACOL-VASC S, V24, P785, DOI 10.1016/0306-3623(93)90151-M; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; MARTEL JC, 1990, MOL PHARMACOL, V38, P494; MORLEY JE, 1987, AM J PHYSIOL, V253, pR516, DOI 10.1152/ajpregu.1987.253.3.R516; MULVANY MJ, 1976, NATURE, V260, P617, DOI 10.1038/260617a0; Nilsson Torun, 1996, Blood Pressure, V5, P164, DOI 10.3109/08037059609062125; OShea D, 1997, ENDOCRINOLOGY, V138, P196, DOI 10.1210/en.138.1.196; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WAHLESTEDT C, 1990, AM J PHYSIOL, V258, pR736, DOI 10.1152/ajpregu.1990.258.3.R736; WEIR JBD, 1990, NUTRITION, V6, P213; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025	27	317	331	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					722	726		10.1038/nm0698-722	http://dx.doi.org/10.1038/nm0698-722			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623984				2022-12-27	WOS:000074008300041
J	Zawada, WM; Cibelli, JB; Choi, PK; Clarkson, ED; Golueke, PJ; Witta, SE; Bell, KP; Kane, J; de Leon, FAP; Jerry, DJ; Robl, JM; Freed, CR; Stice, SL				Zawada, WM; Cibelli, JB; Choi, PK; Clarkson, ED; Golueke, PJ; Witta, SE; Bell, KP; Kane, J; de Leon, FAP; Jerry, DJ; Robl, JM; Freed, CR; Stice, SL			Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats	NATURE MEDICINE			English	Article							FETAL VENTRAL MESENCEPHALON; FIBROBLAST GROWTH-FACTOR; DOPAMINERGIC-NEURONS; NEUROTROPHIC FACTOR; GRAFT-SURVIVAL; DISEASE; MODEL; IMPROVEMENT	Parkinson's disease symptoms can be improved by transplanting fetal dopamine cells into the putamen of parkinsonian patients. Because the supply of human donor tissue is limited and variable, an alternative and genetically modifiable non-human source of tissue would be valuable. We have generated cloned transgenic bovine embryos, 42% of which developed beyond 40 days. Dopamine cells collected from the ventral mesencephalon of the cloned fetuses 42 to 50 days post-conception survived transplantation into immunosuppressed parkinsonian rats and cells from cloned and wild-type embryos improved motor performance. Somatic cell cloning can efficiently produce transgenic animal tissue for treating parkinsonism.	Univ Colorado, Sch Med, Dept Med, Div Clin Pharmacol C237, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Div Clin Pharmacol C237, Denver, CO 80262 USA; Univ Colorado, Sch Med, Neurosci Training Program, Denver, CO 80262 USA; Adv Cell Technol Inc, Worcester, MA 01605 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Massachusetts System; University of Massachusetts Amherst	Freed, CR (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Clin Pharmacol C237, 4200 E 9th Ave, Denver, CO 80262 USA.	Curt.Freed@UCHSC.edu		Cibelli, Jose/0000-0002-2176-3854; Ponce de Leon, Federico/0000-0001-8645-553X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018639] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD7408] Funding Source: Medline; NIGMS NIH HHS [GM 07063] Funding Source: Medline; NINDS NIH HHS [NS 18639] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Aki T, 1997, J BIOCHEM, V122, P271; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BRUNDIN P, 1986, EXP BRAIN RES, V65, P235; CHERNOVSKY AW, 1997, CELL, V889, P17; Clarkson ED, 1997, CELL TISSUE RES, V289, P207, DOI 10.1007/s004410050867; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Doll RF, 1996, GENE THER, V3, P437; Dunnett S. B., 1992, NEURAL TRANSPLANTATI, P1; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREED CR, 1990, ARCH NEUROL-CHICAGO, V47, P505, DOI 10.1001/archneur.1990.00530050021007; FREEMAN TB, 1988, PROG BRAIN RES, V78, P473; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; HUFFAKER TK, 1989, EXP BRAIN RES, V77, P329, DOI 10.1007/BF00274990; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Kopyov OV, 1996, CELL TRANSPLANT, V5, P327, DOI 10.1016/0963-6897(95)02035-7; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; PARK TH, 1992, BRAIN RES, V599, P83, DOI 10.1016/0006-8993(92)90855-4; Peel AL, 1997, GENE THER, V4, P16, DOI 10.1038/sj.gt.3300358; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; PRATHER RS, 1989, BIOL REPROD, V41, P414, DOI 10.1095/biolreprod41.3.414; PURSEL VG, 1993, J ANIM SCI, V71, P10, DOI 10.2527/1993.71suppl_310x; RICHARDS JB, 1990, PHARMACOL BIOCHEM BE, V36, P217, DOI 10.1016/0091-3057(90)90394-W; Saadi S, 1997, LIFE SCI, V62, P365, DOI 10.1016/S0024-3205(97)00964-8; SANDBERG PR, 1996, NAT BIOTECHNOL, V14, P1692; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Shedlock AM, 1997, BIOTECHNIQUES, V22, P394, DOI 10.2144/97223bm03; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; Wagener S, 1996, J BIOTECHNOL, V44, P59, DOI 10.1016/0168-1656(95)00093-3; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115	38	57	71	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					569	574		10.1038/nm0598-569	http://dx.doi.org/10.1038/nm0598-569			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585230				2022-12-27	WOS:000073399900028
J	Tavitian, B; Terrazzino, S; Kuhnast, B; Marzabal, S; Stettler, O; Dolle, F; Deverre, JB; Jobert, A; Hinnen, F; Bendriem, B; Crouzel, C; Di Giamberardino, L				Tavitian, B; Terrazzino, S; Kuhnast, B; Marzabal, S; Stettler, O; Dolle, F; Deverre, JB; Jobert, A; Hinnen, F; Bendriem, B; Crouzel, C; Di Giamberardino, L			In vivo imaging of oligonucleotides with positron emission tomography	NATURE MEDICINE			English	Article							ANTISENSE OLIGONUCLEOTIDES; IN-VIVO; PHARMACOKINETICS; PROBES; VIRUS; DNA		CEA, SHFJ, INSERM, U334, F-91401 Orsay, France; CEA, Serv Hosp Frederic Joliot, Dept Rech Med, Direct Sci Vivant, Orsay, France; CEA, Serv Pharmacol & Immunol, Gif Sur Yvette, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Tavitian, B (corresponding author), CEA, SHFJ, INSERM, U334, 4 Pl Gen Leclerc, F-91401 Orsay, France.	tavitian@shfj.cea.fr	Tavitian, Bertrand M/P-6578-2018; Dollé, Frédéric/R-5756-2017	Tavitian, Bertrand M/0000-0002-5349-8194; Kuhnast, Bertrand/0000-0002-5035-4072				AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; Bendriem B., 1996, Journal of Nuclear Medicine, V37, p170P; Bijsterbosch MK, 1997, NUCLEIC ACIDS RES, V25, P3290, DOI 10.1093/nar/25.16.3290; Cammilleri S, 1996, EUR J NUCL MED, V23, P448, DOI 10.1007/BF01247375; Cammilleri S., 1995, Medecine Nucleaire, V19, P20; CROOKE ST, 1993, ANTISENSE RES APPL, P579; Deverre JR, 1997, NUCLEIC ACIDS RES, V25, P3584, DOI 10.1093/nar/25.18.3584; DEWANJEE MK, 1994, J NUCL MED, V35, P1054; Dolle F, 1997, J LABELLED COMPD RAD, V39, P319, DOI 10.1002/(SICI)1099-1344(199704)39:4<319::AID-JLCR970>3.0.CO;2-7; Dolle F., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P4; GECK P, 1983, ANAL BIOCHEM, V135, P264, DOI 10.1016/0003-2697(83)90681-4; Hildebrandt M, 1996, NUKLEARMED, V35, P126; Jones T, 1996, EUR J NUCL MED, V23, P807, DOI 10.1007/BF00843711; Jones T, 1996, EUR J NUCL MED, V23, P207, DOI 10.1007/BF01731847; Matteucci MD, 1996, NATURE, V384, P20; MOREAUGACHELIN F, 1986, J VIROL, V57, P349, DOI 10.1128/JVI.57.1.349-352.1986; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Stein D, 1997, ANTISENSE NUCLEIC A, V7, P151, DOI 10.1089/oli.1.1997.7.151; URBAIN JLC, 1995, EUR J NUCL MED, V22, P499, DOI 10.1007/BF00817271; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	22	173	193	2	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					467	471		10.1038/nm0498-467	http://dx.doi.org/10.1038/nm0498-467			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546795				2022-12-27	WOS:000072906800044
J	Rieger, R; Edenhofer, F; Lasmezas, CI; Weiss, S				Rieger, R; Edenhofer, F; Lasmezas, CI; Weiss, S			The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells	NATURE MEDICINE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; BINDING-PROTEIN; MAMMALIAN-CELLS; MOLECULAR-BIOLOGY; SCRAPIE; RESISTANT; GENE; INFECTIVITY; DISEASES; HAMSTERS	Prions are thought to consist of infectious proteins that cause transmissible spongiform encephalopathies'. According to overwhelming evidence, the pathogenic prion protein PrPSc converts its host encoded isoform PrPc into insoluble aggregates of PrPSc, concomitant with pathological modifications (for review, see refs. 1-3). Although the physiological role of PrPc is poorly understood(4), studies with PrP knockout mice demonstrated that PrPc is required for the development of prion diseases'. Using the yeast two-hybrid technology in Saccharomyces cerevisiae, we identified the 37-kDa laminin receptor precursor (LRP) as interacting with the cellular prion protein PrPc. Mapping analysis of the LRP-PrP interaction site in S. cerevisiae revealed that PrP and laminin share the same binding domain (amino acids 161 to 180)(6) on LRP. The LRP-PrP interaction was confirmed in vivo in insect (Sf9) and mammalian cells (COS-7). The LRP level was increased in scrapie-infected murine N(2)a cells and in brain and spleen of scrapie-infected mice. In contrast, the LRP concentration was not significantly altered in these organs from mice infected with the bovine spongiform encephalopathic agent (BSE), which have a lower PrPSc accumulation. LRP levels, however, were dramatically increased in brain and pancreas, slightly increased in the spleen and not altered in the liver of scrapie-infected hamsters. These data show that enhanced LRP concentrations are correlated with PrPSc accumulation in organs from mice and hamsters. The laminin receptor precursor, which is highly conserved among mammals and is located on the cell surface, may act as a receptor or coreceptor for the prion protein on mammalian cells.	Univ Munich, Inst Biochem, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany; CRSSA, CEA, Serv Neurovirol, DSV,DRM, F-92265 Fontenay Aux Roses, France	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay	Weiss, S (corresponding author), Univ Munich, Inst Biochem, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.	Weiss@lmb.uni-muenchen.de	Edenhofer, Frank/ABG-9458-2020	Edenhofer, Frank/0000-0002-6489-714X				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Borchelt DR, 1996, CHEM BIOL, V3, P619, DOI 10.1016/S1074-5521(96)90128-3; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; Edenhofer F., 1997, Angewande Chemie - International Edition in English, V36, P1674, DOI 10.1002/anie.199716741; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Farquhar CF, 1996, J GEN VIROL, V77, P1941, DOI 10.1099/0022-1317-77-8-1941; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Jackers P, 1996, ONCOGENE, V13, P495; Jackers P, 1996, BBA-GENE STRUCT EXPR, V1305, P98, DOI 10.1016/0167-4781(95)00206-5; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KEPPEL E, 1991, J CELL SCI, V100, P789; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; MALINOFF HL, 1983, BIOCHEM BIOPH RES CO, V111, P804; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; YE X, 1994, J COMP PATHOL, V110, P153, DOI 10.1016/S0021-9975(08)80187-9; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	39	356	374	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1383	1388		10.1038/nm1297-1383	http://dx.doi.org/10.1038/nm1297-1383			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396609				2022-12-27	WOS:000072249500035
J	Ambrosini, G; Adida, C; Altieri, DC				Ambrosini, G; Adida, C; Altieri, DC			A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma	NATURE MEDICINE			English	Article							CELL-DEATH; BCL-2; PROTEIN; STRAND	Inhibitors of programmed cell death (apoptosis) aberrantly prolonging cell viability may contribute to cancer(1) by facilitating the insurgence of mutations and by promoting resistance to therapy(2). Despite the identification of several new apoptosis inhibitors related to bcl-2(2,3) or to the baculovirus IAP gene(4-9), it is not clear whether apoptosis inhibition plays a general role in neoplasia. Here, we describe a new human gene encoding a structurally unique IAP apoptosis inhibitor, designated survivin. Survivin contains a single baculovirus IAP repeat and lacks a carboxyl-terminal RING finger. Present during fetal development, survivin is undetectable in terminally differentiated adult tissues. However, survivin becomes prominently expressed in transformed cell lines and in all the most common human cancers of lung, colon, pancreas, prostate and breast, in vivo. Survivin is also found in approximately 50% of high-grade non-Hodgkin's lymphomas (centroblastic, immunoblastic), but not in low-grade lymphomas (lymphocytic). Recombinant expression of survivin counteracts apoptosis of B lymphocyte precursors deprived of interleukin 3 (IL-3). These findings suggest that apoptosis inhibition may be a general feature of neoplasia and identify survivin as a potential new target for apoptosis-based therapy in cancer and lymphoma.	YALE UNIV,SCH MED,DEPT PATHOL,BOYER CTR MOL MED,NEW HAVEN,CT 06536	Yale University					NHLBI NIH HHS [HL 54131, R01 HL 43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R01HL043773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 1996, BLOOD, V88, P1457, DOI 10.1182/blood.V88.4.1457.bloodjournal8841457; ALTIERI DC, 1995, FASEB J, V9, P860, DOI 10.1096/fasebj.9.10.7615156; ASCASO R, 1994, EUR J IMMUNOL, V24, P537, DOI 10.1002/eji.1830240307; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; CELANO P, 1992, J BIOL CHEM, V267, P15092; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRAHAM GJ, 1995, J THEOR BIOL, V175, P71, DOI 10.1006/jtbi.1995.0122; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jiang SX, 1996, AM J PATHOL, V148, P837; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIMMELMAN D, 1989, CELL, V59, P687; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEBRUN DP, 1993, AM J PATHOL, V142, P743; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	23	2716	3399	3	220	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					917	921		10.1038/nm0897-917	http://dx.doi.org/10.1038/nm0897-917			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256286				2022-12-27	WOS:A1997XP01400037
J	Chen, YP; Maguire, T; Hileman, RE; Fromm, JR; Esko, JD; Linhardt, RJ; Marks, RM				Chen, YP; Maguire, T; Hileman, RE; Fromm, JR; Esko, JD; Linhardt, RJ; Marks, RM			Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate	NATURE MEDICINE			English	Article							BORNE ENCEPHALITIS-VIRUS; FIBROBLAST GROWTH-FACTOR; RESISTANT MUTANTS; ANTICOAGULANT; BIOSYNTHESIS; GLYCOPROTEIN; ATTACHMENT; SEQUENCE; ADHESION; FEVER	Dengue virus is a human pathogen that has reemerged as an increasingly important public health threat. We found that the cellular receptor utilized by dengue envelope protein to bind to target cells is a highly sulfated type of heparan sulfate. Heparin, highly sulfated heparan sulfate, and the polysulfonate pharmaceutical Suramin effectively prevented dengue virus infection of target cells, indicating that the envelope protein-target cell receptor Interaction is a critical determinant of infectivity. The dengue envelope protein sequence includes two putative glycosaminoglycan-binding motifs at the carboxy terminus; the first could be structurally modeled and formed an unusual extended binding surface of basic amino acids. Similar motifs were also identified in the envelope proteins of other flaviviridae. Developing pharmaceuticals that inhibit target cell binding may be an effective strategy for treating flavivirus infections.	UNIV MICHIGAN, DEPT INTERNAL MED, DIV RHEUMATOL, ANN ARBOR, MI 48109 USA; UNIV OTAGO, HLTH RES COUNCIL, NEW ZEALANDS VIRUS RES GRP, DUNEDIN, NEW ZEALAND; UNIV OTAGO, CTR GENE RES, DUNEDIN, NEW ZEALAND; UNIV IOWA, DIV MED & NAT PROD CHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT CHEM & BIOCHEM ENGN, IOWA CITY, IA 52242 USA; UNIV CALIF SAN DIEGO, CTR CANC, DIV CELLULAR & MOL MED, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA	University of Michigan System; University of Michigan; University of Otago; University of Otago; University of Iowa; University of Iowa; University of California System; University of California San Diego					NIAID NIH HHS [AI 33189] Funding Source: Medline; NIAMS NIH HHS [AR 41703, AR 20557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR041703, P60AR020557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; *CDC, 1996, MMWR-MORBID MORTAL W, V45, pN39; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHEN WB, 1990, NUCLEIC ACIDS RES, V18, P5889, DOI 10.1093/nar/18.19.5889; Chen YP, 1996, J VIROL, V70, P8765, DOI 10.1128/JVI.70.12.8765-8772.1996; COUCHMAN JR, 1993, CELL STRUCTURE EXTRA, V1, P33; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Halstead Scott B., 1992, World Health Statistics Quarterly, V45, P292; HE RT, 1995, J MED VIROL, V45, P451, DOI 10.1002/jmv.1890450417; HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; *I MED US COMM EM, 1992, EM INF MICR THREATS; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JJACKSON T, 1996, J VIROL, V70, P5282; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIN B, 1994, VIROLOGY, V202, P855; Linhardt R. J., 1997, CARBOHYDRATES DRUG D, P277; LINHARDT RJ, 1994, CURRENT PROTOCOLS MO, V2; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MCCLAIN DS, 1994, VIROLOGY, V198, P690, DOI 10.1006/viro.1994.1081; MOHAN P, 1991, Antiviral Chemistry and Chemotherapy, V2, P215; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Ojala WH, 1996, J AM CHEM SOC, V118, P2131, DOI 10.1021/ja951121f; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; RAAKE W, 1989, THROMB RES, V56, P719, DOI 10.1016/0049-3848(89)90289-2; REED L. J., 1938, AMER JOUR HYG, V27, P493; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sanchez IJ, 1996, J GEN VIROL, V77, P2541, DOI 10.1099/0022-1317-77-10-2541; STERNBERGH WC, 1995, J VASC SURG, V21, P477, DOI 10.1016/S0741-5214(95)70290-3; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; TYLER KL, 1996, FIELDS VIROLOGY, V1, P173; *WHO, 1996, N117 WHO; WIMMER E, 1994, COLD SPRING HARBOR M, P1	50	763	803	0	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					866	871		10.1038/nm0897-866	http://dx.doi.org/10.1038/nm0897-866			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256277				2022-12-27	WOS:A1997XP01400028
J	Kang, SM; Schneider, DB; Lin, ZH; Hanahan, D; Dichek, DA; Stock, PG; Baekkeskov, S				Kang, SM; Schneider, DB; Lin, ZH; Hanahan, D; Dichek, DA; Stock, PG; Baekkeskov, S			Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction	NATURE MEDICINE			English	Article							CLASS-II MHC; TRANSGENIC MICE; LYMPHOPROLIFERATIVE SYNDROME; PANCREATIC-ISLETS; DEATH FACTOR; CD95 LIGAND; GENE; APOPTOSIS; MUTATIONS; ANTIGEN	Fas ligand is believed to mediate immune privilege in a variety of tissues, including the eye, testis, and a subset of tumors. We tested whether expression of Pas ligand on pancreatic islets either following adenoviral or germline gene transfer could confer immune privilege after transplantation. Islets were infected with an adenoviral vector containing the murine Pas ligand cDNA (AdFasL), and were transplanted into allogenic diabetic hosts. Paradoxically, AdFasL-infected islets underwent accelerated neutrophilic rejection. The rejection was T cell and B cell independent and required Fas protein expression by host cells, but not on islets. Similarly, transgenic mice expressing Fas ligand in pancreatic beta cells developed massive neutrophilic infiltrates and diabetes at a young age. Thus, Fas ligand expression on pancreatic islets results in neutrophilic infiltration and islet destruction. These results have important implications for the development of Fas ligand-based immunotherapies.	UNIV CALIF SAN FRANCISCO,DEPT SURG,TRANSPLANTAT RES LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Baekkeskov, Steinunn/0000-0003-0878-3188; Dichek, David/0000-0002-5224-2736	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041822, R01DK047043] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK 41822, R01 DK 47043] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLISON J, IN PRESS P NATL ACAD; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CSETE ME, 1995, TRANSPLANTATION, V59, P263, DOI 10.1097/00007890-199501270-00019; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; EFRAT S, 1991, ENDOCRINOLOGY, V128, P897, DOI 10.1210/endo-128-2-897; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; Graham FL, 1991, METHOD MOL BIOL, P109; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANSEN WA, 1989, DIABETES RES CLIN EX, V10, P53; HESSE UJ, 1986, TRANSPLANTATION, V41, P271; IWAI K, 1994, BLOOD, V84, P1201; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LILES WC, 1995, J IMMUNOL, V155, P3289; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OSORIO RW, 1994, TRANSPLANT P, V26, P752; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; SHIROKI R, 1994, TRANSPLANTATION, V57, P1555; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUTHERLAND DER, 1981, DIABETOLOGIA, V20, P161; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574	44	413	431	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					738	743		10.1038/nm0797-738	http://dx.doi.org/10.1038/nm0797-738			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212099				2022-12-27	WOS:A1997XG76700032
J	Wurtman, RJ				Wurtman, RJ			What went right: Why is HIV a treatable disease?	NATURE MEDICINE			English	Editorial Material							PROTEASE; AIDS											BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bush, 1945, SCI THE ENDLESS FRON, DOI DOI 10.1016/j.techsoc.2019.03.007; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P165; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; DIMASI JA, 1996, AM J THER, V3, P1; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAMER L, 1994, REPORTS HOLOCAUST; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Shulman SR, 1995, FOOD DRUG LAW J, V50, P503; SHULTZ R, 1982, BAND PLAYED ON; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122; YOUNG JJ, 1985, AIDS PUBLIC DEBATE, P47	15	7	7	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					714	717						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212090				2022-12-27	WOS:A1997XG76700023
J	Docke, WD; Randow, F; Syrbe, U; Krausch, D; Asadullah, K; Reinke, P; VolK, HD; Kox, W				Docke, WD; Randow, F; Syrbe, U; Krausch, D; Asadullah, K; Reinke, P; VolK, HD; Kox, W			Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment	NATURE MEDICINE			English	Article							TNF-ALPHA; SEPSIS; ENDOTOXIN; CACHECTIN; RECEPTOR; SHOCK; IL-10; MICE	Neutralization of proinflammatory cytokines, such as tumor necrosis factor-alpha. (TNF-alpha) or interleukin-1 (IL-1), decreases mortality in several animal models of sepsis. However, recent clinical trials did not show an unequivocal improvement in survival. In contrast to animals, which succumb to shock during the first 72 hours, we found that many patients die much later with signs of opportunistic infections accompanied by downregulation of their monocytic HLA-DR expression and reduced ability to produce lipopolysaccharide (LPS)-induced TNF-alpha in vitro(1-3). This phenomenon of monocyte deactivation in septic patients with fatal outcome shows similarities to experimental monocytic refractoriness induced by LPS desensitization or by pretreatment with its endogenous mediators IL-10 and transforming growth factor-beta (TCF-beta)(4). In order to strengthen their antimicrobial defense, here we tested whether interferon-gamma (IFN-gamma) can improve monocytic functions in these patients and in experimental monocytic deactivation. The considerably lowered in vitro levels of LPS-induced TNF-alpha in these situations were significantly enhanced by IFN-gamma, but did not reach the extremely high levels of IFN-gamma primed naive cells from healthy donors. Moreover, IFN-gamma applied to septic patients with low monocytic HLA-DR expression restored the deficient HLA-DR expression and in vitro LPS-induced TNF-alpha secretion. Recovery of monocyte function resulted in clearance of sepsis in eight of nine patients. These data suggest that IFN-gamma treatment in carefully selected septic patients is a novel therapeutic strategy worth pursuing.	HUMBOLDT UNIV BERLIN, CLIN ANESTHESIOL & INTENS CARE MED, D-10098 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, VIRCHOW CLIN, DEPT NEPHROL & INTERNAL INTENS CARE, D-13353 BERLIN, GERMANY	Humboldt University of Berlin; Humboldt University of Berlin	Docke, WD (corresponding author), HUMBOLDT UNIV BERLIN, INST MED IMMUNOL, D-10098 BERLIN, GERMANY.		volk, hans-dieter/AAV-8053-2021; Asadullah, Khusru/AAG-9810-2021; Syrbe, Uta/T-7557-2017	volk, hans-dieter/0000-0002-7743-6668; Reinke, Petra/0000-0003-0771-4375; Syrbe, Uta/0000-0001-8463-7890				BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; DOCKE WD, 1996, IMMUNE CONSEQUENCES, V1, P162; DONNELLY RP, 1995, J IMMUNOL, V155, P1420; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; FAIST E, 1991, ANN SURG, V214, P264, DOI 10.1097/00000658-199109000-00009; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; HART PH, 1989, IMMUNOLOGY, V66, P376; HEINZEL FP, 1990, J IMMUNOL, V145, P2920; Kaul M., 1996, European Cytokine Network, V7, P283; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; VOLK HD, 1989, CLIN TRANSPLANT, V3, P246; VOLK HD, 1993, HOST DEFENSE DYSFUNC, P246; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373	20	866	905	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1997	3	6					678	681		10.1038/nm0697-678	http://dx.doi.org/10.1038/nm0697-678			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176497				2022-12-27	WOS:A1997XB97400040
J	Freije, JMP; Lawrence, JA; Hollingshead, MG; DeLaRosa, A; Narayanan, V; Grever, M; Sausville, EA; Paull, K; Steeg, PS				Freije, JMP; Lawrence, JA; Hollingshead, MG; DeLaRosa, A; Narayanan, V; Grever, M; Sausville, EA; Paull, K; Steeg, PS			Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines	NATURE MEDICINE			English	Article							DIFFERENTIAL CYTOTOXICITY DATA; ANTICANCER DRUG SCREEN; DIPHOSPHATE KINASE; BASEMENT-MEMBRANE; NATURAL-PRODUCTS; TUMOR-CELLS; NUDE-MICE; GROWTH; TRANSFECTION; EXPRESSION	We have used the COMPARE computer algorithm and Nm23 expression as a marker of tumor metastatic potential to examine the in vitro antiproliferative activity of chemotherapeutic drugs on human breast carcinoma and melanoma cell lines. None of 171 compounds in clinical use or under development and only 40 of 30,000 repository compounds exhibited preferential growth inhibition of low-Nm23-expressing, metastatically aggressive cell lines with a Pearson correlation coefficient of less than or equal to-0.64. Characterization of one compound, NSC 645306, is presented including in vivo activity in a hollow fiber assay. The data demonstrate a novel approach to drug identification for aggressive human tumors.	NCI, WOMENS CANC SECT, PATHOL LAB, DIV CLIN SCI, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL TESTING BRANCH, DEV THERAPEUT PROGRAM, FREDERICK, MD 21702 USA; NCI, DEV THERAPEUT PROGRAM, ROCKVILLE, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Freije, José M.P./A-6535-2008	Freije, José M.P./0000-0002-4688-8266				ALVAREZ M, 1995, J CLIN INVEST, V95, P2205, DOI 10.1172/JCI117910; BABA H, 1995, CANCER RES, V55, P1977; BAI R, 1991, J BIOL CHEM, V266, P15882; BENEDETTIDOCTOROVICH V, 1994, J MED CHEM, V37, P710, DOI 10.1021/jm00031a023; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Ferguson AW, 1996, CANCER RES, V56, P2931; Fitzsimmons SA, 1996, J NATL CANCER I, V88, P259, DOI 10.1093/jnci/88.5.259; FUKUDA M, INT J CANC; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HERLYN D, 1990, CANCER RES, V50, P2296; HOLLINGSHEAD MG, 1995, LIFE SCI, V57, P131, DOI 10.1016/0024-3205(95)00254-4; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; ILIOPOULOS D, 1989, J NATL CANCER I, V81, P440, DOI 10.1093/jnci/81.6.440; JUHASZ I, 1993, AM J PATHOL, V143, P528; KANTOR JD, 1993, CANCER RES, V53, P1971; KOVACIC P, 1986, ANTI-CANCER DRUG DES, V1, P197; LEE JW, 1977, J PHARM SCI, V66, P986, DOI 10.1002/jps.2600660721; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; PARHAR RS, 1995, INT J CANCER, V60, P204; Paull K.D., 1995, CANC CHEMOTHERAPEUTI, p9?45; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PRICE JE, 1990, CANCER RES, V50, P717; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWARZ LC, 1988, CANCER RES, V48, P6999; SETHI M L, 1979, Journal of Natural Products (Lloydia), V42, P187, DOI 10.1021/np50002a010; SETHI VS, 1976, CANCER RES, V36, P2390; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STERMITZ FR, 1975, J MED CHEM, V18, P708, DOI 10.1021/jm00241a014; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; Suffness M., 1980, ANTICANCER AGENTS BA, P465; TAN GT, 1991, J NAT PROD, V54, P143, DOI 10.1021/np50073a012; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; WANG LK, 1993, CHEM RES TOXICOL, V6, P813, DOI 10.1021/tx00036a010; WEINSTEIN JN, IN PRESS SCIENCE	40	34	39	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1997	3	4					395	401		10.1038/nm0497-395	http://dx.doi.org/10.1038/nm0497-395			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095172				2022-12-27	WOS:A1997WQ82500028
J	Valazquez, P; Cribbs, DH; Poulos, TL; Tenner, AJ				Valazquez, P; Cribbs, DH; Poulos, TL; Tenner, AJ			Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis	NATURE MEDICINE			English	Article							A-CHAIN; PEPTIDE; MICROGLIA; SEQUENCE; REGION; CELLS	Fibrillar amyloid beta-protein has been implicated in the pathogenesis of Alzheimer's disease because of its neurotoxicity and its ability to activate complement(1-3). Reactive microglia, astrocytes(4,5) and complement (C') components (reviewed in ref. 6) are associated with senile plaques, the fibrillar, beta-sheet assemblies of amyloid beta-peptide found predominantly in brain from individuals with AD (ref. 7). These indications of inflammatory events are not prevalent in the nonfibrillar ''diffuse'' plaques often seen in age-matched control cases without dementia. Clinical studies over the past several years have correlated the use of anti-inflammatory drugs with a decrease in the incidence and progression of AD dementia and/or dysfunction, supporting a role for gliosis and inflammation in AD pathogenesis(8,9) (reviewed in ref. 6). C5a, a product of C' activation, is chemotactic for microglia(10). Thus, complement activation provides a specific mechanism for recruiting reactive glial cells to the site of the fibrillar amyloid beta-protein plaque, which could lead to inflammatory events, neuronal dysfunction and degenerations. With the use of truncated amyloid beta-peptides, the region of amyloid beta-protein limited by residues 4 and 11 has been identified as critical in the interaction between amyloid beta-protein and C1q, the recognition component of the classical complement pathway (CCP), which results in the activation of C'. Furthermore, substitution of an isoaspartic acid for aspartic acid at amyloid beta-protein residue 7 resulted in the complete elimination of CCP-activating activity. A molecular model of this interaction has been generated that should be useful in the design of candidate therapeutic inhibitors of CCP activation by amyloid beta-protein.	UNIV CALIF IRVINE,DEPT NEUROL,IRVINE,CA 92697; UNIV CALIF IRVINE,INST BRAIN AGING & DEMENTIA,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine	Valazquez, P (corresponding author), UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,3205 BIOL SCI 2,IRVINE,CA 92697, USA.							Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; COLTON CA, 1993, ADV NEUROL, V59, P321; Cotman CW, 1996, NEUROBIOL AGING, V17, P723; ElKhoury J, 1996, NATURE, V382, P716; GASQUE P, 1995, J IMMUNOL, V154, P4726; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JIANG HX, 1994, J IMMUNOL, V152, P5050; JOHNSON BA, 1991, NEUROBIOL AGING, V12, P19, DOI 10.1016/0197-4580(91)90034-H; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; MAATSCHIEMAN MLC, 1994, J NEUROPATH EXP NEUR, V53, P483, DOI 10.1097/00005072-199409000-00007; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E	25	131	144	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					77	79		10.1038/nm0197-77	http://dx.doi.org/10.1038/nm0197-77			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986745				2022-12-27	WOS:A1997WA73300041
J	Marton, MJ; DeRisi, JL; Bennett, HA; Iyer, VR; Meyer, MR; Roberts, CJ; Stoughton, R; Burchard, J; Slade, D; Dai, HY; Bassett, DE; Hartwell, LH; Brown, PO; Friend, SH				Marton, MJ; DeRisi, JL; Bennett, HA; Iyer, VR; Meyer, MR; Roberts, CJ; Stoughton, R; Burchard, J; Slade, D; Dai, HY; Bassett, DE; Hartwell, LH; Brown, PO; Friend, SH			Drug target validation and identification of secondary drug target effects using DNA microarrays	NATURE MEDICINE			English	Article							GENE-EXPRESSION PATTERNS; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; YEAST; CALCINEURIN; HYBRIDIZATION; PHOSPHATASE; BINDING	We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.	Rosetta Inpharmat, Kirkland, WA 98034 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Merck & Company; Howard Hughes Medical Institute; Stanford University; Fred Hutchinson Cancer Center	Friend, SH (corresponding author), Rosetta Inpharmat, 12040 115th Ave NE, Kirkland, WA 98034 USA.	sfriend@rosetta.org		Bassett, Douglas/0000-0002-1619-4618				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Brachmann CB, 1998, YEAST, V14, P115; BULMER MG, 1979, PRINCIPLES STAT, P224; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SIKORSKI RS, 1989, GENETICS, V122, P19; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437	35	511	577	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1998	4	11					1293	1301		10.1038/3282	http://dx.doi.org/10.1038/3282			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809554				2022-12-27	WOS:000076731000039
J	Komanduri, KV; Viswanathan, MN; Wieder, ED; Schmidt, DK; Bredt, BM; Jacobson, MA; McCune, JM				Komanduri, KV; Viswanathan, MN; Wieder, ED; Schmidt, DK; Bredt, BM; Jacobson, MA; McCune, JM			Restoration of cytomegalovirus-specific CD4(+) T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; CELL CLONES	Recent studies of subjects infected with human immunodeficiency virus (HIV-1) have produced conflicting results about the extent of reconstitution possible in the CD4(+) lymphocyte repertoire after highly active antiretroviral therapy(1-3) (HAART). The effect of HAART on the incidence of opportunistic infections will probably depend on reconstitution of antigen-specific CD4(+) lymphocyte responses to important pathogens, including cytomegalovirus (CMV), the leading cause of blindness in AIDS(4-6) Several studies have demonstrated an important role for CD4(+) lymphocytes in controlling CMV replication in vitro and in clinical studies(7-13). It is now possible to quantitate antigen-specific CD4+ lymphocyte responses by flow cytometry(14). Using this method, we studied CMV-specific CD4(+) lymphocyte responses in individuals infected with HIV-1 with and without a history of active CMV-associated end organ disease (EOD), and in those with quiescent CMV EOD after ganciclovir therapy and HAART. The presence of active CMV-associated EOD strongly correlated with loss of CMV-specific lymphocyte responses (P = 0.0004). In contrast, patients with no history of CMV-associated EOD and most patients with quiescent EOD after HAART demonstrated strong CMV-specific CD4(+) lymphocyte responses. These data indicate that the loss of CMV-specific CD4(+) lymphocyte responses in individuals infected with HIV-1 who have active CMV EOD may be restored after ganciclovir therapy and HAART, which provides evidence for functional immune reconstitution to an important pathogen.	Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gen Clin Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	McCune, JM (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.		Komanduri, Krishna V./G-6012-2011	Komanduri, Krishna V./0000-0003-3715-5236	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040312] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI2763, R01 AI40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALP NJ, 1991, J VIROL, V65, P4812, DOI 10.1128/JVI.65.9.4812-4820.1991; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BALTIMORE D, 1995, CELL, V82, P175, DOI 10.1016/0092-8674(95)90303-8; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CUNNINGHAM ET, 1998, DUANES FUNDAMENTALS, V2, P1; Davignon JL, 1996, J VIROL, V70, P2162, DOI 10.1128/JVI.70.4.2162-2169.1996; Gerard L, 1997, CLIN INFECT DIS, V24, P836, DOI 10.1093/clinids/24.5.836; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HOLLAND GN, 1982, AM J OPHTHALMOL, V93, P393, DOI 10.1016/0002-9394(82)90127-1; IHARA T, 1994, LEUKEMIA RES, V18, P485, DOI 10.1016/0145-2126(94)90086-8; Jacobson MA, 1997, NEW ENGL J MED, V337, P105, DOI 10.1056/NEJM199707103370207; Krause H, 1997, BONE MARROW TRANSPL, V19, P1111, DOI 10.1038/sj.bmt.1700801; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; SABBAJ S, 1992, J CLIN IMMUNOL, V12, P216, DOI 10.1007/BF00918092; SCHRIER RD, 1995, J CLIN INVEST, V95, P1741, DOI 10.1172/JCI117851; SCHULZ H, 1993, J SLEEP RES, V2, P1, DOI 10.1111/j.1365-2869.1993.tb00051.x; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603	20	327	334	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					953	956		10.1038/nm0898-953	http://dx.doi.org/10.1038/nm0898-953			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701250				2022-12-27	WOS:000075107400041
J	Lewin, AS; Drenser, KA; Hauswirth, WW; Nishikawa, S; Yasumura, D; Flannery, JG; LaVail, MM				Lewin, AS; Drenser, KA; Hauswirth, WW; Nishikawa, S; Yasumura, D; Flannery, JG; LaVail, MM			Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa	NATURE MEDICINE			English	Article							INHERITED RETINAL DYSTROPHY; MICE; EXPRESSION; DEGENERATION; EFFICIENT; GENE	Ribozymes, catalytic RNA molecules that cleave a complementary mRNA sequence, have potential as therapeutics for dominantly inherited disease. Twelve percent of American patients with the blinding disease autosomal dominant retinitis pigmentosa (ADRP) carry a substitution of histidine for proline at codon 23 (P23H) in their rhodopsin gene(1), resulting in photoreceptor cell death from the synthesis of the abnormal gene product. Ribozymes can discriminate and catalyze the in vitro destruction of P23H mutant mRNAs from a transgenic rat model of ADRP (ref. 2). Here, we demonstrate that in vivo expression of either a hammerhead or hairpin ribozyme in this rat model considerably slows the rate of photoreceptor degeneration for at least three months. Catalytically inactive control ribozymes had less effect on the retinal degeneration. Intracellular production of ribozymes in photoreceptors was achieved by transduction with a recombinant adeno-associated virus (rAAV) incorporating a rod opsin promoter. Ribozyme-directed cleavage of mutant mRNAs, therefore, may be an effective therapy for ADRP and also may be applicable to other inherited diseases.	Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Gene Therapy Ctr, Gainesville, FL 32610 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, Beckman Vis Ctr, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Vis Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Neurosci, Berkeley, CA 94720 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Lewin, AS (corresponding author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.			Flannery, John/0000-0002-0720-8897; Lewin, Alfred/0000-0002-4192-9727				ALTSCHULER M, 1992, GENE, V122, P85, DOI 10.1016/0378-1119(92)90035-N; Bertrand E, 1997, RNA, V3, P75; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; Drenser KA, 1998, INVEST OPHTH VIS SCI, V39, P681; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Hormes R, 1997, NUCLEIC ACIDS RES, V25, P769, DOI 10.1093/nar/25.4.769; HUANG PC, 1993, P NATL ACAD SCI USA, V90, P8484, DOI 10.1073/pnas.90.18.8484; LAVAIL MM, 1975, EXP EYE RES, V21, P167, DOI 10.1016/0014-4835(75)90080-9; LHuillier PJ, 1996, P NATL ACAD SCI USA, V93, P6698, DOI 10.1073/pnas.93.13.6698; Lieber A, 1996, J VIROL, V70, P3153, DOI 10.1128/JVI.70.5.3153-3158.1996; MICHON JJ, 1991, INVEST OPHTH VIS SCI, V32, P280; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027; ROSENFELD PJ, 1995, MOL GENETICS OCULAR, V1, P99; Rossi JJ, 1997, CIBA F SYMP, V209, P195; Steinberg R. H., 1996, Investigative Ophthalmology and Visual Science, V37, pS698; WEN R, 1995, J NEUROSCI, V15, P7377; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	22	332	356	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					967	971		10.1038/nm0898-967	http://dx.doi.org/10.1038/nm0898-967			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701253				2022-12-27	WOS:000075107400044
J	Ruiz, PJ; Wolkowicz, R; Waisman, A; Hirschberg, DL; Carmi, P; Erez, N; Garren, H; Herkel, J; Karpuj, M; Steinman, L; Rotter, V; Cohen, IR				Ruiz, PJ; Wolkowicz, R; Waisman, A; Hirschberg, DL; Carmi, P; Erez, N; Garren, H; Herkel, J; Karpuj, M; Steinman, L; Rotter, V; Cohen, IR			Idiotypic immunization induces immunity to mutated p53 and tumor rejection	NATURE MEDICINE			English	Article							MUTATIONS; MIMICRY; PROTEIN	The p53 molecule might serve as a common tumor-associated antigen, as the tumor suppressor gene p53 is mutated and the p53 protein is often over-expressed in tumor cells. We report that effective immunity to p53 can be induced through an idiotypic network by immunization of mice with a monoclonal antibody (PAb-240) specific for mutated p53, or with a peptide derived from the complementarity determining region (CDR) 3 of the variable domain of the light chain (VL) of this antibody. The immunized mice produced IgG antibodies to p53 and mounted a cytotoxic reaction to a tumor line bearing mutated p53. The idiotypically immunized mice were resistant to challenge with the tumor cells. Thus antibodies to p53 might serve as immunogens for activating resistance to some tumors. At the basic level, these findings indicate that a network of p53 immunity may be organized naturally within the immune system.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Weizmann Inst Sci, Dept Cellular & Mol Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Stanford University; Weizmann Institute of Science; Weizmann Institute of Science	Steinman, L (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Cohen, Irun R/B-3542-2009; Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Erez, Neta/0000-0001-6506-9074; Steinman, Lawrence/0000-0002-2437-2250; Herkel, Johannes/0000-0001-9055-9999				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Bertholet S, 1997, EUR J IMMUNOL, V27, P798, DOI 10.1002/eji.1830270332; Bona CA, 1996, P SOC EXP BIOL MED, V213, P32; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; Coligan JE., 1994, CURRENT PROTOCOLS IM; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEPOM G, 1982, J EXP MED, V11, P155; NEPOM J T, 1982, Survey of Immunologic Research, V1, P255; NISONOFF A, 1991, J IMMUNOL, V147, P2429; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Vierboom MPM, 1997, J EXP MED, V186, P695, DOI 10.1084/jem.186.5.695; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	19	60	66	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					710	712		10.1038/nm0698-710	http://dx.doi.org/10.1038/nm0698-710			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623981				2022-12-27	WOS:000074008300038
J	Collen, D				Collen, D			Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent	NATURE MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; RECOMBINANT STAPHYLOKINASE; ALTERED IMMUNOREACTIVITY; PLASMINOGEN-ACTIVATOR; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; STREPTOKINASE; THERAPY; GENE; MECHANISM	Thrombosis, the blockage of blood vessels with dots, can lead to acute myocardial infarction and ischemia stroke both leading causes of death. Other than surgical interventions to remove or by pass the blockage or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration of thrombolytic agents to dissolve the blood clot. In this review, Desire Callen considers the properties and characteristics of staphylokinase that make it the thrombolytic agent of choice.	Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene, B-3001 Leuven, Belgium	Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); KU Leuven	Collen, D (corresponding author), Catholic Univ Louvain, Ctr Mol & Vasc Biol, Campus Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.	desire.collen@med.kuleuven.ac.be						BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; Califf RM, 1996, CIRCULATION, V94, P1233, DOI 10.1161/01.CIR.94.6.1233; Califf RM, 1997, AM HEART J, V133, P630, DOI 10.1016/S0002-8703(97)70164-9; CHRISTENSEN LR, 1945, J GEN PHYSIOL, V28, P363, DOI 10.1085/jgp.28.4.363; Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; COLLEN D, 1992, FIBRINOLYSIS, V6, P226, DOI 10.1016/0268-9499(92)90075-S; Collen D, 1997, CIRCULATION, V95, P463; Collen D, 1997, CIRCULATION, V95, P455; Collen D, 1996, CIRCULATION, V94, P207, DOI 10.1161/01.CIR.94.2.207; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; Collen D, 1996, CIRCULATION, V94, P197, DOI 10.1161/01.CIR.94.2.197; COLLEN D, 1993, CIRCULATION, V87, P996, DOI 10.1161/01.CIR.87.3.996; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1992, FIBRINOLYSIS, V6, P232, DOI 10.1016/0268-9499(92)90076-T; COLLEN D, 1992, CORONARY ARTERY DIS, V3, P117; COLLEN D, 1993, J BIOL CHEM, V268, P8284; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; DECLERCK PJ, 1994, THROMB HAEMOSTASIS, V71, P129; GERHEIM EB, 1948, NATURE, V162, P732, DOI 10.1038/162732a0; GRUNEWALD M, 1994, FIBRINOLYSIS, V8, P67, DOI 10.1016/S0268-9499(05)80023-2; KANAE K, 1985, Tokyo Jikeikai Medical Journal, V100, P925; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1964, AM J PHYSIOL, V207, P1044, DOI 10.1152/ajplegacy.1964.207.5.1044; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; SAKO T, 1983, NUCLEIC ACIDS RES, V11, P7679, DOI 10.1093/nar/11.22.7679; SAKO T, 1983, MOL GEN GENET, V190, P271, DOI 10.1007/BF00330650; SCHLANT RC, 1994, CIRCULATION, V90, P2091; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; Schlott B, 1997, J BIOL CHEM, V272, P6067, DOI 10.1074/jbc.272.9.6067; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2050, DOI 10.1161/01.CIR.92.8.2050; Vanderschueren S, 1996, J CARDIOVASC PHARM, V27, P809, DOI 10.1097/00005344-199606000-00007; Vanderschueren S, 1996, THROMB HAEMOSTASIS, V76, P541	46	128	139	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					279	284		10.1038/nm0398-279	http://dx.doi.org/10.1038/nm0398-279			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500599				2022-12-27	WOS:000073616200031
J	Degani, H; Gusis, V; Weinstein, D; Fields, S; Strano, S				Degani, H; Gusis, V; Weinstein, D; Fields, S; Strano, S			Mapping pathophysiological features of breast tumors by MRI at high spatial resolution	NATURE MEDICINE			English	Article							GD-DTPA; QUANTITATIVE-ANALYSIS; ANGIOGENESIS; PERMEABILITY; ENHANCEMENT; PARAMETERS; CARCINOMA	Magnetic resonance imaging (MRI) is a noninvasive method that reveals anatomical details in vivo and detects lesions for diagnosis. Although standard breast MRI cannot clearly delineate breast cancer, contrast-enhanced MRI enables the detection of breast masses with high sensitivity(1,2). Dynamic studies demonstrated that malignant lesions were characterized by a faster signal enhancement rate than benign ones(3). Dynamic MRI of human breast cancer in mice revealed high heterogeneity in the distribution of contrast-enhanced curves and derived pathophysiological features, indicating the importance of high spatial resolution(4,5). With clinical MRI, it is difficult to achieve simultaneously high spatial and temporal resolution. In previous dynamic studies, the emphasis was on high temporal resolution and mainly empiric analyses(6-12). We describe here a new model-based method that optimizes spatial resolution by using only three time points, and yet characterizes tumor heterogeneity in terms of microvascular permeability and extracellular fraction. Mapping these pathophysiological features may aid diagnosis and prognosis assessment, while the high spatial resolution may improve the capacity to detect smaller lesions. The method was tested in human breast tumors implanted in mice and in a limited number of benign and malignant breast lesions of patients.	HADASSAH MED CTR,DEPT RADIOL,IL-91240 JERUSALEM,ISRAEL; KAPLAN HOSP,DEPT RADIOL,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Degani, H (corresponding author), WEIZMANN INST SCI,DEPT REGULAT BIOL,POB 26,IL-76100 REHOVOT,ISRAEL.							BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728-199107000-00018; BUCKLEY DL, 1994, MAGNET RESON MED, V32, P646, DOI 10.1002/mrm.1910320514; DEGANI H, 1994, J MAGN RESON IMAGING, V4, P116; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FROUGE C, 1994, INVEST RADIOL, V29, P1043, DOI 10.1097/00004424-199412000-00006; FURMAN E, 1991, CANCER COMMUN, V3, P287, DOI 10.3727/095535491820873001; FurmanHaran E, 1996, JMRI-J MAGN RESON IM, V6, P195, DOI 10.1002/jmri.1880060135; FurmanHaran E, 1996, P NATL ACAD SCI USA, V93, P6247, DOI 10.1073/pnas.93.13.6247; HARMS SE, 1993, JMRI-J MAGN RESON IM, V3, P277, DOI 10.1002/jmri.1880030139; HEYWANGKOBRUNNER SH, 1994, INVEST RADIOL, V29, P94, DOI 10.1097/00004424-199401000-00019; HOFFMANN U, 1995, MAGNET RESON MED, V33, P506, DOI 10.1002/mrm.1910330408; HULKA CA, 1995, RADIOLOGY, V197, P33, DOI 10.1148/radiology.197.1.7568850; KAISER WA, 1989, RADIOLOGY, V170, P681, DOI 10.1148/radiology.170.3.2916021; KELTZ F, 1996, J MAGN RESON IMAGING, V6, P743; LARSSON HBW, 1990, MAGNET RESON MED, V16, P117, DOI 10.1002/mrm.1910160111; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LucasQuesada FA, 1996, JMRI-J MAGN RESON IM, V6, P753, DOI 10.1002/jmri.1880060508; POON CS, 1992, J NATL CANCER I, V84, P777, DOI 10.1093/jnci/84.10.777; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; TOFTS PS, 1995, MAGN RESON MED, V33, P564, DOI 10.1002/mrm.1910330416; WEIDMANN HJ, 1984, PHYSIOL CHEM PHYS M, V16, P167; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	23	220	241	0	31	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					780	782		10.1038/nm0797-780	http://dx.doi.org/10.1038/nm0797-780			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212107				2022-12-27	WOS:A1997XG76700040
J	Steiner, G; Schoenberg, MP; Linn, JF; Mao, L; Sidransky, D				Steiner, G; Schoenberg, MP; Linn, JF; Mao, L; Sidransky, D			Detection of bladder cancer recurrence by microsatellite analysis of urine	NATURE MEDICINE			English	Article								A reliable, noninvasive method for monitoring patients with transitional cell carcinoma (TCC) of the bladder would be of great clinical benefit. Cystoscopy is currently the ''gold standard,'' but it is invasive, expensive and uncomfortable for the patient. Recently, we demonstrated a novel approach for the detection of primary bladder cancer based on microsatellite analysis of urine DNA. To determine the feasibility of this technique for following-up patients with TCC, we tested serial urine samples from 21 patients who had been treated for bladder cancer with 20 polymorphic microsatellite markers in a blinded fashion. We detected recurrent lesions in 10 out of 11 patients and correctly predicted the existence of a neoplastic cell population in the urine of two patients, 4 and 6 months before cystoscopic evidence of the tumor. The assay was negative in 10 of 10 patients who had no evident cancer. Microsatellite analysis of urine sediment represents a novel and potentially powerful clinical tool for the detection of recurrent bladder cancer.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA	Johns Hopkins University	Steiner, G (corresponding author), JOHNS HOPKINS UNIV HOSP, DEPT UROL, JAMES BUCHANAN BRADY UROL INST, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				*AM JOINT COMM CAN, 1988, MAN STAG CANC, P171; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HRUBAN RH, 1994, NEW ENGL J MED, V330, P1276, DOI 10.1056/NEJM199405053301805; HUDSON MA, 1996, ADULT PEDIAT UROLOGY, P643; Loh CS, 1996, BRIT J UROL, V77, P655, DOI 10.1046/j.1464-410X.1996.09275.x; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAROSDY MF, 1995, J UROLOGY, V154, P379, DOI 10.1016/S0022-5347(01)67054-X; Soloway MS, 1996, J UROLOGY, V156, P363, DOI 10.1016/S0022-5347(01)65851-8; WANG Y, IN PRESS J ELECTROPH	15	217	223	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					621	624		10.1038/nm0697-621	http://dx.doi.org/10.1038/nm0697-621			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176487				2022-12-27	WOS:A1997XB97400030
J	Silvestrini, MC; Cardone, F; Maras, B; Pucci, P; Barra, D; Brunori, M; Pocchiari, M				Silvestrini, MC; Cardone, F; Maras, B; Pucci, P; Barra, D; Brunori, M; Pocchiari, M			Identification of the prion protein allotypes which accumulate in the brain of sporadic and familial Creutzfeldt-Jakob disease patients	NATURE MEDICINE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; AMYLOIDOTIC POLYNEUROPATHY; TRANSTHYRETIN PREALBUMIN; SCRAPIE AGENT; PRP; GENE; VARIANT; FIBRILS; PROPAGATION; RESISTANT	A characteristic feature of Creutzfeldt-jakob disease (CJD) is the accumulation in the brain of the amyloid protease-resistant protein PrPres. PrPres derives from a host-encoded, protease-sensitive isoform, PrPsen. Mutations of this protein are linked to familial variants of the disease, and the presence of a methionine or valine residue at the polymorphic position 129 may be critical in sporadic CJD cases. We found that in the brain of patients heterozygous for the mutation in which isoleucine is substituted for valine at codon 210 (Val210Ile), the PrPres is formed by both the wild-type and mutant PrPsen. We also found that in a sporadic CJD patient, who was heterozygous (Met/Val) at position 129, PrPres is also formed by both allotypes. These data associate transmissible spongiform encephalopathies with other amyloidosis, although the nature of the transmissible agent remains unsettled.	IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; CNR,CTR MOL BIOL,I-00185 ROME,ITALY; UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,I-00185 ROME,ITALY	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Sapienza University Rome			Cardone, Franco/D-1724-2009; Pocchiari, Maurizio/J-8443-2018; Maras, Bruno/A-2020-2010; Barra, Donatella/D-1236-2011	Cardone, Franco/0000-0002-2376-0470; Pocchiari, Maurizio/0000-0002-7269-2486; PUCCI, Pietro/0000-0002-5885-1495; Brunori, Maurizio/0000-0002-7795-1635				Barbanti P, 1996, NEUROLOGY, V47, P734, DOI 10.1212/WNL.47.3.734; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; COME JH, 1994, J AM CHEM SOC, V116, P4109, DOI 10.1021/ja00088a069; DIRINGER H, 1994, ANN NY ACAD SCI, V724, P246, DOI 10.1111/j.1749-6632.1994.tb38915.x; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FURUKAWA H, 1995, MOL BRAIN RES, V30, P385, DOI 10.1016/0169-328X(95)00034-P; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAJDUSEK DC, 1984, MOL NEUROBIOL, V8, P1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GOLDFARB LG, 1995, ANNU REV MED, V46, P57; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Manuelidis L, 1996, VIROLOGY, V216, P46, DOI 10.1006/viro.1996.0033; Mastrianni JA, 1996, NEUROLOGY, V47, P1305, DOI 10.1212/WNL.47.5.1305; MASULLO C, 1994, ANN NY ACAD SCI, V724, P358, DOI 10.1111/j.1749-6632.1994.tb38931.x; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Petraroli R, 1996, AM J HUM GENET, V58, P888; POCCHIARI M, 1993, ANN NEUROL, V34, P802, DOI 10.1002/ana.410340608; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TAWARA S, 1983, BIOCHEM BIOPH RES CO, V116, P880, DOI 10.1016/S0006-291X(83)80224-1; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WESTERMARK P, 1987, CLIN EXP IMMUNOL, V69, P695; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0; XI YG, 1994, J NEUROL SCI, V124, P171, DOI 10.1016/0022-510X(94)90323-9	47	58	58	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					521	525		10.1038/nm0597-521	http://dx.doi.org/10.1038/nm0597-521			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142120				2022-12-27	WOS:A1997WX54300031
J	Bargou, RC; Jurchott, K; Wagener, C; Bergmann, S; Metzner, S; Bommert, K; Mapara, MY; Winzer, KJ; Dietel, M; Dorken, B; Royer, HD				Bargou, RC; Jurchott, K; Wagener, C; Bergmann, S; Metzner, S; Bommert, K; Mapara, MY; Winzer, KJ; Dietel, M; Dorken, B; Royer, HD			Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression	NATURE MEDICINE			English	Article							P-GLYCOPROTEIN; BINDING-PROTEIN; RESISTANCE; TISSUE; SEQUENCE; CELLS	Breast cancers are either primarily resistant to chemotherapy (intrinsic resistance), or respond to chemotherapy but later recur with a multidrug-resistant phenotype because of overexpression of the multidrug transporter P-glycoprotein(1). The MDR1 gene encoding P-glycoprotein may be transcriptionally regulated by a Y-box transcription factor(2). We now report that, in multidrug-resistant MCF-7 breast cancer cells, nuclear localization of YB-1 is associated with MDR-1 gene expression. In drug-sensitive MCF-7 cells, however, YB-1 was localized to the cytoplasm. Regulated overexpression of YB-1 in drug-sensitive diploid breast epithelial cells induced MDR-1 gene expression and multidrug resistance. In 27 out of 27 untreated primary breast cancers, YB-1 protein was expressed in the cytoplasm although it was undetectable in normal breast tissue of these patients. In a subgroup of tumors (9/27), however, YB-1 was also localized to the nucleus and, in these cases, high levels of P-glycoprotein were present. These results show that in a subset of untreated primary breast cancers, nuclear localization of YB-1 protein is associated with intrinsic multidrug resistance. Our data show that YB-1 has an important role in controlling MDR1 gene transcription and this finding provides a basis for the analysis of molecular mechanisms responsible for intrinsic multidrug resistance in human breast cancer.	HUMBOLDT UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ROBERT ROSSLE KLIN,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,INST PATHOL,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,D-10117 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Royer, Hans-dieter/AAH-6293-2019; mapara, markus/A-2134-2013; Bommert, Kurt/G-9247-2011	Jurchott, Karsten/0000-0003-1589-0037				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BITTL A, 1995, ANTICANCER RES, V15, P1007; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grinstein E, 1996, J BIOL CHEM, V271, P9215, DOI 10.1074/jbc.271.16.9215; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE CH, 1994, COLD SPRING HARB SYM, V59, P607, DOI 10.1101/SQB.1994.059.01.069; MADDEN MJ, 1993, J BIOL CHEM, V268, P8209; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; SANFILIPPO O, 1991, EUR J CANCER, V27, P155, DOI 10.1016/0277-5379(91)90476-T; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; VANGROENIGEN M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P138, DOI 10.1016/0167-4781(93)90280-Q; VERELLE P, 1991, J NATL CANCER I, V83, P111; WEINSTEIN RS, 1991, CANCER RES, V51, P2720; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	20	351	376	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					447	450		10.1038/nm0497-447	http://dx.doi.org/10.1038/nm0497-447			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095180				2022-12-27	WOS:A1997WQ82500036
J	Sarid, R; Sato, T; Bohenzky, RA; Russo, JJ; Chang, Y				Sarid, R; Sato, T; Bohenzky, RA; Russo, JJ; Chang, Y			Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; EPSTEIN-BARR-VIRUS; HUMAN B-CELLS; DNA-SEQUENCES; CASTLEMANS DISEASE; PROTEIN; APOPTOSIS; GENE; CLONING; SAIMIRI	Kaposi's sarcoma-associated herpesvirus (KSHV) is a newly discovered herpesvirus etiologically associated with Kaposi's sarcoma (KS) and two lymphoproliferative disorders. We describe a KSHV vbcl-2 gene with homology to the proto-oncogene bcl-2. It is expressed in KS lesions and in cell lines derived from primary effusion lymphomas. Using yeast and human cells we demonstrate the ability of KSHV vBcl-2 protein to suppress Bar toxicity. We show that KSHV vBcl-2 heterodimerizes with human Bcl-2 in a yeast two-hybrid system. These results suggest that KSHV vBcl-2 plays an anti-apoptotic role in virus infected cells.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT OTOLARYNGOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLUMBIA GENOME CTR, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University			Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA67391] Funding Source: Medline; NIGMS NIH HHS [R01 GM5514-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOSHOFF C, 1995, LANCET, V345, P1043; BOYD JM, 1995, ONCOGENE, V11, P1921; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER J, 1996, BIOL CHEM, V271, P8521; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; MILLER G, 1990, VIROLOGY, P1921; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1994, P NATL ACAD SCI USA, V92, P2016; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Strauchen JA, 1996, ANN INTERN MED, V125, P822, DOI 10.7326/0003-4819-125-10-199611150-00006; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	53	277	291	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					293	298		10.1038/nm0397-293	http://dx.doi.org/10.1038/nm0397-293			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055856				2022-12-27	WOS:A1997WL30500030
J	Seino, KI; Kayagaki, N; Okumura, K; Yagita, H				Seino, KI; Kayagaki, N; Okumura, K; Yagita, H			Antitumor effect of locally produced CD95 ligand	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; HUMAN FAS LIGAND; GENE-TRANSFER; ANTI-FAS; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; FACTOR-ALPHA; T-CELLS; EXPRESSION	Activation of the cell-surface antigen CD95 induces apoptosis of CD95-bearing tumor cells. In this study, we investigated the antitumor effect of locally produced CD95 ligand (CD95L) on CD95-negative tumor cells in vivo. Introduction of CD95L cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Neutrophils were primarily responsible for this rejection. A CD8(+) T cell-mediated protective immunity against subsequent challenge with parental tumor cells was also elicited. These results provide evidence for the potential utility of CD95L in tumor eradication and also reveal a proinflammatory function of CD95L.	JUNTENDO UNIV,SCH MED,BUNKYO KU,TOKYO 113,JAPAN; UNIV TSUKUBA,SCH MED,DEPT SURG,TSUKUBA,IBARAKI 305,JAPAN; JAPAN SCI & TECHNOL CORP,CREST,CHIYODA KU,TOKYO 101,JAPAN	Juntendo University; University of Tsukuba; Japan Science & Technology Agency (JST)			seino, kenichiro/F-8823-2012					ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ASHER AL, 1991, J IMMUNOL, V146, P3227; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; CAVALLO F, 1992, J IMMUNOL, V149, P3627; COLOMBO MP, 1994, IMMUNOL TODAY, V15, P48, DOI 10.1016/0167-5699(94)90131-7; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRESHAM HD, 1991, J IMMUNOL, V146, P3911; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774; IWAI K, 1994, BLOOD, V84, P1201; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; LICHTENSTEIN A, 1985, INT J CANCER, V35, P121, DOI 10.1002/ijc.2910350119; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWRANCE JH, 1994, J EXP MED, V180, P1693, DOI 10.1084/jem.180.5.1693; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MAASS G, 1995, P NATL ACAD SCI USA, V92, P5540, DOI 10.1073/pnas.92.12.5540; MCKENZIE RC, 1990, J INVEST DERMATOL, V95, pS105, DOI 10.1111/1523-1747.ep12874955; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; SAITO K, 1996, EUR J IMMUNOL, V20, P3096; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SEUNG LP, 1995, P NATL ACAD SCI USA, V92, P6254, DOI 10.1073/pnas.92.14.6254; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	286	297	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					165	170		10.1038/nm0297-165	http://dx.doi.org/10.1038/nm0297-165			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018234				2022-12-27	WOS:A1997WF08800034
J	BenHaim, SA; Osadchy, D; Schuster, I; Gepstein, L; Hayam, G; Josephson, ME				BenHaim, SA; Osadchy, D; Schuster, I; Gepstein, L; Hayam, G; Josephson, ME			Nonfluoroscopic, in vivo navigation and mapping technology	NATURE MEDICINE			English	Editorial Material									BETH ISRAEL HOSP,HARVARD THORNDIKE ELECTROPHYSIOL INST,BOSTON,MA 02215; BETH ISRAEL HOSP,ARRHYTHMIA SERV,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	BenHaim, SA (corresponding author), TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,CARDIOVASC RES LAB,POB 9649,IL-31096 HAIFA,ISRAEL.		Gepstein, Lior/H-9458-2012					ANZAI Y, 1993, RADIOGRAPHICS, V13, P897, DOI 10.1148/radiographics.13.4.8356275; BENHAIM SA, 1996, PACING CLIN ELECTR 2, V19, P709; CAVAYE DM, 1993, J CARDIOVASC SURG, V34, P13; CHEN TCK, 1991, PACE, V14, P470, DOI 10.1111/j.1540-8159.1991.tb04096.x; DEBAKKER JMT, 1983, J AM COLL CARDIOL, V2, P947, DOI 10.1016/S0735-1097(83)80244-7; GALLAGHER JJ, 1982, AM J CARDIOL, V49, P221, DOI 10.1016/0002-9149(82)90296-X; Groenemeyer D H, 1995, Endosc Surg Allied Technol, V3, P69; HAFALA R, 1995, CIRCULATION, V91, P1480; HAYAM G, 1996, PACING CLIN ELECTR 2, V19, P712; HERMAN GT, 1993, COMPUT MED IMAG GRAP, V17, P231, DOI 10.1016/0895-6111(93)90012-C; HIGGINS WE, 1992, COMPUT MED IMAG GRAP, V16, P17, DOI 10.1016/0895-6111(92)90195-F; JOSEPHSON ME, 1982, AM J CARDIOL, V49, P207, DOI 10.1016/0002-9149(82)90295-8; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; RAICHLEN JS, 1986, J AM COLL CARDIOL, V8, P364, DOI 10.1016/S0735-1097(86)80052-3; SEIBEL RMM, 1994, END SURG ALL TECH, V3, P226; SMEETS JLR, 1996, EUR J CARDIAC PAC S5, V6, P255	16	296	337	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1393	1395		10.1038/nm1296-1393	http://dx.doi.org/10.1038/nm1296-1393			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946843				2022-12-27	WOS:A1996VW51500050
J	Saha, K; Sova, P; Chao, W; Chess, L; Volsky, DJ				Saha, K; Sova, P; Chao, W; Chess, L; Volsky, DJ			Generation of CD4(+) and CD8(+) T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri	NATURE MEDICINE			English	Article							LYMPHOCYTES-T; VIRUS; IMMUNODEFICIENCY; IMMORTALIZATION; REPLICATION; TRANSFORMATION; PATHOGENESIS		COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP,MOL VIROL LAB,NEW YORK,NY 10019; COLUMBIA UNIV COLL PHYS & SURG,DIV RHEUMATOL,NEW YORK,NY 10019	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS031492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BROKER BM, 1993, J IMMUNOL, V151, P1184; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; DECARLI M, 1993, J IMMUNOL, V151, P5022; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HASELTINE WA, 1988, J ACQ IMMUN DEF SYND, V1, P217; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; NICK S, 1993, VIROLOGY, V194, P875, DOI 10.1006/viro.1993.1334; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROIZMAN B, 1990, VIROLOGY; ROSENBERG ZF, 1991, FASEB J, V5, P2383; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SAHA K, 1992, J VIROL, V66, P2639, DOI 10.1128/JVI.66.5.2639-2646.1992; SAHA K, IN PRESS J IMMUNOL; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; TOSO JF, 1995, J INFECT DIS, V172, P964, DOI 10.1093/infdis/172.4.964; Volsky DJ, 1996, J VIROL, V70, P3823, DOI 10.1128/JVI.70.6.3823-3833.1996; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	29	28	29	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1996	2	11					1272	1275		10.1038/nm1196-1272	http://dx.doi.org/10.1038/nm1196-1272			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898759				2022-12-27	WOS:A1996VQ10100049
J	Morris, L; Martin, DJ; Quinn, TC; Chaisson, RE				Morris, L; Martin, DJ; Quinn, TC; Chaisson, RE			The importance of doing HIV research in developing countries	NATURE MEDICINE			English	Editorial Material							VIRAL LOAD; VIRUS LOAD; INFECTION; TRANSMISSION; HYDROXYUREA; DIDANOSINE; DISEASES; THERAPY; AFRICA; IMPACT		Natl Inst Virol, AIDS Virus Res Unit, Johannesburg, South Africa; NIAID, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Morris, L (corresponding author), Natl Inst Virol, AIDS Virus Res Unit, Johannesburg, South Africa.		Morris, Lynn/V-3941-2018	Morris, Lynn/0000-0003-3961-7828				Abdool Karim Q, 1997, AIDS, V11 Suppl B, pS143; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004; CONNOR EM, 1994, NEW ENGL J MED, V331, P1171; Coutsoudis A, 1997, J ACQ IMMUN DEF SYND, V15, P86; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; GOLLETTI D, 1996, J IMMUNOL, V157, P1271; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hofmeyr GJ, 1997, BRIT MED J, V315, P199, DOI 10.1136/bmj.315.7102.199; Hogg RS, 1997, LANCET, V350, P1406, DOI 10.1016/S0140-6736(05)65188-4; Lori F, 1997, JAMA-J AM MED ASSOC, V277, P1437, DOI 10.1001/jama.277.18.1437; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Montaner JSG, 1997, J INFECT DIS, V175, P801, DOI 10.1086/513974; MORRIS L, 1998, 5 C RETR OPP INF CHI; Newell ML, 1997, AIDS, V11, pS165; RUTSCHMANN OT, 1998, 5 C RETR OPP INF CHI; SULKOWSKI M, IN PRESS J INFECT DI; VANPRAAG E, 1997, IAS NEWSLETTER, V8, P6; VUTHIPONGSE P, 1998, MMWR-MORBID MORTAL W, V47, P151	20	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1228	1229		10.1038/3206	http://dx.doi.org/10.1038/3206			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809535				2022-12-27	WOS:000076731000020
J	Piccinni, MP; Beloni, L; Livi, C; Maggi, E; Scarselli, G; Romagnani, S				Piccinni, MP; Beloni, L; Livi, C; Maggi, E; Scarselli, G; Romagnani, S			Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; HUMAN ENDOMETRIUM; BLASTOCYST IMPLANTATION; TH2-TYPE CYTOKINES; IL-10 PRODUCTION; FETAL ALLOGRAFT; MESSENGER-RNA; FACTOR LIF; IFN-GAMMA; EXPRESSION	Leukemia inhibitory factor is essential for embryo implantation, and a shift from type 1 T-helper to type 2 T-helper response at the fetal-maternal interface may contribute to successful pregnancy. We show that LIF production is associated with type 2 T-helper cells, is upregulated by IL-4 and progesterone and is downregulated by IL-12 IFN-gamma and IFN-alpha. We also show a decreased production of LIF, IL-4 and IL-10 by decidual T cells of women with unexplained recurrent abortions in comparison with that of women with normal gestation. The defective production of LIF and/or type 2 T-helper cytokines may contribute to the development of unexplained recurrent abortions.	Univ Florence, Inst Internal Med Immonoallergol, I-50134 Florence, Italy; Univ Florence, Inst Obstet & Gynecol, I-50134 Florence, Italy	University of Florence; University of Florence	Romagnani, S (corresponding author), Univ Florence, Inst Internal Med Immonoallergol, 85 Viale Morgagni, I-50134 Florence, Italy.	s.romagnani@mednuc2.dfc.unifi.it	Maggi, Enrico/AAA-8045-2019	Maggi, Enrico/0000-0002-1824-3583				ARICI A, 1995, J CLIN ENDOCR METAB, V80, P1908, DOI 10.1210/jc.80.6.1908; BERKOWITZ RS, 1988, AM J OBSTET GYNECOL, V158, P199, DOI 10.1016/0002-9378(88)90810-1; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; CHAOUAT G, 1990, J REPROD FERTIL, V89, P447; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; CHAOUAT G, 1990, EOS-RIV IMMUNOL, V10, P45; CHARNOCKJONES DS, 1994, J REPROD FERTIL, V101, P421; CROY BA, 1991, J REPROD IMMUNOL, V19, P149; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DELAGE G, 1995, HUM REPROD, V10, P2483; Deneys V, 1997, TRANSPLANT P, V29, P2467, DOI 10.1016/S0041-1345(97)00451-X; HILL JA, 1995, JAMA-J AM MED ASSOC, V273, P1933, DOI 10.1001/jama.273.24.1933; HILL JA, 1991, BIOL REPROD, V44, P69; JOKHI PP, 1994, J IMMUNOL, V153, P4427; KING A, 1995, CYTOKINE, V7, P364, DOI 10.1006/cyto.1995.0046; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; Krishnan L, 1996, J IMMUNOL, V156, P644; Krishnan L, 1996, J IMMUNOL, V156, P653; Laird SM, 1997, HUM REPROD, V12, P569; Lavranos TC, 1995, J REPROD FERTIL, V105, P331, DOI 10.1530/jrf.0.1050331; LIN H, 1993, J IMMUNOL, V151, P4562; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; NICKERSON P, 1994, CURR OPIN IMMUNOL, V6, P757, DOI 10.1016/0952-7915(94)90081-7; Piccinni MP, 1996, IMMUNOL RES, V15, P141, DOI 10.1007/BF02918503; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUTHANTHIRAN M, 1995, J CLIN IMMUNOL, V15, P161, DOI 10.1007/BF01541085; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; Vogiagis D, 1996, J ENDOCRINOL, V148, P95, DOI 10.1677/joe.0.1480095; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WHITMIRE D, 1992, PHYS WORLD, V5, P21, DOI 10.1088/2058-7058/5/2/25	33	530	551	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1020	1024		10.1038/2006	http://dx.doi.org/10.1038/2006			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734394				2022-12-27	WOS:000075804100034
J	Cairns, JS; D'Souza, MP				Cairns, JS; D'Souza, MP			Chemokines and HIV-1 second receptors: The therapeutic connection	NATURE MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SINGLE-CHAIN ANTIBODY; SELECTIVE-INHIBITION; TYPE-1 GP120; INFECTION; ENTRY; PROGRESSION; REPLICATION; POTENT; CCR5	The discovery that HIV requires a chemokine co-receptor to invade host cells has prompted many investigations into therapeutic strategies that target these receptors in an attempt to block HIV entry. In this review, Scott Cairns and Patricia D'Souza discuss these potentially powerful approaches and how they complement existing antiretroviral drug therapy.	NIAID, Targeted Intervent Branch, Div Aids, Bethesda, MD 20892 USA; NIAID, Pathogenesis & Basic Res Branch, Div Aids, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Souza, MP (corresponding author), NIAID, Targeted Intervent Branch, Div Aids, Solar Bldg 2C34, Bethesda, MD 20892 USA.	PD6N@nih.gov						Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; AMARA A, 1997, NAT MED, V4, P72; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Datema R, 1996, ANTIMICROB AGENTS CH, V40, P750, DOI 10.1128/AAC.40.3.750; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; EDINGER AL, IN PRESS P NATL ACAD; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENRES M, 1997, SCIENCE, V278, P1462; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; GUNTHARD HF, 1994, J INFECT DIS, V170, P1384, DOI 10.1093/infdis/170.6.1384; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; HINKULA J, 1994, J ACQ IMMUN DEF SYND, V7, P940; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Inouye RT, 1997, J VIROL, V71, P4071, DOI 10.1128/JVI.71.5.4071-4078.1997; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; Mhashilkar AM, 1997, J VIROL, V71, P6486, DOI 10.1128/JVI.71.9.6486-6494.1997; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nolan GP, 1997, CELL, V90, P821, DOI 10.1016/S0092-8674(00)80345-1; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; Willett BJ, 1997, J VIROL, V71, P6407, DOI 10.1128/JVI.71.9.6407-6415.1997; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; YANG AG, 1997, P NATL ACAD SCI US; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	76	102	107	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					563	568		10.1038/nm0598-563	http://dx.doi.org/10.1038/nm0598-563			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585229				2022-12-27	WOS:000073399900027
J	Lee, H; Veazey, R; Williams, K; Li, M; Guo, J; Neipel, F; Fleckenstein, B; Lackner, A; Desrosiers, RC; Jung, JU				Lee, H; Veazey, R; Williams, K; Li, M; Guo, J; Neipel, F; Fleckenstein, B; Lackner, A; Desrosiers, RC; Jung, JU			Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus	NATURE MEDICINE			English	Article							OPEN READING FRAME; DNA-SEQUENCES; SAIMIRI; AIDS; IDENTIFICATION; DELETION; PROTEIN; VIRUS; KSHV	At a position equivalent to the gene encoding the saimiri transforming protein (STP) of herpesvirus saimiri (HVS), Kaposi's sarcoma-associated herpesvirus (KSHV) contains a distinct open reading frame called K1. Although KSHV and HVS are related members of the rhadinovirus subgroup of gamma herpesviruses, K1 and STP exhibit no similarity in amino acid sequence or in structural organization. Since STP is required for the oncogenic potential of HVS, we investigated the functional consequence of K1 expression. Expression of the K1 gene in rodent fibroblasts produced morphologic changes and focus formation indicative of transformation. A recombinant herpesvirus in which the STP oncogene of HVS was replaced with K1, immortalized primary T lymphocytes to IL-2 independent growth and induced lymphoma in common marmosets. These results demonstrate the transforming potential of the K1 gene of KSHV.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-8520 Erlangen, Germany	Harvard University; University of Erlangen Nuremberg	Jung, JU (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr, Southborough, MA 01772 USA.	jjung@warren.harvard.med.edu			NCI NIH HHS [CA31363] Funding Source: Medline; NCRR NIH HHS [RR07000] Funding Source: Medline; NIAID NIH HHS [AI38131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 1996, INT J ONCOL, V9, P5; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Desrosiers RC, 1997, J VIROL, V71, P9764, DOI 10.1128/JVI.71.12.9764-9769.1997; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; Duboise SM, 1996, P NATL ACAD SCI USA, V93, P11389, DOI 10.1073/pnas.93.21.11389; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; GANEM D, 1995, CURR BIOL, V5, P469, DOI 10.1016/S0960-9822(95)00093-5; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; GUO J, IN PRESS J VIROL; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; LANGUNOFF M, 1997, VIROLOGY, V236, P147; Lee H, 1997, J VIROL, V71, P3817, DOI 10.1128/JVI.71.5.3817-3825.1997; LI M, 1997, VIROLOGY, V71, P1984; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marchioli CC, 1996, J CLIN MICROBIOL, V34, P2635, DOI 10.1128/JCM.34.10.2635-2638.1996; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; THORNE M, 1997, NATURE, V386, P517; WANG D, 1987, CELL, P831	39	223	237	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					435	440		10.1038/nm0498-435	http://dx.doi.org/10.1038/nm0498-435			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546789				2022-12-27	WOS:000072906800038
J	Poeschla, EM; Wong-Staal, F; Looney, DJ				Poeschla, EM; Wong-Staal, F; Looney, DJ			Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors	NATURE MEDICINE			English	Article							NUCLEOTIDE-SEQUENCE; GENE; INFECTION; ORGANIZATION; INVITRO; GENOME; LINES	The molecular bases for species barriers to lentiviral replication are not well understood, but are of interest for explaining lentiviral pathogenesis, devising therapeutic strategies, and adapting lentiviruses to gene therapy. HIV-l-based lentiviral vectors efficiently transduce nondividing cells', but present complex safety concerns(2). Nonprimate (ungulate or feline) lentiviruses might provide safer alternatives, but these viruses display highly restricted tropisms, and their potential for adaptation as replication-defective vectors capable of transducing human cells is unknown. Feline immunodeficiency virus (FIV) does not infect humans or other non-Felidae despite prevalent natural exposure. Although long terminal repeat (LTR)-directed FIV expression was found to be negligible in human cells, promoter substitution enabled an env-deleted, three-plasmid, human cell-FIV lentiviral vector system to express high levels of FIV proteins and FIV vectors in human cells, thus bypassing the hazards of feline vector producer cells. Pseudotyped FIV vectors efficiently transduced dividing, growth-arrested, and postmitotic human targets. The experiments delineate mechanisms involved in species-restricted replication of this lentivirus and show that human cells support both productive- and infective-phase mechanisms of the FIV life cycle needed for efficient lentiviral vector transduction. Nonprimate lentiviral vectors may offer safety advantages, and FIV vectors provide unique experimental opportunities.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, San Diego Vet Adm Med Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Poeschla, EM (corresponding author), Univ Calif San Diego, Dept Med, 0655, La Jolla, CA 92093 USA.	epoeschla@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U19AI036612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001408] Funding Source: NIH RePORTER; NIAID NIH HHS [1U19 AI3661203, 2P30AI3621404] Funding Source: Medline; NIDDK NIH HHS [3K12-DK01408-10S1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Bachmann MH, 1997, J VIROL, V71, P4241, DOI 10.1128/JVI.71.6.4241-4253.1997; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; ELDER JH, 1993, INFECT AGENT DIS, V2, P361; Emerman M, 1996, NAT BIOTECHNOL, V14, P943, DOI 10.1038/nbt0896-943; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; MIYAZAWA T, 1992, J GEN VIROL, V73, P1543, DOI 10.1099/0022-1317-73-6-1543; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P8088, DOI 10.1073/pnas.86.20.8088; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; Pedersen N. C., 1993, The Retroviridae, volume 2., P181; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; SPARGER EE, 1992, VIROLOGY, V187, P165, DOI 10.1016/0042-6822(92)90305-9; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; TOMONAGA K, 1994, J VET MED SCI, V56, P199, DOI 10.1292/jvms.56.199; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	19	349	372	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					354	357		10.1038/nm0398-354	http://dx.doi.org/10.1038/nm0398-354			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500613				2022-12-27	WOS:000073616200045
J	Perez, GI; Knudson, CM; Leykin, L; Korsmeyer, SJ; Tilly, JL				Perez, GI; Knudson, CM; Leykin, L; Korsmeyer, SJ; Tilly, JL			Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction	NATURE MEDICINE			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; GRANULOSA-CELLS; PRIMORDIAL FOLLICLES; ICE/CED-3 PROTEASE; P53 PROTEIN; RAT OVARY; IN-VIVO; DEATH; BCL-2; EXPRESSION	Female sterility resulting from oocyte destruction is an unfortunate, and in many cases inevitable, consequence of chemotherapy. We show that unfertilized mouse oocytes exposed to therapeutic levels of the antitumor drug, doxorubicin (DXR), undergo apoptosis; however, fertilized oocytes do not initiate apoptosis, but enter cell-cycle arrest, when treated with DXR. Apoptosis induced by DXR in oocytes is blocked by sphingosine-1-phosphate, an inhibitor of ceramide-promoted cell death. Oocytes from Bax-deficient, but not p53-null, female mice display complete resistance to DXR-induced apoptosis in vivo and in vitro. Pretreatment of oocytes with a specific peptide inhibitor of caspases also abrogates the apoptotic response to DXR. These findings indicate that oocyte destruction caused by chemotherapy can be prevented by manipulation of apoptosis-associated signaling pathways.	MASSACHUSETTS GEN HOSP,VINCENT CTR REPROD BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; WASHINGTON UNIV,SCH MED,DEPT MED,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV MOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Perez, Gloria I/GMX-1286-2022	Knudson, Charles Michael/0000-0003-3964-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49712] Funding Source: Medline; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FAMILIARI G, 1993, HUM REPROD, V8, P2080, DOI 10.1093/oxfordjournals.humrep.a137985; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KALPIA A, 1996, ENDOCRINOLOGY, V137, P4864; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUGU K, IN PRESS CELL DEATH; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARAVEI DV, IN PRESS CELL DEATH; Martimbeau S, 1997, CLIN ENDOCRINOL, V46, P241, DOI 10.1046/j.1365-2265.1997.00157.x; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REICHMAN BS, 1994, MONOGR NATL CANC I, V16, P125; RIED HL, 1994, SEMIN ROENTGENOL, V29, P6, DOI 10.1016/S0037-198X(05)80068-9; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly J. L., 1996, CONTEMP OBSTET GYNEC, V41, P59; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Tilly JL, 1997, CELL DEATH DIFFER, V4, P180, DOI 10.1038/sj.cdd.4400238; TILLY KI, 1995, ENDOCRINOLOGY, V136, P1394, DOI 10.1210/en.136.4.1394; TUCKER MJ, 1995, CURR OPIN OBSTET GYN, V7, P188, DOI 10.1097/00001703-199506000-00006; WANG E, 1991, J BIOL CHEM, V266, P14486; WAXMAN J, 1983, J ROY SOC MED, V76, P144, DOI 10.1177/014107688307600212; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	48	281	299	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1228	1232		10.1038/nm1197-1228	http://dx.doi.org/10.1038/nm1197-1228			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359697				2022-12-27	WOS:A1997YD89600031
J	Fan, HR; Oro, AE; Scott, MP; Khavari, PA				Fan, HR; Oro, AE; Scott, MP; Khavari, PA			Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog	NATURE MEDICINE			English	Article							BASEMENT-MEMBRANE PROTEINS; DROSOPHILA; POLARITY; FAMILY; MODEL; TRANSCRIPTION; EPITHELIA; DISEASE; BIOLOGY; ANTIGEN	Hedgehog (HH) signaling proteins mediate inductive events during animal development(1-11). Mutation of the only known HH receptor gene, Patched (PTC) has recently been implicated in inherited and sporadic forms of the most common human cancer, basal cell carcinoma (BCC)(12-14). In Drosophila, HH acts by inactivating PTC function(1,3), raising the possibility that overexpression of Sonic Hedgehog (SHH) in human epidermis might have a tumorigenic effect equivalent to loss of PTC function. We used retroviral transduction of normal human keratinocytes to constitutively express SHH. SHH-expressing cells demonstrated increased expression of both the known HH target, BMP-2B, as well as bcl-2, a protein prominently expressed by keratinocytes in BCCs. These keratinocytes were then used to regenerate human skin transgenic for long terminal repeat-driven SHH (LTR-SHH) on immune-deficient mice. LTR-SHH human skin consistently displays the abnormal specific histologic features seen in BCCs, including downgrowth of epithelial buds into the dermis, basal cell palisading and separation of epidermis from the underlying dermis. In addition, LTR-SHH skin displays the gene expression abnormalities previously described for human BCCs, including decreased BP180/BPAG2 and laminin 5 adhesion proteins and expression of basal epidermal keratins. These data indicate that expression of SHH in human skin recapitulates features of human BCC in vivo, suggest that activation of this conserved signaling pathway contributes to the development of epithelial neoplasia and describe a new transgenic human tissue model of neoplasia.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	Fan, HR (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043799, R01AR043799] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 43799] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Arbeit JM, 1996, CANCER SURV, V26, P7; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BUMBROT DA, 1995, MOL CELL BIOL, V5, P2294; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; DALE BA, 1987, J INVEST DERMATOL, V88, P307; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, DEVELOPMENT, V117, P283; JINNAH HA, 1994, J NEUROSCI, V14, P1164; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lever WF, 1990, HISTOPATHOLOGY SKIN, P622; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; McMahon AP, 1996, NAT MED, V2, P1308, DOI 10.1038/nm1296-1308; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P909, DOI 10.1001/archderm.131.8.909; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORO AE, IN PRESS SCIENCE, V276, P817; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; PURKIS PE, 1990, J CELL SCI, V97, P39; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; SNOUWAERT JN, 1995, AM J RESP CRIT CARE, V151, pS59, DOI 10.1164/ajrccm/151.3_Pt_2.S59; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0	45	222	234	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					788	792		10.1038/nm0797-788	http://dx.doi.org/10.1038/nm0797-788			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212109				2022-12-27	WOS:A1997XG76700042
J	NybergHoffman, C; Shabram, P; Li, W; Giroux, D; AguilarCordova, E				NybergHoffman, C; Shabram, P; Li, W; Giroux, D; AguilarCordova, E			Sensitivity and reproducibility in adenoviral infectious titer determination	NATURE MEDICINE			English	Article							GENE-THERAPY; TOXICITY		CTR CELL & GENE THERAPY,HOUSTON,TX 77030; TEXAS CHILDRENS CANC CTR,HOUSTON,TX 77030; CANJI INC,SAN DIEGO,CA 92121; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine					NCI NIH HHS [CA-58204] Funding Source: Medline; NHLBI NIH HHS [HL-51754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON AC, 1959, BIOCHIM BIOPHYS ACTA, V40, P400; CHUCK AS, 1996, HUM GENE THER, V6, P1527; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Durham HD, 1996, EXP NEUROL, V140, P14, DOI 10.1006/exnr.1996.0110; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; Graham FL, 1991, METHOD MOL BIOL, P109; GREEN M, 1963, VIROLOGY, V20, P199, DOI 10.1016/0042-6822(63)90157-0; HORWITZ MS, 1990, VIROLOGY, V2, P1679; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; MARSHALL AG, 1975, BIOPHYSICAL CHEM PRI; MCALLISTER RM, 1966, P SOC EXP BIOL MED, V122, P455, DOI 10.3181/00379727-122-31160; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; OLIVER CJ, 1976, BIOCHIM BIOPHYS ACTA, V437, P598; SCHNEIDER MD, 1993, CIRCULATION, V88, P1937, DOI 10.1161/01.CIR.88.4.1937; SCHULICK AH, 1995, CIRCULATION, V91, P2407, DOI 10.1161/01.CIR.91.9.2407; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; Strayer DS, 1997, BIOTECHNIQUES, V22, P447, DOI 10.2144/97223bm16; Toloza EM, 1996, CANCER GENE THER, V3, P11; TRAPNELL BC, 1996, NATCHER C CTR P, V1, P59; WINTERS WD, 1971, J GEN VIROL, V10, P181, DOI 10.1099/0022-1317-10-2-181; [No title captured]	24	168	199	1	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					808	811		10.1038/nm0797-808	http://dx.doi.org/10.1038/nm0797-808			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212113				2022-12-27	WOS:A1997XG76700047
J	Klein, KA; Reiter, RE; Redula, J; Morad, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL				Klein, KA; Reiter, RE; Redula, J; Morad, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL			Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice	NATURE MEDICINE			English	Article							(EBV)-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; CIRCULATING TUMOR-CELLS; RECEPTOR GENE; NUDE-MICE; GROWTH-FACTORS; CARCINOMA; MODEL; LNCAP; MUTATION; MOUSE	Prostate cancer mortality results from metastasis to bone and hormone-independent tumor growth. Models to study these progressive changes are lacking. Here we describe the propagation of advanced human prostate cancer by direct transfer of surgical samples from patients into immune-deficient male SCID mice. Explants from six of eight patients formed prostate tumors and two showed unique cytogenetic, biologic and molecular features that were retained through six or more passages. One grew in an androgen-independent fashion, whereas the second formed tumors that regressed following castration then regrew. Micrometastatic disease was detected in the hematopoietic tissues of half of the recipient mice. Thus selected specimens of advanced human prostate cancer can be propagated in SCID mice in a manner that recapitulates the clinical transition from androgen-sensitive to androgen-independent growth, accompanied by micrometastasis.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT UROL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV UTAH,SCH MED,DEPT PEDIAT,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Sawyers, Charles/G-5327-2016; marcelli, marco/AGR-6853-2022		NCI NIH HHS [R01 CA 68615, R01-CA46269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068615, R01CA046269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; BAIOCCHI RA, 1994, P NATL ACAD SCI USA, V91, P5577, DOI 10.1073/pnas.91.12.5577; Brandt B, 1996, CANCER RES, V56, P4556; BRINKMANN AO, 1995, J STEROID BIOCHEM, V53, P443, DOI 10.1016/0960-0760(95)00090-M; BROTHMAN AR, 1990, CANCER RES, V50, P3795; Cher ML, 1996, CANCER RES, V56, P3091; Cooney KA, 1996, CANCER RES, V56, P1142; DEBRUYNE FM, 1993, SCAND J UROL NEPHROL, V162, P115; DEBRUYNE FM, 1993, SCAND J UROL NEPHROL, V162, P65; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GHOSSEIN RA, 1995, J CLIN ONCOL, V13, P1195, DOI 10.1200/JCO.1995.13.5.1195; GLEAVE ME, 1992, CANCER RES, V52, P1598; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; KATZ AE, 1994, UROLOGY, V43, P765, DOI 10.1016/0090-4295(94)90132-5; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Liu AY, 1996, INT J CANCER, V65, P85, DOI 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.3.CO;2-E; LUBEROFF DM, 1995, PROSTATE, V1, P32; MARCELLI M, 1995, ENDOCRINOLOGY, V136, P1040, DOI 10.1210/en.136.3.1040; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MICALE MA, 1993, CANCER GENET CYTOGEN, V69, P7, DOI 10.1016/0165-4608(93)90103-S; Nagabhushan M, 1996, CANCER RES, V56, P3042; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; PANG S, 1995, HUM GENE THER, V6, P1417, DOI 10.1089/hum.1995.6.11-1417; PRETLOW TG, 1991, CANCER RES, V51, P3814; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 2002, MOL CLONING LAB MANU; SEIDEN MV, 1994, J CLIN ONCOL, V12, P2634, DOI 10.1200/JCO.1994.12.12.2634; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; Sutherland RW, 1996, J UROLOGY, V156, P828, DOI 10.1016/S0022-5347(01)65830-0; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WAKASUGI H, 1995, JPN J CANCER RES, V86, P1086, DOI 10.1111/j.1349-7006.1995.tb03025.x; WARE JL, 1989, PATHOL IMMUNOPATH R, V8, P231, DOI 10.1159/000157154; WOOD DP, 1994, CANCER, V74, P2533, DOI 10.1002/1097-0142(19941101)74:9<2533::AID-CNCR2820740922>3.0.CO;2-D; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	43	328	441	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					402	408		10.1038/nm0497-402	http://dx.doi.org/10.1038/nm0497-402			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095173				2022-12-27	WOS:A1997WQ82500029
J	Kaartinen, V; Mononen, I; Voncken, JW; Noronkoski, T; GonzalezGomez, I; Heisterkamp, N; Groffen, J				Kaartinen, V; Mononen, I; Voncken, JW; Noronkoski, T; GonzalezGomez, I; Heisterkamp, N; Groffen, J			A mouse model for the human lysosomal disease aspartylglycosaminuria	NATURE MEDICINE			English	Article							STORAGE DISEASE; MICE; ASPARTYLGLUCOSAMINURIA; GLYCOSYLASPARAGINASE; GENE	Aspartylglycosaminuria (AGU), the most common disorder of glycoprotein degradation in humans, is caused by mutations in the gene encoding the lysosomal enzyme glycosylasparaginase (Aga)(1). The resulting enzyme deficiency allows aspartylglucosamine (GlcNAc-Asn) and other glycoasparagines to accumulate in tissues and body fluids, from early fetal life onward(1). The clinical course is characterized by normal early development, slowly progressing to severe mental and motor retardation in early adulthood(2,3). The exact pathogenesis of AGU in humans is unknown and neither therapy nor an animal model for this debilitating and ultimately fatal disease exists. Through targeted disruption of the mouse Ago gene in embryonic stem cells, we generated mice that completely lack Aga activity. At the age of 5-10 months a massive accumulation of GlcNAc-Asn was detected along with lysosomal vacuolization, axonal swelling in the gracile nucleus and impaired neuromotor coordination. A significant number of older male mice had massively swollen bladders, which was not caused by obstruction, but most likely related to the impaired function of the nervous system. These findings are consistent with the pathogenesis of AGU and provide further data explaining the impaired neurological function in AGU patients.	CHILDRENS HOSP LOS ANGELES,RES INST,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV KUOPIO,DEPT CHEM,FIN-70211 KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT CLIN CHEM,FIN-70211 KUOPIO,FINLAND	Children's Hospital Los Angeles; University of Eastern Finland; Kuopio University Hospital			Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X				ARSTILA AU, 1972, ACTA NEUROPATHOL, V20, P207, DOI 10.1007/BF00686902; AULA P, 1982, GENETIC ERRORS GLYCO, P123; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; ENOMAA N, 1995, HUM GENE THER, V6, P723, DOI 10.1089/hum.1995.6.6-723; FISHER KJ, 1991, J BIOL CHEM, V266, P12105; Guastavino J.-M., 1992, V8, P375; HALTIA M, 1975, ACTA NEUROPATHOL, V31, P243, DOI 10.1007/BF00684563; INDRAVASU S, 1968, NEUROLOGY, V18, P693, DOI 10.1212/WNL.18.7.693; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; KAARTINEN V, 1989, J CHROMATOGR, V490, P292; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; OYNAGI K, 1991, ACTA NEUROPATHOL, V85, P331; Papaioannou V., 1993, Gene targeting: a practical approach., P107; TENHUNEN K, 1995, GENOMICS, V30, P244, DOI 10.1006/geno.1995.9881; THOMAS GH, 1995, METABOLIC MOL BASES, P2545; WURST W, 1993, GENE TARGETING PRACT, P31; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209	20	30	30	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1375	1378		10.1038/nm1296-1375	http://dx.doi.org/10.1038/nm1296-1375			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946839				2022-12-27	WOS:A1996VW51500046
J	Kramer, JR; Dasari, RR; Feld, MS				Kramer, JR; Dasari, RR; Feld, MS			Shedding laser light on the subject	NATURE MEDICINE			English	Editorial Material									MIT,GEORGE R HARRISON SPECT LAB,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	Kramer, JR (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,CLEVELAND,OH 44195, USA.							COTHREN RM, IN PRESS LASERS SURG; FITZMAURICE M, 1989, AM HEART J, V118, P1028, DOI 10.1016/0002-8703(89)90239-1; INGRAMS DR, IN PRESS HEAD NECK; ITZKAN I, 1994, ENCY APPL PHYSICS, V10, P33; KRAMER JR, 1995, P SOC PHOTO-OPT INS, V2395, P376; Manoharan R, 1996, SPECTROCHIM ACTA A, V52, P215, DOI 10.1016/0584-8539(95)01573-6; WANG TD, IN PRESS GASTROENTER; ZANGARO RA, 1996, APPL OPTICS, V35, P1; Zonios GI, 1996, IEEE T BIO-MED ENG, V43, P113, DOI 10.1109/10.481980	9	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1079	1080		10.1038/nm1096-1079	http://dx.doi.org/10.1038/nm1096-1079			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837602				2022-12-27	WOS:A1996VK99500024
J	Desbarats, J; Duke, RC; Newell, MK				Desbarats, J; Duke, RC; Newell, MK			Newly discovered role for Fas ligand in the cell-cycle arrest of CD4(+) T cells	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; CD95 LIGAND; GLD MICE; IN-VIVO; EXPRESSION; STIMULATION; REJECTION; CTLA-4; SUPERANTIGEN; ACTIVATION	Fas Ligand (FasL) can induce apoptosis of Fas-bearing cells. It is expressed on the cell surface of many tumor cells, immune-privileged tissues and activated lymphocytes. We report here that Fast can itself transduce signals, leading to cell-cycle arrest and cell death in CD4(+) T cells. In vitro, Fast engagement inhibited CD4(+) T-cell proliferation, cell-cycle progression, and IL-2 secretion. In vivo, FasL engagement prevented superantigen-mediated CD4(+), but not CD8(+), T-cell expansion. These findings demonstrate that FasL engagement regulates cell-cycle progression, and show that FasL engagement in vivo has a potent anti-inflammatory effect specific for CD4(+) T cells.	Univ Vermont, Coll Med, Dept Med, Div Immunobiol, Burlington, VT 05405 USA; Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Med, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Immunol, Denver, CO 80262 USA	University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Newell, MK (corresponding author), Univ Vermont, Coll Med, Dept Med, Div Immunobiol, Burlington, VT 05405 USA.	mnewell@zoo.uvm.edu		Desbarats, Julie/0000-0002-2495-7152	NIAID NIH HHS [AI40607, AI40394, R01AI33470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040607, R44AI040394, R43AI040394, R01AI033470] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P342; CHANDLER C, 1993, ARCH SURG-CHICAGO, V128, P279; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; CORRY DB, 1994, J IMMUNOL, V153, P4142; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dou QP, 1997, J CELL BIOCHEM, V64, P586; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; Hahne M, 1996, EUR J IMMUNOL, V26, P721, DOI 10.1002/eji.1830260332; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Hutchings P, 1993, Autoimmunity, V15 Suppl, P21, DOI 10.3109/08916939309008856; Itoh N, 1997, J EXP MED, V186, P613, DOI 10.1084/jem.186.4.613; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JU ST, 1995, NATURE, V373, P345; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lau HT, 1997, NAT MED, V3, P727, DOI 10.1038/nm0797-727; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PRUDHOMME GJ, 1993, CLIN IMMUNOL IMMUNOP, V66, P185, DOI 10.1006/clin.1993.1024; Renno T, 1996, J EXP MED, V183, P431, DOI 10.1084/jem.183.2.431; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Seino K, 1997, TRANSPL P, V29, P1092, DOI 10.1016/S0041-1345(96)00421-6; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	41	86	90	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1377	1382		10.1038/3965	http://dx.doi.org/10.1038/3965			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846574				2022-12-27	WOS:000077336900032
J	Finette, BA; O'Neill, JP; Vacek, PM; Albertini, RJ				Finette, BA; O'Neill, JP; Vacek, PM; Albertini, RJ			Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke	NATURE MEDICINE			English	Article							CHILDRENS CANCER GROUP; CHILDHOOD-CANCER; V(D)J RECOMBINATION; PHOSPHORIBOSYLTRANSFERASE GENE; MUTANT FREQUENCIES; CIGARETTE-SMOKING; LUNG-TUMORS; LEUKEMIA; PREGNANCY; HPRT	We have investigated the molecular effects of passive maternal cigarette exposure in a newborn population and consider the possible implications of the observed genetic changes in the development of neoplastic diseases in children. We present a distribution analysis of somatic mutational events in a reporter gene, HPRT, in cord blood T lymphocytes from newborns after transplacental exposure to cigarette smoke. Analysis of 30 HPRT mutant isolates from 12 newborn infants born to mothers with no evidence of environmental exposure to cigarette smoke and 37 HPRT mutant isolates from 12 infants born to mothers exposed to passive cigarette smoke showed a significant difference in the HPRT mutational spectrum in those exposed in utero to cigarette smoke. The most notable change was an increase in 'illegitimate' genomic deletions mediated by V(D)J recombinase, a recombination event associated with hematopoietic malignancies in early childhood. Recent epidemiological studies of maternal and paternal cigarette smoke exposure and childhood cancers may need to be re-interpreted, given these results.	Univ Vermont, Dept Pediat, Burlington, VT 05405 USA; Univ Vermont, Genet Toxicol Lab, Burlington, VT 05405 USA; Univ Vermont, Dept Med, Burlington, VT 05405 USA; Univ Vermont, Dept Med Biostat, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Finette, BA (corresponding author), Univ Vermont, Dept Pediat, Burlington, VT 05405 USA.	finette@salus.med.uvm.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD001010, R01HD033648, R29HD035309] Funding Source: NIH RePORTER; NICHD NIH HHS [1R29HD35309-01A1, 1K11HD01010, 1RO1HDKA33648-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTINI RJ, 1990, PROG CLIN BIOL RES, V340, P15; ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BOTTO F, 1994, BIOCHEM BIOPH RES CO, V205, P1086, DOI 10.1006/bbrc.1994.2777; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BUCKLEY JD, 1989, CANCER RES, V49, P4030; Byrd RS, 1995, PEDIATR ANN, V24, P640, DOI 10.3928/0090-4481-19951201-07; Chen CL, 1996, BLOOD, V88, P2210, DOI 10.1182/blood.V88.6.2210.bloodjournal8862210; CHHABRA SK, 1995, CANCER RES, V55, P6017; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; Finette BA, 1997, MUTAT RES-FUND MOL M, V377, P115, DOI 10.1016/S0027-5107(97)00069-9; FINETTE BA, 1994, MUTAT RES, V308, P223, DOI 10.1016/0027-5107(94)90157-0; Finette BA, 1996, CANCER RES, V56, P1405; FUSCOE JC, 1991, CANCER RES, V51, P6001; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GREAVES MF, 1988, LEUKEMIA, V2, P120; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; INFANTERIVARD C, 1995, LANCET, V346, P177, DOI 10.1016/S0140-6736(95)91233-9; Issa JPJ, 1996, CANCER RES, V56, P3655; Klebanoff MA, 1996, AM J EPIDEMIOL, V144, P1028, DOI 10.1093/oxfordjournals.aje.a008874; Kyrtopoulos SA, 1997, CANCER DETECT PREV, V21, P391; LIPKOWITZ S, 1992, P NATL ACAD SCI USA, V89, P5301, DOI 10.1073/pnas.89.12.5301; MARTIN TR, 1986, AM J EPIDEMIOL, V124, P633, DOI 10.1093/oxfordjournals.aje.a114436; MCGREGOR WG, 1994, CANCER RES, V54, P4207; MORRIS JA, 1991, J CLIN PATHOL, V45, P378; OLDS DL, 1994, PEDIATRICS, V93, P221; ONEILL JP, IN PRESS ENV MOL MUT; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; Pluth JM, 1996, CANCER RES, V56, P2393; SCHMIDT CA, 1994, LEUKEMIA, V8, P102; Shu XO, 1996, JNCI-J NATL CANCER I, V88, P24, DOI 10.1093/jnci/88.1.24; Sorahan T, 1997, BRIT J CANCER, V76, P1525, DOI 10.1038/bjc.1997.589; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; STREISSGUTH AP, 1994, EFFECTS PRENATAL EXP, P148; TATES AD, 1991, MUTAT RES, V250, P483, DOI 10.1016/0027-5107(91)90205-3; VanVunakis H, 1987, ENV CARCINOGENS METH, P317; VREILING H, 1992, CARCINOGENESIS, V13, P1625; Walker VE, 1996, CANCER RES, V56, P4654; YEAZEL MW, 1995, CANCER-AM CANCER SOC, V75, P1718, DOI 10.1002/1097-0142(19950401)75:7<1718::AID-CNCR2820750725>3.0.CO;2-G	45	94	96	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1144	1151		10.1038/2640	http://dx.doi.org/10.1038/2640			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771747				2022-12-27	WOS:000076230100033
J	Kealey, T; Rudenski, A				Kealey, T; Rudenski, A			Endogenous growth theory for natural scientists	NATURE MEDICINE			English	Editorial Material									Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Addenbrooke's Hospital; University of Cambridge	Kealey, T (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Box 232, Cambridge CB2 2QR, England.							AGHION P, 1992, ECONOMETRICA, V60, P323, DOI 10.2307/2951599; ARROW KJ, 1962, REV ECON STUD, V29, P155, DOI 10.2307/2295952; Kealey T, 1998, RES POLICY, V26, P897; Kealey T., 1996, EC LAWS SCI RES; ROMER PM, 1990, J POLIT ECON, V98, pS71, DOI 10.1086/261725; SOLOW RM, 1998, Q J ECON, V70, P65; Swan T.W., 1956, ECON REC, V32, P334, DOI [10.1111/j.1475-4932.1956.tb00434.x, DOI 10.1111/J.1475-4932.1956.TB00434.X]	7	2	2	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					995	999		10.1038/1982	http://dx.doi.org/10.1038/1982			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734383				2022-12-27	WOS:000075804100023
J	Moriya, K; Fujie, H; Shintani, Y; Yotsuyanagi, H; Tsutsumi, T; Ishibashi, K; Matsuura, Y; Kimura, S; Miyamura, T; Koike, K				Moriya, K; Fujie, H; Shintani, Y; Yotsuyanagi, H; Tsutsumi, T; Ishibashi, K; Matsuura, Y; Kimura, S; Miyamura, T; Koike, K			The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice	NATURE MEDICINE			English	Article							RISK FACTOR; EXPRESSION; INFECTION; FEATURES; SUPPRESSION; CIRRHOSIS	Hepatitis C virus (HCV) is the main cause of chronic hepatitis worldwide. Chronic hepatitis ultimately results in the development of hepatocellular carcinoma(1,2) (HCC). However, the mechanism of hepatocarcinogenesis in chronic HCV infection is still unclear. The ability of the core protein of HCV to modulate gene transcription, cell proliferation and cell death(3-8) may be involved in the pathogenesis of HCC. Here, we report the development of HCC in two independent lines of mice transgenic for the HCV core gene, which develop hepatic steatosis early in life as a histological feature characteristic of chronic hepatitis C (ref. 9). After the age of 16 months, mice of both lines developed hepatic tumors that first appeared as adenomas containing fat droplets in the cytoplasm. Then HCC, a more poorly-differentiate neoplasia, developed from within the adenomas, presenting in a 'nodule-in-nodule' manner without cytoplasmic fat droplets; this closely resembled the histopathological characteristics of the early stage of HCC in patients with chronic hepatitis C (refs. 10,11). These results indicate that the HCV core protein has a chief role in the development of HCC, and that these transgenic mice provide good animal models for determining the molecular events in hepatocarcinogenesis with HCV infection.	Univ Tokyo, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138655, Japan; Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	University of Tokyo; Daiichi Sankyo Company Limited; National Institute of Infectious Diseases (NIID)	Koike, K (corresponding author), Univ Tokyo, Dept Internal Med 1, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							BACH N, 1992, HEPATOLOGY, V15, P572, DOI 10.1002/hep.1840150403; CAPORASO N, 1991, J HEPATOL, V12, P367, DOI 10.1016/0168-8278(91)90841-X; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; HINO O, 1994, INTERVIROLOGY, V37, P133, DOI 10.1159/000150368; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; KIM DW, 1994, JPN J MED SCI BIOL, V47, P211, DOI 10.7883/yoken1952.47.211; Koike K, 1997, P NATL ACAD SCI USA, V94, P233, DOI 10.1073/pnas.94.1.233; Matsuda J, 1998, JPN J CANCER RES, V89, P150, DOI 10.1111/j.1349-7006.1998.tb00543.x; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1997, JPN J MED SCI BIOL, V50, P169, DOI 10.7883/yoken1952.50.169; NAKAMURA K, 1992, EXP ANIM TOKYO, V41, P279, DOI 10.1538/expanim1978.41.3_279; NAKASHIMA O, 1995, HEPATOLOGY, V22, P101, DOI 10.1002/hep.1840220116; Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SUGIHARA S, 1992, CANCER, V70, P1488, DOI 10.1002/1097-0142(19920915)70:6<1488::AID-CNCR2820700607>3.0.CO;2-J	23	990	1042	0	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1065	1067		10.1038/2053	http://dx.doi.org/10.1038/2053			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734402				2022-12-27	WOS:000075804100042
J	Sarraf, P; Mueller, E; Jones, D; King, FJ; DeAngelo, DJ; Partridge, JB; Holden, SA; Chen, LB; Singer, S; Fletcher, C; Spiegelman, BM				Sarraf, P; Mueller, E; Jones, D; King, FJ; DeAngelo, DJ; Partridge, JB; Holden, SA; Chen, LB; Singer, S; Fletcher, C; Spiegelman, BM			Differentiation and reversal of malignant changes in colon cancer through PPAR gamma	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR-GAMMA; LAMININ-BINDING PROTEIN; GENE-EXPRESSION; MESSENGER-RNAS; X-RECEPTOR; CELLS; ALPHA; MICE; ADIPOGENESIS	PPAR gamma is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPAR gamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPAR gamma ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPAR gamma.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Shionogi BioRes Corp, Lexington, MA 02421 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Shionogi & Company Limited	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Jones, Daniel/I-7399-2015	Singer, Samuel/0000-0001-9713-8230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK-31405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; CHANTRET I, 1988, CANCER RES, V48, P1936; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawai K, 1997, ARZNEIMITTEL-FORSCH, V47, P356; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KONDOH N, 1992, CANCER RES, V52, P791; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MAFUNE K, 1990, CANCER RES, V50, P3888; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Menck HR, 1997, CA-CANCER J CLIN, V47, P161, DOI 10.3322/canjclin.47.3.161; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; THOMAS P, 1993, METASTATIC POTENTIAL, P1; TOMLINSON IPM, 1995, P NATL ACAD SCI USA, V92, P11130, DOI 10.1073/pnas.92.24.11130; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	887	911	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1046	1052		10.1038/2030	http://dx.doi.org/10.1038/2030			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734398				2022-12-27	WOS:000075804100038
J	Nathanson, N				Nathanson, N			Harnessing research to control AIDS	NATURE MEDICINE			English	Editorial Material									NIH, Off AIDS Res, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nathanson, N (corresponding author), NIH, Off AIDS Res, US Dept HHS, Bldg 31 4C02,9000 Rockville Pike, Bethesda, MD 20892 USA.								0	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					879	881		10.1038/nm0898-879	http://dx.doi.org/10.1038/nm0898-879			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701229	Bronze			2022-12-27	WOS:000075107400019
J	Walker, RE; Carter, CS; Muul, L; Natarajan, V; Herpin, BR; Leitman, SF; Klein, HG; Mullen, CA; Metcalf, JA; Baseler, M; Falloon, J; Davey, RT; Kovacs, JA; Polis, MA; Masur, H; Blaese, RM; Lane, HC				Walker, RE; Carter, CS; Muul, L; Natarajan, V; Herpin, BR; Leitman, SF; Klein, HG; Mullen, CA; Metcalf, JA; Baseler, M; Falloon, J; Davey, RT; Kovacs, JA; Polis, MA; Masur, H; Blaese, RM; Lane, HC			Peripheral expansion of pre-existing mature T cells is an important means of CD4(+) T-cell regeneration HIV-infected adults	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD LYMPHOCYTES; GENE-THERAPY; BONE-MARROW; IN-VIVO; TRIAL	The CD4(+) T-cell pool in HIV-infected patients is in a constant state of flux as CD4(+) T cells are infected and destroyed by HIV and new cells take their place. To study T-cell survival, we adoptively transferred peripheral blood lymphocytes transduced with the neomycin phosphotransferase gene between syngeneic twin pairs discordant for HIV infection. A stable fraction of marked CD4(+) T cells persisted in the circulation for four to eighteen weeks after transfer in all patients. After this time there was a precipitous decline in marked cells in three of the patients. At approximately six months, marked cells were in lymphoid tissues in proportions comparable to those found in peripheral blood. In two patients, the proportion of total signal for the transgene (found by PCR analysis) in the CD4/CD45RA(+) T-cell population relative to the CD4/CD45RO(+) population increased in the weeks after cell infusion. These findings indicate that genetically-marked CD4(+) T cells persist in vivo for weeks to months and that the CD4+ T-cell pool in adults is maintained mostly by the division of mature T cells rather than by differentiation of prethymic stem cells. Thus, after elements of the T-cell repertoire are lost through HIV infection, they may be difficult to replace.	NIAID, Immunoregulat Lab, Clin & Mol Retrovirol Sect, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA; Frederick Canc Res & Dev Ctr, SAIC, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Lane, HC (corresponding author), NIAID, Immunoregulat Lab, Clin & Mol Retrovirol Sect, NIH, Bldg 10 Room 11S231, Bethesda, MD 20892 USA.	clane@nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DEWAR RL, APPL BRANCHED DNA SI; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LEDERMAN M, 1997, 4 C RETR OPP INF WAS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	22	101	103	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					852	856		10.1038/nm0798-852	http://dx.doi.org/10.1038/nm0798-852			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662381				2022-12-27	WOS:000074543900044
J	Kato, M; Wang, HM; Kainulainen, V; Fitzgerald, ML; Ledbetter, S; Ornitz, DM; Bernfield, M				Kato, M; Wang, HM; Kainulainen, V; Fitzgerald, ML; Ledbetter, S; Ornitz, DM; Bernfield, M			Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; RECEPTOR; BINDING; LOCALIZATION; MITOGENESIS	The activity of fibroblast growth factor 2 (FGF-2) is stringently controlled. Inactive in undisturbed tissues, it is activated during injury and is critical for tissue repair. We find that this control can be imposed by the soluble syndecan-1 ectodomain, a heparan sulfate proteoglycan shed from cell surfaces into wound fluids. The ectodomain potently inhibits heparin-mediated FGF-2 mitogenicity because of the poorly sulfated domains in its heparin sulfate chains. Degradation of these regions by platelet heparanase produces heparin-like heparin sulfate fragments that markedly activate FCF-2 mitogenicity and are found in wound fluids. These results establish a novel physiological control for FGF-2 and suggest new ways to modulate FGF activity.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Genzyme Corp, Framingham, MA 01710 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation; Washington University (WUSTL)	Bernfield, M (corresponding author), Harvard Univ, Sch Med, Dept Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	bernfield@a1.tch.harvard.edu		Ornitz, David/0000-0003-1592-7629	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046491] Funding Source: NIH RePORTER; NCI NIH HHS [CA28735] Funding Source: Medline; NHLBI NIH HHS [HL46491] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; FRIZE LMS, 1985, J CELL BIOL, V100, P1041; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HUMPHRIES DE, 1992, ADV EXP MED BIOL, V313, P59; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P1881; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODA JE, 1985, J BIOL CHEM, V260, P8157; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MALI M, 1994, J BIOL CHEM, V269, P27795; MASCATELLI D, 1992, J BIOL CHEM, V267, P25803; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; WALKER A, 1994, J BIOL CHEM, V269, P931; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; Wang HM, 1998, BIOCHEM BIOPH RES CO, V242, P248, DOI 10.1006/bbrc.1997.7864; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	49	285	293	3	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					691	697		10.1038/nm0698-691	http://dx.doi.org/10.1038/nm0698-691			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623978				2022-12-27	WOS:000074008300035
J	Block, TM; Lu, XY; Mehta, AS; Blumberg, BS; Tennant, B; Ebling, M; Korba, B; Lansky, DM; Jacob, GS; Dwek, RA				Block, TM; Lu, XY; Mehta, AS; Blumberg, BS; Tennant, B; Ebling, M; Korba, B; Lansky, DM; Jacob, GS; Dwek, RA			Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking	NATURE MEDICINE			English	Article							HEPATITIS-B VIRUS; IN-VIVO; GLYCOSYLATION	A novel strategy for anti-viral intervention of hepatitis B virus (HBV) through the disruption of the proper folding(1) and transport(2) of the hepadnavirus glycoproteins is described. Laboratory reared woodchucks chronically infected with woodchuck hepatitis virus (WHV) were treated with N-nonyl-deoxynojirimycin (N-nonyl-DNJ), an inhibitor of the endoplasmic reticulum (ER) alpha-glucosidases. The woodchucks experienced significant dose dependent decreases in enveloped WHV, resulting in undetectable amounts in some cases. The reduction in viremia correlated with the levels of hyperglucosylated glycan in the serum of treated animals. This correlation supports the mechanism of action associated with the drug and highlights the extreme sensitivity of the virus to this type of glycan inhibitor(1,2). At N-nonyl-DNJ concentrations that prevented WHV secretion, the glycosylation of most serum glycoproteins appeared unaffected, suggesting great selectivity for this class of therapeutics. Indeed, this may account for the low toxicity of the compound over the treatment period. We provide the first evidence that glucosidase inhibitors can be used in vivo to alter specific steps in the N-linked glycosylation pathway and that this inhibition has anti-viral effects.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Viral Hepatitis Grp, Philadelphia, PA 19107 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; Georgetown Univ, Coll Med, Div Virol, Rockville, MD USA; Monsanto Co, St Louis, MO 63167 USA	Jefferson University; University of Oxford; Fox Chase Cancer Center; Cornell University; Georgetown University; Monsanto	Block, TM (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Viral Hepatitis Grp, Philadelphia, PA 19107 USA.		Lansky, David/AAF-3525-2020					ABE K, 1988, HEPATOLOGY, V8, P88, DOI 10.1002/hep.1840080118; Cullen JM, 1997, ANTIMICROB AGENTS CH, V41, P2076, DOI 10.1128/AAC.41.10.2076; Fontana RJ, 1997, HEPATOLOGY, V26, P234; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; JACOB GS, 1995, CURR OPIN STRUC BIOL, V5, P605, DOI 10.1016/0959-440X(95)80051-4; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; Korba BA, 1996, HEPATOLOGY, V23, P958; Lee William M., 1993, Viral Immunology, V6, P13, DOI 10.1089/vim.1993.6.13; LU XY, 1995, VIROLOGY, V213, P660, DOI 10.1006/viro.1995.0038; Lu XY, 1997, P NATL ACAD SCI USA, V94, P2380, DOI 10.1073/pnas.94.6.2380; Mehta A, 1997, P NATL ACAD SCI USA, V94, P1822, DOI 10.1073/pnas.94.5.1822; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398; Rudd PM, 1997, NATURE, V388, P205, DOI 10.1038/40677; SEIFER M, 1990, VIROLOGY, V179, P300, DOI 10.1016/0042-6822(90)90298-6; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; Tennant Bud C., 1994, P1455; Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1053/jhep.1996.v24.pm0008781348; UEDA K, 1991, J VIROL, V65, P3521, DOI 10.1128/JVI.65.7.3521-3529.1991; WEL Y, 1997, J VIROL, V70, P6455; WERR M, J VIROL, V7, P778; WONG DC, 1982, J CLIN MICROBIOL, V15, P484, DOI 10.1128/JCM.15.3.484-490.1982	23	132	147	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5					610	614		10.1038/nm0598-610	http://dx.doi.org/10.1038/nm0598-610			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585237				2022-12-27	WOS:000073399900035
J	Strand, S; Hofmann, WJ; Grambihler, A; Hug, H; Volkmann, M; Otto, G; Wesch, H; Mariani, SM; Hack, V; Stremmel, W; Krammer, PH; Galle, PR				Strand, S; Hofmann, WJ; Grambihler, A; Hug, H; Volkmann, M; Otto, G; Wesch, H; Mariani, SM; Hack, V; Stremmel, W; Krammer, PH; Galle, PR			Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; INDIAN CHILDHOOD CIRRHOSIS; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; COPPER; FAS; INDUCTION; LIGAND; EXPRESSION	Wilson's disease can result in fulminant liver failure due to hepatic copper overload. The CD95 system mediates apoptosis and has been demonstrated to be involved in liver disease. In this study CD95 mediated apoptosis was investigated in patients with fulminant hepatic failure in the course of Wilson's disease and in an in vitro model of copper treated human hepatoma cells. In patients, hepatic expression of CD95 and CD95L mRNA and apoptosis were detected. Copper overload in vitro resulted in hepatocytic apoptosis which could be reduced with a neutralizing anti-CD95L antibody. Copper treatment of hepatocytes results in activation of the CD95 system and induction of apoptosis which is operative during the course of hepatic failure in acute Wilson's disease.	Univ Heidelberg Hosp, Dept Gastroenterol, D-69115 Heidelberg, Germany; Inst Pathol, D-69120 Heidelberg, Germany; ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; Dept Surg, D-69120 Heidelberg, Germany; German Canc Res Ctr, Tumorimmunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Radiol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Immunochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Galle, PR (corresponding author), Univ Heidelberg Hosp, Dept Gastroenterol, Bergheimerstr 58, D-69115 Heidelberg, Germany.	peter_galle@ukl.uni-heidelberg.de	Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Danks DM, 1995, MOL METABOLIC BASIS, P4125; DHEIN J, 1992, J IMMUNOL, V149, P3166; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hochstein P, 1980, Ann N Y Acad Sci, V355, P240, DOI 10.1111/j.1749-6632.1980.tb21342.x; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LAU SJ, 1974, J BIOL CHEM, V249, P5878; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; LEITHAUSER F, 1993, LAB INVEST, V69, P415; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGRADY JG, 1993, DIS LIVER, P1078; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; PIMENTEL JC, 1975, AM REV RESPIR DIS, V111, P189; POPPER H, 1979, LANCET, V1, P1205; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Scheinberg I. H., 1984, MAJOR PROBLEMS INTER, P1; SELLINS KS, 1987, J IMMUNOL, V139, P3199; STERNLIEB I, 1980, GASTROENTEROLOGY, V78, P1615; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STREMMEL W, 1991, ANN INTERN MED, V115, P720, DOI 10.7326/0003-4819-115-9-720; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vierling J M, 1981, Semin Liver Dis, V1, P293, DOI 10.1055/s-2008-1040733; VOLKMANN M, 1994, ONCOGENE, V9, P195; WESCH H, 1974, NBS SPECIAL PUBLICAT, V422; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	42	209	214	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					588	593		10.1038/nm0598-588	http://dx.doi.org/10.1038/nm0598-588			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585233				2022-12-27	WOS:000073399900031
J	Ferrari, FK; Xiao, X; McCarty, D; Samulski, RJ				Ferrari, FK; Xiao, X; McCarty, D; Samulski, RJ			New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; EXPRESSION; TRANSDUCTION				Ferrari, FK (corresponding author), UNIV N CAROLINA,GENE THERAPY CTR,7119 THURSTON BLDG,CHAPEL HILL,NC 27516, USA.		McCarty, Douglas/E-3623-2011					CARTER BJ, 1990, HDB PARVOVIRUSES, V1, P255; CLARK KR, 1995, HUM GENE THER, V6, P1329, DOI 10.1089/hum.1995.6.10-1329; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1995, GENE THER, V2, P29; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Li JA, 1997, J VIROL, V71, P5236, DOI 10.1128/JVI.71.7.5236-5243.1997; McCoy RD, 1995, HUM GENE THER, V6, P1553, DOI 10.1089/hum.1995.6.12-1553; MONAHAN PE, IN PRESS GENE THER; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SAMULSKI RJ, 1994, GENE THERAPY LAB CLI, P232; Snyder R, 1996, CURRENT PROTOCOLS HU; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997; Xiao X, 1997, EXP NEUROL, V144, P113, DOI 10.1006/exnr.1996.6396; XIAO X, 1996, J VIROL, V70, P8090	19	82	105	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1295	1297		10.1038/nm1197-1295	http://dx.doi.org/10.1038/nm1197-1295			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359708				2022-12-27	WOS:A1997YD89600042
J	Bach, FH; Ferran, C; Soares, M; Wrighton, CJ; Anrather, J; Winkler, H; Robson, SC; Hancock, WW				Bach, FH; Ferran, C; Soares, M; Wrighton, CJ; Anrather, J; Winkler, H; Robson, SC; Hancock, WW			Modification of vascular responses in xenotransplantation: Inflammation and apoptosis	NATURE MEDICINE			English	Editorial Material							DISCORDANT XENOGRAFT REJECTION; ENDOTHELIAL-CELLS; HYPERACUTE REJECTION; PROTEIN-C; ACTIVATION; EXPRESSION; THROMBOMODULIN; INHIBITION; PATHWAY; VIVO		BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Bach, FH (corresponding author), SANDOZ CTR IMMUNOBIOL,BOSTON,MA 02215, USA.		Robson, Simon C./AAA-8537-2021; Soares, Miguel P/G-4188-2011	Soares, Miguel/0000-0002-9314-4833				BACH FH, 1991, TRANSPL P, V23, P205; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BACH FH, IN PRESS IMMUNOL TOD; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; Candinas D, 1996, TRANSPLANTATION, V62, P1920, DOI 10.1097/00007890-199612270-00042; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; COUGHLAN AF, 1993, TRANSPLANT P, V25, P2930; Cowan PJ, 1996, TRANSPLANTATION, V62, P155, DOI 10.1097/00007890-199607270-00002; DALAMSSO AP, 1996, XENOTRANSPLANTATION, V4, P55; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; ESMON CT, 1995, SEMIN CELL BIOL, V6, P259, DOI 10.1006/scel.1995.0035; Ferran C, 1997, TRANSPL P, V29, P879, DOI 10.1016/S0041-1345(96)00184-4; Goodman DJ, 1996, TRANSPLANTATION, V61, P763, DOI 10.1097/00007890-199603150-00016; Grey ST, 1996, J IMMUNOL, V156, P2256; HANCOCK WW, IN PRESS TRANSPLANTA; HANCOCK WW, IN PRESS TRENDS CARD; Hechenleitner P, 1996, XENOTRANSPLANTATION, V3, P279, DOI 10.1111/j.1399-3089.1996.tb00149.x; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; Kaczmarek E, 1997, ECTO-ATPASES, P171; Kopp CW, 1997, TRANSPLANTATION, V63, P749, DOI 10.1097/00007890-199703150-00023; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lawson JH, 1996, TRANSPLANTATION, V62, P303, DOI 10.1097/00007890-199608150-00001; LESNIKOSKI BA, IN PRES XENOTRANSPLA; MARK W, IN PRESS XENOTRANSPL; Millan MT, 1997, TRANSPLANTATION, V63, P421, DOI 10.1097/00007890-199702150-00016; Pruitt SK, 1997, TRANSPLANTATION, V63, P900, DOI 10.1097/00007890-199703270-00017; Robson SC, 1996, TRANSPLANTATION, V61, P862, DOI 10.1097/00007890-199603270-00003; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SIEGEL J, IN PRESS TRANSPLANTA; TRAN TH, IN PRESS TRANSPLANT; WRIGHTON CJ, 1995, TRANSPLANT P, V27, P288	32	100	102	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					944	948		10.1038/nm0997-944	http://dx.doi.org/10.1038/nm0997-944			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288711				2022-12-27	WOS:A1997XT84200017
J	Thomas, M; Northrup, SR; Hornsby, PJ				Thomas, M; Northrup, SR; Hornsby, PJ			Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands	NATURE MEDICINE			English	Article							STEROID 17-ALPHA-HYDROXYLASE; EXPRESSION; MOUSE; SENESCENCE; DELIVERY; GENES; RAT	Xenotransplanted adrenocortical tissue of clonal origin was formed in immunodeficient (scid) mice by using techniques of cell transplantation. The experiments reported here used a single clone of bovine adrenocortical cells, but 5 of 20 other randomly selected clones also formed tissue. Most adrenalectomized animals bearing transplanted cells survived indefinitely, demonstrating that the cells restored the animals' capacity to survive in the absence of sodium supplementation. Formation of well-vascularized tissue at the site of transplantation was associated with stable levels of cortisol in the blood, replacing the mouse glucocorticoid (corticosterone). Ultrastructurally, the cultured cells before transplantation had characteristics of rapidly growing cells, but tissue formed in vivo showed features associated with active steroidogenesis. These experiments show that an endocrine tissue can be derived from a single, normal somatic cell.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	Thomas, M (corresponding author), BAYLOR COLL MED, HUFFINGTON CTR AGING, HOUSTON, TX 77030 USA.		Thomas, Michael/N-5468-2018	Thomas, Michael/0000-0003-2901-824X				Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; APKARIAN R P, 1986, Scanning Electron Microscopy, P1381; BOSMA MJ, 1989, SCID MOUSE CHARACTER; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BUTCHER RN, 1988, J IMMUNOL METHODS, V107, P245, DOI 10.1016/0022-1759(88)90225-6; CHENG CY, 1992, ENDOCRINOLOGY, V130, P2883, DOI 10.1210/en.130.5.2883; CRANE GM, 1995, NAT MED, V1, P1322, DOI 10.1038/nm1295-1322; DUNN TB, 1970, JNCI-J NATL CANCER I, V44, P1323; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEND DS, 1972, J CELL BIOL, V53, P148, DOI 10.1083/jcb.53.1.148; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMMOND KD, 1987, J RECEPTOR RES, V7, P667, DOI 10.3109/10799898709056778; HOMSBY PJ, 1985, ADRENAL CORTEX, P1; HORNSBY PJ, 1991, METHOD ENZYMOL, V206, P371; HORNSBY PJ, 1987, P NATL ACAD SCI USA, V84, P1580, DOI 10.1073/pnas.84.6.1580; HORNSBY PJ, 1986, J CELL PHYSIOL, V129, P395, DOI 10.1002/jcp.1041290319; HORNSBY PJ, 1992, J STEROID BIOCHEM, V43, P385; HORNSBY PJ, 1994, CELL TISSUE CULTUR B, V17; Idelman S, 1970, Int Rev Cytol, V27, P181, DOI 10.1016/S0074-7696(08)61248-6; KEENEY DS, 1995, ENDOCRINOLOGY, V136, P4872, DOI 10.1210/en.136.11.4872; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LI CH, 1972, BIOCHEM BIOPH RES CO, V49, P835, DOI 10.1016/0006-291X(72)90486-X; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MARTIN A, 1993, J CLIN ENDOCR METAB, V77, P305, DOI 10.1210/jc.77.2.305; MOULLIER P, 1995, NAT MED, V1, P353, DOI 10.1038/nm0495-353; Neville A.M., 1982, HUMAN ADRENAL CORTEX; PAULY JE, 1957, ENDOCRINOLOGY, V60, P247, DOI 10.1210/endo-60-2-247; PAVLATH GK, 1994, J CELL BIOL, V127, P1923, DOI 10.1083/jcb.127.6.1923; PERKINS LM, 1988, ENDOCRINOLOGY, V123, P2675, DOI 10.1210/endo-123-6-2675; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Potten C. S., 1997, STEM CELLS; REAVEN E, 1989, J LIPID RES, V30, P1551; RYAN RF, 1989, EXP CELL RES, V180, P36, DOI 10.1016/0014-4827(89)90210-3; TAIT JF, 1979, J ENDOCRINOL, V83, pP3; UHLER M, 1983, J BIOL CHEM, V258, P9444; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; VOGT PM, 1994, P NATL ACAD SCI USA, V91, P9307, DOI 10.1073/pnas.91.20.9307; VOLPE R, 1993, HORM METAB RES, V25, P623, DOI 10.1055/s-2007-1002192; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; Wright N. A., 1984, BIOL EPITHELIAL CELL, V1	41	84	87	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1997	3	9					978	983		10.1038/nm0997-978	http://dx.doi.org/10.1038/nm0997-978			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288723				2022-12-27	WOS:A1997XT84200029
J	Miller, RH; Sarver, N				Miller, RH; Sarver, N			HIV accessory proteins as therapeutic targets	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; VPU PROTEIN; NUCLEAR-LOCALIZATION; CYTOPLASMIC DOMAIN; CD4 LYMPHOCYTES; GENE-PRODUCT; CELL-CYCLE; NEF GENE; T-CELLS; DEGRADATION				Miller, RH (corresponding author), NIAID,DIV AIDS,BASIC SCI PROGRAM,TARGETED INTERVENT BRANCH,SOLAR BLDG,ROOM 2C36A,BETHESDA,MD 20892, USA.							AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; BRIDGES SH, 1995, LANCET, V345, P427, DOI 10.1016/S0140-6736(95)90407-7; Bukovsky AA, 1997, J VIROL, V71, P1013, DOI 10.1128/JVI.71.2.1013-1018.1997; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; DUBROVSKY L, 1995, MOL MED, V1, P217, DOI 10.1007/BF03401569; Ewart GD, 1996, J VIROL, V70, P7108, DOI 10.1128/JVI.70.10.7108-7115.1996; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; RICHMAN DD, 1995, CLIN INFECT DIS, V21, pS166, DOI 10.1093/clinids/21.Supplement_2.S166; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; Schubert U, 1996, J VIROL, V70, P809, DOI 10.1128/JVI.70.2.809-819.1996; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; YAO XJ, 1995, VIROLOGY, V209, P615, DOI 10.1006/viro.1995.1293; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995	49	54	58	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					389	394		10.1038/nm0497-389	http://dx.doi.org/10.1038/nm0497-389			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095171				2022-12-27	WOS:A1997WQ82500027
J	Weidemann, A; Paliga, K; Durrwang, U; Czech, C; Evin, G; Masters, CL; Beyreuther, K				Weidemann, A; Paliga, K; Durrwang, U; Czech, C; Evin, G; Masters, CL; Beyreuther, K			Formation of stable complexes between two Alzheimer's disease gene products: Presenilin-2 and beta-amyloid precursor protein	NATURE MEDICINE			English	Article							MISSENSE MUTATIONS; IDENTIFICATION; PEPTIDE; CELLS; COMPARTMENT; LOCUS	Mutations in the presenilin genes are associated with early onset familial Alzheimer's disease and lead to increased accumulation of beta A4 peptide, the proteolytic product of the amyloid precursor protein (APP). To test whether presenilins interfere with APP metabolism, presenilin-2 (PS2) was coexpressed with APP in mammalian cells. Analysis of PS2 immunoprecipitates revealed that a fraction of APP was associated with the PS2 immunocomplexes. This non-covalent association was specific for the APP family of proteins and restricted to immature forms, occuring probably during transit through the endoplasmic reticulum. Additionally, coexpression with PS2 resulted in a decrease of APP secretion, suggesting a direct participation of presenilins in the intracellular sorting, trafficking and processing of APP molecules.	RHONE POULENC RORER,VITRY SUR SEINE,FRANCE; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Sanofi-Aventis; University of Melbourne	Weidemann, A (corresponding author), UNIV HEIDELBERG,ZENTRUM MOL BIOL,INF 282,D-69120 HEIDELBERG,GERMANY.		Evin, Genevieve M/E-5891-2013	Czech, Christian/0000-0001-7746-0134				CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM TW, 1996, NEUROBIOL AGING, V17, P155; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; KONIG G, 1992, J BIOL CHEM, V267, P10804; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THINAKARAN G, 1996, NEURON, V17, P1; Van Broeckhoven C, 1995, NAT GENET, V11, P230; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	36	198	204	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					328	332		10.1038/nm0397-328	http://dx.doi.org/10.1038/nm0397-328			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055862				2022-12-27	WOS:A1997WL30500036
J	MacLean, M; Anderson, J; Davies, C				MacLean, M; Anderson, J; Davies, C			Making malaria research bite	NATURE MEDICINE			English	Editorial Material									WELLCOME TRUST RES LABS, PRISM, LONDON NW1 2BE, ENGLAND	University of London; University College London								ANDERSON J, 1996, 7 PRISM; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BRADLEY D, 1994, CDR REV, V4, P169; BRUCECHWATT LJ, 1987, ESSENTIAL MALARIOLOG; Garner P, 1996, PARASITOL TODAY, V12, P211, DOI 10.1016/0169-4758(96)30006-9; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; Hoffman SL, 1997, NAT MED, V3, P80, DOI 10.1038/nm0197-80; LEWISON G, 1995, BENCHMARKING INFORMA; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; MICHAUD C, 1996, INVESTING HLTH RES D; MURRAY CJL, 1996, GLOBAL COMP ASSESSME; NEVILLE CG, 1996, J TROP MED INTL HLTH, V1, P139; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; SINDEN RE, Patent No. 15237; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; Wadman M, 1996, NATURE, V379, P287, DOI 10.1038/379287a0; WHO, 1996, WORLD HLTH REP 1996; 1996, NATURE, V380, P99	18	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					14	16		10.1038/nm0197-14	http://dx.doi.org/10.1038/nm0197-14			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986727	Bronze			2022-12-27	WOS:A1997WA73300023
J	Koshland, DE				Koshland, DE			Conformational changes: How small is big enough?	NATURE MEDICINE			English	Editorial Material							SALMONELLA-TYPHIMURIUM; ASPARTATE RECEPTOR; DOMAIN; COOPERATIVITY; LIGAND		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Koshland, DE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P107; BERG H, 1986, P NATL ACAD SCI USA, V83, P8989; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; CHEN X, 1997, BIOCHEM, V39, P11858; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; KOSHLAND DE, 1987, COLD SPRING HARB SYM, V52, P1; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KOSHLAND DE, 1963, SCIENCE, V142, P1533, DOI 10.1126/science.142.3599.1533; KOSHLAND DE, 1963, COLD SPRING HARB SYM, V28, P473, DOI 10.1101/SQB.1963.028.01.063; KOSHLAND DE, 1976, FED PROC, V35, P2104; Koshland Jr D.E, 1980, BACTERIAL CHEMOTAXIS; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; STEITZ TA, 1967, J BIOL CHEM, V242, P4662; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; WYCKOFF HW, 1967, J BIOL CHEM, V242, P3749; YANKEELOV JA, 1965, J BIOL CHEM, V240, P1593	25	84	85	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1112	1114		10.1038/2605	http://dx.doi.org/10.1038/2605			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771734				2022-12-27	WOS:000076230100020
J	Nonogaki, K; Strack, AM; Dallman, MF; Tecott, LH				Nonogaki, K; Strack, AM; Dallman, MF; Tecott, LH			Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FACTOR-ALPHA; OBESE GENE; WEIGHT; EXPRESSION; LOCALIZATION; PROTEIN; BRAIN	Brain serotonin and leptin signaling contribute substantially to the regulation of feeding and energy expenditure. Here we show that young adult mice with a targeted mutation of the serotonin 5-HT2C receptor gene consume more food despite normal responses to exogenous leptin administration. Chronic hyperphagia leads to a 'middle-aged'-onset obesity associated with a partial leptin resistance of late onset. In addition, older mice develop insulin resistance and impaired glucose tolerance. Mutant mice also responded more to high-fat feeding, leading to hyperglycemia without hyperlipidemia. These findings demonstrate a dissociation of serotonin and leptin signaling in the regulation of feeding and indicate that a perturbation of brain serotonin systems can predispose to type 2 diabetes.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tecott, LH (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.							Abel E. Dale, 1996, P530; Blundell JE, 1995, OBES RES, V3, pS471, DOI 10.1002/j.1550-8528.1995.tb00214.x; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CRAPO PA, 1994, JOSLINS DIABETES MEL, P415; Curzon G, 1997, TRENDS PHARMACOL SCI, V18, P21, DOI 10.1016/S0165-6147(96)01003-6; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hotamisligil Gokhan S., 1996, P554; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Simansky KJ, 1996, BEHAV BRAIN RES, V73, P37, DOI 10.1016/0166-4328(96)00066-6; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WRIGHT DE, 1995, J COMP NEUROL, V351, P357, DOI 10.1002/cne.903510304; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666	28	359	378	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1152	1156		10.1038/2647	http://dx.doi.org/10.1038/2647			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771748				2022-12-27	WOS:000076230100034
J	Guo, Q; Fu, WM; Xie, J; Luo, H; Sells, SF; Geddes, JW; Bondada, V; Rangnekar, VM; Mattson, MP				Guo, Q; Fu, WM; Xie, J; Luo, H; Sells, SF; Geddes, JW; Bondada, V; Rangnekar, VM; Mattson, MP			Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; APOPTOSIS	Prostate apoptosis response-4 (Par-4) is a protein containing both a leucine zipper and a death domain that was isolated by differential screening for genes upregulated in prostate cancer cells undergoing apoptosis(1,2). Par-4 is expressed in the nervous system(3), where its function is unknown. In Alzheimer disease (AD), neurons may die by apoptosis, and amyloid beta-protein (A beta) may play a role in this(4-11). We report here that Par-4 expression is increased in vulnerable neurons in AD brain and is induced in cultured neurons undergoing apoptosis. Blockade of Par-4 expression or function prevented neuronal apoptosis induced by Ab and trophic factor withdrawl. Par-4 expression was enhanced, and mitochondrial dysfunction and apoptosis exacerbated, in cells expressing presenilin-1 mutations associated with early-onset inherited AD.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012					Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Keller JN, 1998, J NEUROSCI, V18, P4439; Keller JN, 1998, J NEUROSCI, V18, P687; Kruman I, 1997, J NEUROSCI, V17, P5089; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Mark RJ, 1996, MOL NEUROBIOL, V12, P211, DOI 10.1007/BF02755589; Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MATTSON MP, 1997, ADV CELL AGING GERON, V2, P299; Moretti A., 1997, ADV CELL AGING GERON, V2, P129; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031	27	236	257	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					957	962		10.1038/nm0898-957	http://dx.doi.org/10.1038/nm0898-957			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701251				2022-12-27	WOS:000075107400042
J	Bax, RP; Anderson, R; Crew, J; Fletcher, P; Johnson, T; Kaplan, E; Knaus, B; Kristinsson, K; Malek, M; Strandberg, L				Bax, RP; Anderson, R; Crew, J; Fletcher, P; Johnson, T; Kaplan, E; Knaus, B; Kristinsson, K; Malek, M; Strandberg, L			Antibiotic resistance - what can we do?	NATURE MEDICINE			English	Editorial Material							PENICILLIN; PNEUMONIA; MORTALITY; BACTERIA		SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Bax, RP (corresponding author), SmithKline Beecham Pharmaceut, 3rd Ave, Harlow CM19 5AW, Essex, England.							Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BAX RP, 1988, J ANTIMICROB CHEMOTH, V21, P278, DOI 10.1093/jac/21.3.278; Chopra I, 1996, JAMA-J AM MED ASSOC, V275, P401, DOI 10.1001/jama.275.5.401; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Felmingham D, 1996, J ANTIMICROB CHEMOTH, V38, P1; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Klugman KP, 1996, J ANTIMICROB CHEMOTH, V38, P133, DOI 10.1093/jac/38.suppl_A.133; NYSTROM PO, 1990, WORLD J SURG, V14, P148, DOI 10.1007/BF01664867; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Sack RB, 1997, CLIN INFECT DIS, V24, pS102, DOI 10.1093/clinids/24.Supplement_1.S102; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	13	75	78	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					545	546		10.1038/nm0598-545	http://dx.doi.org/10.1038/nm0598-545			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585218				2022-12-27	WOS:000073399900016
J	Donahue, RE; Bunnell, BA; Zink, MC; Metzger, ME; Westro, RP; Kirby, MR; Unangst, T; Clements, JE; Morgan, RA				Donahue, RE; Bunnell, BA; Zink, MC; Metzger, ME; Westro, RP; Kirby, MR; Unangst, T; Clements, JE; Morgan, RA			Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELLS; IMMUNIZATION; EXPRESSION; THERAPY; MUTANTS; MODELS; VIVO	Simian immunodeficiency virus (SIV) infection of nonhuman primates is one of the most relevant animals models of HIV infection in humans. To test a potential anti-HIV gene therapy strategy in this model, CD4-enriched lymphocytes from three rhesus macaques were subjected to retrovirally mediated gene transfer with a vector expressing an antisense tat/rev gene. This group of animals and three control macaques were subsequently infected with SIVmac239. Blood and lymph nodes from all macaques were sampled for more than a year to monitor the progress of infection. Although all animals became infected, the animals that received the lymphocytes engineered with the antisense vector demonstrated a significant reduction in viral load in both peripheral blood and lymph nodes, had sustained numbers of CD4(+) cells, and exhibited little disruption of lymph node architecture.	NIH, Natl Human Genome Res Inst, Clin Gene Therapy Branch, Bethesda, MD 20892 USA; NHLBI, Hematol Branch, NIH, Rockville, MD 20901 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University	Morgan, RA (corresponding author), NIH, Natl Human Genome Res Inst, Clin Gene Therapy Branch, Bldg 10,Room 10C103,10 Ctr Dr, Bethesda, MD 20892 USA.			Bunnell, Bruce/0000-0001-6196-3722	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035751, P01NS032208] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53248] Funding Source: Medline; NINDS NIH HHS [NS 35751, NS 32208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; Bunnell BA, 1997, BLOOD, V89, P1987, DOI 10.1182/blood.V89.6.1987; CLEMENTS JE, 1995, J VIROL, V69, P2737, DOI 10.1128/JVI.69.5.2737-2744.1995; Donahue RE, 1996, BLOOD, V87, P1644, DOI 10.1182/blood.V87.4.1644.bloodjournal8741644; ENDRES CL, 1995, J VIROL, V69, P5164, DOI 10.1128/JVI.69.8.5164-5166.1995; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; GARDNER MB, 1994, VIRUSES, V3, P133; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINDT TJ, 1992, ADV IMMUNOL, V52, P425, DOI 10.1016/S0065-2776(08)60880-9; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LOHMAN BL, 1994, J VIROL, V68, P7021, DOI 10.1128/JVI.68.11.7021-7029.1994; MANKOWSKI JL, 1994, J VIROL, V68, P8202, DOI 10.1128/JVI.68.12.8202-8208.1994; Morgan RA, 1996, HUM GENE THER, V7, P1281, DOI 10.1089/hum.1996.7.10-1281; Pantaleo G, 1997, NAT MED, V3, P483, DOI 10.1038/nm0597-483; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VANDENDRIESSCHE T, 1995, J VIROL, V69, P4045, DOI 10.1128/JVI.69.7.4045-4052.1995; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889	22	35	43	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1998	4	2					181	186		10.1038/nm0298-181	http://dx.doi.org/10.1038/nm0298-181			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461191				2022-12-27	WOS:000072249800033
J	Lin, YA; Goebels, J; Xia, GL; Ji, P; Vandeputte, M; Waer, M				Lin, YA; Goebels, J; Xia, GL; Ji, P; Vandeputte, M; Waer, M			Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELL; CARDIAC XENOGRAFT SURVIVAL; ENDOTHELIAL-CELLS; TRANSGENIC MICE; REJECTION; ANTIBODIES; ACTIVATION; ANTIGENS; RAT; XENOTRANSPLANTATION	After transplantation of primarily vascularized xenografts (Xgs), T-independent mechanisms may lead to Xg rejection before T-cell activation even takes place. The possibility of achieving T-independent xenotolerance was evaluated in nude rats that normally reject hamster cardiac Xgs within 4 days by non-T cell-mediated mechanisms. After donor antigen infusion, temporary NK-cell depletion and a 4-week administration of Leflunomide, hamster heart grafts survived even after withdrawal of immunosuppression. Tolerant rats accepted second hamster hearts, but promptly rejected mouse heart Xgs. In vivo immunization and in vitro cytotoxicity assays indicated that this species-specific tolerance was based on B-lymphocyte and NK-cell tolerance respectively.	Katholieke Univ Leuven, Lab Expt Transplantat, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Waer, M (corresponding author), Katholieke Univ Leuven, Lab Expt Transplantat, Campus Gasthuisberg,O-N,Herestr 49, B-3000 Louvain, Belgium.	Mark.Waer@Med.KULeuven.ac.be						AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BAKER PJ, 1989, AM J PATHOL, V135, P185; Candinas D, 1996, TRANSPLANTATION, V62, P1920, DOI 10.1097/00007890-199612270-00042; CHAN EYT, 1993, EUR J IMMUNOL, V23, P357, DOI 10.1002/eji.1830230209; COLIGAN JE, 1994, CURRENT PROTOCOLS IM, P11; Collins Braldey H., 1994, Xenotransplantation, V1, P36, DOI 10.1111/j.1399-3089.1994.tb00048.x; Cramer DV, 1997, TRANSPL P, V29, P945, DOI 10.1016/S0041-1345(96)00271-0; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GILES GR, 1970, TRANSPLANT P, V2, P522; Goodman DJ, 1996, TRANSPLANTATION, V61, P763, DOI 10.1097/00007890-199603150-00016; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; Gustavsson ML, 1996, TRANSPLANTATION, V61, P957, DOI 10.1097/00007890-199603270-00019; HANCOCK WW, 1993, TRANSPLANT P, V25, P2932; HOMAN WP, 1981, TRANSPLANTATION, V31, P164, DOI 10.1097/00007890-198103000-00004; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P149; KAKITA A, 1975, J SURG RES, V19, P99, DOI 10.1016/0022-4804(75)90113-4; KIYOHARA T, 1987, CELL IMMUNOL, V106, P223, DOI 10.1016/0008-8749(87)90166-3; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; Lin Y, 1997, J IMMUNOL, V158, P5658; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALNATI MS, 1993, J EXP MED, V178, P961, DOI 10.1084/jem.178.3.961; MOLLER JR, 1985, P NATL ACAD SCI USA, V82, P2456, DOI 10.1073/pnas.82.8.2456; PERPER ROBERT J., 1966, TRANSPLANTATION, V4, P377, DOI 10.1097/00007890-196607000-00002; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; REYNOLDS CW, 1981, J IMMUNOL, V127, P282; RODER JC, 1979, J EXP MED, V150, P471, DOI 10.1084/jem.150.3.471; RODER JC, 1982, J CLIN IMMUNOL, V2, P249, DOI 10.1007/BF00915064; ROONEY CM, 1984, IMMUNOLOGY, V51, P193; ROOZEMOND RC, 1984, ANN INST PASTEUR IMM, VD135, P247, DOI 10.1016/S0769-2625(84)81189-7; SACHS DH, 1990, HUM IMMUNOL, V28, P245, DOI 10.1016/0198-8859(90)90025-K; Salam A, 1996, TRANSPLANTATION, V61, P826, DOI 10.1097/00007890-199603150-00025; SCHAAPHERDER AFM, 1994, TRANSPLANTATION, V57, P1376, DOI 10.1097/00007890-199405150-00016; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; SILVA HT, 1997, MED SCI, V313, P289; SUNDSTROM JB, 1993, INFECT IMMUN, V61, P1340, DOI 10.1128/IAI.61.4.1340-1345.1993; SYKES M, 1993, J EXP MED, V178, P223, DOI 10.1084/jem.178.1.223; SYKES M, 1994, IMMUNOL REV, V141, P245, DOI 10.1111/j.1600-065X.1994.tb00880.x; Umesue M, 1996, TRANSPLANTATION, V61, P116, DOI 10.1097/00007890-199601150-00023; Wu MF, 1997, J IMMUNOL, V158, P1628; Zhao Y, 1996, NAT MED, V2, P1211, DOI 10.1038/nm1196-1211; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	48	75	78	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					173	180		10.1038/nm0298-173	http://dx.doi.org/10.1038/nm0298-173			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461190				2022-12-27	WOS:000072249800032
J	Rampling, R; Cruickshank, G; MacLean, A; Brown, M				Rampling, R; Cruickshank, G; MacLean, A; Brown, M			Therapeutic replication-competent herpes virus	NATURE MEDICINE			English	Letter							SIMPLEX		Univ Glasgow, Dept Clin Oncol, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Inst Virol, Div Virol, Glasgow G11 5JR, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Neurovirol Res Labs, Glasgow G51 4TF, Lanark, Scotland	Beatson Oncology Centre; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow	Rampling, R (corresponding author), Univ Glasgow, Dept Clin Oncol, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland.							KESARI S, 1995, LAB INVEST, V73, P636; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; Martuza RL, 1997, NAT MED, V3, P1323, DOI 10.1038/nm1297-1323	3	15	15	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					133	133		10.1038/nm0298-133c	http://dx.doi.org/10.1038/nm0298-133c			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461166	Bronze			2022-12-27	WOS:000072249800007
J	Calleja, C; Pascussi, JM; Mani, JC; Maurel, P; Vilarem, MJ				Calleja, C; Pascussi, JM; Mani, JC; Maurel, P; Vilarem, MJ			The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor	NATURE MEDICINE			English	Article							CYCLOSPORINE-A OXIDASE; GENE-EXPRESSION; PRIMARY CULTURES; BINDING DOMAIN; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; HUMAN HEPATOCYTES; CYTOCHROMES P450; MAMMALIAN-CELLS; PLASMA-PROTEIN	The glucocorticoid receptor (GR) belongs to a superfamily of ligand-regulated nuclear steroid hormone receptors. The steps in the signal transduction parkway leading to the biological effects of glucocorticoids (GCs) include sequentially binding of the steroid to the GR ligand binding domain (LBD), receptor transformation(1-3), nuclear translocation and either positive or negative gene transactivation(4). Rifampicin (RIF) is a macrocyclic antibiotic used as an antituberculosis agent(5). As the incidence of tuberculosis has been increasing, in part because of the AIDS epidemic, a growing number of patients are being exposed to the adverse effects of this antibiotic(6). Indeed, this compound, as are the GCs (ref. 7), is often implicated in noxious drug interactions, because elf its strong ability to induce drug-metabolizing enzymes(8,9). Moreover, in humans, RIF, as are the GCs (ref. 10), has been described as a potential immunodepressor, associated notably with the reduction of mitogenic responsiveness of human peripheral blood lymphocytes(11,12). Here, we report that RIF activates the human glucocorticoid receptor (hGR). Transient expression of wild-type, deleted or mutated GRs; sucrose density gradient sedimentation; and the BIAcore technique strongly suggest that RIF binds to the receptor with the physiological consequence that this antibiotic acts as an immunodepressor. Given the wide use of RIF in the treatment of coinfection of tuberculosis and HIV, this report is highly relevant to current medical practice.	CNRS, INSERM, U129, IFR 24, F-34293 Montpellier, France; Fac Pharm, UMR 9921, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Vilarem, MJ (corresponding author), CNRS, INSERM, U129, IFR 24, BP 5051,1919 Route Mende, F-34293 Montpellier, France.	vilarem@xerxes.crbm.cnrs-mop.fr	pascussi, jean marc/F-9311-2013	pascussi, jean marc/0000-0002-5168-5383				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BHAKOO HS, 1981, CANCER RES, V41, P1695; CORCOS L, 1992, DRUG METAB DISPOS, V20, P797; CRESTEIL T, 1983, BRIT J CLIN PHARMACO, V16, P651, DOI 10.1111/j.1365-2125.1983.tb02236.x; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FAGERSTAM LG, 1993, HDB AFFINITY CHROMAT, V63, P229; FAGERSTAM LG, 1993, IMMUNOCHEMISTRY, P949; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GRADIN K, 1994, J BIOL CHEM, V269, P23800; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1987, NATURE, V325, P7578; IBRAHIM MS, 1987, CHEMIOTERAPIA, V6, P426; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCGREGOR DB, 1991, MUTAT RES, V261, P29, DOI 10.1016/0165-1218(91)90095-4; MITCHELL L, 1995, LANCET, V4, P555; MITCHISON DA, 1992, J ANTIMICROB CHEMOTH, V29, P477, DOI 10.1093/jac/29.5.477; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; NESSI R, 1974, ARZNEIMITTELFORSCH, V24, P832; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NING YM, 1993, J BIOL CHEM, V268, P6073; OMALLEY BW, 1992, BIOL REPROD, V46, P163, DOI 10.1095/biolreprod46.2.163; OSHANESSY DJ, 1994, METHOD ENZYMOL, V249, P323; Ourlin JC, 1997, ANAL BIOCHEM, V247, P34, DOI 10.1006/abio.1997.2025; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; PICHARD L, 1992, MOL PHARMACOL, V41, P1047; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YU CY, 1995, BIOCHEMISTRY-US, V34, P14163, DOI 10.1021/bi00043a022	43	90	95	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					92	96		10.1038/nm0198-092	http://dx.doi.org/10.1038/nm0198-092			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427613				2022-12-27	WOS:000072249700041
J	Gauduin, MC; Parren, PWHI; Weir, R; Barbas, CF; Burton, DR; Koup, RA				Gauduin, MC; Parren, PWHI; Weir, R; Barbas, CF; Burton, DR; Koup, RA			Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NEUTRALIZATION; CD4 BINDING; INFECTION; GP120; CHIMPANZEES; AIDS; XENOGRAFTS; EPITOPE; PLASMA	How well antibodies can protect against disease due to HIV-1 infection remains a pivotal but unresolved issue with important implications for vaccine design and the use of prophylactic antibody to prevent infection after accidental exposure to the virus and to interrupt transmission of virus from mother to child. Strong doubts about the possible utility of antibodies in vivo have been raised because of the relative resistance of primary viruses to antibody neutralization in vitro. Primary viruses are likely to be close to the viruses transmitted during natural infection in humans. Vaccine studies have been of little value in assessing antibody efficacy in vivo because none of the strategies described to date have elicited significant neutralizing antibody responses to primary viruses (reviewed in ref. 1). Passive immunization studies are similarly hindered by the paucity of reagents able to neutralize primary viruses effectively(2) and a single study has suggested some benefit(3). Here we describe experiments to explore the ability of passive antibody to protect against primary virus challenge in hu-PBL-SCID mice. In this model, severe combined immunodeficient (SCID) mice are populated with human peripheral blood mononuclear cells (PBMCs) and infected with HIV-1 (ref. 4). We find that the potent neutralizing human monoclonal antibody lgG1b12 at high dose is able to completely protect even when given several hours after viral challenge. The results are encouraging for antibody-based postexposure prophylaxis and support the notion that antibody induction could contribute to an effective vaccine.	Scripps Res Inst, Dept Immunol IMM2, La Jolla, CA 92037 USA; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10016 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Rockefeller University; Scripps Research Institute	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol IMM2, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Parren, Paul/0000-0002-4365-3859	NIAID NIH HHS [AI 37470, AI 35522, AI 33292] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037470, R01AI035522, R01AI033292, R37AI035522, R37AI033292] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Burton DR, 1997, AIDS, V11, pS87; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; CUMMINS LM, 1991, BLOOD, V77, P1111; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GAUDUIN MC, 1995, J INFECT DIS, V171, P1203, DOI 10.1093/infdis/171.5.1203; Gauduin MC, 1996, J VIROL, V70, P2586, DOI 10.1128/JVI.70.4.2586-2592.1996; Girard M, 1996, ANTIBIOT CHEMOTHER, V48, P121; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; HESSELTON RM, 1993, J INFECT DIS, V168, P630, DOI 10.1093/infdis/168.3.630; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1991, P NATL ACAD SCI USA, V88, P8949, DOI 10.1073/pnas.88.20.8949; Kessler JA, 1997, AIDS RES HUM RETROV, V13, P575, DOI 10.1089/aid.1997.13.575; Klasse PJ, 1996, J VIROL, V70, P3668, DOI 10.1128/JVI.70.6.3668-3677.1996; Koup R A, 1996, Semin Immunol, V8, P263, DOI 10.1006/smim.1996.0033; KOUP RA, 1994, AIDS RES HUM RETROV, V10, P279, DOI 10.1089/aid.1994.10.279; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1994, TECHNIQUES HIV RES, P107; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Lambert JS, 1997, J INFECT DIS, V175, P283, DOI 10.1093/infdis/175.2.283; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MATTHEWS TJ, 1994, AIDS RES HUM RETROV, V10, P631, DOI 10.1089/aid.1994.10.631; Moore J P, 1995, AIDS, V9 Suppl A, pS117; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; MOSIER DE, 1988, NATURE, V355, P728; PARREN PWHI, 1995, AIDS, V9, pF1, DOI 10.1097/00002030-199506000-00001; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; SAFRIT JT, 1993, AIDS, V7, P15, DOI 10.1097/00002030-199301000-00002; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; ZollaPazner S, 1995, AIDS RES HUM RETROV, V11, P1449, DOI 10.1089/aid.1995.11.1449; ZUCKIER LS, 1989, SEMIN NUCL MED, V19, P166, DOI 10.1016/S0001-2998(89)80012-1	46	229	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1389	1393		10.1038/nm1297-1389	http://dx.doi.org/10.1038/nm1297-1389			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396610				2022-12-27	WOS:000072249500036
J	Goodell, MA; Rosenzweig, M; Kim, H; Marks, DF; DeMaria, M; Paradis, G; Grupp, SA; Sieff, CA; Mulligan, RC; Johnson, RP				Goodell, MA; Rosenzweig, M; Kim, H; Marks, DF; DeMaria, M; Paradis, G; Grupp, SA; Sieff, CA; Mulligan, RC; Johnson, RP			Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species	NATURE MEDICINE			English	Article							LONG-TERM-CULTURE; UMBILICAL-CORD BLOOD; HUMAN FETAL LIVER; BONE-MARROW; PROGENITOR CELLS; GENE-THERAPY; IN-VITRO; DIFFERENTIATION; PURIFICATION; ENGRAFTMENT	We previously described a method for isolating murine hematopoietic stem cells capable of reconstituting lethally irradiated recipients, which depends solely on dual-wavelength flow cytometric analysis of murine bone marrow cells stained with the fluorescent DNA-binding dye Hoechst 33342. This method, which appears to rely on the differential ability of stem cells to efflux the Hoechst dye, defines an extremely small and homogeneous population of cells (termed SP cells). We show here that dual-wavelength analysis of Hoechst dye-stained human, rhesus and miniature swine bone marrow cells reveals a small, distinct population of cells that efflux the dye in a manner identical to murine SP cells. Like the murine SP cells, both human and rhesus SP cells are primarily CD34-negative and lineage marker-negative. In vitro culture studies demonstrated that rhesus SP cells are highly enriched for long-term culture-initiating cells (LTC-ICs), an indicator of primitive hematopoietic cells, and have the capacity for differentiation into T cells. Although rhesus SP cells do not initially possess any hematopoietic colony-forming capability, they acquire the ability to form colonies after long-term culture on bone marrow stroma, coincident with their conversion to a CD34-positive phenotype. These studies suggest the existence of a hitherto unrecognized population of hematopoietic stem cells that lack the CD34 surface marker classically associated with primitive hematopoietic cells.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; MIT, Flow Cytometry Lab, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02115 USA; Partners AIDS Res Ctr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital	Mulligan, RC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.			Goodell, Margaret A./0000-0003-1111-2932	NCRR NIH HHS [RR-00055] Funding Source: Medline; NHLBI NIH HHS [HL54785] Funding Source: Medline; NIAID NIH HHS [AI-36550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036550] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARCENA A, 1993, BLOOD, V82, P3401; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BERENSON RJ, 1991, BLOOD, V77, P1717; BROXMEYER HE, 1990, INT J CELL CLONING, V8, P76, DOI 10.1002/stem.5530080708; Civin CI, 1996, J CLIN ONCOL, V14, P2224, DOI 10.1200/JCO.1996.14.8.2224; Dunbar CE, 1996, ANNU REV MED, V47, P11; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; *GUID CAR US LAB A, 1985, DHHS PUBL, V8523; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; KATAYAMA N, 1993, BLOOD, V82, P2353; KAWAI T, 1994, TRANSPLANT P, V26, P1845; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KRAUSE DS, 1994, BLOOD, V84, P691; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; METCALF D, 1971, HAEMOPOIETIC CELLS, P550; Morel F, 1996, BLOOD, V88, P3774, DOI 10.1182/blood.V88.10.3774.bloodjournal88103774; MULDER AH, 1984, CELL IMMUNOL, V88, P401, DOI 10.1016/0008-8749(84)90173-4; OKADA S, 1992, BLOOD, V80, P3044; Olweus J, 1994, Immunomethods, V5, P179, DOI 10.1006/immu.1994.1054; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Rosenzweig M, 1996, BLOOD, V87, P4040, DOI 10.1182/blood.V87.10.4040.bloodjournal87104040; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUTHERLAND DR, 1994, CULTURE HEMATOPOIETI, P139; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054	31	866	913	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1997	3	12					1337	1345		10.1038/nm1297-1337	http://dx.doi.org/10.1038/nm1297-1337			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396603				2022-12-27	WOS:000072249500029
J	BulfonePaus, S; Ungureanu, D; Pohl, T; Lindner, G; Paus, R; Ruckert, R; Krause, H; Kunzendorf, U				BulfonePaus, S; Ungureanu, D; Pohl, T; Lindner, G; Paus, R; Ruckert, R; Krause, H; Kunzendorf, U			Interleukin-15 protects from lethal apoptosis in vivo	NATURE MEDICINE			English	Article							ANTI-FAS ANTIBODY; T-CELLS; IL-2 RECEPTOR; GROWTH-FACTOR; GAMMA-CHAIN; ALPHA-CHAIN; BETA-CHAIN; B-CELLS; DEATH; EXPRESSION	Interleukin-15 shares many biological activities with IL-2 and signals through the IL-2 receptor beta and gamma chains(1-3). However, IL-15 and IL-2 differ in their controls of expression and secretion, their range of target cells and their functional activities(3-7). These dissimilarities may include differential effects on apoptosis. For ex ample, IL-2 induces or inhibits T-cell apoptosis in vitro, depending on T-cell activation(8), whereas IL-15 inhibits cytokine deprivation-induced apoptosis in activated T cells(9). Studying whether and how IL-15 modulates distinct apoptosis pathways(10-12), we show here that apoptosis induced by anti-fas, anti-CD3, dexamethasone, and/or anti-IgM in activated human T and B cells in vitro is inhibited by IL-15 in a manner dependent on RNA synthesis. In vivo, anti-fas-induced lethal multisystem apoptosis in mice is suppressed by a novel IL-15-IgG2b fusion protein. Only IL-15, but not IL-2, completely protected from lethal hepatic failure. Thus, IL-15 is a potent, general inhibitor of apoptosis in vitro and in vivo with intriguing therapeutic potential.	FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,DEPT UROL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,DEPT NEPHROL,D-12200 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,DEPT DERMATOL,D-10117 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	BulfonePaus, S (corresponding author), FREE UNIV BERLIN,BENJAMIN FRANKLIN MED CTR,INST IMMUNOL,D-12200 BERLIN,GERMANY.			Lindner, Gerd/0000-0003-2336-2058; Krause, Hans/0000-0001-8713-8229; Ungureanu, Daniela/0000-0002-9314-4972				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194; COHEN JJ, 1984, J IMMUNOL, V132, P38; Coligan JE., 1994, CURRENT PROTOCOLS IM; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ORIU A, 1997, J IMMUNOL, V158, P255; Scott DW, 1996, J IMMUNOL, V156, P2352; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Watanabe D, 1995, INT IMMUNOL, V7, P1949, DOI 10.1093/intimm/7.12.1949; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	26	276	282	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1124	1128		10.1038/nm1097-1124	http://dx.doi.org/10.1038/nm1097-1124			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334724				2022-12-27	WOS:A1997XZ28700038
J	Eliasson, MJL; Sampei, K; Mandir, AS; Hurn, PD; Traystman, RJ; Bao, J; Pieper, A; Wang, ZQ; Dawson, TM; Snyder, SH; Dawson, VL				Eliasson, MJL; Sampei, K; Mandir, AS; Hurn, PD; Traystman, RJ; Bao, J; Pieper, A; Wang, ZQ; Dawson, TM; Snyder, SH; Dawson, VL			Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; ZINC SUPEROXIDE-DISMUTASE; CORTICAL CULTURES; TRANSGENIC MICE; DNA-DAMAGE; GLUTAMATE NEUROTOXICITY; ENDOTHELIAL-CELLS; NADPH DIAPHORASE; ISLET CELLS; ACTIVATION	Nitric oxide (NO) and peroxynitrite, formed from NO and superoxide anion, have been implicated as mediators of neuronal damage following focal ischemia, but their molecular targets have not been defined. One candidate pathway is DNA damage leading to activation of the nuclear enzyme, poly(ADP-ribose) polymerase (PARP), which catalyzes attachment of ADP ribose units from NAD to nuclear proteins following DNA damage. Excessive activation of PARP can deplete NAD and ATP, which is consumed in regeneration of NAD, leading to cell death by energy depletion. We show that genetic disruption of PARP provides profound protection against glutamate-NO-mediated ischemic insults in vitro and major decreases in infarct volume after reversible middle cerebral artery occlusion. These results provide compelling evidence for a primary involvement of PARP activation in neuronal damage following focal ischemia and suggest that therapies designed towards inhibiting PARP may provide benefit in the treatment of cerebrovascular disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,BALTIMORE,MD 21287; INT AGCY RES CANC,F-69008 LYON,FRANCE	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; World Health Organization; International Agency for Research on Cancer (IARC)			Dawson, Valina/Y-9757-2019; Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033142, R01NS033277, K08NS001578] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33142, NS33277, NS01578] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BANASIK M, 1994, MOL CELL BIOCHEM, V138, P185, DOI 10.1007/BF00928461; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; CHAN PH, 1990, STROKE, V21, P80; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, J NEUROSCI, V10, P2493; Dawson Ted M., 1997, P319; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; ENDRES M, IN PRESS J CEREB BLO; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HUDAK BB, 1995, AM J PHYSIOL-LUNG C, V269, pL59, DOI 10.1152/ajplung.1995.269.1.L59; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KIRKLAND JB, 1991, BIOCHIM BIOPHYS ACTA, V1092, P319, DOI 10.1016/S0167-4889(97)90007-0; Kupper JH, 1996, HISTOCHEM J, V28, P391, DOI 10.1007/BF02331402; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MIZUMOTO K, 1993, BIOCHEM PHARMACOL, V46, P1811, DOI 10.1016/0006-2952(93)90587-M; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V6, P107; Szabo C, 1997, AM J RESP CELL MOL, V16, P105, DOI 10.1165/ajrcmb.16.2.9032115; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TAKAHASHI K, IN PRESS NEUROSCI AB; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WANG ZQ, IN PRESS GENES DEV; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	47	868	891	0	27	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1089	1095		10.1038/nm1097-1089	http://dx.doi.org/10.1038/nm1097-1089			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334719				2022-12-27	WOS:A1997XZ28700033
J	Horwitz, MS; Evans, CF; McGavern, DB; Rodriguez, M; Oldstone, MBA				Horwitz, MS; Evans, CF; McGavern, DB; Rodriguez, M; Oldstone, MBA			Primary demyelination in transgenic mice expressing interferon-gamma	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; VIRUS-INDUCED DEMYELINATION; ANTIGEN EXPRESSION; GENE-EXPRESSION; CELL EXPRESSION; SJL/J MICE; OLIGODENDROCYTES; NEURONS; INDUCTION	Ever since the use of interferon-gamma to treat patients with multiple sclerosis resulted in enhanced disease, the role of IFN-gamma in demyelination has been under question. To address this issue directly, transgenic mice were generated that expressed the cDNA of murine IFN-gamma in the central nervous system by using an oligodendrocyte-specific promoter. Expression of the transgene occurred after 8 weeks of age, at which time the murine immune and central nervous systems are both fully developed. Directly associated with transgene expression, primary demyelination occurred and was accompanied by clinical abnormalities consistent with CNS disorders. Additionally, multiple hallmarks of immune-mediated CNS disease were observed including upregulation of MHC molecules, gliosis and lymphocytic infiltration. These results demonstrate a direct role for IFN-gamma as an inducer of CNS demyelination leading to disease and provide new opportunities for dissecting the mechanism of demyelination.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; MAYO CLIN & MAYO FDN, DEPT NEUROL & IMMUNOL, ROCHESTER, MN 55905 USA	Scripps Research Institute; Mayo Clinic	Horwitz, MS (corresponding author), Scripps Res Inst, DEPT IMMUNOL IMM 23, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012120, T32MH019185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000080, P01AG004342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09487] Funding Source: Medline; NIA NIH HHS [AG04342] Funding Source: Medline; NIMH NIH HHS [F31 MH012120, MH19185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BERGSTEINSDOTTIR K, 1992, P NATL ACAD SCI USA, V89, P9054, DOI 10.1073/pnas.89.19.9054; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; HANAFUSA T, 1994, DIABETES RES CLIN PR, V24, pS307, DOI 10.1016/0168-8227(94)90267-4; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; LASSMANN H, 1994, ANN NEUROL, V36, pS2; LINTHICUM DS, 1982, CELL IMMUNOL, V73, P299, DOI 10.1016/0008-8749(82)90457-9; LUBLIN FD, 1993, AUTOIMMUNITY, V16, P267, DOI 10.3109/08916939309014645; MASSA PT, 1993, GLIA, V8, P201, DOI 10.1002/glia.440080307; MERRILL JE, 1993, J IMMUNOL, V151, P2132; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994; RENNO T, 1994, J NEUROIMMUNOL, V49, P1, DOI 10.1016/0165-5728(94)90174-0; RODRIGUEZ M, 1995, J VIROL, V69, P7286, DOI 10.1128/JVI.69.11.7286-7290.1995; RODRIGUEZ M, 1987, J IMMUNOL, V138, P3438; RUBIO N, 1991, IMMUNOLOGY, V74, P284; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SHALABY MR, 1985, J INTERFERON RES, V5, P339, DOI 10.1089/jir.1985.5.339; SOBEL RA, 1995, NEUROL CLIN, V13, P1; SUZUMURA A, 1988, J IMMUNOL, V140, P2068; TRAUGOTT U, 1988, J NEUROL SCI, V84, P257, DOI 10.1016/0022-510X(88)90130-X; TURNLEY AM, 1991, NATURE, V353, P566, DOI 10.1038/353566a0; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373	31	151	160	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1037	1041		10.1038/nm0997-1037	http://dx.doi.org/10.1038/nm0997-1037			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288735	Green Accepted, Bronze, Green Published			2022-12-27	WOS:A1997XT84200041
J	Botto, M; Hawkins, PN; Bickerstaff, MCM; Herbert, J; Bygrave, AE; McBride, A; Hutchinson, WL; Tennent, GA; Walport, MJ; Pepys, MB				Botto, M; Hawkins, PN; Bickerstaff, MCM; Herbert, J; Bygrave, AE; McBride, A; Hutchinson, WL; Tennent, GA; Walport, MJ; Pepys, MB			Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; AA-AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; BETA-FIBRILLOSES; ENHANCING FACTOR; FEMALE PROTEIN; INVIVO; MOUSE; SAP; PENTRAXINS	The tissue amyloid deposits that characterize systemic amyloidosis, Alzheimer's disease and the transmissible spongiform encephalopathies always contain serum amyloid P component (SAP) bound to the amyloid fibrils. We have previously proposed that this normal plasma protein may contribute to amyloidogenesis by stabilizing the deposits. Here we show that the induction of reactive amyloidosis is retarded in mice with targeted deletion of the SAP gene. This first demonstration of the participation of SAP in pathogenesis of amyloidosis in vivo confirms that inhibition of SAP binding to amyloid fibrils is an attractive therapeutic target in a range of serious human diseases.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,IMMUNOL MED UNIT,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,RHEUMATOL UNIT,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,RADIOL SCI UNIT,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London; Imperial College London			Hawkins, Philip N/C-5573-2008	Walport, Mark/0000-0001-7220-5273				AXELRAD MA, 1982, LAB INVEST, V47, P139; BALTZ ML, 1980, CLIN EXP IMMUNOL, V39, P355; BENSON MD, 1977, J CLIN INVEST, V59, P412, DOI 10.1172/JCI108654; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CASPI D, 1987, ARTHRITIS RHEUM, V30, P1303, DOI 10.1002/art.1780301115; CATHCART ES, 1967, P SOC EXP BIOL MED, V125, P1123; COE JE, 1990, J EXP MED, V171, P1257, DOI 10.1084/jem.171.4.1257; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; CORIA F, 1988, LAB INVEST, V58, P454; DUONG T, 1989, ACTA NEUROPATHOL, V78, P429, DOI 10.1007/BF00688180; Frank MM., 1994, SAMTERS IMMUNOLOGIC, VFifth, P637; Fricker J, 1997, LANCET, V349, P480; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GANOWIAK K, 1994, BIOCHEM BIOPH RES CO, V199, P306, DOI 10.1006/bbrc.1994.1229; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HAWKINS PN, 1990, CLIN EXP IMMUNOL, V81, P325; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HAWKINS PN, 1995, EUR J NUCL MED, V22, P595, DOI 10.1007/BF01254559; HAWKINS PN, 1993, ARTHRITIS RHEUM, V36, P842, DOI 10.1002/art.1780360616; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HIND CRK, 1984, LANCET, V2, P376; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; JANIGAN DT, 1965, AM J PATHOL, V47, P159; KALARIA RN, 1991, NEUROPATH APPL NEURO, V17, P189, DOI 10.1111/j.1365-2990.1991.tb00714.x; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KISILEVSKY R, 1995, AMYLOID, V2, P128, DOI 10.3109/13506129509031899; KITAMOTO T, 1985, ACTA NEUROPATHOL, V67, P272, DOI 10.1007/BF00687812; NELSON SR, 1991, CLIN CHIM ACTA, V200, P191, DOI 10.1016/0009-8981(91)90090-Y; PEPYS MB, 1979, IMMUNOLOGY, V37, P637; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PEPYS MB, IN PRESS AMYLOID INT; PEPYS MB, 1986, AMYLOIDOSIS, P43; SNEL FWJJ, 1989, CLIN EXP IMMUNOL, V76, P296; TAN SY, 1995, AM J KIDNEY DIS, V26, P267, DOI 10.1016/0272-6386(95)90647-9; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; VIGUSHIN DM, 1994, AMYLOID AMYLOIDOSIS, P685	41	209	220	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					855	859		10.1038/nm0897-855	http://dx.doi.org/10.1038/nm0897-855			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256275				2022-12-27	WOS:A1997XP01400026
J	Lu, XP; Fanjul, A; Picard, N; Pfahl, M; Rungta, D; NaredHood, K; Carter, B; Piedrafita, J; Tang, SP; Fabbrizio, E; Pfahl, M				Lu, XP; Fanjul, A; Picard, N; Pfahl, M; Rungta, D; NaredHood, K; Carter, B; Piedrafita, J; Tang, SP; Fabbrizio, E; Pfahl, M			Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACID; LIGANDS	Lung cancer causes more than 140,000 deaths annually in the United States alone, and the prognosis for non-small cell lung cancer (NSCLC) is particularly poor(1). Therapies using small molecules that preferentially kill lung tumor cells by inducing cellular suicide (apoptosis) would therefore be highly desirable. Retinoids have shown promise as cancer preventive and cancer therapeutic agents(2-5). Retinoid signals are mediated by two classes of nuclear receptors: the retinoic acid receptors (RAR alpha, beta, and gamma) and the retinoid X receptors (RXR alpha, beta and gamma)(5-8). These receptors usually bind as heterodimers to specific DNA sequences(9) and/or interact with other transcriptional regulators, such as AP-1 (ref. 10) to regulate gene transcription. Synthetic retinoids can be made that activate only specific portions of the complex retinoid response network(11-15) and activate selective biological programs. To Identify retinoids with novel biological activities, we used a high-throughput ''biological activity fingerprint'' screen on a large library of retinoids and retinoid-related molecules (RRMs). We identified new structures that are highly effective against lung cancer cells in vitro. Inducing apoptosis. We show here for one of these compounds that it is very effective against a human NSCLC in vivo in an animal model. These new molecules show a distinct pattern of receptor signaling.	GALDERMA RES INC,SAN DIEGO,CA 92121; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; MAXIA PHARMACEUT INC,SAN DIEGO,CA 92121	Galderma R&D SNC					NCI NIH HHS [CA 55681] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GINSBERG RJ, 1993, CANC PRINCIPLES PRAC, V1, P673; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LOTAN R, 1994, CANCER RES, V54, pS1987; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFAHL M, 1996, HORM HEALTH DIS, P127; SHROOT B, 1990, Patent No. 4920140; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	24	89	90	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					686	690		10.1038/nm0697-686	http://dx.doi.org/10.1038/nm0697-686			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176499				2022-12-27	WOS:A1997XB97400042
J	Ravussin, E; Pratley, RE; Maffei, M; Wang, H; Friedman, JM; Bennett, PH; Bogardus, C				Ravussin, E; Pratley, RE; Maffei, M; Wang, H; Friedman, JM; Bennett, PH; Bogardus, C			Relatively low plasma leptin concentrations precede weight gain in Pima Indians	NATURE MEDICINE			English	Article							OBESE GENE-PRODUCT; INSULIN-RESISTANCE; PROTEIN; MICE; RNA	Leptin, the product of the ob gene(1), is a hormone, produced by adipose cells, that inhibits food intake(2-5) and increases energy expenditure(2,3) in rodents. In humans, plasma leptin concentrations correlate closely with the size of the adipose tissue depot; however, there is considerable variation in plasma leptin concentrations at any given degree of fatness(6,7). To investigate whether individuals prone to weight gain are hypoleptinemic, we measured fasting plasma leptin concentrations in two groups of weight-matched nondiabetic Pima Indians followed for approximately 3 years, 19 of whom subsequently gained weight and 17 of whom maintained their weight. After we adjusted for initial percent body fat, mean plasma leptin concentration was lower in those who gained weight than in those whose weight was stable. These data indicate that relatively low plasma leptin concentrations may play a role in the development of obesity in Pima Indians, a population prone to obesity.	ROCKEFELLER UNIV,GENET MOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Ravussin, E (corresponding author), NIDDKD,CLIN DIABET & NUTR SECT,NIH,4212 N 16TH ST,PHOENIX,AZ 85016, USA.		Ravussin, Eric/N-1985-2017; Steib, Lori/B-6628-2014; Friedman, Jeffrey M/E-5784-2011; Bennett, Peter/AAH-9605-2021	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X; 				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NEEL JV, 1962, AM J HUM GENET, V14, P353; Norman RA, 1996, DIABETES, V45, P1229, DOI 10.2337/diabetes.45.9.1229; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SCHWARTZ MW, 1995, J CLIN ENDOCR METAB, V80, P1571, DOI 10.1210/jc.80.5.1571; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STIRLING B, 1995, DIABETES, V44, P999, DOI 10.2337/diabetes.44.8.999; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TARTAGLIA LA, 1995, CELL, V85, P1265; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	229	233	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					238	240		10.1038/nm0297-238	http://dx.doi.org/10.1038/nm0297-238			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018247				2022-12-27	WOS:A1997WF08800047
J	Archer, DR; Cuddon, PA; Lipsitz, D; Duncan, ID				Archer, DR; Cuddon, PA; Lipsitz, D; Duncan, ID			Myelination of the canine central nervous system by glial cell transplantation: A model for repair of human myelin disease	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; DEFICIENT RAT; OLIGODENDROCYTES; ENVIRONMENTS; SURVIVAL; LESIONS; CNS	There is a lack of effective means of promoting remyelination of the central nervous system (CNS) in humans with chronic demyelinating disease. We have investigated the ability of transplanted glia to myelinate areas of the CNS equivalent to focal demyelinated lesions in multiple sclerosis (MS). In these studies we show that transplantation of oligodendrocytes or their progenitors into the CNS of a neonatal or adult canine myelin mutant results in repair of large areas similar in size to many MS plaques. Progenitor or pre-progenitor cells of the oligodendrocyte lineage have the greatest capacity for myelination following grafting, although cells of neonatal origin may also be used. Such an approach may therefore have therapeutic value in the repair of focal lesions in human myelin disease.	EMORY UNIV,DEPT PEDIAT,ATLANTA,GA 30322; COLORADO STATE UNIV,COLL VET MED,FT COLLINS,CO 80523; UNIV WISCONSIN,SCH VET MED,DEPT MED SCI,MADISON,WI 53706	Emory University; Colorado State University; University of Wisconsin System; University of Wisconsin Madison								ARCHER DR, 1994, EXP NEUROL, V125, P268, DOI 10.1006/exnr.1994.1029; BLAKEMORE WF, 1995, GLIA, V13, P79, DOI 10.1002/glia.440130202; BLAKEMORE WF, 1983, VIRUSES DEMYELINATIN, P167; COMPSTON A, 1994, ANN NEUROL, V36, pS146, DOI 10.1002/ana.410360736; Duncan Ian D., 1995, P990; DUNCAN ID, 1992, DEV NEUROSCI-BASEL, V14, P114, DOI 10.1159/000111655; DUNCAN ID, 1995, BRAIN PATHOL, V5, P301, DOI 10.1111/j.1750-3639.1995.tb00607.x; DUNCAN ID, IN PRESS J ANAT; EVERCOOREN AB, 1996, GLIA, V16, P147; FABRE JW, 1995, NAT MED, V1, P403, DOI 10.1038/nm0595-403; FRANKLIN RJM, 1993, SEMIN NEUROSCI, V5, P443; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; HAMMANG JP, 1994, METH NEUROSCI, V21, P281; Honmou O, 1996, J NEUROSCI, V16, P3199; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; KIDD D, 1993, NEUROLOGY, V43, P2632, DOI 10.1212/WNL.43.12.2632; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Li D. W., 1994, Society for Neuroscience Abstracts, V20, P884; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; NADON NL, 1990, DEVELOPMENT, V110, P529; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; ROSENBLUTH J, 1993, J NEUROCYTOL, V22, P967, DOI 10.1007/BF01218354; SATOH J, 1994, J NEUROSCI RES, V39, P260, DOI 10.1002/jnr.490390304; Seilhean D, 1996, ACTA NEUROPATHOL, V91, P82; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; UTZSCHNEIDER DA, 1994, P NATL ACAD SCI USA, V91, P53, DOI 10.1073/pnas.91.1.53; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Wood MJA, 1996, NEUROSCIENCE, V70, P775, DOI 10.1016/S0306-4522(96)83014-4	30	115	119	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					54	59		10.1038/nm0197-54	http://dx.doi.org/10.1038/nm0197-54			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986741				2022-12-27	WOS:A1997WA73300037
J	Bomsel, M				Bomsel, M			Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier	NATURE MEDICINE			English	Article							ADHESION MOLECULES; TRANSMISSION; HIV; MECHANISMS; RECEPTOR; PROTEIN; TYPE-1; FUSION	Contact between various epithelial cell lines and HIV chronically infected mononuclear cell lines results in a massive and rapid budding of HIV virions toward the epithelium followed by their internalization into epithelial endosome-like structures, Here it is shown that as early as 30 minutes after apical contact, primary virus isolates generated from primary peripheral blood leukocytes from HIV-infected patients can cross an epithelial cell line barrier using transcytosis, the characteristic epithelial transcellular vesicular pathway. As the next step in the spread of infection, transcytosed HIV particles can productively infect mononuclear cells located at the basolateral side of the epithelial barrier. These observations suggest an alternative, rapid and efficient mechanism for transmission of HIV across an intact epithelial barrier.			Bomsel, M (corresponding author), INST COCHIN GENET MOL, U332, 22 RUE MECHAIN, F-75014 PARIS, FRANCE.		Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474				AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; APODACA G, 1995, INFECT IMMUN, V63, P1541, DOI 10.1128/IAI.63.4.1541-1551.1995; BALL JM, 1995, IN VITRO CELL DEV-AN, V31, P196; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1991, Current Opinion in Cell Biology, V3, P647, DOI 10.1016/0955-0674(91)90036-X; BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56; CARLOS TM, 1994, BLOOD, V84, P2068; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; FAIS S, 1995, AIDS, V9, P329, DOI 10.1097/00002030-199509040-00003; Fawcett D., 1994, TXB HISTOLOGY; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HAROUSE JM, 1995, J VIROL, V69, P7383, DOI 10.1128/JVI.69.12.7383-7390.1995; MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; PEARCEPRATT R, 1994, J VIROL, V68, P2898, DOI 10.1128/JVI.68.5.2898-2905.1994; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RUSSOMARIE F, 1993, P NATL ACAD SCI USA, V90, P8194, DOI 10.1073/pnas.90.17.8194; Shattock RJ, 1996, J INFECT DIS, V174, P54, DOI 10.1093/infdis/174.1.54; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; WESTON SA, 1992, CYTOMETRY, V13, P739, DOI 10.1002/cyto.990130710; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAHI N, 1991, J VIROL METHODS, V34, P193, DOI 10.1016/0166-0934(91)90099-L; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	32	409	426	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					42	47		10.1038/nm0197-42	http://dx.doi.org/10.1038/nm0197-42			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986739				2022-12-27	WOS:A1997WA73300035
J	Horwitz, MS; Bradley, LM; Harbertson, J; Krahl, T; Lee, J; Sarvetnick, N				Horwitz, MS; Bradley, LM; Harbertson, J; Krahl, T; Lee, J; Sarvetnick, N			Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; T-CELL; IMMUNE-RESPONSE; MICE; PROLIFERATION; PATHOGENESIS; MELLITUS; SUSCEPTIBILITY; INFECTIONS; REPERTOIRE	Viral induction of autoimmunity is thought to occur by either bystander T-cell activation or molecular mimicry. Coxsackie B4 virus is strongly associated with the development of insulin-dependent diabetes mellitus in humans and shares sequence similarity with the islet autoantigen glutamic acid decarboxylase. We infected different strains of mice with Coxsackie B4 virus to discriminate between the two possible induction mechanisms, and found that mice with susceptible MHC alleles had no viral acceleration of diabetes, but mice with a T cell receptor transgene specific for a different islet autoantigen rapidly developed diabetes. These results show that diabetes induced by Coxsackie virus infection is a direct result of local infection leading to inflammation, tissue damage, and the release of sequestered islet antigen resulting in the re-stimulation of resting autoreactive T cells, further indicating that the islet antigen sensitization is an indirect consequence of the viral infection.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	noras@scripps.edu						Andreoletti L, 1997, J MED VIROL, V52, P121, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;121::AID-JMV1&gt;3.0.CO;2-5; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; Balasa B, 1997, J IMMUNOL, V159, P4620; Brabb T, 1997, J IMMUNOL, V159, P497; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Ehl S, 1997, J EXP MED, V185, P1241, DOI 10.1084/jem.185.7.1241; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; HARTIG PC, 1983, J MED VIROL, V11, P23, DOI 10.1002/jmv.1890110104; HYOTY H, 1995, DIABETES, V44, P652, DOI 10.2337/diabetes.44.6.652; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Mueller R, 1997, IMMUNITY, V7, P411, DOI 10.1016/S1074-7613(00)80362-3; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PrevostBlondel A, 1997, VIROLOGY, V233, P93, DOI 10.1006/viro.1997.8604; SEE DM, 1995, J INFECT DIS, V171, P1131, DOI 10.1093/infdis/171.5.1131; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TRIPP RA, 1995, J IMMUNOL, V154, P6013; UTZ U, 1993, NATURE, V364, P243, DOI 10.1038/364243a0; Wahlstrom J, 1997, EUR RESPIR J, V10, P772; WEBB SR, 1976, J EXP MED, V143, P1239, DOI 10.1084/jem.143.5.1239; YOON JW, 1978, J EXP MED, V148, P1068, DOI 10.1084/jem.148.4.1068; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; Zarozinski CC, 1997, J EXP MED, V185, P1629, DOI 10.1084/jem.185.9.1629	35	483	494	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1998	4	7					781	785		10.1038/nm0798-781	http://dx.doi.org/10.1038/nm0798-781			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662368				2022-12-27	WOS:000074543900031
J	Hahn, H; Wojnowski, L; Zimmer, AM; Hall, J; Miller, G; Zimmer, A				Hahn, H; Wojnowski, L; Zimmer, AM; Hall, J; Miller, G; Zimmer, A			Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome	NATURE MEDICINE			English	Article							CELL CARCINOMA SYNDROME; NEVUS SYNDROME; HUMAN HOMOLOG; GENE	Gorlin (or nevoid basal cell carcinoma) syndrome is characterized by a variety of clinical problems including generalized overgrowth of the body, cysts, developmental abnormalities of the skeleton and a predisposition to benign and malignant tumors(1,2). The syndrome results from germline mutations of the human homolog of the drosophila segment polarity gene patched (ptc)(3,4). Here we report that mice heterozygous for ptc develop many of the features characteristic of Gorlin syndrome and that they exhibit a high incidence of rhabdomyosarcomas (RMS), the most common soft-tissue sarcoma in children(5). The downstream signalling partner of ptc, gli1, was overexpressed in all RMSs analyzed, indicating that abnormal signalling of the ptc-gli1 pathway may be common for the various tumors(6,7) associated with the syndrome. igf2, implicated in the formation of RMSs(8), was also overexpressed, suggesting cross-talk between the ptc and igf2 pathways in tumorigenesis. Developemental defects in Gorlin syndrome resemble those induced by ionizing radiation(9). We show that ptc heterozygous mice exhibit increased incidence of radiation-induced teratogenesis. This suggests a role for ptc in the response to ionizing radiation and provides a model for both the systemic (developmental) and stochastic (cancer) abnormalities observed in Gorlin syndrome.	NIMH, Genet Sect, Bethesda, MD 20892 USA; Natl Inst Res Resources, Vet Resources Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA	Zimmer, A (corresponding author), NIMH, Genet Sect, 36 Convent Dr,Room 3006, Bethesda, MD 20892 USA.	zimmer@codon.nih.gov	Zimmer, Andreas/B-8357-2009					Albrecht S, 1996, J NEUROPATH EXP NEUR, V55, P1270, DOI 10.1097/00005072-199612000-00011; ARLETT CF, 1984, BRIT J CANCER, V49, P227; Bale AE, 1997, AM J HUM GENET, V60, P10; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; FEATHERSTONE T, 1983, AM J HUM GENET, V35, P58; Giaccia J., 2018, RADIOBIOLOGY RADIOLO; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Rugh R, 1990, MOUSE ITS REPROD DEV; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; ZHAN SL, 1995, J BIOL CHEM, V270, P27983	20	346	352	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					619	622		10.1038/nm0598-619	http://dx.doi.org/10.1038/nm0598-619			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585239				2022-12-27	WOS:000073399900037
J	Melcher, A; Todryk, S; Hardwick, N; Ford, M; Jacobson, M; Vile, RG				Melcher, A; Todryk, S; Hardwick, N; Ford, M; Jacobson, M; Vile, RG			Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression	NATURE MEDICINE			English	Article							TISSUE-SPECIFIC EXPRESSION; DEAMINASE SUICIDE GENE; MHC CLASS-I; THYMIDINE KINASE; T-CELLS; CANCER-IMMUNOTHERAPY; ANTITUMOR IMMUNITY; APOPTOSIS; VIVO; VACCINATION	In situ killing of tumor cells using suicide gene transfer to generate death by a non-apoptotic pathway was associated with high immunogenicity and induction of heat shock protein (hsp) expression. In contrast, a syngeneic colorectal tumor line, CMT93, killed predominantly by apoptosis, showed low levels of hsp expression and less immunogenicity. When apoptosis was inhibited in CMT93 cells by overexpression of bcl-2, hsp was also induced. Furthermore, when cDNA encoding hsp70 was stably transfected into B16 and CMT93 cells, its expression significantly enhanced the immunogenicity of both tumors. Increased levels of hsp, induced by non-apoptotic cell killing, may provide an immunostimulatory signal in vivo which helps break tolerance to tumor antigens. These findings have important implications for the development of novel anti-cancer therapies aimed at promoting patients' immune responses to their own tumors.	Hammersmith Hosp, Imperial Coll Sci & Med, ICRF, Oncol Unit,Lab Mol Therapy, London W12 0NN, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Imperial College London; GlaxoSmithKline; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Vile, RG (corresponding author), Hammersmith Hosp, Imperial Coll Sci & Med, ICRF, Oncol Unit,Lab Mol Therapy, DuCane Rd, London W12 0NN, England.	R.vile@icrf.icnet.uk	Todryk, Stephen/AAA-3950-2019	Todryk, Stephen/0000-0003-4566-0793				Altman DG, 1991, PRACTICAL STAT MED R, P365; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; Castleden SA, 1997, HUM GENE THER, V8, P2087, DOI 10.1089/hum.1997.8.17-2087; CASTLEDEN SA, 1997, THESIS U LONDON; CAVALLO F, 1993, CANCER RES, V53, P5067; Cayeux S, 1997, J IMMUNOL, V158, P2834; COLOMBO MP, 1992, CANCER RES, V52, P4853; COLUMBANO A, 1995, J CELL BIOCHEM, V58, P181, DOI 10.1002/jcb.240580207; CONSALVO M, 1995, J IMMUNOL, V154, P5302; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Forni G, 1995, CYTOKINES MOL THER, V1, P225; FREEMAN SM, 1993, CANCER RES, V53, P5274; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; HELLSTROM KE, 1995, IMMUNOL REV, V145, P123, DOI 10.1111/j.1600-065X.1995.tb00079.x; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Li Z, 1997, Semin Immunol, V9, P315, DOI 10.1006/smim.1997.0087; LUKACS KV, 1993, J EXP MED, V178, P343, DOI 10.1084/jem.178.1.343; Lukacs KV, 1997, GENE THER, V4, P346, DOI 10.1038/sj.gt.3300386; MAASS G, 1995, P NATL ACAD SCI USA, V92, P5540, DOI 10.1073/pnas.92.12.5540; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MULLEN CA, 1994, CANCER RES, V54, P1503; Multhoff G, 1997, J IMMUNOL, V158, P4341; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; PERRY MD, 1994, GENE, V146, P273, DOI 10.1016/0378-1119(94)90305-0; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; Vile RG, 1996, CANCER METAST REV, V15, P351, DOI 10.1007/BF00046347; VILE RG, 1994, CANCER RES, V54, P6228; VILE RG, 1993, CANCER RES, V53, P3860; Vile RG, 1997, INT J CANCER, V71, P267; Wei YQ, 1996, CANCER RES, V56, P1104; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	44	393	424	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					581	587		10.1038/nm0598-581	http://dx.doi.org/10.1038/nm0598-581			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585232				2022-12-27	WOS:000073399900030
J	Tacket, CO; Mason, HS; Losonsky, G; Clements, JD; Levine, MM; Arntzen, CJ				Tacket, CO; Mason, HS; Losonsky, G; Clements, JD; Levine, MM; Arntzen, CJ			Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato	NATURE MEDICINE			English	Article							B SURFACE-ANTIGEN; ESCHERICHIA-COLI; ORAL IMMUNIZATION; CHOLERA-TOXIN; VACCINE; VOLUNTEERS; EXPRESSION; SAFETY; PLANTS; CELLS	Compared with vaccine delivery by injection, oral vaccines offer the hope of more convenient immunization strategies and a more practical means of implementing universal vaccination programs throughout the world. Oral vaccines act by stimulating the immune system at effector sites (lymphoid tissue) located in the gut. Genetic engineering has been used with variable success to design living and non-living systems as a means to deliver antigens to these sites and to stimulate a desired immune response(1-4). More recently, plant biotechnology techniques have been used to create plants which contain a gene derived from a human pathogen; the resultant plant tissues will accumulate an antigenic protein encoded by the foreign DNA(5-10). I, pre-clinical trials, we found that antigenic proteins produced in transgenic plants retained immunogenic properties when purified; if injected into mice the antigen caused production of protein-specific antibodies(6). Moreover, in some experiments, if the plant tissues were simply fed to mice, a mucosal immune response occurred(7-10). The present study was conducted as a proof of principle to determine if humans would also develop a serum and/or mucosal immune response to an antigen delivered in an uncooked foodstuff.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA; Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA	University System of Maryland; University of Maryland Baltimore; Cornell University; Boyce Thompson Institute for Plant Research; Tulane University	Tacket, CO (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA.	ctacket@umppa1.ab.umd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045251, R01AI036519] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI45251, R01-AI36519] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; BLACK RE, 1987, INFECT IMMUN, V55, P1116, DOI 10.1128/IAI.55.5.1116-1120.1987; EDELMAN R, 1997, NEW GENERATION VACCI, P173; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; LEVINE MM, 1995, J CLIN MICROBIOL, V21, P174; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MASON HS, IN PRESS VACCINE; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TACKET CO, 1994, VACCINE, V12, P1270, DOI 10.1016/S0264-410X(94)80038-2; TACKET CO, 1992, INFECT IMMUN, V60, P536, DOI 10.1128/IAI.60.2.536-541.1992; TACKET CO, 1992, VACCINE, V10, P673, DOI 10.1016/0264-410X(92)90088-2; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; VANDEVERG L, 1990, INFECT IMMUN, V58, P2002, DOI 10.1128/IAI.58.6.2002-2004.1990	15	422	472	1	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1998	4	5					607	609		10.1038/nm0598-607	http://dx.doi.org/10.1038/nm0598-607			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL111	9585236				2022-12-27	WOS:000073399900034
J	Jansen, B; Schlagbauer-Wadl, H; Brown, BD; Bryan, RN; van Elsas, A; Muller, M; Wolff, K; Eichler, HG; Pehamberger, H				Jansen, B; Schlagbauer-Wadl, H; Brown, BD; Bryan, RN; van Elsas, A; Muller, M; Wolff, K; Eichler, HG; Pehamberger, H			bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice	NATURE MEDICINE			English	Article							MALIGNANT-MELANOMA; EXPRESSION	Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy(1). A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene(2). Human melanoma expresses Bcl-2 in up to 90% of all cases(3-7). In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemosensitivity of human melanoma grown in severe combined immunodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.	Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; Genta Inc, San Diego, CA 92121 USA; Univ Hosp, AZL, Dept Clin Oncol, NL-2300 Leiden, Netherlands	University of Vienna; University of Vienna	Jansen, B (corresponding author), Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CERRONI L, 1995, AM J DERMATOPATH, V17, P7, DOI 10.1097/00000372-199502000-00002; Christoffersen RE, 1997, NAT BIOTECHNOL, V15, P483, DOI 10.1038/nbt0697-483; COMIS RL, 1976, CANCER TREAT REP, V60, P165; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P395; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P909, DOI 10.1001/archderm.131.8.909; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; TRON VA, 1995, AM J PATHOL, V146, P643; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994	16	432	453	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					232	234		10.1038/nm0298-232	http://dx.doi.org/10.1038/nm0298-232			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461199				2022-12-27	WOS:000072249800041
J	Parr, MJ; Manome, Y; Tanaka, T; Wen, P; Kufe, DW; Kaelin, WG; Fine, HA				Parr, MJ; Manome, Y; Tanaka, T; Wen, P; Kufe, DW; Kaelin, WG; Fine, HA			Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector	NATURE MEDICINE			English	Article							RETINOBLASTOMA PROTEIN; CDK4 AMPLIFICATION; BRAIN-TUMORS; E2F-1 GENE; DELETION; DNA; GLIOBLASTOMAS; TRANSCRIPTION; PROGRESSION; MAJORITY	Recent data suggest that many tumors, such as malignant gliomas, have disrupted pRB function, either because of RB-1 gene mutations or as a result of mutations affecting upstream regulators of pRB such as cyclin D1 or pl6/INK4a/MTS1 (ref. 1-5). Tumor suppression by pRB has been linked to its ability to repress E2F-responsive promoters such as the E2F-1 promoter(6,7). Thus, a prediction, which has not yet been demonstrated experimentally in vivo, is that EaF-responsive promoters should be more active in tumor cells relative to normal cells because of an excess of ''free'' E2F and loss of pRB/E2F repressor complexes. We demonstrate that adenoviral vectors that contain transgenes driven by the E2F-1 promoter can mediate tumor-selective gene expression in vivo, allowing for eradication of established gliomas with significantly less normal tissue toxicity than seen with standard adenoviral vectors. Our data indicate that de-repression of the E2F-1 promoter occurs in cancer cells in vivo, a finding that can be exploited to design viral vectors that mediate tumor-selective gene expression.	HARVARD UNIV,SCH MED,CTR NEUROONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,LAB CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,LAB NEOPLAST DIS MECHANISMS,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Wen, Patrick/AAE-3776-2022	Manome, Yoshinobu/0000-0002-8755-8976; Parr, Michael/0000-0003-3507-474X				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Dong YH, 1996, HUM GENE THER, V7, P713, DOI 10.1089/hum.1996.7.6-713; FINE HA, 1994, PERSPECT NEUROL SURG, V5, P115; FULTS D, 1992, CANCER RES, V52, P674; GHOSHCHOUDHURY G, 1986, GENE, V50, P161, DOI 10.1016/0378-1119(86)90321-5; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HE J, 1994, CANCER RES, V54, P5804; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JEN J, 1994, CANCER RES, V54, P6353; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOBAYASHI N, 1980, J NEUROSURG, V53, P808, DOI 10.3171/jns.1980.53.6.0808; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; RAM Z, 1993, CANCER RES, V53, P3475; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Ueki K, 1996, CANCER RES, V56, P150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	24	136	169	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1145	1149		10.1038/nm1097-1145	http://dx.doi.org/10.1038/nm1097-1145			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334729				2022-12-27	WOS:A1997XZ28700043
J	Zhou, P; Goldstein, S; Devadas, K; Tewari, D; Notkins, AL				Zhou, P; Goldstein, S; Devadas, K; Tewari, D; Notkins, AL			Human CD4(+) cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression	NATURE MEDICINE			English	Article							LYMPHOCYTE CHEMOATTRACTANT FACTOR; HUMAN LYMPHOKINES; MIGRATION; REPLICATION; MODULATION; RECEPTOR; DOMAINS	Interleukin-16 (IL-16) is secreted by activated CD8+ T lymphocytes and acts on CDC T lymphocytes, monocytes and eosinophils. Recently, the C-terminal 130-amino acid portion of IL-16 was shown to suppress HIV-1 replication in vitro. To explore the potential of human IL-16 for gene therapy, this portion was transfected into HIV-1-susceptible CD4(+) jurkat cells by means of a mammalian expression vector. The stable transfectants synthesized and secreted IL-16 protein. The expression of IL-16 did not alter growth rate and CD4 expression; however, HIV replication was inhibited by as much as 99%. Furthermore, during the initial phase of the infection, equal amounts of HIV-1 proviral DNA were found in cells transfected with IL-16 and with vector alone. In contrast, the 2-kilobase HIV-1 transcripts were markedly reduced and the 4-kb and 9-kb transcripts were undetectable in the cells transfected with IL-16. These findings indicate that IL-16-mediated inhibition of HIV-1 is not at the level of viral entry or reverse transcription, but at messenger RNA expression.	NIAID,IMMUNODEFICIENCY VIRUS SECT,INFECT DIS LAB,NIH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zhou, P (corresponding author), NIDR,BRANCH ORAL INFECT & IMMUN,NIH,BETHESDA,MD 20892, USA.							BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Bannert N, 1996, NATURE, V381, P30, DOI 10.1038/381030a0; Bazan JF, 1996, NATURE, V381, P29, DOI 10.1038/381029a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CENTER DM, 1982, J IMMUNOL, V128, P2563; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; CRUIKSHANK WW, 1991, J IMMUNOL, V146, P2928; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; KWOK S, 1990, TRANSFUSION, V30, P491, DOI 10.1046/j.1537-2995.1990.30690333477.x; LABERGE S, 1995, J IMMUNOL, V155, P2902; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Maniatis T., 1982, MOL CLONING; OBEELIN E, 1996, NATURE, V382, P833; Oravecz T, 1996, J IMMUNOL, V157, P1329; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shaheen F, 1996, J VIROL, V70, P3392, DOI 10.1128/JVI.70.6.3392-3400.1996; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; ZHOU P, 1993, P NATL ACAD SCI USA, V90, P2681, DOI 10.1073/pnas.90.7.2681	31	97	102	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					659	664		10.1038/nm0697-659	http://dx.doi.org/10.1038/nm0697-659			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176493				2022-12-27	WOS:A1997XB97400036
J	Iafrati, MD; Karas, RH; Aronovitz, M; Kim, S; Sullivan, TR; Lubahn, DB; ODonnell, TF; Korach, KS; Mendelsohn, ME				Iafrati, MD; Karas, RH; Aronovitz, M; Kim, S; Sullivan, TR; Lubahn, DB; ODonnell, TF; Korach, KS; Mendelsohn, ME			Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC CORONARY-ARTERIES; NITRIC-OXIDE; MOUSE; EXPRESSION; ESTRADIOL; GENE; 17-BETA-ESTRADIOL; TRANSCRIPTION; ENDOTHELIUM	The atheroprotective effects of estrogen in women are well recognized(1), but the underlying mechanisms responsible are not well understood. Blood vessel cells express the classic estrogen receptor, ER alpha (ref. 2-6), and are directly affected by estrogen, which inhibits the development of atherosclerotic and injury-induced vascular lesions(7,8). We have generated mice in which the ER alpha gene is disrupted(9) and have used a mouse model of carotid arterial injury to compare the effects of estrogen on wild-type and estrogen receptor-deficient mice. Increases in vascular medial area and smooth muscle cell proliferation were quantified following vascular injury in ovariectomized mice treated with vehicle or with physiologic levels of 17 beta-estradiol. Suprisingly, in both wild-type and estrogen receptor-deficient mice, 17 beta-estradiol markedly inhibited to the same degree all measures of vascular injury. These data demonstrate that estrogen inhibits vascular injury by a novel mechanism that is independent of the classic estrogen receptor, ER alpha.	TUFTS UNIV NEW ENGLAND MED CTR,MOL CARDIOL RES CTR,TUPPER RES INST,BOSTON,MA 02111; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65201; NIEHS,REPROD & DEV TOXICOL LAB,NIH,RES TRIANGLE PK,NC 27709	Tufts Medical Center; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)				Korach, Kenneth/0000-0002-7765-418X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056069] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL 30386, R01 HL 56069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; FISCHERDZOGA K, 1983, EXP MOL PATHOL, V39, P355, DOI 10.1016/0014-4800(83)90064-3; GRABER R, 1993, CELL SIGNAL, V5, P181, DOI 10.1016/0898-6568(93)90069-X; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; Johns A, 1996, ENDOCRINOLOGY, V137, P4511, DOI 10.1210/en.137.10.4511; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; Koike H, 1996, J VASC SURG, V23, P477, DOI 10.1016/S0741-5214(96)80014-0; Kolodgie FD, 1996, AM J PATHOL, V148, P969; KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; LINDNER V, 1993, CIRC RES, V73, P792, DOI 10.1161/01.RES.73.5.792; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Moraghan T, 1996, ENDOCRINOLOGY, V137, P5174, DOI 10.1210/en.137.11.5174; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; TOUCHETTE N, 1990, J NIH RES, V2, P71; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	44	387	399	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					545	548		10.1038/nm0597-545	http://dx.doi.org/10.1038/nm0597-545			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142124				2022-12-27	WOS:A1997WX54300035
J	Brown, AJL; Richman, DD				Brown, AJL; Richman, DD			HIV-1: Gambling on the evolution of drug resistance?	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; IN-VIVO; REVERSE-TRANSCRIPTASE; THERAPY; TYPE-1; INFECTION; ZIDOVUDINE; EMERGENCE; DISEASE	Despite the huge size of the HIV population in an infected patient, chance has an unexpected influence on its evolution.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; SAN DIEGO VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Brown, AJL (corresponding author), UNIV EDINBURGH, CTR HIV RES, INST CELL ANIM & POPULAT BIOL, W MAINS RD, EDINBURGH EH9 3JN, MIDLOTHIAN, SCOTLAND.		Leigh Brown, Andrew/F-3802-2010; Brown, Andrew Leigh/ABF-8269-2020	Leigh Brown, Andrew/0000-0002-5700-3128; Brown, Andrew Leigh/0000-0002-5700-3128	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, P30AI036214, U01AI038858] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36214, AI 27670, AI 38858] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZZETTE SA, 1993, J INFECT DIS, V168, P1374, DOI 10.1093/infdis/168.6.1374; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DAQUILA RT, 1996, ANTIVIRAL DRUG RESIS, P191; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DELASSUS S, 1992, J VIROL, V66, P5642, DOI 10.1128/JVI.66.9.5642-5645.1992; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; GULICK RM, 1996, 11 INT C AIDS VANC C, pB931; HALDANE JBS, 1937, P CAMB PHILOS SOC, V28, P838; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HAVLIR DV, 1995, 4 INT HIV DRUG RES W; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; Kelly JK, 1996, J THEOR BIOL, V180, P359, DOI 10.1006/jtbi.1996.0108; KELLY JK, 1994, GENET RES, V64, P1, DOI 10.1017/S0016672300032481; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LARDER B, 1996, ANTIVIRAL DRUG RESIS, P169; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LEIGHBROWN AJ, IN PRESS P NATL ACAD; LEIGHBROWN AJ, 1994, ANNU REV ECOL SYST, V25, P127; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; TAJIMA F, 1983, GENETICS, V105, P437; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WRIGHT S, 1969, THEORY GENE FREQUENC, P512	43	73	76	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					268	271		10.1038/nm0397-268	http://dx.doi.org/10.1038/nm0397-268			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055846				2022-12-27	WOS:A1997WL30500020
J	Helmlinger, G; Yuan, F; Dellian, M; Jain, RK				Helmlinger, G; Yuan, F; Dellian, M; Jain, RK			Interstitial pH and pO(2) gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation	NATURE MEDICINE			English	Article							EXTRACELLULAR PH; NONINVASIVE MEASUREMENT; CYTO-TOXICITY; SCID MICE; OXYGEN; CARCINOMA; GROWTH; SPHEROIDS; GLUCOSE; CELLS	The partial pressure of oxygen (pO(2)) and pH play critical roles in tumor biology and therapy. We report here the first combined, high-resolution (less than or equal to 10 mu m) measurements of interstitial pH and pO(2) profiles between adjacent vessels in a human tumor xenograft, using fluorescence ratio imaging and phosphorescence quenching microscopy. We found (1) heterogeneity in shapes of pH and pO(2) profiles; (2) a discordant relation between local pH profiles and corresponding pO(2) profiles, yet a strong correlation between mean pH and pO(2) profiles; (3) no correlation between perivascular pH/pO(2) and nearest vessel blood flow; and (4) well-perfused tumor vessels that were hypoxic and, consequently, large hypoxic areas in the surrounding interstitium. Such multiparameter measurements of the in vivo microenvironment provide unique insights into biological processes in tumors and their response to treatment.			Helmlinger, G (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, EDWIN L STEELE LAB, BOSTON, MA 02114 USA.		Jain, Rakesh K/I-1384-2017; Yuan, Fan/A-1287-2011	Jain, Rakesh K/0000-0001-7571-3548; 	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKER H, 1987, CANCER RES, V47, P3504; Brizel DM, 1996, CANCER RES, V56, P941; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; CASCIARI JJ, 1988, CANCER RES, V48, P3905; CHAPLIN DJ, 1987, INT J RADIAT ONCOL, V13, P579, DOI 10.1016/0360-3016(87)90075-7; DALY PF, 1989, CANCER RES, V49, P770; Dellian M, 1996, BRIT J CANCER, V74, P1206, DOI 10.1038/bjc.1996.518; DEWHIRST MW, 1992, RADIAT RES, V130, P171, DOI 10.2307/3578274; ENGIN K, 1994, INT J RADIAT ONCOL, V29, P125, DOI 10.1016/0360-3016(94)90234-8; ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457; Evans SM, 1996, CANCER RES, V56, P405; Gerweck LE, 1996, CANCER RES, V56, P1194; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GULLINO PM, 1967, CANCER RES, V27, P1041; GULLINO PM, 1964, CANCER RES, V24, P780; HAWKINS RA, 1988, CANCER METAST REV, V7, P119, DOI 10.1007/BF00046482; Hoeckel Michael, 1993, Radiotherapy and Oncology, V26, P45; JAHDE E, 1989, CANCER RES, V49, P2965; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; JAIN RK, 1984, JNCI-J NATL CANCER I, V73, P429, DOI 10.1093/jnci/73.2.429; KARURI AR, 1993, BRIT J CANCER, V68, P1080, DOI 10.1038/bjc.1993.485; Krtolica A, 1996, CANCER RES, V56, P1168; LEUNIG M, 1992, CANCER RES, V52, P6553; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; MARTIN GR, 1994, CANCER RES, V54, P5670; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Shimizu S, 1996, CANCER RES, V56, P2161; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SKARSGARD LD, 1995, ANTICANCER RES, V15, P219; Song Chang W., 1993, P25; SUIT H, 1995, BLOOD SUBSTITUTES, P187; SUTHERLAND RM, 1986, CANCER RES, V46, P5320; TANNOCK IF, 1989, CANCER RES, V49, P4373; TEICHER BA, 1981, CANCER RES, V41, P73; TORRES IP, 1994, P NATL ACAD SCI USA, V91, P2081, DOI 10.1073/pnas.91.6.2081; TORRES IP, 1993, AM J PHYSIOL, V265, pH1434, DOI 10.1152/ajpheart.1993.265.4.H1434; TURNER GA, 1979, EXPERIENTIA, V35, P1657, DOI 10.1007/BF01953252; VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476; VAUPEL P, 1989, CANCER RES, V49, P6449; VAUPEL PW, 1981, CANCER RES, V41, P2008; Warburg O., 1931, METABOLISM TUMORS; WARD KA, 1988, INT J HYPERTHER, V4, P223, DOI 10.3109/02656738809051100; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; YOUNG PR, 1992, BIOCHIM BIOPHYS ACTA, V1139, P163, DOI 10.1016/0925-4439(92)90096-6; Zheng L, 1996, AM J PHYSIOL-HEART C, V271, pH365, DOI 10.1152/ajpheart.1996.271.1.H365	47	1244	1294	4	197	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					177	182		10.1038/nm0297-177	http://dx.doi.org/10.1038/nm0297-177			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018236				2022-12-27	WOS:A1997WF08800036
J	Basile, AS; Huang, JM; Xie, C; Webster, D; Berlin, C; Skolnick, P				Basile, AS; Huang, JM; Xie, C; Webster, D; Berlin, C; Skolnick, P			N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss	NATURE MEDICINE			English	Article							NMDA-ANTAGONIST; OTOTOXIC DRUGS; RECEPTOR; COCHLEA; IFENPRODIL; EPILEPSY; NEURONS; SITE; CPP	The use of aminoglycoside antibiotics is limited by ototoxicity that can produce permanent hearing loss. We report that concurrent administration of N-methyl-D-aspartate (NMDA) antagonists markedly attenuates both the hearing loss and destruction of cochlear hair cells in guinea pigs treated with aminoglycoside antibiotics. These findings indicate that aminoglycoside-induced hearing loss is mediated, in part, through an excitotoxic process. The high correlation (Spearman correlation coefficient: 0.928; P < 0.01) obtained between the relative cochleotoxicities of a series of aminoglycosides in humans and the potencies of these compounds to produce a polyamine-like enhancement of [H-3]dizocilpine binding to NMDA receptors is consistent with this hypothesis, and provides a simple in vitro assay that can predict this aspect of aminoglycoside-induced ototoxicity.	LOUISIANA STATE UNIV,KRESGE HEARING RES INST S,DEPT OTORHINOLARYNGOL & BIOCOMMUN,NEW ORLEANS,LA 70112	Louisiana State University System	Basile, AS (corresponding author), NIDDKD,NEUROSCI LAB,NIH,BETHESDA,MD 20892, USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000007] Funding Source: NIH RePORTER; NIDCD NIH HHS [T32-DC-0007] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akiyoshi M, 1976, Jpn J Antibiot, V29, P771; BAMONTE F, 1980, ARCH OTO-RHINO-LARYN, V228, P163, DOI 10.1007/BF00454224; BEGG EJ, 1995, BRIT J CLIN PHARMACO, V39, P597; BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BROWN AM, 1989, HEARING RES, V42, P143, DOI 10.1016/0378-5955(89)90140-8; BRUMMETT RE, 1990, ARCH OTOLARYNGOL, V116, P406; BRUMMETT RE, 1978, J ANTIMICROB CHEMOTH, V4, P73, DOI 10.1093/jac/4.suppl_A.73; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHERKOFSKY SC, 1995, J PHARM SCI, V85, P1231; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DESROCHERS CS, 1982, ACTA OTO-LARYNGOL, V93, P233, DOI 10.3109/00016488209130877; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; EYBALIN M, 1993, PHYSIOL REV, V73, P309, DOI 10.1152/physrev.1993.73.2.309; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; HASHIMOTO K, 1994, EUR J PHARM-MOLEC PH, V266, P67, DOI 10.1016/0922-4106(94)90211-9; HENLEY CM, 1995, BRAIN RES REV, V20, P68, DOI 10.1016/0165-0173(94)00006-B; HODGES GR, 1984, AMINOGLYCOSIDE ANTIB, P153; HUANG JM, 1995, HEARING RES, V88, P61, DOI 10.1016/0378-5955(95)00099-P; KIANG NYS, 1976, ANN OTO RHINOL LARYN, V85, P752, DOI 10.1177/000348947608500605; LENOIR M, 1984, HEARING RES, V13, P123, DOI 10.1016/0378-5955(84)90103-5; LIM DJ, 1986, AM J OTOLARYNG, V7, P73, DOI 10.1016/S0196-0709(86)80037-0; LOSCHER W, 1988, EUR J PHARMACOL, V152, P9, DOI 10.1016/0014-2999(88)90830-8; OLIVEIRA JAA, 1989, AUDIOVESTIBULAR TOXI, P223; OLIVEIRA JAA, 1989, AUDIOVESTIBULAR TOXI, P71; PATAT A, 1994, INT CLIN PSYCHOPHARM, V9, P155, DOI 10.1097/00004850-199409000-00003; PUEL JL, 1991, HEARING RES, V51, P255, DOI 10.1016/0378-5955(91)90042-8; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Revai Katalin, 1995, Orvosi Hetilap, V136, P2615; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; SAFIEDDINE S, 1992, NEUROREPORT, V3, P1145, DOI 10.1097/00001756-199212000-00029; SCATTON B, 1994, DIRECT ALLOSTERIC CO, P139; SCHACHT J, 1993, OTOLARYNG CLIN N AM, V26, P845; Stringer SP, 1991, OTOLARYNGOLOGY, P1653; SVEINBJORNSDOTTIR S, 1993, EPILEPSY RES, V16, P165, DOI 10.1016/0920-1211(93)90031-2; USAMI S, 1995, NEUROREPORT, V6, P1161, DOI 10.1097/00001756-199505300-00022; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	39	122	129	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1338	1343		10.1038/nm1296-1338	http://dx.doi.org/10.1038/nm1296-1338			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946832				2022-12-27	WOS:A1996VW51500039
J	Strand, S; Hofmann, WJ; Hug, H; Muller, M; Otto, G; Strand, D; Mariani, SM; Stremmel, W; Krammer, PH; Galle, PR				Strand, S; Hofmann, WJ; Hug, H; Muller, M; Otto, G; Strand, D; Mariani, SM; Stremmel, W; Krammer, PH; Galle, PR			Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?	NATURE MEDICINE			English	Article							MEDIATED CYTOTOXICITY; T-CELL; MONOCLONAL-ANTIBODY; FAS; INDUCTION; PERFORIN; CARCINOMA; PATHWAYS; ANTIGEN; MICE	The CD95 (APO-1/Fas) system is an important mediator of T-cell cytotoxicity. We investigated this system in 22 hepatocellular carcinomas (HCCs) from patients. All HCCs had partially or completely lost the expression of the CD95 receptor constitutively expressed by normal liver cells and might thus evade CD95-mediated killing. We also considered a new mechanism of immune evasion, namely, the active destruction of T-lymphocytes by tumor cells expressing CD95 ligand (CD95L). CD95L messenger RNA and protein could be detected in the HCCs. In coculture experiments, HepG2 hepatoblastoma cells, expressing CD95L mRNA after treatment with cytostatic drugs, killed CD95(+) jurkat lymphocytes. Our data suggest that tumor cells can evade immune attack by downregulation of the CD95 receptor and killing of lymphocytes through expression of CD95L.	UNIV HEIDELBERG HOSP,DEPT GASTROENTEROL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST PATHOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,ZMBH,CTR MOL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG HOSP,DEPT SURG,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAMME,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,DEPT DEV GENET,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; DHEIN J, 1992, J IMMUNOL, V149, P3166; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GALLE PR, 1995, J EXP MED, V182, P223; GILETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STALDER T, 1994, J IMMUNOL, V152, P1127; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VOLKMANN M, 1994, ONCOGENE, V9, P195; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0	30	850	878	1	42	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1361	1366		10.1038/nm1296-1361	http://dx.doi.org/10.1038/nm1296-1361			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946836				2022-12-27	WOS:A1996VW51500043
J	Hamdy, S; Aziz, Q; Rothwell, JC; Singh, KD; Barlow, J; Hughes, DG; Tallis, RC; Thompson, DG				Hamdy, S; Aziz, Q; Rothwell, JC; Singh, KD; Barlow, J; Hughes, DG; Tallis, RC; Thompson, DG			The cortical topography of human swallowing musculature in health and disease	NATURE MEDICINE			English	Article							MAGNETIC STIMULATION; MOTOR CORTEX; DYSPHAGIA; STROKE; ORGANIZATION; MONKEY; BRAIN	Because no detailed information exists regarding the topographic representation of swallowing musculature on the human cerebral cortex in health or disease, we used transcranial magnetic stimulation to study the cortical topography of human oral, pharyngeal and esophageal musculature in 20 healthy individuals and the topography of pharyngeal musculature in two stroke patients, one with and one without dysphagia. Our results demonstrate that swallowing musculature is discretely and somatotopically represented on the motor and premotor cortex of both hemispheres but displays interhemispheric asymmetry, independent of handedness. Following stroke, dysphagia appeared to be associated with smaller pharyngeal representation on the intact hemisphere, which increases in size with recovery of swallowing.	UNIV MANCHESTER, HOPE HOSP, DEPT GASTROENTEROL, MANCHESTER M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT NEURORADIOL, MANCHESTER M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT GERIATR MED, MANCHESTER M6 8HD, LANCS, ENGLAND; INST NEUROL, MRC, HUMAN MOVEMENT & BALANCE UNIT, LONDON WC1N 3BG, ENGLAND; ASTON UNIV, DEPT VIS SCI, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND	University of Manchester; University of Manchester; University of Manchester; University of London; University College London; Aston University			Aziz, Qasim/AAC-4730-2020; Hamdy, Shaheen/O-5039-2014; Singh, Krish/D-1066-2009	Hamdy, Shaheen/0000-0001-9640-7427; Aziz, Qasim/0000-0002-2718-2065; Singh, Krishna/0000-0002-3094-2475; Rothwell, John/0000-0003-1367-6467				ALBERTS M J, 1992, Dysphagia, V7, P170, DOI 10.1007/BF02493452; AZIZ Q, 1995, GASTROENTEROLOGY, V109, P1437, DOI 10.1016/0016-5085(95)90628-2; AZIZ Q, 1994, AM J PHYSIOL-GASTR L, V267, pG827, DOI 10.1152/ajpgi.1994.267.5.G827; BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BARKER AT, 1985, LANCET, V1, P1106; BASTIAN HC, 1898, TREATISE APHASIA OTH, P87; BISHOP DVM, 1990, HANDEDNESS DEV DISOR, P27; BRADSHAW JL, 1983, HUMAN CEREBRAL ASYMM, P21; BRIDGERS SL, 1991, ELECTROEN CLIN NEURO, P170; DOTY RW, 1956, J NEUROPHYSIOL, V19, P44, DOI 10.1152/jn.1956.19.1.44; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; HAST MH, 1974, BRAIN RES, V73, P229, DOI 10.1016/0006-8993(74)91046-4; JALINOUS R, 1991, J CLIN NEUROPHYSIOL, V8, P10, DOI 10.1097/00004691-199101000-00004; Jean A., 1990, NEUROPHYSIOLOGY JAWS, P294; JOHNSON ER, 1992, ARCH PHYS MED REHAB, V73, P419; LEVY WJ, 1991, ELECTROEN CLIN NEURO, P51; Martin Ruth E., 1993, Dysphagia, V8, P195, DOI 10.1007/BF01354538; MCGUINNESS E, 1980, J COMP NEUROL, V193, P591, DOI 10.1002/cne.901930302; MEADOWS JC, 1973, J NEUROL NEUROSUR PS, V36, P853, DOI 10.1136/jnnp.36.5.853; *MED RES COUNC, 1976, AIDS EX PER NERV SYS, P6; MESULAM MM, 1982, J COMP NEUROL, V212, P38, DOI 10.1002/cne.902120104; MILLER AJ, 1977, J DENT RES, V56, P1154, DOI 10.1177/00220345770560100401; MUFSON EJ, 1981, NEUROSCIENCE, V6, P1231, DOI 10.1016/0306-4522(81)90184-6; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Robbins J, 1988, Dysphagia, V3, P11, DOI 10.1007/BF02406275; SATZ P, 1979, SCIENCE, V203, P1131, DOI 10.1126/science.424744; SHIPLEY MT, 1982, BRAIN RES BULL, V8, P139, DOI 10.1016/0361-9230(82)90040-5; SUMI T, 1969, BRAIN RES, V15, P107, DOI 10.1016/0006-8993(69)90313-8; WANG XB, 1994, J PHYS-CONDENS MAT, V6, P10185, DOI 10.1088/0953-8984/6/46/034; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	32	322	350	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1996	2	11					1217	1224		10.1038/nm1196-1217	http://dx.doi.org/10.1038/nm1196-1217			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VQ101	8898748				2022-12-27	WOS:A1996VQ10100036
J	Ehl, S; Aichele, P; Ramseier, H; Barchet, W; Hombach, J; Pircher, H; Hengartner, H; Zinkernagel, RM				Ehl, S; Aichele, P; Ramseier, H; Barchet, W; Hombach, J; Pircher, H; Hengartner, H; Zinkernagel, RM			Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection	NATURE MEDICINE			English	Article							BONE-MARROW; IN-VIVO; AUTOIMMUNE ENCEPHALOMYELITIS; TRANSPLANTATION TOLERANCE; VIRUS-INFECTION; TRANSGENIC MICE; INDUCTION; CHIMERISM; ACTIVATION; RECIPIENTS	We studied antigen-specific T-cell tolerization therapy using skin transplantation across a defined minor histocompatibility antigen difference. Specific tolerization protocols using short-lived peptide or long-lived spleen cells presenting the peptide as antigen prevented graft rejection without immunosuppression when started before or as long as 10 days after transplantation. Peptide-induced T-cell tolerance was transient, and antigen presentation by the graft was not sufficient to maintain tolerance. In contrast, transfer of antigen-expressing lymphoid cells induced long-lasting tolerance correlating with donor cell chimerism. These findings show that antigen-specific tolerization can induce graft acceptance even when begun after transplantation and that long-term graft survival depends on persistence of the tolerizing antigen.	Univ Zurich, Dept Pathol, Inst Expt Immunol, CH-8091 Zurich, Switzerland	University of Zurich	Ehl, S (corresponding author), Univ Zurich, Dept Pathol, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	stephanehl@aol.com; aichele@mpiib-berlin.mpg.de	Ehl, Stephan/AAM-6006-2020	Barchet, Winfried/0000-0002-6745-6606; Ehl, Stephan/0000-0002-9265-2721				Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Antoniou A, 1996, EUR J IMMUNOL, V26, P1094, DOI 10.1002/eji.1830260521; Bachmann MF, 1997, P NATL ACAD SCI USA, V94, P640, DOI 10.1073/pnas.94.2.640; BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; Ehl S, 1997, EUR J IMMUNOL, V27, P3404, DOI 10.1002/eji.1830271240; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GarciaMorales R, 1997, J CLIN INVEST, V99, P1118, DOI 10.1172/JCI119240; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; ILSTAD ST, 1984, NATURE, V307, P168; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LUBAROFF DM, 1973, J IMMUNOL, V111, P65; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MADSEN JC, 1988, NATURE, V332, P161, DOI 10.1038/332161a0; MAEDA T, 1993, J IMMUNOL, V150, P753; MAMALAKI C, 1993, INT IMMUNOL, V5, P1285, DOI 10.1093/intimm/5.10.1285; MILLER RG, 1976, J IMMUNOL, V117, P1913; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MORECKI S, 1987, J EXP MED, V165, P1468, DOI 10.1084/jem.165.6.1468; MOSHKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHASHI PS, 1993, J IMMUNOL, V150, P5185; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P120, DOI 10.1002/eji.1830040211; RAMMENSEE HG, 1984, J IMMUNOL, V133, P2390; Rao AS, 1997, TRANSPL P, V29, P1184, DOI 10.1016/S0041-1345(96)00536-2; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; ROMBALL CG, 1993, J EXP MED, V178, P1637, DOI 10.1084/jem.178.5.1637; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	45	50	51	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1015	1019		10.1038/2001	http://dx.doi.org/10.1038/2001			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734393				2022-12-27	WOS:000075804100033
J	Park', L; Raman, KG; Lee, KJ; Lu, Y; Ferran, LJ; Chow, WS; Stern, D; Schmidt, AM				Park', L; Raman, KG; Lee, KJ; Lu, Y; Ferran, LJ; Chow, WS; Stern, D; Schmidt, AM			Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts	NATURE MEDICINE			English	Article							GLYCOSYLATION END-PRODUCTS; APOE-DEFICIENT MICE; OXIDANT STRESS; CARDIOVASCULAR-DISEASE; LIPOPROTEIN OXIDATION; VASCULAR-DISEASE; BINDING-PROTEINS; APOLIPOPROTEIN-E; CELL-SURFACE; VESSEL WALL	Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St, New York, NY 10032 USA.		YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56881] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DAHLQUIST G, 1982, DIABETES CARE, V5, P399, DOI 10.2337/diacare.5.4.399; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; GOWN AM, 1986, AM J PATHOL, V125, P191; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Jarrett RJ, 1996, DIABETIC MED, V13, pS15; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MOREL DW, 1989, J LIPID RES, V30, P1827; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; YAN SD, 1994, J BIOL CHEM, V269, P9889; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	36	950	986	1	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1025	1031		10.1038/2012	http://dx.doi.org/10.1038/2012			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734395				2022-12-27	WOS:000075804100035
J	Lee, SJ; Liyanage, U; Bickel, PE; Xia, WM; Lansbury, PT; Kosik, KS				Lee, SJ; Liyanage, U; Bickel, PE; Xia, WM; Lansbury, PT; Kosik, KS			A detergent-insoluble membrane compartment contains A beta in vivo	NATURE MEDICINE			English	Article							DISEASE BRAIN; CAVEOLAE; DOMAINS; PROTEIN	Ordered assembly of the amyloid-beta protein (A beta) into amyloid fibrils is a critical step in Alzheimer's disease (AD). To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain(1). The sites of gamma-secretase cleavage are after residues 40 or 42 of A beta. Except in those rare cases of AD caused by a mutation, levels of secreted A beta are not elevated; thus, the secretory pathway may be unaffected, and factors other than the extracellular concentration of A beta may contribute to the aggregation properties of the peptide. A beta is also present in intracellular compartments(2-5). The two gamma-secretase cleavage products, A beta 42 and A beta 40, were found in different compartments: A beta 42 in the endoplasmic reticulum (ER)/intermediate compartment(3-5), and A beta 40 in the trans-Golgi network(2,4) (TGN). The cellular compartments that harbor A beta are target sites for therapeutic intervention. Here we report that in the brain, the principal compartment in which A beta resides is a detergent-insoluble glycolipid-enriched membrane domain (DIG). Also present in the DIC fractions are the endoproteolytic fragments of presenilin-1 (PS1) and APP. The presence of these proteins, which all contribute to the generation of A beta, indicates that the DIG fraction is probably where the intramembranous cleavage of APP occurs.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kosik, KS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, 77 Ave Louis Pasteur,HIM, Boston, MA 02115 USA.	lansbury@cnd.bwh.harvard.edu; Kosik@cnd.bwh.harvard.edu	Bickel, Perry/Q-9185-2019; xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295; Lee, Seung-Jae/0000-0002-5155-5335	NATIONAL INSTITUTE ON AGING [R43AG006501, R01AG008470] Funding Source: NIH RePORTER; NIA NIH HHS [AG08470, AG06501] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jones DH, 1997, BIOCHEMISTRY-US, V36, P12616, DOI 10.1021/bi970547z; JTIENARI PJ, 1997, P NATL ACAD SCI USA, V94, P4125; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOO EH, 1994, J BIOL CHEM, V269, P17386; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; WU C, 1997, J BIOL CHEM, V272, P37554; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; YANAGISAWA K, 1995, NAT MED, V1, P998; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	35	362	369	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					730	734		10.1038/nm0698-730	http://dx.doi.org/10.1038/nm0698-730			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623986				2022-12-27	WOS:000074008300043
J	Reitter, JN; Means, RE; Desrosiers, RC				Reitter, JN; Means, RE; Desrosiers, RC			A role for carbohydrates in immune evasion in AIDS	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED GLYCANS; ENVELOPE GLYCOPROTEIN; PERSISTENT INFECTION; RHESUS-MONKEYS; V3 LOOP; GP120; NEUTRALIZATION; OLIGOSACCHARIDE; RESPONSES	Rhesus monkeys were infected with mutant forms of simian immunodeficiency virus lacking dual combinations of the 4th, 5th and 6th sites for N-linked glycosylation in the external envelope glycoprotein of the virus. When compared with sera from monkeys infected with the parental virus, sera from monkeys infected with the mutant viruses exhibited markedly increased antibody binding to specific peptides from this region and markedly increased neutralizing activity. These results demonstrate a role for N-linked glycosylation in limiting the neutralizing antibody response to SIV and in shielding the virus from immune recognition.	Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA	Harvard University	Desrosiers, RC (corresponding author), Harvard Univ, Sch Med, New England Reg Primate Res Ctr, 1 Pine Hill Dr,Box 9102, Southborough, MA 01772 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI 35365] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141; BENJOUAD A, 1994, FEBS LETT, V341, P244, DOI 10.1016/0014-5793(94)80465-6; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3099, DOI 10.1099/0022-1317-73-12-3099; Bolmstedt A, 1996, J ACQ IMMUN DEF SYND, V12, P213, DOI 10.1097/00042560-199607000-00001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; DOE B, 1994, EUR J IMMUNOL, V24, P2369, DOI 10.1002/eji.1830241017; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KOFF WC, 1994, SCIENCE, V266, P1335, DOI 10.1126/science.7973724; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Means RE, 1997, J VIROL, V71, P7895, DOI 10.1128/JVI.71.10.7895-7902.1997; Pantaleo G, 1996, SEMIN VIROL, V7, P131, DOI 10.1006/smvy.1996.0017; REITTER JN, IN PRESS J VIROL; Schonning K, 1996, J GEN VIROL, V77, P753, DOI 10.1099/0022-1317-77-4-753; Schonning K, 1996, VIROLOGY, V218, P134, DOI 10.1006/viro.1996.0173; WEI, 1995, NATURE, V373, P117; Wiley DC, 1984, BIOL MACROMOL, V1, P299; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996	28	496	518	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					679	684		10.1038/nm0698-679	http://dx.doi.org/10.1038/nm0698-679			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623976				2022-12-27	WOS:000074008300033
J	Kostrikis, LG; Huang, YX; Moore, JP; Wolinsky, SM; Zhang, LQ; Guo, Y; Deutsch, L; Phair, J; Neumann, AU; Ho, DD				Kostrikis, LG; Huang, YX; Moore, JP; Wolinsky, SM; Zhang, LQ; Guo, Y; Deutsch, L; Phair, J; Neumann, AU; Ho, DD			A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation	NATURE MEDICINE			English	Article							INFECTION; RESISTANCE; INDIVIDUALS; GENE	Viral and host factors influence the rate of HIV-1 disease progression(1). For HIV-1 to fuse, a CD4(+) cell must express a co-receptor that the virus can use(2,3). The chemokine receptors CCR5 and CXCR4 are used by R5 and X4 viruses, respectively(4). Most new infections involve transmission of R5 viruses, but variants can arise later that also use CXCR4 (R5-X4 or X4 viruses)2-6. This is associated with an increased rate of CD4(+) T-cell loss and poor prognosis(2-6). The ability of host cells to support HIV-1 entry also influences progression. The absence of CCR5 in approximately 1% of the Caucasian population, due to homozygosity for a 32-nucleotide deletion in the coding region (Delta 32-CCR5 allele), very strongly protects against HIV-1 transmission(7-10). Heterozygosity for the Delta 32-CCR5 allele delays progression typically by 2 years(9,10). A recent study showed that a conservative substitution (V641) in the coding region of CCR2 also has a significant impact on disease progression, but not on HIV-1 transmission(11). This was unexpected, since CCR2 is rarely used as a co-receptor in vitro(2,3) and the V641 change is in a transmembrane region(11). Because a subsequent study did not confirm this effect on progression to disease(12): we analyzed CCR2-V641 using subjects in the Chicago MACS. We show that CCR2-V641 is indeed protective against disease progression and go on to show that the CCR2-V641 allele is in complete linkage disequilibrium with a point mutation in the CCR5 regulatory region.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel	Rockefeller University; Northwestern University; Bar Ilan University	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Guo, Yong/ABF-9338-2020; Wolinsky, Steven/B-2893-2012; KOSTRIKIS, LEONDIOS G/A-5330-2016	KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Wolinsky, Steven/0000-0002-9625-6697	NIAID NIH HHS [AI45218, AI40387, AI35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KOSTRIKIS LG, IN PRESS SCIENCE; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TYAGI S, 1996, NAT BIOTECHNOL, V14, P471; WU L, 1997, J EXP MED, V185, P16381; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	21	339	362	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					350	353		10.1038/nm0398-350	http://dx.doi.org/10.1038/nm0398-350			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500612				2022-12-27	WOS:000073616200044
J	Olive, PL; Johnston, PJ; Banath, JP; Durand, RE				Olive, PL; Johnston, PJ; Banath, JP; Durand, RE			The comet assay: A new method to examine heterogeneity associated with solid tumors	NATURE MEDICINE			English	Article							GEL-ELECTROPHORESIS; INDIVIDUAL CELLS; DNA-DAMAGE; FRACTION		British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Olive, PL (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	olive@unixg.ubc.ca	Durand, Ralph/GQZ-4018-2022		NCI NIH HHS [CA-37879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buschfort C, 1997, CANCER RES, V57, P651; CHAPLIN DJ, 1985, BRIT J CANCER, V51, P569, DOI 10.1038/bjc.1985.79; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; HEPPNER GH, 1989, SEMIN ONCOL, V16, P91; MCKELVEYMARTIN VJ, 1993, MUTAT RES, V288, P47, DOI 10.1016/0027-5107(93)90207-V; Olive P. L., 1990, RADIAT RES, V122, P69; OLIVE PL, 1993, INT J RADIAT BIOL, V64, P349, DOI 10.1080/09553009314551531; Olive PL, 1997, CANCER RES, V57, P5528; OLIVE PL, 1992, CELL PROLIFERAT, V25, P447, DOI 10.1111/j.1365-2184.1992.tb01453.x; OLIVE PL, 1992, J NATL CANCER I, V84, P707, DOI 10.1093/jnci/84.9.707; OLIVE PL, 1995, EXP CELL RES, V221, P19, DOI 10.1006/excr.1995.1348; Olive PL, 1996, CANCER RES, V56, P4460; OLIVE PL, 1993, CANCER RES, V53, P733; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Santos SJ, 1997, EXP CELL RES, V232, P407, DOI 10.1006/excr.1997.3555; SINGH NP, 1994, INT J RADIAT BIOL, V66, P23, DOI 10.1080/09553009414550911; STRAUSS GHS, 1994, MUTAT RES, V304, P211, DOI 10.1016/0027-5107(94)90213-5	18	63	64	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					103	105		10.1038/nm0198-103	http://dx.doi.org/10.1038/nm0198-103			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427615				2022-12-27	WOS:000072249700043
J	Soldan, SS; Berti, R; Salem, N; Secchiero, P; Flamand, L; Calabresi, PA; Brennan, MB; Maloni, HW; McFarland, HF; Lin, HC; Patnaik, M; Jacobson, S				Soldan, SS; Berti, R; Salem, N; Secchiero, P; Flamand, L; Calabresi, PA; Brennan, MB; Maloni, HW; McFarland, HF; Lin, HC; Patnaik, M; Jacobson, S			Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA	NATURE MEDICINE			English	Article							HUMAN HERPESVIRUS-6; INFECTION; EXACERBATIONS; ANTIBODIES	Viruses have long been suggested to be involved in the etiology of multiple sclerosis (MS)(1). This suggestion is based on (1) epidemiological evidence of childhood exposure to infectious agents and increase in disease exacerbations with viral infection(1,2); (2) geographic association of disease susceptibility with evidence of MS clustering(3-4); (3) evidence that migration to and from high-risk areas influences the likelihood of developing MS (refs. 2, 5); (4) abnormal immune responses to a variety of viruses(6,7); and (5) analogy with animal models and other human diseases in which viruses can cause diseases with long incubation periods, a relapsing-remitting course, and demyelination(1,2). Many of these studies involve the demonstration of increased antibody titers to a particular virus, whereas some describe isolation of virus from MS material. However, no virus to date has been definitively associated with this disease. Recently, human herpesvirus 6 (HHV-6), a newly described beta-herpes virus that shares homology with cytomegalovirus (CMV)(8), has been reported to be present in active MS plaques(9). In order to extend these observations, we have demonstrated increased IgM serum antibody responses to HHV-6 early antigen (p41/38) in patients with relapsing-remitting MS (RRMS), compared with patients with chronic progressive MS (CPMS), patients with other neurologic disease (OND), patients with other autoimmune disease (OID), and normal controls. Given the ubiquitous nature of this virus and the challenging precedent of correlating antiviral antibodies with disease association(10), these antibody studies have been supported by the detection of HHV-6 DNA from samples of MS serum as a marker of active viral infection.	NINDS, Viral Immunol Sect, Bethesda, MD 20892 USA; Specialty Labs Inc, Santa Monica, CA 90404 USA; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University System of Maryland; University of Maryland Baltimore	Jacobson, S (corresponding author), NINDS, Viral Immunol Sect, Bldg 10,Room 5B-16,9000 Rockville Pike, Bethesda, MD 20892 USA.		secchiero, paola/G-9689-2015; Soldan, Samantha/AAS-3182-2020; Calabresi, Peter A./AAF-2288-2019	secchiero, paola/0000-0003-4101-7987; Soldan, Samantha/0000-0001-6263-519X; Flamand, Louis/0000-0001-5010-4586				ALTER M, 1966, ARCH NEUROL-CHICAGO, V15, P234, DOI 10.1001/archneur.1966.00470150012002; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; EFSTATHIOU S, 1988, LANCET, V1, P63; HAAHR S, 1997, LANCET, V349, P9056; JACOBSON S, 1985, J EXP MED, V162, P839, DOI 10.1084/jem.162.3.839; JOHNSON RT, 1994, ANN NEUROL, V36, pS54, DOI 10.1002/ana.410360715; KOIKE K, 1987, HEPATOLOGY, V7, P573, DOI 10.1002/hep.1840070326; KURTZKE JF, 1995, ACTA NEUROL SCAND, V91, P321, DOI 10.1111/j.1600-0404.1995.tb07015.x; LUPPI M, 1994, J INFECT DIS, V169, P943, DOI 10.1093/infdis/169.4.943; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; NAGASATO K, 1991, J NEUROIMMUNOL, V32, P105, DOI 10.1016/0165-5728(91)90002-O; NEIGHBOUR PA, 1981, NEUROLOGY, V31, P561, DOI 10.1212/WNL.31.5.561; PANITCH HS, 1994, ANN NEUROL, V36, pS25, DOI 10.1002/ana.410360709; PATNAIK M, 1995, J INFECT DIS, V172, P1364, DOI 10.1093/infdis/172.5.1364; PEARSON GR, 1987, J VIROL METHODS, V21, P97; SECCHIERO P, 1995, J INFECT DIS, V171, P273, DOI 10.1093/infdis/171.2.273; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIKAWA T, 1990, PEDIATR INFECT DIS J, V9, P589, DOI 10.1097/00006454-199008000-00013	20	354	358	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1394	1397		10.1038/nm1297-1394	http://dx.doi.org/10.1038/nm1297-1394			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396611				2022-12-27	WOS:000072249500037
J	Lynch, DH; Andreasen, A; Maraskovsky, E; Whitmore, J; Miller, RE; Schuh, JCL				Lynch, DH; Andreasen, A; Maraskovsky, E; Whitmore, J; Miller, RE; Schuh, JCL			Flt3 ligand induces tumor regression and antitumor immune responses in vivo	NATURE MEDICINE			English	Article							DENDRITIC CELLS	Daily treatment of mice with recombinant human Flt3 ligand (huFlt3L) results in a dramatic numerical increase in the number of dendritic cells (DCs) in vivo. Since DCs are pivotal in the induction of immune responses, we tested whether Flt3L treatment of mice challenged with a syngeneic methylcholanthrene (MCA)-induced fibrosarcoma would augment the generation of effective antitumor immune responses in vivo. Flt3L treatment not only induced complete tumor regression in a significant proportion of mice, but also decreased tumor growth rate in the remaining mice. A preliminary characterization of the cellular mechanisms involved suggests that Flt3L may be important in the treatment of cancer in situ through the generation of specific antitumor immune responses.	IMMUNEX RES & DEV CORP,DEPT BIOMETR,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOL IMMUNOL,SEATTLE,WA 98101		Lynch, DH (corresponding author), IMMUNEX RES & DEV CORP,DEPT IMMUNOBIOL,51 UNIV ST,SEATTLE,WA 98101, USA.			Schuh, JoAnn C. L./0000-0002-2399-8518				Brasel K, 1996, BLOOD, V88, P2004, DOI 10.1182/blood.V88.6.2004.bloodjournal8862004; BRASEL K, 1995, LEUKEMIA, V9, P1212; BRENT L, 1966, PROC R SOC SER B-BIO, V165, P413, DOI 10.1098/rspb.1966.0074; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; Liu B, 1996, J IMMUNOL, V156, P1117; LYMAN SD, 1995, INT J HEMATOL, V62, P63; LYNCH DH, 1991, EUR J IMMUNOL, V21, P1403, DOI 10.1002/eji.1830210612; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; MCKENNA HJ, 1996, BONE MARROW TRANSPL, P85; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THOMSON AW, 1995, STEM CELLS, V13, P622, DOI 10.1002/stem.5530130607; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	19	264	293	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					625	631		10.1038/nm0697-625	http://dx.doi.org/10.1038/nm0697-625			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176488				2022-12-27	WOS:A1997XB97400031
J	Moghaddam, MF; Grant, DF; Cheek, JM; Greene, JF; Williamson, KC; Hammock, BD				Moghaddam, MF; Grant, DF; Cheek, JM; Greene, JF; Williamson, KC; Hammock, BD			Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase	NATURE MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; BURN TOXIN; INDUCTION; INJURY; LIVER; RAT; 9,10-EPOXY-12-OCTADECENOATE; BIOSYNTHESIS; GLUTATHIONE; EXPRESSION	Leukotoxin is a linoleic acic oxide produced by leukocytes and has been associated with the multiple organ failure and adult respiratory distress syndrome seen in some severe burn patients. Leukotoxin has been reported to be toxic when injected into animals intravenously. Herein, we report that this lipid is not, directly cytotoxic in at least two in vitro systems. Using a baculovirus expression system we demonstrate that leukotoxin is only cytotoxic in the presence of epoxide hydrolases. In addition, it is the diol metabolite that proves toxic to pulmonary alveolar epithelial cells, suggesting a critical role for the diol in leukotoxin-associated respiratory disease, In vivo data also support the toxicity of leukotoxin diol. For the first time we demonstrate that soluble epoxide hydrolase can bioactivate epoxides to diols that are apparently cytotoxic. Thus leukotoxin should be regarded as a protoxin corresponding to the more toxic diol. This clearly has implications for designing new clinical interventions.	LAWRENCE LIVERMORE NATL LAB,DEPT ENTOMOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT VET ANAT PHYSIOL & CELL BIOL,DAVIS,CA 95616; DUPONT AGR PROD,EXPT STN,WILMINGTON,DE 19880; UNIV ARKANSAS MED SCI HOSP,DEPT PHARMACOL & TOXICOL,LITTLE ROCK,AR 72205	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; DuPont; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R01ES002710, R37ES002710] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02710, ES04699, ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; BORHAN B, 1993, TETRAHEDRON, V49, P2601, DOI 10.1016/S0040-4020(01)86339-0; CASALS C, 1990, BIOCHIM BIOPHYS ACTA, V1023, P290, DOI 10.1016/0005-2736(90)90425-N; CHEEK JM, 1994, TOXICOL APPL PHARM, V125, P59, DOI 10.1006/taap.1994.1049; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; FUKUSHIMA A, 1988, CARDIOVASC RES, V22, P213, DOI 10.1093/cvr/22.3.213; GIBSON GG, 1990, BIOCHEM SOC T, V18, P97, DOI 10.1042/bst0180097; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; Grant DF, 1996, BIOCHEM PHARMACOL, V51, P503, DOI 10.1016/0006-2952(95)02227-9; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HAMMOCK BD, 1983, TOXICOL APPL PHARM, V71, P254, DOI 10.1016/0041-008X(83)90342-3; HAMMOCK BD, IN PRESS COMPREHENSI, pCH18; HAYAKAWA M, 1990, BIOCHEM INT, V21, P573; HAYAKAWA M, 1986, BIOCHEM BIOPH RES CO, V137, P424, DOI 10.1016/0006-291X(86)91227-1; ISHIZAKI T, 1995, AM J PHYSIOL-LUNG C, V269, pL65, DOI 10.1152/ajplung.1995.269.1.L65; ISHIZAKI T, 1995, AM J PHYSIOL-LUNG C, V268, pL123, DOI 10.1152/ajplung.1995.268.1.L123; ISHIZAKI T, 1995, BIOCHEM BIOPH RES CO, V210, P133, DOI 10.1006/bbrc.1995.1637; Jerina D.M., 1977, ORIGINS HUMAN CANCER, P639; JIANING H, 1988, LUNG, V166, P327; KAUR S, 1985, DRUG METAB DISPOS, V13, P711; KOSAKA K, 1994, MOL CELL BIOCHEM, V139, P141, DOI 10.1007/BF01081737; Moghaddam MF, 1996, BBA-GEN SUBJECTS, V1290, P327, DOI 10.1016/0304-4165(96)00037-2; MULLIN C, 1980, ARCH BIOCHEM BIOPHYS, V216, P423; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; OZAWA T, 1986, BIOCHEM BIOPH RES CO, V134, P1071, DOI 10.1016/0006-291X(86)90360-8; OZAWA T, 1991, ADV PROSTAG THROMB L, V21, P569; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; SAKAI T, 1995, AM J PHYSIOL-LUNG C, V269, pL326, DOI 10.1152/ajplung.1995.269.3.L326; SEVANIAN A, 1979, LIPIDS, V14, P634, DOI 10.1007/BF02533449; TAYLOR AE, 1970, AM J PHYSIOL, V218, P1133, DOI 10.1152/ajplegacy.1970.218.4.1133; VOGELBINDEL U, 1982, EUR J BIOCHEM, V126, P425	32	240	252	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					562	566		10.1038/nm0597-562	http://dx.doi.org/10.1038/nm0597-562			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142128	Green Published			2022-12-27	WOS:A1997WX54300039
J	Deacon, T; Schumacher, J; Dinsmore, J; Thomas, C; Palmer, P; Kott, S; Edge, A; Penney, D; Kassissieh, S; Dempsey, P; Isacson, O				Deacon, T; Schumacher, J; Dinsmore, J; Thomas, C; Palmer, P; Kott, S; Edge, A; Penney, D; Kassissieh, S; Dempsey, P; Isacson, O			Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; MESENCEPHALIC TISSUE; XENOGRAFT REJECTION; RAT MODEL; XENOTRANSPLANTATION; NEURONS; GRAFTS	The movement disorder in Parkinson's disease results from the selective degeneration of a small group of dopaminergic neurons in the substantia nigra pars compacta region of the brain. A number of exploratory studies using human fetal tissue allografts have suggested that transplantation of dopaminergic neurons may become an effective treatment for patients with Parkinson's disease and the difficulty in obtaining human fetal tissue has generated interest in finding corresponding nonhuman donor cells. Here we report a post-mortem histological analysis of fetal pig neural cells that were placed unilaterally into the caudate-putamen brain region of a patient suffering from Parkinson's disease. Long-term (over seven months) graft survival was found and the presence of pig dopaminergic neurons and other pig neural and glial cells is documented. Pig neurons extended axons from the graft sites into the host brain. Furthermore, other graft derived cells were observed several millimeters from the implantation sites. Markers for human microglia and T-cells showed only low reactivity in direct proximity to the grafts. This is the first documentation of neural xenograft survival in the human brain and of appropriate growth of nonhuman dopaminergic neurons for a potential therapeutic response in Parkinson's disease.	HARVARD UNIV, SCH MED, MCLEAN HOSP, NEUROREGENERAT LAB, BELMONT, MA 02178 USA; LAHEY HITCHCOCK CLIN, BURLINGTON, MA 01805 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; DIACRIN INC, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; McLean Hospital; Lahey Hospital & Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Edge, Albert/Q-5448-2019	Isacson, Ole/0000-0001-8091-8302				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; BAILEY LL, 1985, JAMA-J AM MED ASSOC, V254, P3321, DOI 10.1001/jama.254.23.3321; BARTLETT PF, 1990, PROG BRAIN RES, V82, P153, DOI 10.1016/S0079-6123(08)62600-X; CLARKE DJ, 1988, EXP BRAIN RES, V73, P115, DOI 10.1007/BF00279666; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1988, PROG BRAIN RES, V78, P473; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; HAMMER C, 1992, TRANSPLANT P, V24, P2397; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; Honey C R, 1990, Neuroreport, V1, P247, DOI 10.1097/00001756-199011000-00019; HONEY CR, 1991, EXP BRAIN RES, V85, P149; HUFFAKER TK, 1989, EXP BRAIN RES, V77, P329, DOI 10.1007/BF00274990; Ildstad ST, 1996, LANCET, V347, P761, DOI 10.1016/S0140-6736(96)90112-9; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; ISACSON O, 1989, EXP BRAIN RES, V75, P213; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Mott J. L., 1996, Society for Neuroscience Abstracts, V22, P1492; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; PAKZABAN P, 1995, NEUROSCIENCE, V65, P983, DOI 10.1016/0306-4522(94)00626-G; PAKZABAN P, 1994, NEUROSCIENCE, V62, P989, DOI 10.1016/0306-4522(94)90338-7; PEDERSEN EB, 1995, EXP BRAIN RES, V106, P181; REDMOND DE, 1988, SCIENCE, V242, P768, DOI 10.1126/science.2903552; SACHS DH, 1990, HUM IMMUNOL, V28, P245, DOI 10.1016/0198-8859(90)90025-K; Sanberg PR, 1996, NAT BIOTECHNOL, V14, P1692, DOI 10.1038/nbt1296-1692; SLOAN DJ, 1991, TRENDS NEUROSCI, V14, P341, DOI 10.1016/0166-2236(91)90159-R; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; STEELE DJR, 1995, ANNU REV MED, V46, P345; STROMBERG I, 1989, J NEUROSCI, V9, P614; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0	33	351	370	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					350	353		10.1038/nm0397-350	http://dx.doi.org/10.1038/nm0397-350			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055867				2022-12-27	WOS:A1997WL30500041
J	Kidder, LH; Kalasinsky, VF; Luke, JL; Levin, IW; Lewis, EN				Kidder, LH; Kalasinsky, VF; Luke, JL; Levin, IW; Lewis, EN			Visualization of silicone gel in human breast tissue using new infrared imaging spectroscopy	NATURE MEDICINE			English	Article							IMPLANTS; MICROSPECTROSCOPY; SYMPTOMS; DISEASES; RISK	Between 1 and 2 million women in the United States have silicone breast implants. Complications include capsular contracture and calcification and possibly connective tissue diseases such as scleroderma and rheumatoid arthritis, a subject of some controversy(1-7). In order to accurately assess the role of silicone in any histopathologic change, it is necessary to confirm its presence and to identify other foreign materials in the capsular tissue. Although light microscopy is used to visualize regions of tissue containing foreign inclusions, their chemical identity can only be determined using analytical techniques such as infrared or Raman microscopy. However, these conventional microprobe techniques record spectra only at single points and require an a priori knowledge of the locations of the inclusion to be probed. To significantly extend the capabilities of both infrared spectroscopy and optical microscopy, we have developed a new infrared imaging system that completely integrates these two methods. In this manuscript we highlight the ability of the technique to screen rapidly and to determine accurately the presence, size and chemical composition of silicone gel inclusions in human breast tissue.	NIDDKD,CHEM PHYS LAB,NIH,BETHESDA,MD 20892; ARMED FORCES INST PATHOL,DEPT ENVIRONM & TOXICOL PATHOL,WASHINGTON,DC 20306	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Defense			lewis, neil/G-1274-2017	lewis, neil/0000-0002-3049-0667				BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; CENTENO JA, 1993, APPL SPECTROSC, V47, P341, DOI 10.1366/0003702934066613; DUGOWSON CE, 1992, ARHTRITIS RHEUM S, V35, P566; FRANK CJ, 1993, APPL SPECTROSC, V47, P387, DOI 10.1366/0003702934334958; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GABRIEL SE, 1993, ARTHRITIS RHEUM, V36, pS70; GOLDSTEIN SR, IN PRESS J MICROSC; HARDT NS, 1994, MODERN PATHOL, V7, P669; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HOCHBERG MC, 1993, ARTHRITIS RHEUM, V36, pS71; Levin I. W, 1983, ADV RAMAN INFRARED S, V11, P1; LEWIS EN, 1995, ANAL CHEM, V67, P3377, DOI 10.1021/ac00115a003; LEWIS EN, 1836, Patent No. 537703; Morris M.D., 1993, MICROSCOPIC SPECTROS; PARKER FS, 1983, APPLICATIONS INFRARE; PETERS W, 1995, ANN PLAS SURG, V34, P578, DOI 10.1097/00000637-199506000-00003; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; Schaeberle MD, 1996, ANAL CHEM, V68, P1829, DOI 10.1021/ac951245a	18	114	117	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					235	237		10.1038/nm0297-235	http://dx.doi.org/10.1038/nm0297-235			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018246				2022-12-27	WOS:A1997WF08800046
J	Greene, NDE; Copp, AJ				Greene, NDE; Copp, AJ			Inositol prevents folate-resistant neural tube defects in the mouse	NATURE MEDICINE			English	Article							CURLY-TAIL MOUSE; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; RETINOID BINDING-PROTEINS; CRABP-I; DIFFERENTIAL PATTERN; ACID RECEPTORS; DOUBLE-BLIND; MUTANT MICE; YOLK-SAC; EMBRYOS	Clinical trials demonstrate that up to 70% of neural tube defects (NTDs) can be prevented by folic acid supplementation in early pregnancy, whereas the remaining NTDs are resistant to folate. Here, we show that a second vitamin, myo-inositol, is capable of significantly reducing the incidence of spinal NTDs in curly tail mice, a genetic model of folate-resistant NTDs. Inositol increases flux through the inositol/lipid cycle, stimulating protein kinase C activity and upregulating expression of retinoic acid receptor beta, specifically in the caudal portion of the embryonic hindgut. This reduces the delay in closure of the posterior neuropore, the embryonic defect that is known to lead directly to spina bifida in curly tail embryos. Our findings reveal a molecular pathway of NTD prevention and suggest the possible efficacy of combined treatment with folate and inositol in overcoming the majority of human NTDs.	UNIV LONDON,INST CHILD HLTH,NEURAL DEV UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Greene, Nicholas D.E./0000-0002-4170-5248	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028882] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28882] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		BENJAMIN J, 1995, AM J PSYCHIAT, V152, P1084; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BROOK FA, 1991, DEVELOPMENT, V113, P671; CHEN WH, 1995, DEVELOPMENT, V121, P681; CHEN WH, 1994, DEV DYNAM, V199, P93, DOI 10.1002/aja.1001990203; COCKROFT DL, 1992, TERATOLOGY, V45, P223, DOI 10.1002/tera.1420450216; COCKROFT DL, 1988, TERATOLOGY, V38, P281, DOI 10.1002/tera.1420380312; Cockroft DL, 1990, POSTIMPLANTATION MAM, P15; COPP AJ, 1985, J EMBRYOL EXP MORPH, V88, P39; COPP AJ, 1988, DEVELOPMENT, V104, P297; COPP AJ, 1988, DEVELOPMENT, V104, P285; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; ESTIBEIRO JP, 1993, DEVELOPMENT, V119, P113; ESTIBEIRO JP, 1990, POSTIMPLANTATION MAM, P173; GRUNEBERG H, 1954, J GENET, V52, P52, DOI 10.1007/BF02981490; HUBER BE, 1983, CANCER RES, V43, P5552; KUCERA J, 1971, J REPROD MED, V7, P61; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; LEONARD L, 1995, DEV BIOL, V168, P514, DOI 10.1006/dbio.1995.1099; LETTS VA, 1995, GENOMICS, V29, P719, DOI 10.1006/geno.1995.9946; LEVINE J, 1995, AM J PSYCHIAT, V152, P792; LYN S, 1994, DEV DYNAM, V199, P280, DOI 10.1002/aja.1001990404; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Peeters MCE, 1996, ANAT EMBRYOL, V193, P123; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; PINTER E, 1986, AM J OBSTET GYNECOL, V155, P691, DOI 10.1016/S0002-9378(86)80001-1; REECE EA, 1993, CLIN PERINATOL, V20, P517, DOI 10.1016/S0095-5108(18)30381-6; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SELLER MJ, 1981, LIFE SCI, V29, P1607, DOI 10.1016/0024-3205(81)90061-8; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; VANSTRAATEN HWM, 1995, J NUTR, V125, P2733; WALD N, 1991, LANCET, V338, P131; WILKINSON D, 1992, IN SITU HYBRIDISATIO; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	40	172	177	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					60	66		10.1038/nm0197-60	http://dx.doi.org/10.1038/nm0197-60			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986742				2022-12-27	WOS:A1997WA73300038
J	Griffiths, M; Beaumont, N; Yao, SYM; Sundaram, M; Boumah, CE; Davies, A; Kwong, FYP; Coe, I; Cass, CE; Young, JD; Baldwin, SA				Griffiths, M; Beaumont, N; Yao, SYM; Sundaram, M; Boumah, CE; Davies, A; Kwong, FYP; Coe, I; Cass, CE; Young, JD; Baldwin, SA			Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs	NATURE MEDICINE			English	Article							FUNCTIONAL EXPRESSION; SPECIFICITY; SYSTEM; CELLS; GENE	In most mammalian cells nucleoside uptake occurs primarily via broad-specificity, es (e, equilibrative; s, sensitive to NBMPR inhibition) transporters that are potently inhibited by nitroben-zylthioinosine (NBMPR)(1). These transporters are essential for nucleotide synthesis by salvage pathways in hemopoietic and other cells that lack de novo pathways and are the route of cellular uptake for many cytotoxic nucleosides used in cancer and viral chemotherapy(1). They play an important role in adenosine-mediated regulation of many physiological processes, including neurotransmission and platelet aggregation, and are a target for coronary vasodilator drugs. We have previously reported the purification of the prototypic es transporter from human erythrocytes(2) and have shown that this glycoprotein of apparent M(r) 55,000 is immunologically related to nucleoside transporters from several other species and tissues, including human placenta(3,4). Here we report the isolation of a human placental cDNA encoding a 456-residue glycoprotein with functional characteristics typical of an es-type transporter. It is predicted to possess 11 membrane-spanning regions and is homologous to several proteins of unknown function in yeast, nematodes, plants and mammals. Because of its central role in the uptake both of adenosine and of chemotherapeutic nucleosides, study of this protein should not only provide insights into the physiological roles of nucleoside transport but also open the way to improved therapies.	UNIV LEEDS, DEPT BIOCHEM & MOL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV ALBERTA, DEPT PHYSIOL, MEMBRANE TRANSPORT GRP, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT ONCOL, EDMONTON, AB T6G 2H7, CANADA	University of Leeds; University of Alberta; University of Alberta; University of Alberta								BARROS LF, 1995, PFLUG ARCH EUR J PHY, V429, P394, DOI 10.1007/BF00374155; BRYSON HM, 1993, DRUGS, V46, P872, DOI 10.2165/00003495-199346050-00007; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; HANSEN SEW, 1987, EUR J BIOCHEM, V168, P385, DOI 10.1111/j.1432-1033.1987.tb13431.x; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; KAYE SB, 1994, J CLIN ONCOL, V12, P1527, DOI 10.1200/JCO.1994.12.8.1527; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OUELLETTE BFF, 1993, GENOME, V36, P32, DOI 10.1139/g93-005; ROSS SR, 1993, DRUGS, V45, P737, DOI 10.2165/00003495-199345050-00009; RUSTUM YM, 1992, PHARMACOL THERAPEUT, V56, P307, DOI 10.1016/0163-7258(92)90022-R; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895	20	341	356	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1997	3	1					89	93		10.1038/nm0197-89	http://dx.doi.org/10.1038/nm0197-89			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986748				2022-12-27	WOS:A1997WA73300044
J	Navaratnam, DS; Su, HS; Scott, SP; Oberholtzer, JC				Navaratnam, DS; Su, HS; Scott, SP; Oberholtzer, JC			Proliferation in the auditory receptor epithelium mediated by a cyclic AMP-dependent signaling pathway	NATURE MEDICINE			English	Article							HAIR-CELL REGENERATION; AVIAN INNER-EAR; ACOUSTIC TRAUMA; CHICK COCHLEA; IDENTIFICATION; OTOTOXICITY; PATTERNS; CULTURES; PAPILLA	Loss of receptor hair cells in the cochlea accounts for a significant proportion of hearing impairment in the population(1). Hair cells can be lost as a consequence of viral or bacterial insult, aging, and damage from intense sound or aminoglycoside antibiotics. The generation of replacement hair cells following damage by sound or drugs has been clearly demonstrated in birds(2-4); the chick is the best-studied model for auditory hair cell regeneration(5). New hair cells arise as progeny from an otherwise nondividing supporting cell population proliferate by the damage(6-12) Functional hearing accompanies this cellular recovery process(13,14), The signals and pathways responsible for regenerative proliferation are unknown. Here we show that proliferation is induced in the undamaged receptor epithelium by agents that increase cyclic AMP levels, and that following this stimulation hair cells become labeled with proliferation markers. This remarkable proliferative response is blocked by inhibitors of the cAMP-regulated protein kinase A (PKA). In addition we show that the proliferative response induced by in vitro gentamicin damage is also significantly blocked by PKA inhibitors. These observations are the first to identify a signaling pathway that plays a role in regenerative proliferation in the auditory receptor epithelium.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV NEUROPATHOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Scott, Sean-Patrick/0000-0002-8480-1547	NIDCD NIH HHS [K08 DC 00069, R01 DC 02755] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069, R01DC002755] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARTOLAMI S, 1991, J COMP NEUROL, V314, P777, DOI 10.1002/cne.903140410; BHAVE SA, 1995, J NEUROSCI, V15, P4618; CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; COTANCHE DA, 1994, ANAT EMBRYOL, V189, P1; DARTT DA, 1984, J PHYSIOL-LONDON, V352, P375, DOI 10.1113/jphysiol.1984.sp015297; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FORGE A, 1993, J NEUROCYTOL, V22, P854, DOI 10.1007/BF01186357; GIROD DA, 1989, HEARING RES, V42, P175, DOI 10.1016/0378-5955(89)90143-3; HASHINO E, 1992, HEARING RES, V59, P46, DOI 10.1016/0378-5955(92)90101-R; HASHINO E, 1993, J CELL SCI, V105, P23; HENTRICH F, 1985, N-S ARCH PHARMACOL, V330, P245, DOI 10.1007/BF00572440; JORGENSEN JM, 1988, NATURWISSENSCHAFTEN, V75, P319, DOI 10.1007/BF00367330; LAMBERT PR, 1994, LARYNGOSCOPE, V104, P701; LIPPE WR, 1991, HEARING RES, V56, P203, DOI 10.1016/0378-5955(91)90171-5; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MCFADDEN EA, 1989, HEARING RES, V41, P205, DOI 10.1016/0378-5955(89)90012-9; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; OESTERLE EC, 1993, HEARING RES, V70, P85, DOI 10.1016/0378-5955(93)90054-5; RAPHAEL Y, 1992, J NEUROCYTOL, V21, P663, DOI 10.1007/BF01191727; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; STONE JS, 1994, J COMP NEUROL, V341, P50, DOI 10.1002/cne.903410106; TUCCI DL, 1990, OTOLARYNG HEAD NECK, V103, P443, DOI 10.1177/019459989010300317; YAMASHITA H, 1995, P NATL ACAD SCI USA, V92, P3152, DOI 10.1073/pnas.92.8.3152	25	46	49	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1996	2	10					1136	1139		10.1038/nm1096-1136	http://dx.doi.org/10.1038/nm1096-1136			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837614				2022-12-27	WOS:A1996VK99500036
J	Lee, JK; Zaidi, SHE; Liu, P; Dawood, F; Cheah, AYL; Wen, WH; Saiki, Y; Rabinovitch, M				Lee, JK; Zaidi, SHE; Liu, P; Dawood, F; Cheah, AYL; Wen, WH; Saiki, Y; Rabinovitch, M			A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis	NATURE MEDICINE			English	Article							TRIFLUOROMETHYL KETONE INHIBITORS; ENCEPHALOMYOCARDITIS VIRUS; COXSACKIEVIRUS-B3 MYOCARDITIS; DILATED CARDIOMYOPATHY; VIRAL MYOCARDITIS; B3-INDUCED MYOCARDITIS; PROTEOLYTIC ACTIVITY; NEUTROPHIL ELASTASE; LEUKOCYTE ELASTASE; HUMAN-MONOCYTES	In viral myocarditis, inflammation and destruction of cardiac: myocytes leads to fibrosis, causing progressive impairment in cardiac function. Here we show the etiologic importance of serine elastase activity in the pathophysiology of acute viral myocarditis and the therapeutic efficacy of an elastase inhibitor. In DBA/2 mice inoculated with the encephalomyocarditis virus, a more than 150% increase in myocardial serine elastase activity is observed. This is suppressed by a selective serine elastase inhibitor, ZD0892, which is biologically effective after oral administration. Mice treated with this compound had little evidence of microvascular constriction and obstruction associated with myocarditis-induced ischemia reperfusion injury, much less inflammation and necrosis, only mild fibrosis and myocardial collagen deposition, and normal ventricular function, compared with the infected nontreated group.	Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Med, Res Inst,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto Hosp, Dept Med, Div Cardiol,Ctr Cardiovasc Res, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rabinovitch, M (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; CONSTANZONORDIN MR, 1985, J AM COLL CARDIOL, V6, P1078; Cowan B, 1996, J CLIN INVEST, V97, P2452, DOI 10.1172/JCI118692; Crinnion J N, 1994, Cardiovasc Surg, V2, P749; DINERMAN JL, 1990, J AM COLL CARDIOL, V15, P1559, DOI 10.1016/0735-1097(90)92826-N; DONG R, 1992, J CLIN INVEST, V90, P2022, DOI 10.1172/JCI116082; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; FALLON JT, 1987, CONT ISSUES CARDIOVA, V18, P155; FRIZELLE S, 1992, AM J PATHOL, V141, P203; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; Hauck M, 1995, BIOCHEM MOL BIOL INT, V37, P45; Hirasawa K, 1996, J GEN VIROL, V77, P737, DOI 10.1099/0022-1317-77-4-737; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; KEELEY FW, 1984, EXP EYE RES, V39, P533, DOI 10.1016/0014-4835(84)90053-8; KISHIMOTO C, 1990, CIRC RES, V67, P589, DOI 10.1161/01.RES.67.3.589; KISHIMOTO C, 1990, CIRCULATION, V82, P982, DOI 10.1161/01.CIR.82.3.982; KISHIMOTO C, 1989, CIRC RES, V65, P934, DOI 10.1161/01.RES.65.4.934; LANE JR, 1992, J EXP MED, V175, P1123, DOI 10.1084/jem.175.4.1123; LIEBERMAN EB, 1991, J AM COLL CARDIOL, V18, P1617, DOI 10.1016/0735-1097(91)90493-S; LIU P, 1993, CARDIOVASC PATHOL, V2, P247, DOI 10.1016/1054-8807(93)90031-V; MATSUMORI A, 1982, CIRCULATION, V66, P355, DOI 10.1161/01.CIR.66.2.355; MOLLA A, 1993, J VIROL, V67, P4688, DOI 10.1128/JVI.67.8.4688-4695.1993; MYERS ML, 1985, CIRCULATION, V72, P915, DOI 10.1161/01.CIR.72.4.915; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; NICOLINI FA, 1991, AM HEART J, V122, P1245, DOI 10.1016/0002-8703(91)90562-V; OHO S, 1994, AM J PATHOL, V145, P202; REZKALLA S, 1990, CIRCULATION, V81, P1039, DOI 10.1161/01.CIR.81.3.1039; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SEKO Y, 1991, CIRCULATION, V84, P788, DOI 10.1161/01.CIR.84.2.788; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SILVER MA, 1989, AM HEART J, V118, P173, DOI 10.1016/0002-8703(89)90089-6; TAKADA H, 1995, CIRCULATION, V92, P1604, DOI 10.1161/01.CIR.92.6.1604; TESH RB, 1978, AM J TROP MED HYG, V27, P144, DOI 10.4269/ajtmh.1978.27.144; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Tiefenbacher CP, 1997, PFLUG ARCH EUR J PHY, V433, P563, DOI 10.1007/s004240050315; TOMINAGA M, 1991, CIRCULATION, V83, P2021, DOI 10.1161/01.CIR.83.6.2021; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; Veale CA, 1997, J MED CHEM, V40, P3173, DOI 10.1021/jm970250z; YAMADA T, 1994, CIRCULATION, V89, P846, DOI 10.1161/01.CIR.89.2.846; YAMADA T, 1992, JPN CIRC J, V56, P1138, DOI 10.1253/jcj.56.1138; ZIMMERMAN BJ, 1990, AM J PHYSIOL, V259, pH390, DOI 10.1152/ajpheart.1990.259.2.H390	44	56	58	4	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1383	1391		10.1038/3973	http://dx.doi.org/10.1038/3973			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846575				2022-12-27	WOS:000077336900033
J	Brown, MP; Topham, DJ; Sangster, MY; Zhao, JF; Flynn, KJ; Surman, SL; Woodland, DL; Doherty, PC; Farr, AG; Pattengale, PK; Brenner, MK				Brown, MP; Topham, DJ; Sangster, MY; Zhao, JF; Flynn, KJ; Surman, SL; Woodland, DL; Doherty, PC; Farr, AG; Pattengale, PK; Brenner, MK			Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; T-CELLS; TRANSGENIC MICE; ANTIGEN RECEPTOR; VIRUS-INFECTION; SELECTION; EXPRESSION; ACTIVATION; LYMPHOCYTES; THYMOCYTES	Inherited deficiency of the CD40 ligand (X-linked hyper-IgM syndrome) is characterized by failure of immunoglobulin isotype switching and severe defects of cell-mediated immunity. To test the potential for gene transfer therapy to correct this disorder, we transduced murine bone marrow or thymic cells with a retroviral vector containing the cDNA for the murine CD40 ligand (CD40L) and injected them into CD40L(-/-) mice.; Even low-level, constitutive expression of the transgene stimulated humoral and cellular immune functions in these mice. With extended follow-up, however, 12 of 19 treated mice developed T-lymphoproliferative disorders, ranging from polyclonal increases of lymphoblasts to overt monoclonal T-lymphoblastic lymphomas that involved multiple organs. Our findings show that constitutive (rather than tightly regulated), low-level expression of CD40L can produce abnormal proliferative responses in developing T lymphocytes, apparently through aberrant interaction between CD40L(+) and TCR alpha beta(+)CD40(+) thymocytes. Current methods of gene therapy may prove inappropriate for disorders involving highly regulated genes in essential positions in proliferative cascades.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; St Jude Childrens Res Hosp, Cell & Gene Therapy Program, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA	Baylor College of Medicine; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Children's Hospital Los Angeles	Brenner, MK (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 6621 Fannin St,MC3-3320, Houston, TX 77030 USA.		Brenner, Malcolm/Y-2509-2019; Doherty, Peter Charles/C-4185-2013; Brown, Michael/C-2081-2014	Doherty, Peter Charles/0000-0002-5028-3489; Brown, Michael/0000-0002-5796-1932; Sangster, Mark/0000-0002-1599-5894	NATIONAL CANCER INSTITUTE [R01CA078792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029579, R21AI037597, R01AI037597, R01AI029579] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78792] Funding Source: Medline; NIAID NIH HHS [AI-29579, AI-37597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN W, 1990, J IMMUNOL, V144, P3980; Anderson WF, 1998, NATURE, V392, P25; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Clegg CH, 1997, INT IMMUNOL, V9, P1111, DOI 10.1093/intimm/9.8.1111; COLE RA, 1975, LANCET, V1, P767; DANIELS CA, 1980, AM J PATHOL, V100, P663; Dunn RJ, 1997, J HISTOCHEM CYTOCHEM, V45, P129, DOI 10.1177/002215549704500116; EINERHAND MPW, 1993, BLOOD, V81, P254; EZINE S, 1993, INT IMMUNOL, V5, P89, DOI 10.1093/intimm/5.1.89; FANSLOW WC, 1994, J IMMUNOL, V152, P4262; FARINA SF, 1995, BLOOD, V86, P4124, DOI 10.1182/blood.V86.11.4124.bloodjournal86114124; FILIPOVICH AH, 1997, NONHODGKINS LYMPHOMA, P459; Flynn K, 1996, IMMUNOL CELL BIOL, V74, P413, DOI 10.1038/icb.1996.71; FOY TM, 1995, J EXP MED, V182, P1377, DOI 10.1084/jem.182.5.1377; FULEIHAN RL, 1997, IMMUNOLOGIST, V5, P133; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Grewal IS, 1997, IMMUNOL RES, V16, P59, DOI 10.1007/BF02786323; Grossmann ME, 1997, HUM GENE THER, V8, P1935, DOI 10.1089/hum.1997.8.16-1935; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Harlow E., 1988, ANTIBODIES LAB MANUA, P99; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HOAG WG, 1963, ANN NY ACAD SCI, V108, P805, DOI 10.1111/j.1749-6632.1963.tb13421.x; HOLLENBAUGH D, 1994, IMMUNOL REV, V138, P23, DOI 10.1111/j.1600-065X.1994.tb00845.x; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Kohn DB, 1996, BONE MARROW TRANSPL, V18, pS55; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; MILLER G, 1990, VIROLOGY, P563; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; Qazilbash M H, 1995, J Hematother, V4, P91, DOI 10.1089/scd.1.1995.4.91; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; SANGSTER M, 1995, VIROLOGY, V212, P13, DOI 10.1006/viro.1995.1448; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Strzadala L, 1997, INT IMMUNOL, V9, P127, DOI 10.1093/intimm/9.1.127; Tokoro Y, 1996, EUR J IMMUNOL, V26, P1012, DOI 10.1002/eji.1830260509; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; Zhou T, 1997, J CLIN IMMUNOL, V17, P74, DOI 10.1023/A:1027392613714; ZHOU T, 1993, J IMMUNOL, V150, P3651	52	102	105	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1253	1260		10.1038/3233	http://dx.doi.org/10.1038/3233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809548				2022-12-27	WOS:000076731000033
J	Hislop, AD; Good, MF; Mateo, L; Gardner, J; Gatei, MH; Daniel, RCW; Meyers, BV; Lavin, MF; Suhrbier, A				Hislop, AD; Good, MF; Mateo, L; Gardner, J; Gatei, MH; Daniel, RCW; Meyers, BV; Lavin, MF; Suhrbier, A			Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge	NATURE MEDICINE			English	Article							VIRUS; CELLS; INFECTION; MACAQUES; CD8(+); SHEEP	The development of prophylactic vaccines against retroviral diseases has been impeded by the lack of obvious immune correlates for protection(1,2). Cytotoxic T-lymphocyte (CTL)(3,4), CD4-lymphocyte(5), chemokine(6) and/or antibody responses(7) have all been associated with protection against HIV and AIDS; however, effective and safe vaccination strategies remain elusive(1,8). Here we show that vaccination with a minimal ovine CTL peptide epitope identified within gp51 of the retrovirus bovine leukemia virus (BLV), consistently induced peptide-specific CTLs. Only sheep whose CTLs were also capable of recognizing retrovirus-infected cells were fully protected when challenged with BLV. This retrovirus displays limited sequence variation(9); thus, in the relative absence of confounding CTL escape variants(10), virus-specific CTLs targeting a single epitope were able to prevent the establishment of a latent retroviral infection.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Univ Queensland, Sch Vet Sci & Anim Prod, St Lucia, Qld 4067, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Suhrbier, A (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Suhrbier, Andreas/0000-0001-8986-9025				ANDREW M, 1995, VET IMMUNOL IMMUNOP, V47, P311, DOI 10.1016/0165-2427(94)05410-T; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; BURTON DR, 1998, NAT MED, V54, P495; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COULSTON J, 1990, J GEN VIROL, V71, P1737, DOI 10.1099/0022-1317-71-8-1737; Dalgleish AG, 1998, CURR OPIN INFECT DIS, V11, P195, DOI 10.1097/00001432-199804000-00019; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Garzino-Demo A, 1998, J CLIN IMMUNOL, V18, P243, DOI 10.1023/A:1027329721892; GATEI MH, 1993, J VIROL, V67, P1803, DOI 10.1128/JVI.67.4.1803-1810.1993; Kent SJ, 1996, J VIROL, V70, P4941, DOI 10.1128/JVI.70.8.4941-4947.1996; Kettmann R., 1994, The retroviridae: Volume 3, P39; MAMMERICKX M, 1988, LEUKEMIA, V2, P103; McClure SJ, 1995, IMMUNOL CELL BIOL, V73, P552, DOI 10.1038/icb.1995.87; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SCALZO AA, 1995, J VIROL, V69, P1306, DOI 10.1128/JVI.69.2.1306-1309.1995; Thomson SA, 1998, J IMMUNOL, V160, P1717; YASUTOMI Y, 1995, J VIROL, V69, P2279, DOI 10.1128/JVI.69.4.2279-2284.1995	20	39	40	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1193	1196		10.1038/2690	http://dx.doi.org/10.1038/2690			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771756				2022-12-27	WOS:000076230100042
J	Tang, BW; Bottinger, EP; Jakowlew, SB; Bagnall, KM; Mariano, J; Anver, MR; Letterio, JJ; Wakefield, LM				Tang, BW; Bottinger, EP; Jakowlew, SB; Bagnall, KM; Mariano, J; Anver, MR; Letterio, JJ; Wakefield, LM			Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency	NATURE MEDICINE			English	Article							FACTOR-BETA; DISEASE PROGRESSION; TRANSGENIC MICE; SKIN TUMORS; IN-VIVO; GENE; GROWTH-FACTOR-BETA-1; TGF-BETA-1; INHIBITION; EXPRESSION	Components of the transforming growth factor-beta (TGF-beta) signal pathway function as classic tumor suppressors, but the role of the TGF-beta s themselves is less clear. Here we show that mice heterozygous for deletion of the TGF-beta 1 gene express only 10-30% of wild-type TGF-beta 1 protein levels. Although grossly normal, these mice have a subtly altered proliferative phenotype, with increased cell turnover in the liver and lung. Treatment of these mice with chemical carcinogens resulted in enhanced tumorigenesis when compared with wild-type littermates. However, tumors in the heterozygous mice did not lose the remaining wild-type TGF-beta 1 allele, indicating that the TCF-beta 1 ligand is a new form of tumor suppressor that shows true haploid insufficiency in its ability to protect against tumorigenesis.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Natl Canc Inst, Cell & Canc Biol Dept, Rockville, MD 20850 USA; Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, Pathol Histotechnol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Wakefield, LM (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, 41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.	wakefiel@dce41.nci.nih.gov	Wakefield, Lalage M/M-1963-2017	Wakefield, Lalage M/0000-0003-4124-5250				BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Bottinger EP, 1997, CANCER RES, V57, P5564; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Cambien F, 1996, HYPERTENSION, V28, P881, DOI 10.1161/01.HYP.28.5.881; CARR BI, 1986, CANCER RES, V46, P2330; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROCKER TT, 1970, CANCER RES, V30, P357; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DANIELPOUR D, 1995, J IMMUNOL METHODS, V180, P265, DOI 10.1016/0022-1759(94)00322-N; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DIWAN BA, 1984, CANCER LETT, V23, P223, DOI 10.1016/0304-3835(84)90157-5; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fajardo LF, 1996, LAB INVEST, V74, P600; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FIRTH CH, 1984, PATHOLOGY TUMORS LAB, V2, P223; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glick AB, 1996, CANCER RES, V56, P3645; GORSCH SM, 1992, CANCER RES, V52, P6949; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Iavarone A, 1997, NATURE, V387, P417; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jakowlew SB, 1998, MOL CARCINOGEN, V22, P46, DOI 10.1002/(SICI)1098-2744(199805)22:1<46::AID-MC6>3.0.CO;2-J; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756-3282(96)00363-8; MARKOWITZ S, 1995, SCIENCE, V268, P336; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RAVITZMJ, 1997, ADV CANC RES, V71, P65; Rehm S, 1994, IARC Sci Publ, P325; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tashiro H, 1997, CORONARY ARTERY DIS, V8, P143, DOI 10.1097/00019501-199703000-00004; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	45	272	284	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					802	807		10.1038/nm0798-802	http://dx.doi.org/10.1038/nm0798-802			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662371				2022-12-27	WOS:000074543900034
J	Hilleman, MR				Hilleman, MR			Six decades of vaccine development - a personal history	NATURE MEDICINE			English	Review							HEPATITIS-A VACCINE; PNEUMOCOCCAL POLYSACCHARIDE VACCINES; VIRUS-VACCINE; ATTENUATED HEPATITIS; CONJUGATE VACCINE; HEALTHY-CHILDREN; B POLYSACCHARIDE; SURFACE-ANTIGEN; HEPATOMA-CELLS; LIVE		Merck Res Labs, Merck Inst Therapeut Res, W Point, PA 19486 USA	Merck & Company	Hilleman, MR (corresponding author), Merck Res Labs, Merck Inst Therapeut Res, W Point, PA 19486 USA.							Austrian R, 1976, Trans Assoc Am Physicians, V89, P184; AUSTRIAN R, 1981, REV INFECT DIS, V3, P183; BUTEL JS, 1994, ENCY VIROLOGY, V3, P1322; BUYNAK EB, 1976, JAMA-J AM MED ASSOC, V235, P2832, DOI 10.1001/jama.235.26.2832; BUYNAK EB, 1966, P SOC EXP BIOL MED, V123, P768, DOI 10.3181/00379727-123-31599; BUYNAK EB, 1978, P SOC EXP BIOL MED, V157, P636; BUYNAK EB, 1969, AM J DIS CHILD, V118, P347, DOI 10.1001/archpedi.1969.02100040349033; BUYNAK EB, 1968, J AMER MED ASSOC, V204, P195, DOI 10.1001/jama.204.3.195; CHARNEY J, 1961, JAMA-J AM MED ASSOC, V177, P591, DOI 10.1001/jama.1961.03040350001001; DASCOMB HE, 1956, AM J MED, V21, P161, DOI 10.1016/0002-9343(56)90049-3; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; ENDERS JF, 1949, SCIENCE, V109, P85, DOI 10.1126/science.109.2822.85; ENDERS JF, 1960, NEW ENGL J MED, V263, P153, DOI 10.1056/NEJM196007282630401; ENDERS JF, 1956, SCIENCE, V124, P119, DOI 10.1126/science.124.3212.119; FEDSON DS, 1988, VACCINES, P271; GIARDI AJ, 1963, P SOC EXP BIOL MED, V112, P662; GIRARDI AJ, 1962, P SOC EXP BIOL MED, V109, P649, DOI 10.3181/00379727-109-27298; GOLDNER H, 1964, P SOC EXP BIOL MED, V117, P851; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; HAMPARIAN V. V., 1963, AMER REV RESP DIS, V88, P269; HAMPARIAN VV, 1964, P SOC EXP BIOL MED, V116, P976, DOI 10.3181/00379727-116-29426; HAMPARIAN VV, 1961, P SOC EXP BIOL MED, V103, P444; HAMPARIN VV, 1964, P SOC EXP BIOL MED, V117, P469, DOI 10.3181/00379727-117-29611; HATZIANDREU EJ, 1994, COST BENEFIT ANAL ME; HILL R M, 1987, Journal of Biological Physics, V15, P2, DOI 10.1007/BF01875279; Hilleman MR, 1955, AM J PUBLIC HEALTH N, V45, P203, DOI 10.2105/AJPH.45.2.203; Hilleman M R, 1975, Dev Biol Stand, V30, P418; HILLEMAN M R, 1958, Mil Med, V123, P23; Hilleman M R, 1975, Dev Biol Stand, V30, P383; HILLEMAN M R, 1953, Bull World Health Organ, V8, P613; Hilleman M. R., 1978, VIRAL HEPATITIS, P525; HILLEMAN MR, 1981, REV INFECT DIS, V3, pS31; HILLEMAN MR, 1955, AM J HYG, V61, P163, DOI 10.1093/oxfordjournals.aje.a119746; HILLEMAN MR, 1957, JAMA-J AM MED ASSOC, V163, P4, DOI 10.1001/jama.1957.02970360006002; HILLEMAN MR, 1958, ARCH INTERN MED, V102, P428, DOI 10.1001/archinte.1958.00030010428013; HILLEMAN MR, 1978, B WORLD HEALTH ORGAN, V56, P371; HILLEMAN MR, 1954, P SOC EXP BIOL MED, V85, P183, DOI 10.3181/00379727-85-20825; HILLEMAN MR, 1990, J MED VIROL, V31, P5, DOI 10.1002/jmv.1890310104; HILLEMAN MR, 1962, JAMA-J AM MED ASSOC, V180, P445, DOI 10.1001/jama.1962.03050190007002; HILLEMAN MR, 1963, AM REV RESPIR DIS, V87, P165; HILLEMAN MR, 1977, B WORLD HEALTH ORGAN, V55, P31; HILLEMAN MR, 1955, P SOC EXP BIOL MED, V90, P555; HILLEMAN MR, 1955, P SOC EXP BIOL MED, V89, P587, DOI 10.3181/00379727-89-21884; HILLEMAN MR, 1952, J IMMUNOL, V69, P343; HILLEMAN MR, 1951, PUBLIC HEALTH REP, V66, P1195, DOI 10.2307/4587855; HILLEMAN MR, 1948, J IMMUNOL, V59, P349; HILLEMAN MR, 1946, J IMMUNOL, V53, P201; Hilleman MR, 1996, VACCINIA, VACCINATION, VACCINOLOGY, P283; HILLEMAN MR, 1956, P SOC EXP BIOL MED, V92, P377, DOI 10.3181/00379727-92-22484; HILLEMAN MR, 1993, J HEPATOL, V18, pS5, DOI 10.1016/S0168-8278(05)80370-8; HILLEMAN MR, 1972, AVIAN DIS, V16, P191, DOI 10.2307/1588912; HILLEMAN MR, 1958, JAMA-J AM MED ASSOC, V166, P1134, DOI 10.1001/jama.1958.02990100022005; HILLEMAN MR, 1975, AM J MED SCI, V270, P401, DOI 10.1097/00000441-197509000-00025; Hilleman MR, 1996, VACCINIA, VACCINATION, VACCINOLOGY, P199; HILLEMAN MR, 1969, AM J DIS CHILD, V118, P166, DOI 10.1001/archpedi.1969.02100040168002; HILLEMAN MR, 1968, NEW ENGL J MED, V279, P300, DOI 10.1056/NEJM196808082790607; HILLEMAN MR, 1950, PUBLIC HEALTH REP, V65, P771, DOI 10.2307/4587371; HILLEMAN MR, 1962, AM J PUBLIC HEALTH N, V52, P44, DOI 10.2105/AJPH.52.Suppl_2.44; HILLEMAN MR, 1950, P SOC EXP BIOL MED, V75, P829, DOI 10.3181/00379727-75-18361; HILLEMAN MR, 1955, AM J HYG, V62, P29, DOI 10.1093/oxfordjournals.aje.a119764; HILLEMAN MR, 1967, NEW ENGL J MED, V276, P252, DOI 10.1056/NEJM196702022760501; HILLEMAN MR, 1945, J INFECT DIS, V76, P96, DOI 10.1093/infdis/76.2.96; HILLEMAN MR, 1968, J AMER MED ASSOC, V206, P587, DOI 10.1001/jama.206.3.587; HILLEMAN MR, IN PRESS COMBINATION; HILLEMAN MR, 1960, ACAD MED N J SPECIAL, V6, P1; HILLEMAN MR, 1982, VIRAL HEPATITIS, P385; HILLEMAN MR, 1979, J INFECTION, V1, P1; HILLEMAN MR, 1985, J HONG KONG MED ASS, V37, P75; HILLEMAN MR, 1979, ADV EXPER MED BIOL S, P47; HILLEMAN MR, 1996, MICROBE HUNTERS THEN, P221; HILLEMAN MR, 1967, ERGEBNISSE MIKROBIOL, V41, P1; HILLEMAN MR, 1954, ANNU REV MICROBIOL, V8, P3111; HILLEMAN MR, 1984, VIRAL HEPATITIS LIVE, P307; HILLEMAN MR, 1993, J GASTROEN HEPATOL, V8, pS21; HILLEMAN MR, 1979, VIRUS LIVER, P389; HILLEMAN MR, 1974, VIRUSES EVOLUTION CA, P549; HILLEMAN MR, 1979, HEPATITIS B VACCINES, P17; HILLEMAN MR, 1966, PAHO SCI PUBL, V147, P141; HILLEMAN MR, 1998, IN PRESS DEV BIOL ST; HILLEMAN MR, 1980, ROYAL SOC MED INT C, V27, P67; HILLEMAN MR, 1993, P S HIGHL VIR HEP HE, P86; HUGHES WF, 1963, AVIAN DIS, V7, P154, DOI 10.2307/1588044; HULL RN, 1968, VIROL MONOGR, P2; Jenner E, 1798, INQUIRY CAUSES EFFEC; KALABUS F, 1967, AM J EPIDEMIOL, V86, P93, DOI 10.1093/oxfordjournals.aje.a120736; KATZ SL, 1960, NEW ENGL J MED, V263, P159, DOI 10.1056/NEJM196007282630402; KETLER A, 1962, P SOC EXP BIOL MED, V110, P821, DOI 10.3181/00379727-110-27662; LEAGUS MB, 1967, AM REV RESPIR DIS, V95, P838; LEPOW ML, 1994, VACCINES, P503; LEVINE AJ, 1994, ADV CANCER RES, V65, P141, DOI 10.1016/S0065-230X(08)60067-6; LEWIS JA, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P94; MASCOLI CC, 1973, P SOC EXP BIOL MED, V142, P276, DOI 10.3181/00379727-142-37005; MASCOLI CC, 1966, P SOC EXP BIOL MED, V121, P1264, DOI 10.3181/00379727-121-31024; MASCOLI CC, 1967, P SOC EXP BIOL MED, V124, P845, DOI 10.3181/00379727-124-31868; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MCALEER WJ, 1983, J VIROL METHODS, V7, P263, DOI 10.1016/0166-0934(83)90078-2; MCALEER WJ, 1984, P SOC EXP BIOL MED, V175, P314, DOI 10.3181/00379727-175-41801; MELNICK JL, 1988, VACCINES, P115; MEYER HM, 1957, P SOC EXP BIOL MED, V95, P609, DOI 10.3181/00379727-95-23306; MIDTHUN K, 1991, J INFECT DIS, V163, P735, DOI 10.1093/infdis/163.4.735; MIDTHUN K, 1992, J INFECT DIS, V327, P453; NEFF BJ, 1981, P SOC EXP BIOL MED, V166, P339, DOI 10.3181/00379727-166-41071; OKAZAKI W, 1970, AVIAN DIS, V14, P413, DOI 10.2307/1588488; PARKMAN PD, 1962, P SOC EXP BIOL MED, V111, P225, DOI 10.3181/00379727-111-27750; PELON W, 1961, AM J HYG, V73, P36, DOI 10.1093/oxfordjournals.aje.a120164; PLOTKIN MSL, 1988, VACCINES, P1; PROVOST PJ, 1975, P SOC EXP BIOL MED, V148, P532; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; PROVOST PJ, 1982, P SOC EXP BIOL MED, V170, P8, DOI 10.3181/00379727-170-41387; PROVOST PJ, 1986, J MED VIROL, V19, P23, DOI 10.1002/jmv.1890190105; PROVOST PJ, 1975, AM J MED SCI, V270, P87, DOI 10.1097/00000441-197507000-00013; PROVOST PJ, 1973, P SOC EXP BIOL MED, V142, P1257, DOI 10.3181/00379727-142-37220; PROVOST PJ, 1986, J MED VIROL, V20, P165, DOI 10.1002/jmv.1890200208; PROVOST PJ, 1978, P SOC EXP BIOL MED, V159, P201, DOI 10.3181/00379727-159-40314; REILLY CM, 1961, NEW ENGL J MED, V265, P165, DOI 10.1056/NEJM196107272650403; Robbins F. C, 1988, VACCINES, P98; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; SABIN AB, 1943, JAMA-J AM MED ASSOC, V122, P478; SALK J, 1988, VACCINES, P158; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613; STALLONES RA, 1957, JAMA-J AM MED ASSOC, V163, P9, DOI 10.1001/jama.1957.02970360011003; STOKES J, 1961, NEW ENGL J MED, V265, P507, DOI 10.1056/NEJM196109142651101; STOKES J, 1962, AM J PUBLIC HEALTH N, V52, P29, DOI 10.2105/AJPH.52.Suppl_2.29; STOKES J, 1969, PEDIATRICS, V44, P217; STOKES J, 1967, PEDIATRICS, V39, P363; STOKES J, 1969, S SERIES IMMUNOBIOL, V11, P415; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; Sweet BH, 1960, 2 INT C LIV POL VACC, P79; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TAI JY, 1987, P SOC EXP BIOL MED, V184, P154, DOI 10.3181/00379727-184-42460; TAKAHASHI M, 1985, MICROBIOL SCI, V2, P249; TOUSIMIS AJ, 1957, VIROLOGY, V4, P499, DOI 10.1016/0042-6822(57)90082-X; TYRREL DAJ, 1961, BRIT MED J, V5223, P393; TYRRELL DAJ, 1963, SCIENCE, V141, P152, DOI 10.1126/science.141.3576.152; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; VELLA PP, 1969, AM REV RESPIR DIS, V99, P526; Webster R. G, 1994, ENCY VIROLOGY, V2, P709; WEIBEL RE, 1966, PEDIATRICS, V37, P913; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WEIBEL RE, 1967, NEW ENGL J MED, V276, P245, DOI 10.1056/NEJM196702022760501; WEIBEL RE, 1966, AM REV RESPIR DIS, V94, P362; WEIBEL RE, 1967, AM REV RESPIR DIS, V96, P724; WEIBEL RE, 1976, P SOC EXP BIOL MED, V153, P436, DOI 10.3181/00379727-153-39563; WEIBEL RE, 1969, AM J DIS CHILD, V118, P226, DOI 10.1001/archpedi.1969.02100040228012; WEIBEL RE, 1968, J AMER MED ASSOC, V205, P554; WELLER TH, 1962, P SOC EXP BIOL MED, V111, P215, DOI 10.3181/00379727-111-27749; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; *WHO, 1997, CVI STRAT PLAN MAG O; WHO, 1996, WORLD HLTH REP 1996; WOODHOUR AF, 1966, AM REV RESPIR DIS, V94, P350	152	43	47	4	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1998	4	5		S			507	514		10.1038/nm0598supp-507	http://dx.doi.org/10.1038/nm0598supp-507			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZL625	9585201	Bronze			2022-12-27	WOS:000073453500019
J	Miller, SD; Vanderlugt, CL; Begolka, WS; Pao, W; Yauch, RL; Neville, KL; KatzLevy, Y; Carrizosa, A; Kim, BS				Miller, SD; Vanderlugt, CL; Begolka, WS; Pao, W; Yauch, RL; Neville, KL; KatzLevy, Y; Carrizosa, A; Kim, BS			Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; (TMEV)-INDUCED DEMYELINATING DISEASE; T-CELL RESPONSES; IMMUNE TOLERANCE; MULTIPLE-SCLEROSIS; ENCEPHALOMYELITIS; SYSTEM; TMEV; INHIBITION; PATHOLOGY	Multiple sclerosis (MS) is a T cell-mediated autoimmune demyelinating disease(1), which may be initiated by a virus infection(2). Theiler's murine encephalomyelitis virus (TMEV), a natural mouse pathogen, is a picornavirus that induces a chronic, CD4(+) T cell-mediated demyelinating disease with a clinical course and histopathology similar to that of chronic progressive MS (ref. 3). Demyelination in TMEV-infected mice is initiated by a mononuclear inflammatory response mediated by virus-specific CD4(+) T cells targeting virus, which chronically persists in the CNS (ref. 4-6). We show that beginning 3-4 weeks after disease onset, T-cell responses to multiple myelin autoepitopes arise in an ordered progression and may play a pathologic role in chronic disease. Kinetic and functional studies show that T-cell responses to the immunodominant myelin proteolipid protein epitope (PLP139-151) did not arise because of cross-reactivity between TMEV and self epitopes (that is, molecular mimicry)(7,8), but because of de novo priming of self-reactive T cells to sequestered autoantigens released secondary to virus-specific T cell-mediated demyelination (that is, epitope spreading)(9,10). Epitope spreading is an important alternate mechanism to explain the etiology of virus-induced organ-specific autoimmune diseases.	NORTHWESTERN UNIV,SCH MED,INTERDEPT IMMUNOBIOL CTR,CHICAGO,IL 60611; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Northwestern University; Harvard University; Brigham & Women's Hospital	Miller, SD (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT IMMUNOL MICROBIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Kim, Byung/AAU-7450-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035814, R01NS028752, P01NS023349] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23349, NS 35814, NS 28752] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernard C C, 1991, Acta Neurol (Napoli), V13, P171; CLATCH RJ, 1986, J IMMUNOL, V136, P920; CLATCH RJ, 1990, VIROLOGY, V176, P244, DOI 10.1016/0042-6822(90)90249-Q; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; KARPUS WJ, 1995, J IMMUNOL, V155, P947; KENNEDY MK, 1990, J IMMUNOL, V144, P909; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; KYU B, 1992, CIRCULATION, V86, P522, DOI 10.1161/01.CIR.86.2.522; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; MILLER SD, 1987, J IMMUNOL, V138, P3776; MILLER SD, 1990, J NEUROIMMUNOL, V26, P9, DOI 10.1016/0165-5728(90)90115-4; Miller SD, 1990, SEMIN VIROL, V1, P263; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; Pope JG, 1996, J IMMUNOL, V156, P4050; Rose NR, 1996, CLIN IMMUNOL IMMUNOP, V80, pS92, DOI 10.1006/clin.1996.0146; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; Wekerle H, 1991, Acta Neurol (Napoli), V13, P197; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	20	424	429	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1133	1136		10.1038/nm1097-1133	http://dx.doi.org/10.1038/nm1097-1133			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334726				2022-12-27	WOS:A1997XZ28700040
J	Lundberg, JON; Lundberg, JM; Alving, K; Weitzberg, E				Lundberg, JON; Lundberg, JM; Alving, K; Weitzberg, E			Nitric oxide and inflammation: The answer is blowing in the wind	NATURE MEDICINE			English	Review							EXHALED AIR; ASTHMATIC-PATIENTS; SYNTHASE; INDUCTION; HUMANS		KAROLINSKA INST,DEPT ANESTHESIOL & INTENS CARE,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet	Lundberg, JON (corresponding author), KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,S-17177 STOCKHOLM,SWEDEN.		Alving, Kjell/M-4579-2014	Alving, Kjell/0000-0003-0784-0443; Lundberg, Jon/0000-0002-0174-5210				ALVING K, 1993, EUR RESPIR J, V6, P1368; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889, DOI 10.1164/ajrccm.151.6.7767536; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LENFANT C, 1995, GLOBAL STRATEGY ASTH, P1; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; Lundberg JON, 1996, UROLOGY, V48, P700, DOI 10.1016/S0090-4295(96)00423-2; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323, DOI 10.1136/adc.75.4.323; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; LUNDBERG JON, 1995, LANCET, V345, P449; LUNDBERG JON, 1994, LANCET, V344, P1673, DOI 10.1016/S0140-6736(94)90460-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; SMITH NKB, 1993, LANCET, V342, P338	19	56	60	0	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					30	31		10.1038/nm0197-30	http://dx.doi.org/10.1038/nm0197-30			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986736				2022-12-27	WOS:A1997WA73300032
J	Manolios, N; Collier, S; Taylor, J; Pollard, J; Harrison, LC; Bender, V				Manolios, N; Collier, S; Taylor, J; Pollard, J; Harrison, LC; Bender, V			T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease	NATURE MEDICINE			English	Article							ANTIBODY	This study describes a novel method of inhibiting T-cell function by the use of peptides rationally designed from the T-cell antigen receptor (TCR) alpha-chain transmembrane sequence involved with TCR receptor assembly. The most effective peptide (core peptide, CP) modulating in vitro and in vivo T-cell function contained nine amino acids two of which, lysine and arginine, were hydrophilic and separated by four hydrophobic amino acids. CP without chemical modification or conjugation was able to enter non-T and T cells. Conjugation of CP at the carboxyl terminus with palmitic acid resulted in a greater inhibition of cell interleukin-2 (IL-2) production in vitro than peptide alone. When examined for effects in vivo, CP reduced clinical signs of inflammation in three T cell-mediated disease models including adjuvant-induced arthritis, experimental allergic neuritis, and cyclophosphamide-induced diabetes in NOD/Lt(F) mice. This peptide or its analogues has potential as a therapeutic agent in human inflammatory and autoimmune disorders.	UNIV SYDNEY,NEUROPHYSIOL INST,SYDNEY,NSW 2006,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; CSIRO,DIV BIOMOL ENGN,SYDNEY,NSW 2113,AUSTRALIA	University of Sydney; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Manolios, N (corresponding author), ROYAL N SHORE HOSP,DEPT RHEUMATOL,SYDNEY,NSW 2065,AUSTRALIA.			Manolios, Nicholas/0000-0002-6525-7830; Taylor, Jude/0000-0003-2796-0768				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; HOLMDAHL R, 1992, CLIN EXP IMMUNOL, V88, P96; HONEYMAN MC, 1993, SPRINGER SEMIN IMMUN, V14, P253; KIKUTANI H, 1992, ADV IMMUNOL, V51, P285, DOI 10.1016/S0065-2776(08)60490-3; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; PEARSON CM, 1961, J EXP MED, V113, P485, DOI 10.1084/jem.113.3.485; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SPIES JM, 1995, J NEUROIMMUNOL, V57, P77, DOI 10.1016/0165-5728(94)00164-J; WHITEHOUSE MW, 1990, AGENTS ACTIONS, V31, P47, DOI 10.1007/BF02003221; WHITTAKER RG, 1993, PEPTIDE RES, V6, P125	14	89	100	1	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					84	88		10.1038/nm0197-84	http://dx.doi.org/10.1038/nm0197-84			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986747				2022-12-27	WOS:A1997WA73300043
J	Kane, C; Shepherd, RM; Squires, PE; Johnson, PRV; James, RFL; Milla, PJ; AynsleyGreen, A; Lindley, KJ; Dunne, MJ				Kane, C; Shepherd, RM; Squires, PE; Johnson, PRV; James, RFL; Milla, PJ; AynsleyGreen, A; Lindley, KJ; Dunne, MJ			Loss of functional K-ATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy	NATURE MEDICINE			English	Article							INSULIN-SECRETING CELLS; SULFONYLUREA RECEPTOR; CYSTIC-FIBROSIS; NESIDIOBLASTOSIS; MUTATIONS; FORM; GENE	Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a disorder of childhood associated with inappropriate hypersecretion of insulin by the pancreas. The pathogenesis of the condition has hitherto remained controversial. We show here that insulin-secreting cells from a homogeneous group of five infants with PHHI lack ATP-sensitive K+ channel (K-ATP) activity. As a consequence, PHHI beta-cells are spontaneously electrically active with high basal cytosolic Ca2+ concentrations due to Ca2+ influx. Our findings define the pathogenesis of this disease as a novel K+ channel disorder.	UNIV SHEFFIELD,DEPT BIOMED SCI,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT SURG,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Sheffield; University of Leicester; University of London; University College London				Squires, Paul/0000-0003-4547-6777	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AYNSLEYGREEN A, 1981, DEV MED CHILD NEUROL, V23, P372; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; BRANDT AM, 1993, COMPOS STRUCT, V25, P51, DOI 10.1016/0263-8223(93)90150-O; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Lebrun P, 1996, J PHARMACOL EXP THER, V277, P156; Lindley KJ, 1996, ARCH DIS CHILD, V74, P373, DOI 10.1136/adc.74.5.373; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; Morris AAM, 1996, ARCH DIS CHILD, V75, P115, DOI 10.1136/adc.75.2.115; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Sempoux C, 1995, DIABETES METAB, V21, P402; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SPITZ L, 1992, ARCH DIS CHILD, V67, P201, DOI 10.1136/adc.67.2.201; SQUIRES PE, 1994, PFLUG ARCH EUR J PHY, V427, P181, DOI 10.1007/BF00585959; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1995, PEDIATR RES, V37, pA100; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WOOLF DA, 1991, ARCH DIS CHILD, V66, P529, DOI 10.1136/adc.66.4.529	26	218	221	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1344	1347		10.1038/nm1296-1344	http://dx.doi.org/10.1038/nm1296-1344			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946833				2022-12-27	WOS:A1996VW51500040
J	Tian, JD; ClareSalzler, M; Herschenfeld, A; Middleton, B; Newman, D; Mueller, R; Arita, S; Evans, C; Atkinson, MA; Mullen, Y; Sarvetnick, N; Tobin, AJ; Lehmann, PV; Kaufman, DL				Tian, JD; ClareSalzler, M; Herschenfeld, A; Middleton, B; Newman, D; Mueller, R; Arita, S; Evans, C; Atkinson, MA; Mullen, Y; Sarvetnick, N; Tobin, AJ; Lehmann, PV; Kaufman, DL			Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice	NATURE MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; NOD MICE; IMMUNE-RESPONSE; T-CELLS; IMMUNOTHERAPY; PATHOGENESIS; IMMUNIZATION; TOLERANCE; INSULITIS; MELLITUS	In nonobese diabetic (NOD) mice, beta-cell reactive T-helper type 1 (Th1) responses develop spontaneously and gradually spread, creating a cascade of responses that ultimately destroys the beta-cells. The diversity of the autoreactive T-cell repertoire creates a major obstacle to the development of therapeutics. We show that even in the presence of established Th1 responses, it is possible to induce autoantigen-specific anti-inflammatory Th2 responses. Immune deviation of T-cell responses to the beta-cell autoantigen glutamate decarboxylase (GAD65), induced an active form of self-tolerance that was associated with an inhibition of disease progression in prediabetic mice and prolonged survival of syngeneic islet grafts in diabetic NOD mice. Thus, modulation of autoantigen-specific Th1/Th2 balances may provide a minimally invasive means of downregulating established pathogenic autoimmune responses.	UNIV CALIF LOS ANGELES, DEPT NEUROL & PHYSIOL SCI, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT PSYCHIAT & BEHAV SCI, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT SURG, LOS ANGELES, CA 90095 USA; UNIV FLORIDA, DEPT PATHOL, GAINESVILLE, FL 32609 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; CASE WESTERN RESERVE UNIV, DEPT PATHOL, CLEVELAND, OH 44106 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; Scripps Research Institute; Case Western Reserve University			Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; FAIRCHILD PJ, 1994, IMMUNOLOGY, V81, P487; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LACY PE, 1993, DIABETES REV, V1, P76; LEE DS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P157, DOI 10.1016/0167-4781(93)90056-J; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUIR A, 1995, J CLIN INVEST, V95, P628, DOI 10.1172/JCI117707; PALMER JP, 1993, DIABETES REV, V1, P104; PLEAU JM, 1995, CLIN IMMUNOL IMMUNOP, V76, P90, DOI 10.1006/clin.1995.1092; QIN HY, 1993, J IMMUNOL, V150, P2072; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Rossini A.A., 1993, DIABETES REV ALEX, V1, P43; SUTHERLAND DER, 1993, DIABETES REV, V1, P152; THAI AC, 1993, DIABETES REV, V1, P1; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TISCH R, 1994, P NATL ACAD SCI USA, V91, P437, DOI 10.1073/pnas.91.2.437; WICKER LS, 1986, DIABETES, V35, P855, DOI 10.2337/diabetes.35.8.855; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	29	221	230	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1348	1353		10.1038/nm1296-1348	http://dx.doi.org/10.1038/nm1296-1348			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946834				2022-12-27	WOS:A1996VW51500041
J	Conway, KA; Harper, JD; Lansbury, PT				Conway, KA; Harper, JD; Lansbury, PT			Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; LEWY BODIES; PROTEIN; SCRAPIE	Two mutations in the gene encoding alpha-synuclein have been linked to early-onset Parkinson's disease(1-3) (PD). alpha-Synuclein is a component of Lewy bodies, the fibrous cytoplasmic inclusions characteristic of nigral dopaminergic neurons in the PD brain(4). This connection between genetics and pathology suggests that the alpha-synuclein mutations may promote PD pathogenesis by accelerating Lewy body formation. To test this, we studied alpha-synuclein folding and aggregation in vitro, in the absence of other Lewy body-associated molecules. We demonstrate here that both mutant forms of alpha-synuclein (A53T and A30P) are, like wild-type alpha-synuclein(5) (WT), disordered in dilute solution. However, at higher concentrations, Lewy body-like fibrils and discrete spherical assemblies are formed; most rapidly by A53T. Thus, mutation-induced acceleration of alpha-synuclein fibril formation may contribute to the early onset of familial PD.	Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Lansbury, PT (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		Harper, James D/B-8701-2011	Harper, James/0000-0001-7895-8268				Baba M, 1998, AM J PATHOL, V152, P879; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; FORNO LS, 1993, NEURODEGENERATION, V2, P19; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	22	1208	1238	3	102	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1318	1320		10.1038/3311	http://dx.doi.org/10.1038/3311			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809558	Bronze			2022-12-27	WOS:000076731000043
J	Thomsen, L; Robinson, TL; Lee, JCF; Farraway, LA; Hughes, MJG; Andrews, DW; Huizinga, JD				Thomsen, L; Robinson, TL; Lee, JCF; Farraway, LA; Hughes, MJG; Andrews, DW; Huizinga, JD			Interstitial cells of Cajal generate a rhythmic pacemaker current	NATURE MEDICINE			English	Article							COLON SMOOTH-MUSCLE; ACTION-POTENTIALS; CANINE COLON; SMALL-INTESTINE; PROTOONCOGENE; FREQUENCY	Networks of interstitial cells of Cajal embedded in the musculature of the gastrointestinal tract are involved in the generation of electrical pacemaker activity for gastrointestinal motility(1,2). This pacemaker activity manifests itself as rhythmic slow waves in membrane potential, and controls the frequency and propagation characteristics of gut contractile activity(3-6). Mice that lack a functional Kit receptor fail to develop the network of interstitial cells of Cajal associated with Auerbach's plexus in the moose small intestine(7,8) and do not generate slow wave activity(9,10). These cells could provide an essential component of slow wave activity (for example, a biochemical trigger that would be transferred to smooth muscle cells), or provide an actual pacemaker current that could initiate slow waves. Here we provide direct evidence that a single cell, identified as an interstitial cell of Cajal by light microscopy, electron microscopy and expression of Kit mRNA, generates spontaneous contractions and a rhythmic inward current that is insensitive to L-type calcium channel blockers. Identification of the pacemaker of gut motility will aid in the elucidation of the pathophysiology of intestinal motor disorders, and provide a target cell for pharmacological treatment.	McMaster Univ, Dept Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Intestinal Dis Res Program, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Huizinga, JD (corresponding author), McMaster Univ, Dept Biomed Sci, Hamilton, ON L8N 3Z5, Canada.	huizinga@mcmaster.ca		Andrews, David/0000-0002-9266-7157				Der-Silaphet T, 1998, GASTROENTEROLOGY, V114, P724, DOI 10.1016/S0016-5085(98)70586-4; Faussone Pellegrini M S, 1977, Arch Ital Anat Embriol, V82, P157; GOKKEL E, 1992, ONCOGENE, V7, P1423; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P15, DOI 10.1113/jphysiol.1991.sp018779; Huizinga JD, 1997, TRENDS PHARMACOL SCI, V18, P393, DOI 10.1016/S0165-6147(97)90668-4; Huizinga JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/j.1469-7793.1998.843bv.x; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P31, DOI 10.1113/jphysiol.1991.sp018780; Kluppel M, 1998, DEV DYNAM, V211, P60; Komuro T, 1996, J AUTONOM NERV SYST, V61, P169, DOI 10.1016/S0165-1838(96)00078-1; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; Lecoin L, 1996, DEVELOPMENT, V122, P725; LEE HK, 1993, J PHYSIOL-LONDON, V460, P135, DOI 10.1113/jphysiol.1993.sp019463; LIU LWC, 1995, J PHARMACOL EXP THER, V275, P1058; Malysz J, 1995, CAN J PHYSIOL PHARM, V73, P1502, DOI 10.1139/y95-208; Malysz J, 1996, AM J PHYSIOL-GASTR L, V271, pG387, DOI 10.1152/ajpgi.1996.271.3.G387; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; THUNEBERG L, 1989, HDB PHYSL GASTROINTE, V1, P349; Tokutomi N, 1995, PFLUG ARCH EUR J PHY, V431, P169, DOI 10.1007/BF00410188; TOMITA T, 1981, SMOOTH MUSCLE ASSESS, P127; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; WARD SM, 1992, J PHYSIOL-LONDON, V455, P321, DOI 10.1113/jphysiol.1992.sp019304; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343	25	348	373	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					848	851		10.1038/nm0798-848	http://dx.doi.org/10.1038/nm0798-848			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662380				2022-12-27	WOS:000074543900043
J	Burnett, AL; Johns, DG; Kriegsfeld, LJ; Klein, SL; Calvin, DC; Demas, GE; Schramm, LP; Nelson, RJ; Snyder, SH; Poss, KD				Burnett, AL; Johns, DG; Kriegsfeld, LJ; Klein, SL; Calvin, DC; Demas, GE; Schramm, LP; Nelson, RJ; Snyder, SH; Poss, KD			Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE; PENILE ERECTION; RELAXATION; MEDIATOR	Nitric oxide (NO) is well established as a neurotransmitter in the central and peripheral nervous systems(1). More recently, another gas, carbon monoxide (CO) has also been implicated in neurotransmission. In the nervous system CO is formed by a subtype of heme oxygenase (HO) designated HO2 (ref. 2). HO2 is localized to discrete neuronal populations in the brain resembling localizations of soluble guanylyl cyclase, which is activated by CO (ref. 3). CO may also function in the peripheral autonomic nervous system, in conjunction with NO. The majority of ganglia in the myenteric plexus possess both HO2 and neuronal NO synthase (NOS)(4). Defects in myenteric plexus neurotransmission occur both in mice with targeted deletion of genes for HO2 and neuronal NOS (ref. 5). HO2 also occurs in other autonomic ganglia including the petrosal, superior cervical and nodose ganglia(4). Neuronal NOS is localized to neurons regulating male reproductive behavior, such as penile erection, and NOS inhibitors prevent erection(6). Because of the other parallels between NO and CO, we speculated that CO may play a role in male reproductive behavior. In the present study we describe HO2 localization in neuronal structures regulating copulatory reflexes. Reflex activity of the bulbospongiosus muscle, which mediates ejaculation and ejaculatory behavior, is markedly diminished in mice with targeted deletion of the gene for HO2 (HO2(-)).	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Coll Arts & Sci, Dept Psychol, Baltimore, MD 21218 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Massachusetts Institute of Technology (MIT)	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Demas, Gregory/Y-1783-2019	Demas, Gregory/0000-0003-3914-0900; Poss, Kenneth/0000-0002-6743-5709; Nelson, Randy/0000-0002-8194-4016	NICHD NIH HHS [HD-22201] Funding Source: Medline; NIDA NIH HHS [DA-00266, DA-00074] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Benson G. S., 1994, PHYSL REPROD, V1, P1489; Burnett AL, 1996, MOL MED, V2, P288, DOI 10.1007/BF03401627; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; GULBENKIAN S, 1987, J AUTONOM NERV SYST, V18, P235, DOI 10.1016/0165-1838(87)90122-6; JAFFREY SR, 1995, CELL DEV BIOL, V11, P417; JANICAK PG, 1994, PRINCIPLES PRACTICE; Kriegsfeld LJ, 1996, AM J PHYSIOL-REG I, V270, pR1013, DOI 10.1152/ajpregu.1996.270.5.R1013; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARSON L, 1994, PHARMACOL BIOCHEM BE, V47, P883, DOI 10.1016/0091-3057(94)90292-5; MCGILL TE, 1964, SCIENCE, V145, P514, DOI 10.1126/science.145.3631.514; MCKENNA KE, 1991, AM J PHYSIOL, V30, pR1276; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; SPECTOR IP, 1990, ARCH SEX BEHAV, V19, P389, DOI 10.1007/BF01541933; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795; ZAKHARY R, IN PRESS P NATL ACAD	20	94	97	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1998	4	1					84	87		10.1038/nm0198-084	http://dx.doi.org/10.1038/nm0198-084			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427611				2022-12-27	WOS:000072249700039
J	McKinney, RA; Debanne, D; Gahwiler, BH; Thompson, SM				McKinney, RA; Debanne, D; Gahwiler, BH; Thompson, SM			Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: Implications for the genesis of posttraumatic epilepsy	NATURE MEDICINE			English	Article							NERVE GROWTH-FACTOR; FIBER SYNAPTIC REORGANIZATION; SLICE CULTURES; REACTIVE SYNAPTOGENESIS; CELLULAR MECHANISMS; RAT HIPPOCAMPUS; DENTATE GYRUS; MESSENGER-RNA; TREATED RATS; ADULT-RATS	The delayed development of recurring seizures is a common consequence of traumatic head injury; the cause of such epilepsy is unknown. We demonstrate here that transection of the mature axons of CA3 pyramidal cells in hippocampal slice cultures leads to the formation by CA3 pyramidal cells of new axon collaterals that are immunoreactive with the growth-associated protein GAP-43. Individual CA3 cell axons had an elevated number of presynaptic boutons 14 days after the lesion, and dual intracellular recordings revealed an increased probability that any two CA3 pyramidal cells were connected by an excitatory synapse. Lesioned cultures were hyperexcitable and synaptic responses often displayed unusual prolonged polysynaptic components. We thus demonstrate that recurrent axon collaterals are newly sprouted by pyramidal cells as a consequence of axonal injury and suggest that this underlies the development of posttraumatic epilepsy.			McKinney, RA (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,CH-8029 ZURICH,SWITZERLAND.		Debanne, Dominique/O-4673-2016; Thompson, Scott M/K-8921-2015	Debanne, Dominique/0000-0001-8581-5695; 				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Cotman C.W., 1978, NEURONAL PLASTICITY, P227; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; Dugan Ellen M., 1994, Emergency Medicine Clinics of North America, V12, P1081; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; GOLDOWITZ D, 1979, BRAIN RES, V170, P427, DOI 10.1016/0006-8993(79)90962-4; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Jennett B, 1979, Adv Neurol, V22, P137; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOWENSTEIN DH, 1993, NEUROSCIENCE, V56, P597, DOI 10.1016/0306-4522(93)90359-N; MAJKOWSKI J, 1990, COMPREHENSIVE EPILEP, P281; MCGUIRE CB, 1988, DEV BRAIN RES, V41, P277, DOI 10.1016/0165-3806(88)90189-7; MEBERG PJ, 1991, NEUROSCIENCE, V45, P721, DOI 10.1016/0306-4522(91)90284-U; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MELDRUM BS, 1984, GREENFIELDS NEUROPAT, P921; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; Ramon y Cajal S., 1914, ESTUDIOS DEGENERACIO; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Salin P, 1995, J NEUROSCI, V15, P8234; SCANZIANI M, 1994, NEUROSCIENCE, V61, P823, DOI 10.1016/0306-4522(94)90405-7; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STREIT P, 1989, EUR J NEUROSCI, V1, P603, DOI 10.1111/j.1460-9568.1989.tb00366.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Traub R.D., 1991, NEURONAL NETWORKS HI; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; Weidenman B., 1985, CELL, V41, P1017; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1993, NEUROL CLIN, V11, P823, DOI 10.1016/S0733-8619(18)30126-9; Wuarin JP, 1996, J NEUROSCI, V16, P4438	44	126	129	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					990	996		10.1038/nm0997-990	http://dx.doi.org/10.1038/nm0997-990			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288725				2022-12-27	WOS:A1997XT84200031
J	Burnett, AL; Calvin, DC; Chamness, SL; Liu, JX; Nelson, RJ; Klein, SL; Dawson, VL; Dawson, TM; Snyder, SH				Burnett, AL; Calvin, DC; Chamness, SL; Liu, JX; Nelson, RJ; Klein, SL; Dawson, VL; Dawson, TM; Snyder, SH			Urinary bladder urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans	NATURE MEDICINE			English	Article							IMMUNOHISTOCHEMICAL LOCALIZATION; NADPH DIAPHORASE; RAT; INNERVATION; ORGANS; PENIS; GENE	Idiopathic voiding disorders affect up to 10-15% of men and women. We describe bladder abnormalities in mice with targeted deletion of the gene for neuronal nitric oxide synthase which model the clinical disorders. The mice possess hypertrophic dilated bladders and dysfunctional urinary outlets which do not relax in response to electrical field stimulation or L-arginine. The mice also display increased urinary frequency.	JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT UROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,COLL ARTS & SCI,DEPT PHYSIOL & PSYCHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Nelson, Randy/0000-0002-8194-4016; Dawson, Valina/0000-0002-2915-3970	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-22201] Funding Source: Medline; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALM P, 1993, ACTA PHYSIOL SCAND, V148, P421, DOI 10.1111/j.1748-1716.1993.tb09578.x; BENNETT BC, 1995, J UROLOGY, V153, P2004, DOI 10.1016/S0022-5347(01)67391-9; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BURNETT AL, 1995, UROLOGY, V45, P435, DOI 10.1016/S0090-4295(99)80012-0; BURNETT AL, 1993, J UROLOGY, V150, P73, DOI 10.1016/S0022-5347(17)35401-0; Burnett AL, 1996, MOL MED, V2, P288, DOI 10.1007/BF03401627; BURNETT AL, 1995, BIOL REPROD, V52, P1, DOI 10.1095/biolreprod52.1.1; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; COUILLARD DR, 1905, UROLOGIC CLIN N AM E, P593; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; GULBENKIAN S, 1987, J AUTONOM NERV SYST, V18, P235, DOI 10.1016/0165-1838(87)90122-6; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KAPLAN SA, 1995, UROL CLIN N AM, V22, P309; KOUTTS J, 1974, SEMIN HEMATOL, V11, P115; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; PERSSON K, 1993, BRIT J PHARMACOL, V110, P521, DOI 10.1111/j.1476-5381.1993.tb13842.x; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; TURNERWARWICK R, 1979, UROLOGIC CLIN N AM C, P13; VIZZARD MA, 1994, BRAIN RES, V646, P279, DOI 10.1016/0006-8993(94)90090-6	19	114	119	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					571	574		10.1038/nm0597-571	http://dx.doi.org/10.1038/nm0597-571			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142130				2022-12-27	WOS:A1997WX54300041
J	Wilson, SM; AlSuwaidi, Z; McNerney, R; Porter, J; Drobniewski, F				Wilson, SM; AlSuwaidi, Z; McNerney, R; Porter, J; Drobniewski, F			Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis	NATURE MEDICINE			English	Editorial Material							WORLD-HEALTH-ORGANIZATION; RESISTANT TUBERCULOSIS; RIFAMPICIN-RESISTANCE; INFECTION; SPECIMENS; PCR		UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Wilson, SM (corresponding author), DULWICH HOSP,PUBL HLTH LAB SERV,MYCOBACTERIUM REFERENCE UNIT,E DULWICH GROVE,LONDON SE22 8QF,ENGLAND.			MCNERNEY, Ruth/0000-0002-1957-443X				DAVID HL, 1980, ANN INST PASTEUR VIR, V131, P167, DOI 10.1016/0769-2617(80)90031-3; DEBEENHOUWER H, 1995, TUBERCLE LUNG DIS, V76, P425, DOI 10.1016/0962-8479(95)90009-8; DROBNIEWSKI FA, 1996, BR J HOSP MED, V56, P205; FOLEYTHOMAS EM, 1995, MICROBIOL-SGM, V141, P1173, DOI 10.1099/13500872-141-5-1173; Groothuis D. G., 1991, DIAGNOSTIC PUBLIC HL; Hawkey P. M., 1994, Reviews in Medical Microbiology, V5, P21; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MILLER N, 1994, J CLIN MICROBIOL, V32, P393, DOI 10.1128/JCM.32.2.393-397.1994; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Snider Dixie E. Jr., 1994, P3; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VARELDZIS BP, 1994, TUBERCLE LUNG DIS, V75, P1, DOI 10.1016/0962-8479(94)90096-5; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729	15	112	150	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	APR	1997	3	4					465	468		10.1038/nm0497-465	http://dx.doi.org/10.1038/nm0497-465			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WQ825	9095184				2022-12-27	WOS:A1997WQ82500040
J	Chinnaiyan, AM; Woffendin, C; Dixit, VM; Nabel, GJ				Chinnaiyan, AM; Woffendin, C; Dixit, VM; Nabel, GJ			The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; ACTIVATION-INDUCED APOPTOSIS; CD4(+) T-CELLS; INFECTED-CELLS; VIRUS; AIDS; THERAPY; PATHOGENESIS; HYPOTHESIS; CED-3	Accelerated programmed cell death, or apoptosis, contributes to the CD4(+) T-cell depletion characteristic of infection by human immunodeficiency virus (HIV). It has therefore been proposed that limiting apoptosis may represent a therapeutic modality for HIV infection. We found, however, that T leukemia cells or peripheral blood mononuclear cells (PBMCs) exposed to HIV-1 underwent enhanced viral replication in the presence of the cell death inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk). Furthermore, z-VAD-fmk, which targets the pro-apoptotic interleukin-1 beta-converting enzyme (ICE)-like proteases, stimulated endogenous virus production in activated PBMCs derived from HIV-1-infected asymptomatic individuals. These findings suggest that programmed cell death may serve as a beneficial host mechanism to limit HIV spread and that strategies to inhibit it may have deleterious consequences for the infected host.	UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIGMS NIH HHS [GM 07863] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; AMEISEN JC, 1995, ADV EXP MED BIOL, V374, P139; ANDRIEU JM, 1995, J INFECT DIS, V171, P523, DOI 10.1093/infdis/171.3.523; ANTONI BA, 1995, J VIROL, V69, P2384, DOI 10.1128/JVI.69.4.2384-2392.1995; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Corbeil J, 1996, J EXP MED, V183, P39, DOI 10.1084/jem.183.1.39; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; ESTAQUIER J, 1995, J EXP MED, V182, P1759, DOI 10.1084/jem.182.6.1759; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LU W, 1995, AIDS, V9, P35, DOI 10.1097/00002030-199501000-00005; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, ADV EXP MED BIOL, V374, P129; MARTIN SJ, 1994, J IMMUNOL, V152, P330; Meyaard L, 1995, Curr Top Microbiol Immunol, V200, P213; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1995, NAT MED, V1, P118, DOI 10.1038/nm0295-118; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Sandstrom PA, 1996, J VIROL, V70, P4617, DOI 10.1128/JVI.70.7.4617-4622.1996; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMSON AW, 1995, ADV EXP MED BIOL, V374, P211; WANG YJ, 1993, PROG FOOD NUTR SCI, V17, P351; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	48	75	78	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					333	337		10.1038/nm0397-333	http://dx.doi.org/10.1038/nm0397-333			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055863				2022-12-27	WOS:A1997WL30500037
J	Fisher, KJ; Jooss, K; Alston, J; Yang, YP; Haecker, SE; High, K; Pathak, R; Raper, SE; Wilson, JM				Fisher, KJ; Jooss, K; Alston, J; Yang, YP; Haecker, SE; High, K; Pathak, R; Raper, SE; Wilson, JM			Recombinant adeno-associated virus for muscle directed gene therapy	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS; PHENOTYPIC CORRECTION; NONDIVIDING CELLS; SYSTEMIC DELIVERY; EXPRESSION; VECTORS; TRANSDUCTION; INTEGRATION; DNA; MYOBLASTS	Although gene transfer with adeno-associated virus (AAV) vectors has typically been low, transduction can be enhanced in the presence of adenovirus gene products through the formation of double stranded, non-integrated AAV genomes. We describe the unexpected finding of high level and stable transgene expression in mice following intramuscular injection of purified recombinant AAV (rAAV). The rAAV genome is efficiently incorporated into nuclei of differentiated muscle fibers where it persists as head-to-tail concatamers. Fluorescent in situ hybridization of muscle tissue suggests single integration sites. Neutralizing antibody against AAV capsid proteins does not prevent readministration of vector. Remarkably, no humoral or cellular immune responses are elicited to the neoantigenic transgene product E. coli beta-galactosidase. The favorable biology of rAAV in muscle-directed gene therapy described in this study expands the potential of this vector for the treatment of inherited and acquired diseases.	UNIV PENN HLTH SYST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT SURG,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PEDIAT,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; The Wistar Institute			High, Katherine A./AAB-9322-2020; Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BERNS KI, 1990, MICROBIOL REV, V54, P316, DOI 10.1128/MMBR.54.3.316-329.1990; BLAU HM, 1990, ADV EXP MED BIOL, V280, P167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; MUZCYZKA N, 1992, CURR TOP MICROBIOL I, V158, P97; PODSAKOFF G, 1994, J VIROL, V68, P5656, DOI 10.1128/JVI.68.9.5656-5666.1994; RICE SA, 1985, J VIROL, V56, P767, DOI 10.1128/JVI.56.3.767-778.1985; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; TRATSCHIN JD, 1985, MOL CELL BIOL, V5, P3251, DOI 10.1128/MCB.5.11.3251; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703; YAO SN, 1994, GENE THER, V1, P99	33	555	598	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1997	3	3					306	312		10.1038/nm0397-306	http://dx.doi.org/10.1038/nm0397-306			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055858				2022-12-27	WOS:A1997WL30500032
J	Correale, J; Gilmore, W; Lopez, J; Li, SQ; McMillan, M; Weiner, LP				Correale, J; Gilmore, W; Lopez, J; Li, SQ; McMillan, M; Weiner, LP			Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN LYMPHOCYTES-T; GROWTH-FACTOR-BETA; SELF-TOLERANCE; DEMYELINATING DISEASES; MONOCLONAL-ANTIBODY; CELL ACTIVATION; INDUCTION; RECEPTOR; ANERGY	We have recently isolated a panel of T-cell clones from chronic progressive multiple sclerosis (MS) patients that are capable of functioning as antigen-presenting cells and of expressing the costimulatory molecules B7-1 and B7-2. In this report we show that these T-cell clones are resistant to inhibitory regulation, including the induction of anergy and sensitivity to tumor growth factor-beta (TCF-beta)-induced growth inhibition. The resistance to anergy induction was associated with expression of B7 costimulatory molecules. These data suggest that lack of responsiveness to peripheral inhibitory signals may account for the entry of autoimmune diseases into a chronic progressive phase.	UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT CELL & NEUROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California	Correale, J (corresponding author), UNIV SO CALIF,SCH MED,DEPT NEUROL,1333 SAN PABLO ST,MCK 142,LOS ANGELES,CA 90033, USA.		Correale, Jorge/AAG-4245-2020; Gilmore, Wendy/AAB-5562-2020					BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; BOSSU P, 1993, J IMMUNOL, V151, P7233; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; CHEN CY, 1994, IMMUNITY, V1, P147, DOI 10.1016/1074-7613(94)90108-2; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; CORREALE J, 1995, NEUROLOGY, V45, P1370, DOI 10.1212/WNL.45.7.1370; CORREALE J, IN PRESS J NEUROIMMU; DAYAN CM, 1993, J IMMUNOL, V151, P1606; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KROEMER G, 1992, IMMUNOL TODAY, V13, P401, DOI 10.1016/0167-5699(92)90090-T; KUIPER HM, 1995, RES IMMUNOL, V146, P180, DOI 10.1016/0923-2494(96)80255-0; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MARCOS MAR, 1988, IMMUNOL TODAY, V9, P204, DOI 10.1016/0167-5699(88)91214-5; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLER SD, 1995, IMMUNOL REV, V144, P225, DOI 10.1111/j.1600-065X.1995.tb00071.x; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; OLSSON T, 1992, EUR J IMMUNOL, V22, P1083, DOI 10.1002/eji.1830220431; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RACKE MK, 1991, J IMMUNOL, V146, P3012; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; VANDENBARK AA, 1995, J IMMUNOL, V155, P5861; VANKEMENADE FJ, 1993, EUR J IMMUNOL, V23, P635, DOI 10.1002/eji.1830230309; WILLIAMS ME, 1992, J IMMUNOL, V149, P1921	40	17	17	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1354	1360		10.1038/nm1296-1354	http://dx.doi.org/10.1038/nm1296-1354			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946835				2022-12-27	WOS:A1996VW51500042
J	Wieczorek, AM; Waterman, JLF; Waterman, MJF; Halazonetis, TD				Wieczorek, AM; Waterman, JLF; Waterman, MJF; Halazonetis, TD			Structure-based rescue of common tumor-derived p53 mutants	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; IN-VIVO; MUTATIONS; FORMS; TRANSFORMATION; SUPPRESSOR; COMPLEX; DOMAIN	The p53 tumor suppressor protein induces cell-cycle arrest or cell death in response to DNA-damaging agents, such as radiation and many of the chemotherapeutics used in cancer therapy(1,2). The function of p53 is dependent on its ability to bind DNA in a sequence-specific manner(3), but in one-half of all human tumors, its sequence-specific DNA binding domain is compromised by single-amino acid substitutions(4). The nature of these substitutions, which target residues that directly contact DNA or that stabilize the structure of the DNA binding domain(5), has raised concerns as to whether the function of p53 mutants could ever be rescued(6). Nevertheless, pharmaceuticals that restore function to p53 mutants could specifically suppress proliferation of cancer cells in patients. To determine whether tumor-derived p53 mutants are irreversibly inactivated, we introduced basic residues in their DNA binding domains, aiming to establish novel contacts between p53 and the DNA phosphate backbone. In three of the seven most common p53 mutants, replacement of Thr284 with Arg significantly enhanced DNA binding affinity, without affecting DNA binding specificity, and rescued their transactivation and tumor suppressor functions. Thus, many tumor-derived p53 mutants retain their sequence-specific DNA binding determinants and can be activated to suppress tumor growth.	WISTAR INST ANAT & BIOL,DEPT MOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,PROGRAM MOL BIOL & GENET,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania			Halazonetis, Thanos/D-7923-2011					CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; NIEWOLIK D, 1995, ONCOGENE, V10, P881; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158	20	81	86	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1143	1146		10.1038/nm1096-1143	http://dx.doi.org/10.1038/nm1096-1143			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837616				2022-12-27	WOS:A1996VK99500038
J	Kakinuma, Y; Hama, H; Sugiyama, F; Yagami, K; Goto, K; Murakami, K; Fukamizu, A				Kakinuma, Y; Hama, H; Sugiyama, F; Yagami, K; Goto, K; Murakami, K; Fukamizu, A			Impaired blood-brain barrier function in angiotensinogen-deficient mice	NATURE MEDICINE			English	Article							IV BINDING-SITES; ASTROCYTE RESPONSES; RECEPTOR SUBTYPE; MESSENGER-RNA; EXPRESSION; INJURY; GFAP; CULTURES	Astrocytes in the central nervous system have physiologically important roles in the response to brain injury(1,2). Brain damage results in disruption of the blood-brain barrier (BBB), producing detachment of astrocyte endfeet from endothelial cells(3). The resultant leakage of serum proteins from loosened tight junctions between endothelial cells produces brain edema. At the same time, reactive astrocytes migrate to the injured area, where they proliferate and produce extracellular matrix(4-6), thereby reconstituting the BBB. As astrocytes are known to express angiotensinogen(7,8), which is the precursor of angiotensins (Al to AIV), we have investigated a possible functional contribution of angiotensinogen or one of its metabolites to BBB reconstitution. The astrocytes of angiotensinogen knockout mice had very attenuated expression of glial fibrially acidic protein and decreased laminin production in response to cold injury, and ultimately incomplete reconstitution of impaired BBB function. Although these abnormalities were rescued by administration of All or AIV, the restoration of BBB function was not inhibited by All type 1 and 2 receptor antagonists. These findings provide evidence that astrocytes with angiotensins are required for functional maintenance of the BBB.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Lab Anim Res Ctr, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Natl Inst Adv Interdisciplinary Res, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan.	akif@sakura.cc.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Kakinuma, Yoshihiko/0000-0001-5470-9128				CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; deOliveira AM, 1995, BRAIN RES, V705, P177, DOI 10.1016/0006-8993(95)01158-7; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; GOLDSTEIN GW, 1986, SCI AM, V255, P70; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LEPRINCE G, 1991, GLIA, V4, P322, DOI 10.1002/glia.440040310; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LUDWIN SK, 1985, LAB INVEST, V52, P20; MILLERWING AV, 1993, J PHARMACOL EXP THER, V266, P1718; MILSTED A, 1990, P NATL ACAD SCI USA, V87, P5720, DOI 10.1073/pnas.87.15.5720; Moeller I, 1996, BRAIN RES, V712, P307, DOI 10.1016/0006-8993(95)01482-9; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; REIER PJ, 1986, CELL BIOL PATHOLOGY, P263; ROBERTS KA, 1995, BRAIN RES, V682, P13, DOI 10.1016/0006-8993(95)00289-3; SHIBOUTA Y, 1993, J PHARMACOL EXP THER, V266, P114; STORNETTA RL, 1988, SCIENCE, V242, P1444, DOI 10.1126/science.3201232; Sugiyama F, 1997, LAB ANIM SCI, V47, P545; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; WARNICK RE, 1995, J NEUROSCI METH, V58, P167, DOI 10.1016/0165-0270(94)00172-D; WRIGHT JW, 1995, FRONT NEUROENDOCRIN, V16, P23, DOI 10.1006/frne.1995.1002; Wright JW, 1996, PEPTIDES, V17, P1365, DOI 10.1016/S0196-9781(96)00226-4	25	119	123	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1078	1080		10.1038/2070	http://dx.doi.org/10.1038/2070			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734405	Green Submitted			2022-12-27	WOS:000075804100045
J	Kern, F; Surel, IP; Brock, C; Freistedt, B; Radtke, H; Scheffold, A; Blasczyk, R; Reinke, P; Schneider-Mergener, J; Radbruch, A; Walden, P; Volk, HD				Kern, F; Surel, IP; Brock, C; Freistedt, B; Radtke, H; Scheffold, A; Blasczyk, R; Reinke, P; Schneider-Mergener, J; Radbruch, A; Walden, P; Volk, HD			T-cell epitope mapping by flow cytometry	NATURE MEDICINE			English	Article							RARE CELLS; FREQUENCY; CYTOMEGALOVIRUS; PROTEIN; CTL		Humboldt Univ, Fak Med, Inst Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Fak Med, Dermatol Klin, D-10098 Berlin, Germany; Humboldt Univ, Fak Med, Inst Transfus Med & Immunhamatol, D-10098 Berlin, Germany; Deutsch Rheuma Forsch Zentrum, D-10115 Berlin, Germany; Humboldt Univ, Fak Med, Med Klin, Schwerpunkt Hamatol & Onkol, D-13353 Berlin, Germany; Humboldt Univ, Fak Med, Med Klin, Schwerpunkt Nephrol & Intens Med, D-13353 Berlin, Germany	Humboldt University of Berlin; Humboldt University of Berlin; Humboldt University of Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); Humboldt University of Berlin; Humboldt University of Berlin	Kern, F (corresponding author), Humboldt Univ, Fak Med, Inst Med Immunol, Campus Mitte, D-10098 Berlin, Germany.	kern@rz.charite.hu-berlin.de	volk, hans-dieter/AAV-8053-2021; Kern, Florian/AAE-6784-2022; Scheffold, Alexander/S-2090-2016	volk, hans-dieter/0000-0002-7743-6668; Kern, Florian/0000-0002-0368-8408; Scheffold, Alexander/0000-0002-0626-343X; Radbruch, Andreas/0000-0001-5753-0000; Blasczyk, Rainer/0000-0003-3875-3190; Reinke, Petra/0000-0003-0771-4375				Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; BORYSIEWICZ LK, 1988, J EXP MED, V168, P919, DOI 10.1084/jem.168.3.919; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; Diamond DJ, 1997, BLOOD, V90, P1751, DOI 10.1182/blood.V90.5.1751; GROSS HJ, 1993, CYTOMETRY, V14, P519, DOI 10.1002/cyto.990140511; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; PARKER KC, 1994, J IMMUNOL, V152, P163; RADBRUCH A, 1995, CURR OPIN IMMUNOL, V7, P270, DOI 10.1016/0952-7915(95)80014-X; Rammensee HG, 1997, MOL B INT U, P1; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	14	240	253	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1998	4	8					975	978		10.1038/nm0898-975	http://dx.doi.org/10.1038/nm0898-975			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701254				2022-12-27	WOS:000075107400046
J	Kononen, J; Bubendorf, L; Kallioniemi, A; Barlund, M; Schraml, P; Leighton, S; Torhorst, J; Mihatsch, MJ; Sauter, G; Kallioniemi, OP				Kononen, J; Bubendorf, L; Kallioniemi, A; Barlund, M; Schraml, P; Leighton, S; Torhorst, J; Mihatsch, MJ; Sauter, G; Kallioniemi, OP			Tissue microarrays for high-throughput molecular profiling of tumor specimens	NATURE MEDICINE			English	Article							HUMAN BREAST-CANCER; AMPLIFICATION; HYBRIDIZATION; EXPRESSION; CARCINOMAS; ONCOGENE; BLOCK	Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes(1,2). These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray, Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.	Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33521 Tampere, Finland; Tampere Univ Hosp, FIN-33521 Tampere, Finland; Beecher Instruments, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel; Tampere University; Tampere University; Tampere University Hospital	Kallioniemi, OP (corresponding author), Natl Human Genome Res Inst, Canc Genet Lab, NIH, 49 Convent Dr MSC 4470,Room 4A24, Bethesda, MD 20892 USA.		Bubendorf, Lukas/G-5299-2015; Kallioniemi, Olli P/H-5111-2011; Bubendorfl, Lukas/H-5880-2011	Bubendorf, Lukas/0000-0001-5970-1803; Kallioniemi, Olli P/0000-0002-3231-0332; Kallioniemi, Anne/0000-0003-3552-8158; Kononen, Juha/0000-0002-0157-2137; Barlund, Maarit/0000-0002-1469-5654				ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107; Barbareschi M, 1997, INT J CANCER, V74, P171, DOI 10.1002/(SICI)1097-0215(19970422)74:2<171::AID-IJC5>3.0.CO;2-W; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BATTIFORA H, 1990, LAB INVEST, V63, P722; BATTIFORA H, 1986, LAB INVEST, V55, P244; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Courjal F, 1997, CANCER RES, V57, P4360; DeRisi J, 1996, NAT GENET, V14, P457; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Molino A, 1997, BREAST CANCER RES TR, V45, P241, DOI 10.1023/A:1005769925670; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; NobenTrauth K, 1996, GENOMICS, V35, P610, DOI 10.1006/geno.1996.0408; Pauletti G, 1996, ONCOGENE, V13, P63; Persons DL, 1997, MODERN PATHOL, V10, P720; PRESS MF, 1994, CANCER RES, V54, P2771; Ried T, 1998, AM J PATHOL, V152, P325; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANNER MM, 1994, CANCER RES, V54, P4257; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	20	3288	3675	4	233	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					844	847		10.1038/nm0798-844	http://dx.doi.org/10.1038/nm0798-844			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662379				2022-12-27	WOS:000074543900042
J	Kendall, AL; Rayment, FD; Torres, EM; Baker, HF; Ridley, RM; Dunnett, SB				Kendall, AL; Rayment, FD; Torres, EM; Baker, HF; Ridley, RM; Dunnett, SB			Functional integration of striatal allografts in a primate model of Huntington's disease	NATURE MEDICINE			English	Article							FETAL NEOSTRIATAL ALLOGRAFTS; 3-NITROPROPIONIC ACID; RHESUS-MONKEY; LESIONS; GRAFTS; DEFICITS; DOPAMINE; CELLS	Huntington's disease is an autosomal dominant, inherited disorder that results in progressive degeneration of the basal ganglia (especially the neostriatal caudate nucleus and putamen) and other forebrain structures and is associated with a clinical profile of movement, cognitive and psychiatric impairments for which there is at present no effective therapy(1). Neuropathological, neurochemical and behavioral features of the disease can all be reproduced in experimental animals by local injection of excitotoxic(2,3) or metabolic(4,5) toxins into the neostriatum. All these features of the disease can be alleviated, at least in rats, by transplantation of embryonic striatal tissue into the degenerated striatum(6-8), which was the basis for commencing the first clinical trials of striatal transplantation in Huntington's patients(9,10). However, although rat striatal xenografts may temporarily reduce apomorphine-induced dyskinesias in monkeys(11), there has been no demonstration that allograft techniques that work well in rats translate effectively to the much larger differentiated striatum of primates(12). Here we demonstrate good survival, differentiation and integration of striatal allografts in the primate neostriatum, and recovery in a test of skilled motor performance. Long-term graft survival in primates indicates probable success for clinical transplants in Huntington's disease; in addition, our data suggest that graft placement has a direct influence on the pattern and extent of functional recovery.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, MRC, Cambridge Ctr Brain Repair, Cambridge CB2 3EB, England	University of Cambridge; University of Cambridge	Kendall, AL (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.		Dunnett, Stephen B/A-5869-2010	Dunnett, Stephen B/0000-0003-1826-1578				ANNETT LE, 1994, EXP NEUROL, V125, P228, DOI 10.1006/exnr.1994.1026; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bjorklund A., 1994, FUNCTIONAL NEURAL TR, P157; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Dunnett S.B., 1992, NEURAL TRANSPLANTATI; DUNNETT SB, 1988, NEUROSCIENCE, V24, P813, DOI 10.1016/0306-4522(88)90069-3; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; HARPER P. S., 1996, HUNTINGTONS DIS; HELM GA, 1992, NEUROSCIENCE, V50, P163, DOI 10.1016/0306-4522(92)90390-N; HELM GA, 1993, EXP NEUROL, V123, P174, DOI 10.1006/exnr.1993.1150; ISACSON O, 1989, EXP BRAIN RES, V75, P213; MADRAZO I, 1995, NEUROL RES, V17, P312, DOI 10.1080/01616412.1995.11740334; Marshall JWB, 1996, NEURODEGENERATION, V5, P275, DOI 10.1006/neur.1996.0036; OUIMET CC, 1984, J NEUROSCI, V4, P111; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; Palfi SP, 1996, J NEUROSCI, V16, P3019; Philpott LM, 1997, CELL TRANSPLANT, V6, P203, DOI 10.1016/S0963-6897(97)00028-6; STEHAN H, 1980, BRAIN COMMON MARMOSE; WICTORIN K, 1992, PROG NEUROBIOL, V38, P611, DOI 10.1016/0301-0082(92)90044-F	21	120	126	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1998	4	6					727	729		10.1038/nm0698-727	http://dx.doi.org/10.1038/nm0698-727			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZR733	9623985				2022-12-27	WOS:000074008300042
J	Herwald, H; Morgelin, M; Olsen, A; Rhen, M; Dahlback, B; Muller-Esterl, W; Bjorck, L				Herwald, H; Morgelin, M; Olsen, A; Rhen, M; Dahlback, B; Muller-Esterl, W; Bjorck, L			Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases	NATURE MEDICINE			English	Article							ESCHERICHIA-COLI; SALMONELLA-ENTERITIDIS; AGGREGATIVE FIMBRIAE; BINDING; KININOGENS; FIBRONECTIN; BRADYKININ; CURLI; THIN; PURIFICATION	Fever, hypotension and bleeding disorders are common symptoms of sepsis and septic shock. The activation of the contact-phase system is thought to contribute to the development of these severe disease states by triggering proinflammatory and procoagulatory cascades; however, the underlying molecular mechanisms are obscure. Here we report that the components of the contact-phase system are assembled on the surface of Escherichia coli and Salmonella through their specific interactions with fibrous bacterial surface proteins, curli and fimbriae. As a consequence, the proinflammatory pathway is activated through the release of bradykinin, a potent inducer of fever, pain and hypotension. Absorption of contact-phase proteins and fibrinogen by bacterial surface proteins depletes relevant coagulation factors and causes a hypocoagulatory state. Thus, the complex interplay of microbe surface proteins and host contact-phase factors may contribute to the symptoms of sepsis and septic shock.	Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Karolinska Inst, Microbiol & Tumor Biol Ctr MTC, S-17177 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Johannes Gutenberg Universitat Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Lund University; Karolinska Institutet; Lund University; Skane University Hospital; Johannes Gutenberg University of Mainz	Herwald, H (corresponding author), Lund Univ, Dept Cell & Mol Biol, POB 94, S-22100 Lund, Sweden.	Heiko.Herwald@medkem.lu.se	Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842; Dahlback, Bjorn/0000-0003-1546-0328				BECKER U, 1984, THROMB RES, V35, P475, DOI 10.1016/0049-3848(84)90280-9; BenNasr A, 1996, MOL MICROBIOL, V20, P927; COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991; COLLINSON SK, 1993, J BACTERIOL, V175, P12, DOI 10.1128/JB.175.1.12-18.1993; COLMAN RW, 1986, CRC CR REV ONCOL-HEM, V5, P57, DOI 10.1016/S1040-8428(86)80053-1; EGBERG N, 1982, THROMB RES, V25, P437, DOI 10.1016/0049-3848(82)90134-7; EVANS DG, 1977, INFECT IMMUN, V18, P330, DOI 10.1128/IAI.18.2.330-337.1977; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; HOCK J, 1990, J BIOL CHEM, V265, P12005; KAPLAN AP, 1987, BLOOD, V70, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1989, THROMB HAEMOSTASIS, V61, P2; NILSSON IM, 1974, HAEMORRHAGIC THROMBA, P217; ODEGARD OR, 1975, THROMB RES, V6, P287, DOI 10.1016/0049-3848(75)90078-X; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; PONJEE GAE, 1991, CLIN CHEM, V37, P1235; RISBERG B, 1991, ACTA ANAESTH SCAND, V35, P60, DOI 10.1111/j.1399-6576.1991.tb03401.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; Sukupolvi S, 1997, INFECT IMMUN, V65, P838, DOI 10.1128/IAI.65.2.838-842.1997; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4	27	156	165	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1998	4	3					298	302		10.1038/nm0398-298	http://dx.doi.org/10.1038/nm0398-298			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500602				2022-12-27	WOS:000073616200034
J	Pollman, MJ; Hall, JL; Mann, MJ; Zhang, LN; Gibbons, GH				Pollman, MJ; Hall, JL; Mann, MJ; Zhang, LN; Gibbons, GH			Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease	NATURE MEDICINE			English	Article							ATHEROSCLEROSIS; OLIGONUCLEOTIDES; DEATH; HYPERPLASIA; RESTENOSIS; BCL-X(L); INJURY; KINASE; GENE	We postulated that activation of a genetic program that tonically inhibits intimal cell death is a necessary condition for the pathogenesis of vascular disease. Studies of vascular lesions in humans and animal models documented increased expression of the anti-apoptotic gene product Bcl-x(L) within intimal cells. Downregulation of intimal cell bcl-x(L) expression with the use of antisense oligonucleotides induced apoptosis and acute regression of vascular lesions. These findings indicate that apoptosis regulatory genes such as bcl-x(L) are critical determinants of intimal lesion formation and that targeted apoptosis may be a novel therapy for intimal vascular disease.	Brigham & Womens Hosp, Thorn Cardiovasc Res Labs, Boston, MA 02115 USA; Stanford Univ, Falk CArdiovasc Res Ctr, Div Cardiovasc Med, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Stanford University	Gibbons, GH (corresponding author), Brigham & Womens Hosp, Thorn Cardiovasc Res Labs, 1326,75 Francis St, Boston, MA 02115 USA.							BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHINNAIYAN AM, 1997, SCIENCE, V275, P122; FAXON DP, 1982, ARTERIOSCLEROSIS, V2, P125, DOI 10.1161/01.ATV.2.2.125; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENG YJ, 1995, AM J PATHOL, V147, P251; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; HAN DKM, 1995, AM J PATHOL, V147, P267; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Perlman H, 1997, CIRCULATION, V95, P981; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHINOMIYA M, 1992, ATHEROSCLEROSIS, V97, P143, DOI 10.1016/0021-9150(92)90127-3; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	24	240	255	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					222	227		10.1038/nm0298-222	http://dx.doi.org/10.1038/nm0298-222			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461197				2022-12-27	WOS:000072249800039
J	Wang, G; Chopra, RK; Royal, RE; Yang, JC; Rosenberg, SA; Hwu, P				Wang, G; Chopra, RK; Royal, RE; Yang, JC; Rosenberg, SA; Hwu, P			A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen	NATURE MEDICINE			English	Article							TUMOR-CELLS; ZETA-CHAIN; LYMPHOCYTES; SPECIFICITY; EXPRESSION; VECTORS; LONG	In order to treat common cancers with immunotherapy, chimeric receptors have been developed that combine the tumor specificity of antibodies with T-cell effector functions. Previously, we demonstrated that T cells transduced with a chimeric receptor gene against human ovarian cancer were able to recognize ovarian cancer cells in vitro and in vivo. We now report that recipients of bone marrow cells transduced with these genes exhibited significant antitumor activity in vivo. Moreover, in vivo depletion of T cells in reconstituted mice did not affect antitumor activity, suggesting that other immune cells expressing the chimeric receptor gene may play an important role in tumor rejection.	NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hwu, P (corresponding author), NCI, Surg Branch, NIH, Bldg 10,Room 2B42,10 Ctr Dr, Bethesda, MD 20892 USA.							BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BROCKER T, 1995, J EXP MED, V181, P1653, DOI 10.1084/jem.181.5.1653; CONEY LR, 1991, CANCER RES, V51, P6125; ESHHAR Z, 1990, BRIT J CANCER, V62, P27; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; GROSS G, 1992, FASEB J, V6, P3370, DOI 10.1096/fasebj.6.15.1464371; HOATLIN ME, 1995, J MOL MED, V73, P113, DOI 10.1007/BF00198238; HWU P, 1995, CANCER RES, V55, P3369; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARP SE, 1993, J IMMUNOL, V150, P896; KRUISBEEK AD, 1991, CURRENT PROTOCOLS IM; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIOTTI S, 1987, INT J CANCER, V39, P297, DOI 10.1002/ijc.2910390306; MORITZ D, 1994, P NATL ACAD SCI USA, V91, P4318, DOI 10.1073/pnas.91.10.4318; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PARDOLL DM, 1988, J IMMUNOL, V140, P4091; ROBERTS MR, 1994, BLOOD, V84, P2878; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; Royal R. E., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P481; SHILONI E, 1993, CANCER IMMUNOL IMMUN, V37, P286, DOI 10.1007/BF01518450; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SYKES M, 1993, TRANSPLANTATION, V55, P197, DOI 10.1097/00007890-199301000-00037; TRAN AC, 1995, J IMMUNOL, V155, P1000; Walker RE, 1996, HUM GENE THER, V7, P367, DOI 10.1089/hum.1996.7.3-367; WELS W, 1995, GENE, V159, P73, DOI 10.1016/0378-1119(94)00786-R	32	49	70	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					168	172		10.1038/nm0298-168	http://dx.doi.org/10.1038/nm0298-168			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461189				2022-12-27	WOS:000072249800031
J	Zhou, M; Sutliff, RL; Paul, RJ; Lorenz, JN; Hoying, JB; Haudenschild, CC; Yin, MY; Coffin, JD; Kong, L; Kranias, EG; Luo, WS; Boivin, GP; Duffy, J; Pawlowski, SA; Doetschman, T				Zhou, M; Sutliff, RL; Paul, RJ; Lorenz, JN; Hoying, JB; Haudenschild, CC; Yin, MY; Coffin, JD; Kong, L; Kranias, EG; Luo, WS; Boivin, GP; Duffy, J; Pawlowski, SA; Doetschman, T			Fibroblast growth factor 2 control of vascular tone	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; HEAVY-CHAIN ISOFORMS; CROUZON-SYNDROME; MICE LACKING; GENE; EXPRESSION; INDUCTION; MUTATIONS; ATHEROSCLEROSIS; HEMATOPOIESIS	Vascular tone control is essential in blood pressure regulation, shock, ischemia-reperfusion, inflammation, vessel injury/repair, wound healing, temperature regulation, digestion, exercise physiology, and metabolism. Here we show that a well-known growth factor, FGF2, long thought to be involved in many developmental and homeostatic processes, including growth of the tissue layers of vessel walls, functions in vascular tone control. Fgf2 knockout mice are morphologically normal and display decreased vascular smooth muscle contractility, low blood pressure and thrombocytosis. Following intra-arterial mechanical injury, FGF2-deficient vessels undergo a normal hyperplastic response. These results force us to reconsider the function of FGF2 in vascular development and homeostasis in terms of vascular tone control.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Hematol Oncol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA; McLaughlin Res Inst, Great Falls, MT 59405 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; American Red Cross; McLaughlin Research Institute for Biomedical Sciences, Inc.	Doetschman, T (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Christian, Haudenschild C/D-1602-2009	NOIRI, Eisei/0000-0002-9515-7582	NHLBI NIH HHS [R01 HL070174, HL 58511, HL 41496, R01 HL054829, HL 46826] Funding Source: Medline; NICHD NIH HHS [R01 HD026471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826, P01HL041496, R01HL070174, R01HL054829, R01HL058511] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; ALI S, 1993, J BIOL CHEM, V268, P17397; ALLOUCHE M, 1995, LEUKEMIA, V9, P937; ARAKAWA T, 1995, J PROTEIN CHEM, V14, P263, DOI 10.1007/BF01886783; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BURSTEIN SA, 1979, BLOOD, V54, P169; CAMPBELL GR, 1990, ANN NY ACAD SCI, V598, P143, DOI 10.1111/j.1749-6632.1990.tb42286.x; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CRISTIANI C, 1994, J CARDIOVASC PHARM, V23, P988, DOI 10.1097/00005344-199406000-00018; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; Davis MG, 1997, J MOL CELL CARDIOL, V29, P1061, DOI 10.1006/jmcc.1997.0383; DOETSCHMAN T, 1993, HYPERTENSION, V22, P618, DOI 10.1161/01.HYP.22.4.618; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MACMILLAN V, 1993, STROKE, V24, P1735, DOI 10.1161/01.STR.24.11.1735; MERLE PL, 1995, J BIOL CHEM, V270, P17361, DOI 10.1074/jbc.270.29.17361; MIWA AY, 1992, SCIENCE, V257, P1401; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SCHNEIDER MD, 1992, BASIC RES CARDIOL, V87, P33; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; SLACK JMW, 1994, DEV BIOL, V161, P313, DOI 10.1006/dbio.1994.1031; SUGI Y, 1993, DEV BIOL, V157, P28, DOI 10.1006/dbio.1993.1109; SUTTER MC, 1977, ACTA PHYSIOL SCAND, V99, P484, DOI 10.1111/j.1748-1716.1977.tb10402.x; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Tsuboi Ryoji, 1992, Journal of Dermatology (Tokyo), V19, P673; WEISS RH, 1993, J BIOL CHEM, V268, P5724	44	289	294	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					201	207		10.1038/nm0298-201	http://dx.doi.org/10.1038/nm0298-201			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461194	Green Accepted			2022-12-27	WOS:000072249800036
J	Ptashne, M				Ptashne, M			Control of gene transcription: An outline	NATURE MEDICINE			English	Editorial Material											Ptashne, M (corresponding author), HARVARD UNIV,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.								0	13	16	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1069	1072		10.1038/nm1097-1069	http://dx.doi.org/10.1038/nm1097-1069			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334708				2022-12-27	WOS:A1997XZ28700022
J	Arai, H; Chan, SY; Bishop, DK; Nabel, GJ				Arai, H; Chan, SY; Bishop, DK; Nabel, GJ			Inhibition of the alloantibody response by CD95 ligand	NATURE MEDICINE			English	Article							LIMITING DILUTION ANALYSIS; TUMOR-NECROSIS-FACTOR; HUMAN B-LYMPHOCYTES; FAS-LIGAND; T-CELLS; INDUCED APOPTOSIS; GRAFT-REJECTION; ACTIVATION; DEATH; DISCRIMINATE	We investigated the effect of Fas/APO1-ligand (CD95L) gene transfer on allogeneic immune responses in vivo. A colon carcinoma cell line from BALB/c mice, CT26, was stably transfected with a vector encoding mouse CD95L and was inoculated into C57BL/6 mice. CD95L expression markedly reduced allogeneic cytotoxic T lymphocyte and helper T lymphocyte activity directed toward CT26. Strikingly, expression of CD95L on these allogeneic tumors completely inhibited the generation of alloantibodies of both IgM and IgG subclasses. Thus, CD95L inhibited alloantibody production and conferred localized immune suppression through this mechanism. These results provide insight into the role of CD95L in regulating the alloantibody response and the generation of local immune responses.	UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SURG,SECT GEN SURG,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031946] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI31946] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bishop D K, 1995, Transpl Immunol, V3, P222, DOI 10.1016/0966-3274(95)80028-X; BISHOP DK, 1994, TRANSPLANTATION, V58, P576, DOI 10.1097/00007890-199409150-00009; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; BRADLEY JA, 1992, IMMUNOL TODAY, V13, P434, DOI 10.1016/0167-5699(92)90069-J; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHAN SY, 1995, TRANSPLANTATION, V59, P1155, DOI 10.1097/00007890-199504270-00014; CLEARY AM, 1995, J IMMUNOL, V155, P3329; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLISON JW, 1982, NUCLEIC ACIDS RES, V10, P4071, DOI 10.1093/nar/10.13.4071; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OROSZ CG, 1989, TRANSPLANTATION, V47, P189, DOI 10.1097/00007890-198901000-00039; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SAYEGH MH, 1994, TRANSPLANTATION, V57, P1295, DOI 10.1097/00007890-199405150-00001; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	32	76	83	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					843	848		10.1038/nm0897-843	http://dx.doi.org/10.1038/nm0897-843			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256273				2022-12-27	WOS:A1997XP01400024
J	DSouza, MP; Harden, VA				DSouza, MP; Harden, VA			Chemokines and HIV-1 second receptors - Confluence of two fields generates optimism in AIDS research	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD8+ T-CELLS; CD26 ANTIGEN; ENVELOPE GLYCOPROTEIN; REPLICATION; FUSION; INFECTION; GENE; CD4; LYMPHOCYTES		NIH,HIST OFF,BETHESDA,MD 20892; NIH,DEWITT STETTEN JR MUSEUM MED RES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	DSouza, MP (corresponding author), NIAID,DIV AIDS,PATHOGENESIS & BASIC RES BRANCH,NIH,BLDG 31,2B09,MSC 2092,BETHESDA,MD 20892, USA.							ALIZON M, 1994, SCIENCE, V264, P1161, DOI 10.1126/science.7909962; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BRINCHMANN JE, 1991, J ACQ IMMUN DEF SYND, V4, P480; BRODER CC, 1994, SCIENCE, V264, P1156, DOI 10.1126/science.7909959; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CASTRO BA, 1991, CELL IMMUNOL, V132, P246, DOI 10.1016/0008-8749(91)90023-5; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Cohen J, 1996, SCIENCE, V272, P809, DOI 10.1126/science.272.5263.809; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P936; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOMEZ AM, 1994, CLIN EXP IMMUNOL, V97, P68; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; HYERYUN C, 1996, CELL, V85, P1135; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KLATZMANN D, 1984, NATURE, V312, P20; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Litwin V, 1996, J VIROL, V70, P6437, DOI 10.1128/JVI.70.9.6437-6441.1996; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MACKEWICZ CE, 1994, CELL IMMUNOL, V153, P329, DOI 10.1006/cimm.1994.1032; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MORIUCHI H, 1996, J ACQUIR IMMUNE DEFI; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PATIENCE C, 1994, SCIENCE, V264, P1159, DOI 10.1126/science.7909960; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; POWELL JD, 1993, CLIN EXP IMMUNOL, V91, P473; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WERNER A, 1994, AIDS, V8, P1348, DOI 10.1097/00002030-199409000-00023; WEST WHL, 1994, AIDS, V8, P1349, DOI 10.1097/00002030-199409000-00024; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	80	265	273	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1293	1300		10.1038/nm1296-1293	http://dx.doi.org/10.1038/nm1296-1293			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946819				2022-12-27	WOS:A1996VW51500026
J	Franken, M; Estabrooks, A; Cavacini, L; Sherburne, B; Wang, F; Scadden, DT				Franken, M; Estabrooks, A; Cavacini, L; Sherburne, B; Wang, F; Scadden, DT			Epstein-Barr virus-driven gene therapy for EBV-related lymphomas	NATURE MEDICINE			English	Article							SIGNAL-BINDING-PROTEIN; CELLS; EXPRESSION; CANCER; INFECTION; ELEMENTS; INVITRO	Genetic alterations in malignant tissues are potential targets for gene-based cancer therapies. Alternatively, aberrant expression of certain specific genes associated with malignant transformation may be envisioned to enhance the expression of chemosensitizing drugs. Epstein-Barr virus (EBV)-related B-cell lymphomas are fatal complications of immunosuppression due to AIDS, organ transplantation or congenital immune abnormalities. The malignant cells latently infected with EBV typically express the transcription factor EBNA2 as one of nine latent viral genes. We tested whether an EBNA2-responsive EBV promoter may selectively target EBV-related lymphoma cells by virus-regulated expression of a suicide gene. Using the BamC promoter driving a hygromycin-thymidine kinase fusion gene or controls, we demonstrated that sensitivity to ganciclovir was selectively enhanced in cells expressing EBNA2. Further, there was complete macroscopic regression of established B-cell lymphomas in mice with severe combined immunodeficiency disease (SCID mice) treated with a single course of ganciclovir. These data provide in vitro and in vivo support for a model of exploiting the molecular basis of tumor development to enhance the specificity of gene therapy.	HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02138 USA; MASSACHUSETTS GEN HOSP, MGH CANC CTR, AIDS RES CTR, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA055520] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 55520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASHIR R, 1993, NEUROLOGY, V43, P2358, DOI 10.1212/WNL.43.11.2358; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; Deisseroth A B, 1994, Hum Gene Ther, V5, P1507; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GHOSH D, 1990, J VIROL, V64, P1855, DOI 10.1128/JVI.64.4.1855-1858.1990; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMILTONDUTOIT SJ, 1993, AM J PATHOL, V143, P1072; HAN XL, 1995, P NATL ACAD SCI USA, V92, P9747, DOI 10.1073/pnas.92.21.9747; HASEGAWA Y, 1995, J MOL MED-JMM, V73, P107, DOI 10.1007/BF00198237; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HURFORD RK, 1995, NAT GENET, V10, P430, DOI 10.1038/ng0895-430; Knowles Daniel M., 1993, Current Opinion in Oncology, V5, P845, DOI 10.1097/00001622-199309000-00012; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; OSHIRO EM, 1995, CANCER GENE THER, V2, P87; REA D, 1994, ANN ONCOL, V5, pS113, DOI 10.1093/annonc/5.suppl_1.S113; ROONEY CM, 1992, J VIROL, V66, P496, DOI 10.1128/JVI.66.1.496-504.1992; SHEWACH DS, 1994, CANCER GENE THER, V1, P107; VILE RG, 1993, CANCER RES, V53, P962; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	24	39	41	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1996	2	12					1379	1382		10.1038/nm1296-1379	http://dx.doi.org/10.1038/nm1296-1379			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946840				2022-12-27	WOS:A1996VW51500047
J	Rubel, EW; Stone, JS				Rubel, EW; Stone, JS			Stimulating hair cell regeneration: On a wing and a prayer	NATURE MEDICINE			English	Editorial Material							EAR SENSORY EPITHELIA; MAMMALIAN INNER-EAR; ACOUSTIC TRAUMA; PROLIFERATION				Rubel, EW (corresponding author), UNIV WASHINGTON,VIRGINIA MERRILL BLOEDEL HEARING RES CTR,SEATTLE,WA 98195, USA.							CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; COTANCHE DA, 1993, ANAT EMBRYOL, V198, P1; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; LAMBERT PR, 1994, LARYNGOSCOPE, V104, P701; LENOIR M, 1996, LIFE SCI, V319, P269; Navaratnam DS, 1996, NAT MED, V2, P1136, DOI 10.1038/nm1096-1136; OESTERLE EC, 1993, HEARING RES, V70, P85, DOI 10.1016/0378-5955(93)90054-5; RUBEL EW, 1995, SCIENCE, V267, P701, DOI 10.1126/science.7839150; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Stone LS, 1937, J COMP NEUROL, V68, P83, DOI 10.1002/cne.900680105; TANYERI H, 1995, HEARING RES, V89, P194, DOI 10.1016/0378-5955(95)00137-7; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; YAMASHITA H, 1995, P NATL ACAD SCI USA, V92, P3152, DOI 10.1073/pnas.92.8.3152	15	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1082	1083		10.1038/nm1096-1082	http://dx.doi.org/10.1038/nm1096-1082			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837604				2022-12-27	WOS:A1996VK99500026
J	Saegusa, A				Saegusa, A			Japan renews gene therapy efforts ...	NATURE MEDICINE			English	News Item																		1998, NATURE MED, V4, P260	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1213	1213		10.1038/3175	http://dx.doi.org/10.1038/3175			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809522				2022-12-27	WOS:000076731000006
J	Terada, M				Terada, M			National Cancer Center Research Institute: History, current status, and priorities	NATURE MEDICINE			English	Editorial Material									Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.								0	5	5	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1221	1224		10.1038/3198	http://dx.doi.org/10.1038/3198			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809533				2022-12-27	WOS:000076731000018
J	Soares, MP; Lin, Y; Anrather, J; Csizmadia, E; Takigami, K; Sato, K; Grey, ST; Colvin, RB; Choi, AM; Poss, KD; Bach, FH				Soares, MP; Lin, Y; Anrather, J; Csizmadia, E; Takigami, K; Sato, K; Grey, ST; Colvin, RB; Choi, AM; Poss, KD; Bach, FH			Expression of heme oxygenase-1 can determine cardiac xenograft survival	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; REJECTION; STRESS; ACCOMMODATION; ANTIOXIDANT; RESISTANCE; APOPTOSIS; FERRITIN; PROTEIN	The rejection of concordant xenografts, such as mouse-to-rat cardiac xenografts, is very similar to the delayed rejection of porcine-to-primate discordant xenografts(1,2-6). In concordant models, this type of rejection is prevented by brief complement inhibition by cobra venom factor (CVF) and sustained T-cell immunosuppression by cyclosporin A (CyA) (refs. 7-10). Mouse hearts that survive indefinitely in rats treated with CVF plus CyA express the anti-inflammatory gene heme oxygenase-l (HO-1) in their endothelial cells and smooth muscle cells(9,11-14). The anti-inflammatory properties of HO-1 are thought to rely on the ability of this enzyme to degrade heme and generate bilirubin, free iron and carbon monoxide(15) Bilirubin is a potent anti-oxidant(13), free iron upregulates the transcription of the cytoprotective gene, ferritin(16), and carbon monoxide is thought to be essential in regulating vascular relaxation in a manner similar to nitric oxide(15). We show here that the expression of the HO-1 gene is functionally associated with xenograft survival, and that rapid expression of HO-1 in cardiac xenografts can be essential to ensure long-term xenograft survival.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Sect, New Haven, CT 06513 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital; Yale University; Massachusetts Institute of Technology (MIT)	Soares, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA.		Soares, Miguel P/G-4188-2011; Grey, Shane T/B-3020-2008	Grey, Shane T/0000-0003-2160-1625; Poss, Kenneth/0000-0002-6743-5709; Soares, Miguel/0000-0002-9314-4833				Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BALLA G, 1992, J BIOL CHEM, V267, P18148; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; HASAN R, 1992, TRANSPLANTATION, V54, P408, DOI 10.1097/00007890-199209000-00004; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Koyamada N, 1998, TRANSPLANTATION, V65, P1210, DOI 10.1097/00007890-199805150-00012; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin SS, 1998, J CLIN INVEST, V101, P1745, DOI 10.1172/JCI2134; Lin YA, 1998, NAT MED, V4, P173, DOI 10.1038/nm0298-173; LOZADA C, 1995, P NATL ACAD SCI USA, V92, P8378, DOI 10.1073/pnas.92.18.8378; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Miyatake T, 1998, J IMMUNOL, V160, P4114; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; PLATT JL, 1994, IMMUNOL REV, V141, P127, DOI 10.1111/j.1600-065X.1994.tb00875.x; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Slowik MR, 1997, LAB INVEST, V77, P257; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	30	543	589	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1998	4	9					1073	1077		10.1038/2063	http://dx.doi.org/10.1038/2063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734404				2022-12-27	WOS:000075804100044
J	Geula, C; Wu, CK; Saroff, D; Lorenzo, A; Yuan, ML; Yankner, BA				Geula, C; Wu, CK; Saroff, D; Lorenzo, A; Yuan, ML; Yankner, BA			Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity	NATURE MEDICINE			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; TRANSGENIC MICE; CEREBRAL-CORTEX; SENILE PLAQUES; PEPTIDE; INVITRO; TAU; PHOSPHORYLATION; AGGREGATION	The formation of fibrillar deposits of amyloid beta protein (A beta) in the brain is a pathological hallmark of Alzheimer's disease(1.2) (AD). A central question is whether A beta plays a direct role in the neurodegenerative process in AD (refs. 3,4). The involvement of A beta in the neurodegenerative process is suggested by the neurotoxicity of the fibrillar form of A beta in vitro(5-11). However, mice transgenic for the A beta precursor protein that develop amyloid deposits in the brain do not show the degree of neuronal loss or tau phosphorylation found in AD (refs. 12-16). Here we show that microinjection of plaque-equivalent concentrations of fibrillar, but not soluble, A beta in the aged rhesus monkey cerebral cortex results in profound neuronal loss, tau phosphorylation and microglial proliferation. Fibrillar A beta at plaque-equivalent concentrations is not toxic in the young adult rhesus brain. A beta toxicity in vivo is also highly species-specific; toxicity is greater in aged rhesus monkeys than in aged marmoset monkeys, and is not significant in aged rats. These results suggest that AB neurotoxicity in vivo is a pathological response of the aging brain, which is most pronounced in higher order primates. Thus, longevity may contribute to the unique susceptibility of humans to Alzheimer's disease by rendering the brain vulnerable to A beta neurotoxicity.	Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Sect Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Geula, C (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA.	cgeula@west.bidmc.harvard.edu			NIA NIH HHS [AG10282] Funding Source: Medline; NINDS NIH HHS [NS30352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONS N, 1991, NEUROBIOL AGING, V13, P99; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; Frey P, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P447; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giulian D, 1996, J NEUROSCI, V16, P6021; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROSCI, V17, P7053; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MANDELKOW EM, 1993, ANN NY ACAD SCI, V695, P209, DOI 10.1111/j.1749-6632.1993.tb23054.x; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1993, AM J PATHOL, V142, P17; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; STRUBLE RG, 1985, BRAIN RES, V361, P267, DOI 10.1016/0006-8993(85)91298-3; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; WALKER LC, 1990, ACTA NEUROPATHOL, V80, P381, DOI 10.1007/BF00307691; Weldon DT, 1998, J NEUROSCI, V18, P2161; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	36	472	496	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1998	4	7					827	831		10.1038/nm0798-827	http://dx.doi.org/10.1038/nm0798-827			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX687	9662375				2022-12-27	WOS:000074543900038
J	Contag, PR; Olomu, IN; Stevenson, DK; Contag, CH				Contag, PR; Olomu, IN; Stevenson, DK; Contag, CH			Bioluminescent indicators in living mammals	NATURE MEDICINE			English	Article							LONG TERMINAL REPEAT; TRANSGENIC MICE; IN-VIVO; LUCIFERASE; EXPRESSION; ACTIVATION; SKIN; TECHNOLOGY; LIGHT; CELLS		Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Xenogen Corp, Stanford, CA 94309 USA	Stanford University	Contag, CH (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 300 Pasteur Dr, Stanford, CA 94305 USA.		Wilson, Matthew H/K-3193-2013	Contag, Christopher/0000-0002-1011-8278	NCRR NIH HHS [RR00070] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Contag C. H., 1996, OSA Trends in Optics and Photonics on Biomedical Optical Spectroscopy and Diagnostics. Vol.3. From the Topical Meeting, P220; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; Hickey MJ, 1996, ANTIMICROB AGENTS CH, V40, P400, DOI 10.1128/AAC.40.2.400; HOOPER CE, 1994, J BIOLUM CHEMILUM, V9, P113, DOI 10.1002/bio.1170090303; HOOPER CE, 1990, J BIOLUM CHEMILUM, V5, P123, DOI 10.1002/bio.1170050208; MORREY JD, 1991, J VIROL, V65, P5045, DOI 10.1128/JVI.65.9.5045-5051.1991; MORREY JD, 1992, J ACQ IMMUN DEF SYND, V5, P1195; MORREY JD, 1994, INTERVIROLOGY, V37, P315, DOI 10.1159/000150395; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; WHITE MRH, 1995, J CELL SCI, V108, P441; ZHANG LR, 1994, CLIN EXP METASTAS, V12, P87, DOI 10.1007/BF01753974	13	407	448	1	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					245	247		10.1038/nm0298-245	http://dx.doi.org/10.1038/nm0298-245			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461201				2022-12-27	WOS:000072249800043
J	Gorochov, G; Neumann, AU; Kereveur, A; Parizot, C; Li, TS; Katlama, C; Karmochkine, M; Raguin, G; Autran, B; Debre, P				Gorochov, G; Neumann, AU; Kereveur, A; Parizot, C; Li, TS; Katlama, C; Karmochkine, M; Raguin, G; Autran, B; Debre, P			Perturbation of CD4(+) and CD8(+) T-cell repertoires during progression to AIDS and regulation of the CD4(+) repertoire during antiviral therapy	NATURE MEDICINE			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; HIV-1 INFECTION; GENE USAGE; IN-VIVO; VIRUS; EXPANSION; SEGMENT; RECOGNITION; VARIABILITY; DISEASE	The T-cell antigen receptor (TCR) repertoire was studied longitudinally by analyzing the varying lengths of the beta chain CDR3 hypervariable region during the course of HIV-1 infection and following combination antiretroviral therapy. Drastic restrictions in CD8(+) T-cell repertoire usage were found at all stages of natural progression and persisted during the first six months of treatment. In contrast, significant CD4(+) T-cell repertoire perturbations were not found in early stages of infection but correlated with progression to AIDS. Out of ten patients presenting with pretreatment perturbations, normalization of the CD4(+) repertoire was observed in eight good responders, but not in two cases of unsuccessful therapy. These results indicate that, besides CD4(+) cell count rise, an efficient control of HIV replication may allow qualitative modifications of the CD4(+) repertoire balance.	Hop La Pitie Salpetriere, CERVI, Cellular Immunol Lab, CNRS,URA 625, F-75013 Paris, France; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Hop La Pitie Salpetriere, Serv Malad Infect & Trop, F-75013 Paris, France; Hop Croix St Simon, Serv Med Interne, F-75020 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Bar Ilan University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Gorochov, G (corresponding author), Hop La Pitie Salpetriere, CERVI, Cellular Immunol Lab, CNRS,URA 625, 83 Blvd Hop, F-75013 Paris, France.		Gorochov, Guy/P-2911-2017	Gorochov, Guy/0000-0003-2097-9677				AKOLKAR PN, 1993, J IMMUNOL, V150, P2761; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAHADORAN P, 1993, EUR J IMMUNOL, V23, P2041, DOI 10.1002/eji.1830230850; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FITZGERALD JE, 1995, J IMMUNOL, V154, P3538; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GOROCHOV G, 1994, BLOOD, V83, P587; Haas G, 1996, J IMMUNOL, V157, P4212; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JORES R, 1993, J IMMUNOL, V151, P6110; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; Kepler TB, 1996, J IMMUNOL, V157, P4451; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; Levraud JP, 1996, J EXP MED, V183, P439, DOI 10.1084/jem.183.2.439; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MORLEY JK, 1995, J IMMUNOL, V154, P6182; Musette P, 1996, EUR J IMMUNOL, V26, P618, DOI 10.1002/eji.1830260317; Neumann AU, 1997, NAT MED, V3, P703, DOI 10.1038/nm0797-703b; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Roglic M, 1997, CLIN EXP IMMUNOL, V107, P21, DOI 10.1046/j.1365-2249.1997.d01-886.x; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Schwab R, 1997, J IMMUNOL, V158, P4493; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057	36	382	396	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					215	221		10.1038/nm0298-215	http://dx.doi.org/10.1038/nm0298-215			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461196				2022-12-27	WOS:000072249800038
J	Pakker, NG; Notermans, DW; de Boer, RJ; Roos, MTL; de Wolf, F; Hill, A; Leonard, JM; Danner, SA; Miedema, F; Schellekens, PTA				Pakker, NG; Notermans, DW; de Boer, RJ; Roos, MTL; de Wolf, F; Hill, A; Leonard, JM; Danner, SA; Miedema, F; Schellekens, PTA			Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation	NATURE MEDICINE			English	Article							FUNCTION IN-VITRO; IMMUNOLOGICAL MEMORY; CUBIC MILLIMETER; TURNOVER; ADULTS; LYMPHOCYTES; ZIDOVUDINE; PLASMA; COUNTS; LENGTH	The origin of CD4(+) T cells reappearing in the blood following antiretroviral therapy in human immunodeficiency virus type-1 (HIV-1) infection is still controversial. Here we show, using mathematical modeling, that redistribution of T cells to the blood can explain the striking correlation between the initial CD4(+) and CD8(+) memory T-cell repopulation and the observation that 3 weeks after the start of treatment memory CD4(+) T-cell numbers reach a plateau. The increase in CD4(+) T cells following therapy most likely is a composite of initial redistribution, accompanied by a continuous slow repopulation with newly produced naive T cells.	Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht, NL-3584 CH Utrecht, Netherlands; Abbott Labs, Abbott Pk, IL 60064 USA; Glaxo Wellcome Res & Dev Ltd, Greenford UB6 0HE, Middx, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Abbott Laboratories; GlaxoSmithKline	Miedema, F (corresponding author), Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	miedema@clb.nl	de Boer, Rob/B-6050-2011	de Boer, Rob/0000-0002-2130-691X				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Giorgi J. V., 1996, IMMUNOLOGY HIV INFEC, P181; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOOT M, 1993, J INFECT DIS, V168, P733, DOI 10.1093/infdis/168.3.733; Lafeuillade A, 1996, J INFECT DIS, V174, P404, DOI 10.1093/infdis/174.2.404; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; NOTERMANS DW, IN PRESS AIDS; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Ottinger HD, 1996, BLOOD, V88, P2775, DOI 10.1182/blood.V88.7.2775.bloodjournal8872775; Paganin C, 1997, J CLIN INVEST, V99, P663, DOI 10.1172/JCI119209; Pakker NG, 1997, J ACQ IMMUN DEF SYND, V16, P318, DOI 10.1097/00042560-199712150-00002; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Rep MHG, 1997, J CLIN INVEST, V99, P2225, DOI 10.1172/JCI119396; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Wang LQ, 1997, VIROLOGY, V228, P141, DOI 10.1006/viro.1996.8397; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; ZHANG Z, IN PRESS P NATL ACAD; 1992, MMWR MORBID MORTAL W, V41, P1	41	600	613	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1998	4	2					208	214		10.1038/nm0298-208	http://dx.doi.org/10.1038/nm0298-208			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461195	Green Submitted			2022-12-27	WOS:000072249800037
J	Dullforce, P; Sutton, DC; Heath, AW				Dullforce, P; Sutton, DC; Heath, AW			Enhancement of T cell-independent immune responses in vivo by CD40 antibodies	NATURE MEDICINE			English	Article							B-CELLS; CAPSULAR POLYSACCHARIDE; PNEUMOCOCCAL VACCINE; CD40-DEFICIENT MICE; DEFICIENT MICE; LIGAND; EXPRESSION; INDUCTION; INFECTION; DISTINCT	In this report we describe a potentially powerful method for vaccinating infants against encapsulated bacterial pathogens such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. High levels of antibody directed against the polysaccharides of the bacterial capsule are normally protective(1-3). Unfortunately, the capsular polysaccharides are T cell-independent antigens (TI); lacking T-cell help, they induce only weak, predominantly IgM antibody responses, with infants responding especially poorly(4). T-cell help, given to B cells during responses to protein antigens, causes stronger antibody responses and isotype switching to the Ige isotypes. T-cel help is mainly mediated through ligation of the B-cell surface antigen, CD40, by its cognate T-cell ligand, CD154 (ref. 5-9). Here we show that administering anti-CD40 monoclonal antibody to mice, along with pneumococcal polysaccharide, provides a substitute for T-cell help and results in the generation of strong, isotype-switched antibody responses, which are protective, The work points the way coward a possible effective and inexpensive means of protecting susceptible groups against important. bacterial pathogens.	Univ Sheffield, Sch Med, Div Med & Mol Genet, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Sch Med, Sheffield Inst Vaccine Studies, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; University of Sheffield	Dullforce, P (corresponding author), Univ Sheffield, Sch Med, Div Med & Mol Genet, F Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed F, 1996, J INFECT DIS, V173, P83, DOI 10.1093/infdis/173.1.83; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; CARSON PJ, 1995, J INFECT DIS, V172, P340, DOI 10.1093/infdis/172.2.340; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DEVELASCO EA, 1995, MICROBIOL REV, V59, P591; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FANSLOW WC, 1994, J IMMUNOL, V152, P4262; Ferlin WG, 1996, EUR J IMMUNOL, V26, P2911, DOI 10.1002/eji.1830261216; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYHTY H, 1984, PEDIATRICS, V74, P857; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KONRADSEN HB, 1993, J IMMUNOL METHODS, V164, P13, DOI 10.1016/0022-1759(93)90270-H; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LEE HJ, 1995, VACCINE, V13, P1533, DOI 10.1016/0264-410X(95)00093-G; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RIJKERS GT, 1996, REV MED MICROBIOL, V7, P3; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SCHER I, 1982, IMMUNOL REV, V64, P117, DOI 10.1111/j.1600-065X.1982.tb00421.x; SCHULTZ CL, 1992, J IMMUNOL, V149, P60; WARREN WD, 1995, J IMMUNOL, V155, P5637; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	29	94	108	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1998	4	1					88	91		10.1038/nm0198-088	http://dx.doi.org/10.1038/nm0198-088			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ391	9427612	Bronze			2022-12-27	WOS:000072249700040
J	Bryan, TM; Englezou, A; DallaPozza, L; Dunham, MA; Reddel, RR				Bryan, TM; Englezou, A; DallaPozza, L; Dunham, MA; Reddel, RR			Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines	NATURE MEDICINE			English	Article							P16(INK4) EXPRESSION; IMMORTAL CELLS; CANCER; CARCINOMA; P53; FIBROBLASTS; ASSOCIATION; REPEATS; SKIN; GENE	The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potentia(1-3). Telomerase is an enzyme that restores telomeric DNA sequences(4), and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo(5). Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues(6,7). It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date(7). It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization(8-11) presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres)(11). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA; NEW CHILDRENS HOSP,WESTMEAD,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; University of Sydney; University of Sydney			Bryan, Tracy M/B-8468-2014; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gupta J, 1996, J NATL CANCER I, V88, P1152, DOI 10.1093/jnci/88.16.1152; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hsiao RS, 1997, ANTICANCER RES, V17, P827; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Mehle C, 1996, ONCOGENE, V13, P161; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Noble JR, 1996, ONCOGENE, V13, P1259; NURNBERG P, 1993, HUM GENET, V91, P190; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SPRUNG CN, IN PRESS MUTAT RES; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yasumoto S, 1996, ONCOGENE, V13, P433	39	979	1010	0	48	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1271	1274		10.1038/nm1197-1271	http://dx.doi.org/10.1038/nm1197-1271			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359704				2022-12-27	WOS:A1997YD89600038
J	Chen, JD; Bai, XF; Yang, AG; Cong, YP; Chen, SY				Chen, JD; Bai, XF; Yang, AG; Cong, YP; Chen, SY			Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy	NATURE MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; IMMUNODEFICIENCY-VIRUS; ENDOPLASMIC-RETICULUM; SYNTHESIZED PROTEINS; GENE-TRANSFER; CELLS; LESTR/FUSIN; DEGRADATION; PROGRESSION; ANTIBODY	CXC-chemokine receptor (CXCR)4/fusin, a newly discovered co-receptor for T-cell line (T)-tropic HIV-1 virus, plays a critical role in T-tropic virus fusion and entry into permissive cells. The occurrence of T-tropic HIV viruses is associated with CD4-positive cell decline and progression to AIDS, suggesting that the T-tropic HIV-1 contributes to AIDS pathogenesis. In this study, we used a novel strategy to inactivate CXCR-4 by targeting a modified CXC-chemokine to the endoplasmic reticulum (ER) to block the surface expression of newly synthesized CXCR-4. The genetically modified lymphocytes expressing this intracellular chemokine, termed ''intrakine,'' are immune to T-tropic virus infection and appear to retain normal biological features. Thus, this genetic intrakine strategy is uniquely targeted at the conserved cellular receptor for the prevention of HIV-1 entry and may be developed into an effective treatment for HIV-1 infection and AIDS.	WAKE FOREST UNIV,CTR COMPREHENS CANC,DEPT CANC BIOL,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center								Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BUONOCORE L, 1993, P NATL ACAD SCI USA, V90, P2695, DOI 10.1073/pnas.90.7.2695; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; CHEN SY, 1994, HUM GENE THER, V5, P595, DOI 10.1089/hum.1994.5.5-595; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FENG Y, 1996, SCIENCE, V272, P809; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pear Warren S., 1997, P41; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Rudoll T, 1996, GENE THER, V3, P695; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TERSMETTE M, 1989, LANCET, V1, P983; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46; YANG AG, IN PRESS P NATL ACAD; YU M, 1994, GENE THER, V1, P13	43	91	107	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1110	1116		10.1038/nm1097-1110	http://dx.doi.org/10.1038/nm1097-1110			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334722				2022-12-27	WOS:A1997XZ28700036
J	Lavie, A; Schlichting, I; Vetter, IR; Konrad, M; Reinstein, J; Goody, RS				Lavie, A; Schlichting, I; Vetter, IR; Konrad, M; Reinstein, J; Goody, RS			The bottleneck in AZT activation	NATURE MEDICINE			English	Article							REVERSE-TRANSCRIPTASE; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; DNA-POLYMERASES; CELLS; 5'-TRIPHOSPHATE; TRIPHOSPHATE; INHIBITION; EXPRESSION	Nucleoside-based inhibitors of reverse transcriptase were the first drugs to be used in the chemotherapy of AIDS. After entering the cell, these substances are activated to their triphosphate form by cellular kinases, after which they are potent chain terminators for the growing viral DNA (ref. 1). The two main factors limiting their efficacy are probably interrelated. These are the insufficient degree of reduction of viral load at the commencement of treatment and the emergence of resistant variants of the virus. The reason for the relatively poor suppression of viral replication appears to be inefficient metabolic activation. Thus, for the most extensively used drug, 3'-azido-3'-deoxythymidine (AZT), whereas phosphorylation to the monophosphate is facile, the product is a very poor substrate for the next kinase in the cascade, thymidylate kinase(2,3). Because of this, although high concentrations of the monophosphate can be reached in the cell, the achievable concentration of the active triphosphate is several orders of magnitude lower. Determination of the structure of thymidylate kinase as a complex with AZT monophosphate (AZTMP) together with studies on the kinetics of its phosphorylation have now led to a detailed understanding of the reasons for and consequences of the poor substrate properties.	MAX PLANCK INST MOL PHYSIOL,DEPT STRUCT PHYSIOL,D-44139 DORTMUND,GERMANY; MAX PLANCK INST BIOPHYS CHEM,DEPT MOL GENET,D-37018 GOTTINGEN,GERMANY	Max Planck Society; Max Planck Society	Lavie, A (corresponding author), MAX PLANCK INST MOL PHYSIOL,DEPT PHYS BIOCHEM,RHEINLANDDAMM 201,D-44139 DORTMUND,GERMANY.		Schlichting, Ilme/I-1339-2013; Goody, Roger S/J-8845-2014; Lavie, Arnon/H-4927-2012	Goody, Roger S/0000-0002-0772-0444; Lavie, Arnon/0000-0001-5591-8722				BERGHAUSER J, 1975, BIOCHIM BIOPHYS ACTA, V397, P370, DOI 10.1016/0005-2744(75)90126-6; BRIDGES EG, 1993, BIOCHEM PHARMACOL, V45, P1571, DOI 10.1016/0006-2952(93)90296-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P918, DOI 10.1128/AAC.37.4.918; HUANG P, 1990, J BIOL CHEM, V265, P11914; LAVIE A, IN PRESS NATRUE STRU; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; NICKEL W, 1992, J BIOL CHEM, V267, P848; QIAN MX, 1994, BIOCHEM PHARMACOL, V48, P383, DOI 10.1016/0006-2952(94)90111-2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TORNEVIK Y, 1995, BIOCHEM PHARMACOL, V49, P829, DOI 10.1016/0006-2952(94)00453-S; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836	16	122	128	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					922	924		10.1038/nm0897-922	http://dx.doi.org/10.1038/nm0897-922			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256287				2022-12-27	WOS:A1997XP01400038
J	Sternberg, EM				Sternberg, EM			Emotions and disease: From balance of humors to balance of molecules	NATURE MEDICINE			English	Editorial Material							CORTICOTROPIN-RELEASING FACTOR; PITUITARY-ADRENAL AXIS; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; INTERLEUKIN-1 RECEPTOR; LEWIS RATS; LOCALIZATION; CYTOKINES; MICE	A new field of research investigates how the immune and nervous systems communicate with each other.			Sternberg, EM (corresponding author), NIMH, SECT NEUROENDOCRINE IMMUNOL & BEHAV,NIH,BLDG 10, RM 2D-46,10 CTR DR, MSC 1284, BETHESDA, MD 20892 USA.							BARTFAI T, 1993, NEUROCHEM INT, V22, P435, DOI 10.1016/0197-0186(93)90038-7; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BERNTON EW, 1987, SCIENCE, V238, P519, DOI 10.1126/science.2821620; BLUTHE RM, 1994, CR ACAD SCI III-VIE, V317, P499; BRADY LS, 1994, J NEUROSCI, V14, P4951; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; Breder CD, 1996, BRAIN RES, V713, P64, DOI 10.1016/0006-8993(95)01474-8; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; BROWN DH, 1993, INFECT IMMUN, V61, P4793, DOI 10.1128/IAI.61.11.4793-4800.1993; BROWN DH, IN PRESS INFECT IMMU; BROWN TM, 1993, COMPANION ENCY HIST, V1; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; CORTNUMMIUS J, 1677, MORTO ATTONITO LIBER; CRUWYS SC, 1995, NEUROSCI LETT, V193, P205, DOI 10.1016/0304-3940(95)11704-Z; EDWARDS CK, 1991, P NATL ACAD SCI USA, V88, P2274, DOI 10.1073/pnas.88.6.2274; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; ERICSSON A, 1994, J NEUROSCI, V14, P897; EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W; Felten S. Y., 1991, PSYCHONEUROIMMUNOLOG, P27, DOI DOI 10.1016/B978-0-12-043780-1.50006-3; GOETZL EJ, 1985, J IMMUNOL S2, V135; HERMANN G, 1993, J NEUROIMMUNOL, V47, P83, DOI 10.1016/0165-5728(93)90287-9; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Kuhn Thomas S, 1970, INT ENCY UNIFIED SCI, V2; LICINIO J, 1991, ENDOCRINOLOGY, V129, P562, DOI 10.1210/endo-129-1-562; MACPHEE IAM, 1989, J EXP MED, V169, P431, DOI 10.1084/jem.169.2.431; MATUCCI CM, 1995, J RHEUMATOL, V22, P1447; MCMURRAY RW, 1995, J RHEUMATOL, V22, P2084; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; MISIEWICZ B, IN PRESS EXP NEUROL; PAYAN DG, 1987, AM REV RESPIR DIS, V136, pS39, DOI 10.1164/ajrccm/136.6_Pt_2.S39; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Scammell TE, 1996, AM J PHYSIOL-REG I, V271, pR333, DOI 10.1152/ajpregu.1996.271.2.R333; SEI Y, 1995, NEUROIMMUNOMODULAT, V2, P121, DOI 10.1159/000096881; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; SUNDAR SK, 1989, P NATL ACAD SCI USA, V86, P6398, DOI 10.1073/pnas.86.16.6398; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; Thyagarajan S., 1996, Society for Neuroscience Abstracts, V22, P1793; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0; WICK G, 1987, IMMUNOL LETT, V16, P249, DOI 10.1016/0165-2478(87)90154-4; WILLIS T, 1679, REMAINING MED WORKS; Wong Mal-Li, 1994, Neuroimmunomodulation, V1, P181, DOI 10.1159/000097159; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581	45	54	54	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1997	3	3					264	267		10.1038/nm0397-264	http://dx.doi.org/10.1038/nm0397-264			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WL305	9055845				2022-12-27	WOS:A1997WL30500019
J	Reinhart, TA; Rogan, MJ; Viglianti, GA; Rausch, DM; Eiden, LE; Haase, AT				Reinhart, TA; Rogan, MJ; Viglianti, GA; Rausch, DM; Eiden, LE; Haase, AT			A new approach to investigating the relationship between productive infection and cytopathicity in vivo	NATURE MEDICINE			English	Article							FOLLICULAR DENDRITIC CELLS; IMMUNODEFICIENCY SYNDROME AIDS; LYMPH-NODE; RHESUS-MONKEYS; VIRUS TYPE-1; HIV-1; MACROPHAGES; PROGRESSION; EXPRESSION; PARTICLES	We describe a novel experimental approach to analyzing virus-host relationships and potential mechanisms of cytopathicity in vivo in simian immunodeficiency virus (SIV) infections. Progressive destruction of lymphoid tissue in the course of infection by SIV or human immunodeficiency virus (HIV) accompanies the loss of CD4(+) T lymphocytes and sets the stage for AIDS(1,2). Because one of the important early events in this pathological process is lysis of follicular dendritic cells(3) (FDCs), we investigated the controversial role of productive SIV infection in the destruction of FDCs. To differentiate productive infections from the known association of virus with FDCs as immune complexes trapped on cell surfaces(4-6), we used detection of spliced viral mRNAs in cells as evidence of productive infection. We found that spliced and unspliced viral RNAs could be detected by in situ hybridization (ISH) with specific antisense oligonucleotide probes in lymphocytes and macrophages with sensitivities of fewer than ten copies of spliced viral RNA per cell. We detected only unspliced RNA in germinal centers where FDCs reside. Thus, no productive infection of these cells can be detected in vivo by this assay, and their destruction likely occurs by indirect mechanisms that have yet to be determined.	UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; NIMH,CELL BIOL LAB,BETHESDA,MD	University of Minnesota System; University of Minnesota Twin Cities; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Eiden, Lee/0000-0001-7524-944X; Viglianti, Gregory/0000-0002-0244-8293				ARMSTRONG JA, 1984, LANCET, V2, P370; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; CHAKRABARTI L, 1994, J VIROL, V68, P6634, DOI 10.1128/JVI.68.10.6634-6643.1994; DIEBOLD J, 1985, PATHOL RES PRACT, V180, P590, DOI 10.1016/S0344-0338(85)80037-6; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; MURRAY EA, 1992, SCIENCE, V255, P1246, DOI 10.1126/science.1546323; PARMENTIER HK, 1990, AM J PATHOL, V137, P247; PENG HR, 1995, VIROLOGY, V206, P16, DOI 10.1016/S0042-6822(95)80015-8; RAUSCH DM, 1994, J NEUROPATH EXP NEUR, V53, P165, DOI 10.1097/00005072-199403000-00008; Reinhart TA, 1996, VIROLOGY, V224, P338, DOI 10.1006/viro.1996.0539; SCHMITZ J, 1994, J IMMUNOL, V153, P1352; SCHUURMAN HJ, 1985, J PATHOL, V147, P269, DOI 10.1002/path.1711470405; SPIEGEL H, 1992, AM J PATHOL, V140, P15; SPRENGER R, 1995, MED MICROBIOL IMMUN, V184, P129, DOI 10.1007/BF00224349; STAHMER I, 1991, EUR J IMMUNOL, V21, P1873, DOI 10.1002/eji.1830210814; STAHMER J, 1996, J ACQUIR IMMUN DEFIC, V11, P1; TENNERRACZ K, 1994, RES VIROLOGY, V145, P177, DOI 10.1016/S0923-2516(07)80020-3; Tsunoda R, 1996, AIDS, V10, P595, DOI 10.1097/00002030-199606000-00004; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990	26	33	33	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					218	221		10.1038/nm0297-218	http://dx.doi.org/10.1038/nm0297-218			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018242				2022-12-27	WOS:A1997WF08800042
J	Taylor, DA; Atkins, BZ; Hungspreugs, P; Jones, TR; Reedy, MC; Hutcheson, KA; Glower, DD; Kraus, WE				Taylor, DA; Atkins, BZ; Hungspreugs, P; Jones, TR; Reedy, MC; Hutcheson, KA; Glower, DD; Kraus, WE			Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation	NATURE MEDICINE			English	Article							LONG-TERM SURVIVAL; RABBITS	The adult heart lacks reserve cardiocytes and cannot regenerate. Therefore, a large acute myocardial infarction often develops into congestive heart failure. To attempt to prevent this progression, we transplanted skeletal myoblasts into cryoinfarcted myocardium of the same rabbits tautologous transfer), monitored cardiac function in vivo for two to six weeks and examined serial sections of the hearts by light and electron microscopy. Islands of different sizes comprising elongated, striated cells that retained characteristics of both skeletal and cardiac cells were found in the cryoinfarct. In rabbits in which myoblasts were incorporated, myocardial performance was improved. The ability to regenerate functioning muscle after autologous myoblast transplantation could have a important effect on patients after acute myocardial infarction.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Taylor, DA (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3327, Durham, NC 27710 USA.			Kraus, William E/0000-0003-1930-9684	NHLBI NIH HHS [2R01HL5798-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISCHOFF R, 1975, ANAT REC, V182, P215, DOI 10.1002/ar.1091820207; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; DRAKEHOLLAND AJ, 1993, BASIC RES CARDIOL, V88, P250; GILL W, 1970, CRYOBIOLOGY, V6, P347, DOI 10.1016/S0011-2240(70)80089-X; GILL W, 1971, BRIT J SURG, V58, P870; GLANTZ SA, 1978, CIRC RES, V42, P171, DOI 10.1161/01.RES.42.2.171; GLOWER DD, 1985, CIRCULATION, V71, P994, DOI 10.1161/01.CIR.71.5.994; Guerette B, 1997, CELL TRANSPLANT, V6, P101, DOI 10.1016/S0963-6897(96)00230-8; Jarvis JC, 1997, BAKKEN RES, V11, P269; KLUNG MG, 1996, J CLIN INVEST, V98, P216; KOH GY, 1993, AM J PHYSIOL, V264, pH1727, DOI 10.1152/ajpheart.1993.264.5.H1727; MAGID NM, 1992, AM J PHYSIOL, V263, pH226, DOI 10.1152/ajpheart.1992.263.1.H226; Marelli D, 1992, Cell Transplant, V1, P383; Robinson SW, 1996, CELL TRANSPLANT, V5, P77, DOI 10.1016/0963-6897(95)02016-0; Silvestry SC, 1996, J MOL CELL CARDIOL, V28, P815, DOI 10.1006/jmcc.1996.0076; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; STOCKDALE FE, 1990, ADV EXP MED BIOL, V280, P7; Taylor DA, 1997, P ASSOC AM PHYSICIAN, V109, P245; WATT DJ, 1994, NATURE, V368, P406, DOI 10.1038/368406a0	19	852	969	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					929	933		10.1038/nm0898-929	http://dx.doi.org/10.1038/nm0898-929			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701245				2022-12-27	WOS:000075107400036
J	Ruegg, C; Yilmaz, A; Bieler, G; Bamat, J; Chaubert, P; Lejeune, FJ				Ruegg, C; Yilmaz, A; Bieler, G; Bamat, J; Chaubert, P; Lejeune, FJ			Evidence for the involvement of endothelial cell integrin alpha V beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; SYNERGISTIC INDUCTION; ISOLATION PERFUSION; HUMAN-MELANOMA; ANGIOGENESIS; EXPRESSION; ACTIVATION; INHIBITION; RECEPTORS	Administration of tumor necrosis factor (TNF) and gamma interferon (IFN-gamma) to melanoma patients causes selective disruption of the tumor vasculature but the mechanism of this disruption is unknown. Here we report that exposure of human endothelial cells to TNF and IFN-gamma results in a reduced activation of integrin alpha V beta 3, an adhesion receptor that plays a key role in tumor angiogenesis, leading to a decreased alpha V beta 3-dependent endothelial cell adhesion and survival. Detachment and apoptosis of angiogenic endothelial cells was demonstrated in vivo in melanoma metastases of patients treated with TNF and IFN-gamma. These results implicate integrin alpha V beta 3 in the anti-vascular activity of TNF and IFN-gamma and demonstrate a new mechanism by which cytokines control cell adhesion.	Univ Lausanne, CHU Vaudois, ISREC, Sch Med,Ctr Pluridisciplinaire Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland; Univ Lausanne, Sch Med, Inst Pathol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research; University of Lausanne	Ruegg, C (corresponding author), Univ Lausanne, CHU Vaudois, ISREC, Sch Med,Ctr Pluridisciplinaire Oncol, 155 Chem Boveresses, CH-1066 Epalinges, Switzerland.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DOUKAS J, 1990, J IMMUNOL, V145, P1727; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GERAIN J, 1992, CYTOKINE, V4, P585, DOI 10.1016/1043-4666(92)90024-L; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; LAHM H, 1994, INT J CANCER, V59, P440, DOI 10.1002/ijc.2910590325; LEJEUNE F, 1994, J CELL BIOCHEM, V56, P52, DOI 10.1002/jcb.240560110; Lejeune F., 1997, Melanoma Research, V7, pS48, DOI 10.1097/00008390-199706001-00167; LEJEUNE FJ, 1995, EUR J CANCER, V31A, P1009, DOI 10.1016/0959-8049(94)00512-5; LIENARD D, 1994, MELANOMA RES, V4, P21; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHMORI Y, 1995, J IMMUNOL, V154, P5235; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RENARD N, 1995, J PATHOL, V176, P279, DOI 10.1002/path.1711760310; RENARD N, 1994, INT J CANCER, V57, P656, DOI 10.1002/ijc.2910570508; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH JW, 1994, J BIOL CHEM, V269, P960; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	50	395	411	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1998	4	4					408	414		10.1038/nm0498-408	http://dx.doi.org/10.1038/nm0498-408			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546785				2022-12-27	WOS:000072906800034
J	Nestle, FO; Alijagic, S; Gilliet, M; Sun, YS; Grabbe, S; Dummer, R; Burg, G; Schadendorf, D				Nestle, FO; Alijagic, S; Gilliet, M; Sun, YS; Grabbe, S; Dummer, R; Burg, G; Schadendorf, D			Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; ANTITUMOR IMMUNITY; MURINE TUMORS; IN-VITRO; T-CELLS; INDUCTION; IMMUNIZATION; RESPONSES; THERAPY; ALPHA	Melanoma is the main cause of death in patients with skin cancer(1). Cytotoxic T lymphocytes (CTLs) attack melanoma cells in an HLA-restricted and tumor antigen-specific manner. Several melanoma-associated tumor antigens have been identified(2). These antigens are suitable candidates for a vaccination therapy of melanoma. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized for the induction of a primary T-cell response(3). Mouse studies have demonstrated the potent capacity of DCs to induce antitumor immunity(4-11). In the present clinical pilot study, DCs were generated in the presence of granulocyte/macrophage-colony stimulating factor (CM-CSF) and interleukin 4 (IL-4) and were pulsed with tumor lysate or a cocktail of peptides known to be recognized by CTLs, depending on the patient's HLA haplotype. Keyhole limpet hemocyanin (KLH) was added as a CD4 helper antigen and immunological tracer molecule. Sixteen patients with advanced melanoma were immunized on an outpatient basis. Vaccination was well tolerated. No physical sign bf autoimmunity was detected in any of the patients. DC vaccination induced delayed-type hypersensitivity (DTH) reactivity toward KLH in all patients, as well as a positive DTH reaction to peptide-pulsed DCs in 11 patients. Recruitment of peptide-specific CTLs to the DTH challenge site was also demonstrated. Therefore, antigen-specific immunity was induced during DC vaccination. Objective responses were evident in 5 out of 16 evaluated patients (two complete responses, three partial responses) with regression of metastases in various organs (skin, soft tissue, lung, pancreas) and one additional minor response. These data indicate that vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma. Further studies are necessary to demonstrate clinical effectiveness and impact on the survival of melanoma patients.	Univ Heidelberg, Klinikum Mannheim, Clin Cooperat Unit Dermatooncol DKFZ, D-68135 Mannheim, Germany; Univ Zurich, Sch Med, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Munstervon, Dept Dermatol, D-48149 Munster, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Zurich; University of Munster	Schadendorf, D (corresponding author), Univ Heidelberg, Klinikum Mannheim, Clin Cooperat Unit Dermatooncol DKFZ, Theodor Kutzer Ufer 1, D-68135 Mannheim, Germany.		Grabe, Stephan/AAJ-4578-2021; Schadendorf, Dirk/AAE-8206-2019	Grabe, Stephan/0000-0002-6863-8719; 				ALIJAGIC S, 1995, EUR J IMMUNOL, V25, P3100, DOI 10.1002/eji.1830251117; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Cormier JN, 1997, CANCER J, V3, P37; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; JAGER E, 1996, INT J CANCER, V66, P162; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; MACKIE RM, 1995, BRIT MED BULL, V51, P570, DOI 10.1093/oxfordjournals.bmb.a072980; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mayordomo JI, 1996, J EXP MED, V183, P1357, DOI 10.1084/jem.183.4.1357; MUKHERJI B, 1995, P NATL ACAD SCI USA, V92, P8078, DOI 10.1073/pnas.92.17.8078; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Porgador A, 1996, J IMMUNOL, V156, P2918; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHIMIZU J, 1989, J IMMUNOL, V142, P1053; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	25	2469	2707	2	237	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					328	332		10.1038/nm0398-328	http://dx.doi.org/10.1038/nm0398-328			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500607				2022-12-27	WOS:000073616200039
J	Laske, DW; Youle, RJ; Oldfield, EH				Laske, DW; Youle, RJ; Oldfield, EH			Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors	NATURE MEDICINE			English	Article							TRANSFERRIN RECEPTOR; MONOCLONAL-ANTIBODY; NATIONAL SURVEY; NERVOUS-SYSTEM; PROTEIN TOXINS; CELL LYMPHOMA; RICIN; IMMUNOTOXIN; CARCINOMA; DELIVERY	We investigated regional therapy of recurrent malignant brain tumors with transferrin-CRM107, a conjugate of human transferrin (Tf) and a genetic mutant of diphtheria toxin (CRM107) that lacks native toxin binding. Physiological barriers to delivering proteins to tumor and surrounding infiltrated brain were circumvented with high-flow interstitial microinfusion. At least a 50% reduction in tumor volume on magnetic resonance imaging (MRI) occurred in 9 of 15 patients who could be evaluated (60%), including two complete responses. Peritumoral toxicity developed 1-4 weeks after treatment in three of three patients at 1.0 mu g/ml, but in zero of nine patients treated at lower concentrations. No symptomatic systemic toxicity occurred. Regional perfusion with Tf-CRM107 produces tumor responses without systemic toxicity in patients with malignant brain tumors refractory to conventional therapy. Direct interstitial infusion can be used successfully to distribute a large protein in the tumor and infiltrated brain surrounding the tumor.	NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Oldfield, EH (corresponding author), NINDS, Surg Neurol Branch, NIH, 10 Ctr Dr,10-5D37, Bethesda, MD 20892 USA.							[Anonymous], 1990, MALIGNANT CEREBRAL G; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CONNOR JR, 1986, BRAIN RES, V368, P319, DOI 10.1016/0006-8993(86)90576-7; FAULK WP, 1980, LANCET, V2, P390; Garfield J, 1975, Clin Oncol, V1, P213; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; GILLILAND DG, 1980, P NATL ACAD SCI-BIOL, V77, P4539, DOI 10.1073/pnas.77.8.4539; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; GROSSBARD ML, 1992, BLOOD, V79, P576; HESKETH P, 1993, J CLIN ONCOL, V11, P1682, DOI 10.1200/JCO.1993.11.9.1682; JAIN RK, 1989, JNCI-J NATL CANCER I, V81, P570, DOI 10.1093/jnci/81.8.570; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; JOHNSON VG, 1989, J NEUROSURG, V70, P240, DOI 10.3171/jns.1989.70.2.0240; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; KARNOFSKY DA, 1951, ARCH INTERN MED, V87, P477, DOI 10.1001/archinte.1951.03810040002001; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KROIN JS, 1982, NEUROSURGERY, V10, P349, DOI 10.1227/00006123-198203000-00009; KROLICK KA, 1980, P NATL ACAD SCI-BIOL, V77, P5419, DOI 10.1073/pnas.77.9.5419; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; LASKE DW, 1994, J NEUROSURG, V80, P520, DOI 10.3171/jns.1994.80.3.0520; LIEBERMAN DM, 1995, J NEUROSURG, V82, P1021, DOI 10.3171/jns.1995.82.6.1021; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MOOLTEN FL, 1970, SCIENCE, V169, P68, DOI 10.1126/science.169.3940.68; MORRISON PF, 1994, AM J PHYSIOL, V266, pR292, DOI 10.1152/ajpregu.1994.266.1.R292; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PRIOR R, 1990, VIRCHOWS ARCH A, V416, P491, DOI 10.1007/BF01600299; RECHT L, 1990, J NEUROSURG, V72, P941, DOI 10.3171/jns.1990.72.6.0941; RYBAK SM, 1991, IMMUNOL ALLERGY CLIN, V11, P359; SENDELBECK SL, 1985, BRAIN RES, V328, P251; SHINDELMAN JE, 1981, INT J CANCER, V27, P329, DOI 10.1002/ijc.2910270311; SPITLER LE, 1987, CANCER RES, V47, P1717; THORPE PE, 1978, NATURE, V271, P752, DOI 10.1038/271752a0; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; VITETTA ES, 1991, CANCER RES, V51, P4052; WALKER AE, 1985, NEUROLOGY, V35, P219, DOI 10.1212/WNL.35.2.219; WEINER LM, 1989, CANCER RES, V49, P4062; YOULE RJ, 1980, P NATL ACAD SCI-BIOL, V77, P5483, DOI 10.1073/pnas.77.9.5483; YOULE RJ, 1986, MONOCLONAL ANTIBODIE, P173; ZOVICKIAN J, 1987, J NEUROSURG, V66, P850, DOI 10.3171/jns.1987.66.6.0850	42	411	435	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1997	3	12					1362	1368		10.1038/nm1297-1362	http://dx.doi.org/10.1038/nm1297-1362			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ389	9396606				2022-12-27	WOS:000072249500032
J	Iotsova, V; Caamano, J; Loy, J; Yang, Y; Lewin, A; Bravo, R				Iotsova, V; Caamano, J; Loy, J; Yang, Y; Lewin, A; Bravo, R			Osteopetrosis in mice lacking NF-kappa B1 and NF-kappa B2	NATURE MEDICINE			English	Article							NF-KAPPA-B; C-FOS; TARGETED DISRUPTION; BONE; OSTEOCLAST; DIFFERENTIATION; CELLS; REL; PROTOONCOGENE; PROTEINS	The nfkb1 and nfkb2 genes encode closely related products regulating immune and inflammatory responses. Their role during development and differentiation remains unclear. The generation of nfkb1 null mice (p50(-/-)) resulted in altered immune responses, but had no effect on development(4). Similarly, nfkb2 knockout mice (p52(-/-)) did not show developmental defects (J.C. et ol., manuscript submitted). We have investigated the potential for in vivo compensatory functions of these genes by generating double-knockout mice. The surprising result was that the animals developed osteopetrosis because of a defect in osteoclast differentiation, suggesting redundant functions of NF-kappa B1 and NF-kappa B2 proteins in the development of this cell lineage. The osteopetrotic phenotype was rescued by bone marrow transplantation, indicating that the hematopoietic component was impaired. These results define a new mouse osteopetrotic mutant and implicate NF-kappa B proteins in bone development, raising new directions in the treatment of bone disorders.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT EXPT PATHOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb			Caamano, Jorge/I-6778-2012; Caamano, Jorge/O-7530-2019	Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056				COLIGAN JE, 1992, ISOLATION FRACTIONAT; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GRILLI M, 1993, INT REV CYTOL, V143, P1; Jimi E, 1996, J BIOL CHEM, V271, P4605; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192-0561(94)00089-7; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; PRALLET B, 1992, J BONE MINER RES, V7, P405; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52	24	719	749	2	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1285	1289		10.1038/nm1197-1285	http://dx.doi.org/10.1038/nm1197-1285			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359707				2022-12-27	WOS:A1997YD89600041
J	Jain, RK; Schlenger, K; Hockel, M; Yuan, F				Jain, RK; Schlenger, K; Hockel, M; Yuan, F			Quantitative angiogenesis assays: Progress and problems	NATURE MEDICINE			English	Review							FIBROBLAST GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; MICROVASCULAR ARCHITECTURE; NEOPLASTIC TRANSFORMATION; MAMMARY-GLAND; NORMAL TISSUE; NUDE-MICE; IN-VIVO		UNIV MAINZ, DEPT GYNECOL & OBSTET, D-55101 MAINZ, GERMANY; DUKE UNIV, DEPT BIOMED ENGN, DURHAM, NC 27708 USA	Johannes Gutenberg University of Mainz; Duke University	Jain, RK (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, STEELE LAB, BOSTON, MA 02114 USA.		Yuan, Fan/A-1287-2011; Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548	NCI NIH HHS [R35-CA-56591] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSANDRI G, 1983, CANCER RES, V43, P1790; Alessandri G, 1997, ACTA ONCOL, V36, P383, DOI 10.3109/02841869709001284; Algire GH, 1943, J NATL CANCER I, V4, P1; ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73; AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; AUERBACH R, 1975, INT J CANCER, V15, P241, DOI 10.1002/ijc.2910150209; AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BREM S, 1972, J NATL CANCER I, V48, P347; BREM SS, 1977, SCIENCE, V195, P880, DOI 10.1126/science.402692; Briscoe DM, 1997, KIDNEY INT, pS22; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Clark ER, 1930, ANAT REC, V47, P187, DOI 10.1002/ar.1090470205; Dellian M, 1996, AM J PATHOL, V149, P59; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; DEWHIRST MW, 1989, INT J RADIAT ONCOL, V17, P91, DOI 10.1016/0360-3016(89)90375-1; DUDAR TE, 1983, MICROVASC RES, V25, P1, DOI 10.1016/0026-2862(83)90040-7; DVORAK HF, 1987, LAB INVEST, V57, P673; EDDY HA, 1973, MICROVASC RES, V6, P63, DOI 10.1016/0026-2862(73)90007-1; ENDRICH B, 1979, CANCER RES, V39, P17; Fan TPD, 1997, TUMOUR ANGIOGENESIS, P5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, MOL BASIS CANC, P206; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fukumura D, 1997, AM J PATHOL, V151, P679; Gasparini G, 1997, TUMOUR ANGIOGENESIS, P29; GERLOWSKI LE, 1986, MICROVASC RES, V31, P288, DOI 10.1016/0026-2862(86)90018-X; GIMBRONE MA, 1976, CANCER RES, V36, P2611; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GIMBRONE MA, 1974, J NATL CANCER I, V52, P413, DOI 10.1093/jnci/52.2.413; GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111; GULLINO PM, 1962, J NATL CANCER I, V28, P211; GULLINO PM, 1961, J NATL CANCER I, V27, P679; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HEUSER LS, 1986, CANCER, V57, P461, DOI 10.1002/1097-0142(19860201)57:3<461::AID-CNCR2820570310>3.0.CO;2-6; HOCKEL M, 1993, ARCH SURG-CHICAGO, V128, P423; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jain RK, 1997, MICROCIRCULATION, V4, P3; JAIN RK, 1988, CANCER RES, V48, P2641; JAIN RK, 1997, INT WORKSH TUM MICR; JOYNER WL, 1986, MICROCIRCULATORY TEC, P3; KLINTWORTH GK, 1991, CORNEAL ANGIOGENESIS; KOWALSKI J, 1992, EXP MOL PATHOL, V56, P1, DOI 10.1016/0014-4800(92)90019-8; LEIGHTON J, 1967, SPREAD CANC PATHOGEN; Less JR, 1997, MICROCIRCULATION-LON, V4, P25, DOI 10.3109/10739689709148315; LESS JR, 1991, CANCER RES, V51, P265; LEUNIG M, 1992, CANCER RES, V52, P6553; LEUNIG M, 1994, LAB INVEST, V71, P300; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LUCKE B, 1950, CANCER RES, V10, P231; LUTZ BR, 1950, CANCER RES, V10, P231; MAHADEVAN V, 1989, CANCER RES, V49, P415; MAIORANA A, 1978, CANCER RES, V38, P4409; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1992, EUR J CLIN INVEST, V22, P504, DOI 10.1111/j.1365-2362.1992.tb01498.x; MUTHUKKARUPPAN V, 1979, SCIENCE, V205, P1416, DOI 10.1126/science.472760; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; NORRBY K, 1990, MICROVASC RES, V39, P341, DOI 10.1016/0026-2862(90)90047-U; PASSANITI A, 1992, LAB INVEST, V67, P519; Patan S, 1996, MICROVASC RES, V51, P260, DOI 10.1006/mvre.1996.0025; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; PLUNKETT ML, 1990, LAB INVEST, V62, P510; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RUNKEL S, 1991, RADIAT RES, V126, P237, DOI 10.2307/3577824; Sandison JC, 1924, ANAT REC, V28, P281, DOI 10.1002/ar.1090280403; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SCHLENGER K, 1994, J SURG RES, V56, P235, DOI 10.1006/jsre.1994.1037; SCKELL A, 1997, MICROCIRCULATION, V4, P145; SHOLLEY MM, 1984, LAB INVEST, V51, P624; SIDKY YA, 1975, J EXP MED, V141, P1084, DOI 10.1084/jem.141.5.1084; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; TAYLOR CM, 1984, INT J MICROCIRC, V3, P337; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; YAMADA S, 1995, BLOOD, V86, P3487, DOI 10.1182/blood.V86.9.3487.bloodjournal8693487; YUAN F, 1994, CANCER RES, V54, P4564; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; ZAWICKI DF, 1981, MICROVASC RES, V21, P27, DOI 10.1016/0026-2862(81)90003-0; ZEIDMAN I, 1961, CANCER RES, V21, P38; ZIETMAN AL, 1988, CANCER RES, V48, P6510	82	318	344	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1997	3	11					1203	1208		10.1038/nm1197-1203	http://dx.doi.org/10.1038/nm1197-1203			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359693				2022-12-27	WOS:A1997YD89600027
J	Skobe, M; Rockwell, P; Goldstein, N; Vosseler, S; Fusenig, NE				Skobe, M; Rockwell, P; Goldstein, N; Vosseler, S; Fusenig, NE			Halting angiogenesis suppresses carcinoma cell invasion	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TUMOR-GROWTH; IN-VIVO; MALIGNANT PROGRESSION; TRANSGENIC MICE; HUMAN SKIN; EXPRESSION; TUMORIGENESIS; METASTASIS	The importance of angiogenesis in malignant tumor growth has been interpreted mainly in terms of oxygen and nutrient supply. Here we demonstrate its fundamental role for tumor invasion of malignant human keratinocytes in surface transplants on nude mice. Distinct patterns of angiogenesis and vascular endothelial growth factor receptor-2 (VECFR-2) expression allowed us to distinguish between benign and malignant cells. Functional inactivation of VEGF-RZ by a blocking antibody disrupted ongoing angiogenesis and prevented invasion of malignant cells, without reducing tumor cell proliferation. The reversion of a malignant into a benign phenotype by halting angiogenesis demonstrates a significant function of vascular endothelium for tumor invasion.	DEUTSCH KREBSFORSCHUNGSZENTRUM,GERMAN CANC RES CTR,DIV CARINOGENESIS & DIFFERENTIAT,D-69120 HEIDELBERG,GERMANY; IMCLONE SYST INC,DEPT IMMUNOL,NEW YORK,NY 10014	Helmholtz Association; German Cancer Research Center (DKFZ); Eli Lilly								ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREITKREUTZ D, 1991, CANCER RES, V51, P4402; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; Claffey KP, 1996, CANCER RES, V56, P172; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FUSENIG NE, 1991, ORAL CANC, P218; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Larcher F, 1996, CANCER RES, V56, P5391; LIOTTA LA, 1974, CANCER RES, V34, P997; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; NICOSIA RF, 1986, CLIN EXP METASTAS, V4, P91, DOI 10.1007/BF00119076; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; Relf M, 1997, CANCER RES, V57, P963; Rockwell Patricia, 1995, Molecular and Cellular Differentiation, V3, P91; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1995, AM J PATHOL, V147, P9; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	40	387	404	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1222	1227		10.1038/nm1197-1222	http://dx.doi.org/10.1038/nm1197-1222			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359696				2022-12-27	WOS:A1997YD89600030
J	Sanberg, PR; Borlongan, CV; Othberg, AI; Saporta, S; Freeman, TB; Cameron, DF				Sanberg, PR; Borlongan, CV; Othberg, AI; Saporta, S; Freeman, TB; Cameron, DF			Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats	NATURE MEDICINE			English	Article							NEUROTROPHIC FACTOR GDNF; PARKINSONS-DISEASE; TRANSPLANTATION; SURVIVAL; MODEL	Neural tissue transplantation has become an alternative treatment for Parkinson's disease (PD)(1.2) and other neurodegenerative disorders. The clinical use of neural grafts as a source of dopamine for Parkinson's disease patients, although beneficial, is associated with logistical and ethical issues. Thus, alternative graft sources have been explored including polymer-encapsulated cells and nonneural cells (that is, adrenal chromaffin cells) or genetically modified cells that secrete dopamine and/or trophic factors(3-5). Although progress has been made, no current alternative graft source has ideal characteristics for transplantation. Emerging evidence suggests the importance of trophic factors in enhancing survival and regeneration of intrinsic dopaminergic neurons(6). It would be desirable to transplant cells that are readily available, immunologically accepted by the central nervous system and capable of producing dopamine and/or trophic factors. Sertoli cells have been shown to secrete CD-95 ligand(7) and regulatory proteins(8), as well as trophic, tropic, and immunosuppressive factors(9,10) that provide the testis, in part, with its ''immunoprivileged'' status, The present study demonstrated that transplantation of rat testis-derived Sertoli cells into adult rat brains ameliorated behavioral deficits in rats with 6-hydroxydopamine-induced hemiparkinsonism. This was associated with enhanced tyrosine hydroxylase (TH) immunoreactivity in the striatum in the area around the transplanted Sertoli cells. Furthermore, in vitro experiments demonstrated enhanced dopaminergic neuronal survival and outgrowth when embryonic neurons were cultured with medium in which rat Sertoli cells had been grown. Transplantation of Sertoli cells may provide a useful alternative treatment for PD and other neurodegenerative disorders.	UNIV S FLORIDA,COLL MED,PROGRAM NEUROSCI,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT SURG,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT NEUROL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PSYCHIAT,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT PHARMACOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT ANAT,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sanberg, PR (corresponding author), UNIV S FLORIDA,COLL MED,DIV NEUROL SURG,MDC BOX 16,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.		Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782				APPEL SH, 1993, EXP NEUROL, V124, P100, DOI 10.1006/exnr.1993.1180; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; CHOILUNDBERG DL, 1995, DEV BRAIN RES, V85, P80, DOI 10.1016/0165-3806(94)00197-8; Emerich D F, 1992, Cell Transplant, V1, P401; EMERICH DF, 1992, NEUROSCI BIOBEHAV R, V16, P437, DOI 10.1016/S0149-7634(05)80185-X; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; KAWAJA MD, 1992, J COMP NEUROL, V317, P102, DOI 10.1002/cne.903170108; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDVALL O, 1987, ANN NEUROL, V22, P457, DOI 10.1002/ana.410220403; MIAO N, 1996, CELL TRANSPLANT, V55, P17; OTHBERG A, 1995, EXP BRAIN RES, V105, P111; Sanberg PR, 1996, NAT BIOTECHNOL, V14, P1692, DOI 10.1038/nbt1296-1692; Sanberg PR, 1997, CELL TRANSPLANT, V6, P191, DOI 10.1016/S0963-6897(96)00257-6; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SKINNER MK, 1993, SERTOLI CELL, P237; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	20	84	94	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1129	1132		10.1038/nm1097-1129	http://dx.doi.org/10.1038/nm1097-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334725				2022-12-27	WOS:A1997XZ28700039
J	Cantwell, M; Hua, T; Pappas, J; Kipps, TJ				Cantwell, M; Hua, T; Pappas, J; Kipps, TJ			Acquired CD40-ligand deficiency in chronic lymphocytic leukemia	NATURE MEDICINE			English	Article							ACTIVATED T-CELLS; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; CD40 LIGAND; B-CELLS; DEFECTIVE EXPRESSION; ANTIGEN; ENDOCYTOSIS; MICE; RESPONSIVENESS	Patients with B-cell chronic lymphocytic leukemia (CLL) acquire an immunodeficiency with many characteristics similar to those of persons with inherited defects in the gene encoding the CD40-ligand (CD154). We found that the blood and splenic CD4(+) T cells of patients with CLL failed to express surface CD154 after CD3 ligation. However, using an enzyme-linked immunosorbent assay (ELISA)-based quantitative competitive polymerase chain reaction (PCR), we noted that CD3 ligation could induce such T cells to express CD154 messenger RNA at levels similar to that of CD3-activated T cells from normal donors. Moreover, addition of Increasing numbers of CLL B cells to activated normal donor T cells rapidly resulted in progressively greater down-modulation of CD154. Such down-modulation of CD154 could be blocked by addition of CD40 monoclonal antibody to cultures in vitro. We propose that leukemia cell-mediated down-modulation of CD154 on activated T cells accounts for some of the acquired immune defects of patients with CLL.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA049870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041897] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA49870R01] Funding Source: Medline; NIAMS NIH HHS [P01-AR41897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AYANLARBATUMAN O, 1986, BLOOD, V67, P279; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BENAISSA H, 1988, ANTICANCER RES, V8, P443; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; BOWEN F, 1995, EUR J IMMUNOL, V25, P2830, DOI 10.1002/eji.1830251018; CALLERY RT, 1980, CLIN IMMUNOL IMMUNOP, V17, P451, DOI 10.1016/0090-1229(80)90116-6; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; CASTLE BE, 1993, J IMMUNOL, V151, P1777; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FERNANDEZ LA, 1977, CANCER, V39, P1168, DOI 10.1002/1097-0142(197703)39:3<1168::AID-CNCR2820390323>3.0.CO;2-G; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HAMBLIN TJ, 1986, J CLIN PATHOL, V39, P713, DOI 10.1136/jcp.39.7.713; HAN SH, 1995, J IMMUNOL, V155, P556; HAN T, 1982, BLOOD, V60, P1075; HERRMANN P, 1993, EUR J IMMUNOL, V23, P961; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KAY NE, 1984, BRIT J HAEMATOL, V57, P105, DOI 10.1111/j.1365-2141.1984.tb08504.x; KAY NE, 1986, BLOOD, V67, P578; KIPPS TJ, 1995, WILLIAMS HEMATOLOGY, P1017; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LOTZ M, 1994, J EXP MED, V179, P999, DOI 10.1084/jem.179.3.999; LUCIVERO G, 1983, J CLIN IMMUNOL, V3, P111, DOI 10.1007/BF00915481; MATUTES E, 1981, BRIT J HAEMATOL, V49, P635, DOI 10.1111/j.1365-2141.1981.tb07274.x; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Pammer J, 1996, AM J PATHOL, V148, P1387; Patel HR, 1996, J IMMUNOL, V156, P1781; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PLATSOUCAS CD, 1980, J IMMUNOL, V125, P1216; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; Rossi E, 1996, LEUKEMIA, V10, P494; ROY M, 1993, J IMMUNOL, V151, P2497; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SEMENZATO G, 1981, CANCER-AM CANCER SOC, V48, P2191, DOI 10.1002/1097-0142(19811115)48:10<2191::AID-CNCR2820481013>3.0.CO;2-9; STORRIE B, 1977, CELL, V11, P707, DOI 10.1016/0092-8674(77)90087-3; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; TOTTERMAN TH, 1989, BLOOD, V74, P786; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; WESTBROOK CA, 1984, SEMIN ONCOL, V11, P514; YELLIN MJ, 1994, J IMMUNOL, V152, P598	46	149	153	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					984	989		10.1038/nm0997-984	http://dx.doi.org/10.1038/nm0997-984			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288724				2022-12-27	WOS:A1997XT84200030
J	Perlin, MW				Perlin, MW			Rapid construction of genome maps	NATURE MEDICINE			English	Article							RADIATION HYBRID MAP; PHYSICAL MAP; STS MARKERS; HUMAN-CHROMOSOME-11; CHROMOSOMES; GENES		UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15261; CYBERGENET INC,PITTSBURGH,PA 15217	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Perlin, MW (corresponding author), CARNEGIE MELLON UNIV,DEPT COMP SCI,PITTSBURGH,PA 15213, USA.							Andrews C, 1997, GENOMICS, V41, P141, DOI 10.1006/geno.1997.4652; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; Coulson A, 1995, METHOD CELL BIOL, V48, P533; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kumlien J, 1996, MAMM GENOME, V7, P758, DOI 10.1007/s003359900227; Little P, 1996, NATURE, V382, P408, DOI 10.1038/382408a0; MONACO AP, 1991, NUCLEIC ACIDS RES, V19, P3315, DOI 10.1093/nar/19.12.3315; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON SF, 1993, NAT GENET, V4, P11, DOI 10.1038/ng0593-11; OLSON MV, 1995, SCIENCE, V270, P394, DOI 10.1126/science.270.5235.394; PERLIN M, 1993, GENOMICS, V18, P283, DOI 10.1006/geno.1993.1467; PERLIN MW, 1995, GENOMICS, V28, P315, DOI 10.1006/geno.1995.1148; PERLIN MW, IN PRESS MATH MODEL; QIN S, 1993, GENOMICS, V16, P580, DOI 10.1006/geno.1993.1233; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22	26	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1046	1048		10.1038/nm0997-1046	http://dx.doi.org/10.1038/nm0997-1046			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288736				2022-12-27	WOS:A1997XT84200042
J	Dieterich, W; Ehnis, T; Bauer, M; Donner, P; Volta, U; Riecken, EO; Schuppan, D				Dieterich, W; Ehnis, T; Bauer, M; Donner, P; Volta, U; Riecken, EO; Schuppan, D			Identification of tissue transglutaminase as the autoantigen of celiac disease	NATURE MEDICINE			English	Article							CROSS-LINKING; CELLULAR TRANSGLUTAMINASE; ANTIBODIES; COMPLEXES; SUBSTRATE; ANTIGLIADIN; FIBRONECTIN; DIAGNOSIS; COLLAGEN; GLIADIN	Celiac disease is characterized by small intestinal damage with loss of absorptive villi and hyperplasia of the crypts, typically leading to malabsorption(1). In addition to nutrient deficiencies, prolonged celiac disease is associated with an increased risk for malignancy, especially intestinal T-cell lymphoma(1-3). Celiac disease is precipitated by ingestion of the protein gliadin, a component of wheat gluten, and usually resolves on its withdrawal. Gliadin initiates mucosal damage which involves an immunological process in individuals with a genetic predisposition. However, the mechanism responsible for the small intestinal damage characteristic of celiac disease is still under debate(4-6). Small intestinal biopsy with the demonstration of a flat mucosa which is reversed on a gluten-free diet is considered the main approach for diagnosis of classical celiac disease(7). In addition, IgA antibodies against gliadin and endomysium, a structure of the smooth muscle connective tissue, are valuable tools for the detection of patients with celiac disease and for therapy control(7-9). Incidence rates of childhood celiac disease range from 1:300 in Western Ireland to 1:4700 in other European countries(10-12), and subclinical cases detected by serological screening revealed prevalences of 3.3 and 4 per 1000 in Italy and the USA, respectively IgA antibodies to endomysium are particularly specific indicators of celiac disease(9,15), suggesting that this structure contains one or more target autoantigens that play a role in the pathogenesis of the disease(16,17). However, the identification of the endomysial autoantigen(s) has remained elusive. We identified tissue transglutaminase as the unknown endomysial autoantigen. Interestingly, gliadin is a preferred substrate for this enzyme, giving rise to novel antigenic epitopes.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, DEPT GASTROENTEROL, D-12200 BERLIN, GERMANY; SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY; POLICLIN S ORSOLA, IST CLIN MED GEN & TERAPIA MED, I-40138 BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; IRCCS Azienda Ospedaliero-Universitaria di Bologna				Volta, Umberto/0000-0003-3405-3808				AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; FERGUSON A, 1995, MALIGNANCY CHRONIC I, P51; GENTILE V, 1991, J BIOL CHEM, V266, P478; Greco L., 1992, COMMON FOOD INTOLERA, P25; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; LADINSER B, 1994, GUT, V35, P776, DOI 10.1136/gut.35.6.776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lankisch PG, 1996, Z GASTROENTEROL, V34, P473; LERNER A, 1994, CLIN EXP IMMUNOL, V95, P78; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maki M, 1996, LANCET, V348, P1046, DOI 10.1016/S0140-6736(05)64411-X; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MYLOTTE M, 1973, BMJ-BRIT MED J, V1, P703, DOI 10.1136/bmj.1.5855.703; Not T, 1996, GASTROENTEROLOGY, V110, pA351; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; Picarelli A, 1996, LANCET, V348, P1065, DOI 10.1016/S0140-6736(96)03060-7; SANDFORTH F, 1991, Z GASTROENTEROL, V29, P327; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOSROSENO W, 1995, J ROY SOC MED, V88, P14; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; SZABOLCS M, 1987, Acta Paediatrica Hungarica, V28, P215; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	37	1518	1579	3	170	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1997	3	7					797	801		10.1038/nm0797-797	http://dx.doi.org/10.1038/nm0797-797			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212111				2022-12-27	WOS:A1997XG76700044
J	Heise, C; SampsonJohannes, A; Williams, A; McCormick, F; VonHoff, DD; Kirn, DH				Heise, C; SampsonJohannes, A; Williams, A; McCormick, F; VonHoff, DD; Kirn, DH			ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents	NATURE MEDICINE			English	Article							CARCINOMA CELL-LINES; P53 GENE; IN-VIVO; CANCER-CELLS; SOLID TUMORS; G(1) ARREST; THERAPY; EXPRESSION; APOPTOSIS; TRANSFECTION	The 55-kilodalton (kDa) protein from the E1B-region of adenovirus binds to and inactivates the p53 gene, which is mutated in half of human cancers. We have previously shown that the replication and cytopathogenicity of an E1B, 55-kDa gene-attenuated adenovirus, ONYX-015, is blocked by functional p53 in RKO and U2OS carcinoma lines. We now report that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5-9), were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or intravenous administration of ONYX-015 to nude mouse-human tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone.	ONYX PHARMACEUT,RICHMOND,CA 94806; CANC THERAPY & RES CTR S TEXAS,SAN ANTONIO,TX 78245	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio								BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DVORAK HF, 1988, AM J PATHOL, V133, P95; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FUJIWARA T, 1994, CANCER RES, V54, P2287; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG HS, 1994, INFECT AGENT DIS, V3, P1; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Kirn DH, 1996, EXPERT OPINION INVES, V5, P753; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LI CY, 1995, ONCOGENE, V11, P1885; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacCallum DE, 1996, ONCOGENE, V13, P2575; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roth J, 1996, P NATL ACAD SCI USA, V93, P4781, DOI 10.1073/pnas.93.10.4781; RUGGERI B, 1992, ONCOGENE, V7, P1503; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; VAN MEIR EG, 1994, CANCER RES, V54, P649; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG NP, 1993, ONCOGENE, V8, P279; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	38	767	839	2	33	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUN	1997	3	6					639	645		10.1038/nm0697-639	http://dx.doi.org/10.1038/nm0697-639			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XB974	9176490				2022-12-27	WOS:A1997XB97400033
J	Crowe, MJ; Bresnahan, JC; Shuman, SL; Masters, JN; Beattie, MS				Crowe, MJ; Bresnahan, JC; Shuman, SL; Masters, JN; Beattie, MS			Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; MACACA-MULATTA; METHYLPREDNISOLONE; NECROSIS; SURVIVAL	Apoptosis is a morphologically defined form of programmed cell death seen in a variety of circumstances, including immune cell selection, carcinogenesis and development(1,2). Apoptosis has very recently been seen after ischemic or traumatic injury to the central nervous system (CNS)(3-5), suggesting that active cell death as well as passive necrosis may mediate damage after CNS injury. After spinal cord injury (SCI) in the rat, typical post-traumatic necrosis occurred, but in addition, apoptotic cells were found from 6 hours to 3 weeks after injury, especially in the spinal white matter. Apoptotic cells were positive for oligodendrocyte markers. After SCI in monkeys, apoptotic cells were found within remote degenerating fiber tracts. Both secondary degeneration at the site of SCI and the chronic demyelination of tracts away from the injury appear to be due in part to apoptosis. As cytokines have been shown to mediate oligodendrocyte death in vitro(6), it seems likely that chronic demyelination after CNS injury shares features with chronic degenerative disorders like multiple sclerosis.	OHIO STATE UNIV,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DIV NEUROSURG,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,NEUROSCI PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Beattie, Michael S/A-8953-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010165, R01NS032000, R01NS031193] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10165, NS 31193, NS 32000] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BHAT RV, GLIA, V17, P169; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; Bunge RP, 1994, NEUROBIOLOGY CENTRAL, P329; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Crowe M. J., 1995, Society for Neuroscience Abstracts, V21, P232; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HALL ED, 1992, J NEUROTRAUM, V9, pS425; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MAJNO G, 1995, AM J PATHOL, V146, P3; POPOVICH PG, IN PRESS J COMP NEUR; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RINK A, 1995, AM J PATHOL, V147, P1575; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321	25	930	976	0	54	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JAN	1997	3	1					73	76		10.1038/nm0197-73	http://dx.doi.org/10.1038/nm0197-73			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WA733	8986744				2022-12-27	WOS:A1997WA73300040
J	Hoffman, SL; Rogers, WO; Carucci, DJ; Venter, JC				Hoffman, SL; Rogers, WO; Carucci, DJ; Venter, JC			From genomics to vaccines: Malaria as a model system	NATURE MEDICINE			English	Editorial Material							PLASMODIUM		USN, Med Res Ctr, Malaria Program, Rockville, MD 20852 USA; Celera Genom Inc, Rockville, MD 20850 USA; Inst Genom Res, Rockville, MD 20850 USA	United States Department of Defense; United States Navy; J. Craig Venter Institute	Hoffman, SL (corresponding author), USN, Med Res Ctr, Malaria Program, 12300 Washington Ave, Rockville, MD 20852 USA.							BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; Butler D, 1997, NATURE, V388, P701, DOI 10.1038/41826; CHRISTOPHERS S. R., 1924, Indian Journal of Medical Research, V12, P273; Doolan DL, 1997, PHILOS T R SOC B, V352, P1361, DOI 10.1098/rstb.1997.0121; Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0; Doolan DL, 1997, PARASITOL TODAY, V13, P171, DOI 10.1016/S0169-4758(97)01040-5; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; Hoffman SL, 1997, NATURE, V387, P647, DOI 10.1038/42571; Hoffman SL, 1996, MALARIA VACCINE DEV; Sidney J, 1996, IMMUNOL TODAY, V17, P261, DOI 10.1016/0167-5699(96)80542-1; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476	12	59	60	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1351	1353		10.1038/3934	http://dx.doi.org/10.1038/3934			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846563	Bronze			2022-12-27	WOS:000077336900020
J	Fink, L; Seeger, W; Ermert, L; Hanze, J; Stahl, U; Grimminger, F; Kummer, W; Bohle, RM				Fink, L; Seeger, W; Ermert, L; Hanze, J; Stahl, U; Grimminger, F; Kummer, W; Bohle, RM			Real-time quantitative RT-PCR after laser-assisted cell picking	NATURE MEDICINE			English	Article							SINGLE CELLS		Univ Giessen, Dept Pathol, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med, D-35390 Giessen, Germany; Univ Giessen, Dept Pediat, D-35390 Giessen, Germany; Univ Giessen, Inst Anat & Cell Biol, D-35390 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen	Fink, L (corresponding author), Univ Giessen, Dept Pathol, Langhansstr 10, D-35392 Giessen, Germany.			Grimminger, Friedrich/0000-0001-8725-6276; Kummer, Wolfgang/0000-0002-3946-0683; Hanze, Jorg/0000-0001-5424-7808; Seeger, Werner/0000-0003-1946-0894				Becker I, 1997, HISTOCHEM CELL BIOL, V108, P447, DOI 10.1007/s004180050185; BRADY G, 1993, METHOD ENZYMOL, V225, P611; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; ENSER JE, 1995, AM J PHYSIOL, V269, pC1140; ERMERT L, IN PRESS J PHARM EXP; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLLON SD, 1991, J CONSULT CLIN PSYCH, V59, P88, DOI 10.1037/0022-006X.59.1.88; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; Kueppers Ralf, 1993, EMBO (European Molecular Biology Organization) Journal, V12, P4955; Kummer W, 1998, NEUROREPORT, V9, P2209, DOI 10.1097/00001756-199807130-00011; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; LIVAK KJ, 1995, PCR METH APPL, V4, P357; OLIVER JC, 1993, LYMPHOKINE CYTOK RES, V12, P115; *PERK ELM CORP, 1997, US B PERK ELM CORP, V2; SEEGER W, 1994, METHOD ENZYMOL, V233, P549	16	517	530	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1329	1333		10.1038/3327	http://dx.doi.org/10.1038/3327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809560				2022-12-27	WOS:000076731000045
J	Fehr, T; Naim, HY; Bachmann, MF; Ochsenbein, AF; Spielhofer, P; Bucher, E; Hengartner, H; Billeter, MA; Zinkernagel, RM				Fehr, T; Naim, HY; Bachmann, MF; Ochsenbein, AF; Spielhofer, P; Bucher, E; Hengartner, H; Billeter, MA; Zinkernagel, RM			T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; LYMPHOCYTES-B; ACTIVATION; ANTIGEN; MICE; IMMUNOGENICITY; INACTIVATION; MODEL	B-cell activation depends on the intensity of B-cell receptor cross-linking. Studies of haptenated antigens' and vesicular stomatitis virus(2) (VSV) have demonstrated a correlation between antigen repetitiveness and the degree to which B-cell activation is independent of T cells. Here, we compare neutralizing antibody responses to inactivated VSV with those to two inactivated human pathogenic viruses: highly cytopathic poliovirus (PV) and poorly cytopathic measles virus (MV). The rigidly structured PV efficiently induced neutralizing IgM antibodies independent of T cells. In contrast, neutralizing antibodies to the pleomorphic MV were dependent on helper T cells. To test whether this resulted from the differences in virus structure or the capacity of MV to induce cell fusion and/or immunosuppression, we analyzed antibody responses to chimeric MV expressing VSV glycoprotein instead of MV fusion protein and hemagglutinin(3). IgM antibodies were independent of T cells; in addition, we found IgG responses dependent on T-cell help that were enduring and protective against lethal VSV infection. Because chimeric MV viruses look like MV ultrastructurally, we conclude that not only structural differences in the envelope but also the ability of MV to induce immunosuppression may limit its capacity to directly activate B cells. These findings are relevant for our understanding of E-cell activation by two prototypic human pathogenic viruses and for the design of new recombinant vaccines.	Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Zurich Honggerberg, Inst Mol Biol 1, CH-8093 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Zinkernagel, RM (corresponding author), Univ Zurich Hosp, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.			Ochsenbein, Adrian/0000-0003-1773-5436				BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; Bachmann MF, 1996, IMMUNOL TODAY, V17, P553, DOI 10.1016/S0167-5699(96)10066-9; BACHMANN MF, 1994, MED MICROBIOL IMMUN, V183, P95, DOI 10.1007/BF00277160; BORCA MV, 1986, IMMUNOLOGY, V59, P261; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNS WH, 1975, NATURE, V256, P654, DOI 10.1038/256654a0; CHARAN S, 1986, J IMMUNOL, V136, P3057; DINTZIS RZ, 1983, J IMMUNOL, V131, P2196; DRILLIEN R, 1988, P NATL ACAD SCI USA, V85, P1252, DOI 10.1073/pnas.85.4.1252; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; GOODMANSNITKOFF G, 1981, J EXP MED, V153, P1489, DOI 10.1084/jem.153.6.1489; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KIMURA S, 1987, J IMMUNOL, V138, P4387; MANGENEY M, 1989, CELL IMMUNOL, V122, P329, DOI 10.1016/0008-8749(89)90081-6; MCCHESNEY MB, 1987, J VIROL, V61, P3441, DOI 10.1128/JVI.61.11.3441-3447.1987; MCCHESNEY MB, 1986, J EXP MED, V163, P1331; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; SzomolanyiTsuda E, 1996, J EXP MED, V183, P403, DOI 10.1084/jem.183.2.403; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985	25	40	43	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					945	948		10.1038/nm0898-945	http://dx.doi.org/10.1038/nm0898-945			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701248	Bronze			2022-12-27	WOS:000075107400039
J	Palfi, S; Conde, F; Riche, D; Brouillet, E; Dautry, C; Mittoux, V; Chibois, A; Peschanski, M; Hantraye, P				Palfi, S; Conde, F; Riche, D; Brouillet, E; Dautry, C; Mittoux, V; Chibois, A; Peschanski, M; Hantraye, P			Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease	NATURE MEDICINE			English	Article							EXCITOTOXIC LESIONS; BRAIN; PERFORMANCE; IMPAIRMENT; MOVEMENTS; DARPP-32; RECOVERY	Substitutive therapy using fetal striatal grafts in animal models of Huntington disease (HD) have already demonstrated obvious beneficial effects on motor indices(1). Using a new phenotypic model of HD recently designed in primates(2,3), we demonstrate here complete and persistent recovery in a frontal-type cognitive task two to five months after intrastriatal allografting. The striatal allografts also reduce the occurence of dystonia, a major abnormal movement associated with HD. These results show the capacity of fetal neurons to provide a renewed substrate for both cognitive and motor systems in the lesioned adult brain. They also support the use of neural transplantation as a potential therapy for HD.	Serv Hosp Frederic Joliot, CNRS,URA 2210, CEA, DSV,DRM, F-91401 Orsay, France; Fac Med, INSERM, U421, F-94010 Creteil, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Hantraye, P (corresponding author), Serv Hosp Frederic Joliot, CNRS,URA 2210, CEA, DSV,DRM, 4 Pl Gen Leclerc, F-91401 Orsay, France.		Peschanski, Marc/N-5769-2017; Brouillet, Emmanuel/B-4784-2014	Brouillet, Emmanuel/0000-0001-6322-7403				BRANDT J, 1988, ANN NEUROL, V23, P555, DOI 10.1002/ana.410230605; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; BRUNDIN P, 1985, BRAIN RES, V331, P251, DOI 10.1016/0006-8993(85)91550-1; BURNS LH, 1995, NEUROSCIENCE, V64, P1007, DOI 10.1016/0306-4522(94)00431-4; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; CHEN KS, 1994, FUNCTIONAL NEURAL TR, P295; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; DUNNETT SB, 1994, FUNCTIONAL NEURAL TR, P217; HANTRAYE P, 1990, EXP NEUROL, V108, P91, DOI 10.1016/0014-4886(90)90014-J; HANTRAYE P, 1992, P NATL ACAD SCI USA, V89, P4187, DOI 10.1073/pnas.89.9.4187; HARPER PS, 1991, HUNTINGTONS DIS, V1; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; MAYER E, 1992, EUR J NEUROSCI, V4, P119, DOI 10.1111/j.1460-9568.1992.tb00858.x; Naimi S, 1996, EXP NEUROL, V137, P15, DOI 10.1006/exnr.1996.0002; PAKZABAN P, 1993, EXP BRAIN RES, V97, P13; Palfi SP, 1996, J NEUROSCI, V16, P3019; PESCHANSKI M, 1995, NEUROSCIENCE, V68, P273, DOI 10.1016/0306-4522(95)00162-C; SCHNEIDER JS, 1992, VULN BRAIN ENV, P293; Sinden J. D., 1994, FUNCTIONAL NEURAL TR, P253; STERNBERGER LA, 1985, IMMUNOCYTOCHEMISTRY; SZABO J, 1984, J COMP NEUROL, V222, P265, DOI 10.1002/cne.902220208	24	120	122	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					963	966		10.1038/nm0898-963	http://dx.doi.org/10.1038/nm0898-963			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701252				2022-12-27	WOS:000075107400043
J	Pantaleo, G; Cohen, OJ; Schacker, T; Vaccarezza, M; Graziosi, C; Rizzardi, GP; Kahn, J; Fox, CH; Schnittman, SM; Schwartz, DH; Corey, L; Fauci, AS				Pantaleo, G; Cohen, OJ; Schacker, T; Vaccarezza, M; Graziosi, C; Rizzardi, GP; Kahn, J; Fox, CH; Schnittman, SM; Schwartz, DH; Corey, L; Fauci, AS			Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy	NATURE MEDICINE			English	Article							TYPE-1; PLASMA; DISEASE; TISSUE; CELLS; AIDS; RESERVOIRS; MACAQUES; VIREMIA; ORGANS	Evolutionary patterns of virus replication and distribution in lymphoid tissue during the early phases of HIV infection have not been delineated. Lymph node (LN) biopsies were excised from patients at different times after the estimated time of primary infection. Within 3 months of the acute viral syndrome, HIV was mostly present in individual virus-expressing cells in LNs; trapping of virions in the follicular dendritic cell (FDC) network was minimal or absent, but was the predominant form of HIV detected in LNs of subjects with chronic infection, either recent (4-20 months after primary infection) or long-term (>2-3 years after primary infection). Plasma viremia was significantly higher in patients during the first 3 months than in those recently infected; however, there were no significant differences in the number of virus-expressing cells per square millimeter of LN tissue in these two groups. Numbers of virus-expressing cells in lymphoid tissue were significantly lower in the subjects with long-term infection than in the other two groups. Therefore, during the transition from primary to chronic HIV infection, the level of HIV replication in lymphoid tissue remains elevated despite the fact that viremia is significantly downregulated These findings have implications for therapeutic strategies in primary HIV infection and in recent seroconvertors.	CHU Vaudois, Lab AIDS Immunopathogenesis, Dept Med, Div Infect Dis, CH-1011 Lausanne, Switzerland; NIAID, Lab Immunoregulat, Bethesda, MD 20892 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Sch Med, San Francisco, CA 94110 USA; Mol Histol Inc, Gaithersburg, MD 20879 USA; NIAID, Div Aids, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Washington, Virol Res Clin, Seattle, WA 98104 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; University of Washington; University of Washington Seattle	Pantaleo, G (corresponding author), CHU Vaudois, Lab AIDS Immunopathogenesis, Dept Med, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Pantaleo, Giuseppe/K-6163-2016; VACCAREZZA, Mauro/S-9637-2019; Corey, Lawrence/AAE-1796-2020; graziosi, cecilia/M-1882-2019	Corey, Lawrence/0000-0002-2179-2436; VACCAREZZA, Mauro/0000-0003-3060-318X				ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; CHAKRABARTI L, 1994, AM J PATHOL, V144, P1226; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; Cohen OJ, 1996, J INFECT DIS, V173, P849, DOI 10.1093/infdis/173.4.849; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Martin LN, 1997, J INFECT DIS, V176, P374, DOI 10.1086/514054; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; SPIEGEL H, 1992, AM J PATHOL, V140, P15; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TENNERRACZ K, 1985, LANCET, V1, P105	23	106	106	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					341	345		10.1038/nm0398-341	http://dx.doi.org/10.1038/nm0398-341			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500610				2022-12-27	WOS:000073616200042
J	Rivera-Quinones, C; McGavern, D; Schmelzer, JD; Hunter, SF; Low, PA; Rodriguez, M				Rivera-Quinones, C; McGavern, D; Schmelzer, JD; Hunter, SF; Low, PA; Rodriguez, M			Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis	NATURE MEDICINE			English	Article							VIRUS-INDUCED DEMYELINATION; CENTRAL-NERVOUS-SYSTEM; THEILERS VIRUS; SODIUM-CHANNELS; NA+ CHANNELS; MICE; REMYELINATION; AXONS; ENCEPHALOMYELITIS; SUSCEPTIBILITY	Demyelination alone has been considered sufficient for development of neurological deficits following central nervous system (CNS) disease. However, extensive demyelination is not always associated with clinical deficits in patients with multiple sclerosis (MS), the most common primary demyelinating disease in humans. We used the Theiler's murine encephalomyelitis virus model of demyelination to investigate the role of major histocompatibility complex (MHC) class I and class II gene products in the development of functional and neurophysiological deficits following demyelination. We measured spontaneous clinical activity by two independent assays and recorded hind-limb motor-evoked potentials in infected class I-deficient and class Il-deficient mice of an identical genetic background as well as in highly susceptible SJL/J mice. The results show that despite a similar distribution and extent of demyelinated lesions in all mice, only class I-deficient mice were functionally normal. We propose that the mechanism by which demyelinated class I-deficient mice maintain neurologic function results from increased sodium channel densities and the relative preservation of axons. These findings are the first to implicate a role for MHC class I in the development of neurological deficits following demyelination.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rodriguez.moses@mayo.edu	McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X; Rodriguez, Moses/0000-0001-6328-6497	NIAID NIH HHS [N01-AI-4-5197] Funding Source: Medline; NIMH NIH HHS [F31 MH012120] Funding Source: Medline; NINDS NIH HHS [R01 NS24180, R01 NS32129, R01 NS024180, R01 NS032129] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032129, R01NS024180] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACK JA, 1991, BRAIN RES, V544, P59, DOI 10.1016/0006-8993(91)90885-Y; BOSTOCK H, 1980, J PHYSIOL-LONDON, V308, pP21; BRINKMEIER H, 1992, PFLUG ARCH EUR J PHY, V420, P621, DOI 10.1007/BF00374643; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FIETTE L, 1993, J VIROL, V67, P589, DOI 10.1128/JVI.67.1.589-592.1993; FILIPPI M, 1995, NEUROLOGY, V45, P255, DOI 10.1212/WNL.45.2.255; FOSTER RE, 1980, SCIENCE, V210, P661, DOI 10.1126/science.6159685; GILBERT JJ, 1983, ARCH NEUROL-CHICAGO, V40, P533, DOI 10.1001/archneur.1983.04050080033003; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; IULIANO BA, 1994, J NEUROL SCI, V123, P186, DOI 10.1016/0022-510X(94)90222-4; MACKAY RP, 1967, ARCH NEUROL-CHICAGO, V17, P588, DOI 10.1001/archneur.1967.00470300030007; MCDONALD WI, 1970, BRAIN, V93, P583, DOI 10.1093/brain/93.3.583; Miller DJ, 1995, J NEUROSCI, V15, P8345; Miller DJ, 1996, INT IMMUNOL, V8, P131, DOI 10.1093/intimm/8.1.131; MOLL C, 1991, BRAIN RES, V556, P311, DOI 10.1016/0006-8993(91)90321-L; MOURRE C, 1990, BRAIN RES, V533, P196, DOI 10.1016/0006-8993(90)91340-M; Njenga MK, 1996, J VIROL, V70, P1729, DOI 10.1128/JVI.70.3.1729-1737.1996; PULLEN LC, 1993, EUR J IMMUNOL, V23, P2287, DOI 10.1002/eji.1830230935; ROBB RA, 1989, COMPUT MED IMAG GRAP, V13, P433, DOI 10.1016/0895-6111(89)90285-1; RODRIGUEZ M, 1993, J IMMUNOL, V151, P266; RODRIGUEZ M, 1986, J EXP MED, V163, P620, DOI 10.1084/jem.163.3.620; RODRIGUEZ M, 1988, J IMMUNOL, V140, P2950; RODRIGUEZ M, 1985, J IMMUNOL, V135, P2145; RODRIGUEZ M, 1987, CRIT REV IMMUNOL, V7, P325; SIBLEY WA, 1985, LANCET, V1, P1313; SMITH KJ, 1982, J NEUROL SCI, V54, P13, DOI 10.1016/0022-510X(82)90215-5; WAXMAN SG, 1992, J NEUROTRAUM, V9, pS105	28	167	172	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1998	4	2					187	193		10.1038/nm0298-187	http://dx.doi.org/10.1038/nm0298-187			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YZ392	9461192	Green Accepted			2022-12-27	WOS:000072249800034
J	Deconinck, N; Tinsley, J; DeBacker, F; Fisher, R; Kahn, D; Phelps, S; Davies, K; Gillis, JM				Deconinck, N; Tinsley, J; DeBacker, F; Fisher, R; Kahn, D; Phelps, S; Davies, K; Gillis, JM			Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice	NATURE MEDICINE			English	Article							ADENOVIRUS-MEDIATED TRANSFER; DUCHENNE MUSCULAR-DYSTROPHY; TRANSGENIC MDX MICE; SKELETAL-MUSCLE; CYTOSOLIC CALCIUM; DMD PATIENTS; MOUSE; FIBERS; CONTRACTIONS; PHENOTYPE	Dystrophin-deficient mice (mdx) expressing a truncated (trc) utrophin transgene show amelioration of the dystrophic phenotype. Here we report a multifunctional study demonstrating that trc-utrophin expression leads to major improvements of the mechanical performance of muscle (that is, force development, mechanical resistance to forced lengthenings and maximal spontaneous activity) and of the maintenance of the intracellular calcium homeostasis. These are two essential functions of muscle fibers, known to be impaired in mdx mouse muscles and Duchenne muscular dystrophy (DMD) patients. Our results bring strong support to the hypothesis that muscle wasting in dystrophin-deficient DMD patients could be prevented by upregulation of utrophin.	UNIV CATHOLIQUE LOUVAIN,DEPT PHYSIOL,B-1200 BRUSSELS,BELGIUM; UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND	Universite Catholique Louvain; University of Oxford								Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BODENSTEINER JB, 1978, NEUROLOGY, V28, P439, DOI 10.1212/WNL.28.5.439; CARLSON CG, 1990, MUSCLE NERVE, V13, P480, DOI 10.1002/mus.880130603; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; HEAD SI, 1993, J PHYSIOL-LONDON, V469, P11, DOI 10.1113/jphysiol.1993.sp019801; Karpati G, 1997, NAT MED, V3, P22, DOI 10.1038/nm0197-22; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCARDLE A, 1994, MUSCLE NERVE, V17, P1378, DOI 10.1002/mus.880171206; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MIZUNO Y, 1993, J NEUROL SCI, V119, P43, DOI 10.1016/0022-510X(93)90190-A; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; PRESSMAR J, 1994, PFLUG ARCH EUR J PHY, V426, P499, DOI 10.1007/BF00378527; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGITA H, 1993, ACTA CARDIOMIOLOGICA, V5, P11; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; TAKESHIMA Y, 1994, NEUROLOGY, V44, P1648, DOI 10.1212/WNL.44.9.1648; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; WEBSTER C, 1988, CELL, V52, P502; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; [No title captured]	35	199	205	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1216	1221		10.1038/nm1197-1216	http://dx.doi.org/10.1038/nm1197-1216			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359695				2022-12-27	WOS:A1997YD89600029
J	Stenbit, AE; Tsao, TS; Li, J; Burcelin, R; Geenen, DL; Factor, SM; Houseknecht, K; Katz, EB; Charron, MJ				Stenbit, AE; Tsao, TS; Li, J; Burcelin, R; Geenen, DL; Factor, SM; Houseknecht, K; Katz, EB; Charron, MJ			GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes	NATURE MEDICINE			English	Article							GLUCOSE-TRANSPORTER EXPRESSION; RAT SKELETAL-MUSCLE; PLASMA-MEMBRANE; ADIPOSE-TISSUE; ZUCKER RATS; OBESE; CELL; TRANSLOCATION; NIDDM	GLUT4, the insulin-responsive glucose transporter, plays an important role in postprandial glucose disposal. Altered GLUT I activity is suggested to be one of the factors responsible for decreased glucose uptake in muscle and adipose tissue in obesity and diabetes. To assess the effect of GLUT4 expression on whole-body glucose homeostasis, we disrupted the murine GLUT4 gene by homologous recombination. Male mice heterozygous for the mutation (GLUT4(+/-)) exhibited a decrease in GLUT4 expression in adipose tissue and skeletal muscle. This decrease in GLUT4 expression did not result in obesity but led to increased serum glucose and insulin, reduced muscle glucose uptake, hypertension, and diabetic histopathologies in the heart and liver similar to those of humans with non-insulin-dependent diabetes mellitus (NIDDM). The male GLUT4(+/-) mice represent a good model for studying the development of NIDDM without the complications associated with obesity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; PURDUE UNIV, DEPT ANIM SCI, W LAFAYETTE, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA13330] Funding Source: Medline; NHLBI NIH HHS [HL 15498] Funding Source: Medline; NIDDK NIH HHS [DK 47425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BENNETT PH, 1991, DIABETES MELLITUS TH, P357; BONADONNA RC, 1993, DIABETES, V42, P191, DOI 10.2337/diabetes.42.1.191; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHAN TM, 1984, BIOCHIM BIOPHYS ACTA, V798, P325, DOI 10.1016/0304-4165(84)90106-5; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CUSHMAN SW, 1978, J LIPID RES, V19, P269; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEMEYTS P, 1993, ADV EXP MED BIOL, V334, P89; FACTOR SM, 1980, AM HEART J, V99, P446, DOI 10.1016/0002-8703(80)90379-8; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HORTON ES, 1991, DIABETES MELLITUS TH, P457; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1992, J CELL BIOCHEM, V48, P122, DOI 10.1002/jcb.240480203; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PENICAUD L, 1987, DIABETES, V36, P626, DOI 10.2337/diabetes.36.5.626; SHERMAN WM, 1988, AM J PHYSIOL, V255, pE374, DOI 10.1152/ajpendo.1988.255.3.E374; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451; WYSE BM, 1970, DIABETOLOGIA, V6, P268, DOI 10.1007/BF01212237; YORK DA, 1972, METABOLISM, V21, P277, DOI 10.1016/0026-0495(72)90070-4; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	30	258	267	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	1997	3	10					1096	1101		10.1038/nm1097-1096	http://dx.doi.org/10.1038/nm1097-1096			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XZ287	9334720				2022-12-27	WOS:A1997XZ28700034
J	Dessart, G				Dessart, G			The American Cancer Society versus tobacco - The first 40 years or the last?	NATURE MEDICINE			English	Editorial Material											Dessart, G (corresponding author), AMER CANC SOC,1599 CLIFTON RD NE,ATLANTA,GA 30329, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					712	713		10.1038/nm0797-712	http://dx.doi.org/10.1038/nm0797-712			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212089				2022-12-27	WOS:A1997XG76700022
J	Taylor, RM; Wolfe, JH				Taylor, RM; Wolfe, JH			Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase	NATURE MEDICINE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; CENTRAL-NERVOUS-SYSTEM; MEDIATED GENE-TRANSFER; DEFICIENCY; EXPRESSION; MICE; CELLS	A deficiency of beta-glucuronidase (GUSB) causes the multisystem progressive degenerative syndrome, mucopolysaccharidosis (MPS) type VII (Sly disease)(1), which includes mental retardation(2). Animal homologues of MPS VII (ref. 3, 4) are models for testing somatic gene transfer approaches to treat the central nervous system in this and other lysosomal storage disorders(5). Previous attempts to correct murine MPS VII by gene therapy have successfully treated lesions in some organs but not in the brain(6-8). Other experimental modalities have forestalled some disease progression in the brain, but only if done at birth(9,10), before the onset of severe lesions, when the animals are phenotypically normal. We tested whether therapeutic amounts of GUSB could be delivered to the diseased adult brain by transplanting cells engineered to super-secrete the normal enzyme for export to surrounding neural tissues. Lysosomal distention was cleared from neurons and glial cells in the vicinity of the grafts, showing that the secreted enzyme could reach the diseased cells and reverse lesions in the severely diseased brain. The ability to correct established lesions will be important for the treatment of many lysosomal storage diseases affecting the brain, because most patients are not diagnosed until lesions are advanced enough to affect phenotype or developmental milestones in early childhood, and some forms of the diseases do not become apparent until later in life(11).	UNIV PENN,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,CTR COMPARAT MED GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NIDDK NIH HHS [DK 42707, DK 47757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757, R01DK042707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; FISHER LJ, 1993, PHYSIOL REV, V73, P583, DOI 10.1152/physrev.1993.73.3.583; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; KYLE JW, 1990, P NATL ACAD SCI USA, V87, P3914, DOI 10.1073/pnas.87.10.3914; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; SCRIVER CR, 1995, METABOLIC MOL BASES, P2427; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; TAYLOR RM, 1994, EXP CELL RES, V214, P606, DOI 10.1006/excr.1994.1298; Taylor RM, 1997, J NEUROCHEM, V68, P2079; Wolfe J, 1996, PROTOCOLS GENE TRANS, P263; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	19	136	147	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1997	3	7					771	774		10.1038/nm0797-771	http://dx.doi.org/10.1038/nm0797-771			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XG767	9212105				2022-12-27	WOS:A1997XG76700038
J	Licinio, J; Mantzoros, C; Negrao, AB; Cizza, G; Wong, ML; Bongiorno, PB; Chrousos, GP; Karp, B; Allen, C; Flier, JS; Gold, PW				Licinio, J; Mantzoros, C; Negrao, AB; Cizza, G; Wong, ML; Bongiorno, PB; Chrousos, GP; Karp, B; Allen, C; Flier, JS; Gold, PW			Human leptin levels are pulsatile and inversely related to pituitary-adrenal function	NATURE MEDICINE			English	Article							MESSENGER-RIBONUCLEIC-ACID; HORMONE; VASOPRESSIN; RECEPTORS; RATS	Leptin communicates nutritional status to regulatory centers in the brain(1,2). Because peripheral leptin influences the activity of the highly pulsatile adrenal and gonadal axes(3,4), we sought to determine whether leptin levels in the blood are pulsatile. We measured circulating leptin levels every 7 minutes for 24 hours, in six healthy men, and found that total circulating leptin levels exhibited a pattern indicative of pulsatile release, with 32.0 +/- 1.5 pulses every 24 hours and a pulse duration of 32.8 +/- 1.6 minutes. We also show an inverse relation between rapid fluctuations in plasma levels of leptin and those of adrenocorticotropic hormone (ACTH) and cortisol that could not be accounted for on the basis of glucocorticoid suppression of leptin. As leptin levels are pulsatile, we propose that a key function of the CNS is regulated by a peripheral pulsatile signal. In a separate pilot study we compared leptin pulsatility in 414 plasma samples collected every 7 minutes for 24 hours from one obese woman and one normal-weight woman. We found that high leptin levels in the obese subject were due solely to increased leptin pulse height; all concentration-independent pulsatility parameters were almost identical in the two women. Leptin pulsatility therefore can be preserved in the obese.	HARVARD UNIV,BETH ISRAEL DEACONESS MED CTR,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; NICHHD,DEV ENDOCRINOL BRANCH,NIH,BETHESDA,MD 20892; NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA	Licinio, J (corresponding author), NIMH,CLIN NEUROENDOCRINOL BRANCH,NIH,BLDG 10,ROOM 2D46,10 CTR DR,BETHESDA,MD 20892, USA.		Mantzoros, Christos/Y-2902-2019; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020; Flier, jeffrey/AAG-6223-2019; Licinio, Julio/L-4244-2013; NegrÃo, AndrÃ© Brooking/C-9526-2014	Wong, Ma-Li/0000-0003-1512-3073; Licinio, Julio/0000-0001-6905-5884; NegrÃo, AndrÃ© Brooking/0000-0002-8133-6723				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; AULITZKY W, 1989, INT J ANDROL, V12, P265, DOI 10.1111/j.1365-2605.1989.tb01313.x; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; FEHMWOLFSDORF G, 1988, PSYCHOPHARMACOLOGY, V94, P496, DOI 10.1007/BF00212844; Glaum SR, 1996, MOL PHARMACOL, V50, P230; GOLD PW, 1983, NEW ENGL J MED, V308, P1117, DOI 10.1056/NEJM198305123081902; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; HAISENLEDER DJ, 1993, ENDOCRINOLOGY, V132, P1292, DOI 10.1210/en.132.3.1292; HOMBURG R, 1989, BRIT MED J, V298, P809, DOI 10.1136/bmj.298.6676.809; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Jenkins G., 1968, SPECTRAL ANAL ITS AP; LICINIO J, 1993, ENDOCRINE, V1, P120; LopezFernandez J, 1996, ENDOCRINOLOGY, V137, P4384, DOI 10.1210/en.137.10.4384; MAITER D, 1988, ENDOCRINOLOGY, V123, P1053, DOI 10.1210/endo-123-2-1053; MICHELSON D, 1994, J CLIN ENDOCR METAB, V79, P848, DOI 10.1210/jc.79.3.848; OERTER KE, 1986, COMPUT BIOMED RES, V19, P170, DOI 10.1016/0010-4809(86)90014-5; SCHWARTZ MW, 1996, AM J PHYSIOL, V98, P1101; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Sinha MK, 1996, BIOCHEM BIOPH RES CO, V228, P733, DOI 10.1006/bbrc.1996.1724; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUTTON RE, 1982, NATURE, V297, P331, DOI 10.1038/297331a0; TURZILLO AM, 1995, BIOL REPROD, V53, P418, DOI 10.1095/biolreprod53.2.418; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; VELDHUIS JD, 1990, CLIN OBSTET GYNECOL, V33, P538, DOI 10.1097/00003081-199009000-00021; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZINAMAN MJ, 1995, J CLIN ENDOCR METAB, V80, P2088, DOI 10.1210/jc.80.7.2088	29	520	535	0	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAY	1997	3	5					575	579		10.1038/nm0597-575	http://dx.doi.org/10.1038/nm0597-575			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WX543	9142131				2022-12-27	WOS:A1997WX54300042
J	Goulder, PJR; Phillips, RE; Colbert, RA; McAdam, S; Ogg, G; Nowak, MA; Giangrande, P; Luzzi, G; Morgan, B; Edwards, A; McMichael, AJ; RowlandJones, S				Goulder, PJR; Phillips, RE; Colbert, RA; McAdam, S; Ogg, G; Nowak, MA; Giangrande, P; Luzzi, G; Morgan, B; Edwards, A; McMichael, AJ; RowlandJones, S			Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS	NATURE MEDICINE			English	Article							HIV-1 INFECTION; PEPTIDE BINDING; VIRUS; CELLS; RECOGNITION; DISEASE; IDENTIFICATION; VARIANTS; AFFINITY; VIREMIA	The precise role played by HIV-specific cytotoxic T lymphocytes (CTL) in HIV infection remains controversial. Despite strong CTL responses being generated during the asymptomatic phase, the virus persists and AIDS ultimately develops. It has been argued that the virus is so variable, and the virus turnover so great that escape from CTL recognition would occur continually, but so far there is limited evidence for CTL escape. The opposing argument is that evidence for CTL escape is present but hard to find because multiple anti-HIV immune responses are acting simultaneously during the asymptomatic phase of infection. We describe six donors who make a strong CTL response to an immunodominant HLA-B27-restricted epitope. In the two donors who progressed to AIDS, CTL escape to fixation by the same mutation was observed, but only after 9-12 years of epitope stability. CTL escape may play an important role in the pathogenesis of HIV infection.	UNIV OXFORD,INST MOL MED,OXFORD OX3 9DU,ENGLAND; CHILDRENS HOSP,MED CTR,WILLIAM S ROWE DIV RHEUMATOL,CINCINNATI,OH 45229; UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND; WYCOMBE GEN HOSP,S BUCKINGHAMSHIRE NHS TRUST,HIGH WYCOMBE HP11 2TT,BUCKS,ENGLAND; RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND	University of Oxford; Cincinnati Children's Hospital Medical Center; University of Oxford; University of Oxford; Radcliffe Infirmary	Goulder, PJR (corresponding author), UNIV OXFORD,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.		Nowak, Martin A/A-6977-2008	Ogg, Graham/0000-0002-3097-045X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEVAN MJ, 1995, P NATL ACAD SCI USA, V92, P5765, DOI 10.1073/pnas.92.13.5765; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; GOTCH F, 1987, THESIS U OXFORD; GOULDER PJR, IN PRESS AIDS; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; McNeil AJ, 1996, QJM-INT J MED, V89, P177; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; MYERS G, 1995, HUMAN RETROVIRUSES A; NIETFELD W, 1995, J IMMUNOL, V154, P2188; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NIXON DF, 1990, THESIS U OXFORD; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	34	998	1023	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					212	217		10.1038/nm0297-212	http://dx.doi.org/10.1038/nm0297-212			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018241				2022-12-27	WOS:A1997WF08800041
J	McInnes, IB; Leung, BP; Sturrock, RD; Field, M; Liew, FY				McInnes, IB; Leung, BP; Sturrock, RD; Field, M; Liew, FY			Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis	NATURE MEDICINE			English	Article							IL-2 RECEPTOR; INFLAMMATORY ARTHRITIS; GROWTH-FACTOR; KILLER-CELLS; BETA-CHAIN; EXPRESSION; LYMPHOCYTES; SYNOVITIS; INDUCTION; CYTOKINE	Tumor necrosis factor-alpha occupies a central role in rheumatoid arthritis (RA) pathogenesis. We now report that interleukin-15 (IL-15) can induce TNF-alpha production in RA through activation of synovial T cells. Peripheral blood (PB) T cells activated by IL-15 induced significant TNF-alpha production by macrophages via a cell-contact-dependent mechanism. Freshly isolated RA synovial T cells possessed similar capability, and in vitro, IL-15 was necessary to maintain this activity. IL-15 also induced direct TNF-alpha production by synovial T cells. In contrast, IL-2 induced significantly lower TNF-alpha production in either cell-contact-dependent or direct culture, and IL-8 and MIP-1 alpha were ineffective. Antibodies against CD69, LFA-1 or ICAM-1 significantly inhibited the ability of T cells to activate macrophages by cell contact.	UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,CTR RHEUMAT DIS,DEPT MED,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Leung, Bernard/O-2409-2013	Leung, Bernard/0000-0002-1119-4934; McInnes, Iain/0000-0002-6462-4280				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; AlMughales J, 1996, CLIN EXP IMMUNOL, V106, P230, DOI 10.1046/j.1365-2249.1996.d01-836.x; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; BURMESTER GR, 1983, RHEUMATOL INT, V3, P173, DOI 10.1007/BF00541597; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; ELLIOTT MJ, 1995, LANCET, V344, P1105; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FERNANDEZGUTIERREZ B, 1995, J RHEUMATOL, V22, P413; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HARRISON WB, 1992, 2 LINE AGENTS TREATM; IANNONE F, 1994, EUR J IMMUNOL, V24, P2706, DOI 10.1002/eji.1830241120; ISLER P, 1993, EUR CYTOKINE NETW, V4, P15; Kanegane H, 1996, BLOOD, V88, P230; Kohem CL, 1996, ARTHRITIS RHEUM, V39, P844, DOI 10.1002/art.1780390518; LACRAZ S, 1994, J BIOL CHEM, V269, P22027; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; Miossec P, 1996, IMMUNOL TODAY, V17, P170, DOI 10.1016/0167-5699(96)80615-3; MONZON CG, 1990, GASTROENTEROLOGY, V98, P1029; Nieto M, 1996, EUR J IMMUNOL, V26, P1302, DOI 10.1002/eji.1830260619; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; PERRELLA O, 1993, EUR NEUROL, V33, P152, DOI 10.1159/000116923; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798; STRUYK L, 1995, ARTHRITIS RHEUM-US, V38, P577, DOI 10.1002/art.1780380502; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; ULFGREN AK, 1995, ANN RHEUM DIS, V54, P654, DOI 10.1136/ard.54.8.654; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255	40	409	440	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1997	3	2					189	195		10.1038/nm0297-189	http://dx.doi.org/10.1038/nm0297-189			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WF088	9018238				2022-12-27	WOS:A1997WF08800038
J	Bao, LR; Loda, M; Janmey, PA; Stewart, R; AnandApte, B; Zetter, BR				Bao, LR; Loda, M; Janmey, PA; Stewart, R; AnandApte, B; Zetter, BR			Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer	NATURE MEDICINE			English	Article							F-ACTIN; ANTIGEN; ADENOCARCINOMA; POLYMERIZATION; DICTYOSTELIUM; EXPRESSION; PREDICTION; GELSOLIN; MODEL; RNA	The Dunning rat prostatic carcinoma is a model system where cell motility closely correlates with the metastatic phenotype. We have identified a novel gene, upregulated in the highly motile and metastatic Dunning cancer cell lines, that represents a new member of the thymosin-beta family, thymosin beta 15. Transfection of antisense thymosin beta 15 constructs into rat prostatic carcinoma cells demonstrates that this molecule positively regulates cell motility, a critical component of the metastatic pathway. Thymosin beta 15 levels are elevated in human prostate cancer and correlate positively with the Gleason tumor grade. Thymosin beta 15 may represent a potential new biochemical marker for human prostate cancer progression.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG & CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,DEACONESS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASPINALL JO, 1995, J UROLOGY, V154, P622, DOI 10.1016/S0022-5347(01)67123-4; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BUBB MR, 1995, BIOCHEMISTRY-US, V34, P3921, DOI 10.1021/bi00012a008; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P157; COOKSON MS, 1995, J UROLOGY, V154, P1070, DOI 10.1016/S0022-5347(01)66979-9; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FREEMAN MR, 1994, J CELL PHYSIOL, V158, P325, DOI 10.1002/jcp.1041580215; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HAEMMERLI G, 1981, INT J CANCER, V27, P603, DOI 10.1002/ijc.2910270506; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOSAKA S, 1978, GANN, V69, P273; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liotta L A, 1988, Cancer Treat Res, V40, P223; MIHELIC M, 1994, AMINO ACIDS, V6, P1, DOI 10.1007/BF00808118; MOHLER JL, 1988, CANCER RES, V48, P4312; MOHLER JL, 1993, CANCER METAST REV, V12, P53, DOI 10.1007/BF00689790; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; PIENTA KJ, 1993, CANCER SURV, V11, P255; SAFER D, 1991, J BIOL CHEM, V266, P4029; SOGANI PC, 1985, UROLOGY, V25, P223, DOI 10.1016/0090-4295(85)90316-4; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; YU FX, 1993, J BIOL CHEM, V268, P502; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZHOU BS, 1992, CANCER RES, V52, P4280	36	134	144	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	DEC	1996	2	12					1322	1328		10.1038/nm1296-1322	http://dx.doi.org/10.1038/nm1296-1322			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VW515	8946830				2022-12-27	WOS:A1996VW51500037
J	Vandenbark, AA; Chou, YK; Whitham, R; Mass, M; Buenafe, A; Liefeld, D; Kavanagh, D; Cooper, S; Hashim, GA; Offner, H; Bourdette, DN				Vandenbark, AA; Chou, YK; Whitham, R; Mass, M; Buenafe, A; Liefeld, D; Kavanagh, D; Cooper, S; Hashim, GA; Offner, H; Bourdette, DN			Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; V-BETA-6.1 CDR2 PEPTIDES; CENTRAL-NERVOUS-SYSTEM; V-BETA USAGE; ORAL TOLERIZATION; TCR PEPTIDES; VACCINATION; IMMUNIZATION	A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.	OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201; COUNCIL TOBACCO RES,NEW YORK,NY 10022	Oregon Health & Science University; Oregon Health & Science University	Vandenbark, AA (corresponding author), VET AFFAIRS MED CTR,3710 SW VET HOSP RD,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS 23444, NS 23221] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023444, R01NS023221] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; BOURDETTE DN, 1994, J IMMUNOL, V152, P2510; BROEREN CPM, 1994, P NATL ACAD SCI USA, V91, P5997, DOI 10.1073/pnas.91.13.5997; CHOU YK, 1994, J IMMUNOL, V152, P2520; CHOU YK, IN PRESS J NEUROSCI; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DESQUENNECLARK L, 1991, P NATL ACAD SCI USA, V88, P7219, DOI 10.1073/pnas.88.16.7219; DIEBLER GE, 1984, NEUROCHEMISTRY, V9, P1371; FALCIONI F, 1995, J EXP MED, V182, P249, DOI 10.1084/jem.182.1.249; GOODKIN DE, 1995, ANN NEUROL, V37, P30, DOI 10.1002/ana.410370108; GREGORIAN SK, 1993, AM ASS IMMUNOL, V150, pA28; HAQQI TM, 1995, 9TH INT C IMMUN ABST, V5014, P845; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JERNE NK, 1984, IMMUNOL REV, V79, P5, DOI 10.1111/j.1600-065X.1984.tb00484.x; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; KUHROBER A, 1994, EUR J IMMUNOL, V24, P1172, DOI 10.1002/eji.1830240525; KUMAR V, 1993, J EXP MED, V178, P909, DOI 10.1084/jem.178.3.909; KURTZKE JF, 1965, NEUROLOGY, V15, P654, DOI 10.1212/WNL.15.7.654; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MATSUMOTO Y, 1994, CELL IMMUNOL, V153, P468, DOI 10.1006/cimm.1994.1043; MILLER A, 1993, J IMMUNOL, V151, P7307; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; SHIMONKEVITZ R, 1995, ANN NY ACAD SCI, V756, P305, DOI 10.1111/j.1749-6632.1995.tb44527.x; STEVENS DB, 1992, J NEUROIMMUNOL, V37, P123, DOI 10.1016/0165-5728(92)90163-F; SWAIN SL, 1991, RES IMMUNOL, V142, P14, DOI 10.1016/0923-2494(91)90004-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; VANDENBARK AA, 1993, NEUROLOGY, V43, P2416, DOI 10.1212/WNL.43.11.2416; Vandenbark AA, 1996, J NEUROSCI RES, V43, P391, DOI 10.1002/(SICI)1097-4547(19960215)43:4<391::AID-JNR1>3.0.CO;2-A; VANDENBARK AA, 1992, J NEUROIMMUNOL, V39, P251, DOI 10.1016/0165-5728(92)90259-N; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VANDENBARK AA, 1994, J IMMUNOL, V153, P910; VOSKUHL RR, 1993, AUTOIMMUNITY, V15, P137, DOI 10.3109/08916939309043888; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WILLIAMS WV, 1988, IMMUNOL RES, V7, P339, DOI 10.1007/BF02935538; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	50	167	184	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	OCT	1996	2	10					1109	1115		10.1038/nm1096-1109	http://dx.doi.org/10.1038/nm1096-1109			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK995	8837609				2022-12-27	WOS:A1996VK99500031
J	Kemp, S; Wei, HM; Lu, JF; Braiterman, LT; McGuinness, MC; Moser, AB; Watkins, PA; Smith, KD				Kemp, S; Wei, HM; Lu, JF; Braiterman, LT; McGuinness, MC; Moser, AB; Watkins, PA; Smith, KD			Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy	NATURE MEDICINE			English	Article							PEROXISOMAL MEMBRANE-PROTEIN; FETAL HEMOGLOBIN PRODUCTION; ACID BETA-OXIDATION; SICKLE-CELL-ANEMIA; CHAIN FATTY-ACIDS; ABC-TRANSPORTER; SACCHAROMYCES-CEREVISIAE; SODIUM-BUTYRATE; ALD-GENE; EXPRESSION	As more functional redundancy in mammalian cells is discovered, enhanced expression of genes involved in alternative pathways may become an effective form of gene therapy. X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder with impaired very-long-chain fatty acid metabolism. The X-ALD gene encodes a peroxisomal membrane protein (ALDP) that is part of a small family of related peroxisomal membrane proteins. We show that 4-phenylbutyrate treatment of cells from both X-ALD patients and X-ALD knockout mice results in decreased levels of and increased beta-oxidation of very-long-chain fatty acids; increased expression of the peroxisomal protein ALDRP; and induction of peroxisome proliferation. We also demonstrate that ALDP and ALDRP are functionally related, by ALDRP cDNA complementation of X-ALD fibroblasts. Finally, we demonstrate the in vivo efficacy of dietary 4-phenylbutyrate treatment through its production of a substantial reduction of very-long-chain fatty acid levels in the brain and adrenal glands of X-ALD mice.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Smith, KD (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway,Room 400A, Baltimore, MD 21205 USA.		Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X; Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD24061, HD10981] Funding Source: Medline; NIDDK NIH HHS [DK51149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051149] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albet S, 1997, FEBS LETT, V405, P394, DOI 10.1016/S0014-5793(97)00122-1; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V201, P1541, DOI 10.1006/bbrc.1994.1879; BOLES DJ, 1991, BIOCHEM MED METAB B, V45, P74, DOI 10.1016/0885-4505(91)90010-I; Braiterman LT, 1998, HUM MOL GENET, V7, P239, DOI 10.1093/hmg/7.2.239; CARSTEA ED, 1992, BIOCHEM BIOPH RES CO, V184, P1477, DOI 10.1016/S0006-291X(05)80049-X; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Cooke J, 1997, TRENDS GENET, V13, P360, DOI 10.1016/S0168-9525(97)01233-X; DENG G, 1992, CANCER RES, V52, P3378; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1994, BLOOD, V84, P339; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Feigenbaum V, 1996, AM J HUM GENET, V58, P1135; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; FREGEAU CJ, 1992, NUCLEIC ACIDS RES, V20, P3113, DOI 10.1093/nar/20.12.3113; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KEMP S, 1994, BIOCHEM BIOPH RES CO, V202, P647, DOI 10.1006/bbrc.1994.1979; Kemp S, 1996, J INHERIT METAB DIS, V19, P667, DOI 10.1007/BF01799844; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; Krasemann EW, 1996, HUM GENET, V97, P194, DOI 10.1007/BF02265264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; LIU L, 1995, CYTOKINE, V7, P449, DOI 10.1006/cyto.1995.0061; LOES DJ, 1994, AM J NEURORADIOL, V15, P1767; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; MOSER HW, 1995, METABOLIC BASIS INHE, P4256; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; OHBA T, 1994, GENOMICS, V24, P370, DOI 10.1006/geno.1994.1630; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Pineau T, 1996, BIOCHEM PHARMACOL, V52, P659, DOI 10.1016/0006-2952(96)00340-1; POULOS A, 1994, ANN NEUROL, V36, P741, DOI 10.1002/ana.410360509; POWERS JM, 1985, CLIN NEUROPATHOL, V4, P181; RAM Z, 1994, CANCER RES, V54, P2923; RASMUSSEN M, 1994, NEUROCHEM RES, V19, P1073, DOI 10.1007/BF00968719; Reddy J. K., 1996, ANN NY ACAD SCI, V804, P801; Roush W, 1997, SCIENCE, V276, P35, DOI 10.1126/science.276.5309.35; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; WATKINS PA, 1995, AM J HUM GENET, V57, P292; ZENGERHAIN J, 1992, NEW DEV FATTY ACID O, P339	57	189	200	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1998	4	11					1261	1268		10.1038/3242	http://dx.doi.org/10.1038/3242			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	134EY	9809549				2022-12-27	WOS:000076731000034
J	Martinerie, J; Adam, C; Le Van Quyen, M; Baulac, M; Clemenceau, S; Renault, B; Varela, FJ				Martinerie, J; Adam, C; Le Van Quyen, M; Baulac, M; Clemenceau, S; Renault, B; Varela, FJ			Epileptic seizures can be anticipated by non-linear analysis	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; RECONSTRUCTION; DYNAMICS; BRAIN	Epileptic seizures are a principal brain dysfunction with important public health implications, as they affect 0.8% of humans. Many of these patients (20%) are resistant to treatment with drugs'. The ability to anticipate the onset of seizures in such cases would permit clinical interventions. The view of chronic focal epilepsy now is that abnormally discharging neurons act as pacemakers to recruit and entrain other normal neurons by loss of inhibition and synchronization into a critical mass(2). Thus, preictal changes should be detectable during the stages of recruitment. Traditional signal analyses, such as the count of focal spike density(3), the frequency coherence(4) or spectral analyses are not reliable predictors. Non-linear indicators may undergo consistent changes around seizure onset(5-7). Our objective was to follow the transition into seizure by reconstructing intracranial recordings in implanted patients as trajectories in a phase space and then introduce non-linear indicators to characterize them(8,9). These indicators take into account the extended spatio-temporal nature of the epileptic recruitment processes(10) and the corresponding physiological events governed by short-term causalities in the time series. We demonstrate that in most cases (17 of 19), seizure onset could be anticipated well in advance (between 2-6 minutes beforehand), and that all subjects seemed to share a similar 'route' towards seizure.	Hop La Pitie Salpetriere, CNRS UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Unite Epileptol, F-75651 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Martinerie, J (corresponding author), Hop La Pitie Salpetriere, CNRS UPR 640, Lab Neurosci Cognit & Imagerie Cerebrale, 47 Blvd Hop, F-75651 Paris 13, France.							ABARBANEL HDI, 1995, ANAL OBSERVED CHAOTI, P17; Casdagli MC, 1997, ELECTROEN CLIN NEURO, V102, P98, DOI 10.1016/S0921-884X(96)95195-4; Casdagli MC, 1997, PHYSICA D, V108, P12, DOI 10.1016/S0167-2789(97)82003-9; DASILVA FHL, 1995, HDB BRAIN THEORY NEU, P367; DUCKROW RB, 1992, ELECTROEN CLIN NEURO, V82, P415, DOI 10.1016/0013-4694(92)90046-K; GOTMAN J, 1982, EPILEPSIA, V23, P432; Lachaux JP, 1997, HUM BRAIN MAPP, V5, P26, DOI 10.1002/(SICI)1097-0193(1997)5:1<26::AID-HBM4>3.0.CO;2-P; LANGE HH, 1983, ELECTROEN CLIN NEURO, V56, P543, DOI 10.1016/0013-4694(83)90022-6; LASEMIDIS LD, 1991, MEASURING CHAOS BRAI, P49; Lehnertz K, 1998, PHYS REV LETT, V80, P5019, DOI 10.1103/PhysRevLett.80.5019; Lerner DE, 1996, PHYSICA D, V97, P563, DOI 10.1016/0167-2789(96)00085-1; Manuca R, 1998, MATH BIOSCI, V147, P1, DOI 10.1016/S0025-5564(97)00055-2; McLachlan RS, 1997, J CLIN NEUROPHYSIOL, V14, P358, DOI 10.1097/00004691-199709000-00002; PRICHARD D, 1994, PHYS REV LETT, V73, P951, DOI 10.1103/PhysRevLett.73.951; ROSENSTEIN MT, 1994, PHYSICA D, V73, P82, DOI 10.1016/0167-2789(94)90226-7; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; VELASCO F, 1995, EPILEPSIA, V36, P63, DOI 10.1111/j.1528-1157.1995.tb01667.x; WEISER HG, 1989, REFLEX SEIZURES REFL, P49; WYLER AR, 1992, EPILEPSY WINDOW BRAI, P415	20	336	369	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1173	1176		10.1038/2667	http://dx.doi.org/10.1038/2667			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771751				2022-12-27	WOS:000076230100037
J	Mignon, A; Guidotti, JE; Mitchell, C; Fabre, M; Wernet, A; De La Coste, A; Soubrane, O; Gilgenkrantz, H; Kahn, A				Mignon, A; Guidotti, JE; Mitchell, C; Fabre, M; Wernet, A; De La Coste, A; Soubrane, O; Gilgenkrantz, H; Kahn, A			Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes	NATURE MEDICINE			English	Article							GENE-THERAPY; MICE; TRANSPLANTATION; REGENERATION; APOPTOSIS; VECTORS	Hepatocyte transplantation might represent a potential therapeutic alternative to liver transplantation in the future(1,2); however, transplanted cells have a limited capacity to repopulate the liver, as they do not proliferate under normal conditions. Recently, studies in urokinase (uPA) transgenic mice(3-5) and in fumarylacetoacetate hydrolase (FAH)-deficient mice(6) have shown that the liver can be repopulated by genetically engineered hepatocytes harboring a selective advantage over resident hepatocytes(7). We have reported that transgenic mice expressing human Bcl-2 in their hepatocytes are protected from Fas/CD95-mediated liver apoptosis(8). We now show that Bcl-2 transplanted hepatocytes selectively repopulate the liver of mice treated with nonlethal doses of the anti-fas antibody Jo2. FK 506 immunosuppressed mice were transplanted by splenic injection with Bcl-2 hepatocytes. The livers of female recipients were repopulated by male Bcl-2 transgenic hepatocytes, as much as 16%, after 8 to 12 administrations of Jo2. This only occurred after anti-fas treatment, confirming that resistance to Fas-induced apoptosis constituted the selective advantage of these transplanted hepatocytes. Thus, we have demonstrated a method for increasing genetic reconstitution of the liver through selective repopulation with modified transgenic hepatocytes, which will allow optimization of cell and gene therapy in the liver.	Univ Paris 05, INSERM U129 ICGM, F-75014 Paris, France; Hop Kremlin Bicetre, F-94275 Le Kremlin Bicetre, France; Hop Cochin, Serv Chirurg Digest, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Kahn, A (corresponding author), Univ Paris 05, INSERM U129 ICGM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	kahn@icgm.cochin.inserm.fr	Guidotti, Jacques-Emmanuel/M-9014-2018; Gilgenkrantz, Helene/G-5534-2017; Soubrane, Olivier/H-7799-2016; Soubrane, Olivier/ABB-4434-2021	gilgenkrantz, helene/0000-0001-6770-4561; guidotti, jacques-emmanuel/0000-0001-9285-8167				BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lake JR, 1998, NEW ENGL J MED, V338, P1463, DOI 10.1056/NEJM199805143382012; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peeters MJTFDV, 1997, HEPATOLOGY, V25, P884, DOI 10.1002/hep.510250416; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; SAMBROOK J, 1989, MOL CLONING LAB MANA; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Wilson JM, 1996, NAT GENET, V12, P232, DOI 10.1038/ng0396-232; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	17	149	159	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1998	4	10					1185	1188		10.1038/2681	http://dx.doi.org/10.1038/2681			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771754				2022-12-27	WOS:000076230100040
J	Safar, J; Wille, H; Itrri, V; Groth, D; Serban, H; Torchia, M; Cohen, FE; Prusiner, SB				Safar, J; Wille, H; Itrri, V; Groth, D; Serban, H; Torchia, M; Cohen, FE; Prusiner, SB			Eight prion strains have PrPSc molecules with different conformations	NATURE MEDICINE			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; NUCLEIC-ACIDS; SCRAPIE ISOFORM; PROTEIN; AGENT; FORM; PATHOGENESIS; PURIFICATION; PROPAGATION	Variations in prions, which cause different incubation times and deposition patterns of the prion protein isoform called PrPSc, are often referred to as 'strains'. We report here a highly sensitive, conformation-dependent immunoassay that discriminates PrPSc molecules among eight different prion strains propagated in Syrian hamsters. This immunoassay quantifies PrP isoforms by simultaneously following antibody binding to the denatured and native forms of a protein. In a plot of the ratio of antibody binding to denatured/native PrP graphed as a function of the concentration of PrPSc, each strain occupies a unique position, indicative of a particular PrPSc conformation. This conclusion is supported by a unique pattern of equilibrium unfolding of PrPSc found with each strain. Our findings indicate that each of the eight prion strains has a PrPSc molecule with a unique conformation and, in accordance with earlier results, indicate the biological properties of prion strains are 'enciphered' in the conformation of PrPSc and that the variation in incubation times is related to the relative protease sensitivity of PrPSc in each strain.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Wille, Holger/C-2280-2008; Safar, Jiri G/G-6512-2013	Wille, Holger/0000-0001-5102-8706; 	NIA NIH HHS [AG10770, AG02132] Funding Source: Medline; NINDS NIH HHS [NS22786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132, P01AG010770] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brown P, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P447; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GIBBS CJ, 1996, BOVINE SPONGIFORM EN, P84; HEMMILA I, 1995, BIOANALYTICAL APPL L, P113; HUANG Z, 1995, FOLDING DESIGN, V1, P13; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KELLINGS K, 1994, PHILOS T R SOC B, V343, P425, DOI 10.1098/rstb.1994.0039; KIMBERLIN RH, 1987, MICROB PATHOGENESIS, V2, P405, DOI 10.1016/0882-4010(87)90047-7; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MARSH RF, 1991, J GEN VIROL, V72, P589, DOI 10.1099/0022-1317-72-3-589; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1961, J COMP PATHOL THERAP, V71, P101, DOI 10.1016/S0368-1742(61)80013-1; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; PRUSINER SB, IN PRESS PRIX NOBEL; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Scott MR, 1997, P NATL ACAD SCI USA, V94, P14279, DOI 10.1073/pnas.94.26.14279; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SIGURDSSON BJORN, 1954, BRIT VET JOUR, V110, P341; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Williamson RA, 1996, P NATL ACAD SCI USA, V93, P7279, DOI 10.1073/pnas.93.14.7279	58	1014	1054	1	67	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1998	4	10					1157	1165		10.1038/2654	http://dx.doi.org/10.1038/2654			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	125GY	9771749				2022-12-27	WOS:000076230100035
J	Nasu, Y; Timme, TL; Yang, G; Bangma, CH; Li, LK; Ren, CZ; Park, SH; DeLeon, M; Wang, JX; Thompson, TC				Nasu, Y; Timme, TL; Yang, G; Bangma, CH; Li, LK; Ren, CZ; Park, SH; DeLeon, M; Wang, JX; Thompson, TC			Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells	NATURE MEDICINE			English	Article							BCL-2; CHOLESTEROL	Although prostate cancer cells are often initially sensitive to androgen ablation, they eventually lose this response and continue to survive, grow and spread in the absence of androgenic steroids. The mechanism(s) that underlie resistance to androgen ablation therapy remain mostly unknown. We have demonstrated that elevated caveolin protein levels are associated with human prostate cancer progression in pathological specimens(1). Here we show that suppression of caveolin expression by a stably transfected antisense caveolin-1 cDNA vector converted androgen-insensitive metastatic mouse prostate cancer cells to an androgen-sensitive phenotype. Orthotopically grown tumors and low-density cell cultures derived from antisense caveolin clones had increased apoptosis in the absence of androgenic steroids, whereas similarly grown tumors and cells from vector (control) clones and parental cells were not sensitive to androgens. Studies using a representative antisense caveolin clone showed that selection for androgen resistance in vivo correlated with increased caveolin levels, and that adenovirus-mediated caveolin expression blocked androgen sensitivity. Our results identify a new candidate gene for hormone-resistant prostate cancer in man and indicate that androgen insensitivity can be an inherent property of metastatic prostate cancer.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Thompson, TC (corresponding author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.	timothyt@bcm.tmc.edu	de Leon, Mony/AAP-7890-2021		NCI NIH HHS [CA50588, CA68814] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050588, R01CA068814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Furuya Y, 1996, CLIN CANCER RES, V2, P389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; Hall S. J., 1997, CLIN EXP METASTAS, V15, P484; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huggins C, 1941, CANCER RES, V1, P293; Krajewska M, 1996, AM J PATHOL, V148, P1567; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; THOMPSON TC, 1995, ONCOGENE, V10, P869; Yang G, 1996, CANCER, V78, P1267, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1267::AID-CNCR15>3.0.CO;2-Z; Yang G, 1998, CLIN CANCER RES, V4, P1873	15	168	176	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1998	4	9					1062	1064		10.1038/2048	http://dx.doi.org/10.1038/2048			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	117VV	9734401				2022-12-27	WOS:000075804100041
J	Buttini, M; Westland, CE; Masliah, E; Yafeh, AM; Wyss-Coray, T; Mucke, L				Buttini, M; Westland, CE; Masliah, E; Yafeh, AM; Wyss-Coray, T; Mucke, L			Novel role of human CD4 molecule identified in neurodegeneration	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; MICROGLIAL CELLS; HIV-1 INFECTION; T-CELLS; BRAIN; EXPRESSION; MOUSE; GP120; MACROPHAGES	The human CD4 molecule (hCD4) is expressed on T lymphocytes and macrophages and acts as a key component of the cellular receptor for HIV. At baseline, hCD4 transgenic mice expressed hCD4 on microglia, the resident mononuclear phagocytes of the brain, and showed no neuronal damage. Activation of brain microglia by peripheral immune challenges elicited neurodegeneration in hCD4 mice but not in nontransgenic controls. In post-mortem brain tissues from AIDS patients with opportunistic infections, but without typical HIV encephalitis, hCD4 expression correlated with neurodegeneration. We conclude that hCD4 may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system.	Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco	Mucke, L (corresponding author), Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA.	lennart_mucke@quickmail.ucsf.edu	Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831; Buttini, Manuel/0000-0003-1805-0279; Mucke, Lennart/0000-0001-6256-9559	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH045294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034602] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45294] Funding Source: Medline; NINDS NIH HHS [NS34602] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORROW P, 1995, J NEUROIMMUNOL, V61, P133, DOI 10.1016/0165-5728(95)00082-D; BUDKA H, 1992, CURR OPIN NEUROL NEU, V5, P917; Buttini M, 1996, NEUROCHEM INT, V29, P25, DOI 10.1016/0197-0186(95)00141-7; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CROCKER PR, 1987, J EXP MED, V166, P613, DOI 10.1084/jem.166.2.613; FORTE P, 1993, IMMUNOGENETICS, V38, P455; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; Giulian D, 1996, J NEUROSCI, V16, P3139; Giulian D, 1996, J NEUROSCI, V16, P6021; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; IMAM SH, 1992, CURR MICROBIOL, V25, P1, DOI 10.1007/BF01570075; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MASLIAH E, 1992, LAB INVEST, V66, P285; MUCKE L, IN PRESS MOL NEUROLO; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; SOBEL RA, 1990, J NEUROPATH EXP NEUR, V49, P468, DOI 10.1097/00005072-199009000-00002; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TRAUGOTT U, 1985, CELL IMMUNOL, V91, P240, DOI 10.1016/0008-8749(85)90047-4; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VANDAM AM, 1992, BRAIN RES, V588, P291, DOI 10.1016/0006-8993(92)91588-6; VIGNALI DAA, 1993, PHILOS T R SOC B, V342, P13, DOI 10.1098/rstb.1993.0130	29	22	22	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1998	4	4					441	446		10.1038/nm0498-441	http://dx.doi.org/10.1038/nm0498-441			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF531	9546790				2022-12-27	WOS:000072906800039
J	McDonald, JW; Althomsons, SP; Hyrc, KL; Choi, DW; Goldberg, MP				McDonald, JW; Althomsons, SP; Hyrc, KL; Choi, DW; Goldberg, MP			Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity	NATURE MEDICINE			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; METHYL-D-ASPARTATE; GLUTAMATE RECEPTORS; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; GLUCOSE DEPRIVATION; CEREBRAL-CORTEX; PROGENITOR-CELL	Little is known of the molecular mechanisms that trigger oligodendrocyte death and demyelination in many acute central nervous system insults. Since oligodendrocytes express functional alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate-type glutamate receptors, we examined the possibility that oligodendrocyte death can be mediated by glutamate receptor overactivation. Oligodendrocytes in primary cultures from mouse forebrain were selectively killed by low concentrations of AMPA, kainate or glutamate, or by deprivation of oxygen and glucose. This toxicity could be blocked by the AMPA/kainate receptor antagonist 6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione (NBQX).,ln vivo, differentiated oligodendrocytes in subcortical white matter expressed AMPA receptors and were selectively injured by microstereotaxic injection of AMPA but not NMDA. These data suggest that oligodendrocytes share with neurons a high vulnerability to AMPA/kainate receptor-mediated death, a mechanism that may contribute to white matter injury in CNS disease.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Goldberg, MP (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@neuro.wustl.edu		Hyrc, Krzysztof/0000-0002-8830-6324; Goldberg, Mark/0000-0003-3534-6979	NINDS NIH HHS [NS 32140, NS 36265, NS 01931] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032140, K08NS001931, R01NS036265] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P32; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; BUNGE RP, 1993, ADV NEUROL, V59, P75; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; David JC, 1996, J NEUROSCI, V16, P200; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; DUSART I, 1992, NEUROSCIENCE, V51, P137, DOI 10.1016/0306-4522(92)90478-K; FISHER CM, 1965, NEUROLOGY, V15, P774, DOI 10.1212/WNL.15.8.774; FRANDSEN A, 1990, INT J DEV NEUROSCI, V8, P209, DOI 10.1016/0736-5748(90)90013-R; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; Ginsberg M D, 1979, Adv Neurol, V26, P21; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HIRANO A, 1967, J NEUROPATH EXP NEUR, V26, P200, DOI 10.1097/00005072-196704000-00002; HOLTZCLAW LA, 1995, J NEUROSCI RES, V42, P1124; ISHII S, 1992, DEV NEUROSCI-BASEL, V14, P230; KAHN MA, 1994, GLIA, V12, P87, DOI 10.1002/glia.440120202; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1990, J NEUROSCI, V10, P693; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCDONALD, 1997, BRAIN RES, V759, P228; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511; Miller RH, 1996, TRENDS NEUROSCI, V19, P92, DOI 10.1016/S0166-2236(96)80036-1; Noble M, 1996, PERSPECT DEV NEUROBI, V3, P121; Oh LYS, 1996, GLIA, V17, P237; OKA A, 1993, J NEUROSCI, V13, P1441; OKEDA R, 1981, ACTA NEUROPATHOL, V54, P1, DOI 10.1007/BF00691327; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PLUM F, 1962, ARCH INTERN MED, V110, P56; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; RATAN RR, 1994, J NEUROCHEM, V62, P37; RIVKIN MJ, 1993, SEMIN NEUROL, V13, P30, DOI 10.1055/s-2008-1041104; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHEARDOWN MJ, 1993, EUR J PHARMACOL, V236, P347, DOI 10.1016/0014-2999(93)90470-3; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; WAHL P, 1991, INT J DEV NEUROSCI, V9, P287, DOI 10.1016/0736-5748(91)90049-R; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; YAMADA KA, 1992, J PHYSIOL-LONDON, V458, P409, DOI 10.1113/jphysiol.1992.sp019424; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; ZACZEK R, 1980, J NEUROPATH EXP NEUR, V39, P245, DOI 10.1097/00005072-198005000-00003; ZHONG J, 1994, MOL PHARMACOL, V45, P846	60	443	458	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1998	4	3					291	297		10.1038/nm0398-291	http://dx.doi.org/10.1038/nm0398-291			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZN163	9500601				2022-12-27	WOS:000073616200033
J	Ogilvie, BM				Ogilvie, BM			Philanthropic goals	NATURE MEDICINE			English	Editorial Material											Ogilvie, BM (corresponding author), WELLCOME TRUST RES LABS,183 EUSTON RD,LONDON NW1 2BE,ENGLAND.							May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793	1	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1997	3	11					1185	1187		10.1038/nm1197-1185	http://dx.doi.org/10.1038/nm1197-1185			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	YD896	9359683				2022-12-27	WOS:A1997YD89600017
J	Cook, DG; Forman, MS; Sung, JC; Leight, S; Kolson, DL; Iwatsubo, T; Lee, VMY; Doms, RW				Cook, DG; Forman, MS; Sung, JC; Leight, S; Kolson, DL; Iwatsubo, T; Lee, VMY; Doms, RW			Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; HUMAN NEURONAL SYSTEM; SENILE PLAQUES; IN-VIVO; PRESENILIN-1; DISEASE; INHIBITION; EXPRESSION; SURFACE	Alzheimer's disease (AD) is a neurodegenerative disorder involving the florid deposition of vascular and cerebral plaques composed chiefly of amyloid beta-peptide (A beta) derived from cleavage of the amyloid precursor protein (APP)(1-2). Varying in length from 39 to 43 amino acids, A beta, particularly the longer A beta(42), is thought to play a significant role in AD pathogenesis(3-4). To better understand AD it is important to identify the subcellular organelles generating A beta. Studies using agents that disrupt endosomal/lysosomal function suggest that A beta is generated late in the secretory and endocytic pathways(5). However, much of what is known about A beta biosynthesis has been inferred by monitoring extracellular A beta levels since intracellular A beta is undetectable in most cell types. Consequently, the precise site or sites that generate A beta, or whether A beta(1-40) and A beta(1-42) are generated at the same point in the biosynthetic pathway, is not known. Using human NT2N neurons, we found that retention of APP in the endoplasmic reticulum/intermediate compartment (ER/IC) by three independent approaches eliminated production of intracellular A beta(1-40), but did not alter intracellular A beta(1-42) synthesis. These findings suggest that the ER/IC may be an important site for generating this highly amyloidogenic species of A beta.	UNIV PENN,ABRAMSON RES CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT NEUROPATHOL & NEUROSCI,TOKYO 113,JAPAN	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Tokyo					NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG11542] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Simons M, 1996, J NEUROSCI, V16, P899; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966	20	391	406	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	SEP	1997	3	9					1021	1023		10.1038/nm0997-1021	http://dx.doi.org/10.1038/nm0997-1021			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XT842	9288730				2022-12-27	WOS:A1997XT84200036
J	Carbone, M; Rizzo, P; Grimley, PM; Procopio, A; Mew, DJY; Shridhar, V; DeBartolomeis, A; Esposito, V; Giuliano, MT; Steinberg, SM; Levine, AS; Giordano, A; Pass, HI				Carbone, M; Rizzo, P; Grimley, PM; Procopio, A; Mew, DJY; Shridhar, V; DeBartolomeis, A; Esposito, V; Giuliano, MT; Steinberg, SM; Levine, AS; Giordano, A; Pass, HI			Simian virus-40 large-T antigen binds p53 in human mesotheliomas	NATURE MEDICINE			English	Article							LUNG-CARCINOMA; RAS MUTATIONS; MONKEY CELLS; ASBESTOS; GENE; DNA; TRANSFORMATION; INDUCTION; LINES	We found that simian virus 40 (SV40) induces mesotheliomas in hamsters(1) and that 60% of human mesotheliomas contain and express SV40 sequences', results now confirmed by others [ref. 3-5, and presentations by D. Griffiths & R. Weiss, F. Galateau-SallE, and H.I.P. at ''Simian virus 40: A possible human polyoma virus,'' NIH workshop, 27-28 January 1997, Bethesda, MD (transcript available through SAG Corp., Washington, DC 20008)]. Mesothelioma(6-8), an aggressive malignancy resistant to therapy, originates from the serosal lining of the pleural, pericardial and peritoneal cavities. The incidence of mesothelioma continues to increase worldwide because of exposure to crocidolite asbestos. However, at least 20% of mesotheliomas in the United States are not associated with asbestos exposure, and only a minority of people exposed to high concentrations of asbestos develop mesothelioma(6-8). Thus, other carcinogens may induce mesothelioma in individuals not exposed to asbestos, and/or may render particular individuals more susceptible to the carcinogenic effect of asbestos. We investigated whether the expression of the 5V40 large T-antigen (Tag) interferes with the normal expression of the tumor suppressor gene p53 in human mesotheliomas. We found that SV40 Tag retains its ability to bind and to inactivate p53, a cellular protein that when normally expressed plays an important role in suppressing tumor growth and in inducing sensitivity to therapy. Our findings do not establish a cause-and-effect relation, but indicate that the possibility that SV40 contributes to the development of human mesotheliomas should be carefully investigated.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20889; UNIV CHIETI,LAB FISIOPATOL MOL,I-66013 CHIETI,ITALY; KARMANOS CANC INST,AERODIGEST PROGRAM,DETROIT,MI 48201; NIMH,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES,PHILADELPHIA,PA 19107; NCI,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; G d'Annunzio University of Chieti-Pescara; Barbara Ann Karmanos Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Carbone, M (corresponding author), LOYOLA UNIV,DEPT PATHOL,CANC IMMUNOL PROGRAM,CARDINAL BERNARDIN CANC CTR,ROOM 205,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.		Giordano, Antonio/F-1927-2010; Procopio, Antonio Domenico/AAB-2451-2021	Giordano, Antonio/0000-0002-5959-016X; Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; Esposito, Vincenzo/0000-0003-4696-2363; Giuliano, Mariateresa/0000-0002-7338-9200; de Bartolomeis, Andrea/0000-0002-3188-5652; rizzo, paola/0000-0001-7174-9674	NCI NIH HHS [CA 60999-01A1, CA 77220-01A1] Funding Source: Medline; NINDS NIH HHS [NS 36466-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077220, R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1995, INT J CANCER, V63, P330, DOI 10.1002/ijc.2910630304; APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; CARBONE M, IN PRESS ONCOGENE; CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DEBARTOLOMEIS A, 1994, BRAIN RES MOL BRAIN, V21, P312; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DUBES GR, 1993, JP AM ASS CANC RES, V34, P185; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; JENSEN F, 1964, J NATL CANCER I, V32, P917; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, IN PRESS INT J CANC; LEHMAN TA, 1991, CANCER RES, V51, P4090; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSELLA JM, IN PRESS ENV HLTH PE; MARSHALL J, 1991, ONCOGENE, V6, P1673; Martini F, 1996, CANCER RES, V56, P4820; MAYALL FG, 1993, HISTOPATHOLOGY, V22, P383, DOI 10.1111/j.1365-2559.1993.tb00140.x; METCALF RA, 1992, CANCER RES, V52, P2610; METHA CR, 1984, BIOMETRICS, V40, P819; MICHIELI P, 1994, CANCER RES, V54, P3391; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; MOSSMAN BT, 1996, CANC INVEST, V14, P464; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; Ruley H. Earl, 1996, P37; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995	42	224	225	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	AUG	1997	3	8					908	912		10.1038/nm0897-908	http://dx.doi.org/10.1038/nm0897-908			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP014	9256284				2022-12-27	WOS:A1997XP01400035
